{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import nltk\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.tag import pos_tag\n",
    "import io\n",
    "from nltk.corpus import stopwords "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "file = open(\"text.txt\",\"r\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<_io.TextIOWrapper name='text.txt' mode='r' encoding='cp1252'>"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "lines = file.read()\n",
    "text = lines.split()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['WNT',\n",
       " 'signalling',\n",
       " 'orchestrates',\n",
       " 'a',\n",
       " 'number',\n",
       " 'of',\n",
       " 'developmental',\n",
       " 'programs.',\n",
       " 'In',\n",
       " 'response',\n",
       " 'to',\n",
       " 'this',\n",
       " 'stimulus,',\n",
       " 'cytoplasmic',\n",
       " 'beta-catenin',\n",
       " '(encoded',\n",
       " 'by',\n",
       " 'CTNNB1)',\n",
       " 'is',\n",
       " 'stabilized,',\n",
       " 'enabling',\n",
       " 'downstream',\n",
       " 'transcriptional',\n",
       " 'activation',\n",
       " 'by',\n",
       " 'members',\n",
       " 'of',\n",
       " 'the',\n",
       " 'LEF/TCF',\n",
       " 'family.',\n",
       " 'One',\n",
       " 'of',\n",
       " 'the',\n",
       " 'target',\n",
       " 'genes',\n",
       " 'for',\n",
       " 'beta-catenin/TCF',\n",
       " 'encodes',\n",
       " 'c-MYC,',\n",
       " 'explaining',\n",
       " 'why',\n",
       " 'constitutive',\n",
       " 'activation',\n",
       " 'of',\n",
       " 'the',\n",
       " 'WNT',\n",
       " 'pathway',\n",
       " 'can',\n",
       " 'lead',\n",
       " 'to',\n",
       " 'cancer,',\n",
       " 'particularly',\n",
       " 'in',\n",
       " 'the',\n",
       " 'colon.',\n",
       " 'Most',\n",
       " 'colon',\n",
       " 'cancers',\n",
       " 'arise',\n",
       " 'from',\n",
       " 'mutations',\n",
       " 'in',\n",
       " 'the',\n",
       " 'gene',\n",
       " 'encoding',\n",
       " 'adenomatous',\n",
       " 'polyposis',\n",
       " 'coli',\n",
       " '(APC),',\n",
       " 'a',\n",
       " 'protein',\n",
       " 'required',\n",
       " 'for',\n",
       " 'ubiquitin-mediated',\n",
       " 'degradation',\n",
       " 'of',\n",
       " 'beta-catenin,',\n",
       " 'but',\n",
       " 'a',\n",
       " 'small',\n",
       " 'percentage',\n",
       " 'of',\n",
       " 'colon',\n",
       " 'and',\n",
       " 'some',\n",
       " 'other',\n",
       " 'cancers',\n",
       " 'harbour',\n",
       " 'beta-catenin-stabilizing',\n",
       " 'mutations.',\n",
       " 'Recently,',\n",
       " 'we',\n",
       " 'discovered',\n",
       " 'that',\n",
       " 'transgenic',\n",
       " 'mice',\n",
       " 'expressing',\n",
       " 'an',\n",
       " 'activated',\n",
       " 'beta-catenin',\n",
       " 'are',\n",
       " 'predisposed',\n",
       " 'to',\n",
       " 'developing',\n",
       " 'skin',\n",
       " 'tumours',\n",
       " 'resembling',\n",
       " 'pilomatricomas.',\n",
       " 'Given',\n",
       " 'that',\n",
       " 'the',\n",
       " 'skin',\n",
       " 'of',\n",
       " 'these',\n",
       " 'adult',\n",
       " 'mice',\n",
       " 'also',\n",
       " 'exhibits',\n",
       " 'signs',\n",
       " 'of',\n",
       " 'de',\n",
       " 'novo',\n",
       " 'hair-follicle',\n",
       " 'morphogenesis,',\n",
       " 'we',\n",
       " 'wondered',\n",
       " 'whether',\n",
       " 'human',\n",
       " 'pilomatricomas',\n",
       " 'might',\n",
       " 'originate',\n",
       " 'from',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cells',\n",
       " 'and',\n",
       " 'whether',\n",
       " 'they',\n",
       " 'might',\n",
       " 'possess',\n",
       " 'beta-catenin-stabilizing',\n",
       " 'mutations.',\n",
       " 'Here,',\n",
       " 'we',\n",
       " 'explore',\n",
       " 'the',\n",
       " 'cell',\n",
       " 'origin',\n",
       " 'and',\n",
       " 'aetiology',\n",
       " 'of',\n",
       " 'this',\n",
       " 'common',\n",
       " 'human',\n",
       " 'skin',\n",
       " 'tumour.',\n",
       " 'We',\n",
       " 'found',\n",
       " 'nuclear',\n",
       " 'LEF-1',\n",
       " 'in',\n",
       " 'the',\n",
       " 'dividing',\n",
       " 'tumour',\n",
       " 'cells,',\n",
       " 'providing',\n",
       " 'biochemical',\n",
       " 'evidence',\n",
       " 'that',\n",
       " 'pilomatricomas',\n",
       " 'are',\n",
       " 'derived',\n",
       " 'from',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cells.',\n",
       " 'At',\n",
       " 'least',\n",
       " '75%',\n",
       " 'of',\n",
       " 'these',\n",
       " 'tumours',\n",
       " 'possess',\n",
       " 'mutations',\n",
       " 'affecting',\n",
       " 'the',\n",
       " 'amino-terminal',\n",
       " 'segment,',\n",
       " 'normally',\n",
       " 'involved',\n",
       " 'in',\n",
       " 'phosphorylation-dependent,',\n",
       " 'ubiquitin-mediated',\n",
       " 'degradation',\n",
       " 'of',\n",
       " 'the',\n",
       " 'protein.',\n",
       " 'This',\n",
       " 'percentage',\n",
       " 'of',\n",
       " 'CTNNB1',\n",
       " 'mutations',\n",
       " 'is',\n",
       " 'greater',\n",
       " 'than',\n",
       " 'in',\n",
       " 'all',\n",
       " 'other',\n",
       " 'human',\n",
       " 'tumours',\n",
       " 'examined',\n",
       " 'thus',\n",
       " 'far,',\n",
       " 'and',\n",
       " 'directly',\n",
       " 'implicates',\n",
       " 'beta-catenin/LEF',\n",
       " 'misregulation',\n",
       " 'as',\n",
       " 'the',\n",
       " 'major',\n",
       " 'cause',\n",
       " 'of',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cell',\n",
       " 'tumorigenesis',\n",
       " 'in',\n",
       " 'humans..',\n",
       " 'Hereditary',\n",
       " 'hemochromatosis',\n",
       " '(HH)',\n",
       " 'is',\n",
       " 'a',\n",
       " 'common',\n",
       " 'autosomal',\n",
       " 'recessive',\n",
       " 'genetic',\n",
       " 'disorder',\n",
       " 'of',\n",
       " 'iron',\n",
       " 'metabolism.',\n",
       " 'The',\n",
       " 'HFE',\n",
       " 'candidate',\n",
       " 'gene',\n",
       " 'encoding',\n",
       " 'an',\n",
       " 'HLA',\n",
       " 'class',\n",
       " 'I-like',\n",
       " 'protein',\n",
       " 'involved',\n",
       " 'in',\n",
       " 'HH',\n",
       " 'was',\n",
       " 'identified',\n",
       " 'in',\n",
       " '1996.',\n",
       " 'Two',\n",
       " 'missense',\n",
       " 'mutations',\n",
       " 'have',\n",
       " 'been',\n",
       " 'described',\n",
       " 'C282Y,',\n",
       " 'accounting',\n",
       " 'for',\n",
       " '80%',\n",
       " 'to',\n",
       " '90%',\n",
       " 'of',\n",
       " 'HH',\n",
       " 'chromosomes,',\n",
       " 'and',\n",
       " 'H63D,',\n",
       " 'which',\n",
       " 'is',\n",
       " 'associated',\n",
       " 'with',\n",
       " 'a',\n",
       " 'milder',\n",
       " 'form',\n",
       " 'of',\n",
       " 'the',\n",
       " 'disease',\n",
       " 'representing',\n",
       " '40%',\n",
       " 'to',\n",
       " '70%',\n",
       " 'of',\n",
       " 'non-C282Y',\n",
       " 'HH',\n",
       " 'chromosomes.',\n",
       " 'We',\n",
       " 'report',\n",
       " 'here',\n",
       " 'on',\n",
       " 'the',\n",
       " 'analysis',\n",
       " 'of',\n",
       " 'C282Y,',\n",
       " 'H63D,',\n",
       " 'and',\n",
       " 'the',\n",
       " '193A--',\n",
       " '>',\n",
       " 'T',\n",
       " 'substitution',\n",
       " 'leading',\n",
       " 'to',\n",
       " 'the',\n",
       " 'S65C',\n",
       " 'missense',\n",
       " 'substitution',\n",
       " 'in',\n",
       " 'a',\n",
       " 'large',\n",
       " 'series',\n",
       " 'of',\n",
       " 'probands',\n",
       " 'and',\n",
       " 'controls.',\n",
       " 'The',\n",
       " 'results',\n",
       " 'confirm',\n",
       " 'that',\n",
       " 'the',\n",
       " 'C282Y',\n",
       " 'substitution',\n",
       " 'was',\n",
       " 'the',\n",
       " 'main',\n",
       " 'mutation',\n",
       " 'involved',\n",
       " 'in',\n",
       " 'hemochromatosis,',\n",
       " 'accounting',\n",
       " 'for',\n",
       " '85%',\n",
       " 'of',\n",
       " 'carrier',\n",
       " 'chromosomes,',\n",
       " 'whereas',\n",
       " 'the',\n",
       " 'H63D',\n",
       " 'substitution',\n",
       " 'represented',\n",
       " '39%',\n",
       " 'of',\n",
       " 'the',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'that',\n",
       " 'did',\n",
       " 'not',\n",
       " 'carry',\n",
       " 'the',\n",
       " 'C282Y',\n",
       " 'mutation.',\n",
       " 'In',\n",
       " 'addition,',\n",
       " 'our',\n",
       " 'screening',\n",
       " 'showed',\n",
       " 'that',\n",
       " 'the',\n",
       " 'S65C',\n",
       " 'substitution',\n",
       " 'was',\n",
       " 'significantly',\n",
       " 'enriched',\n",
       " 'in',\n",
       " 'probands',\n",
       " 'with',\n",
       " 'at',\n",
       " 'least',\n",
       " 'one',\n",
       " 'chromosome',\n",
       " 'without',\n",
       " 'an',\n",
       " 'assigned',\n",
       " 'mutation.',\n",
       " 'This',\n",
       " 'substitution',\n",
       " 'accounted',\n",
       " 'for',\n",
       " '7.',\n",
       " '8%',\n",
       " 'of',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'that',\n",
       " 'were',\n",
       " 'neither',\n",
       " 'C282Y',\n",
       " 'nor',\n",
       " 'H63D.',\n",
       " 'This',\n",
       " 'enrichment',\n",
       " 'of',\n",
       " 'S65C',\n",
       " 'among',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'suggests',\n",
       " 'that',\n",
       " 'the',\n",
       " 'S65C',\n",
       " 'substitution',\n",
       " 'is',\n",
       " 'associated',\n",
       " 'with',\n",
       " 'the',\n",
       " 'mild',\n",
       " 'form',\n",
       " 'of',\n",
       " 'hemochromatosis.',\n",
       " 'The',\n",
       " 'objective',\n",
       " 'of',\n",
       " 'this',\n",
       " 'study',\n",
       " 'was',\n",
       " 'to',\n",
       " 'provide',\n",
       " 'more',\n",
       " 'accurate',\n",
       " 'frequency',\n",
       " 'estimates',\n",
       " 'of',\n",
       " 'breast',\n",
       " 'cancer',\n",
       " 'susceptibility',\n",
       " 'gene',\n",
       " '1',\n",
       " '(BRCA1)',\n",
       " 'germline',\n",
       " 'alterations',\n",
       " 'in',\n",
       " 'the',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'population.',\n",
       " 'To',\n",
       " 'achieve',\n",
       " 'this,',\n",
       " 'we',\n",
       " 'determined',\n",
       " 'the',\n",
       " 'prevalence',\n",
       " 'of',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'in',\n",
       " 'a',\n",
       " 'population-based',\n",
       " 'series',\n",
       " 'of',\n",
       " 'consecutive',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'cases.',\n",
       " 'This',\n",
       " 'is',\n",
       " 'the',\n",
       " 'first',\n",
       " 'population-based',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'study',\n",
       " 'reporting',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'derived',\n",
       " 'from',\n",
       " 'a',\n",
       " 'comprehensive',\n",
       " 'screen',\n",
       " 'of',\n",
       " 'the',\n",
       " 'entire',\n",
       " 'coding',\n",
       " 'region.',\n",
       " 'One',\n",
       " 'hundred',\n",
       " 'and',\n",
       " 'seven',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " 'were',\n",
       " 'analyzed',\n",
       " 'for',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'using',\n",
       " 'the',\n",
       " 'RNase',\n",
       " 'mismatch',\n",
       " 'cleavage',\n",
       " 'assay',\n",
       " 'followed',\n",
       " 'by',\n",
       " 'direct',\n",
       " 'sequencing.',\n",
       " 'Two',\n",
       " 'truncating',\n",
       " 'mutations,',\n",
       " '962del4',\n",
       " 'and',\n",
       " '3600del11,',\n",
       " 'were',\n",
       " 'identified.',\n",
       " 'Both',\n",
       " 'patients',\n",
       " 'had',\n",
       " 'a',\n",
       " 'family',\n",
       " 'history',\n",
       " 'of',\n",
       " 'breast',\n",
       " 'or',\n",
       " 'ovarian',\n",
       " 'cancer.',\n",
       " 'Several',\n",
       " 'novel',\n",
       " 'as',\n",
       " 'well',\n",
       " 'as',\n",
       " 'previously',\n",
       " 'reported',\n",
       " 'uncharacterized',\n",
       " 'variants',\n",
       " 'were',\n",
       " 'also',\n",
       " 'identified,',\n",
       " 'some',\n",
       " 'of',\n",
       " 'which',\n",
       " 'were',\n",
       " 'associated',\n",
       " 'with',\n",
       " 'a',\n",
       " 'family',\n",
       " 'history',\n",
       " 'of',\n",
       " 'cancer.',\n",
       " 'The',\n",
       " 'frequency',\n",
       " 'distribution',\n",
       " 'of',\n",
       " 'common',\n",
       " 'polymorphisms',\n",
       " 'was',\n",
       " 'determined',\n",
       " 'in',\n",
       " 'the',\n",
       " '91',\n",
       " 'Caucasian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " 'in',\n",
       " 'this',\n",
       " 'series',\n",
       " 'and',\n",
       " '24',\n",
       " 'sister',\n",
       " 'controls',\n",
       " 'using',\n",
       " 'allele-specific',\n",
       " 'amplification.',\n",
       " 'The',\n",
       " 'rare',\n",
       " 'form',\n",
       " 'of',\n",
       " 'the',\n",
       " 'Q356R',\n",
       " 'polymorphism',\n",
       " 'was',\n",
       " 'significantly',\n",
       " '(P',\n",
       " '=',\n",
       " '0.',\n",
       " '03)',\n",
       " 'associated',\n",
       " 'with',\n",
       " 'a',\n",
       " 'family',\n",
       " 'history',\n",
       " 'of',\n",
       " 'ovarian',\n",
       " 'cancer,',\n",
       " 'suggesting',\n",
       " 'that',\n",
       " 'this',\n",
       " 'polymorphism',\n",
       " 'may',\n",
       " 'influence',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'risk.',\n",
       " 'In',\n",
       " 'summary,',\n",
       " 'our',\n",
       " 'data',\n",
       " 'suggest',\n",
       " 'a',\n",
       " 'role',\n",
       " 'for',\n",
       " 'some',\n",
       " 'uncharacterized',\n",
       " 'variants',\n",
       " 'and',\n",
       " 'rare',\n",
       " 'forms',\n",
       " 'of',\n",
       " 'polymorphisms',\n",
       " 'in',\n",
       " 'determining',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'risk,',\n",
       " 'and',\n",
       " 'highlight',\n",
       " 'the',\n",
       " 'necessity',\n",
       " 'to',\n",
       " 'screen',\n",
       " 'for',\n",
       " 'missense',\n",
       " 'alterations',\n",
       " 'as',\n",
       " 'well',\n",
       " 'as',\n",
       " 'truncating',\n",
       " 'mutations',\n",
       " 'in',\n",
       " 'this',\n",
       " 'population.',\n",
       " 'The',\n",
       " 'adenomatous',\n",
       " 'polyposis',\n",
       " 'coli',\n",
       " '(APC)',\n",
       " 'tumour-suppressor',\n",
       " 'protein',\n",
       " 'controls',\n",
       " 'the',\n",
       " 'Wnt',\n",
       " 'signalling',\n",
       " 'pathway',\n",
       " 'by',\n",
       " 'forming',\n",
       " 'a',\n",
       " 'complex',\n",
       " 'with',\n",
       " 'glycogen',\n",
       " 'synthase',\n",
       " 'kinase',\n",
       " '3beta',\n",
       " '(GSK-3beta),',\n",
       " 'axin/conductin',\n",
       " 'and',\n",
       " 'betacatenin.',\n",
       " 'Complex',\n",
       " 'formation',\n",
       " 'induces',\n",
       " 'the',\n",
       " 'rapid',\n",
       " 'degradation',\n",
       " 'of',\n",
       " 'betacatenin.',\n",
       " 'In',\n",
       " 'colon',\n",
       " 'carcinoma',\n",
       " 'cells,',\n",
       " 'loss',\n",
       " 'of',\n",
       " 'APC',\n",
       " 'leads',\n",
       " 'to',\n",
       " 'the',\n",
       " 'accumulation',\n",
       " 'of',\n",
       " 'betacatenin',\n",
       " 'in',\n",
       " 'the',\n",
       " 'nucleus,',\n",
       " 'where',\n",
       " 'it',\n",
       " 'binds',\n",
       " 'to',\n",
       " 'and',\n",
       " 'activates',\n",
       " 'the',\n",
       " 'Tcf-4',\n",
       " 'transcription',\n",
       " 'factor',\n",
       " '(reviewed',\n",
       " 'in',\n",
       " '[1]',\n",
       " '[2]).',\n",
       " 'Here,',\n",
       " 'we',\n",
       " 'report',\n",
       " 'the',\n",
       " 'identification',\n",
       " 'and',\n",
       " 'genomic',\n",
       " 'structure',\n",
       " 'of',\n",
       " 'APC',\n",
       " 'homologues.',\n",
       " 'Mammalian',\n",
       " 'APC2,',\n",
       " 'which',\n",
       " 'closely',\n",
       " 'resembles',\n",
       " 'APC',\n",
       " 'in',\n",
       " 'overall',\n",
       " 'domain',\n",
       " 'structure,',\n",
       " 'was',\n",
       " 'functionally',\n",
       " 'analyzed',\n",
       " 'and',\n",
       " 'shown',\n",
       " 'to',\n",
       " 'contain',\n",
       " 'two',\n",
       " 'SAMP',\n",
       " 'domains,',\n",
       " 'both',\n",
       " 'of',\n",
       " 'which',\n",
       " 'are',\n",
       " 'required',\n",
       " 'for',\n",
       " 'binding',\n",
       " 'to',\n",
       " 'conductin.',\n",
       " 'Like',\n",
       " 'APC,',\n",
       " 'APC2',\n",
       " 'regulates',\n",
       " 'the',\n",
       " 'formation',\n",
       " 'of',\n",
       " 'active',\n",
       " 'betacatenin-Tcf',\n",
       " 'complexes,',\n",
       " 'as',\n",
       " 'demonstrated',\n",
       " 'using',\n",
       " 'transient',\n",
       " 'transcriptional',\n",
       " 'activation',\n",
       " 'assays',\n",
       " 'in',\n",
       " 'APC',\n",
       " '-/-',\n",
       " 'colon',\n",
       " 'carcinoma',\n",
       " 'cells.',\n",
       " 'Human',\n",
       " 'APC2',\n",
       " 'maps',\n",
       " 'to',\n",
       " 'chromosome',\n",
       " '19p13.',\n",
       " '3.',\n",
       " 'APC',\n",
       " 'and',\n",
       " 'APC2',\n",
       " 'may',\n",
       " 'therefore',\n",
       " 'have',\n",
       " 'comparable',\n",
       " 'functions',\n",
       " 'in',\n",
       " 'development',\n",
       " 'and',\n",
       " 'cancer.The',\n",
       " 'serum',\n",
       " 'of',\n",
       " 'a',\n",
       " '29-year',\n",
       " 'old',\n",
       " 'woman',\n",
       " 'with',\n",
       " 'a',\n",
       " 'recent',\n",
       " 'episode',\n",
       " 'of',\n",
       " 'disseminated',\n",
       " 'gonococcal',\n",
       " 'infection',\n",
       " 'and',\n",
       " 'a',\n",
       " 'history',\n",
       " 'of',\n",
       " 'meningococcal',\n",
       " 'meningitis',\n",
       " 'and',\n",
       " 'arthritis',\n",
       " 'as',\n",
       " 'a',\n",
       " 'child',\n",
       " 'was',\n",
       " 'found',\n",
       " 'to',\n",
       " 'lack',\n",
       " 'serum',\n",
       " 'hemolytic',\n",
       " 'complement',\n",
       " 'activity.',\n",
       " 'The',\n",
       " 'seventh',\n",
       " 'component',\n",
       " 'of',\n",
       " 'complement',\n",
       " '(C7)',\n",
       " 'was',\n",
       " 'not',\n",
       " 'detected',\n",
       " 'by',\n",
       " 'functional',\n",
       " 'or',\n",
       " 'immunochemical',\n",
       " 'assays,',\n",
       " 'whereas',\n",
       " 'other',\n",
       " 'components',\n",
       " 'were',\n",
       " 'normal',\n",
       " 'by',\n",
       " 'hemolytic',\n",
       " 'and',\n",
       " 'immunochemical',\n",
       " 'assessment.',\n",
       " 'Her',\n",
       " 'fresh',\n",
       " 'serum',\n",
       " 'lacked',\n",
       " 'complement-mediated',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'against',\n",
       " 'Neisseria',\n",
       " 'gonorrhoeae,',\n",
       " 'but',\n",
       " 'the',\n",
       " 'addition',\n",
       " 'of',\n",
       " 'fresh',\n",
       " 'normal',\n",
       " 'serum',\n",
       " 'or',\n",
       " 'purified',\n",
       " 'C7',\n",
       " 'restored',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'as',\n",
       " 'well',\n",
       " 'as',\n",
       " 'hemolytic',\n",
       " 'activity.',\n",
       " 'The',\n",
       " 'absence',\n",
       " 'of',\n",
       " 'functional',\n",
       " 'C7',\n",
       " 'activity',\n",
       " 'could',\n",
       " 'not',\n",
       " 'be',\n",
       " 'accounted',\n",
       " 'for',\n",
       " 'on',\n",
       " 'the',\n",
       " 'basis',\n",
       " 'of',\n",
       " 'an',\n",
       " 'inhibitor.',\n",
       " 'Opsonization',\n",
       " 'and',\n",
       " 'generation',\n",
       " 'of',\n",
       " 'chemotactic',\n",
       " 'activity',\n",
       " 'functioned',\n",
       " 'normally.',\n",
       " 'Complete',\n",
       " 'absence',\n",
       " 'of',\n",
       " 'C7',\n",
       " 'was',\n",
       " 'also',\n",
       " 'found',\n",
       " 'in',\n",
       " 'one',\n",
       " 'sibling',\n",
       " 'who',\n",
       " 'had',\n",
       " 'the',\n",
       " 'clinical',\n",
       " 'syndrome',\n",
       " 'of',\n",
       " 'meningococcal',\n",
       " 'meningitis',\n",
       " 'and',\n",
       " 'arthritis',\n",
       " 'as',\n",
       " 'a',\n",
       " 'child',\n",
       " 'and',\n",
       " 'in',\n",
       " 'this',\n",
       " 'siblings',\n",
       " 'clinically',\n",
       " 'well',\n",
       " 'eight-year-old',\n",
       " 'son.',\n",
       " 'HLA',\n",
       " 'histocompatibility',\n",
       " 'typing',\n",
       " 'of',\n",
       " 'the',\n",
       " 'family',\n",
       " 'members',\n",
       " 'did',\n",
       " 'not',\n",
       " 'demonstrate',\n",
       " 'evidence',\n",
       " 'for',\n",
       " 'genetic',\n",
       " 'linkage',\n",
       " 'of',\n",
       " 'C7',\n",
       " 'deficiency',\n",
       " 'with',\n",
       " 'the',\n",
       " 'major',\n",
       " 'histocompatibility',\n",
       " 'loci.',\n",
       " 'This',\n",
       " 'report',\n",
       " 'represents',\n",
       " 'the',\n",
       " 'first',\n",
       " 'cases',\n",
       " 'of',\n",
       " 'C7',\n",
       " 'deficiency',\n",
       " 'associated',\n",
       " 'with',\n",
       " 'infectious',\n",
       " 'complications',\n",
       " 'and',\n",
       " 'suggests',\n",
       " 'that',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'may',\n",
       " 'be',\n",
       " 'important',\n",
       " 'in',\n",
       " 'host',\n",
       " 'defense',\n",
       " 'against',\n",
       " 'bacteremic',\n",
       " 'neisseria',\n",
       " 'infections.The',\n",
       " 'authors',\n",
       " 'report',\n",
       " 'a',\n",
       " 'mutation',\n",
       " 'in',\n",
       " 'exon',\n",
       " '5',\n",
       " 'of',\n",
       " 'GCH1',\n",
       " 'in',\n",
       " 'a',\n",
       " 'patient',\n",
       " 'with',\n",
       " 'adult-onset',\n",
       " 'oromandibular',\n",
       " 'dystonia',\n",
       " 'and',\n",
       " 'no',\n",
       " 'obvious',\n",
       " 'family',\n",
       " 'history',\n",
       " 'of',\n",
       " 'dystonia.',\n",
       " 'The',\n",
       " ...]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#stop_words = set(stopwords.words('english')) \n",
    "#line = file.read()# Use this to read file content as a stream: \n",
    "#words = line.split() \n",
    "#for r in words: \n",
    "#    if not r in stop_words: \n",
    "#        appendFile = open('filteredtext.txt','a') \n",
    "#        appendFile.write(\" \"+r) \n",
    "#        appendFile.close() \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#with open('filteredtext.txt',\"r\") as myfile:\n",
    "   # data=myfile.read().replace('\\n', '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "wordsFiltered = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def preprocess(sent):\n",
    "    sent = nltk.word_tokenize(sent)\n",
    "    stopWords = set(stopwords.words('english'))\n",
    "    for w in sent:\n",
    "        if w not in stopWords:\n",
    "            wordsFiltered.append(w)\n",
    "    filteredTags = nltk.pos_tag(sent)\n",
    "    return filteredTags"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "wordsFilter = []\n",
    "def bigramz(text):\n",
    "    for words in text:\n",
    "        if words not in stopWords:\n",
    "            wordsFilter.append(words)\n",
    "    tokens = nltk.word_tokenize(text)\n",
    "    bigrms = nltk.bigrams(tokens)\n",
    "    return bigrms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('WNT', 'NNP'),\n",
       " ('signalling', 'VBG'),\n",
       " ('orchestrates', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('number', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('developmental', 'JJ'),\n",
       " ('programs', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('response', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('this', 'DT'),\n",
       " ('stimulus', 'NN'),\n",
       " (',', ','),\n",
       " ('cytoplasmic', 'JJ'),\n",
       " ('beta-catenin', 'NN'),\n",
       " ('(', '('),\n",
       " ('encoded', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('CTNNB1', 'NNP'),\n",
       " (')', ')'),\n",
       " ('is', 'VBZ'),\n",
       " ('stabilized', 'VBN'),\n",
       " (',', ','),\n",
       " ('enabling', 'VBG'),\n",
       " ('downstream', 'JJ'),\n",
       " ('transcriptional', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('by', 'IN'),\n",
       " ('members', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('LEF/TCF', 'NNP'),\n",
       " ('family', 'NN'),\n",
       " ('.', '.'),\n",
       " ('One', 'CD'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('target', 'NN'),\n",
       " ('genes', 'NNS'),\n",
       " ('for', 'IN'),\n",
       " ('beta-catenin/TCF', 'JJ'),\n",
       " ('encodes', 'NNS'),\n",
       " ('c-MYC', 'JJ'),\n",
       " (',', ','),\n",
       " ('explaining', 'VBG'),\n",
       " ('why', 'WRB'),\n",
       " ('constitutive', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('WNT', 'NNP'),\n",
       " ('pathway', 'NN'),\n",
       " ('can', 'MD'),\n",
       " ('lead', 'VB'),\n",
       " ('to', 'TO'),\n",
       " ('cancer', 'NN'),\n",
       " (',', ','),\n",
       " ('particularly', 'RB'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('colon', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Most', 'JJS'),\n",
       " ('colon', 'NN'),\n",
       " ('cancers', 'NNS'),\n",
       " ('arise', 'VBP'),\n",
       " ('from', 'IN'),\n",
       " ('mutations', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('gene', 'NN'),\n",
       " ('encoding', 'VBG'),\n",
       " ('adenomatous', 'JJ'),\n",
       " ('polyposis', 'NN'),\n",
       " ('coli', 'NN'),\n",
       " ('(', '('),\n",
       " ('APC', 'NNP'),\n",
       " (')', ')'),\n",
       " (',', ','),\n",
       " ('a', 'DT'),\n",
       " ('protein', 'NN'),\n",
       " ('required', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('ubiquitin-mediated', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('beta-catenin', 'NN'),\n",
       " (',', ','),\n",
       " ('but', 'CC'),\n",
       " ('a', 'DT'),\n",
       " ('small', 'JJ'),\n",
       " ('percentage', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('colon', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('some', 'DT'),\n",
       " ('other', 'JJ'),\n",
       " ('cancers', 'NNS'),\n",
       " ('harbour', 'VBP'),\n",
       " ('beta-catenin-stabilizing', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Recently', 'RB'),\n",
       " (',', ','),\n",
       " ('we', 'PRP'),\n",
       " ('discovered', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('transgenic', 'JJ'),\n",
       " ('mice', 'NN'),\n",
       " ('expressing', 'VBG'),\n",
       " ('an', 'DT'),\n",
       " ('activated', 'VBN'),\n",
       " ('beta-catenin', 'NN'),\n",
       " ('are', 'VBP'),\n",
       " ('predisposed', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('developing', 'VBG'),\n",
       " ('skin', 'JJ'),\n",
       " ('tumours', 'NNS'),\n",
       " ('resembling', 'VBG'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Given', 'VBN'),\n",
       " ('that', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('skin', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('adult', 'NN'),\n",
       " ('mice', 'NN'),\n",
       " ('also', 'RB'),\n",
       " ('exhibits', 'VBZ'),\n",
       " ('signs', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('de', 'FW'),\n",
       " ('novo', 'FW'),\n",
       " ('hair-follicle', 'NN'),\n",
       " ('morphogenesis', 'NN'),\n",
       " (',', ','),\n",
       " ('we', 'PRP'),\n",
       " ('wondered', 'VBD'),\n",
       " ('whether', 'IN'),\n",
       " ('human', 'JJ'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('might', 'MD'),\n",
       " ('originate', 'VB'),\n",
       " ('from', 'IN'),\n",
       " ('hair', 'NN'),\n",
       " ('matrix', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('whether', 'IN'),\n",
       " ('they', 'PRP'),\n",
       " ('might', 'MD'),\n",
       " ('possess', 'VB'),\n",
       " ('beta-catenin-stabilizing', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Here', 'RB'),\n",
       " (',', ','),\n",
       " ('we', 'PRP'),\n",
       " ('explore', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('cell', 'NN'),\n",
       " ('origin', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('aetiology', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('common', 'JJ'),\n",
       " ('human', 'JJ'),\n",
       " ('skin', 'FW'),\n",
       " ('tumour', 'NN'),\n",
       " ('.', '.'),\n",
       " ('We', 'PRP'),\n",
       " ('found', 'VBD'),\n",
       " ('nuclear', 'JJ'),\n",
       " ('LEF-1', 'NNP'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('dividing', 'VBG'),\n",
       " ('tumour', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " (',', ','),\n",
       " ('providing', 'VBG'),\n",
       " ('biochemical', 'JJ'),\n",
       " ('evidence', 'NN'),\n",
       " ('that', 'IN'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('are', 'VBP'),\n",
       " ('derived', 'VBN'),\n",
       " ('from', 'IN'),\n",
       " ('hair', 'NN'),\n",
       " ('matrix', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('At', 'IN'),\n",
       " ('least', 'JJS'),\n",
       " ('75', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('these', 'DT'),\n",
       " ('tumours', 'NNS'),\n",
       " ('possess', 'VBP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('affecting', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('amino-terminal', 'JJ'),\n",
       " ('segment', 'NN'),\n",
       " (',', ','),\n",
       " ('normally', 'RB'),\n",
       " ('involved', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('phosphorylation-dependent', 'JJ'),\n",
       " (',', ','),\n",
       " ('ubiquitin-mediated', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('protein', 'NN'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('percentage', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('CTNNB1', 'NNP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('is', 'VBZ'),\n",
       " ('greater', 'JJR'),\n",
       " ('than', 'IN'),\n",
       " ('in', 'IN'),\n",
       " ('all', 'DT'),\n",
       " ('other', 'JJ'),\n",
       " ('human', 'JJ'),\n",
       " ('tumours', 'NNS'),\n",
       " ('examined', 'VBD'),\n",
       " ('thus', 'RB'),\n",
       " ('far', 'RB'),\n",
       " (',', ','),\n",
       " ('and', 'CC'),\n",
       " ('directly', 'RB'),\n",
       " ('implicates', 'VBZ'),\n",
       " ('beta-catenin/LEF', 'JJ'),\n",
       " ('misregulation', 'NN'),\n",
       " ('as', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('major', 'JJ'),\n",
       " ('cause', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('hair', 'NN'),\n",
       " ('matrix', 'NN'),\n",
       " ('cell', 'NN'),\n",
       " ('tumorigenesis', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('humans..', 'JJ'),\n",
       " ('Hereditary', 'NNP'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('(', '('),\n",
       " ('HH', 'NNP'),\n",
       " (')', ')'),\n",
       " ('is', 'VBZ'),\n",
       " ('a', 'DT'),\n",
       " ('common', 'JJ'),\n",
       " ('autosomal', 'JJ'),\n",
       " ('recessive', 'JJ'),\n",
       " ('genetic', 'JJ'),\n",
       " ('disorder', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('iron', 'NN'),\n",
       " ('metabolism', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('HFE', 'NNP'),\n",
       " ('candidate', 'NN'),\n",
       " ('gene', 'NN'),\n",
       " ('encoding', 'VBG'),\n",
       " ('an', 'DT'),\n",
       " ('HLA', 'NNP'),\n",
       " ('class', 'NN'),\n",
       " ('I-like', 'NNP'),\n",
       " ('protein', 'NN'),\n",
       " ('involved', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('HH', 'NNP'),\n",
       " ('was', 'VBD'),\n",
       " ('identified', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('1996', 'CD'),\n",
       " ('.', '.'),\n",
       " ('Two', 'CD'),\n",
       " ('missense', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('have', 'VBP'),\n",
       " ('been', 'VBN'),\n",
       " ('described', 'VBN'),\n",
       " ('C282Y', 'NNP'),\n",
       " (',', ','),\n",
       " ('accounting', 'VBG'),\n",
       " ('for', 'IN'),\n",
       " ('80', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('90', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " (',', ','),\n",
       " ('and', 'CC'),\n",
       " ('H63D', 'NNP'),\n",
       " (',', ','),\n",
       " ('which', 'WDT'),\n",
       " ('is', 'VBZ'),\n",
       " ('associated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('milder', 'NN'),\n",
       " ('form', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('disease', 'NN'),\n",
       " ('representing', 'VBG'),\n",
       " ('40', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('70', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('non-C282Y', 'JJ'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('We', 'PRP'),\n",
       " ('report', 'VBP'),\n",
       " ('here', 'RB'),\n",
       " ('on', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('analysis', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('C282Y', 'NNP'),\n",
       " (',', ','),\n",
       " ('H63D', 'NNP'),\n",
       " (',', ','),\n",
       " ('and', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('193A', 'CD'),\n",
       " ('--', ':'),\n",
       " ('>', 'JJ'),\n",
       " ('T', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('leading', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('the', 'DT'),\n",
       " ('S65C', 'NNP'),\n",
       " ('missense', 'NN'),\n",
       " ('substitution', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('large', 'JJ'),\n",
       " ('series', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('probands', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('controls', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('results', 'NNS'),\n",
       " ('confirm', 'VBP'),\n",
       " ('that', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('main', 'JJ'),\n",
       " ('mutation', 'NN'),\n",
       " ('involved', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " (',', ','),\n",
       " ('accounting', 'VBG'),\n",
       " ('for', 'IN'),\n",
       " ('85', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('carrier', 'NN'),\n",
       " ('chromosomes', 'NNS'),\n",
       " (',', ','),\n",
       " ('whereas', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('H63D', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('represented', 'VBD'),\n",
       " ('39', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('did', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('carry', 'VB'),\n",
       " ('the', 'DT'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('mutation', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('addition', 'NN'),\n",
       " (',', ','),\n",
       " ('our', 'PRP$'),\n",
       " ('screening', 'NN'),\n",
       " ('showed', 'VBD'),\n",
       " ('that', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('S65C', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('significantly', 'RB'),\n",
       " ('enriched', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('probands', 'NNS'),\n",
       " ('with', 'IN'),\n",
       " ('at', 'IN'),\n",
       " ('least', 'JJS'),\n",
       " ('one', 'CD'),\n",
       " ('chromosome', 'NN'),\n",
       " ('without', 'IN'),\n",
       " ('an', 'DT'),\n",
       " ('assigned', 'JJ'),\n",
       " ('mutation', 'NN'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('substitution', 'NN'),\n",
       " ('accounted', 'VBD'),\n",
       " ('for', 'IN'),\n",
       " ('7', 'CD'),\n",
       " ('.', '.'),\n",
       " ('8', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('that', 'WDT'),\n",
       " ('were', 'VBD'),\n",
       " ('neither', 'DT'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('nor', 'CC'),\n",
       " ('H63D', 'NNP'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('enrichment', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('S65C', 'NNP'),\n",
       " ('among', 'IN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('suggests', 'VBZ'),\n",
       " ('that', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('S65C', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('is', 'VBZ'),\n",
       " ('associated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('mild', 'JJ'),\n",
       " ('form', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('objective', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('study', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('to', 'TO'),\n",
       " ('provide', 'VB'),\n",
       " ('more', 'JJR'),\n",
       " ('accurate', 'JJ'),\n",
       " ('frequency', 'NN'),\n",
       " ('estimates', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('breast', 'NN'),\n",
       " ('cancer', 'NN'),\n",
       " ('susceptibility', 'NN'),\n",
       " ('gene', 'NN'),\n",
       " ('1', 'CD'),\n",
       " ('(', '('),\n",
       " ('BRCA1', 'NNP'),\n",
       " (')', ')'),\n",
       " ('germline', 'NN'),\n",
       " ('alterations', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('population', 'NN'),\n",
       " ('.', '.'),\n",
       " ('To', 'TO'),\n",
       " ('achieve', 'VB'),\n",
       " ('this', 'DT'),\n",
       " (',', ','),\n",
       " ('we', 'PRP'),\n",
       " ('determined', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('prevalence', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('population-based', 'JJ'),\n",
       " ('series', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('consecutive', 'JJ'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('is', 'VBZ'),\n",
       " ('the', 'DT'),\n",
       " ('first', 'JJ'),\n",
       " ('population-based', 'JJ'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('study', 'NN'),\n",
       " ('reporting', 'VBG'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('derived', 'VBD'),\n",
       " ('from', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('comprehensive', 'JJ'),\n",
       " ('screen', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('entire', 'JJ'),\n",
       " ('coding', 'NN'),\n",
       " ('region', 'NN'),\n",
       " ('.', '.'),\n",
       " ('One', 'CD'),\n",
       " ('hundred', 'CD'),\n",
       " ('and', 'CC'),\n",
       " ('seven', 'CD'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('analyzed', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('using', 'VBG'),\n",
       " ('the', 'DT'),\n",
       " ('RNase', 'NNP'),\n",
       " ('mismatch', 'NN'),\n",
       " ('cleavage', 'NN'),\n",
       " ('assay', 'VBP'),\n",
       " ('followed', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('direct', 'JJ'),\n",
       " ('sequencing', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Two', 'CD'),\n",
       " ('truncating', 'VBG'),\n",
       " ('mutations', 'NNS'),\n",
       " (',', ','),\n",
       " ('962del4', 'CD'),\n",
       " ('and', 'CC'),\n",
       " ('3600del11', 'CD'),\n",
       " (',', ','),\n",
       " ('were', 'VBD'),\n",
       " ('identified', 'VBN'),\n",
       " ('.', '.'),\n",
       " ('Both', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('had', 'VBD'),\n",
       " ('a', 'DT'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('breast', 'NN'),\n",
       " ('or', 'CC'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Several', 'JJ'),\n",
       " ('novel', 'NN'),\n",
       " ('as', 'RB'),\n",
       " ('well', 'RB'),\n",
       " ('as', 'IN'),\n",
       " ('previously', 'RB'),\n",
       " ('reported', 'VBN'),\n",
       " ('uncharacterized', 'JJ'),\n",
       " ('variants', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('also', 'RB'),\n",
       " ('identified', 'VBN'),\n",
       " (',', ','),\n",
       " ('some', 'DT'),\n",
       " ('of', 'IN'),\n",
       " ('which', 'WDT'),\n",
       " ('were', 'VBD'),\n",
       " ('associated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('cancer', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('frequency', 'NN'),\n",
       " ('distribution', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('common', 'JJ'),\n",
       " ('polymorphisms', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('determined', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('91', 'CD'),\n",
       " ('Caucasian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('series', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('24', 'CD'),\n",
       " ('sister', 'NN'),\n",
       " ('controls', 'NNS'),\n",
       " ('using', 'VBG'),\n",
       " ('allele-specific', 'JJ'),\n",
       " ('amplification', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('rare', 'JJ'),\n",
       " ('form', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('Q356R', 'NNP'),\n",
       " ('polymorphism', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('significantly', 'RB'),\n",
       " ('(', '('),\n",
       " ('P', 'NNP'),\n",
       " ('=', 'VBZ'),\n",
       " ('0', 'CD'),\n",
       " ('.', '.'),\n",
       " ('03', 'CD'),\n",
       " (')', ')'),\n",
       " ('associated', 'VBN'),\n",
       " ('with', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " (',', ','),\n",
       " ('suggesting', 'VBG'),\n",
       " ('that', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('polymorphism', 'NN'),\n",
       " ('may', 'MD'),\n",
       " ('influence', 'VB'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('risk', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('summary', 'JJ'),\n",
       " (',', ','),\n",
       " ('our', 'PRP$'),\n",
       " ('data', 'NNS'),\n",
       " ('suggest', 'VBP'),\n",
       " ('a', 'DT'),\n",
       " ('role', 'NN'),\n",
       " ('for', 'IN'),\n",
       " ('some', 'DT'),\n",
       " ('uncharacterized', 'JJ'),\n",
       " ('variants', 'NNS'),\n",
       " ('and', 'CC'),\n",
       " ('rare', 'JJ'),\n",
       " ('forms', 'NNS'),\n",
       " ('of', 'IN'),\n",
       " ('polymorphisms', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('determining', 'VBG'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('risk', 'NN'),\n",
       " (',', ','),\n",
       " ('and', 'CC'),\n",
       " ('highlight', 'VBD'),\n",
       " ('the', 'DT'),\n",
       " ('necessity', 'NN'),\n",
       " ('to', 'TO'),\n",
       " ('screen', 'VB'),\n",
       " ('for', 'IN'),\n",
       " ('missense', 'JJ'),\n",
       " ('alterations', 'NNS'),\n",
       " ('as', 'RB'),\n",
       " ('well', 'RB'),\n",
       " ('as', 'IN'),\n",
       " ('truncating', 'VBG'),\n",
       " ('mutations', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('this', 'DT'),\n",
       " ('population', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('adenomatous', 'JJ'),\n",
       " ('polyposis', 'NN'),\n",
       " ('coli', 'NN'),\n",
       " ('(', '('),\n",
       " ('APC', 'NNP'),\n",
       " (')', ')'),\n",
       " ('tumour-suppressor', 'NN'),\n",
       " ('protein', 'NN'),\n",
       " ('controls', 'VBZ'),\n",
       " ('the', 'DT'),\n",
       " ('Wnt', 'NNP'),\n",
       " ('signalling', 'VBG'),\n",
       " ('pathway', 'RB'),\n",
       " ('by', 'IN'),\n",
       " ('forming', 'VBG'),\n",
       " ('a', 'DT'),\n",
       " ('complex', 'JJ'),\n",
       " ('with', 'IN'),\n",
       " ('glycogen', 'NN'),\n",
       " ('synthase', 'NN'),\n",
       " ('kinase', 'NN'),\n",
       " ('3beta', 'CD'),\n",
       " ('(', '('),\n",
       " ('GSK-3beta', 'NNP'),\n",
       " (')', ')'),\n",
       " (',', ','),\n",
       " ('axin/conductin', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Complex', 'JJ'),\n",
       " ('formation', 'NN'),\n",
       " ('induces', 'VBZ'),\n",
       " ('the', 'DT'),\n",
       " ('rapid', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('colon', 'NN'),\n",
       " ('carcinoma', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " (',', ','),\n",
       " ('loss', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('APC', 'NNP'),\n",
       " ('leads', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('the', 'DT'),\n",
       " ('accumulation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('in', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('nucleus', 'NN'),\n",
       " (',', ','),\n",
       " ('where', 'WRB'),\n",
       " ('it', 'PRP'),\n",
       " ('binds', 'VBZ'),\n",
       " ('to', 'TO'),\n",
       " ('and', 'CC'),\n",
       " ('activates', 'VBZ'),\n",
       " ('the', 'DT'),\n",
       " ('Tcf-4', 'JJ'),\n",
       " ('transcription', 'NN'),\n",
       " ('factor', 'NN'),\n",
       " ('(', '('),\n",
       " ('reviewed', 'VBN'),\n",
       " ('in', 'IN'),\n",
       " ('[', 'JJ'),\n",
       " ('1', 'CD'),\n",
       " (']', 'JJ'),\n",
       " ('[', '$'),\n",
       " ('2', 'CD'),\n",
       " (']', 'NN'),\n",
       " (')', ')'),\n",
       " ('.', '.'),\n",
       " ('Here', 'RB'),\n",
       " (',', ','),\n",
       " ('we', 'PRP'),\n",
       " ('report', 'VBP'),\n",
       " ('the', 'DT'),\n",
       " ('identification', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('genomic', 'JJ'),\n",
       " ('structure', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('APC', 'NNP'),\n",
       " ('homologues', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Mammalian', 'JJ'),\n",
       " ('APC2', 'NNP'),\n",
       " (',', ','),\n",
       " ('which', 'WDT'),\n",
       " ('closely', 'RB'),\n",
       " ('resembles', 'VBZ'),\n",
       " ('APC', 'NNP'),\n",
       " ('in', 'IN'),\n",
       " ('overall', 'JJ'),\n",
       " ('domain', 'NN'),\n",
       " ('structure', 'NN'),\n",
       " (',', ','),\n",
       " ('was', 'VBD'),\n",
       " ('functionally', 'RB'),\n",
       " ('analyzed', 'VBN'),\n",
       " ('and', 'CC'),\n",
       " ('shown', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('contain', 'VB'),\n",
       " ('two', 'CD'),\n",
       " ('SAMP', 'NNP'),\n",
       " ('domains', 'NNS'),\n",
       " (',', ','),\n",
       " ('both', 'DT'),\n",
       " ('of', 'IN'),\n",
       " ('which', 'WDT'),\n",
       " ('are', 'VBP'),\n",
       " ('required', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('binding', 'VBG'),\n",
       " ('to', 'TO'),\n",
       " ('conductin', 'VB'),\n",
       " ('.', '.'),\n",
       " ('Like', 'IN'),\n",
       " ('APC', 'NNP'),\n",
       " (',', ','),\n",
       " ('APC2', 'NNP'),\n",
       " ('regulates', 'VBZ'),\n",
       " ('the', 'DT'),\n",
       " ('formation', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('active', 'JJ'),\n",
       " ('betacatenin-Tcf', 'NN'),\n",
       " ('complexes', 'NNS'),\n",
       " (',', ','),\n",
       " ('as', 'IN'),\n",
       " ('demonstrated', 'VBN'),\n",
       " ('using', 'VBG'),\n",
       " ('transient', 'JJ'),\n",
       " ('transcriptional', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('assays', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('APC', 'NNP'),\n",
       " ('-/-', 'NNP'),\n",
       " ('colon', 'NN'),\n",
       " ('carcinoma', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Human', 'NNP'),\n",
       " ('APC2', 'NNP'),\n",
       " ('maps', 'NNS'),\n",
       " ('to', 'TO'),\n",
       " ('chromosome', 'VB'),\n",
       " ('19p13', 'CD'),\n",
       " ('.', '.'),\n",
       " ('3', 'CD'),\n",
       " ('.', '.'),\n",
       " ('APC', 'NNP'),\n",
       " ('and', 'CC'),\n",
       " ('APC2', 'NNP'),\n",
       " ('may', 'MD'),\n",
       " ('therefore', 'RB'),\n",
       " ('have', 'VB'),\n",
       " ('comparable', 'JJ'),\n",
       " ('functions', 'NNS'),\n",
       " ('in', 'IN'),\n",
       " ('development', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('cancer.The', 'NN'),\n",
       " ('serum', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('29-year', 'JJ'),\n",
       " ('old', 'JJ'),\n",
       " ('woman', 'NN'),\n",
       " ('with', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('recent', 'JJ'),\n",
       " ('episode', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('disseminated', 'JJ'),\n",
       " ('gonococcal', 'JJ'),\n",
       " ('infection', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('a', 'DT'),\n",
       " ('history', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('meningococcal', 'JJ'),\n",
       " ('meningitis', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ('arthritis', 'NN'),\n",
       " ('as', 'IN'),\n",
       " ('a', 'DT'),\n",
       " ('child', 'NN'),\n",
       " ('was', 'VBD'),\n",
       " ('found', 'VBN'),\n",
       " ('to', 'TO'),\n",
       " ('lack', 'VB'),\n",
       " ('serum', 'JJ'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('complement', 'NN'),\n",
       " ('activity', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('seventh', 'JJ'),\n",
       " ('component', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('complement', 'NN'),\n",
       " ('(', '('),\n",
       " ('C7', 'NNP'),\n",
       " (')', ')'),\n",
       " ('was', 'VBD'),\n",
       " ('not', 'RB'),\n",
       " ('detected', 'VBN'),\n",
       " ('by', 'IN'),\n",
       " ('functional', 'JJ'),\n",
       " ('or', 'CC'),\n",
       " ('immunochemical', 'JJ'),\n",
       " ('assays', 'NNS'),\n",
       " (',', ','),\n",
       " ('whereas', 'IN'),\n",
       " ('other', 'JJ'),\n",
       " ('components', 'NNS'),\n",
       " ('were', 'VBD'),\n",
       " ('normal', 'JJ'),\n",
       " ('by', 'IN'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('and', 'CC'),\n",
       " ('immunochemical', 'JJ'),\n",
       " ('assessment', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Her', 'PRP$'),\n",
       " ('fresh', 'JJ'),\n",
       " ('serum', 'NN'),\n",
       " ('lacked', 'VBD'),\n",
       " ('complement-mediated', 'JJ'),\n",
       " ('bactericidal', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('against', 'IN'),\n",
       " ('Neisseria', 'NNP'),\n",
       " ('gonorrhoeae', 'NN'),\n",
       " (',', ','),\n",
       " ('but', 'CC'),\n",
       " ('the', 'DT'),\n",
       " ('addition', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('fresh', 'JJ'),\n",
       " ('normal', 'JJ'),\n",
       " ('serum', 'NN'),\n",
       " ('or', 'CC'),\n",
       " ('purified', 'VBN'),\n",
       " ('C7', 'NNP'),\n",
       " ('restored', 'VBD'),\n",
       " ('bactericidal', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('as', 'RB'),\n",
       " ('well', 'RB'),\n",
       " ('as', 'IN'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('absence', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('functional', 'JJ'),\n",
       " ('C7', 'NNP'),\n",
       " ('activity', 'NN'),\n",
       " ('could', 'MD'),\n",
       " ('not', 'RB'),\n",
       " ('be', 'VB'),\n",
       " ('accounted', 'VBN'),\n",
       " ('for', 'IN'),\n",
       " ('on', 'IN'),\n",
       " ('the', 'DT'),\n",
       " ('basis', 'NN'),\n",
       " ('of', 'IN'),\n",
       " ('an', 'DT'),\n",
       " ('inhibitor', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Opsonization', 'NN'),\n",
       " ('and', 'CC'),\n",
       " ...]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokens = preprocess(lines)\n",
    "tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<generator object bigrams at 0x000001A8915A9888>"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bigrms = bigramz(lines)\n",
    "bigrms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'stuti' == 'stuti'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "tokens = ['one','two']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "dictio = ['one','two','three']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "one one\n",
      "one two\n",
      "one three\n",
      "two one\n",
      "two two\n",
      "two three\n"
     ]
    }
   ],
   "source": [
    "listk =[]\n",
    "for t in tokens:\n",
    "    for d in dictio:\n",
    "        if t == d:\n",
    "            print(t,d)\n",
    "            listk.append(t)\n",
    "        else:\n",
    "            print(t,d)\n",
    "            listk.append(0)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['one', 0, 0, 0, 'two', 0]"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "listk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WNT signalling, signalling orchestrates, orchestrates a, a number, number of, of developmental, developmental programs, programs ., . In, In response, response to, to this, this stimulus, stimulus ,, , cytoplasmic, cytoplasmic beta-catenin, beta-catenin (, ( encoded, encoded by, by CTNNB1, CTNNB1 ), ) is, is stabilized, stabilized ,, , enabling, enabling downstream, downstream transcriptional, transcriptional activation, activation by, by members, members of, of the, the LEF/TCF, LEF/TCF family, family ., . One, One of, of the, the target, target genes, genes for, for beta-catenin/TCF, beta-catenin/TCF encodes, encodes c-MYC, c-MYC ,, , explaining, explaining why, why constitutive, constitutive activation, activation of, of the, the WNT, WNT pathway, pathway can, can lead, lead to, to cancer, cancer ,, , particularly, particularly in, in the, the colon, colon ., . Most, Most colon, colon cancers, cancers arise, arise from, from mutations, mutations in, in the, the gene, gene encoding, encoding adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) ,, , a, a protein, protein required, required for, for ubiquitin-mediated, ubiquitin-mediated degradation, degradation of, of beta-catenin, beta-catenin ,, , but, but a, a small, small percentage, percentage of, of colon, colon and, and some, some other, other cancers, cancers harbour, harbour beta-catenin-stabilizing, beta-catenin-stabilizing mutations, mutations ., . Recently, Recently ,, , we, we discovered, discovered that, that transgenic, transgenic mice, mice expressing, expressing an, an activated, activated beta-catenin, beta-catenin are, are predisposed, predisposed to, to developing, developing skin, skin tumours, tumours resembling, resembling pilomatricomas, pilomatricomas ., . Given, Given that, that the, the skin, skin of, of these, these adult, adult mice, mice also, also exhibits, exhibits signs, signs of, of de, de novo, novo hair-follicle, hair-follicle morphogenesis, morphogenesis ,, , we, we wondered, wondered whether, whether human, human pilomatricomas, pilomatricomas might, might originate, originate from, from hair, hair matrix, matrix cells, cells and, and whether, whether they, they might, might possess, possess beta-catenin-stabilizing, beta-catenin-stabilizing mutations, mutations ., . Here, Here ,, , we, we explore, explore the, the cell, cell origin, origin and, and aetiology, aetiology of, of this, this common, common human, human skin, skin tumour, tumour ., . We, We found, found nuclear, nuclear LEF-1, LEF-1 in, in the, the dividing, dividing tumour, tumour cells, cells ,, , providing, providing biochemical, biochemical evidence, evidence that, that pilomatricomas, pilomatricomas are, are derived, derived from, from hair, hair matrix, matrix cells, cells ., . At, At least, least 75, 75 %, % of, of these, these tumours, tumours possess, possess mutations, mutations affecting, affecting the, the amino-terminal, amino-terminal segment, segment ,, , normally, normally involved, involved in, in phosphorylation-dependent, phosphorylation-dependent ,, , ubiquitin-mediated, ubiquitin-mediated degradation, degradation of, of the, the protein, protein ., . This, This percentage, percentage of, of CTNNB1, CTNNB1 mutations, mutations is, is greater, greater than, than in, in all, all other, other human, human tumours, tumours examined, examined thus, thus far, far ,, , and, and directly, directly implicates, implicates beta-catenin/LEF, beta-catenin/LEF misregulation, misregulation as, as the, the major, major cause, cause of, of hair, hair matrix, matrix cell, cell tumorigenesis, tumorigenesis in, in humans.., humans.. Hereditary, Hereditary hemochromatosis, hemochromatosis (, ( HH, HH ), ) is, is a, a common, common autosomal, autosomal recessive, recessive genetic, genetic disorder, disorder of, of iron, iron metabolism, metabolism ., . The, The HFE, HFE candidate, candidate gene, gene encoding, encoding an, an HLA, HLA class, class I-like, I-like protein, protein involved, involved in, in HH, HH was, was identified, identified in, in 1996, 1996 ., . Two, Two missense, missense mutations, mutations have, have been, been described, described C282Y, C282Y ,, , accounting, accounting for, for 80, 80 %, % to, to 90, 90 %, % of, of HH, HH chromosomes, chromosomes ,, , and, and H63D, H63D ,, , which, which is, is associated, associated with, with a, a milder, milder form, form of, of the, the disease, disease representing, representing 40, 40 %, % to, to 70, 70 %, % of, of non-C282Y, non-C282Y HH, HH chromosomes, chromosomes ., . We, We report, report here, here on, on the, the analysis, analysis of, of C282Y, C282Y ,, , H63D, H63D ,, , and, and the, the 193A, 193A --, -- >, > T, T substitution, substitution leading, leading to, to the, the S65C, S65C missense, missense substitution, substitution in, in a, a large, large series, series of, of probands, probands and, and controls, controls ., . The, The results, results confirm, confirm that, that the, the C282Y, C282Y substitution, substitution was, was the, the main, main mutation, mutation involved, involved in, in hemochromatosis, hemochromatosis ,, , accounting, accounting for, for 85, 85 %, % of, of carrier, carrier chromosomes, chromosomes ,, , whereas, whereas the, the H63D, H63D substitution, substitution represented, represented 39, 39 %, % of, of the, the HH, HH chromosomes, chromosomes that, that did, did not, not carry, carry the, the C282Y, C282Y mutation, mutation ., . In, In addition, addition ,, , our, our screening, screening showed, showed that, that the, the S65C, S65C substitution, substitution was, was significantly, significantly enriched, enriched in, in probands, probands with, with at, at least, least one, one chromosome, chromosome without, without an, an assigned, assigned mutation, mutation ., . This, This substitution, substitution accounted, accounted for, for 7, 7 ., . 8, 8 %, % of, of HH, HH chromosomes, chromosomes that, that were, were neither, neither C282Y, C282Y nor, nor H63D, H63D ., . This, This enrichment, enrichment of, of S65C, S65C among, among HH, HH chromosomes, chromosomes suggests, suggests that, that the, the S65C, S65C substitution, substitution is, is associated, associated with, with the, the mild, mild form, form of, of hemochromatosis, hemochromatosis ., . The, The objective, objective of, of this, this study, study was, was to, to provide, provide more, more accurate, accurate frequency, frequency estimates, estimates of, of breast, breast cancer, cancer susceptibility, susceptibility gene, gene 1, 1 (, ( BRCA1, BRCA1 ), ) germline, germline alterations, alterations in, in the, the ovarian, ovarian cancer, cancer population, population ., . To, To achieve, achieve this, this ,, , we, we determined, determined the, the prevalence, prevalence of, of BRCA1, BRCA1 alterations, alterations in, in a, a population-based, population-based series, series of, of consecutive, consecutive ovarian, ovarian cancer, cancer cases, cases ., . This, This is, is the, the first, first population-based, population-based ovarian, ovarian cancer, cancer study, study reporting, reporting BRCA1, BRCA1 alterations, alterations derived, derived from, from a, a comprehensive, comprehensive screen, screen of, of the, the entire, entire coding, coding region, region ., . One, One hundred, hundred and, and seven, seven ovarian, ovarian cancer, cancer cases, cases were, were analyzed, analyzed for, for BRCA1, BRCA1 alterations, alterations using, using the, the RNase, RNase mismatch, mismatch cleavage, cleavage assay, assay followed, followed by, by direct, direct sequencing, sequencing ., . Two, Two truncating, truncating mutations, mutations ,, , 962del4, 962del4 and, and 3600del11, 3600del11 ,, , were, were identified, identified ., . Both, Both patients, patients had, had a, a family, family history, history of, of breast, breast or, or ovarian, ovarian cancer, cancer ., . Several, Several novel, novel as, as well, well as, as previously, previously reported, reported uncharacterized, uncharacterized variants, variants were, were also, also identified, identified ,, , some, some of, of which, which were, were associated, associated with, with a, a family, family history, history of, of cancer, cancer ., . The, The frequency, frequency distribution, distribution of, of common, common polymorphisms, polymorphisms was, was determined, determined in, in the, the 91, 91 Caucasian, Caucasian cancer, cancer cases, cases in, in this, this series, series and, and 24, 24 sister, sister controls, controls using, using allele-specific, allele-specific amplification, amplification ., . The, The rare, rare form, form of, of the, the Q356R, Q356R polymorphism, polymorphism was, was significantly, significantly (, ( P, P =, = 0, 0 ., . 03, 03 ), ) associated, associated with, with a, a family, family history, history of, of ovarian, ovarian cancer, cancer ,, , suggesting, suggesting that, that this, this polymorphism, polymorphism may, may influence, influence ovarian, ovarian cancer, cancer risk, risk ., . In, In summary, summary ,, , our, our data, data suggest, suggest a, a role, role for, for some, some uncharacterized, uncharacterized variants, variants and, and rare, rare forms, forms of, of polymorphisms, polymorphisms in, in determining, determining ovarian, ovarian cancer, cancer risk, risk ,, , and, and highlight, highlight the, the necessity, necessity to, to screen, screen for, for missense, missense alterations, alterations as, as well, well as, as truncating, truncating mutations, mutations in, in this, this population, population ., . The, The adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) tumour-suppressor, tumour-suppressor protein, protein controls, controls the, the Wnt, Wnt signalling, signalling pathway, pathway by, by forming, forming a, a complex, complex with, with glycogen, glycogen synthase, synthase kinase, kinase 3beta, 3beta (, ( GSK-3beta, GSK-3beta ), ) ,, , axin/conductin, axin/conductin and, and betacatenin, betacatenin ., . Complex, Complex formation, formation induces, induces the, the rapid, rapid degradation, degradation of, of betacatenin, betacatenin ., . In, In colon, colon carcinoma, carcinoma cells, cells ,, , loss, loss of, of APC, APC leads, leads to, to the, the accumulation, accumulation of, of betacatenin, betacatenin in, in the, the nucleus, nucleus ,, , where, where it, it binds, binds to, to and, and activates, activates the, the Tcf-4, Tcf-4 transcription, transcription factor, factor (, ( reviewed, reviewed in, in [, [ 1, 1 ], ] [, [ 2, 2 ], ] ), ) ., . Here, Here ,, , we, we report, report the, the identification, identification and, and genomic, genomic structure, structure of, of APC, APC homologues, homologues ., . Mammalian, Mammalian APC2, APC2 ,, , which, which closely, closely resembles, resembles APC, APC in, in overall, overall domain, domain structure, structure ,, , was, was functionally, functionally analyzed, analyzed and, and shown, shown to, to contain, contain two, two SAMP, SAMP domains, domains ,, , both, both of, of which, which are, are required, required for, for binding, binding to, to conductin, conductin ., . Like, Like APC, APC ,, , APC2, APC2 regulates, regulates the, the formation, formation of, of active, active betacatenin-Tcf, betacatenin-Tcf complexes, complexes ,, , as, as demonstrated, demonstrated using, using transient, transient transcriptional, transcriptional activation, activation assays, assays in, in APC, APC -/-, -/- colon, colon carcinoma, carcinoma cells, cells ., . Human, Human APC2, APC2 maps, maps to, to chromosome, chromosome 19p13, 19p13 ., . 3, 3 ., . APC, APC and, and APC2, APC2 may, may therefore, therefore have, have comparable, comparable functions, functions in, in development, development and, and cancer.The, cancer.The serum, serum of, of a, a 29-year, 29-year old, old woman, woman with, with a, a recent, recent episode, episode of, of disseminated, disseminated gonococcal, gonococcal infection, infection and, and a, a history, history of, of meningococcal, meningococcal meningitis, meningitis and, and arthritis, arthritis as, as a, a child, child was, was found, found to, to lack, lack serum, serum hemolytic, hemolytic complement, complement activity, activity ., . The, The seventh, seventh component, component of, of complement, complement (, ( C7, C7 ), ) was, was not, not detected, detected by, by functional, functional or, or immunochemical, immunochemical assays, assays ,, , whereas, whereas other, other components, components were, were normal, normal by, by hemolytic, hemolytic and, and immunochemical, immunochemical assessment, assessment ., . Her, Her fresh, fresh serum, serum lacked, lacked complement-mediated, complement-mediated bactericidal, bactericidal activity, activity against, against Neisseria, Neisseria gonorrhoeae, gonorrhoeae ,, , but, but the, the addition, addition of, of fresh, fresh normal, normal serum, serum or, or purified, purified C7, C7 restored, restored bactericidal, bactericidal activity, activity as, as well, well as, as hemolytic, hemolytic activity, activity ., . The, The absence, absence of, of functional, functional C7, C7 activity, activity could, could not, not be, be accounted, accounted for, for on, on the, the basis, basis of, of an, an inhibitor, inhibitor ., . Opsonization, Opsonization and, and generation, generation of, of chemotactic, chemotactic activity, activity functioned, functioned normally, normally ., . Complete, Complete absence, absence of, of C7, C7 was, was also, also found, found in, in one, one sibling, sibling who, who had, had the, the clinical, clinical syndrome, syndrome of, of meningococcal, meningococcal meningitis, meningitis and, and arthritis, arthritis as, as a, a child, child and, and in, in this, this siblings, siblings clinically, clinically well, well eight-year-old, eight-year-old son, son ., . HLA, HLA histocompatibility, histocompatibility typing, typing of, of the, the family, family members, members did, did not, not demonstrate, demonstrate evidence, evidence for, for genetic, genetic linkage, linkage of, of C7, C7 deficiency, deficiency with, with the, the major, major histocompatibility, histocompatibility loci, loci ., . This, This report, report represents, represents the, the first, first cases, cases of, of C7, C7 deficiency, deficiency associated, associated with, with infectious, infectious complications, complications and, and suggests, suggests that, that bactericidal, bactericidal activity, activity may, may be, be important, important in, in host, host defense, defense against, against bacteremic, bacteremic neisseria, neisseria infections.The, infections.The authors, authors report, report a, a mutation, mutation in, in exon, exon 5, 5 of, of GCH1, GCH1 in, in a, a patient, patient with, with adult-onset, adult-onset oromandibular, oromandibular dystonia, dystonia and, and no, no obvious, obvious family, family history, history of, of dystonia, dystonia ., . The, The patient, patient responded, responded positively, positively to, to treatment, treatment with, with L-dopa, L-dopa ., . These, These findings, findings demonstrate, demonstrate that, that GCH1, GCH1 mutations, mutations must, must be, be considered, considered even, even in, in patients, patients with, with dystonic, dystonic symptoms, symptoms not, not typical, typical of, of dopa-responsive, dopa-responsive dystonia.HFE, dystonia.HFE is, is the, the protein, protein product, product of, of the, the gene, gene mutated, mutated in, in the, the autosomal, autosomal recessive, recessive disease, disease hereditary, hereditary hemochromatosis, hemochromatosis (, ( Feder, Feder ,, , J., J. N., N. ,, , Gnirke, Gnirke ,, , A., A. ,, , Thomas, Thomas ,, , W., W. ,, , Tsuchihashi, Tsuchihashi ,, , Z., Z. ,, , Ruddy, Ruddy ,, , D., D. A., A. ,, , Basava, Basava ,, , A., A. ,, , Dormishian, Dormishian ,, , F., F. ,, , Domingo, Domingo ,, , R., R. J., J. ,, , Ellis, Ellis ,, , M., M. C., C. ,, , Fullan, Fullan ,, , A., A. ,, , Hinton, Hinton ,, , L., L. M., M. ,, , Jones, Jones ,, , N., N. L., L. ,, , Kimmel, Kimmel ,, , B., B. E., E. ,, , Kronmal, Kronmal ,, , G., G. S., S. ,, , Lauer, Lauer ,, , P., P. ,, , Lee, Lee ,, , V., V. K., K. ,, , Loeb, Loeb ,, , D., D. B., B. ,, , Mapa, Mapa ,, , F., F. A., A. ,, , McClelland, McClelland ,, , E., E. ,, , Meyer, Meyer ,, , N., N. C., C. ,, , Mintier, Mintier ,, , G., G. A., A. ,, , Moeller, Moeller ,, , N., N. ,, , Moore, Moore ,, , T., T. ,, , Morikang, Morikang ,, , E., E. ,, , Prasss, Prasss ,, , C., C. E, E ., . ,, , Quintana, Quintana ,, , L., L. ,, , Starnes, Starnes ,, , S., S. M, M ., . ,, , Schatzman, Schatzman ,, , R., R. C, C ., . ,, , Brunke, Brunke ,, , K., K. J, J ., . ,, , Drayna, Drayna ,, , D., D. T., T. ,, , Risch, Risch ,, , N., N. J, J ., . ,, , Bacon, Bacon ,, , B., B. R, R ., . ,, , and, and Wolff, Wolff ,, , R., R. R, R ., . (, ( 1996, 1996 ), ) Nat, Nat ., . Genet, Genet ., . 13, 13 ,, , 399-408, 399-408 ), ) ., . At, At the, the cell, cell surface, surface ,, , HFE, HFE complexes, complexes with, with transferrin, transferrin receptor, receptor (, ( TfR, TfR ), ) ,, , increasing, increasing the, the dissociation, dissociation constant, constant of, of transferrin, transferrin (, ( Tf, Tf ), ) for, for its, its receptor, receptor 10-fold, 10-fold (, ( Gross, Gross ,, , C., C. N, N ., . ,, , Irrinki, Irrinki ,, , A., A. ,, , Feder, Feder ,, , J., J. N, N ., . ,, , and, and Enns, Enns ,, , C., C. A, A ., . (, ( 1998, 1998 ), ) J., J. Biol, Biol ., . Chem, Chem ., . 273, 273 ,, , 22068-22074, 22068-22074 ;, ; Feder, Feder ,, , J., J. N., N. ,, , Penny, Penny ,, , D., D. M., M. ,, , Irrinki, Irrinki ,, , A., A. ,, , Lee, Lee ,, , V., V. K., K. ,, , Lebron, Lebron ,, , J, J ., . A., A. ,, , Watson, Watson ,, , N., N. ,, , Tsuchihashi, Tsuchihashi ,, , Z., Z. ,, , Sigal, Sigal ,, , E., E. ,, , Bjorkman, Bjorkman ,, , P., P. J., J. ,, , and, and Schatzman, Schatzman ,, , R., R. C., C. (, ( 1998, 1998 ), ) Proc, Proc ., . Natl, Natl ., . Acad, Acad ., . Sci, Sci ., . U, U S, S A, A 95, 95 ,, , 1472-1477, 1472-1477 ), ) ., . HFE, HFE does, does not, not remain, remain at, at the, the cell, cell surface, surface ,, , but, but traffics, traffics with, with TfR, TfR to, to Tf-positive, Tf-positive internal, internal compartments, compartments (, ( Gross, Gross et, et al., al. ,, , 1998, 1998 ), ) ., . Using, Using a, a HeLa, HeLa cell, cell line, line in, in which, which the, the expression, expression of, of HFE, HFE is, is controlled, controlled by, by tetracycline, tetracycline ,, , we, we show, show that, that the, the expression, expression of, of HFE, HFE reduces, reduces 55Fe, 55Fe uptake, uptake from, from Tf, Tf by, by 33, 33 %, % but, but does, does not, not affect, affect the, the endocytic, endocytic or, or exocytic, exocytic rates, rates of, of TfR, TfR cycling, cycling ., . Therefore, Therefore ,, , HFE, HFE appears, appears to, to reduce, reduce cellular, cellular acquisition, acquisition of, of iron, iron from, from Tf, Tf within, within endocytic, endocytic compartments, compartments ., . HFE, HFE specifically, specifically reduces, reduces iron, iron uptake, uptake from, from Tf, Tf ,, , as, as non-Tf-mediated, non-Tf-mediated iron, iron uptake, uptake from, from Fe-nitrilotriacetic, Fe-nitrilotriacetic acid, acid is, is not, not altered, altered ., . These, These results, results explain, explain the, the decreased, decreased ferritin, ferritin levels, levels seen, seen in, in our, our HeLa, HeLa cell, cell system, system and, and demonstrate, demonstrate the, the specific, specific control, control of, of HFE, HFE over, over the, the Tf-mediated, Tf-mediated pathway, pathway of, of iron, iron uptake, uptake ., . These, These results, results also, also have, have implications, implications for, for the, the understanding, understanding of, of cellular, cellular iron, iron homeostasis, homeostasis in, in organs, organs such, such as, as the, the liver, liver ,, , pancreas, pancreas ,, , heart, heart ,, , and, and spleen, spleen that, that are, are iron, iron loaded, loaded in, in hereditary, hereditary hemochromatotic, hemochromatotic individuals, individuals lacking, lacking functional, functional HFE.Familial, HFE.Familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) is, is a, a recessive, recessive disorder, disorder characterized, characterized by, by episodes, episodes of, of fever, fever with, with serositis, serositis or, or synovitis, synovitis ., . The, The FMF, FMF gene, gene (, ( MEFV, MEFV ), ) was, was cloned, cloned recently, recently ,, , and, and four, four missense, missense mutations, mutations were, were identified, identified ., . Here, Here we, we present, present data, data from, from non-Ashkenazi, non-Ashkenazi Jewish, Jewish and, and Arab, Arab patients, patients in, in whom, whom we, we had, had not, not originally, originally found, found mutations, mutations and, and from, from a, a new, new ,, , more, more ethnically, ethnically diverse, diverse panel, panel ., . Among, Among 90, 90 symptomatic, symptomatic mutation-positive, mutation-positive individuals, individuals ,, , 11, 11 mutations, mutations accounted, accounted for, for 79, 79 %, % of, of carrier, carrier chromosomes, chromosomes ., . Of, Of the, the two, two mutations, mutations that, that are, are novel, novel ,, , one, one alters, alters the, the same, same residue, residue (, ( 680, 680 ), ) as, as a, a previously, previously known, known mutation, mutation ,, , and, and the, the other, other (, ( P369S, P369S ), ) is, is located, located in, in exon, exon 3, 3 ., . Consistent, Consistent with, with another, another recent, recent report, report ,, , the, the E148Q, E148Q mutation, mutation was, was observed, observed in, in patients, patients of, of several, several ethnicities, ethnicities and, and on, on multiple, multiple microsatellite, microsatellite haplotypes, haplotypes ,, , but, but haplotype, haplotype data, data indicate, indicate an, an ancestral, ancestral relationships, relationships between, between non-Jewish, non-Jewish Italian, Italian and, and Ashkenazi, Ashkenazi Jewish, Jewish patients, patients with, with FMF, FMF and, and other, other affected, affected populations, populations ., . Among, Among approximately, approximately 200, 200 anonymous, anonymous Ashkenazi, Ashkenazi Jewish, Jewish DNA, DNA samples, samples ,, , the, the MEFV, MEFV carrier, carrier frequency, frequency was, was 21, 21 %, % ,, , with, with E148Q, E148Q the, the most, most common, common mutation, mutation ., . Several, Several lines, lines of, of evidence, evidence indicate, indicate reduced, reduced penetrance, penetrance among, among Ashkenazi, Ashkenazi Jews, Jews ,, , especially, especially for, for E148Q, E148Q ,, , P369S, P369S ,, , and, and K695R, K695R ., . Nevertheless, Nevertheless ,, , E148Q, E148Q helps, helps account, account for, for recessive, recessive inheritance, inheritance in, in an, an Ashkenazi, Ashkenazi family, family previously, previously reported, reported as, as an, an unusual, unusual case, case of, of dominantly, dominantly inherited, inherited FMF, FMF ., . The, The presence, presence of, of three, three frequent, frequent MEFV, MEFV mutations, mutations in, in multiple, multiple Mediterranean, Mediterranean populations, populations strongly, strongly suggests, suggests a, a heterozygote, heterozygote advantage, advantage in, in this, this geographic, geographic region.Autoimmune, region.Autoimmune lymphoproliferative, lymphoproliferative syndrome, syndrome (, ( ALPS, ALPS ), ) is, is a, a disorder, disorder of, of lymphocyte, lymphocyte homeostasis, homeostasis and, and immunological, immunological tolerance, tolerance ., . Most, Most patients, patients have, have a, a heterozygous, heterozygous mutation, mutation in, in the, the APT1, APT1 gene, gene ,, , which, which encodes, encodes Fas, Fas (, ( CD95, CD95 ,, , APO-1, APO-1 ), ) ,, , mediator, mediator of, of an, an apoptotic, apoptotic pathway, pathway crucial, crucial to, to lymphocyte, lymphocyte homeostasis, homeostasis ., . Of, Of 17, 17 unique, unique APT1, APT1 mutations, mutations in, in unrelated, unrelated ALPS, ALPS probands, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "probands ,, , 12, 12 (, ( 71, 71 %, % ), ) occurred, occurred in, in exons, exons 7-9, 7-9 ,, , which, which encode, encode the, the intracellular, intracellular portion, portion of, of Fas, Fas ., . In, In vitro, vitro ,, , activated, activated lymphocytes, lymphocytes from, from all, all 17, 17 patients, patients showed, showed apoptotic, apoptotic defects, defects when, when exposed, exposed to, to an, an anti-Fas, anti-Fas agonist, agonist monoclonal, monoclonal antibody, antibody ., . Similar, Similar defects, defects were, were found, found in, in a, a Fas-negative, Fas-negative cell, cell line, line transfected, transfected with, with cDNAs, cDNAs bearing, bearing each, each of, of the, the mutations, mutations ., . In, In cotransfection, cotransfection experiments, experiments ,, , Fas, Fas constructs, constructs with, with either, either intra-, intra- or, or extracellular, extracellular mutations, mutations caused, caused dominant, dominant inhibition, inhibition of, of apoptosis, apoptosis mediated, mediated by, by wild-type, wild-type Fas, Fas ., . Two, Two missense, missense Fas, Fas variants, variants ,, , not, not restricted, restricted to, to patients, patients with, with ALPS, ALPS ,, , were, were identified, identified ., . Variant, Variant A, A (, ( -1, -1 ), ) T, T at, at the, the Fas, Fas signal-sequence, signal-sequence cleavage, cleavage site, site ,, , which, which mediates, mediates apoptosis, apoptosis less, less well, well than, than wild-type, wild-type Fas, Fas and, and is, is partially, partially inhibitory, inhibitory ,, , was, was present, present in, in 13, 13 %, % of, of African, African American, American alleles, alleles ., . Among, Among the, the ALPS-associated, ALPS-associated Fas, Fas mutants, mutants ,, , dominant, dominant inhibition, inhibition of, of apoptosis, apoptosis was, was much, much more, more pronounced, pronounced in, in mutants, mutants affecting, affecting the, the intracellular, intracellular ,, , versus, versus extracellular, extracellular ,, , portion, portion of, of the, the Fas, Fas receptor, receptor ., . Mutations, Mutations causing, causing disruption, disruption of, of the, the intracellular, intracellular Fas, Fas death, death domain, domain also, also showed, showed a, a higher, higher penetrance, penetrance of, of ALPS, ALPS phenotype, phenotype features, features in, in mutation-bearing, mutation-bearing relatives, relatives ., . Significant, Significant ALPS-related, ALPS-related morbidity, morbidity occurred, occurred in, in 44, 44 %, % of, of relatives, relatives with, with intracellular, intracellular mutations, mutations ,, , versus, versus 0, 0 %, % of, of relatives, relatives with, with extracellular, extracellular mutations, mutations ., . Thus, Thus ,, , the, the location, location of, of mutations, mutations within, within APT1, APT1 strongly, strongly influences, influences the, the development, development and, and the, the severity, severity of, of ALPS.BACKGROUND, ALPS.BACKGROUND X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) is, is an, an inherited, inherited disease, disease characterized, characterized by, by progressive, progressive neurologic, neurologic dysfunction, dysfunction ,, , occasionally, occasionally associated, associated with, with adrenal, adrenal insufficiency, insufficiency ., . The, The classic, classic form, form of, of ALD, ALD usually, usually has, has onset, onset in, in childhood, childhood (, ( childhood, childhood cerebral, cerebral ALD, ALD ), ) ,, , with, with rapid, rapid neurologic, neurologic deterioration, deterioration leading, leading to, to a, a vegetative, vegetative state, state ., . Adult-onset, Adult-onset cerebral, cerebral ALD, ALD also, also presents, presents with, with rapidly, rapidly progressive, progressive neurologic, neurologic dysfunction, dysfunction ., . Milder, Milder phenotypes, phenotypes such, such as, as adrenomyeloneuropathy, adrenomyeloneuropathy and, and Addison, Addison disease, disease only, only also, also have, have been, been recognized, recognized ., . Despite, Despite discovery, discovery of, of the, the causative, causative gene, gene ,, , a, a molecular, molecular basis, basis for, for the, the diverse, diverse clinical, clinical presentations, presentations remains, remains to, to be, be elucidated, elucidated ., . OBJECTIVES, OBJECTIVES To, To conduct, conduct mutational, mutational analyses, analyses in, in 29, 29 Japanese, Japanese patients, patients with, with ALD, ALD from, from 29, 29 unrelated, unrelated families, families ,, , to, to obtain, obtain knowledge, knowledge of, of the, the spectrum, spectrum of, of mutations, mutations in, in this, this gene, gene ,, , and, and to, to study, study genotype-phenotype, genotype-phenotype correlations, correlations in, in Japanese, Japanese patients, patients ., . METHODS, METHODS The, The 29, 29 patients, patients comprised, comprised 13, 13 patients, patients with, with childhood, childhood cerebral, cerebral ALD, ALD ,, , 11, 11 patients, patients with, with adult-onset, adult-onset cerebral, cerebral ALD, ALD ,, , and, and 5, 5 patients, patients with, with adrenomyeloneuropathy, adrenomyeloneuropathy ., . We, We conducted, conducted detailed, detailed mutational, mutational analyses, analyses of, of 29, 29 unrelated, unrelated Japanese, Japanese patients, patients with, with ALD, ALD by, by genomic, genomic Southern, Southern blot, blot analysis, analysis and, and direct, direct nucleotide, nucleotide sequence, sequence analysis, analysis of, of reverse, reverse transcriptase-polymerase, transcriptase-polymerase chain, chain reaction, reaction products, products derived, derived from, from total, total RNA, RNA that, that was, was extracted, extracted from, from cultured, cultured skin, skin fibroblasts, fibroblasts ,, , lymphoblastoid, lymphoblastoid cells, cells ,, , or, or peripheral, peripheral blood, blood leukocytes, leukocytes ., . RESULTS, RESULTS Three, Three patients, patients with, with adult-onset, adult-onset cerebral, cerebral ALD, ALD were, were identified, identified as, as having, having large, large genomic, genomic rearrangements, rearrangements ., . The, The remaining, remaining 26, 26 patients, patients were, were identified, identified as, as having, having 21, 21 independent, independent mutations, mutations ,, , including, including 12, 12 novel, novel mutations, mutations resulting, resulting in, in small, small nucleotide, nucleotide alterations, alterations in, in the, the ALD, ALD gene, gene ., . Eighteen, Eighteen (, ( 69, 69 %, % ), ) of, of 26, 26 mutations, mutations were, were missense, missense mutations, mutations ., . Most, Most missense, missense mutations, mutations involved, involved amino, amino acids, acids conserved, conserved in, in homologous, homologous gene, gene products, products ,, , including, including PMP70, PMP70 ,, , mALDRP, mALDRP ,, , and, and Pxa1p, Pxa1p ., . The, The AG, AG dinucleotide, dinucleotide deletion, deletion at, at position, position 1081-1082, 1081-1082 ,, , which, which has, has been, been reported, reported previously, previously to, to be, be the, the most, most common, common mutation, mutation in, in white, white patients, patients (, ( 12, 12 %, % -17, -17 %, % ), ) ,, , was, was also, also identified, identified as, as the, the most, most common, common mutation, mutation in, in Japanese, Japanese patients, patients (, ( 12, 12 %, % ), ) ., . All, All phenotypes, phenotypes were, were associated, associated with, with mutations, mutations resulting, resulting in, in protein, protein truncation, truncation or, or subtle, subtle amino, amino acid, acid changes, changes ., . There, There were, were no, no differences, differences in, in phenotypic, phenotypic expressions, expressions between, between missense, missense mutations, mutations involving, involving conserved, conserved amino, amino acids, acids and, and those, those involving, involving nonconserved, nonconserved amino, amino acids, acids ., . CONCLUSIONS, CONCLUSIONS There, There are, are no, no obvious, obvious correlations, correlations between, between the, the phenotypes, phenotypes of, of patients, patients with, with ALD, ALD and, and their, their genotypes, genotypes ,, , suggesting, suggesting that, that other, other genetic, genetic or, or environmental, environmental factors, factors modify, modify the, the phenotypic, phenotypic expressions, expressions of, of ALD.., ALD.. A, A previously, previously healthy, healthy 40-year-old, 40-year-old man, man presenting, presenting with, with fever, fever ,, , arthritis, arthritis ,, , and, and cutaneous, cutaneous vasculitis, vasculitis was, was found, found to, to have, have chronic, chronic meningococcemia, meningococcemia ., . Evaluation, Evaluation of, of his, his complement, complement system, system showed, showed an, an absence, absence of, of functional, functional and, and antigenic, antigenic C7, C7 ,, , compatible, compatible with, with a, a complete, complete deficiency, deficiency of, of the, the seventh, seventh component, component of, of complement, complement ., . Study, Study of, of the, the patients, patients family, family spanning, spanning four, four generations, generations showed, showed heterozygous, heterozygous deficiency, deficiency of, of C7, C7 in, in five, five members, members ., . Chronic, Chronic neisserial, neisserial infection, infection can, can be, be associated, associated with, with C7, C7 deficiency, deficiency and, and must, must be, be distinguished, distinguished from, from other, other causes, causes of, of cutaneous, cutaneous vasculitis.., vasculitis.. Dihydropyrimidine, Dihydropyrimidine dehydrogenase, dehydrogenase (, ( DPD, DPD ), ) deficiency, deficiency is, is an, an autosomal, autosomal recessive, recessive disease, disease characterised, characterised by, by thymine-uraciluria, thymine-uraciluria in, in homozygous, homozygous deficient, deficient patients, patients and, and has, has been, been associated, associated with, with a, a variable, variable clinical, clinical phenotype, phenotype ., . In, In order, order to, to understand, understand the, the genetic, genetic and, and phenotypic, phenotypic basis, basis for, for DPD, DPD deficiency, deficiency ,, , we, we have, have reviewed, reviewed 17, 17 families, families presenting, presenting 22, 22 patients, patients with, with complete, complete deficiency, deficiency of, of DPD, DPD ., . In, In this, this group, group of, of patients, patients ,, , 7, 7 different, different mutations, mutations have, have been, been identified, identified ,, , including, including 2, 2 deletions, deletions [, [ 295-298delTCAT, 295-298delTCAT ,, , 1897delC, 1897delC ], ] ,, , 1, 1 splice-site, splice-site mutation, mutation [, [ IVS14, IVS14 +, + 1G, 1G >, > A, A ), ) ], ] and, and 4, 4 missense, missense mutations, mutations (, ( 85T, 85T >, > C, C ,, , 703C, 703C >, > T, T ,, , 2658G, 2658G >, > A, A ,, , 2983G, 2983G >, > T, T ), ) ., . Analysis, Analysis of, of the, the prevalence, prevalence of, of the, the various, various mutations, mutations among, among DPD, DPD patients, patients has, has shown, shown that, that the, the G, G --, -- >, > A, A point, point mutation, mutation in, in the, the invariant, invariant splice, splice donor, donor site, site is, is by, by far, far the, the most, most common, common (, ( 52, 52 %, % ), ) ,, , whereas, whereas the, the other, other six, six mutations, mutations are, are less, less frequently, frequently observed, observed ., . A, A large, large phenotypic, phenotypic variability, variability has, has been, been observed, observed ,, , with, with convulsive, convulsive disorders, disorders ,, , motor, motor retardation, retardation and, and mental, mental retardation, retardation being, being the, the most, most abundant, abundant manifestations, manifestations ., . A, A clear, clear correlation, correlation between, between the, the genotype, genotype and, and phenotype, phenotype has, has not, not been, been established, established ., . An, An altered, altered beta-alanine, beta-alanine ,, , uracil, uracil and, and thymine, thymine homeostasis, homeostasis might, might underlie, underlie the, the various, various clinical, clinical abnormalities, abnormalities encountered, encountered in, in patients, patients with, with DPD, DPD deficiency.We, deficiency.We have, have developed, developed a, a rapid, rapid and, and simple, simple method, method to, to diagnose, diagnose the, the molecular, molecular defects, defects of, of glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency in, in Chinese, Chinese in, in Taiwan, Taiwan ., . This, This method, method involves, involves the, the selective, selective amplification, amplification of, of a, a DNA, DNA fragment, fragment from, from human, human G6PD, G6PD gene, gene with, with specific, specific oligonucleotide, oligonucleotide primers, primers followed, followed by, by digestion, digestion with, with restriction, restriction enzymes, enzymes that, that recognize, recognize artificially, artificially created, created or, or naturally, naturally occurring, occurring restriction, restriction sites, sites ., . Ninety-four, Ninety-four Chinese, Chinese males, males with, with G6PD, G6PD deficiency, deficiency were, were studied, studied ., . The, The results, results show, show that, that 50, 50 %, % (, ( 47, 47 of, of 94, 94 ), ) were, were G, G to, to T, T mutation, mutation at, at nucleotide, nucleotide (, ( nt, nt ), ) 1376, 1376 ,, , 21, 21 ., . 3, 3 %, % (, ( 20, 20 of, of 94, 94 ), ) were, were G, G to, to A, A mutation, mutation at, at nt, nt 1388, 1388 ,, , 7, 7 ., . 4, 4 %, % (, ( 7, 7 of, of 94, 94 ), ) were, were A, A to, to G, G mutation, mutation at, at nt, nt 493, 493 ,, , 7, 7 ., . 4, 4 %, % (, ( 7, 7 of, of 94, 94 ), ) were, were A, A to, to G, G mutation, mutation at, at nt, nt 95, 95 ,, , 4, 4 ., . 2, 2 %, % (, ( 4, 4 of, of 94, 94 ), ) were, were C, C to, to T, T mutation, mutation at, at nt, nt 1024, 1024 ,, , 1, 1 ., . 1, 1 %, % (, ( 1, 1 of, of 94, 94 ), ) was, was G, G to, to T, T mutation, mutation at, at nt, nt 392, 392 ,, , and, and 1, 1 ., . 1, 1 %, % (, ( 1, 1 of, of 94, 94 ), ) was, was G, G to, to A, A mutation, mutation at, at nt, nt 487, 487 ., . These, These results, results show, show that, that the, the former, former five, five mutations, mutations account, account for, for more, more than, than 90, 90 %, % of, of G6PD, G6PD deficiency, deficiency cases, cases in, in Taiwan, Taiwan ., . Aside, Aside from, from showing, showing that, that G, G to, to T, T change, change at, at nt, nt 1376, 1376 is, is the, the most, most common, common mutation, mutation ,, , our, our research, research indicates, indicates that, that nt, nt 493, 493 mutation, mutation is, is a, a frequent, frequent mutation, mutation among, among Chinese, Chinese in, in Taiwan, Taiwan ., . We, We compared, compared G6PD, G6PD activity, activity among, among different, different mutations, mutations ,, , without, without discovering, discovering significant, significant differences, differences between, between them.apoB, them.apoB DNA, DNA ,, , RNA, RNA ,, , and, and protein, protein from, from two, two patients, patients with, with homozygous, homozygous hypobetalipoproteinemia, hypobetalipoproteinemia (, ( HBL, HBL ), ) were, were evaluated, evaluated and, and compared, compared with, with normal, normal individuals, individuals ., . Southern, Southern blot, blot analysis, analysis with, with 10, 10 different, different cDNA, cDNA probes, probes revealed, revealed a, a normal, normal gene, gene without, without major, major insertions, insertions ,, , deletions, deletions ,, , or, or rearrangements, rearrangements ., . Northern, Northern and, and slot, slot blot, blot analyses, analyses of, of total, total liver, liver mRNA, mRNA from, from HBL, HBL patients, patients documented, documented a, a normal, normal size, size apoB, apoB mRNA, mRNA that, that was, was present, present in, in greatly, greatly reduced, reduced quantities, quantities ., . ApoB, ApoB protein, protein was, was detected, detected within, within HBL, HBL hepatocytes, hepatocytes utilizing, utilizing immunohistochemical, immunohistochemical techniques, techniques ;, ; however, however ,, , it, it was, was markedly, markedly reduced, reduced in, in quantity, quantity when, when compared, compared with, with control, control samples, samples ., . No, No apoB, apoB was, was detectable, detectable in, in the, the plasma, plasma of, of HBL, HBL individuals, individuals with, with an, an ELISA, ELISA assay, assay ., . These, These data, data are, are most, most consistent, consistent with, with a, a mutation, mutation in, in the, the coding, coding portion, portion of, of the, the apoB, apoB gene, gene in, in HBL, HBL patients, patients ,, , leading, leading to, to an, an abnormal, abnormal apoB, apoB protein, protein and, and apoB, apoB mRNA, mRNA instability, instability ., . These, These results, results are, are distinct, distinct from, from those, those previously, previously noted, noted in, in abetalipoproteinemia, abetalipoproteinemia ,, , which, which was, was characterized, characterized by, by an, an elevated, elevated level, level of, of hepatic, hepatic apoB, apoB mRNA, mRNA and, and accumulation, accumulation of, of intracellular, intracellular hepatic, hepatic apoB, apoB protein.., protein.. BACKGROUND, BACKGROUND AND, AND METHODS, METHODS Hereditary, Hereditary hemochromatosis, hemochromatosis is, is associated, associated with, with homozygosity, homozygosity for, for the, the C282Y, C282Y mutation, mutation in, in the, the hemochromatosis, hemochromatosis (, ( HFE, HFE ), ) gene, gene on, on chromosome, chromosome 6, 6 ,, , elevated, elevated serum, serum transferrin, transferrin saturation, saturation ,, , and, and excess, excess iron, iron deposits, deposits throughout, throughout the, the body, body ., . To, To assess, assess the, the prevalence, prevalence and, and clinical, clinical expression, expression of, of the, the HFE, HFE gene, gene ,, , we, we conducted, conducted a, a population-based, population-based study, study in, in Busselton, Busselton ,, , Australia, Australia ., . In, In 1994, 1994 ,, , we, we obtained, obtained blood, blood samples, samples for, for the, the determination, determination of, of serum, serum transferrin, transferrin saturation, saturation and, and ferritin, ferritin levels, levels and, and the, the presence, presence or, or absence, absence of, of the, the C282Y, C282Y mutation, mutation and, and the, the H63D, H63D mutation, mutation (, ( which, which may, may contribute, contribute to, to increased, increased hepatic, hepatic iron, iron levels, levels ), ) in, in 3011, 3011 unrelated, unrelated white, white adults, adults ., . We, We evaluated, evaluated all, all subjects, subjects who, who had, had persistently, persistently elevated, elevated transferrin-saturation, transferrin-saturation values, values (, ( 45, 45 percent, percent or, or higher, higher ), ) or, or were, were homozygous, homozygous for, for the, the C282Y, C282Y mutation, mutation ., . We, We recommended, recommended liver, liver biopsy, biopsy for, for subjects, subjects with, with serum, serum ferritin, ferritin levels, levels of, of 300, 300 ng, ng per, per milliliter, milliliter or, or higher, higher ., . The, The subjects, subjects were, were followed, followed for, for up, up to, to four, four years, years ., . RESULTS, RESULTS Sixteen, Sixteen of, of the, the subjects, subjects (, ( 0, 0 ., . 5, 5 percent, percent ), ) were, were homozygous, homozygous for, for the, the C282Y, C282Y mutation, mutation ,, , and, and 424, 424 (, ( 14, 14 ., . 1, 1 percent, percent ), ) were, were heterozygous, heterozygous ., . The, The serum, serum transferrin, transferrin saturation, saturation was, was 45, 45 percent, percent or, or higher, higher in, in 15, 15 of, of the, the 16, 16 who, who were, were homozygous, homozygous ;, ; in, in 1, 1 subject, subject it, it was, was 43, 43 percent, percent ., . Four, Four of, of the, the homozygous, homozygous subjects, subjects had, had previously, previously been, been given, given a, a diagnosis, diagnosis of, of hemochromatosis, hemochromatosis ,, , and, and 12, 12 had, had not, not ., . Seven, Seven of, of these, these 12, 12 patients, patients had, had elevated, elevated serum, serum ferritin, ferritin levels, levels in, in 1994, 1994 ;, ; 6, 6 of, of the, the 7, 7 had, had further, further increases, increases in, in 1998, 1998 ,, , and, and 1, 1 had, had a, a decrease, decrease ,, , although, although the, the value, value remained, remained elevated, elevated ., . The, The serum, serum ferritin, ferritin levels, levels in, in the, the four, four other, other homozygous, homozygous patients, patients remained, remained in, in the, the normal, normal range, range ., . Eleven, Eleven of, of the, the 16, 16 homozygous, homozygous subjects, subjects underwent, underwent liver, liver biopsy, biopsy ;, ; 3, 3 had, had hepatic, hepatic fibrosis, fibrosis ,, , and, and 1, 1 ,, , who, who had, had a, a history, history of, of excessive, excessive alcohol, alcohol consumption, consumption ,, , had, had cirrhosis, cirrhosis and, and mild, mild microvesicular, microvesicular steatosis, steatosis ., . Eight, Eight of, of the, the 16, 16 homozygous, homozygous subjects, subjects had, had clinical, clinical findings, findings that, that were, were consistent, consistent with, with the, the presence, presence of, of hereditary, hereditary hemochromatosis, hemochromatosis ,, , such, such as, as hepatomegaly, hepatomegaly ,, , skin, skin pigmentation, pigmentation ,, , and, and arthritis, arthritis ., . CONCLUSIONS, CONCLUSIONS In, In a, a population, population of, of white, white adults, adults of, of northern, northern European, European ancestry, ancestry ,, , 0, 0 ., . 5, 5 percent, percent were, were homozygous, homozygous for, for the, the C282Y, C282Y mutation, mutation in, in the, the HFE, HFE gene, gene ., . However, However ,, , only, only half, half of, of those, those who, who were, were homozygous, homozygous had, had clinical, clinical features, features of, of hemochromatosis, hemochromatosis ,, , and, and one, one quarter, quarter had, had serum, serum ferritin, ferritin levels, levels that, that remained, remained normal, normal over, over a, a four-year, four-year period.Pelizaeus-Merzbacher, period.Pelizaeus-Merzbacher disease, disease is, is a, a rare, rare ,, , sex-linked, sex-linked recessive, recessive ,, , dysmyelinating, dysmyelinating disease, disease of, of the, the central, central nervous, nervous system, system that, that has, has been, been associated, associated with, with mutations, mutations in, in the, the myelin, myelin proteolipid, proteolipid protein, protein (, ( PLP, PLP ), ) gene, gene ., . Only, Only 25, 25 %, % of, of patients, patients studied, studied with, with Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease have, have exonic, exonic mutations, mutations in, in this, this gene, gene ,, , the, the underlying, underlying cause, cause of, of the, the disease, disease in, in the, the remaining, remaining patients, patients is, is unknown, unknown ., . The, The PLP, PLP gene, gene encodes, encodes two, two major, major alternatively, alternatively spliced, spliced transcripts, transcripts called, called PLP, PLP and, and DM20, DM20 ., . PLP, PLP messenger, messenger RNA, RNA is, is specifically, specifically expressed, expressed in, in central, central nervous, nervous system, system tissue, tissue ,, , whereas, whereas DM20, DM20 messenger, messenger RNA, RNA is, is found, found in, in central, central nervous, nervous system, system ,, , cardiac, cardiac ,, , and, and other, other tissues, tissues ., . We, We studied, studied cultured, cultured skin, skin fibroblasts, fibroblasts from, from 2, 2 brothers, brothers with, with Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease who, who exhibited, exhibited no, no detectable, detectable exonic, exonic mutation, mutation of, of the, the PLP, PLP gene, gene ., . Examination, Examination of, of RNA, RNA from, from these, these cells, cells showed, showed that, that the, the level, level of, of DM20, DM20 messenger, messenger RNA, RNA is, is elevated, elevated sixfold, sixfold relative, relative to, to male, male control, control skin, skin fibroblasts, fibroblasts ., . An, An unrelated, unrelated female, female carrier, carrier ,, , also, also with, with no, no detectable, detectable exonic, exonic mutation, mutation ,, , showed, showed a, a threefold, threefold increase, increase in, in DM20, DM20 messenger, messenger RNA, RNA in, in cultured, cultured skin, skin fibroblasts, fibroblasts ., . Our, Our findings, findings suggest, suggest that, that in, in some, some patients, patients ,, , Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease is, is caused, caused by, by overexpression, overexpression of, of PLP, PLP gene, gene transcripts, transcripts ,, , and, and that, that in, in these, these families, families a, a 50, 50 %, % increase, increase of, of DM20, DM20 messenger, messenger RNA, RNA in, in females, females ,, , relative, relative to, to the, the increase, increase in, in affected, affected males, males ,, , can, can identify, identify a, a female, female carrier.., carrier.. Atypical, Atypical or, or variant, variant forms, forms of, of well-known, well-known chondrodysplasias, chondrodysplasias may, may pose, pose diagnostic, diagnostic problems, problems ., . We, We report, report on, on a, a girl, girl with, with clinical, clinical features, features suggesting, suggesting diastrophic, diastrophic dysplasia, dysplasia but, but with, with unusual, unusual radiographic, radiographic features, features including, including severe, severe platyspondyly, platyspondyly ,, , wide, wide metaphyses, metaphyses ,, , and, and fibular, fibular overgrowth, overgrowth ,, , which, which are, are partially, partially reminiscent, reminiscent of, of metatropic, metatropic dysplasia, dysplasia ., . The, The diagnosis, diagnosis was, was clarified, clarified by, by molecular, molecular analysis, analysis of, of the, the DTDST, DTDST gene, gene ,, , which, which revealed, revealed homozygosity, homozygosity for, for a, a previously, previously undescribed, undescribed mutation, mutation leading, leading to, to a, a Q454P, Q454P substitution, substitution in, in the, the 10th, 10th transmembrane, transmembrane domain, domain of, of the, the DTDST, DTDST sulfate, sulfate transporter, transporter ., . Molecular, Molecular analysis, analysis may, may be, be of, of particular, particular value, value in, in such, such atypical, atypical cases.., cases.. We, We report, report carrier, carrier identification, identification and, and a, a prenatal, prenatal diagnosis, diagnosis using, using DNA, DNA polymorphisms, polymorphisms in, in 2, 2 families, families with, with X-linked, X-linked Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease (, ( PMD, PMD ), ) ., . In, In both, both families, families ,, , the, the proteolipid, proteolipid protein, protein (, ( PLP, PLP ), ) gene, gene in, in the, the single, single affected, affected male, male could, could be, be traced, traced back, back to, to his, his unaffected, unaffected maternal, maternal grandfather, grandfather ., . Therefore, Therefore ,, , each, each family, family contains, contains a, a new, new mutation, mutation ., . In, In the, the case, case of, of the, the prenatal, prenatal diagnosis, diagnosis ,, , the, the fetus, fetus was, was shown, shown by, by cytogenetic, cytogenetic analysis, analysis to, to be, be a, a female, female ,, , who, who we, we predict, predict will, will be, be a, a noncarrier, noncarrier of, of PMD, PMD based, based on, on her, her genotype, genotype with, with the, the PLP, PLP intragenic, intragenic polymorphism.., polymorphism.. We, We described, described a, a 15-year-old, 15-year-old boy, boy with, with Gardner, Gardner syndrome, syndrome (, ( GS, GS ), ) ,, , mental, mental retardation, retardation ,, , and, and craniofacial, craniofacial abnormalities, abnormalities ., . High-resolution, High-resolution banding, banding analysis, analysis showed, showed an, an interstitial, interstitial deletion, deletion of, of the, the long, long arm, arm of, of chromosome, chromosome 5, 5 (, ( q22, q22 ., . 1, 1 --, -- --, -- q31, q31 1, 1 --, -- --, -- q31, q31 ., . 1, 1 ), ) ., . The, The breakpoints, breakpoints in, in the, the present, present case, case and, and in, in 3, 3 previously, previously reported, reported 5q-, 5q- patients, patients with, with adenomatous, adenomatous polyposis, polyposis coli, coli suggest, suggest that, that the, the gene, gene responsible, responsible for, for GS/or, GS/or familial, familial polyposis, polyposis coli, coli (, ( FPC, FPC ), ) is, is in, in the, the 5q22, 5q22 region, region ,, , a, a result, result consistent, consistent with, with the, the findings, findings of, of linkage, linkage studies, studies Two, Two variants, variants of, of a, a genetic, genetic deficiency, deficiency of, of complement, complement protein, protein C2, C2 (, ( C2D, C2D ), ) have, have been, been previously, previously identified, identified ., . No, No C2, C2 protein, protein translation, translation is, is detected, detected in, in type, type I, I deficiency, deficiency ,, , while, while type, type II, II deficiency, deficiency is, is characterized, characterized by, by a, a selective, selective block, block in, in C2, C2 secretion, secretion ., . Type, Type I, I C2, C2 deficiency, deficiency was, was described, described in, in a, a family, family in, in which, which the, the C2, C2 null, null allele, allele (, ( C2Q0, C2Q0 ), ) is, is associated, associated with, with the, the major, major histocompatibility, histocompatibility haplotype/complotype, haplotype/complotype HLA-A25, HLA-A25 ,, , B18, B18 ,, , C2Q0, C2Q0 ,, , BfS, BfS ,, , C4A4, C4A4 ,, , C4B2, C4B2 ,, , Drw2, Drw2 ;, ; this, this extended, extended haplotype, haplotype occurs, occurs in, in over, over 90, 90 %, % of, of C2-deficient, C2-deficient individuals, individuals (, ( common, common complotype/haplotype, complotype/haplotype ), ) ., . To, To determine, determine the, the molecular, molecular basis, basis of, of type, type I, I C2, C2 deficiency, deficiency ,, , the, the C2, C2 gene, gene and, and cDNA, cDNA were, were characterized, characterized from, from a, a homozygous, homozygous type, type I, I C2-deficient, C2-deficient individual, individual with, with the, the common, common associated, associated haplotype/complotype, haplotype/complotype ., . We, We found, found a, a 28-base, 28-base pair, pair deletion, deletion in, in the, the type, type I, I C2Q0, C2Q0 gene, gene ,, , beginning, beginning 9, 9 base, base pairs, pairs upstream, upstream of, of the, the 3-end, 3-end of, of exon, exon 6, 6 ,, , that, that generates, generates a, a C2, C2 transcript, transcript with, with a, a complete, complete deletion, deletion of, of exon, exon 6, 6 (, ( 134, 134 base, base pair, pair ), ) and, and a, a premature, premature termination, termination codon, codon ., . In, In studies, studies of, of eight, eight kindred, kindred ,, , the, the 28-base, 28-base pair, pair deletion, deletion was, was observed, observed in, in all, all C2Q0, C2Q0 alleles, alleles associated, associated with, with the, the common, common type, type I, I deficient, deficient complotype/haplotype, complotype/haplotype ;, ; this, this deletion, deletion was, was not, not present, present in, in normal, normal C2, C2 nor, nor in, in type, type II, II C2-deficient, C2-deficient genes, genes ., . These, These data, data demonstrate, demonstrate that, that 1, 1 ), ) type, type I, I human, human complement, complement C2, C2 deficiency, deficiency is, is caused, caused by, by a, a 28-base, 28-base pair, pair genomic, genomic deletion, deletion that, that causes, causes skipping, skipping of, of exon, exon 6, 6 during, during RNA, RNA splicing, splicing ,, , resulting, resulting in, in generation, generation of, of a, a premature, premature termination, termination codon, codon ,, , 2, 2 ), ) the, the 28-base, 28-base pair, pair deletion, deletion in, in the, the type, type I, I C2Q0, C2Q0 gene, gene is, is strongly, strongly associated, associated with, with the, the HLA, HLA haplotype/complotype, haplotype/complotype A25, A25 ,, , B18, B18 ,, , C2Q0, C2Q0 ,, , BfS, BfS ,, , C4A4, C4A4 ,, , C4B2, C4B2 ,, , Drw2, Drw2 ,, , suggesting, suggesting that, that all, all C2-deficient, C2-deficient individuals, individuals with, with this, this haplotype/complotype, haplotype/complotype will, will harbor, harbor the, the 28-base, 28-base pair, pair C2, C2 gene, gene deletion, deletion ,, , and, and 3, 3 ), ) type, type II, II C2, C2 deficiency, deficiency is, is caused, caused by, by a, a different, different ,, , as, as yet, yet uncharacterized, uncharacterized ,, , molecular, molecular genetic, genetic defect.., defect.. Fragile, Fragile X, X syndrome, syndrome is, is a, a common, common cause, cause of, of mental, mental retardation, retardation involving, involving loss, loss of, of expression, expression of, of the, the FMR1, FMR1 gene, gene ., . The, The role, role of, of FMR1, FMR1 remains, remains undetermined, undetermined but, but the, the protein, protein appears, appears to, to be, be involved, involved in, in RNA, RNA metabolism, metabolism ., . Fmr1, Fmr1 knockout, knockout mice, mice exhibit, exhibit a, a phenotype, phenotype with, with some, some similarities, similarities to, to humans, humans ,, , such, such as, as macroorchidism, macroorchidism and, and behavioral, behavioral abnormalities, abnormalities ., . As, As a, a step, step toward, toward understanding, understanding the, the function, function of, of FMR1, FMR1 and, and the, the determination, determination of, of the, the potential, potential for, for therapeutic, therapeutic approaches, approaches to, to fragile, fragile X, X syndrome, syndrome ,, , yeast, yeast artificial, artificial chromosome, chromosome (, ( YAC, YAC ), ) transgenic, transgenic mice, mice were, were generated, generated in, in order, order to, to determine, determine whether, whether the, the Fmr1, Fmr1 knockout, knockout mouse, mouse phenotype, phenotype could, could be, be rescued, rescued ., . Several, Several transgenic, transgenic lines, lines were, were generated, generated that, that carried, carried the, the entire, entire FMR1, FMR1 locus, locus with, with extensive, extensive amounts, amounts of, of flanking, flanking sequence, sequence ., . We, We observed, observed that, that the, the YAC, YAC transgene, transgene supported, supported production, production of, of the, the human, human protein, protein (, ( FMRP, FMRP ), ) which, which was, was present, present at, at levels, levels 10, 10 to, to 15, 15 times, times that, that of, of endogenous, endogenous protein, protein and, and was, was expressed, expressed in, in a, a cell-, cell- and, and tissue-specific, tissue-specific manner, manner ., . Macro-orchidism, Macro-orchidism was, was absent, absent in, in knockout, knockout mice, mice carrying, carrying the, the YAC, YAC transgene, transgene indicating, indicating functional, functional rescue, rescue by, by the, the human, human protein, protein ., . Given, Given the, the complex, complex behavioral, behavioral phenotype, phenotype in, in fragile, fragile X, X patients, patients and, and the, the mild, mild phenotype, phenotype previously, previously reported, reported for, for the, the Fmr1, Fmr1 knockout, knockout mouse, mouse ,, , we, we performed, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "performed a, a more, more thorough, thorough evaluation, evaluation of, of the, the Fmr1, Fmr1 knockout, knockout phenotype, phenotype using, using additional, additional behavioral, behavioral assays, assays that, that had, had not, not previously, previously been, been reported, reported for, for this, this animal, animal model, model ., . The, The mouse, mouse displayed, displayed reduced, reduced anxiety-related, anxiety-related responses, responses with, with increased, increased exploratory, exploratory behavior, behavior ., . FMR1, FMR1 YAC, YAC transgenic, transgenic mice, mice overexpressing, overexpressing the, the human, human protein, protein did, did produce, produce opposing, opposing behavioral, behavioral responses, responses and, and additional, additional abnormal, abnormal behaviors, behaviors were, were also, also observed, observed ., . These, These findings, findings have, have significant, significant implications, implications for, for gene, gene therapy, therapy for, for fragile, fragile X, X syndrome, syndrome since, since overexpression, overexpression of, of the, the gene, gene may, may harbor, harbor its, its own, own phenotype.., phenotype.. Fabry, Fabry disease, disease (, ( FD, FD ), ) (, ( angiokeratoma, angiokeratoma corporis, corporis diffusum, diffusum ), ) is, is an, an X-linked, X-linked inborn, inborn error, error of, of glycosphingolipid, glycosphingolipid metabolism, metabolism caused, caused by, by defects, defects in, in the, the lysosomal, lysosomal alpha-galactosidase, alpha-galactosidase A, A gene, gene (, ( GLA, GLA ), ) ., . The, The enzymatic, enzymatic defect, defect leads, leads to, to the, the systemic, systemic accumulation, accumulation of, of neutral, neutral glycosphingolipids, glycosphingolipids with, with terminal, terminal alpha-galactosyl, alpha-galactosyl moieties, moieties ., . Clinically, Clinically ,, , affected, affected hemizygous, hemizygous males, males have, have angiokeratoma, angiokeratoma ,, , severe, severe acroparesthesia, acroparesthesia ,, , renal, renal failure, failure ,, , and, and vasculopathy, vasculopathy of, of the, the heart, heart and, and brain, brain ., . While, While demonstration, demonstration of, of alpha-galactosidase, alpha-galactosidase deficiency, deficiency in, in leukocytes, leukocytes is, is diagnostic, diagnostic in, in affected, affected males, males ,, , enzymatic, enzymatic detection, detection of, of female, female carriers, carriers is, is often, often inconclusive, inconclusive ,, , due, due to, to random, random X-chromosomal, X-chromosomal inactivation, inactivation ,, , underlining, underlining the, the need, need of, of molecular, molecular investigations, investigations for, for accurate, accurate genetic, genetic counseling, counseling ., . By, By use, use of, of chemical, chemical cleavage, cleavage of, of mismatches, mismatches adapted, adapted to, to fluorescence-based, fluorescence-based detection, detection systems, systems ,, , we, we have, have characterized, characterized the, the mutations, mutations underlying, underlying alpha-Gal, alpha-Gal A, A deficiency, deficiency in, in 16, 16 individuals, individuals from, from six, six unrelated, unrelated families, families with, with FD, FD ., . The, The mutational, mutational spectrum, spectrum included, included five, five missense, missense mutations, mutations (, ( C202W, C202W ,, , C223G, C223G ,, , N224D, N224D ,, , R301Q, R301Q ,, , and, and Q327K, Q327K ), ) and, and one, one splice-site, splice-site mutation, mutation [, [ IVS3, IVS3 G, G (, ( -1, -1 ), ) --, -- >, > C, C ], ] ., . Studies, Studies at, at the, the mRNA, mRNA level, level showed, showed that, that the, the latter, latter led, led to, to altered, altered pre-mRNA, pre-mRNA splicing, splicing with, with consequent, consequent alteration, alteration of, of the, the mRNA, mRNA translational, translational reading, reading frame, frame and, and generation, generation of, of a, a premature, premature termination, termination codon, codon of, of translation, translation ., . By, By use, use of, of this, this strategy, strategy ,, , carrier, carrier status, status was, was accurately, accurately assessed, assessed in, in all, all seven, seven at-risk, at-risk females, females tested, tested ,, , whereas, whereas enzymatic, enzymatic dosages, dosages failed, failed to, to diagnose, diagnose or, or exclude, exclude heterozygosity.., heterozygosity.. A, A susceptibility, susceptibility gene, gene on, on chromosome, chromosome 18, 18 and, and a, a parent-of-origin, parent-of-origin effect, effect have, have been, been suggested, suggested for, for bipolar, bipolar affective, affective disorder, disorder (, ( BPAD, BPAD ), ) ., . We, We have, have studied, studied 28, 28 nuclear, nuclear families, families selected, selected for, for apparent, apparent unilineal, unilineal transmission, transmission of, of the, the BPAD, BPAD phenotype, phenotype ,, , by, by using, using 31, 31 polymorphic, polymorphic markers, markers spanning, spanning chromosome, chromosome 18, 18 ., . Evidence, Evidence for, for linkage, linkage was, was tested, tested with, with affected-sib-pair, affected-sib-pair and, and LOD, LOD score, score methods, methods under, under two, two definitions, definitions of, of the, the affected, affected phenotype, phenotype ., . The, The affected-sibpair, affected-sibpair analyses, analyses indicated, indicated excess, excess allele, allele sharing, sharing for, for markers, markers on, on 18p, 18p within, within the, the region, region reported, reported previously, previously ., . The, The greatest, greatest sharing, sharing was, was at, at D18S37, D18S37 64, 64 %, % in, in bipolar, bipolar and, and recurrent, recurrent unipolar, unipolar (, ( RUP, RUP ), ) sib, sib pairs, pairs (, ( P, P =, = ., . 0006, 0006 ), ) ., . In, In addition, addition ,, , excess, excess sharing, sharing of, of the, the paternally, paternally ,, , but, but not, not maternally, maternally ,, , transmitted, transmitted alleles, alleles was, was observed, observed at, at three, three markers, markers on, on 18q, 18q at, at D18S41, D18S41 ,, , 51, 51 bipolar, bipolar and, and RUP, RUP sib, sib pairs, pairs were, were concordant, concordant for, for paternally, paternally transmitted, transmitted alleles, alleles ,, , and, and 21, 21 pairs, pairs were, were discordant, discordant (, ( P, P =, = 0004, 0004 ), ) ., . The, The evidence, evidence for, for linkage, linkage to, to loci, loci on, on both, both 18p, 18p and, and 18q, 18q was, was strongest, strongest in, in the, the 11, 11 paternal, paternal pedigrees, pedigrees ,, , i., i. e, e e., e. ,, , those, those in, in which, which the, the father, father or, or one, one of, of the, the fathers, fathers sibs, sibs is, is affected, affected ., . In, In these, these pedigrees, pedigrees ,, , the, the greatest, greatest allele, allele sharing, sharing (, ( 81, 81 %, % ;, ; P, P =, = ., . 00002, 00002 ), ) and, and the, the highest, highest LOD, LOD score, score (, ( 3, 3 ., . 51, 51 ;, ; phi, phi =, = 0, 0 ., . 0, 0 ), ) were, were observed, observed at, at D18S41, D18S41 ., . Our, Our results, results provide, provide further, further support, support for, for linkage, linkage of, of BPAD, BPAD to, to chromosome, chromosome 18, 18 and, and the, the first, first molecular, molecular evidence, evidence for, for a, a parent-of-origin, parent-of-origin effect, effect operating, operating in, in this, this disorder, disorder ., . The, The number, number of, of loci, loci involved, involved ,, , and, and their, their precise, precise location, location ,, , require, require further, further study, study BACKGROUND, BACKGROUND ., . Inherited, Inherited mutations, mutations in, in the, the BRCA1, BRCA1 gene, gene are, are associated, associated with, with a, a high, high risk, risk of, of breast, breast and, and ovarian, ovarian cancer, cancer in, in some, some families, families ., . However, However ,, , little, little is, is known, known about, about the, the contribution, contribution of, of BRCA1, BRCA1 mutations, mutations to, to breast, breast cancer, cancer in, in the, the general, general population, population ., . We, We analyzed, analyzed DNA, DNA samples, samples from, from women, women enrolled, enrolled in, in a, a population-based, population-based study, study of, of early-onset, early-onset breast, breast cancer, cancer to, to assess, assess the, the spectrum, spectrum and, and frequency, frequency of, of germ-line, germ-line BRCA1, BRCA1 mutations, mutations in, in young, young women, women with, with breast, breast cancer, cancer ., . METHODS, METHODS ., . We, We studied, studied 80, 80 women, women in, in whom, whom breast, breast cancer, cancer was, was diagnosed, diagnosed before, before the, the age, age of, of 35, 35 ,, , and, and who, who were, were not, not selected, selected on, on the, the basis, basis of, of family, family history, history ., . Genomic, Genomic DNA, DNA was, was studied, studied for, for BRCA1, BRCA1 mutations, mutations by, by analysis, analysis involving, involving single-strand, single-strand conformation, conformation polymorphisms, polymorphisms and, and with, with allele-specific, allele-specific assays, assays ., . Alterations, Alterations were, were defined, defined by, by DNA, DNA sequencing, sequencing ., . RESULTS, RESULTS ., . Germ-line, Germ-line BRCA1, BRCA1 mutations, mutations were, were identified, identified in, in 6, 6 of, of the, the 80, 80 women, women ., . Four, Four additional, additional rare, rare sequence, sequence variants, variants of, of unknown, unknown functional, functional importance, importance were, were also, also identified, identified ., . Two, Two of, of the, the mutations, mutations and, and three, three of, of the, the rare, rare sequence, sequence variants, variants were, were found, found among, among the, the 39, 39 women, women who, who reported, reported no, no family, family history, history of, of breast, breast or, or ovarian, ovarian cancer, cancer ., . None, None of, of the, the mutations, mutations and, and only, only one, one of, of the, the rare, rare variants, variants was, was identified, identified in, in a, a reference, reference population, population of, of 73, 73 unrelated, unrelated subjects, subjects ., . CONCLUSIONS, CONCLUSIONS ., . Alterations, Alterations in, in BRCA1, BRCA1 were, were identified, identified in, in approximately, approximately 10, 10 percent, percent of, of this, this cohort, cohort of, of young, young women, women with, with breast, breast cancer, cancer ., . The, The risk, risk of, of harboring, harboring a, a mutation, mutation was, was not, not limited, limited to, to women, women with, with family, family histories, histories of, of breast, breast or, or ovarian, ovarian cancer, cancer ., . These, These results, results represent, represent a, a minimal, minimal estimate, estimate of, of the, the frequency, frequency of, of BRCA1, BRCA1 mutations, mutations in, in this, this population, population ., . Comprehensive, Comprehensive methods, methods of, of identifying, identifying BRCA1, BRCA1 mutations, mutations and, and understanding, understanding their, their importance, importance will, will be, be needed, needed before, before testing, testing of, of women, women in, in the, the general, general population, population can, can be, be undertaken.., undertaken.. X-linked, X-linked retinoschisis, retinoschisis is, is characterized, characterized by, by microcystic-like, microcystic-like changes, changes of, of the, the macular, macular region, region and, and schisis, schisis within, within the, the inner, inner retinal, retinal layers, layers ,, , leading, leading to, to visual, visual deterioration, deterioration in, in males, males ., . Many, Many missense, missense and, and protein-truncating, protein-truncating mutations, mutations of, of the, the causative, causative gene, gene RS1, RS1 have, have now, now been, been identified, identified and, and are, are thought, thought to, to be, be inactivating, inactivating ., . RS1, RS1 encodes, encodes a, a 224, 224 amino, amino acid, acid protein, protein ,, , retinoschisin, retinoschisin ,, , which, which contains, contains a, a discoidin, discoidin domain, domain but, but is, is of, of unknown, unknown function, function ., . We, We have, have generated, generated a, a polyclonal, polyclonal antibody, antibody against, against a, a peptide, peptide from, from a, a unique, unique region, region within, within retinoschisin, retinoschisin ,, , which, which detects, detects a, a protein, protein of, of approximately, approximately 28, 28 kDa, kDa in, in retinal, retinal samples, samples reduced, reduced with, with dithiothreitol, dithiothreitol ,, , but, but multimers, multimers sized, sized >, > 40, 40 kDa, kDa under, under non-reducing, non-reducing conditions, conditions ., . A, A screen, screen of, of human, human tissues, tissues with, with this, this antibody, antibody reveals, reveals retinoschisin, retinoschisin to, to be, be retina, retina specific, specific and, and the, the antibody, antibody detects, detects a, a protein, protein of, of similar, similar size, size in, in bovine, bovine and, and murine, murine retinae, retinae ., . We, We investigated, investigated the, the expression, expression pattern, pattern in, in the, the retina, retina of, of both, both RS1, RS1 mRNA, mRNA (, ( using, using in, in situ, situ hybridization, hybridization with, with riboprobes, riboprobes ), ) and, and retinoschisin, retinoschisin (, ( using, using immunohistochemistry, immunohistochemistry ), ) ., . The, The antisense, antisense riboprobe, riboprobe detected, detected RS1, RS1 mRNA, mRNA only, only in, in the, the photoreceptor, photoreceptor layer, layer but, but the, the protein, protein product, product of, of the, the gene, gene was, was present, present both, both in, in the, the photoreceptors, photoreceptors and, and within, within the, the inner, inner portions, portions of, of the, the retina, retina ., . Furthermore, Furthermore ,, , differentiated, differentiated retinoblastoma, retinoblastoma cells, cells (, ( Weri-Rb1, Weri-Rb1 cells, cells ), ) were, were found, found to, to express, express RS1, RS1 mRNA, mRNA and, and to, to release, release retinoschisin, retinoschisin ., . These, These results, results suggest, suggest that, that retinoschisin, retinoschisin is, is released, released by, by photo-receptors, photo-receptors and, and has, has functions, functions within, within the, the inner, inner retinal, retinal layers, layers ., . Thus, Thus ,, , X-linked, X-linked retinoschisis, retinoschisis is, is caused, caused by, by abnormalities, abnormalities in, in a, a putative, putative secreted, secreted photoreceptor, photoreceptor protein, protein and, and is, is the, the first, first example, example of, of a, a secreted, secreted photo-receptor, photo-receptor protein, protein associated, associated with, with a, a retinal, retinal dystrophy.., dystrophy.. Choroideremia, Choroideremia (, ( CHM, CHM ), ) is, is an, an X-linked, X-linked progressive, progressive degeneration, degeneration of, of the, the choroid, choroid and, and retina, retina ., . 12, 12 %, % of, of unrelated, unrelated male, male patients, patients carry, carry deletions, deletions of, of the, the partially, partially cloned, cloned CHM, CHM gene, gene ., . In, In Finland, Finland ,, , there, there are, are more, more than, than 120, 120 living, living CHM, CHM patients, patients belonging, belonging to, to eight, eight apparently, apparently unrelated, unrelated pedigrees, pedigrees ., . Molecular, Molecular deletions, deletions involving, involving the, the CHM, CHM gene, gene have, have been, been detected, detected in, in three, three families, families ., . We, We have, have screened, screened the, the remaining, remaining five, five families, families for, for point, point mutations, mutations ., . In, In one, one large, large family, family a, a single, single nucleotide, nucleotide (, ( T, T ), ) insertion, insertion into, into the, the donor, donor splice, splice site, site of, of exon, exon C, C leads, leads to, to two, two aberrantly, aberrantly spliced, spliced mRNAs, mRNAs both, both producing, producing a, a premature, premature stop, stop codon, codon ., . The, The mutation, mutation can, can be, be assayed, assayed easily, easily by, by amplification, amplification and, and digestion, digestion with, with Msel, Msel ., . Our, Our findings, findings provide, provide additional, additional evidence, evidence for, for the, the pathogenetic, pathogenetic role, role of, of CHM, CHM mutations, mutations and, and provide, provide a, a diagnostic, diagnostic tool, tool for, for one, one fifth, fifth of, of the, the worlds, worlds known, known CHM, CHM patients.., patients.. Fragments, Fragments of, of the, the adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) cDNA, cDNA from, from a, a patient, patient with, with adolescent, adolescent ALD, ALD were, were amplified, amplified by, by polymerase, polymerase chain, chain reaction, reaction and, and subcloned, subcloned ., . Bidirectional, Bidirectional sequencing, sequencing of, of the, the entire, entire coding, coding ALD, ALD gene, gene disclosed, disclosed a, a cytosine, cytosine to, to guanine, guanine transversion, transversion at, at nucleotide, nucleotide 1451, 1451 in, in exon, exon five, five ,, , resulting, resulting in, in substitution, substitution of, of proline, proline 484, 484 by, by arginine, arginine ., . Five, Five of, of nine, nine siblings, siblings of, of the, the patient, patient ,, , comprising, comprising two, two cerebral, cerebral ALD, ALD ,, , one, one adrenomyeloneuropathy, adrenomyeloneuropathy ,, , one, one Addison, Addison only, only as, as well, well as, as the, the symptomatic, symptomatic mother, mother (, ( all, all accumulating, accumulating very, very long, long chain, chain fatty, fatty acids, acids ), ) carried, carried this, this mutation, mutation ,, , which, which was, was not, not found, found in, in the, the unaffected, unaffected persons, persons ,, , in, in five, five unrelated, unrelated ALD, ALD patients, patients ,, , and, and in, in twenty, twenty controls, controls ., . We, We propose, propose that, that this, this missense, missense mutation, mutation generated, generated the, the disease, disease per, per se, se as, as well, well as, as the, the metabolic, metabolic defect, defect ;, ; the, the different, different phenotypes, phenotypes ,, , however, however ,, , must, must have, have originated, originated by, by means, means of, of additional, additional pathogenetic, pathogenetic factors.., factors.. Analysis, Analysis of, of the, the age, age incidence, incidence curves, curves for, for unilateral, unilateral and, and bilateral, bilateral retinoblastoma, retinoblastoma led, led Knudson, Knudson to, to propose, propose that, that hereditary, hereditary tumours, tumours may, may arise, arise by, by a, a single, single event, event and, and sporadic, sporadic tumours, tumours by, by a, a two, two stage, stage mutation, mutation process, process ., . It, It has, has been, been suggested, suggested recently, recently that, that sporadic, sporadic renal, renal cell, cell carcinoma, carcinoma may, may arise, arise from, from a, a two, two stage, stage mutation, mutation process, process ., . We, We analysed, analysed the, the age, age incidence, incidence curves, curves for, for symptomatic, symptomatic renal, renal cell, cell carcinoma, carcinoma (, ( n, n =, = 26, 26 ), ) and, and cerebellar, cerebellar haemangioblastoma, haemangioblastoma (, ( n, n =, = 68, 68 ), ) in, in 109, 109 patients, patients with, with von, von Hippel-Lindau, Hippel-Lindau (, ( VHL, VHL ), ) disease, disease ,, , and, and compared, compared them, them to, to 104, 104 patients, patients with, with sporadic, sporadic renal, renal cell, cell carcinoma, carcinoma and, and 43, 43 patients, patients with, with sporadic, sporadic cerebellar, cerebellar haemangioblastoma, haemangioblastoma ., . The, The age, age incidence, incidence curves, curves for, for renal, renal cell, cell carcinoma, carcinoma and, and cerebellar, cerebellar haemangioblastoma, haemangioblastoma in, in VHL, VHL disease, disease were, were compatible, compatible with, with a, a single, single mutation, mutation model, model ,, , whereas, whereas the, the age, age incidence, incidence curves, curves for, for sporadic, sporadic renal, renal cell, cell carcinoma, carcinoma and, and cerebellar, cerebellar haemangioblastoma, haemangioblastoma suggested, suggested a, a two, two stage, stage mutation, mutation process, process ., . These, These data, data are, are compatible, compatible with, with the, the VHL, VHL gene, gene functioning, functioning as, as a, a recessive, recessive tumour, tumour suppressor, suppressor gene, gene ., . Sporadic, Sporadic cerebellar, cerebellar haemangioblastoma, haemangioblastoma and, and some, some renal, renal cell, cell carcinoma, carcinoma may, may arise, arise from, from somatic, somatic mutations, mutations inactivating, inactivating both, both alleles, alleles at, at the, the VHL, VHL locus.., locus.. The, The oculocerebrorenal, oculocerebrorenal syndrome, syndrome of, of Lowe, Lowe (, ( OCRL, OCRL ), ) is, is an, an X-linked, X-linked disorder, disorder characterized, characterized by, by major, major abnormalities, abnormalities of, of eyes, eyes ,, , nervous, nervous system, system ,, , and, and kidneys, kidneys ., . Mutations, Mutations in, in the, the OCRL1, OCRL1 gene, gene have, have been, been associated, associated with, with the, the disease, disease ., . OCRL1, OCRL1 encodes, encodes a, a phosphatidylinositol, phosphatidylinositol 4, 4 ,, , 5-biphosphate, 5-biphosphate (, ( PtdIns, PtdIns [, [ 4, 4 ,, , 5, 5 ], ] P2, P2 ), ) 5-phosphatase, 5-phosphatase ., . We, We have, have examined, examined the, the OCRL1, OCRL1 gene, gene in, in eight, eight unrelated, unrelated patients, patients with, with OCRL, OCRL and, and have, have found, found seven, seven new, new mutations, mutations and, and one, one recurrent, recurrent in-frame, in-frame deletion, deletion ., . Among, Among the, the new, new mutations, mutations ,, , two, two nonsense, nonsense mutations, mutations (, ( R317X, R317X and, and E558X, E558X ), ) and, and three, three other, other frameshift, frameshift mutations, mutations caused, caused premature, premature termination, termination of, of the, the protein, protein ., . A, A missense, missense mutation, mutation ,, , R483G, R483G ,, , was, was located, located in, in the, the highly, highly conserved, conserved PtdIns, PtdIns (, ( 4, 4 ,, , 5, 5 ), ) P2, P2 5-phosphatase, 5-phosphatase domain, domain ., . Finally, Finally ,, , one, one frameshift, frameshift mutation, mutation ,, , 2799delC, 2799delC ,, , modifies, modifies the, the C-terminal, C-terminal part, part of, of OCRL1, OCRL1 ,, , with, with an, an extension, extension of, of six, six amino, amino acids, acids ., . Altogether, Altogether ,, , 70, 70 %, % of, of missense, missense mutations, mutations are, are located, located in, in exon, exon 15, 15 ,, , and, and 52, 52 %, % of, of all, all mutations, mutations cluster, cluster in, in exons, exons 11-15, 11-15 ., . We, We also, also identified, identified two, two new, new microsatellite, microsatellite markers, markers for, for the, the OCRL1, OCRL1 locus, locus ,, , and, and we, we detected, detected a, a germline, germline mosaicism, mosaicism in, in one, one family, family ., . This, This observation, observation has, has direct, direct implications, implications for, for genetic, genetic counseling, counseling of, of Lowe, Lowe syndrome, syndrome families.., families.. Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) is, is caused, caused by, by mutations, mutations in, in the, the dystrophin, dystrophin gene, gene ,, , leading, leading to, to the, the absence, absence of, of the, the dystrophin, dystrophin protein, protein in, in striated, striated muscle, muscle ., . A, A significant, significant number, number of, of these, these mutations, mutations are, are premature, premature stop, stop codons, codons ., . On, On the, the basis, basis of, of the, the observation, observation that, that aminoglycoside, aminoglycoside treatment, treatment can, can suppress, suppress stop, stop codons, codons in, in cultured, cultured cells, cells ,, , we, we tested, tested the, the effect, effect of, of gentamicin, gentamicin on, on cultured, cultured muscle, muscle cells, cells from, from the, the mdx, mdx mouse, mouse -, - an, an animal, animal model, model for, for DMD, DMD that, that possesses, possesses a, a premature, premature stop, stop codon, codon in, in the, the dystrophin, dystrophin gene, gene ., . Exposure, Exposure of, of mdx, mdx myotubes, myotubes to, to gentamicin, gentamicin led, led to, to the, the expression, expression and, and localization, localization of, of dystrophin, dystrophin to, to the, the cell, cell membrane, membrane ., . We, We then, then evaluated, evaluated the, the effects, effects of, of differing, differing dosages, dosages of, of gentamicin, gentamicin on, on expression, expression and, and functional, functional protection, protection of, of the, the muscles, muscles of, of mdx, mdx mice, mice ., . We, We identified, identified a, a treatment, treatment regimen, regimen that, that resulted, resulted in, in the, the presence, presence of, of dystrophin, dystrophin in, in the, the cell, cell membrane, membrane in, in all, all striated, striated muscles, muscles examined, examined and, and that, that provided, provided functional, functional protection, protection against, against muscular, muscular injury, injury ., . To, To our, our knowledge, knowledge ,, , our, our results, results are, are the, the first, first to, to demonstrate, demonstrate that, that aminoglycosides, aminoglycosides can, can suppress, suppress stop, stop codons, codons not, not only, only in, in vitro, vitro but, but also, also in, in vivo, vivo ., . Furthermore, Furthermore ,, , these, these results, results raise, raise the, the possibility, possibility of, of a, a novel, novel treatment, treatment regimen, regimen for, for muscular, muscular dystrophy, dystrophy and, and other, other diseases, diseases caused, caused by, by premature, premature stop, stop codon, codon mutations, mutations ., . This, This treatment, treatment could, could prove, prove effective, effective in, in up, up to, to 15, 15 %, % of, of patients, patients with, with DMD.., DMD.. We, We have, have previously, previously described, described a, a disorder, disorder ,, , normotriglyceridemic, normotriglyceridemic abetalipoproteinemia, abetalipoproteinemia ,, , that, that is, is characterized, characterized by, by the, the virtual, virtual absence, absence of, of plasma, plasma low, low density, density lipoproteins, lipoproteins and, and complete, complete absence, absence of, of apoB-100, apoB-100 ,, , but, but with, with apparently, apparently normal, normal secretion, secretion of, of triglyceride-rich, triglyceride-rich lipoproteins, lipoproteins containing, containing apoB-48, apoB-48 ., . The, The patients, patients plasma, plasma lipoproteins, lipoproteins were, were shown, shown on, on polyacrylamide, polyacrylamide gels, gels and, and by, by antibody, antibody mapping, mapping to, to have, have a, a new, new truncated, truncated apoB, apoB variant, variant ,, , apoB-50, apoB-50 ,, , circulating, circulating along, along with, with her, her apoB-48, apoB-48 ., . We, We have, have found, found this, this individual, individual to, to be, be homozygous, homozygous for, for a, a single, single C-to-T, C-to-T nucleotide, nucleotide substitution, substitution at, at apoB, apoB codon, codon 2252, 2252 ,, , which, which produces, produces a, a premature, premature in-frame, in-frame stop, stop codon, codon ., . Thus, Thus ,, , this, this is, is a, a rare, rare example, example of, of homozygous, homozygous hypobetalipoproteinemia, hypobetalipoproteinemia ., . Electron, Electron photomicrographs, photomicrographs revealed, revealed that, that the, the diameters, diameters of, of particles, particles in, in the, the d, d less, less than, than 1, 1 ., . 006, 006 g/ml, g/ml lipoprotein, lipoprotein fraction, fraction ,, , in, in both, both the, the postprandial, postprandial and, and postabsorptive, postabsorptive state, state ,, , are, are bimodally, bimodally distributed, distributed ., . The, The molar, molar ratio, ratio of, of apoE, apoE to, to apoB, apoB in, in these, these particles, particles is, is 3, 3 ., . 5, 5 1, 1 ,, , similar, similar to, to normal, normal VLDL, VLDL ., . The, The plasma, plasma LDL, LDL interval, interval contains, contains both, both spherical, spherical and, and cuboidal, cuboidal particles, particles ., . Autologous, Autologous reinfusion, reinfusion of, of labeled, labeled d, d less, less than, than 1, 1 ., . 006, 006 g/ml, g/ml lipoproteins, lipoproteins showed, showed exponential, exponential disappearance, disappearance from, from plasma, plasma ,, , with, with an, an apparent, apparent half-removal, half-removal time, time of, of 50, 50 min, min ,, , somewhat, somewhat slower, slower than, than for, for normal, normal chylomicrons, chylomicrons but, but within, within the, the normal, normal range, range for, for VLDL, VLDL ., . The, The calculated, calculated production, production rate, rate for, for apoB, apoB was, was within, within the, the normal, normal range, range in, in this, this subject, subject ., . von, von Willebrand, Willebrand factor, factor (, ( vWF, vWF ), ) is, is a, a multimeric, multimeric glycoprotein, glycoprotein that, that mediates, mediates the, the adhesion, adhesion of, of platelets, platelets to, to the, the subendothelium, subendothelium by, by binding, binding to, to platelet, platelet glycoprotein, glycoprotein Ib, Ib ., . For, For human, human vWF, vWF ,, , this, this interaction, interaction can, can be, be induced, induced in, in vitro, vitro by, by the, the antibiotic, antibiotic ristocetin, ristocetin or, or the, the snake, snake venom, venom protein, protein botrocetin, botrocetin ., . A, A missense, missense mutation, mutation ,, , Gly-561, Gly-561 --, -- >, > Ser, Ser ,, , was, was identified, identified within, within the, the proposed, proposed glycoprotein, glycoprotein Ib, Ib binding, binding domain, domain of, of vWF, vWF in, in the, the proband, proband with, with von, von Willebrand, Willebrand disease, disease type, type B, B ,, , a, a unique, unique variant, variant characterized, characterized by, by no, no ristocetin-induced, ristocetin-induced ,, , but, but normal, normal botrocetin-induced, botrocetin-induced ,, , binding, binding to, to glycoprotein, glycoprotein Ib, Ib ., . The, The corresponding, corresponding mutant, mutant recombinant, recombinant protein, protein ,, , rvWF, rvWF (, ( G561S, G561S ), ) ,, , formed, formed normal, normal multimers, multimers and, and exhibited, exhibited the, the same, same functional, functional defect, defect as, as the, the patients, patients plasma, plasma vWF, vWF ,, , confirming, confirming that, that this, this mutation, mutation causes, causes von, von Willebrand, Willebrand disease, disease type, type B, B ., . These, These data, data show, show that, that botrocetin, botrocetin and, and ristocetin, ristocetin cofactor, cofactor activities, activities of, of vWF, vWF can, can be, be dissociated, dissociated by, by a, a point, point mutation, mutation and, and confirm, confirm that, that these, these mediators, mediators promote, promote vWF, vWF binding, binding to, to platelets, platelets by, by different, different mechanisms, mechanisms ., . The, The normal, normal botrocetin-induced, botrocetin-induced binding, binding and, and the, the defective, defective ristocetin-induced, ristocetin-induced binding, binding of, of rvWF, rvWF (, ( G561S, G561S ), ) suggest, suggest that, that the, the primary, primary defect, defect in, in von, von Willebrand, Willebrand disease, disease type, type B, B may, may be, be a, a failure, failure of, of normal, normal allosteric, allosteric regulation, regulation of, of the, the glycoprotein, glycoprotein Ib, Ib binding, binding function, function of, of vWF.., vWF.. We, We have, have analyzed, analyzed 20, 20 breast-ovarian, breast-ovarian cancer, cancer families, families ,, , the, the majority, majority of, of which, which show, show positive, positive evidence, evidence of, of linkage, linkage to, to chromosome, chromosome 17q12, 17q12 for, for germ-line, germ-line mutations, mutations in, in the, the BRCA1, BRCA1 gene, gene ., . BRCA1, BRCA1 mutations, mutations cosegregating, cosegregating with, with breast, breast and, and ovarian, ovarian cancer, cancer susceptibility, susceptibility were, were identified, identified in, in 16"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", 16 families, families ,, , including, including 1, 1 family, family with, with a, a case, case of, of male, male breast, breast cancer, cancer ., . Nine, Nine of, of these, these mutations, mutations have, have not, not been, been reported, reported previously, previously ., . The, The majority, majority of, of mutations, mutations were, were found, found to, to generate, generate a, a premature, premature stop, stop codon, codon leading, leading to, to the, the formation, formation of, of a, a truncated, truncated BRCA1, BRCA1 protein, protein of, of 2, 2 %, % -88, -88 %, % of, of the, the expected, expected normal, normal length, length ., . Two, Two mutations, mutations altered, altered the, the RING, RING finger, finger domain, domain ., . Sequencing, Sequencing of, of genomic, genomic DNA, DNA led, led to, to the, the identification, identification of, of a, a mutation, mutation in, in the, the coding, coding region, region of, of BRCA1, BRCA1 in, in 12, 12 families, families ,, , and, and cDNA, cDNA analysis, analysis revealed, revealed an, an abnormal, abnormal or, or missing, missing BRCA1, BRCA1 transcript, transcript in, in 4, 4 of, of the, the 8, 8 remaining, remaining families, families ., . A, A total, total of, of eight, eight mutations, mutations were, were associated, associated with, with a, a reduced, reduced quantity, quantity of, of BRCA1, BRCA1 transcript, transcript ., . We, We were, were unable, unable to, to detect, detect BRCA1, BRCA1 mutations, mutations in, in 4, 4 of, of the, the 20, 20 families, families ,, , but, but only, only 1, 1 of, of these, these was, was clearly, clearly linked, linked to, to BRCA1, BRCA1 ., . It, It is, is expected, expected that, that the, the majority, majority of, of clear, clear examples, examples of, of the, the breast-ovarian, breast-ovarian syndrome, syndrome will, will be, be associated, associated with, with germ-line, germ-line mutations, mutations in, in the, the coding, coding region, region of, of BRCA1.., BRCA1.. The, The Na, Na +/glucose, +/glucose cotransporter, cotransporter gene, gene SGLT1, SGLT1 encodes, encodes the, the primary, primary carrier, carrier protein, protein responsible, responsible for, for the, the uptake, uptake of, of the, the dietary, dietary sugars, sugars glucose, glucose and, and galactose, galactose from, from the, the intestinal, intestinal lumen, lumen ., . SGLT1, SGLT1 transport, transport activity, activity is, is currently, currently exploited, exploited in, in oral, oral rehydration, rehydration therapy, therapy ., . The, The 75-kDa, 75-kDa glycoprotein, glycoprotein is, is localized, localized in, in the, the brush, brush border, border of, of the, the intestinal, intestinal epithelium, epithelium and, and is, is predicted, predicted to, to comprise, comprise 12, 12 membrane, membrane spans, spans ., . In, In two, two patients, patients with, with the, the autosomal, autosomal recessive, recessive disease, disease glucose/galactose, glucose/galactose malabsorption, malabsorption ,, , the, the underlying, underlying cause, cause was, was found, found to, to be, be a, a missense, missense mutation, mutation in, in SGLT1, SGLT1 ,, , and, and the, the Asp28, Asp28 --, -- >, > Asn, Asn change, change was, was demonstrated, demonstrated in, in vitro, vitro to, to eliminate, eliminate SGLT1, SGLT1 transport, transport activity, activity ., . The, The SGLT1, SGLT1 gene, gene was, was previously, previously shown, shown to, to reside, reside on, on the, the distal, distal q, q arm, arm of, of chromosome, chromosome 22, 22 (, ( 11, 11 ., . 2, 2 --, -- >, > qter, qter ), ) ., . We, We have, have used, used a, a cosmid, cosmid probe, probe for, for fluorescence, fluorescence in, in situ, situ hybridization, hybridization ,, , which, which refines, refines the, the localization, localization to, to 22q13, 22q13 ., . 1, 1 ,, , and, and provide, provide an, an example, example of, of the, the utility, utility of, of the, the SGLT1, SGLT1 probe, probe as, as a, a diagnostic, diagnostic for, for genetic, genetic diseases, diseases associated, associated with, with translocations, translocations of, of chromosome, chromosome 22.Deficiency, 22.Deficiency of, of beta-hexosaminidase, beta-hexosaminidase A, A (, ( Hex, Hex A, A ), ) activity, activity typically, typically results, results in, in Tay-Sachs, Tay-Sachs disease, disease ., . However, However ,, , healthy, healthy subjects, subjects found, found to, to be, be deficient, deficient in, in Hex, Hex A, A activity, activity (, ( i., i. e., e. ,, , pseudodeficient, pseudodeficient ), ) by, by means, means of, of in, in vitro, vitro biochemical, biochemical tests, tests have, have been, been described, described ., . We, We analyzed, analyzed the, the HEXA, HEXA gene, gene of, of one, one pseudodeficient, pseudodeficient subject, subject and, and identified, identified both, both a, a C739-to-T, C739-to-T substitution, substitution that, that changes, changes Arg247, Arg247 --, -- --, -- Trp, Trp on, on one, one allele, allele and, and a, a previously, previously identified, identified Tay-Sachs, Tay-Sachs disease, disease mutation, mutation on, on the, the second, second allele, allele ., . Six, Six additional, additional pseudodeficient, pseudodeficient subjects, subjects were, were found, found to, to have, have the, the C739-to-T, C739-to-T mutation, mutation ., . This, This allele, allele accounted, accounted for, for 32, 32 %, % (, ( 20/62, 20/62 ), ) of, of non-Jewish, non-Jewish enzyme-defined, enzyme-defined Tay-Sachs, Tay-Sachs disease, disease carriers, carriers but, but for, for none, none of, of 36, 36 Jewish, Jewish enzyme-defined, enzyme-defined carriers, carriers who, who did, did not, not have, have one, one of, of three, three known, known mutations, mutations common, common to, to this, this group, group ., . The, The C739-to-T, C739-to-T allele, allele ,, , together, together with, with a, a ``, `` true, true ``, `` Tay-Sachs, Tay-Sachs disease, disease allele, allele ,, , causes, causes Hex, Hex A, A pseudodeficiency, pseudodeficiency ., . Given, Given both, both the, the large, large proportion, proportion of, of non-Jewish, non-Jewish carriers, carriers with, with this, this allele, allele and, and that, that standard, standard biochemical, biochemical screening, screening can, can not, not differentiate, differentiate between, between heterozygotes, heterozygotes for, for the, the C739-to-T, C739-to-T mutations, mutations and, and Tay-Sachs, Tay-Sachs disease, disease carriers, carriers ,, , DNA, DNA testing, testing for, for this, this mutation, mutation in, in at-risk, at-risk couples, couples is, is essential, essential ., . A, A study, study was, was undertaken, undertaken to, to characterize, characterize the, the mutation, mutation (, ( s, s ), ) responsible, responsible for, for Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) in, in a, a Cajun, Cajun population, population in, in southwest, southwest Louisiana, Louisiana and, and to, to identify, identify the, the origins, origins of, of these, these mutations, mutations ., . Eleven, Eleven of, of 12, 12 infantile, infantile TSD, TSD alleles, alleles examined, examined in, in six, six families, families had, had the, the beta-hexosaminidase, beta-hexosaminidase A, A (, ( Hex, Hex A, A ), ) alpha-subunit, alpha-subunit exon, exon 11, 11 insertion, insertion mutation, mutation that, that is, is present, present in, in approximately, approximately 70, 70 %, % of, of Ashkenazi, Ashkenazi Jewish, Jewish TSD, TSD heterozygotes, heterozygotes ., . The, The mutation, mutation in, in the, the remaining, remaining allele, allele was, was a, a single-base, single-base transition, transition in, in the, the donor, donor splice, splice site, site of, of the, the alpha-subunit, alpha-subunit intron, intron 9, 9 ., . To, To determine, determine the, the origins, origins of, of these, these two, two mutations, mutations in, in the, the Cajun, Cajun population, population ,, , the, the TSD, TSD carrier, carrier status, status was, was enzymatically, enzymatically determined, determined for, for 90, 90 members, members of, of four, four of, of the, the six, six families, families ,, , and, and extensive, extensive pedigrees, pedigrees were, were constructed, constructed for, for all, all carriers, carriers ., . A, A single, single ancestral, ancestral couple, couple from, from France, France was, was found, found to, to be, be common, common to, to most, most of, of the, the carriers, carriers of, of the, the exon, exon 11, 11 insertion, insertion ., . Pedigree, Pedigree data, data suggest, suggest that, that this, this mutation, mutation has, has been, been in, in the, the Cajun, Cajun population, population since, since its, its founding, founding over, over 2, 2 centuries, centuries ago, ago and, and that, that it, it may, may be, be widely, widely distributed, distributed within, within the, the population, population ., . In, In contrast, contrast ,, , the, the intron, intron 9, 9 mutation, mutation apparently, apparently was, was introduced, introduced within, within the, the last, last century, century and, and probably, probably is, is limited, limited to, to a, a few, few Louisiana, Louisiana families.., families.. Canavan, Canavan disease, disease ,, , or, or spongy, spongy degeneration, degeneration of, of the, the brain, brain ,, , is, is a, a severe, severe leukodystrophy, leukodystrophy caused, caused by, by the, the deficiency, deficiency of, of aspartoacylase, aspartoacylase (, ( ASPA, ASPA ), ) ., . Recently, Recently ,, , a, a missense, missense mutation, mutation was, was identified, identified in, in human, human ASPA, ASPA coding, coding sequence, sequence from, from patients, patients with, with Canavan, Canavan disease, disease ., . The, The human, human ASPA, ASPA gene, gene has, has been, been cloned, cloned and, and found, found to, to span, span 29, 29 kb, kb of, of the, the genome, genome ., . Human, Human aspartoacylase, aspartoacylase is, is coded, coded by, by six, six exons, exons intervened, intervened by, by five, five introns, introns ., . The, The exons, exons vary, vary from, from 94, 94 (, ( exon, exon III, III ), ) to, to 514, 514 (, ( exon, exon VI, VI ), ) bases, bases ., . The, The exon/intron, exon/intron splice, splice junction, junction sites, sites follow, follow the, the gt/ag, gt/ag consensus, consensus sequence, sequence rule, rule ., . Southern, Southern blot, blot analysis, analysis of, of genomic, genomic DNA, DNA from, from human/mouse, human/mouse somatic, somatic cell, cell hybrid, hybrid cell, cell lines, lines localized, localized ASPA, ASPA to, to human, human chromosome, chromosome 17, 17 ., . The, The human, human ASPA, ASPA locus, locus was, was further, further mapped, mapped in, in the, the 17p13-ter, 17p13-ter region, region by, by fluorescence, fluorescence in, in situ, situ hybridization, hybridization ., . The, The bovine, bovine aspa, aspa gene, gene has, has also, also been, been cloned, cloned ,, , and, and its, its exon/intron, exon/intron organization, organization is, is identical, identical to, to that, that of, of the, the human, human gene, gene ., . The, The 500-base, 500-base sequence, sequence upstream, upstream of, of the, the initiator, initiator ATG, ATG codon, codon in, in the, the human, human gene, gene and, and that, that in, in the, the bovine, bovine gene, gene are, are 77, 77 %, % identical, identical ., . Human, Human ASPA, ASPA coding, coding sequences, sequences cross-hybridize, cross-hybridize with, with genomic, genomic DNA, DNA from, from yeast, yeast ,, , chicken, chicken ,, , rabbit, rabbit ,, , cow, cow ,, , dog, dog ,, , mouse, mouse ,, , rat, rat ,, , and, and monkey, monkey ., . The, The specificity, specificity of, of cross-species, cross-species hybridization, hybridization of, of coding, coding sequences, sequences suggests, suggests that, that aspartoacylase, aspartoacylase has, has been, been conserved, conserved during, during evolution, evolution ., . It, It should, should now, now be, be possible, possible to, to identify, identify mutations, mutations in, in the, the noncoding, noncoding genomic, genomic sequences, sequences that, that lead, lead to, to Canavan, Canavan disease, disease and, and to, to study, study the, the regulation, regulation of, of ASPA.., ASPA.. Adrenoleukodystrophy, Adrenoleukodystrophy (, ( ALD, ALD ), ) is, is a, a genetically, genetically determined, determined disorder, disorder associated, associated with, with progressive, progressive central, central demyelination, demyelination and, and adrenal, adrenal cortical, cortical insufficiency, insufficiency ., . All, All affected, affected persons, persons show, show increased, increased levels, levels of, of saturated, saturated unbranched, unbranched very-long-chain, very-long-chain fatty, fatty acids, acids ,, , particularly, particularly hexacosanoate, hexacosanoate (, ( C26, C26 0, 0 ), ) ,, , because, because of, of impaired, impaired capacity, capacity to, to degrade, degrade these, these acids, acids ., . This, This degradation, degradation normally, normally takes, takes place, place in, in a, a subcellular, subcellular organelle, organelle called, called the, the peroxisome, peroxisome ,, , and, and ALD, ALD ,, , together, together with, with Zellwegers, Zellwegers cerebrohepatorenal, cerebrohepatorenal syndrome, syndrome ,, , is, is now, now considered, considered to, to belong, belong to, to the, the newly, newly formed, formed category, category of, of peroxisomal, peroxisomal disorders, disorders ., . Biochemical, Biochemical assays, assays permit, permit prenatal, prenatal diagnosis, diagnosis ,, , as, as well, well as, as identification, identification of, of most, most heterozygotes, heterozygotes ., . We, We have, have identified, identified 303, 303 patients, patients with, with ALD, ALD in, in 217, 217 kindreds, kindreds ., . These, These patients, patients show, show a, a wide, wide phenotypic, phenotypic variation, variation ., . Sixty, Sixty percent, percent of, of patients, patients had, had childhood, childhood ALD, ALD and, and 17, 17 %, % adrenomyeloneuropathy, adrenomyeloneuropathy ,, , both, both of, of which, which are, are X-linked, X-linked ,, , with, with the, the gene, gene mapped, mapped to, to Xq28, Xq28 ., . Neonatal, Neonatal ALD, ALD ,, , a, a distinct, distinct entity, entity with, with autosomal, autosomal recessive, recessive inheritance, inheritance and, and points, points of, of resemblance, resemblance to, to Zellwegers, Zellwegers syndrome, syndrome ,, , accounted, accounted for, for 7, 7 %, % of, of the, the cases, cases ., . Although, Although excess, excess C26, C26 0, 0 in, in the, the brain, brain of, of patients, patients with, with ALD, ALD is, is partially, partially of, of dietary, dietary origin, origin ,, , dietary, dietary C26, C26 0, 0 restriction, restriction did, did not, not produce, produce clear, clear benefit, benefit ., . Bone, Bone marrow, marrow transplant, transplant lowered, lowered the, the plasma, plasma C26, C26 0, 0 level, level but, but failed, failed to, to arrest, arrest neurological, neurological progression.., progression.. Segregation, Segregation distortion, distortion has, has been, been reported, reported to, to occur, occur in, in a, a number, number of, of the, the trinucleotide, trinucleotide repeat, repeat disorders, disorders ., . On, On the, the basis, basis of, of a, a sperm, sperm typing, typing study, study performed, performed in, in patients, patients of, of Japanese, Japanese descent, descent with, with Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) ,, , it, it was, was reported, reported that, that disease, disease alleles, alleles are, are preferentially, preferentially transmitted, transmitted during, during meiosis, meiosis ., . We, We performed, performed a, a sperm, sperm typing, typing study, study of, of five, five MJD, MJD patients, patients of, of French, French descent, descent and, and analysis, analysis of, of the, the pooled, pooled data, data shows, shows a, a ratio, ratio of, of mutant, mutant to, to normal, normal alleles, alleles of, of 379, 379 436, 436 (, ( 46, 46 ., . 5, 5 53, 53 ., . 5, 5 %, % ), ) ,, , which, which does, does not, not support, support meiotic, meiotic segregation, segregation distortion, distortion ., . To, To confirm, confirm these, these results, results ,, , sperm, sperm typing, typing analysis, analysis was, was also, also performed, performed using, using a, a polymorphic, polymorphic marker, marker ,, , D14S1050, D14S1050 ,, , closely, closely linked, linked to, to the, the MJD1, MJD1 gene, gene ., . Among, Among 910, 910 sperm, sperm analyzed, analyzed ,, , the, the allele, allele linked, linked to, to the, the disease, disease chromosome, chromosome was, was detected, detected in, in 50, 50 ., . 3, 3 %, % of, of the, the samples, samples and, and the, the allele, allele linked, linked to, to the, the normal, normal chromosome, chromosome was, was found, found in, in 49, 49 ., . 6, 6 %, % of, of the, the sperm, sperm ., . The, The difference, difference in, in frequency, frequency of, of these, these two, two alleles, alleles is, is not, not significant, significant (, ( P, P =, = 0, 0 ., . 8423, 8423 ), ) ., . Likelihood-based, Likelihood-based analysis, analysis of, of segregation, segregation distortion, distortion in, in the, the single, single sperm, sperm data, data using, using the, the SPERMSEG, SPERMSEG program, program also, also showed, showed no, no support, support for, for segregation, segregation distortion, distortion at, at the, the gamete, gamete level, level in, in this, this patient, patient population, population ., . The, The previous, previous report, report on, on the, the Japanese, Japanese patients, patients also, also suggested, suggested that, that disease, disease allele, allele stability, stability may, may be, be influenced, influenced by, by a, a trans, trans effect, effect of, of an, an intragenic, intragenic polymorphism, polymorphism (, ( 987, 987 G/C, G/C ), ) in, in the, the wild-type, wild-type allele, allele ., . All, All of, of the, the French, French patients, patients were, were heterozygous, heterozygous for, for this, this polymorphism, polymorphism ., . However, However ,, , analysis, analysis of, of the, the variance, variance in, in repeat, repeat number, number in, in sperm, sperm from, from the, the French, French MJD, MJD patients, patients overlapped, overlapped significantly, significantly with, with the, the variance, variance in, in repeat, repeat number, number observed, observed in, in the, the C/C, C/C homozygous, homozygous Japanese, Japanese patients.The, patients.The presence, presence of, of nebulin, nebulin in, in a, a muscle, muscle specimen, specimen from, from a, a patient, patient with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) due, due to, to a, a large, large deletion, deletion precludes, precludes the, the possibility, possibility that, that this, this protein, protein is, is the, the DMD, DMD gene, gene product.., product.. Alkaptonuria, Alkaptonuria (, ( AKU, AKU ;, ; McKusick, McKusick no, no ., . 203500, 203500 ), ) is, is a, a rare, rare autosomal, autosomal recessive, recessive disorder, disorder caused, caused by, by the, the lack, lack of, of homogentisic, homogentisic acid, acid oxidase, oxidase activity, activity ., . Patients, Patients excrete, excrete large, large amounts, amounts of, of homogentisic, homogentisic acid, acid in, in their, their urine, urine and, and a, a black, black ochronotic, ochronotic pigment, pigment is, is deposited, deposited in, in their, their cartilage, cartilage and, and collagenous, collagenous tissues, tissues ., . Ochronosis, Ochronosis is, is the, the predominant, predominant clinical, clinical complication, complication of, of the, the disease, disease leading, leading to, to ochronotic, ochronotic arthropathy, arthropathy ,, , dark, dark urine, urine ,, , pigment, pigment changes, changes of, of the, the skin, skin ,, , and, and other, other clinical, clinical features, features ., . A, A mutation, mutation causing, causing alkaptonuria, alkaptonuria in, in the, the mouse, mouse has, has mapped, mapped to, to chromosome, chromosome 16, 16 ., . Considering, Considering conserved, conserved synteny, synteny ,, , we, we were, were able, able to, to map, map the, the human, human gene, gene to, to chromosome, chromosome 3q, 3q in, in six, six alkaptonuria, alkaptonuria pedigrees, pedigrees of, of Slovak, Slovak origin.., origin.. Although, Although gastric, gastric cancer, cancer is, is the, the most, most common, common cancer, cancer in, in the, the world, world ,, , genetic, genetic changes, changes during, during its, its carcinogenesis"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", carcinogenesis are, are not, not well, well understood, understood ., . Since, Since some, some gastric, gastric cancers, cancers are, are considered, considered to, to originate, originate from, from the, the intestinal, intestinal metaplasia, metaplasia ,, , it, it is, is likely, likely that, that the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene ,, , the, the mutation, mutation of, of which, which causes, causes adenomatous, adenomatous polyps, polyps in, in the, the colon, colon ,, , is, is associated, associated with, with carcinogenesis, carcinogenesis of, of gastric, gastric cancer, cancer ., . Based, Based on, on this, this idea, idea ,, , DNAs, DNAs isolated, isolated from, from gastric, gastric cancers, cancers were, were examined, examined by, by means, means of, of a, a RNase, RNase protection, protection analysis, analysis coupled, coupled with, with polymerase, polymerase chain, chain reaction, reaction followed, followed by, by sequencing, sequencing of, of the, the polymerase, polymerase chain, chain reaction, reaction products, products ., . By, By screening, screening nearly, nearly one-half, one-half of, of the, the coding, coding region, region of, of the, the APC, APC gene, gene in, in 44, 44 tumors, tumors ,, , somatic, somatic mutations, mutations were, were detected, detected in, in three, three tumors, tumors a, a missense, missense mutation, mutation ,, , a, a nonsense, nonsense mutation, mutation ,, , and, and a, a 5-base, 5-base pair, pair deletion, deletion resulting, resulting in, in a, a frame, frame shift, shift which, which causes, causes truncation, truncation of, of the, the gene, gene product, product ., . These, These results, results suggest, suggest that, that the, the mutation, mutation of, of the, the APC, APC gene, gene also, also plays, plays an, an important, important role, role during, during the, the carcinogenesis, carcinogenesis of, of at, at least, least some, some gastric, gastric cancers.., cancers.. Deficiency, Deficiency of, of the, the ninth, ninth component, component of, of human, human complement, complement (, ( C9, C9 ), ) is, is the, the most, most common, common complement, complement deficiency, deficiency in, in Japan, Japan ,, , with, with an, an incidence, incidence of, of approximately, approximately one, one homozygote, homozygote in, in 1000, 1000 ,, , but, but is, is very, very rare, rare in, in other, other countries, countries ., . Genetic, Genetic analyses, analyses of, of Japanese, Japanese C9, C9 deficiency, deficiency have, have shown, shown that, that a, a C-to-T, C-to-T transition, transition leading, leading to, to TGA, TGA stop, stop codon, codon for, for Arg95, Arg95 in, in exon, exon 4, 4 of, of the, the C9, C9 gene, gene (, ( Arg95Stop, Arg95Stop ), ) is, is common, common in, in Japanese, Japanese C9, C9 deficiency, deficiency ., . To, To determine, determine the, the prevalence, prevalence of, of heterozygous, heterozygous carriers, carriers of, of the, the Arg95Stop, Arg95Stop mutation, mutation in, in a, a Japanese, Japanese population, population ,, , we, we collected, collected DNA, DNA samples, samples from, from 300, 300 individuals, individuals in, in two, two of, of the, the four, four main, main islands, islands of, of Japan, Japan ., . Heterozygote, Heterozygote detection, detection was, was performed, performed with, with an, an allele-specific, allele-specific polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) system, system designed, designed to, to detect, detect exclusively, exclusively only, only one, one of, of the, the normal, normal and, and mutant, mutant alleles, alleles ,, , followed, followed by, by confirmation, confirmation with, with PCR/single-strand, PCR/single-strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) analysis, analysis and, and direct, direct sequencing, sequencing ., . Twenty, Twenty individuals, individuals were, were heterozygous, heterozygous for, for the, the Arg95Stop, Arg95Stop mutation, mutation ., . None, None was, was homozygous, homozygous ., . The, The prevalence, prevalence of, of carriers, carriers of, of the, the Arg95Stop, Arg95Stop mutation, mutation was, was 6, 6 ., . 7, 7 %, % (, ( 20/300, 20/300 ), ) ., . An, An estimated, estimated frequency, frequency (, ( 0, 0 ., . 12, 12 %, % ), ) of, of complete, complete C9, C9 deficiency, deficiency due, due to, to homozygous, homozygous Arg95Stop, Arg95Stop mutation, mutation was, was consistent, consistent with, with frequencies, frequencies determined, determined by, by serological, serological studies, studies We, We report, report the, the identification, identification of, of a, a female, female patient, patient with, with the, the X-linked, X-linked recessive, recessive Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome (, ( hypoxanthine, hypoxanthine phosphoribosyltransferase, phosphoribosyltransferase [, [ HPRT, HPRT ], ] deficiency, deficiency ), ) ., . Cytogenetic, Cytogenetic and, and carrier, carrier studies, studies revealed, revealed structurally, structurally normal, normal chromosomes, chromosomes for, for this, this patient, patient and, and her, her parents, parents and, and demonstrated, demonstrated that, that this, this mutation, mutation arose, arose through, through a, a de, de novo, novo gametic, gametic event, event ., . Comparison, Comparison of, of this, this patients, patients DNA, DNA with, with the, the DNA, DNA of, of her, her parents, parents revealed, revealed that, that a, a microdeletion, microdeletion ,, , which, which occurred, occurred within, within a, a maternal, maternal gamete, gamete and, and involved, involved the, the entire, entire HPRT, HPRT gene, gene ,, , was, was partially, partially responsible, responsible for, for the, the disease, disease in, in this, this patient, patient ., . Somatic, Somatic cell, cell hybrids, hybrids ,, , generated, generated to, to separate, separate maternal, maternal and, and paternal, paternal X, X chromosomes, chromosomes ,, , showed, showed that, that expression, expression of, of two, two additional, additional X-linked, X-linked enzymes, enzymes ,, , phosphoglycerate, phosphoglycerate kinase, kinase and, and glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase ,, , were, were expressed, expressed only, only in, in cells, cells that, that contained, contained the, the maternal, maternal X, X chromosome, chromosome ,, , suggesting, suggesting the, the presence, presence of, of a, a functionally, functionally inactive, inactive paternal, paternal X, X chromosome, chromosome ., . Furthermore, Furthermore ,, , comparison, comparison of, of methylation, methylation patterns, patterns within, within a, a region, region of, of the, the HPRT, HPRT gene, gene known, known to, to be, be important, important in, in gene, gene regulation, regulation revealed, revealed differences, differences between, between DNA, DNA from, from the, the father, father and, and the, the patient, patient ,, , in, in keeping, keeping with, with an, an active, active HPRT, HPRT locus, locus in, in the, the father, father and, and an, an inactive, inactive HPRT, HPRT locus, locus in, in the, the patient, patient ., . Together, Together these, these data, data indicate, indicate that, that nonrandom, nonrandom inactivation, inactivation of, of the, the cytogenetically, cytogenetically normal, normal paternal, paternal X, X chromosome, chromosome and, and a, a microdeletion, microdeletion of, of the, the HPRT, HPRT gene, gene on, on an, an active, active maternal, maternal X, X chromosome, chromosome were, were responsible, responsible for, for the, the absence, absence of, of HPRT, HPRT in, in this, this patient.., patient.. Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EDMD, EDMD ), ) is, is an, an X-linked, X-linked recessive, recessive muscular, muscular dystrophy, dystrophy characterized, characterized by, by early, early contractures, contractures of, of the, the elbows, elbows ,, , Achilles, Achilles tendons, tendons and, and spine, spine ,, , slowly, slowly progressive, progressive muscle, muscle wasting, wasting and, and weakness, weakness ,, , and, and cardiomyopathy, cardiomyopathy associated, associated with, with cardiac, cardiac conduction, conduction defects, defects ., . The, The emerin, emerin gene, gene has, has been, been mapped, mapped to, to Xq28, Xq28 and, and encodes, encodes a, a 34-kDa, 34-kDa serine-rich, serine-rich protein, protein ,, , emerin, emerin ,, , which, which has, has been, been localized, localized to, to the, the nuclear, nuclear envelope, envelope in, in a, a wide, wide variety, variety of, of tissues, tissues ,, , including, including skeletal, skeletal and, and cardiac, cardiac muscle, muscle ., . Mutations, Mutations spanning, spanning the, the emerin, emerin gene, gene have, have been, been identified, identified in, in patients, patients with, with EDMD, EDMD ., . We, We present, present here, here the, the effect, effect ,, , on, on emerin, emerin protein, protein expression, expression ,, , of, of two, two missense, missense mutations, mutations identified, identified in, in unrelated, unrelated EDMD, EDMD patients, patients ., . These, These alterations, alterations predict, predict the, the replacement, replacement of, of a, a proline, proline residue, residue at, at position, position 183, 183 with, with either, either a, a histidine, histidine or, or a, a threonine, threonine ., . Biochemical, Biochemical analysis, analysis has, has demonstrated, demonstrated that, that the, the mobility, mobility and, and expression, expression levels, levels of, of the, the mutant, mutant forms, forms of, of emerin, emerin are, are indistinguishable, indistinguishable from, from that, that of, of wild-type, wild-type emerin, emerin ,, , but, but that, that they, they have, have weakened, weakened interactions, interactions with, with nuclear, nuclear lamina, lamina components, components ., . In, In comparison, comparison with, with the, the usual, usual EDMD, EDMD phenotype, phenotype ,, , patients, patients with, with P183, P183 missense, missense mutations, mutations have, have a, a later, later age, age at, at onset, onset of, of first, first symptoms, symptoms ,, , elbow, elbow contractures, contractures ,, , ankle, ankle contractures, contractures ,, , upper, upper limb, limb weakness, weakness and, and lower, lower limb, limb weakness, weakness ,, , but, but there, there is, is no, no difference, difference for, for the, the age, age at, at onset, onset of, of cardiac, cardiac involvement, involvement ., . This, This is, is the, the first, first report, report of, of protein, protein studies, studies on, on patients, patients with, with missense, missense mutations, mutations resulting, resulting in, in the, the clinical, clinical features, features of, of EDMD, EDMD ., . These, These studies, studies demonstrate, demonstrate the, the importance, importance of, of proline, proline 183, 183 for, for the, the proper, proper structure/function, structure/function of, of emerin.., emerin.. We, We have, have characterized, characterized expression, expression of, of the, the familial, familial breast, breast and, and ovarian, ovarian cancer, cancer gene, gene ,, , BRCA1, BRCA1 ,, , in, in cases, cases of, of non-hereditary, non-hereditary (, ( sporadic, sporadic ), ) breast, breast cancer, cancer and, and analyzed, analyzed the, the effect, effect of, of antisense, antisense inhibition, inhibition of, of BRCA1, BRCA1 on, on the, the proliferative, proliferative rate, rate of, of mammary, mammary epithelial, epithelial cells, cells ., . BRCA1, BRCA1 mRNA, mRNA levels, levels are, are markedly, markedly decreased, decreased during, during the, the transition, transition from, from carcinoma, carcinoma in, in situ, situ to, to invasive, invasive cancer, cancer ., . Experimental, Experimental inhibition, inhibition of, of BRCA1, BRCA1 expression, expression with, with antisense, antisense oligonucleotides, oligonucleotides produced, produced accelerated, accelerated growth, growth of, of normal, normal and, and malignant, malignant mammary, mammary cells, cells ,, , but, but had, had no, no effect, effect on, on non-mammary, non-mammary epithelial, epithelial cells, cells ., . These, These studies, studies suggest, suggest that, that BRCA1, BRCA1 may, may normally, normally serve, serve as, as a, a negative, negative regulator, regulator of, of mammary, mammary epithelial, epithelial cell, cell growth, growth whose, whose function, function is, is compromised, compromised in, in breast, breast cancer, cancer either, either by, by direct, direct mutation, mutation or, or alterations, alterations in, in gene, gene expression.., expression.. The, The proteolipid, proteolipid protein, protein gene, gene (, ( PLP, PLP ), ) is, is normally, normally present, present at, at chromosome, chromosome Xq22, Xq22 ., . Mutations, Mutations and, and duplications, duplications of, of this, this gene, gene are, are associated, associated with, with Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease (, ( PMD, PMD ), ) ., . Here, Here we, we describe, describe two, two new, new families, families in, in which, which males, males affected, affected with, with PMD, PMD were, were found, found to, to have, have a, a copy, copy of, of PLP, PLP on, on the, the short, short arm, arm of, of the, the X, X chromosome, chromosome ,, , in, in addition, addition to, to a, a normal, normal copy, copy on, on Xq22, Xq22 ., . In, In the, the first, first family, family ,, , the, the extra, extra copy, copy was, was first, first detected, detected by, by the, the presence, presence of, of heterozygosity, heterozygosity of, of the, the AhaII, AhaII dimorphism, dimorphism within, within the, the PLP, PLP gene, gene ., . The, The results, results of, of FISH, FISH analysis, analysis showed, showed an, an additional, additional copy, copy of, of PLP, PLP in, in Xp22, Xp22 ., . 1, 1 ,, , although, although no, no chromosomal, chromosomal rearrangements, rearrangements could, could be, be detected, detected by, by standard, standard karyotype, karyotype analysis, analysis ., . Another, Another three, three affected, affected males, males from, from the, the family, family had, had similar, similar findings, findings ., . In, In a, a second, second unrelated, unrelated family, family with, with signs, signs of, of PMD, PMD ,, , cytogenetic, cytogenetic analysis, analysis showed, showed a, a pericentric, pericentric inversion, inversion of, of the, the X, X chromosome, chromosome ., . In, In the, the inv, inv (, ( X, X ), ) carried, carried by, by several, several affected, affected family, family members, members ,, , FISH, FISH showed, showed PLP, PLP signals, signals at, at Xp11, Xp11 ., . 4, 4 and, and Xq22, Xq22 ., . A, A third, third family, family has, has previously, previously been, been reported, reported ,, , in, in which, which affected, affected members, members had, had an, an extra, extra copy, copy of, of the, the PLP, PLP gene, gene detected, detected at, at Xq26, Xq26 in, in a, a chromosome, chromosome with, with an, an otherwise, otherwise normal, normal banding, banding pattern, pattern ., . The, The identification, identification of, of three, three separate, separate families, families in, in which, which PLP, PLP is, is duplicated, duplicated at, at a, a noncontiguous, noncontiguous site, site suggests, suggests that, that such, such duplications, duplications could, could be, be a, a relatively, relatively common, common but, but previously, previously undetected, undetected cause, cause of, of genetic, genetic disorders.We, disorders.We have, have studied, studied the, the genetic, genetic linkage, linkage of, of two, two markers, markers ,, , the, the apolipoprotein, apolipoprotein C1, C1 (, ( APOC1, APOC1 ), ) gene, gene and, and a, a cytochrome, cytochrome P450, P450 (, ( CYP2A, CYP2A ), ) gene, gene ,, , in, in relation, relation to, to the, the gene, gene for, for myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ., . A, A peak, peak lod, lod score, score of, of 9, 9 ., . 29, 29 at, at 2, 2 cM, cM was, was observed, observed for, for APOC1-DM, APOC1-DM ,, , with, with a, a lod, lod score, score of, of 8, 8 ., . 55, 55 at, at 4, 4 cM, cM for, for CYP2A-DM, CYP2A-DM ., . These, These two, two markers, markers also, also show, show close, close linkage, linkage to, to each, each other, other (, ( theta, theta max, max =, = 0, 0 ., . 05, 05 ,, , Zmax, Zmax =, = 9, 9 ., . 09, 09 ), ) ., . From, From examination, examination of, of the, the genotypes, genotypes of, of the, the recombinant, recombinant individuals, individuals ,, , CYP2A, CYP2A appears, appears to, to map, map proximal, proximal to, to DM, DM because, because in, in one, one recombinant, recombinant individual, individual CYP2A, CYP2A ,, , APOC2, APOC2 and, and CKMM, CKMM had, had all, all recombined, recombined with, with DM, DM ., . Evidence, Evidence from, from another, another CYP2A-DM, CYP2A-DM recombinant, recombinant individual, individual places, places CYP2A, CYP2A proximal, proximal to, to APOC2, APOC2 and, and CKMM, CKMM ., . Localisation, Localisation of, of CYP2A, CYP2A on, on a, a panel, panel of, of somatic, somatic cell, cell hybrids, hybrids also, also suggests, suggests that, that it, it is, is proximal, proximal to, to DM, DM and, and APOC2/C1/E, APOC2/C1/E gene, gene cluster, cluster ., . GM1-gangliosidosis, GM1-gangliosidosis is, is a, a lysosomal, lysosomal storage, storage disorder, disorder caused, caused by, by deficiency, deficiency of, of acid, acid beta-galactosidase, beta-galactosidase (, ( GLB1, GLB1 ), ) ., . We, We report, report five, five new, new beta-galactosidase, beta-galactosidase gene, gene mutations, mutations in, in nine, nine Italian, Italian patients, patients and, and one, one fetus, fetus ,, , segregating, segregating in, in seven, seven unrelated, unrelated families, families ., . Six, Six of, of the, the eight, eight patients, patients with, with the, the infantile, infantile ,, , severe, severe form, form of, of the, the disease, disease presented, presented cardiac, cardiac involvement, involvement ,, , a, a feature, feature rarely, rarely associated, associated with, with GM1-gangliosidosis, GM1-gangliosidosis ., . Molecular, Molecular analysis, analysis of, of the, the patients, patients RNA, RNA and, and DNA, DNA identified, identified two, two new, new RNA, RNA splicing, splicing defects, defects ,, , three, three new, new and, and three, three previously, previously described, described amino, amino acid, acid substitutions, substitutions ., . Interestingly, Interestingly ,, , all, all patients, patients with, with cardiac, cardiac involvement, involvement were, were homozygous, homozygous for, for one, one of, of these, these mutations, mutations R59H, R59H ,, , Y591C, Y591C ,, , Y591N, Y591N ,, , or, or IVS14-2A, IVS14-2A >, > G., G. In, In contrast, contrast ,, , all, all other, other patients, patients were, were compound, compound heterozygous, heterozygous for, for one, one of, of the, the following, following mutations, mutations R201H, R201H ,, , R482H, R482H ,, , G579D, G579D ,, , IVS8, IVS8 +, + 2T, 2T >, > C., C. Although, Although we, we could, could not, not directly, directly correlate, correlate the, the presence, presence of, of cardiac, cardiac abnormalities, abnormalities with, with specific, specific genetic, genetic lesions, lesions ,, , the, the mutations, mutations identified, identified in, in patients, patients with, with cardiomyopathy, cardiomyopathy fell, fell in, in the, the GLB1, GLB1 cDNA, cDNA region, region common, common to, to the, the lysosomal, lysosomal enzyme, enzyme and, and the, the Hbeta-Gal-related, Hbeta-Gal-related protein, protein ,, , also, also known, known as, as the, the elastin, elastin binding, binding protein, protein (, ( EBP, EBP ), ) ., . Consequently, Consequently ,, , both, both molecules, molecules are, are affected, affected by, by the, the mutations, mutations ,, , and, and they, they may, may contribute, contribute differently, differently to, to the, the occurrence, occurrence of, of specific, specific clinical, clinical manifestations.., manifestations.. We, We studied, studied the, the relationship, relationship between, between the, the autosomal, autosomal recessive, recessive trait, trait familial, familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) and, and the, the serum, serum amyloid, amyloid A, A (, ( SAA, SAA ), ) genes, genes by, by comparing, comparing alleles, alleles of, of a, a highly, highly polymorphic, polymorphic dinucleotide, dinucleotide repeat, repeat and, and a, a conventional, conventional restriction, restriction fragment, fragment length, length polymorphism, polymorphism (, ( RFLP, RFLP ), ) in, in the, the SAA, SAA gene, gene cluster, cluster in, in Israeli, Israeli FMF, FMF kindreds, kindreds ., . By, By haplotype, haplotype analysis, analysis ,, , our, our data, data indicate, indicate a, a minimum, minimum crossover, crossover frequency, frequency of, of 22, 22 %, % between, between the, the SAA, SAA gene, gene marker, marker and, and FMF, FMF ., . By, By conventional, conventional linkage, linkage analysis, analysis this, this eliminates, eliminates a, a minimum, minimum of, of 10, 10 ., . 4, 4 cM, cM including, including and, and surrounding, surrounding the, the SAA, SAA gene, gene cluster, cluster as, as the, the site, site of, of the, the FMF, FMF mutation, mutation although, although SAA, SAA proteins, proteins are, are prominent, prominent physiologic, physiologic markers, markers of, of the, the acute, acute attacks, attacks ., . Expansion, Expansion of, of a, a CTG, CTG trinucleotide, trinucleotide repeat, repeat in, in the, the 3, 3 UTR, UTR of, of the, the gene, gene DMPK, DMPK at, at the, the DM1, DM1 locus, locus on, on chromosome, chromosome 19, 19 causes, causes myotonic, myotonic dystrophy, dystrophy ,, , a, a dominantly, dominantly inherited, inherited disease, disease characterized, characterized by, by skeletal, skeletal muscle, muscle dystrophy, dystrophy and, and myotonia, myotonia ,, , cataracts, cataracts and, and cardiac, cardiac conduction, conduction defects, defects ., . Targeted, Targeted deletion, deletion of, of Dm15, Dm15 ,, , the, the mouse, mouse orthologue, orthologue of, of human, human DMPK, DMPK ,, , produced, produced mice, mice with, with a, a mild, mild myopathy, myopathy and, and cardiac, cardiac conduction, conduction abnormalities, abnormalities ,, , but, but without, without other, other features, features of, of myotonic, myotonic dystrophy, dystrophy ,, , such, such as, as myotonia, myotonia and, and cataracts, cataracts ., . We, We ,, , and, and others, others ,, , have, have demonstrated, demonstrated that, that repeat, repeat expansion, expansion decreases, decreases expression, expression of, of the, the adjacent, adjacent gene, gene SIX5, SIX5 (, ( refs, refs 7, 7 ,, , 8, 8 ), ) ,, , which, which encodes, encodes a, a homeodomain, homeodomain transcription, transcription factor, factor ., . To, To determine, determine whether, whether SIX5, SIX5 deficiency, deficiency contributes, contributes to, to the, the myotonic, myotonic dystrophy, dystrophy phenotype, phenotype ,, , we, we disrupted, disrupted mouse, mouse Six5, Six5 by, by replacing, replacing the, the first, first exon, exon with, with a, a beta-galactosidase, beta-galactosidase reporter, reporter ., . Six5-mutant, Six5-mutant mice, mice showed, showed reporter, reporter expression, expression in, in multiple, multiple tissues, tissues ,, , including, including the, the developing, developing lens, lens ., . Homozygous, Homozygous mutant, mutant mice, mice had, had no, no apparent, apparent abnormalities, abnormalities of, of skeletal, skeletal muscle, muscle function, function ,, , but, but developed, developed lenticular, lenticular opacities, opacities at, at a, a higher, higher rate, rate than, than controls, controls ., . Our, Our results, results suggest, suggest that, that SIX5, SIX5 deficiency, deficiency contributes, contributes to, to the, the cataract, cataract phenotype, phenotype in, in myotonic, myotonic dystrophy, dystrophy ,, , and, and that, that myotonic, myotonic dystrophy, dystrophy represents, represents a, a multigenic, multigenic disorder.., disorder.. We, We report, report here, here the, the result, result of, of a, a screening, screening for, for germ-line, germ-line mutations, mutations in, in the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene in, in 61, 61 new, new familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) patients, patients as, as well, well as, as a, a summary, summary of, of the, the results, results of, of 150, 150 patients, patients ., . Examination, Examination of, of the, the entire, entire coding, coding region, region of, of the, the APC, APC gene, gene ,, , based, based on, on a, a ribonuclease, ribonuclease protection, protection assay, assay coupled, coupled with, with the, the polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) ,, , disclosed, disclosed mutations, mutations that, that were, were considered, considered to, to cause, cause significant, significant defects, defects in, in the, the APC, APC product, product in, in 97, 97 of, of 150, 150 unrelated, unrelated FAP, FAP patients, patients ., . Our, Our findings, findings revealed, revealed the, the following, following characteristics, characteristics of, of the, the germ-line, germ-line mutations, mutations of, of APC, APC 1, 1 ), ) the, the great, great majority, majority of, of the, the mutations, mutations were, were found, found to, to truncate, truncate the, the APC, APC product, product ;, ; 2, 2 ), ) almost, almost all, all of, of the, the mutations, mutations were, were located, located within, within the, the first, first half, half of, of the, the coding, coding region, region ;, ; 3, 3 ), ) no, no correlation, correlation was, was observed, observed between, between the, the locations, locations of, of germ-line, germ-line mutations, mutations and, and extracolonic, extracolonic manifestations, manifestations in, in FAP, FAP patients, patients ;, ; 4, 4 ), ) more, more than, than 80, 80 %, % of, of base, base substitutions, substitutions in, in the, the APC, APC gene, gene were, were from, from cytosine, cytosine to, to other, other nucleotides, nucleotides ,, , nearly, nearly one-third, one-third of, of which, which occurred, occurred at, at the, the GpG, GpG site, site ., . Our, Our results, results provide, provide information, information helpful, helpful to, to an, an understanding, understanding of, of the, the APC, APC gene, gene and, and will, will also, also contribute, contribute to, to presymptomatic, presymptomatic diagnosis, diagnosis of, of members, members in, in FAP, FAP families.., families.. A, A 29-year-old, 29-year-old woman, woman with, with discoid, discoid lupus, lupus erythematosus, erythematosus had, had undetectable, undetectable classic, classic pathway, pathway complement, complement activity, activity ., . Hypocomplementemia, Hypocomplementemia was, was due, due to, to selective, selective deficiency, deficiency of, of C5, C5 ., . One, One of, of her, her children, children was, was also, also deficient, deficient ., . To, To our, our knowledge, knowledge this, this is, is the, the first, first documented, documented case, case of, of an, an association, association between, between discoid, discoid lupus, lupus erythematosus, erythematosus and, and C5, C5 deficiency.., deficiency.. Familial, Familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) is, is a, a recessive, recessive disorder, disorder characterized, characterized by, by episodes, episodes of, of fever, fever with, with serositis, serositis or, or synovitis, synovitis ., . Recently, Recently the, the FMF, FMF gene, gene (, ( MEFV, MEFV ), ) was, was cloned, cloned ;, ; the, the protein, protein product, product ,, , pyrin/marenostrin, pyrin/marenostrin ,, , is, is thought, thought to, to regulate, regulate inflammation, inflammation in, in myeloid, myeloid cells, cells ., . In, In this, this manuscript, manuscript we, we report, report the, the mouse, mouse and, and rat, rat homologs, homologs of, of MEFV, MEFV ., . The, The murine, murine gene, gene contains, contains ten, ten exons, exons with, with a, a coding, coding sequence, sequence of, of 2304, 2304 bp, bp ,, , while, while the, the rat, rat homolog, homolog has, has nine, nine exons, exons with, with a, a coding, coding sequence, sequence of, of 2253, 2253 bp, bp ., . A, A considerable, considerable amino, amino acid, acid sequence, sequence homology, homology was, was observed, observed between, between the, the mouse, mouse and, and human, human (, ( 47, 47 ., . 6, 6 %, % identity, identity and, and 65, 65 ., . 5, 5 %, % similarity, similarity ), ) and, and between, between the, the mouse, mouse and, and rat, rat genes, genes (, ( 73, 73 ., . 5, 5 %, % identity, identity and, and 82, 82 ., . 1, 1 %, % similarity, similarity ), ) ., . The, The predicted, predicted rodent, rodent proteins, proteins have, have several, several important, important domains, domains and, and signals, signals found, found in, in human, human pyrin, pyrin ,, , including, including a, a B-box, B-box zinc, zinc finger, finger domain, domain ,, , Robbins-Dingwall, Robbins-Dingwall nuclear, nuclear localization, localization signal, signal ,, , and, and coiled-coil, coiled-coil domain, domain ., . However, However ,, , perhaps, perhaps because, because of, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "of an, an ancient, ancient frame-shift, frame-shift mutation, mutation ,, , neither, neither the, the mouse, mouse nor, nor the, the rat, rat protein, protein has, has an, an intact, intact C-terminal, C-terminal B30, B30 ., . 2, 2 domain, domain ,, , in, in which, which most, most FMF-associated, FMF-associated mutations, mutations have, have been, been found, found in, in human, human MEFV, MEFV ., . Nevertheless, Nevertheless ,, , like, like the, the human, human gene, gene ,, , mouse, mouse Mefv, Mefv is, is expressed, expressed in, in peripheral, peripheral blood, blood granulocytes, granulocytes but, but not, not lymphocytes, lymphocytes ., . Consistent, Consistent with, with its, its expression, expression in, in granulocytes, granulocytes ,, , Mefv, Mefv was, was detected, detected at, at high, high levels, levels in, in the, the primary, primary follicles, follicles and, and marginal, marginal zones, zones of, of the, the splenic, splenic white, white pulp, pulp ., . Mefv, Mefv is, is localized, localized on, on mouse, mouse Chromosome, Chromosome (, ( Chr, Chr ), ) 16, 16 ,, , region, region A3-B1, A3-B1 ,, , extending, extending a, a region, region of, of synteny, synteny with, with human, human Chr, Chr 16p13, 16p13 ., . 3, 3 ., . Development, Development of, of knockout, knockout and, and knockin, knockin mouse, mouse models, models may, may provide, provide further, further insights, insights into, into the, the functional, functional evolution, evolution of, of this, this gene, gene ., . We, We report, report on, on a, a thrombocytopenic, thrombocytopenic female, female belonging, belonging to, to a, a pedigree, pedigree with, with the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) ., . Restriction, Restriction fragment, fragment length, length polymorphism, polymorphism (, ( RFLP, RFLP ), ) analysis, analysis with, with probe, probe M27, M27 beta, beta ,, , closely, closely linked, linked to, to the, the WAS, WAS gene, gene ,, , demonstrated, demonstrated that, that she, she is, is a, a carrier, carrier of, of WAS, WAS ., . Both, Both small-sized, small-sized and, and normal-sized, normal-sized platelets, platelets were, were present, present ,, , suggesting, suggesting that, that ,, , unlike, unlike the, the vast, vast majority, majority of, of WAS, WAS carriers, carriers ,, , she, she does, does not, not manifest, manifest nonrandom, nonrandom X-chromosome, X-chromosome inactivation, inactivation in, in the, the thrombopoietic, thrombopoietic cell, cell lineage, lineage ., . Study, Study of, of X-chromosome, X-chromosome inactivation, inactivation by, by means, means of, of RFLP, RFLP and, and methylation, methylation analysis, analysis demonstrated, demonstrated that, that the, the pattern, pattern of, of X-chromosome, X-chromosome inactivation, inactivation was, was nonrandom, nonrandom in, in T, T lymphocytes, lymphocytes ,, , but, but random, random in, in granulocytes, granulocytes ., . While, While this, this is, is the, the first, first complete, complete report, report on, on the, the occurrence, occurrence of, of thrombocytopenia, thrombocytopenia in, in a, a carrier, carrier female, female of, of WAS, WAS as, as the, the result, result of, of atypical, atypical lyonization, lyonization ,, , it, it also, also suggests, suggests that, that expression, expression of, of the, the WAS, WAS gene, gene occurs, occurs at, at (, ( or, or extends, extends up, up to, to ), ) a, a later, later stage, stage than, than the, the multipotent, multipotent stem, stem cell, cell along, along the, the hematopoietic, hematopoietic differentiation, differentiation pathway.., pathway.. Mutations, Mutations in, in the, the BRCA1, BRCA1 (, ( ref, ref ., . 1, 1 ), ) tumour, tumour suppressor, suppressor gene, gene are, are found, found in, in almost, almost all, all of, of the, the families, families with, with inherited, inherited breast, breast and, and ovarian, ovarian cancers, cancers and, and about, about half, half of, of the, the families, families with, with only, only breast, breast cancer, cancer ., . Although, Although the, the biochemical, biochemical function, function of, of BRCA1, BRCA1 is, is not, not well, well understood, understood ,, , it, it is, is important, important for, for DNA, DNA damage, damage repair, repair and, and cell-cycle, cell-cycle checkpoint, checkpoint ., . BRCA1, BRCA1 exists, exists in, in nuclear, nuclear foci, foci but, but is, is hyperphosphorylated, hyperphosphorylated and, and disperses, disperses after, after DNA, DNA damage, damage ., . It, It is, is not, not known, known whether, whether BRCA1, BRCA1 phosphorylation, phosphorylation and, and dispersion, dispersion and, and its, its function, function in, in DNA, DNA damage, damage response, response are, are related, related ., . In, In yeast, yeast the, the DNA, DNA damage, damage response, response and, and the, the replication-block, replication-block checkpoint, checkpoint are, are mediated, mediated partly, partly through, through the, the Cds1, Cds1 kinase, kinase family, family ., . Here, Here we, we report, report that, that the, the human, human Cds1, Cds1 kinase, kinase (, ( hCds1/Chk2, hCds1/Chk2 ), ) regulates, regulates BRCA1, BRCA1 function, function after, after DNA, DNA damage, damage by, by phosphorylating, phosphorylating serine, serine 988, 988 of, of BRCA1, BRCA1 ., . We, We show, show that, that hCds1, hCds1 and, and BRCA1, BRCA1 interact, interact and, and co-localize, co-localize within, within discrete, discrete nuclear, nuclear foci, foci but, but separate, separate after, after gamma, gamma irradiation, irradiation ., . Phosphorylation, Phosphorylation of, of BRCA1, BRCA1 at, at serine, serine 988, 988 is, is required, required for, for the, the release, release of, of BRCA1, BRCA1 from, from hCds1, hCds1 ., . This, This phosphorylation, phosphorylation is, is also, also important, important for, for the, the ability, ability of, of BRCA1, BRCA1 to, to restore, restore survival, survival after, after DNA, DNA damage, damage in, in the, the BRCA1-mutated, BRCA1-mutated cell, cell line, line HCC1937.., HCC1937.. Spinocerebellar, Spinocerebellar ataxia, ataxia type-3, type-3 or, or Machado-Joseph, Machado-Joseph disease, disease (, ( SCA3/MJD, SCA3/MJD ), ) is, is a, a member, member of, of the, the CAG/polyglutamine, CAG/polyglutamine repeat, repeat disease, disease family, family ., . In, In this, this family, family of, of disorders, disorders ,, , a, a normally, normally polymorphic, polymorphic CAG, CAG repeat, repeat becomes, becomes expanded, expanded ,, , resulting, resulting in, in expression, expression of, of an, an expanded, expanded polyglutamine, polyglutamine domain, domain in, in the, the disease, disease gene, gene product, product ., . Experimental, Experimental models, models of, of polyglutamine, polyglutamine disease, disease implicate, implicate the, the nucleus, nucleus in, in pathogenesis, pathogenesis ;, ; however, however ,, , the, the link, link between, between intranuclear, intranuclear expression, expression of, of expanded, expanded polyglutamine, polyglutamine and, and neuronal, neuronal dysfunction, dysfunction remains, remains unclear, unclear ., . Here, Here we, we demonstrate, demonstrate that, that ataxin-3, ataxin-3 ,, , the, the disease, disease protein, protein in, in SCA3/MJD, SCA3/MJD ,, , adopts, adopts a, a unique, unique conformation, conformation when, when expressed, expressed within, within the, the nucleus, nucleus of, of transfected, transfected cells, cells ., . The, The monoclonal, monoclonal antibody, antibody 1C2, 1C2 is, is known, known preferentially, preferentially to, to bind, bind expanded, expanded polyglutamine, polyglutamine ,, , but, but we, we find, find that, that it, it also, also binds, binds a, a fragment, fragment of, of ataxin-3, ataxin-3 containing, containing a, a normal, normal glutamine, glutamine repeat, repeat ., . In, In addition, addition ,, , expression, expression of, of ataxin-3, ataxin-3 within, within the, the nucleus, nucleus exposes, exposes the, the glutamine, glutamine domain, domain of, of the, the full-length, full-length non-pathological, non-pathological protein, protein ,, , allowing, allowing it, it to, to bind, bind the, the monoclonal, monoclonal antibody, antibody 1C2, 1C2 ., . Fractionation, Fractionation and, and immunochemical, immunochemical experiments, experiments indicate, indicate that, that this, this novel, novel conformation, conformation of, of intranuclear, intranuclear ataxin-3, ataxin-3 is, is not, not due, due to, to proteolysis, proteolysis ,, , suggesting, suggesting instead, instead that, that association, association with, with nuclear, nuclear protein, protein (, ( s, s ), ) alters, alters the, the structure, structure of, of full-length, full-length ataxin-3, ataxin-3 which, which exposes, exposes the, the polyglutamine, polyglutamine domain, domain ., . This, This conformationally, conformationally altered, altered ataxin-3, ataxin-3 is, is bound, bound to, to the, the nuclear, nuclear matrix, matrix ., . The, The pathological, pathological form, form of, of ataxin-3, ataxin-3 with, with an, an expanded, expanded polyglutamine, polyglutamine domain, domain also, also associates, associates with, with the, the nuclear, nuclear matrix, matrix ., . These, These data, data suggest, suggest that, that an, an early, early event, event in, in the, the pathogenesis, pathogenesis of, of SCA3/MJD, SCA3/MJD may, may be, be an, an altered, altered conformation, conformation of, of ataxin-3, ataxin-3 within, within the, the nucleus, nucleus that, that exposes, exposes the, the polyglutamine, polyglutamine domain.., domain.. The, The Wilms, Wilms tumor, tumor -suppressor, -suppressor gene, gene ,, , WT1, WT1 ,, , plays, plays a, a key, key role, role in, in urogenital, urogenital development, development ,, , and, and WT1, WT1 dysfunction, dysfunction is, is implicated, implicated in, in both, both neoplastic, neoplastic (, ( Wilms, Wilms tumor, tumor ,, , mesothelioma, mesothelioma ,, , leukemias, leukemias ,, , and, and breast, breast cancer, cancer ), ) and, and nonneoplastic, nonneoplastic (, ( glomerulosclerosis, glomerulosclerosis ), ) disease, disease ., . The, The analysis, analysis of, of diseases, diseases linked, linked specifically, specifically with, with WT1, WT1 mutations, mutations ,, , such, such as, as Denys-Drash, Denys-Drash syndrome, syndrome (, ( DDS, DDS ), ) ,, , can, can provide, provide valuable, valuable insight, insight concerning, concerning the, the role, role of, of WT1, WT1 in, in development, development and, and disease, disease ., . DDS, DDS is, is a, a rare, rare childhood, childhood disease, disease characterized, characterized by, by a, a nephropathy, nephropathy involving, involving mesangial, mesangial sclerosis, sclerosis ,, , XY, XY pseudohermaphroditism, pseudohermaphroditism ,, , and/or, and/or Wilms, Wilms tumor, tumor (, ( WT, WT ), ) ., . DDS, DDS patients, patients are, are constitutionally, constitutionally heterozygous, heterozygous for, for exonic, exonic point, point mutations, mutations in, in WT1, WT1 ,, , which, which include, include mutations, mutations predicted, predicted to, to truncate, truncate the, the protein, protein within, within the, the C-terminal, C-terminal zinc, zinc finger, finger (, ( ZF, ZF ), ) region, region ., . We, We report, report that, that heterozygosity, heterozygosity for, for a, a targeted, targeted murine, murine Wt1, Wt1 allele, allele ,, , Wt1, Wt1 (, ( tmT396, tmT396 ), ) ,, , which, which truncates, truncates ZF3, ZF3 at, at codon, codon 396, 396 ,, , induces, induces mesangial, mesangial sclerosis, sclerosis characteristic, characteristic of, of DDS, DDS in, in adult, adult heterozygous, heterozygous and, and chimeric, chimeric mice, mice ., . Male, Male genital, genital defects, defects also, also were, were evident, evident and, and there, there was, was a, a single, single case, case of, of Wilms, Wilms tumor, tumor in, in which, which the, the transcript, transcript of, of the, the nontargeted, nontargeted allele, allele showed, showed an, an exon, exon 9, 9 skipping, skipping event, event ,, , implying, implying a, a causal, causal link, link between, between Wt1, Wt1 dysfunction, dysfunction and, and Wilms, Wilms tumorigenesis, tumorigenesis in, in mice, mice ., . However, However ,, , the, the mutant, mutant WT1, WT1 (, ( tmT396, tmT396 ), ) protein, protein accounted, accounted for, for only, only 5, 5 %, % of, of WT1, WT1 in, in both, both heterozygous, heterozygous embryonic, embryonic stem, stem cells, cells and, and the, the WT, WT ., . This, This has, has implications, implications regarding, regarding the, the mechanism, mechanism by, by which, which the, the mutant, mutant allele, allele exerts, exerts its, its effect.Glucose-6-phosphate, effect.Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) ;, ; EC, EC 1, 1 ., . 1, 1 ., . 1, 1 ., . 49, 49 from, from thirty-six, thirty-six unrelated, unrelated Spanish, Spanish males, males was, was partially, partially purified, purified from, from blood, blood ,, , and, and the, the variants, variants were, were characterized, characterized biochemically, biochemically and, and electrophoretically, electrophoretically according, according to, to the, the methods, methods recommended, recommended by, by the, the world, world Health, Health Organization, Organization ., . Subjects, Subjects were, were from, from multiple, multiple geographic, geographic regions, regions within, within Spain, Spain ,, , and, and all, all suffered, suffered from, from hemolytic, hemolytic anemia, anemia ,, , either, either acute, acute (, ( 34, 34 cases, cases ), ) or, or chronic, chronic nonspherocytic, nonspherocytic (, ( 2, 2 cases, cases ), ) ., . Almost, Almost all, all the, the variants, variants studied, studied presented, presented residual, residual erythrocyte, erythrocyte G6PD, G6PD activity, activity ranging, ranging from, from 0, 0 to, to 10, 10 %, % of, of normal, normal ,, , and, and five, five different, different mutants, mutants were, were responsible, responsible for, for the, the deficient, deficient phenotype, phenotype ., . Three, Three variants, variants were, were similar, similar to, to others, others previously, previously described, described G6PD, G6PD Mediterranean, Mediterranean (, ( 11, 11 cases, cases ), ) ,, , G6PD, G6PD Athens-like, Athens-like (, ( 3, 3 cases, cases ), ) ,, , and, and G6PD, G6PD Union, Union (, ( 2, 2 cases, cases ), ) ., . The, The remaining, remaining variants, variants were, were different, different from, from the, the numerous, numerous variants, variants already, already reported, reported and, and have, have been, been considered, considered as, as new, new mutants, mutants ., . Provisionally, Provisionally they, they are, are called, called G6PD, G6PD Betica, Betica (, ( 19, 19 cases, cases ), ) and, and G6PD, G6PD Menorca, Menorca (, ( 1, 1 case, case ), ) ., . The, The present, present study, study constitutes, constitutes the, the first, first attempt, attempt to, to characterize, characterize the, the deficient, deficient G6PD, G6PD variants, variants found, found in, in Spain, Spain and, and supplies, supplies new, new data, data on, on the, the relationship, relationship between, between molecular, molecular characteristics, characteristics of, of deficient, deficient variants, variants and, and their, their clinical, clinical manifestations, manifestations ., . The, The most, most important, important findings, findings can, can be, be summarized, summarized as, as follows, follows (, ( 1, 1 ), ) The, The Spanish, Spanish population, population is, is characterized, characterized by, by an, an important, important heterogeneity, heterogeneity in, in G6PD, G6PD deficiency, deficiency ., . (, ( 2, 2 ), ) Although, Although G6PD, G6PD Mediterranean, Mediterranean is, is very, very frequent, frequent ,, , it, it presents, presents a, a relatively, relatively high, high degree, degree of, of polymorphism, polymorphism ., . (, ( 3, 3 ), ) Favism, Favism has, has been, been observed, observed associated, associated with, with all, all kinds, kinds of, of variants, variants described, described here, here ., . (, ( 4, 4 ), ) G6PD, G6PD Betica, Betica ,, , which, which is, is the, the most, most frequent, frequent variant, variant found, found in, in subjects, subjects of, of Southern, Southern Spanish, Spanish origin, origin ,, , has, has been, been observed, observed associated, associated with, with favism, favism in, in all, all cases, cases except, except one, one ., . A, A boy, boy developed, developed contractures, contractures of, of the, the Achilles, Achilles tendons, tendons at, at 3, 3 years, years and, and of, of the, the postcervical, postcervical muscles, muscles at, at 7, 7 years, years ,, , although, although neither, neither contractures, contractures of, of the, the elbows, elbows nor, nor cardiac, cardiac abnormality, abnormality were, were recognized, recognized by, by the, the age, age of, of 9, 9 years, years ., . Muscle, Muscle computed, computed tomography, tomography scanning, scanning revealed, revealed changes, changes characteristic, characteristic of, of muscle, muscle involvement, involvement ., . Emerin, Emerin was, was not, not detected, detected in, in the, the biopsied, biopsied muscle, muscle ,, , and, and RT-PCR, RT-PCR and, and PCR-based, PCR-based genomic, genomic DNA, DNA analyses, analyses of, of the, the emerin, emerin gene, gene demonstrated, demonstrated no, no amplification, amplification product, product in, in the, the patient, patient ., . These, These results, results confirmed, confirmed the, the diagnosis, diagnosis of, of X-linked, X-linked Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EDMD, EDMD ), ) ,, , and, and reinforce, reinforce the, the necessity, necessity of, of molecular, molecular genetic, genetic diagnosis, diagnosis of, of the, the membrane, membrane protein, protein emerin, emerin in, in younger, younger patients, patients with, with possible, possible EDMD, EDMD before, before appearance, appearance of, of the, the typical, typical symptoms, symptoms ,, , to, to avoid, avoid sudden, sudden cardiac, cardiac death.., death.. Rearrangement, Rearrangement of, of the, the BCL1, BCL1 (, ( B-cell, B-cell lymphoma, lymphoma 1, 1 ), ) region, region on, on chromosome, chromosome 11q13, 11q13 appears, appears to, to be, be highly, highly characteristic, characteristic of, of centrocytic, centrocytic lymphoma, lymphoma and, and also, also is, is found, found infrequently, infrequently in, in other, other B-cell, B-cell neoplasms, neoplasms ., . Rearrangement, Rearrangement is, is thought, thought to, to deregulate, deregulate a, a nearby, nearby protooncogene, protooncogene ,, , but, but transcribed, transcribed sequences, sequences in, in the, the immediate, immediate vicinity, vicinity of, of BCL1, BCL1 breakpoints, breakpoints had, had not, not been, been identified, identified ., . PRAD1, PRAD1 ,, , previously, previously designated, designated D11S287E, D11S287E ,, , was, was identified, identified on, on 11q13, 11q13 as, as a, a chromosomal, chromosomal breakpoint, breakpoint region, region rearranged, rearranged with, with the, the parathyroid, parathyroid hormone, hormone gene, gene in, in a, a subset, subset of, of parathyroid, parathyroid adenomas, adenomas ;, ; this, this highly, highly conserved, conserved putative, putative oncogene, oncogene ,, , which, which encodes, encodes a, a novel, novel cyclin, cyclin ,, , has, has been, been linked, linked to, to BCL1, BCL1 and, and implicated, implicated also, also in, in subsets, subsets of, of breast, breast and, and squamous, squamous cell, cell neoplasms, neoplasms with, with 11q13, 11q13 amplification, amplification ., . We, We report, report pulsed-field, pulsed-field gel, gel electrophoresis, electrophoresis data, data showing, showing BCL1, BCL1 and, and PRAD1, PRAD1 to, to be, be no, no more, more than, than 130, 130 kilobases, kilobases apart, apart ., . PRAD1, PRAD1 mRNA, mRNA is, is abundantly, abundantly expressed, expressed in, in seven, seven of, of seven, seven centrocytic, centrocytic lymphomas, lymphomas (, ( Kiel, Kiel classification, classification ), ) ,, , in, in contrast, contrast to, to 13, 13 closely, closely related, related but, but noncentrocytic, noncentrocytic lymphomas, lymphomas ., . Three, Three of, of the, the seven, seven centrocytic, centrocytic lymphomas, lymphomas had, had detectable, detectable BCL1, BCL1 DNA, DNA rearrangement, rearrangement ., . Also, Also ,, , two, two unusual, unusual cases, cases of, of CLL, CLL with, with BCL1, BCL1 rearrangement, rearrangement overexpressed, overexpressed PRAD1, PRAD1 ,, , in, in contrast, contrast to, to five, five CLL, CLL controls, controls ., . Thus, Thus ,, , PRAD1, PRAD1 is, is an, an excellent, excellent candidate, candidate ``, `` BCL1, BCL1 oncogene., oncogene. ``, `` Its, Its overexpression, overexpression may, may be, be a, a key, key consequence, consequence of, of rearrangement, rearrangement of, of the, the BCL1, BCL1 vicinity, vicinity in, in B-cell, B-cell neoplasms, neoplasms and, and a, a unifying, unifying pathogenetic, pathogenetic feature, feature in, in centrocytic, centrocytic lymphoma, lymphoma ., . With, With a, a new, new method, method we, we measured, measured the, the saturated, saturated very, very long, long chain, chain fatty, fatty acids, acids in, in the, the plasma, plasma of, of adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) hemizygotes, hemizygotes ,, , ALD, ALD heterozygotes, heterozygotes ,, , and, and controls, controls ., . ALD, ALD hemizygotes, hemizygotes showed, showed increased, increased levels, levels of, of hexacosanoate, hexacosanoate (, ( C26, C26 fatty, fatty acid, acid ), ) which, which represented, represented 0, 0 ., . 081, 081 +/-, +/- 0, 0 ., . 0066, 0066 %, % (, ( SEM, SEM ), ) of, of total, total fatty, fatty acids, acids ,, , compared, compared to, to 0, 0 ., . 015, 015 +/-, +/- 0, 0 ., . 0032, 0032 %, % in, in the, the controls, controls ., . C25, C25 ,, , C24, C24 ,, , and, and C23, C23 fatty, fatty acids, acids were, were also, also increased, increased ,, , but, but the, the C22, C22 and, and C20, C20 fatty, fatty acids, acids were, were normal, normal ., . C26, C26 levels, levels were, were also, also increased, increased in, in most, most ALD, ALD heterozygotes, heterozygotes ,, , with, with a, a mean, mean level, level 0, 0 ., . 057, 057 +/-, +/- 0, 0 ., . 0063, 0063 %, % of, of total, total fatty, fatty acids, acids ., . The, The technique, technique can, can be, be used, used for, for diagnosis, diagnosis and, and carrier, carrier identification, identification ,, , and, and in, in the, the evaluation, evaluation of, of therapy.Glucose-6-phosphate, therapy.Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ;, ; EC, EC 1, 1 ., . 1, 1 ., . 1, 1 ., . 49, 49 ), ) -deficient, -deficient red, red blood, blood cells, cells from, from male, male hemizygotes, hemizygotes and, and female, female heterozygotes, heterozygotes from, from the, the island, island of, of Sardinia, Sardinia were, were studied, studied for, for their, their ability, ability to, to support, support growth, growth in, in vitro, vitro of, of the, the malaria-causing, malaria-causing organism, organism Plasmodium, Plasmodium falciparum, falciparum ., . Parasite, Parasite growth, growth was, was approximately, approximately one-third, one-third of, of normal, normal in, in both, both hemi-, hemi- and, and heterozygotes, heterozygotes for, for G6PD, G6PD deficiency, deficiency ., . In, In Sardinians, Sardinians with, with the, the beta, beta 0-thalassemia, 0-thalassemia trait, trait ,, , parasite, parasite growth, growth was, was normal, normal except, except when, when G6PD, G6PD deficiency, deficiency occurred, occurred together, together with, with the, the thalassemia, thalassemia trait, trait ., . The, The data, data support, support the, the hypothesis, hypothesis that, that G6PD, G6PD deficiency, deficiency may, may confer, confer a, a selective, selective advantage, advantage in, in a, a malarious, malarious area, area ;, ; the, the female, female heterozygote, heterozygote may, may be, be at, at a, a particular, particular advantage, advantage because, because resistance, resistance to, to malaria, malaria equals, equals that, that of, of male, male hemizygotes, hemizygotes ,, , but, but the, the risk, risk of, of fatal, fatal hemolysis, hemolysis may, may be, be less, less ., . However, However ,, , more, more female, female heterozygotes, heterozygotes must, must be, be studied, studied to, to confirm, confirm this, this hypothesis, hypothesis ., . No, No protective, protective effect, effect of, of beta, beta 0-thalassemia, 0-thalassemia trait, trait could, could be, be demonstrated, demonstrated in, in vitro, vitro ., . We, We describe, describe a, a patient, patient with, with myasthenia, myasthenia gravis, gravis ,, , systemic, systemic lupus, lupus erythematosus, erythematosus ,, , and, and angioedema, angioedema associated, associated with, with heterozygous, heterozygous complement, complement factor, factor 2, 2 (, ( C2, C2 ), ) deficiency, deficiency ., . The, The significance, significance of, of this, this association, association is, is controversial, controversial ,, , though, though the, the association, association of, of C2, C2 deficiency, deficiency with, with certain, certain histocompatibility, histocompatibility antigens, antigens suggests, suggests possible, possible linkage, linkage to, to immune, immune response, response genes, genes ., . To, To our, our knowledge, knowledge this, this is, is the, the first, first report, report of, of heterozygous, heterozygous C2, C2 deficiency, deficiency in, in association, association with, with this, this combination, combination of, of autoimmune, autoimmune disorders, disorders ,, , and, and we, we discuss, discuss the, the aetiological, aetiological implications.., implications.. A, A 10-year-old, 10-year-old Laotian, Laotian boy, boy had, had homozygous, homozygous deficiency, deficiency of, of the, the third, third component, component of, of complement, complement and, and recurrent, recurrent bacterial, bacterial infections, infections beginning, beginning at, at age, age 5, 5 months, months ., . Cellular, Cellular and, and humoral, humoral immunity, immunity were, were normal, normal ,, , as, as were, were polymorphonuclear, polymorphonuclear leukocyte, leukocyte chemotaxis, chemotaxis and, and bactericidal, bactericidal activities, activities ., . Serum, Serum complement-mediated, complement-mediated hemolytic, hemolytic ,, , chemotactic, chemotactic ,, , and, and opsonic, opsonic activities, activities were, were deficient, deficient ., . In, In vitro, vitro addition, addition of, of purified, purified C3, C3 to, to patient, patient serum, serum restored, restored hemolytic, hemolytic complement, complement to, to normal, normal levels, levels ,, , and, and plasma, plasma infusion, infusion during, during each, each of, of four, four episodes, episodes of, of pneumonia, pneumonia significantly, significantly enhanced, enhanced serum, serum opsonic, opsonic activity, activity for, for as, as long, long as, as 36, 36 hours, hours ., . A, A renal, renal biopsy, biopsy specimen, specimen revealed, revealed mesangiopathic, mesangiopathic glomerulonephritis, glomerulonephritis ,, , although, although significant, significant levels, levels of, of circulating, circulating IgG, IgG immune, immune complexes, complexes were, were not, not detected, detected ., . These, These findings, findings further, further support, support the, the association, association of, of C3, C3 deficiency, deficiency with, with immune-complex, immune-complex disease, disease and, and suggest, suggest that, that plasma, plasma infusion, infusion may, may be, be an, an adjunct, adjunct to, to antibiotic, antibiotic therapy, therapy in, in the, the management, management of, of severe, severe pyogenic, pyogenic infections, infections in, in patients, patients with, with C3, C3 deficiency.., deficiency.. Whole, Whole genomic, genomic hprt, hprt clones, clones were, were used, used in, in Southern, Southern analysis, analysis to, to screen, screen the, the integrity, integrity of, of the, the hprt, hprt gene, gene in, in a, a family, family that, that includes, includes a, a patient, patient with, with HPRT, HPRT enzyme, enzyme deficiency, deficiency causal, causal to, to Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . A, A 5, 5 kb, kb DNA, DNA sequence, sequence deletion, deletion was, was found, found to, to have, have its, its endpoints, endpoints in, in the, the first, first and, and third, third introns, introns ., . The, The probes, probes identified, identified the, the carrier, carrier status, status of, of female, female family, family members, members ,, , aided, aided by"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", by an, an RFLP, RFLP carried, carried by, by the, the mothers, mothers normal, normal X-chromosome.., X-chromosome.. BRCA1, BRCA1 encodes, encodes a, a tumor, tumor suppressor, suppressor that, that is, is mutated, mutated in, in familial, familial breast, breast and, and ovarian, ovarian cancers, cancers ., . Here, Here ,, , it, it is, is shown, shown that, that BRCA1, BRCA1 interacts, interacts in, in vitro, vitro and, and in, in vivo, vivo with, with hRad50, hRad50 ,, , which, which forms, forms a, a complex, complex with, with hMre11, hMre11 and, and p95/nibrin, p95/nibrin ., . Upon, Upon irradiation, irradiation ,, , BRCA1, BRCA1 was, was detected, detected in, in discrete, discrete foci, foci in, in the, the nucleus, nucleus ,, , which, which colocalize, colocalize with, with hRad50, hRad50 ., . Formation, Formation of, of irradiation-induced, irradiation-induced foci, foci positive, positive for, for BRCA1, BRCA1 ,, , hRad50, hRad50 ,, , hMre11, hMre11 ,, , or, or p95, p95 was, was dramatically, dramatically reduced, reduced in, in HCC/1937, HCC/1937 breast, breast cancer, cancer cells, cells carrying, carrying a, a homozygous, homozygous mutation, mutation in, in BRCA1, BRCA1 but, but was, was restored, restored by, by transfection, transfection of, of wild-type, wild-type BRCA1, BRCA1 ., . Ectopic, Ectopic expression, expression of, of wild-type, wild-type ,, , but, but not, not mutated, mutated ,, , BRCA1, BRCA1 in, in these, these cells, cells rendered, rendered them, them less, less sensitive, sensitive to, to the, the DNA, DNA damage, damage agent, agent ,, , methyl, methyl methanesulfonate, methanesulfonate ., . These, These data, data suggest, suggest that, that BRCA1, BRCA1 is, is important, important for, for the, the cellular, cellular responses, responses to, to DNA, DNA damage, damage that, that are, are mediated, mediated by, by the, the hRad50-hMre11-p95, hRad50-hMre11-p95 complex.., complex.. Monoclonal, Monoclonal antibodies, antibodies which, which recognize, recognize different, different epitopes, epitopes on, on either, either titin, titin or, or nebulin, nebulin show, show normal, normal staining, staining patterns, patterns on, on frozen, frozen sections, sections of, of three, three muscle, muscle biopsies, biopsies of, of Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . Gel, Gel electrophoresis, electrophoresis and, and immunoblotting, immunoblotting performed, performed on, on two, two of, of these, these muscle, muscle biopsies, biopsies show, show the, the normal, normal pattern, pattern of, of titin, titin and, and nebulin, nebulin polypeptides, polypeptides ., . Since, Since the, the donor, donor of, of one, one of, of these, these biopsies, biopsies has, has a, a large, large deletion, deletion of, of the, the 5-region, 5-region of, of the, the DMD, DMD gene, gene ,, , our, our results, results argue, argue against, against the, the recent, recent proposal, proposal that, that nebulin, nebulin is, is the, the gene, gene mutated, mutated in, in DMD.., DMD.. The, The clinical, clinical manifestation, manifestation of, of myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is correlated, correlated to, to the, the extent, extent of, of expansion, expansion of, of an, an unstable, unstable [, [ CTG, CTG ], ] n, n DNA, DNA motif, motif ., . Recent, Recent studies, studies have, have demonstrated, demonstrated that, that this, this trinucleotide, trinucleotide motif, motif forms, forms part, part of, of the, the last, last ,, , 3, 3 untranslated, untranslated exon, exon of, of a, a gene, gene which, which potentially, potentially encodes, encodes multiple, multiple protein, protein isoforms, isoforms of, of a, a serine/threonine, serine/threonine protein, protein kinase, kinase (, ( myotonic, myotonic dystrophy, dystrophy protein, protein kinase, kinase ,, , DM-PK, DM-PK ), ) ., . We, We report, report here, here on, on the, the development, development of, of antisera, antisera against, against synthetic, synthetic DM-PK, DM-PK peptide, peptide antigens, antigens and, and their, their use, use in, in biochemical, biochemical and, and histochemical, histochemical studies, studies ., . Immunoreactive, Immunoreactive DM-kinase, DM-kinase protein, protein of, of 53, 53 kD, kD is, is present, present at, at low, low levels, levels in, in skeletal, skeletal and, and cardiac, cardiac muscle, muscle extracts, extracts of, of DM, DM patients, patients and, and normal, normal controls, controls ., . Immunohistochemical, Immunohistochemical staining, staining revealed, revealed that, that DM-PK, DM-PK is, is localised, localised prominently, prominently at, at sites, sites of, of neuromuscular, neuromuscular and, and myotendinous, myotendinous junctions, junctions (, ( NMJs, NMJs and, and MTJs, MTJs ), ) of, of human, human and, and rodent, rodent skeletal, skeletal muscles, muscles ., . Furthermore, Furthermore ,, , very, very low, low levels, levels of, of immunoreactive, immunoreactive DM-PK, DM-PK protein, protein are, are present, present in, in the, the sarcoplasm, sarcoplasm of, of predominantly, predominantly type, type I, I fibres, fibres in, in various, various muscles, muscles ., . Strikingly, Strikingly ,, , presence, presence of, of the, the protein, protein can, can also, also be, be demonstrated, demonstrated for, for NMJs, NMJs of, of muscular, muscular tissues, tissues of, of adult, adult and, and congenital, congenital cases, cases of, of DM, DM ,, , with, with no, no gross, gross changes, changes in, in structural, structural organisation, organisation ., . Our, Our findings, findings provide, provide a, a basis, basis for, for further, further characterisation, characterisation of, of the, the role, role of, of the, the kinase, kinase in, in protein, protein assembly, assembly processes, processes or, or signal, signal mediation, mediation at, at synaptic, synaptic sites, sites and, and ultimately, ultimately for, for the, the understanding, understanding of, of the, the complex, complex pathophysiology, pathophysiology of, of DM.., DM.. Six, Six new, new variants, variants of, of human, human erythrocyte, erythrocyte G6PD, G6PD have, have been, been characterized, characterized ., . All, All of, of them, them were, were found, found in, in Italian, Italian males, males and, and all, all were, were associated, associated with, with enzyme, enzyme deficiency, deficiency ,, , but, but only, only two, two with, with signs, signs of, of haemolysis, haemolysis ., . These, These and, and other, other variants, variants reported, reported in, in the, the literature, literature ,, , which, which must, must thus, thus far, far be, be regarded, regarded as, as sporadic, sporadic ,, , are, are found, found to, to map, map in, in parts, parts of, of Italy, Italy where, where common, common types, types of, of G6PD, G6PD deficiency, deficiency are, are also, also prevalent.., prevalent.. Approximately, Approximately 0, 0 ., . 5, 5 %, % -1, -1 %, % of, of the, the general, general population, population has, has been, been estimated, estimated to, to be, be heterozygous, heterozygous for, for a, a germline, germline mutation, mutation in, in the, the ATM, ATM gene, gene ., . Mutations, Mutations in, in the, the ATM, ATM gene, gene are, are responsible, responsible for, for the, the autosomal, autosomal recessive, recessive disorder, disorder ataxia-telangiectasia, ataxia-telangiectasia (, ( A-T, A-T ), ) (, ( MIM, MIM 208900, 208900 ), ) ., . The, The finding, finding that, that ATM-heterozygotes, ATM-heterozygotes have, have an, an increased, increased relative, relative risk, risk for, for breast, breast cancer, cancer was, was supported, supported by, by some, some studies, studies but, but not, not confirmed, confirmed by, by others, others ., . In, In view, view of, of this, this discrepancy, discrepancy ,, , we, we examined, examined the, the frequency, frequency of, of ATM, ATM germline, germline mutations, mutations in, in a, a selected, selected group, group of, of Dutch, Dutch patients, patients with, with breast, breast cancer, cancer ., . We, We have, have analyzed, analyzed ATM, ATM germline, germline mutations, mutations in, in normal, normal blood, blood lymphocytes, lymphocytes ,, , using, using the, the protein-truncation, protein-truncation test, test followed, followed by, by genomic-sequence, genomic-sequence analysis, analysis ., . A, A high, high percentage, percentage of, of ATM, ATM germline, germline mutations, mutations was, was demonstrated, demonstrated among, among patients, patients with, with sporadic, sporadic breast, breast cancer, cancer ., . The, The 82, 82 patients, patients included, included in, in this, this study, study had, had developed, developed breast, breast cancer, cancer at, at age, age <, < 45, 45 and, and had, had survived, survived >, > /=, /= 5, 5 years, years (, ( mean, mean 15, 15 years, years ), ) ,, , and, and in, in 33, 33 (, ( 40, 40 %, % ), ) of, of the, the patients, patients a, a contralateral, contralateral breast, breast tumor, tumor had, had been, been diagnosed, diagnosed ., . Among, Among these, these patients, patients we, we identified, identified seven, seven (, ( 8, 8 ., . 5, 5 %, % ), ) ATM, ATM germline, germline mutations, mutations ,, , of, of which, which five, five are, are distinct, distinct ., . One, One splice-site, splice-site mutation, mutation (, ( IVS10-6T, IVS10-6T --, -- >, > G, G ), ) was, was detected, detected three, three times, times in, in our, our series, series ., . Four, Four heterozygous, heterozygous carriers, carriers were, were patients, patients with, with bilateral, bilateral breast, breast cancer, cancer ., . Our, Our results, results indicate, indicate that, that the, the mutations, mutations identified, identified in, in this, this study, study are, are ``, `` A-T, A-T disease-causing, disease-causing ``, `` mutations, mutations that, that might, might be, be associated, associated with, with an, an increased, increased risk, risk of, of breast, breast cancer, cancer in, in heterozygotes, heterozygotes ., . We, We conclude, conclude that, that ATM, ATM heterozygotes, heterozygotes have, have an, an approximately, approximately ninefold-increased, ninefold-increased risk, risk of, of developing, developing a, a type, type of, of breast, breast cancer, cancer characterized, characterized by, by frequent, frequent bilateral, bilateral occurrence, occurrence ,, , early, early age, age at, at onset, onset ,, , and, and long-term, long-term survival, survival ., . The, The specific, specific characteristics, characteristics of, of our, our population, population of, of patients, patients may, may explain, explain why, why such, such a, a high, high frequency, frequency was, was not, not found, found in, in other, other series, series ., . Autoimmune, Autoimmune lymphoproliferative, lymphoproliferative syndrome, syndrome (, ( ALPS, ALPS ), ) is, is characterized, characterized by, by autoimmune, autoimmune features, features and, and lymphoproliferations, lymphoproliferations and, and is, is generally, generally caused, caused by, by defective, defective Fas-mediated, Fas-mediated apoptosis, apoptosis ., . This, This report, report describes, describes a, a child, child with, with clinical, clinical features, features of, of ALPS, ALPS without, without detectable, detectable Fas, Fas expression, expression on, on freshly, freshly isolated, isolated blood, blood leukocytes, leukocytes ., . Detection, Detection of, of FAS, FAS transcripts, transcripts via, via real-time, real-time quantitative, quantitative PCR, PCR made, made a, a severe, severe transcriptional, transcriptional defect, defect unlikely, unlikely ., . Sequencing, Sequencing of, of the, the FAS, FAS gene, gene revealed, revealed a, a 20-nucleotide, 20-nucleotide duplication, duplication in, in the, the last, last exon, exon affecting, affecting the, the cytoplasmic, cytoplasmic signaling, signaling domain, domain ., . The, The patient, patient was, was homozygous, homozygous for, for this, this mutation, mutation ,, , whereas, whereas the, the consanguineous, consanguineous parents, parents and, and the, the siblings, siblings were, were heterozygous, heterozygous ., . The, The patient, patient reported, reported here, here is, is a, a human, human homologue, homologue of, of the, the Fas-null, Fas-null mouse, mouse ,, , inasmuch, inasmuch as, as she, she carries, carries an, an autosomal, autosomal homozygous, homozygous mutation, mutation in, in the, the FAS, FAS gene, gene and, and she, she shows, shows the, the severe, severe and, and accelerated, accelerated ALPS, ALPS phenotype, phenotype ., . The, The heterozygous, heterozygous family, family members, members did, did not, not have, have the, the ALPS, ALPS phenotype, phenotype ,, , indicating, indicating that, that the, the disease-causing, disease-causing FAS, FAS mutation, mutation in, in this, this family, family is, is autosomal, autosomal recessive.., recessive.. OBJECTIVE, OBJECTIVE To, To define, define the, the mutation, mutation causing, causing galactosemia, galactosemia in, in patients, patients of, of black, black American, American origin, origin who, who have, have no, no galactose-1-phosphate, galactose-1-phosphate uridyltransferase, uridyltransferase (, ( GALT, GALT ), ) activity, activity in, in erythrocytes, erythrocytes but, but good, good clinical, clinical outcome, outcome ., . METHODS, METHODS We, We discovered, discovered a, a mutation, mutation caused, caused by, by a, a C, C --, -- >, > T, T transition, transition at, at base-pair, base-pair 1158, 1158 of, of the, the GALT, GALT gene, gene that, that results, results in, in a, a serine-to-leucine, serine-to-leucine substitution, substitution at, at codon, codon 135, 135 (, ( S135L, S135L ), ) ., . We, We developed, developed a, a method, method with, with which, which to, to screen, screen populations, populations for, for its, its prevalence, prevalence ., . We, We compared, compared galactose-1-phosphate, galactose-1-phosphate uridyltransferase, uridyltransferase among, among erythrocytes, erythrocytes ,, , leukocytes, leukocytes ,, , and, and transformed, transformed lymphoblasts, lymphoblasts ,, , as, as well, well as, as total, total body, body oxidation, oxidation of, of D-, D- (, ( 13C, 13C ), ) -galactose, -galactose to, to 13CO2, 13CO2 among, among three, three genotypes, genotypes for, for GALT, GALT (, ( S135L/S135L, S135L/S135L ,, , Q188R/Q188R, Q188R/Q188R ,, , and, and Normal/Normal, Normal/Normal ), ) ., . RESULTS, RESULTS We, We found, found a, a 48, 48 %, % prevalence, prevalence of, of the, the S135L, S135L mutation, mutation among, among 17, 17 black, black American, American patients, patients with, with classic, classic galactosemia, galactosemia and, and a, a 1, 1 %, % prevalence, prevalence in, in a, a population, population of, of 50, 50 black, black Americans, Americans without, without galactosemia, galactosemia ., . The, The S135L, S135L mutation, mutation was, was not, not found, found in, in 84, 84 white, white patients, patients with, with G/G, G/G galactosemia, galactosemia nor, nor in, in 87, 87 white, white control, control subjects, subjects without, without galactosemia, galactosemia ., . We, We found, found normal, normal whole, whole body, body oxidation, oxidation of, of D-, D- (, ( 13C, 13C ), ) -galactose, -galactose by, by the, the patient, patient homozygous, homozygous for, for S135L, S135L and, and various, various degrees, degrees of, of enzyme, enzyme impairment, impairment among, among different, different tissues, tissues ., . CONCLUSIONS, CONCLUSIONS The, The S135L, S135L mutation, mutation in, in the, the GALT, GALT gene, gene is, is a, a prevalent, prevalent cause, cause of, of galactosemia, galactosemia among, among black, black patients, patients ., . Because, Because GALT, GALT activity, activity varies, varies in, in different, different tissues, tissues of, of patients, patients homozygous, homozygous for, for S135L, S135L ,, , they, they may, may have, have a, a better, better clinical, clinical outcome, outcome than, than patients, patients who, who are, are homozygous, homozygous for, for Q188R, Q188R when, when both, both are, are treated, treated from, from infancy.., infancy.. Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is the, the most, most prevalent, prevalent inherited, inherited neuromuscular, neuromuscular disease, disease in, in adults, adults ., . The, The genetic, genetic defect, defect is, is a, a CTG, CTG triplet, triplet repeat, repeat expansion, expansion in, in the, the 3-untranslated, 3-untranslated region, region of, of the, the myotonic, myotonic dystrophy, dystrophy protein, protein kinase, kinase (, ( DMPK, DMPK ), ) gene, gene ,, , consisting, consisting of, of 15, 15 exons, exons ., . Using, Using a, a transgenic, transgenic DMPK-overexpressor, DMPK-overexpressor mouse, mouse model, model ,, , we, we demonstrate, demonstrate here, here that, that the, the endogenous, endogenous mouse, mouse DMPK, DMPK gene, gene and, and the, the human, human DMPK, DMPK transgene, transgene produce, produce six, six major, major alternatively, alternatively spliced, spliced mRNAs, mRNAs which, which have, have almost, almost identical, identical cell, cell type-dependent, type-dependent distribution, distribution frequencies, frequencies and, and expression, expression patterns, patterns ., . Use, Use of, of a, a cryptic, cryptic 5, 5 splice, splice site, site in, in exon, exon 8, 8 ,, , which, which results, results in, in absence, absence or, or presence, presence of, of 15, 15 nucleotides, nucleotides specifying, specifying a, a VSGGG, VSGGG peptide, peptide motif, motif ,, , and/or, and/or use, use of, of a, a cryptic, cryptic 3, 3 splice, splice site, site in, in exon, exon 14, 14 ,, , which, which leads, leads to, to a, a frameshift, frameshift in, in the, the mRNA, mRNA reading, reading frame, frame ,, , occur, occur as, as independent, independent stochastic, stochastic events, events in, in all, all tissues, tissues examined, examined ., . In, In contrast, contrast ,, , the, the excision, excision of, of exons, exons 13/14, 13/14 that, that causes, causes a, a frameshift, frameshift and, and creates, creates a, a C-terminally, C-terminally truncated, truncated protein, protein is, is clearly, clearly cell, cell type, type dependent, dependent and, and occurs, occurs predominantly, predominantly in, in smooth, smooth muscle, muscle ., . We, We generated, generated all, all six, six full-length, full-length mouse, mouse cDNAs, cDNAs that, that result, result from, from combinations, combinations of, of these, these three, three major, major splicing, splicing events, events and, and show, show that, that their, their transfection, transfection into, into cells, cells in, in culture, culture leads, leads to, to production, production of, of four, four different, different approximately, approximately 74, 74 kDa, kDa full-length, full-length (, ( heart-, heart- ,, , skeletal, skeletal muscle-, muscle- or, or brain-specific, brain-specific ), ) and, and two, two C-terminally, C-terminally truncated, truncated approximately, approximately 68, 68 kDa, kDa (, ( smooth, smooth muscle-specific, muscle-specific ), ) isoforms, isoforms ., . Information, Information on, on DMPK, DMPK mRNA, mRNA and, and protein, protein isoform, isoform expression, expression patterns, patterns will, will be, be useful, useful for, for recognizing, recognizing differential, differential effects, effects of, of (, ( CTG, CTG ), ) (, ( n, n ), ) expansion, expansion in, in DM, DM manifestation.., manifestation.. van, van der, der Woude, Woude syndrome, syndrome (, ( VWS, VWS ), ) ,, , which, which has, has been, been mapped, mapped to, to 1q32-41, 1q32-41 ,, , is, is characterized, characterized by, by pits, pits and/or, and/or sinuses, sinuses of, of the, the lower, lower lip, lip ,, , cleft, cleft lip/palate, lip/palate (, ( CL/P, CL/P ), ) ,, , cleft, cleft palate, palate (, ( CP, CP ), ) ,, , bifid, bifid uvula, uvula ,, , and, and hypodontia, hypodontia (, ( H, H ), ) ., . The, The expression, expression of, of VWS, VWS ,, , which, which has, has incomplete, incomplete penetrance, penetrance ,, , is, is highly, highly variable, variable ., . Both, Both the, the occurrence, occurrence of, of CL/P, CL/P and, and CP, CP within, within the, the same, same genealogy, genealogy and, and a, a recurrence, recurrence risk, risk <, < 40, 40 %, % for, for CP, CP among, among descendants, descendants with, with VWS, VWS have, have suggested, suggested that, that the, the development, development of, of clefts, clefts in, in this, this syndrome, syndrome is, is influenced, influenced by, by modifying, modifying genes, genes at, at other, other loci, loci ., . To, To test, test this, this hypothesis, hypothesis ,, , we, we have, have conducted, conducted linkage, linkage analysis, analysis in, in a, a large, large Brazilian, Brazilian kindred, kindred with, with VWS, VWS ,, , considering, considering as, as affected, affected the, the individuals, individuals with, with CP, CP ,, , regardless, regardless of, of whether, whether it, it is, is associated, associated with, with other, other clinical, clinical signs, signs of, of VWS, VWS ., . Our, Our results, results suggest, suggest that, that a, a gene, gene at, at 17p11, 17p11 ., . 2-11, 2-11 2-11, 2-11 ., . 1, 1 ,, , together, together with, with the, the VWS, VWS gene, gene at, at 1p32-41, 1p32-41 ,, , enhances, enhances the, the probability, probability of, of CP, CP in, in an, an individual, individual carrying, carrying the, the two, two at-risk, at-risk genes, genes ., . If, If this, this hypothesis, hypothesis is, is confirmed, confirmed in, in other, other VWS, VWS pedigrees, pedigrees ,, , it, it will, will represent, represent one, one of, of the, the first, first examples, examples of, of a, a gene, gene ,, , mapped, mapped through, through linkage, linkage analysis, analysis ,, , which, which modifies, modifies the, the expression, expression of, of a, a major, major gene, gene ., . Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ;, ; EC, EC 1, 1 ., . 1, 1 ., . 1, 1 ., . 49, 49 ), ) deficiency, deficiency is, is a, a common, common genetic, genetic abnormality, abnormality affecting, affecting an, an estimated, estimated 400, 400 million, million people, people worldwide, worldwide ., . Clinical, Clinical and, and biochemical, biochemical analyses, analyses have, have identified, identified many, many variants, variants exhibiting, exhibiting a, a range, range of, of phenotypes, phenotypes ,, , which, which have, have been, been well, well characterized, characterized from, from the, the hematological, hematological point, point of, of view, view ., . However, However ,, , until, until now, now ,, , their, their precise, precise molecular, molecular basis, basis has, has remained, remained unknown, unknown ., . We, We have, have cloned, cloned and, and sequenced, sequenced seven, seven mutant, mutant G6PD, G6PD alleles, alleles ., . In, In the, the nondeficient, nondeficient polymorphic, polymorphic African, African variant, variant G6PD, G6PD A, A we, we have, have found, found a, a single, single point, point mutation, mutation ., . The, The other, other six, six mutants, mutants investigated, investigated were, were all, all associated, associated with, with enzyme, enzyme deficiency, deficiency ., . In, In one, one of, of the, the commonest, commonest ,, , G6PD, G6PD Mediterranean, Mediterranean ,, , which, which is, is associated, associated with, with favism, favism among, among other, other clinical, clinical manifestations, manifestations ,, , a, a single, single amino, amino acid, acid replacement, replacement was, was found, found (, ( serine, serine --, -- --, -- phenylalanine, phenylalanine ), ) it, it must, must be, be responsible, responsible for, for the, the decreased, decreased stability, stability and, and the, the reduced, reduced catalytic, catalytic efficiency, efficiency of, of this, this enzyme, enzyme ., . Single, Single point, point mutations, mutations were, were also, also found, found in, in G6PD, G6PD Metaponto, Metaponto (, ( Southern, Southern Italy, Italy ), ) and, and in, in G6PD, G6PD Ilesha, Ilesha (, ( Nigeria, Nigeria ), ) ,, , which, which are, are asymptomatic, asymptomatic ,, , and, and in, in G6PD, G6PD Chatham, Chatham ,, , which, which was, was observed, observed in, in an, an Indian, Indian boy, boy with, with neonatal, neonatal jaundice, jaundice ., . In, In G6PD, G6PD ``, `` Matera, Matera ,, , ``, `` which, which is, is now, now known, known to, to be, be the, the same, same as, as G6PD, G6PD A-, A- ,, , two, two separate, separate point, point mutations, mutations were, were found, found ,, , one, one of, of which, which is, is the, the same, same as, as in, in G6PD, G6PD A, A ., . In, In G6PD, G6PD Santiago, Santiago ,, , a, a de, de novo, novo mutation, mutation (, ( glycine, glycine --, -- --, -- arginine, arginine ), ) is, is associated, associated with, with severe, severe chronic, chronic hemolytic, hemolytic anemia, anemia ., . The, The mutations, mutations observed, observed show, show a, a striking, striking predominance, predominance of, of C, C --, -- --, -- T, T transitions, transitions ,, , with, with CG, CG doublets, doublets involved, involved in, in four, four of, of seven, seven cases, cases ., . Thus, Thus ,, , diverse, diverse point, point mutations, mutations may, may account, account largely, largely for, for the, the phenotypic, phenotypic heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency ., . BACKGROUND, BACKGROUND AND, AND METHODS, METHODS ., . The, The plasma, plasma cholesteryl-ester, cholesteryl-ester transfer, transfer protein, protein (, ( CETP, CETP ), ) catalyzes, catalyzes the, the transfer, transfer of, of cholesteryl, cholesteryl esters, esters from, from high-density, high-density lipoprotein, lipoprotein (, ( HDL, HDL ), ) to, to other, other lipoproteins, lipoproteins ., . We, We recently, recently described, described a, a Japanese, Japanese family, family with, with increased, increased HDL, HDL levels, levels and, and CETP, CETP deficiency, deficiency due, due to, to a, a splicing, splicing defect, defect of, of the, the CETP, CETP gene, gene ., . To, To assess, assess the, the frequency, frequency and, and phenotype, phenotype of, of this, this condition, condition ,, , we, we screened, screened 11, 11 additional, additional families, families with, with high, high HDL, HDL levels, levels by, by means, means of, of a, a radioimmunoassay, radioimmunoassay for, for CETP, CETP and, and DNA, DNA analysis, analysis ., . RESULTS, RESULTS ., . We, We found, found the, the same, same CETP, CETP gene, gene mutation, mutation in, in four, four families, families from, from three, three different, different regions, regions of, of Japan, Japan ., . Analysis, Analysis of, of restriction-fragment-length, restriction-fragment-length polymorphisms, polymorphisms of, of the, the mutant, mutant CETP, CETP allele, allele showed, showed that, that all, all probands, probands were, were homozygous, homozygous for, for the, the identical, identical haplotype, haplotype ., . Family, Family members, members homozygous, homozygous for, for CETP, CETP deficiency, deficiency (, ( n, n =, = 10, 10 ), ) had, had moderate, moderate hypercholesterolemia, hypercholesterolemia (, ( mean, mean total, total cholesterol, cholesterol level, level [, [ +/-, +/- SD, SD ], ] ,, , 7, 7 ., . 01, 01 +/-, +/- 0, 0 ., . 83, 83 mmol, mmol per, per liter, liter ), ) ,, , markedly, markedly increased, increased levels, levels of, of HDL, HDL cholesterol, cholesterol (, ( 4, 4 ., . 24, 24 +/-, +/- 1, 1 ., . 01, 01 mmol, mmol per, per liter, liter ), ) and, and apolipoprotein, apolipoprotein A-I, A-I ,, , and, and decreased, decreased levels, levels of, of low-density, low-density lipoprotein, lipoprotein cholesterol, cholesterol (, ( 1, 1 ., . 99, 99 +/-, +/- 0, 0 ., . 80, 80 mmol, mmol per, per liter, liter ), ) and, and apolipoprotein, apolipoprotein B, B ., . Members, Members heterozygous, heterozygous for, for the, the deficiency, deficiency (, ( n, n =, = 20, 20 ), ) ,, , whose, whose CETP, CETP levels, levels were, were in, in the, the lower, lower part, part of, of the, the normal, normal range, range ,, , had, had moderately, moderately increased, increased levels, levels of, of HDL, HDL cholesterol, cholesterol and, and apolipoprotein, apolipoprotein A-I, A-I and, and an, an increased, increased ratio, ratio of, of HDL, HDL subclass, subclass 2, 2 to, to HDL, HDL subclass, subclass 3, 3 ,, , as, as compared, compared with, with unaffected, unaffected family, family members, members (, ( 1, 1 ., . 5, 5 +/-, +/- 0, 0 ., . 8, 8 vs., vs. 0, 0 ., . 7, 7 +/-, +/- 0, 0 ., . 4, 4 ), ) ., . CETP, CETP deficiency, deficiency was, was not, not found, found in, in six, six unrelated, unrelated subjects, subjects with, with elevated, elevated HDL, HDL cholesterol, cholesterol levels, levels who, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "who were, were from, from different, different parts, parts of, of the, the United, United States, States ., . CONCLUSIONS, CONCLUSIONS ., . CETP, CETP deficiency, deficiency appears, appears to, to be, be a, a frequent, frequent cause, cause of, of increased, increased HDL, HDL levels, levels in, in the, the population, population of, of Japan, Japan ,, , possibly, possibly because, because of, of a, a founder, founder effect, effect ., . The, The results, results that, that we, we observed, observed in, in heterozygotes, heterozygotes suggest, suggest that, that CETP, CETP normally, normally plays, plays a, a part, part in, in the, the regulation, regulation of, of levels, levels of, of HDL, HDL subclass, subclass 2, 2 ., . There, There was, was no, no evidence, evidence of, of premature, premature atherosclerosis, atherosclerosis in, in the, the families, families with, with CETP, CETP deficiency, deficiency ., . In, In fact, fact ,, , the, the lipoprotein, lipoprotein profile, profile of, of persons, persons with, with CETP, CETP deficiency, deficiency is, is potentially, potentially antiatherogenic, antiatherogenic and, and may, may be, be associated, associated with, with an, an increased, increased life, life span, span ., . Terminal, Terminal complement, complement component, component deficiency, deficiency predisposes, predisposes to, to meningococcal, meningococcal infection, infection and, and is, is inherited, inherited in, in an, an autosomal, autosomal co-dominant, co-dominant manner, manner ., . An, An Irish, Irish family, family is, is described, described ,, , in, in which, which 2, 2 of, of 3, 3 brothers, brothers had, had recurrent, recurrent meningococcal, meningococcal infection, infection ., . A, A novel, novel screening, screening assay, assay was, was used, used to, to investigate, investigate for, for terminal, terminal complement, complement deficiency, deficiency and, and the, the 2, 2 affected, affected brothers, brothers were, were found, found to, to be, be completely, completely deficient, deficient in, in the, the seventh, seventh component, component of, of complement, complement (, ( C7, C7 ), ) ., . Enzyme-linked, Enzyme-linked immunosorbent, immunosorbent assay, assay for, for C7, C7 revealed, revealed lower, lower than, than normal, normal levels, levels in, in the, the remaining, remaining brother, brother and, and parents, parents ., . C7, C7 M/N, M/N protein, protein polymorphism, polymorphism allotyping, allotyping ,, , used, used to, to investigate, investigate the, the segregation, segregation of, of the, the C7, C7 deficiency, deficiency genes, genes ,, , showed, showed that, that the, the apparently, apparently complement, complement sufficient, sufficient brother, brother was, was heterozygous, heterozygous C7, C7 deficient, deficient and, and a, a carrier, carrier of, of one, one of, of the, the deficiency, deficiency genes, genes ., . Complement, Complement screening, screening should, should be, be carried, carried out, out in, in any, any individual, individual suffering, suffering recurrent, recurrent meningococcal, meningococcal infection, infection or, or infection, infection with, with an, an uncommon, uncommon meningococcal, meningococcal serogroup, serogroup ., . Identification, Identification of, of complement, complement deficient, deficient patients, patients allows, allows the, the implementation, implementation of, of strategies, strategies to, to prevent, prevent recurrent, recurrent infection.., infection.. We, We have, have analysed, analysed over, over 300, 300 patients, patients suffering, suffering from, from Duchenne, Duchenne or, or Becker, Becker muscular, muscular dystrophy, dystrophy (, ( DMD, DMD or, or BMD, BMD ), ) ., . Deletions, Deletions have, have been, been characterised, characterised which, which encompass, encompass either, either the, the pERT87, pERT87 (, ( DXS164, DXS164 ), ) locus, locus only, only ,, , the, the XJ1, XJ1 ., . 1, 1 (, ( DXS206, DXS206 ), ) and, and HIP25, HIP25 loci, loci only, only ,, , or, or all, all three, three loci, loci ., . These, These loci, loci have, have been, been shown, shown to, to lie, lie within, within the, the DMD, DMD region, region covering, covering several, several hundred, hundred kilobases, kilobases (, ( kb, kb ), ) of, of DNA, DNA ., . One, One mildly, mildly affected, affected BMD, BMD patient, patient possesses, possesses a, a deletion, deletion of, of at, at least, least 110, 110 kb, kb including, including exons, exons of, of the, the DMD, DMD gene, gene ., . Other, Other patients, patients with, with similar, similar exon, exon deletions, deletions ,, , or, or smaller, smaller deletions, deletions ,, , show, show the, the more, more severe, severe phenotype, phenotype typical, typical of, of DMD, DMD ., . We, We conclude, conclude from, from these, these studies, studies that, that the, the severity, severity of, of the, the clinical, clinical phenotype, phenotype can, can not, not be, be explained, explained on, on the, the basis, basis of, of the, the size, size of, of the, the deletion, deletion ., . We, We discuss, discuss this, this in, in the, the context, context of, of candidate, candidate gene, gene sequences, sequences ., . In, In hereditary, hereditary retinoblastoma, retinoblastoma ,, , different, different epidemiological, epidemiological studies, studies have, have indicated, indicated a, a preferential, preferential paternal, paternal transmission, transmission of, of mutant, mutant retinoblastoma, retinoblastoma alleles, alleles to, to offspring, offspring ,, , suggesting, suggesting the, the occurrence, occurrence of, of a, a meiotic, meiotic drive, drive ., . To, To investigate, investigate this, this mechanism, mechanism ,, , we, we analyzed, analyzed sperm, sperm samples, samples from, from six, six individuals, individuals from, from five, five unrelated, unrelated families, families affected, affected with, with hereditary, hereditary retinoblastoma, retinoblastoma ., . Single-sperm, Single-sperm typing, typing techniques, techniques were, were performed, performed for, for each, each sample, sample by, by study, study of, of two, two informative, informative short, short tandem, tandem repeats, repeats located, located either, either in, in or, or close, close to, to the, the retinoblastoma, retinoblastoma gene, gene (, ( RB1, RB1 ), ) ., . The, The segregation, segregation probability, probability of, of mutant, mutant RB1, RB1 alleles, alleles in, in sperm, sperm samples, samples was, was assessed, assessed by, by use, use of, of the, the SPERMSEG, SPERMSEG program, program ,, , which, which includes, includes experimental, experimental parameters, parameters ,, , recombination, recombination fractions, fractions between, between the, the markers, markers ,, , and, and segregation, segregation parameters, parameters ., . A, A total, total of, of 2, 2 ,, , 952, 952 single, single sperm, sperm from, from the, the six, six donors, donors were, were analyzed, analyzed ., . We, We detected, detected a, a significant, significant segregation, segregation distortion, distortion in, in the, the data, data as, as a, a whole, whole (, ( P, P =, = ., . 0099, 0099 ), ) and, and a, a significant, significant heterogeneity, heterogeneity in, in the, the segregation, segregation rate, rate across, across donors, donors (, ( ., . 0092, 0092 ), ) ., . Further, Further analysis, analysis shows, shows that, that this, this result, result can, can be, be explained, explained by, by segregation, segregation distortion, distortion in, in favor, favor of, of the, the normal, normal allele, allele in, in one, one donor, donor only, only and, and that, that it, it does, does not, not provide, provide evidence, evidence of, of a, a significant, significant segregation, segregation distortion, distortion in, in the, the other, other donors, donors ., . The, The segregation, segregation distortion, distortion favoring, favoring the, the mutant, mutant RB1, RB1 allele, allele does, does not, not seem, seem to, to occur, occur during, during spermatogenesis, spermatogenesis ,, , and, and ,, , thus, thus ,, , meiotic, meiotic drive, drive may, may result, result either, either from, from various, various mechanisms, mechanisms ,, , including, including a, a fertilization, fertilization advantage, advantage or, or a, a better, better mobility, mobility in, in sperm, sperm bearing, bearing a, a mutant, mutant RB1, RB1 gene, gene ,, , or, or from, from the, the existence, existence of, of a, a defectively, defectively imprinted, imprinted gene, gene located, located on, on the, the human, human X, X chromosome.The, chromosome.The PDS, PDS gene, gene encodes, encodes a, a transmembrane, transmembrane protein, protein ,, , known, known as, as pendrin, pendrin ,, , which, which functions, functions as, as a, a transporter, transporter of, of iodide, iodide and, and chloride, chloride ., . Mutations, Mutations in, in this, this gene, gene are, are responsible, responsible for, for Pendred, Pendred syndrome, syndrome and, and autosomal, autosomal recessive, recessive non-syndromic, non-syndromic hearing, hearing loss, loss at, at the, the DFNB4, DFNB4 locus, locus on, on chromosome, chromosome 7q31, 7q31 ., . A, A screen, screen of, of 20, 20 individuals, individuals from, from the, the midwestern, midwestern USA, USA with, with non-syndromic, non-syndromic hearing, hearing loss, loss and, and dilated, dilated vestibular, vestibular aqueducts, aqueducts identified, identified three, three people, people (, ( 15, 15 %, % ), ) with, with PDS, PDS mutations, mutations ., . To, To determine, determine whether, whether PDS, PDS mutations, mutations in, in individuals, individuals with, with Pendred, Pendred syndrome, syndrome differ, differ functionally, functionally from, from PDS, PDS mutations, mutations in, in individuals, individuals with, with non-syndromic, non-syndromic hearing, hearing loss, loss ,, , we, we compared, compared three, three common, common Pendred, Pendred syndrome, syndrome allele, allele variants, variants (, ( L236P, L236P ,, , T416P, T416P and, and E384G, E384G ), ) ,, , with, with three, three PDS, PDS mutations, mutations reported, reported only, only in, in individuals, individuals with, with non-syndromic, non-syndromic hearing, hearing loss, loss (, ( V480D, V480D ,, , V653A, V653A and, and I490L/G497S, I490L/G497S ), ) ., . The, The mutations, mutations associated, associated with, with Pendred, Pendred syndrome, syndrome have, have complete, complete loss, loss of, of pendrin-induced, pendrin-induced chloride, chloride and, and iodide, iodide transport, transport ,, , while, while alleles, alleles unique, unique to, to people, people with, with DFNB4, DFNB4 are, are able, able to, to transport, transport both, both iodide, iodide and, and chloride, chloride ,, , albeit, albeit at, at a, a much, much lower, lower level, level than, than wild-type, wild-type pendrin, pendrin ., . We, We hypothesize, hypothesize that, that this, this residual, residual level, level of, of anion, anion transport, transport is, is sufficient, sufficient to, to eliminate, eliminate or, or postpone, postpone the, the onset, onset of, of goiter, goiter in, in individuals, individuals with, with DFNB4, DFNB4 ., . We, We propose, propose a, a model, model for, for pendrin, pendrin function, function in, in the, the thyroid, thyroid in, in which, which pendrin, pendrin transports, transports iodide, iodide across, across the, the apical, apical membrane, membrane of, of the, the thyrocyte, thyrocyte into, into the, the colloid, colloid space.., space.. We, We report, report on, on a, a new, new allele, allele at, at the, the arylsulfatase, arylsulfatase A, A (, ( ARSA, ARSA ), ) locus, locus causing, causing late-onset, late-onset metachromatic, metachromatic leukodystrophy, leukodystrophy (, ( MLD, MLD ), ) ., . In, In that, that allele, allele arginine84, arginine84 ,, , a, a residue, residue that, that is, is highly, highly conserved, conserved in, in the, the arylsulfatase, arylsulfatase gene, gene family, family ,, , is, is replaced, replaced by, by glutamine, glutamine ., . In, In contrast, contrast to, to alleles, alleles that, that cause, cause early-onset, early-onset MLD, MLD ,, , the, the arginine84, arginine84 to, to glutamine, glutamine substitution, substitution is, is associated, associated with, with some, some residual, residual ARSA, ARSA activity, activity ., . A, A comparison, comparison of, of genotypes, genotypes ,, , ARSA, ARSA activities, activities ,, , and, and clinical, clinical data, data on, on 4, 4 individuals, individuals carrying, carrying the, the allele, allele of, of 81, 81 patients, patients with, with MLD, MLD examined, examined ,, , further, further validates, validates the, the concept, concept that, that different, different degrees, degrees of, of residual, residual ARSA, ARSA activity, activity are, are the, the basis, basis of, of phenotypical, phenotypical variation, variation in, in MLD.., MLD.. Heterozygous, Heterozygous mutations, mutations in, in the, the CD95, CD95 (, ( APO-1/Fas, APO-1/Fas ), ) receptor, receptor occur, occur in, in most, most individuals, individuals with, with autoimmune, autoimmune lymphoproliferative, lymphoproliferative syndrome, syndrome (, ( ALPS, ALPS ), ) and, and dominantly, dominantly interfere, interfere with, with apoptosis, apoptosis by, by an, an unknown, unknown mechanism, mechanism ., . We, We show, show that, that local, local or, or global, global alterations, alterations in, in the, the structure, structure of, of the, the cytoplasmic, cytoplasmic death, death domain, domain from, from nine, nine independent, independent ALPS, ALPS CD95, CD95 death-domain, death-domain mutations, mutations result, result in, in a, a failure, failure to, to bind, bind the, the FADD/MORT1, FADD/MORT1 signaling, signaling protein, protein ., . Despite, Despite heterozygosity, heterozygosity for, for the, the abnormal, abnormal allele, allele ,, , lymphocytes, lymphocytes from, from ALPS, ALPS patients, patients showed, showed markedly, markedly decreased, decreased FADD, FADD association, association and, and a, a loss, loss of, of caspase, caspase recruitment, recruitment and, and activation, activation after, after CD95, CD95 crosslinking, crosslinking ., . These, These data, data suggest, suggest that, that intracytoplasmic, intracytoplasmic CD95, CD95 mutations, mutations in, in ALPS, ALPS impair, impair apoptosis, apoptosis chiefly, chiefly by, by disrupting, disrupting death-domain, death-domain interactions, interactions with, with the, the signaling, signaling protein, protein FADD/MORT1.., FADD/MORT1.. Classical, Classical galactosemia, galactosemia is, is caused, caused by, by a, a deficiency, deficiency in, in activity, activity of, of the, the enzyme, enzyme galactose-1-phosphate, galactose-1-phosphate uridyl, uridyl transferase, transferase (, ( GALT, GALT ), ) ,, , which, which ,, , in, in turn, turn ,, , is, is caused, caused by, by mutations, mutations at, at the, the GALT, GALT gene, gene ., . The, The disorder, disorder exhibits, exhibits considerable, considerable allelic, allelic heterogeneity, heterogeneity and, and ,, , at, at the, the end, end of, of 1998, 1998 ,, , more, more than, than 150, 150 different, different base, base changes, changes were, were recorded, recorded in, in 24, 24 different, different populations, populations and, and ethnic, ethnic groups, groups in, in 15, 15 countries, countries worldwide, worldwide ., . The, The mutations, mutations most, most frequently, frequently cited, cited are, are Q188R, Q188R ,, , K285N, K285N ,, , S135L, S135L ,, , and, and N314D, N314D ., . Q188R, Q188R is, is the, the most, most common, common mutation, mutation in, in European, European populations, populations or, or in, in those, those predominantly, predominantly of, of European, European descent, descent ., . Overall, Overall ,, , it, it accounts, accounts for, for 60-70, 60-70 %, % of, of mutant, mutant chromosomes, chromosomes ,, , but, but there, there are, are significant, significant differences, differences in, in its, its relative, relative frequency, frequency in, in individual, individual populations, populations ., . Individuals, Individuals homoallelic, homoallelic for, for Q188R, Q188R tend, tend to, to have, have a, a severe, severe phenotype, phenotype and, and this, this is, is in, in keeping, keeping with, with the, the virtually, virtually complete, complete loss, loss of, of enzyme, enzyme activity, activity observed, observed in, in in, in vitro, vitro expression, expression systems, systems ., . Globally, Globally ,, , K285N, K285N is, is rarer, rarer ,, , but, but in, in many, many European, European populations, populations it, it can, can be, be found, found on, on 25-40, 25-40 %, % of, of mutant, mutant chromosomes, chromosomes ., . It, It is, is invariably, invariably associated, associated with, with a, a severe, severe phenotype, phenotype ., . S135L, S135L is, is found, found almost, almost exclusively, exclusively in, in African, African Americans, Americans ., . In, In vitro, vitro expression, expression results, results are, are discrepant, discrepant ,, , but, but some, some individuals, individuals carrying, carrying S135L, S135L appear, appear to, to exhibit, exhibit GALT, GALT activity, activity in, in some, some tissues, tissues ., . Duarte, Duarte 1, 1 (, ( or, or Los, Los Angeles, Angeles ), ) and, and Duarte, Duarte 2, 2 (, ( or, or Duarte, Duarte ), ) variants, variants carry, carry the, the same, same amino, amino acid, acid substitution, substitution ,, , N314D, N314D ,, , even, even though, though D1, D1 is, is associated, associated with, with increased, increased erythrocyte, erythrocyte GALT, GALT activity, activity and, and D2, D2 with, with reduced, reduced activity, activity ., . N314D, N314D is, is in, in linkage, linkage disequilibrium, disequilibrium with, with other, other base, base changes, changes that, that differ, differ on, on the, the D1, D1 and, and D2, D2 alleles, alleles ., . N314D, N314D does, does not, not impair, impair GALT, GALT activity, activity in, in in, in vitro, vitro expression, expression systems, systems ., . However, However ,, , there, there are, are differences, differences in, in the, the abundance, abundance of, of GALT, GALT protein, protein in, in lymphoblastoid, lymphoblastoid cells, cells lines, lines from, from D2, D2 and, and D1, D1 individuals, individuals ., . It, It is, is unclear, unclear whether, whether the, the specific, specific molecular, molecular changes, changes that, that distinguish, distinguish the, the D1, D1 and, and D2, D2 alleles, alleles account, account for, for the, the different, different activities, activities ., . The, The considerable, considerable genetic, genetic heterogeneity, heterogeneity documented, documented to, to date, date undoubtedly, undoubtedly contributes, contributes to, to the, the phenotypic, phenotypic heterogeneity, heterogeneity that, that is, is observed, observed in, in galactosemia, galactosemia ., . The, The additional, additional effects, effects of, of nonallelic, nonallelic variation, variation and, and other, other constitutional, constitutional factors, factors on, on phenotypic, phenotypic variability, variability remain, remain to, to be, be elucidated.., elucidated.. BACKGROUND, BACKGROUND X-linked, X-linked retinoschisis, retinoschisis (, ( XLRS, XLRS ), ) is, is a, a relatively, relatively rare, rare vitreoretinal, vitreoretinal dystrophy, dystrophy that, that causes, causes visual, visual loss, loss in, in young, young men, men ., . Recently, Recently ,, , a, a gene, gene responsible, responsible for, for this, this disease, disease ,, , designated, designated XLRS1, XLRS1 ,, , was, was identified, identified ,, , and, and several, several deleterious, deleterious gene, gene mutations, mutations were, were reported, reported ., . OBJECTIVE, OBJECTIVE To, To analyze, analyze Japanese, Japanese patients, patients clinically, clinically diagnosed, diagnosed as, as having, having XLRS, XLRS formutational, formutational changes, changes in, in the, the XLRS1, XLRS1 gene, gene ., . METHODS, METHODS Ten, Ten patients, patients with, with XLRS, XLRS underwent, underwent full, full ophthalmologic, ophthalmologic examination, examination ,, , including, including slitlamp, slitlamp biomicroscopy, biomicroscopy and, and dilated, dilated funduscopy, funduscopy ., . Genomic, Genomic DNA, DNA was, was isolated, isolated from, from leukocytes, leukocytes ,, , and, and all, all exons, exons of, of the, the XLRS1, XLRS1 gene, gene were, were amplified, amplified by, by polymerase, polymerase chain, chain reaction, reaction and, and analyzed, analyzed using, using a, a direct, direct sequencing, sequencing method, method ., . RESULTS, RESULTS Point, Point mutations, mutations in, in the, the XLRS1, XLRS1 gene, gene were, were identified, identified in, in all, all 10, 10 patients, patients ., . The, The mutations, mutations were, were identical, identical in, in each, each of, of 2, 2 pairs, pairs of, of brothers, brothers ., . Six, Six of, of the, the point, point mutations, mutations represented, represented missense, missense mutations, mutations ,, , 1, 1 was, was a, a nonsense, nonsense mutation, mutation ,, , and, and 1, 1 was, was a, a frameshift, frameshift mutation, mutation ., . Five, Five of, of the, the mutations, mutations are, are newly, newly reported, reported herein, herein ., . CONCLUSIONS, CONCLUSIONS The, The discovery, discovery of, of new, new point, point mutations, mutations in, in this, this study, study increases, increases the, the available, available information, information regarding, regarding the, the spectrum, spectrum of, of genetic, genetic abnormalities, abnormalities and, and clinical, clinical manifestations, manifestations of, of XLRS, XLRS ., . However, However ,, , the, the limited, limited data, data failed, failed to, to reveal, reveal a, a correlation, correlation between, between mutation, mutation and, and disease, disease phenotype, phenotype ., . CLINICAL, CLINICAL RELEVANCE, RELEVANCE Identification, Identification of, of mutations, mutations in, in the, the XLRS1, XLRS1 gene, gene and, and expanded, expanded information, information on, on clinical, clinical manifestations, manifestations will, will facilitate, facilitate early, early diagnosis, diagnosis ,, , appropriate, appropriate early, early therapy, therapy ,, , and, and genetic, genetic counseling, counseling regarding, regarding the, the prognosis, prognosis of, of XLRS.., XLRS.. OBJECTIVE, OBJECTIVE To, To examine, examine the, the relationship, relationship of, of phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) genotypes, genotypes to, to biochemical, biochemical phenotype, phenotype and, and cognitive, cognitive development, development in, in maternal, maternal phenylketonuria, phenylketonuria (, ( PKU, PKU ), ) ., . METHODOLOGY, METHODOLOGY PAH, PAH gene, gene mutations, mutations were, were examined, examined in, in 222, 222 hyperphenylalaninemic, hyperphenylalaninemic females, females enrolled, enrolled in, in the, the Maternal, Maternal PKU, PKU Collaborative, Collaborative Study, Study (, ( MPKUCS, MPKUCS ), ) ., . A, A total, total of, of 84, 84 different, different mutations, mutations were, were detected, detected ,, , and, and complete, complete genotype, genotype was, was obtained, obtained in, in 199, 199 individuals, individuals ., . Based, Based on, on previous, previous knowledge, knowledge about, about mutation-phenotype, mutation-phenotype associations, associations ,, , 78, 78 of, of the, the mutations, mutations could, could be, be assigned, assigned to, to one, one of, of four, four classes, classes of, of severity, severity (, ( severe, severe PKU, PKU ,, , moderate, moderate PKU, PKU ,, , mild, mild PKU, PKU ,, , and, and mild, mild hyperphenylalaninemia, hyperphenylalaninemia [, [ MHP, MHP ], ] ), ) ., . Then, Then ,, , 189, 189 MPKUCS, MPKUCS subjects, subjects were, were grouped, grouped according, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "according to, to the, the various, various combinations, combinations of, of mutation, mutation classifications, classifications ., . The, The sample, sample sizes, sizes were, were large, large enough, enough for, for statistical, statistical testing, testing in, in four, four groups, groups with, with at, at least, least one, one mutation, mutation that, that completely, completely abolishes, abolishes enzyme, enzyme activity, activity ., . These, These patients, patients are, are considered, considered functionally, functionally hemizygous, hemizygous ., . RESULTS, RESULTS The, The biochemical, biochemical phenotype, phenotype predicted, predicted from, from the, the genotype, genotype in, in functionally, functionally hemizygous, hemizygous patients, patients was, was related, related significantly, significantly to, to the, the assigned, assigned phenylalanine, phenylalanine level, level ., . Cognitive, Cognitive performance, performance (, ( IQ, IQ ), ) was, was also, also significantly, significantly related, related to, to genotype, genotype ., . The, The IQ, IQ of, of PAH-deficient, PAH-deficient mothers, mothers with, with a, a severe, severe PKU, PKU mutation, mutation in, in combination, combination with, with a, a MHP, MHP mutation, mutation or, or a, a mild, mild PKU, PKU mutation, mutation was, was 99, 99 and, and 96, 96 ,, , respectively, respectively ,, , whereas, whereas the, the IQ, IQ of, of PKU, PKU mothers, mothers with, with two, two severe, severe PKU, PKU mutations, mutations or, or with, with one, one severe, severe and, and one, one moderate, moderate PKU, PKU mutation, mutation was, was 83, 83 and, and 84, 84 ,, , respectively, respectively ., . Of, Of the, the patients, patients with, with PKU, PKU ,, , 92, 92 %, % had, had been, been treated, treated during, during childhood, childhood ., . Those, Those who, who were, were untreated, untreated or, or treated, treated late, late had, had lower, lower than, than average, average IQ, IQ scores, scores for, for their, their group, group of, of mutation, mutation combinations, combinations ., . Females, Females with, with moderate, moderate or, or mild, mild PKU, PKU who, who were, were treated, treated early, early and, and treated, treated for, for >, > 6, 6 years, years showed, showed IQ, IQ scores, scores 10, 10 points, points above, above average, average for, for their, their group, group ., . CONCLUSIONS, CONCLUSIONS The, The reproductive, reproductive outcome, outcome in, in maternal, maternal phenylketonuria, phenylketonuria is, is dependent, dependent on, on prenatal, prenatal metabolic, metabolic control, control and, and postnatal, postnatal environmental, environmental circumstances, circumstances ., . Both, Both factors, factors depend, depend on, on the, the intellectual, intellectual resources, resources of, of the, the mother, mother with, with PKU, PKU ., . The, The significant, significant relationship, relationship among, among genotype, genotype ,, , biochemical, biochemical phenotype, phenotype ,, , and, and cognitive, cognitive performance, performance observed, observed in, in the, the present, present study, study is, is of, of importance, importance for, for the, the development, development of, of an, an optimal, optimal strategy, strategy for, for future, future treatment, treatment of, of females, females with, with PKU, PKU who, who plan, plan pregnancy.., pregnancy.. Proteolipid, Proteolipid protein, protein (, ( PLP, PLP ;, ; M, M (, ( r, r ), ) 30, 30 ,, , 000, 000 ), ) is, is a, a highly, highly conserved, conserved major, major polytopic, polytopic membrane, membrane protein, protein in, in myelin, myelin but, but its, its cellular, cellular function, function remains, remains obscure, obscure ., . Neurological, Neurological mutant, mutant mice, mice can, can often, often provide, provide model, model systems, systems for, for human, human genetic, genetic disorders, disorders ., . Mutations, Mutations of, of the, the X-chromosome-linked, X-chromosome-linked PLP, PLP gene, gene are, are lethal, lethal ,, , identified, identified first, first in, in the, the jimpy, jimpy mouse, mouse and, and subsequently, subsequently in, in patients, patients with, with Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease ., . The, The unexplained, unexplained phenotype, phenotype of, of these, these mutations, mutations includes, includes degeneration, degeneration and, and premature, premature cell, cell death, death of, of oligodendrocytes, oligodendrocytes with, with associated, associated hypomyelination, hypomyelination ., . Here, Here we, we show, show that, that a, a new, new mouse, mouse mutant, mutant rumpshaker, rumpshaker is, is defined, defined by, by the, the amino-acid, amino-acid substitution, substitution Ile-to-Thr, Ile-to-Thr at, at residue, residue 186, 186 in, in a, a membrane-embedded, membrane-embedded domain, domain of, of PLP, PLP ., . Surprisingly, Surprisingly ,, , rumpshaker, rumpshaker mice, mice ,, , although, although myelin-deficient, myelin-deficient ,, , have, have normal, normal longevity, longevity and, and a, a full, full complement, complement of, of morphologically, morphologically normal, normal oligodendrocytes, oligodendrocytes ., . Hypomyelination, Hypomyelination can, can thus, thus be, be genetically, genetically separated, separated from, from the, the PLP-dependent, PLP-dependent oligodendrocyte, oligodendrocyte degeneration, degeneration ., . We, We suggest, suggest that, that PLP, PLP has, has a, a vital, vital function, function in, in glial, glial cell, cell development, development ,, , distinct, distinct from, from its, its later, later role, role in, in myelin, myelin assembly, assembly ,, , and, and that, that this, this dichotomy, dichotomy of, of action, action may, may explain, explain the, the clinical, clinical spectrum, spectrum of, of Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease.., disease.. Alkaptonuria, Alkaptonuria (, ( AKU, AKU ), ) ,, , the, the prototypic, prototypic inborn, inborn error, error of, of metabolism, metabolism ,, , has, has recently, recently been, been shown, shown to, to be, be caused, caused by, by loss, loss of, of function, function mutations, mutations in, in the, the homogentisate-1, homogentisate-1 ,, , 2-dioxygenase, 2-dioxygenase gene, gene (, ( HGO, HGO ), ) ., . So, So far, far 17, 17 mutations, mutations have, have been, been characterised, characterised in, in AKU, AKU patients, patients of, of different, different ethnic, ethnic origin, origin ., . We, We describe, describe three, three novel, novel mutations, mutations (, ( R58fs, R58fs ,, , R330S, R330S ,, , and, and H371R, H371R ), ) and, and one, one common, common AKU, AKU mutation, mutation (, ( M368V, M368V ), ) ,, , detected, detected by, by mutational, mutational and, and polymorphism, polymorphism analysis, analysis of, of the, the HGO, HGO gene, gene in, in five, five Finnish, Finnish AKU, AKU pedigrees, pedigrees ., . The, The three, three novel, novel AKU, AKU mutations, mutations are, are most, most likely, likely specific, specific for, for the, the Finnish, Finnish population, population and, and have, have originated, originated recently.., recently.. Adrenoleukodystrophy, Adrenoleukodystrophy (, ( ALD, ALD ), ) is, is an, an X-linked, X-linked disease, disease affecting, affecting 1/20, 1/20 ,, , 000, 000 males, males either, either as, as cerebral, cerebral ALD, ALD in, in childhood, childhood or, or as, as adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) in, in adults, adults ., . Childhood, Childhood ALD, ALD is, is the, the more, more severe, severe form, form ,, , with, with onset, onset of, of neurological, neurological symptoms, symptoms between, between 5-12, 5-12 years, years of, of age, age ., . Central, Central nervous, nervous system, system demyelination, demyelination progresses, progresses rapidly, rapidly and, and death, death occurs, occurs within, within a, a few, few years, years ., . AMN, AMN is, is a, a milder, milder form, form of, of the, the disease, disease with, with onset, onset at, at 15-30, 15-30 years, years of, of age, age and, and a, a more, more progressive, progressive course, course ., . Adrenal, Adrenal insufficiency, insufficiency (, ( Addisons, Addisons disease, disease ), ) may, may remain, remain the, the only, only clinical, clinical manifestation, manifestation of, of ALD, ALD ., . The, The principal, principal biochemical, biochemical abnormality, abnormality of, of ALD, ALD is, is the, the accumulation, accumulation of, of very-long-chain, very-long-chain fatty, fatty acids, acids (, ( VLCFA, VLCFA ), ) because, because of, of impaired, impaired beta-oxidation, beta-oxidation in, in peroxisomes, peroxisomes ., . The, The normal, normal oxidation, oxidation of, of VLCFA-CoA, VLCFA-CoA in, in patients, patients fibroblasts, fibroblasts suggested, suggested that, that the, the gene, gene coding, coding for, for the, the VLCFA-CoA, VLCFA-CoA synthetase, synthetase could, could be, be a, a candidate, candidate gene, gene for, for ALD, ALD ., . Here, Here we, we use, use positional, positional cloning, cloning to, to identify, identify a, a gene, gene partially, partially deleted, deleted in, in 6, 6 of, of 85, 85 independent, independent patients, patients with, with ALD, ALD ., . In, In familial, familial cases, cases ,, , the, the deletions, deletions segregated, segregated with, with the, the disease, disease ., . An, An identical, identical deletion, deletion was, was detected, detected in, in two, two brothers, brothers presenting, presenting with, with different, different clinical, clinical ALD, ALD phenotypes, phenotypes ., . Candidate, Candidate exons, exons were, were identified, identified by, by computer, computer analysis, analysis of, of genomic, genomic sequences, sequences and, and used, used to, to isolate, isolate complementary, complementary DNAs, DNAs by, by exon, exon connection, connection and, and screening, screening of, of cDNA, cDNA libraries, libraries ., . The, The deduced, deduced protein, protein sequence, sequence shows, shows significant, significant sequence, sequence identity, identity to, to a, a peroxisomal, peroxisomal membrane, membrane protein, protein of, of M, M (, ( r, r ), ) 70K, 70K that, that is, is involved, involved in, in peroxisome, peroxisome biogenesis, biogenesis and, and belongs, belongs to, to the, the ATP-binding, ATP-binding cassette, cassette superfamily, superfamily of, of transporters.., transporters.. BACKGROUND, BACKGROUND Mutations, Mutations in, in the, the gene, gene encoding, encoding the, the human, human cardiac, cardiac Na, Na (, ( +, + ), ) channel, channel alpha-subunit, alpha-subunit (, ( hH1, hH1 ), ) are, are responsible, responsible for, for chromosome, chromosome 3-linked, 3-linked congenital, congenital long-QT, long-QT syndrome, syndrome (, ( LQT3, LQT3 ), ) and, and idiopathic, idiopathic ventricular, ventricular fibrillation, fibrillation (, ( IVF, IVF ), ) ., . An, An auxiliary, auxiliary beta, beta (, ( 1, 1 ), ) -subunit, -subunit ,, , widely, widely expressed, expressed in, in excitable, excitable tissues, tissues ,, , shifts, shifts the, the voltage, voltage dependence, dependence of, of steady-state, steady-state inactivation, inactivation toward, toward more, more negative, negative potentials, potentials and, and restores, restores normal, normal gating, gating kinetics, kinetics of, of brain, brain and, and skeletal, skeletal muscle, muscle Na, Na (, ( +, + ), ) channels, channels expressed, expressed in, in Xenopus, Xenopus oocytes, oocytes but, but has, has little, little if, if any, any functional, functional effect, effect on, on the, the cardiac, cardiac isoform, isoform ., . Here, Here ,, , we, we characterize, characterize the, the altered, altered effects, effects of, of a, a human, human beta, beta (, ( 1, 1 ), ) -subunit, -subunit (, ( hbeta, hbeta (, ( 1, 1 ), ) ), ) on, on the, the heterologously, heterologously expressed, expressed hH1, hH1 mutation, mutation (, ( T1620M, T1620M ), ) previously, previously associated, associated with, with IVF, IVF ., . METHODS, METHODS AND, AND RESULTS, RESULTS When, When expressed, expressed alone, alone in, in Xenopus, Xenopus oocytes, oocytes ,, , T1620M, T1620M exhibited, exhibited no, no persistent, persistent currents, currents ,, , in, in contrast, contrast to, to the, the LQT3, LQT3 mutant, mutant channels, channels ,, , but, but the, the midpoint, midpoint of, of steady-state, steady-state inactivation, inactivation (, ( V, V (, ( 1/2, 1/2 ), ) ), ) was, was significantly, significantly shifted, shifted toward, toward more, more positive, positive potentials, potentials than, than for, for wild-type, wild-type hH1, hH1 ., . Coexpression, Coexpression of, of hbeta, hbeta (, ( 1, 1 ), ) did, did not, not significantly, significantly alter, alter current, current decay, decay or, or recovery, recovery from, from inactivation, inactivation of, of wild-type, wild-type hH1, hH1 ;, ; however, however ,, , it, it further, further shifted, shifted the, the V, V (, ( 1/2, 1/2 ), ) and, and accelerated, accelerated the, the recovery, recovery from, from inactivation, inactivation of, of T1620M, T1620M ., . Oocyte, Oocyte macropatch, macropatch analysis, analysis revealed, revealed that, that the, the activation, activation kinetics, kinetics of, of T1620M, T1620M were, were normal, normal ., . CONCLUSIONS, CONCLUSIONS It, It is, is suggested, suggested that, that coexpression, coexpression of, of hbeta, hbeta (, ( 1, 1 ), ) exposes, exposes a, a more, more severe, severe functional, functional defect, defect that, that results, results in, in a, a greater, greater overlap, overlap in, in the, the relationship, relationship between, between channel, channel inactivation, inactivation and, and activation, activation (, ( window, window current, current ), ) in, in T1620M, T1620M ,, , which, which is, is proposed, proposed to, to be, be a, a potential, potential pathophysiological, pathophysiological mechanism, mechanism of, of IVF, IVF in, in vivo, vivo ., . One, One possible, possible explanation, explanation for, for our, our finding, finding is, is an, an altered, altered alpha-/beta, alpha-/beta (, ( 1, 1 ), ) -subunit, -subunit association, association in, in the, the mutant.., mutant.. Familial, Familial neurohypophyseal, neurohypophyseal diabetes, diabetes insipidus, insipidus is, is an, an autosomal, autosomal dominant, dominant disorder, disorder characterized, characterized by, by post-natal, post-natal development, development of, of arginine, arginine vasopressin, vasopressin (, ( AVP, AVP ), ) deficiency, deficiency due, due to, to mutations, mutations in, in the, the AVP, AVP gene, gene ., . All, All published, published mutations, mutations affect, affect the, the signal, signal peptide, peptide or, or the, the neurophysin-II, neurophysin-II carrier, carrier protein, protein and, and are, are presumed, presumed to, to interfere, interfere with, with processing, processing of, of the, the preprohormone, preprohormone ,, , leading, leading to, to neuronal, neuronal damage, damage ., . We, We studied, studied an, an unusual, unusual Palestinian, Palestinian family, family consisting, consisting of, of asymptomatic, asymptomatic first, first cousin, cousin parents, parents and, and three, three children, children affected, affected with, with neurohypophyseal, neurohypophyseal diabetes, diabetes insipidus, insipidus ,, , suggesting, suggesting autosomal, autosomal recessive, recessive inheritance, inheritance ., . All, All three, three affected, affected children, children were, were homozygous, homozygous and, and the, the parents, parents heterozygous, heterozygous for, for a, a single, single novel, novel mutation, mutation (, ( C301-, C301- >, > T, T ), ) in, in exon, exon 1, 1 ,, , replacing, replacing Pro7, Pro7 of, of mature, mature AVP, AVP with, with Leu, Leu (, ( Leu-AVP, Leu-AVP ), ) ., . Leu-AVP, Leu-AVP was, was a, a weak, weak agonist, agonist with, with approximately, approximately 30-fold, 30-fold reduced, reduced binding, binding to, to the, the human, human V2, V2 receptor, receptor ., . Measured, Measured by, by radioimmunoassay, radioimmunoassay with, with a, a synthetic, synthetic Leu-AVP, Leu-AVP standard, standard ,, , serum, serum Leu-AVP, Leu-AVP levels, levels were, were elevated, elevated in, in all, all three, three children, children and, and further, further increased, increased during, during water, water deprivation, deprivation to, to as, as high, high as, as 30, 30 times, times normal, normal ., . The, The youngest, youngest child, child (, ( 2, 2 years, years old, old ), ) was, was only, only mildly, mildly affected, affected but, but had, had Leu-AVP, Leu-AVP levels, levels similar, similar to, to her, her severely, severely affected, affected 8-year-old, 8-year-old brother, brother ,, , suggesting, suggesting that, that unknown, unknown mechanisms, mechanisms may, may partially, partially compensate, compensate for, for a, a deficiency, deficiency of, of active, active AVP, AVP in, in very, very young, young children.., children.. In, In a, a large, large pedigree, pedigree with, with autosomal, autosomal dominant, dominant aniridia, aniridia ,, , we, we found, found close, close linkage, linkage between, between the, the aniridia, aniridia locus, locus AN2, AN2 and, and the, the markers, markers catalase, catalase (, ( CAT, CAT ), ) (, ( zeta, zeta =, = 7, 7 ., . 27, 27 at, at theta, theta =, = 0, 0 ., . 00, 00 ), ) and, and D11S151, D11S151 (, ( zeta, zeta =, = 3, 3 ., . 86, 86 at, at theta, theta =, = 0, 0 ., . 10, 10 ), ) flanking, flanking the, the AN2, AN2 locus, locus on, on 11p13, 11p13 ., . Positive, Positive lod, lod scores, scores were, were also, also obtained, obtained for, for the, the 11p13, 11p13 --, -- --, -- 11p14, 11p14 markers, markers D11S16, D11S16 and, and FSHB, FSHB with, with the, the linkage, linkage group, group CAT/AN2/D11S151, CAT/AN2/D11S151 ., . We, We conclude, conclude that, that the, the autosomal, autosomal dominant, dominant aniridia, aniridia in, in this, this family, family is, is due, due to, to a, a mutation, mutation at, at the, the AN2, AN2 locus, locus on, on 11p13, 11p13 ., . We, We have, have excluded, excluded linkage, linkage (, ( zeta, zeta less, less than, than -2, -2 at, at theta, theta less, less than, than 0, 0 ., . 18, 18 ), ) between, between the, the aniridia, aniridia and, and the, the chromosome, chromosome 2p25, 2p25 marker, marker D2S1, D2S1 (, ( linked, linked to, to ACP1, ACP1 ), ) .We, .We report, report on, on a, a 4-year-old, 4-year-old boy, boy with, with Knobloch, Knobloch syndrome, syndrome ., . He, He has, has vitreoretinal, vitreoretinal degeneration, degeneration ,, , high, high myopia, myopia ,, , cataract, cataract ,, , telecanthus, telecanthus ,, , hypertelorism, hypertelorism ,, , and, and a, a high-arched, high-arched palate, palate ., . He, He also, also has, has a, a defect, defect of, of the, the anterior, anterior midline, midline scalp, scalp with, with involvement, involvement of, of the, the frontal, frontal bone, bone as, as documented, documented by, by a, a computed, computed tomography, tomography (, ( CT, CT ), ) scan, scan ., . The, The brain, brain was, was normal, normal on, on CT, CT scan, scan and, and magnetic, magnetic resonance, resonance imaging, imaging ., . We, We present, present a, a review, review of, of the, the 23, 23 published, published cases, cases with, with this, this syndrome, syndrome ., . Our, Our patient, patient illustrates, illustrates the, the importance, importance of, of investigating, investigating for, for underlying, underlying ocular, ocular and, and central, central nervous, nervous system, system pathology, pathology whenever, whenever midline, midline scalp, scalp defects, defects are, are present.., present.. Pendred, Pendred syndrome, syndrome comprises, comprises congenital, congenital sensorineural, sensorineural hearing, hearing loss, loss ,, , thyroid, thyroid goiter, goiter ,, , and, and positive, positive perchlorate, perchlorate discharge, discharge test, test ., . Recently, Recently ,, , this, this autosomal, autosomal recessive, recessive disorder, disorder was, was shown, shown to, to be, be caused, caused by, by mutations, mutations in, in the, the PDS, PDS gene, gene ,, , which, which encodes, encodes an, an anion, anion transporter, transporter called, called pendrin, pendrin ., . Molecular, Molecular analysis, analysis of, of the, the PDS, PDS gene, gene was, was performed, performed in, in two, two consanguineous, consanguineous large, large families, families from, from Southern, Southern Tunisia, Tunisia comprising, comprising a, a total, total of, of 23, 23 individuals, individuals affected, affected with, with profound, profound congenital, congenital deafness, deafness ;, ; the, the same, same missense, missense mutation, mutation ,, , L445W, L445W ,, , was, was identified, identified in, in all, all affected, affected individuals, individuals ., . A, A widened, widened vestibular, vestibular aqueduct, aqueduct was, was found, found in, in all, all patients, patients who, who underwent, underwent computed, computed tomography, tomography (, ( CT, CT ), ) scan, scan exploration, exploration of, of the, the inner, inner ear, ear ., . In, In contrast, contrast ,, , goiter, goiter was, was present, present in, in only, only 11, 11 affected, affected individuals, individuals ,, , who, who interestingly, interestingly had, had a, a normal, normal result, result of, of the, the perchlorate, perchlorate discharge, discharge test, test whenever, whenever performed, performed ., . The, The present, present results, results question, question the, the sensitivity, sensitivity of, of the, the perchlorate, perchlorate test, test for, for the, the diagnosis, diagnosis of, of Pendred, Pendred syndrome, syndrome and, and support, support the, the use, use of, of a, a molecular, molecular analysis, analysis of, of the, the PDS, PDS gene, gene in, in the, the assessment, assessment of, of individuals, individuals with, with severe, severe to, to profound, profound congenital, congenital hearing, hearing loss, loss associated, associated with, with inner, inner ear, ear morphological, morphological anomaly, anomaly even, even in, in the, the absence, absence of, of a, a thyroid, thyroid goiter.., goiter.. APC, APC is, is often, often cited, cited as, as a, a prime, prime example, example of, of a, a tumor, tumor suppressor, suppressor gene, gene ., . Truncating, Truncating germline, germline and, and somatic, somatic mutations, mutations (, ( or, or ,, , infrequently, infrequently ,, , allelic, allelic loss, loss ), ) occur, occur in, in tumors, tumors in, in FAP, FAP (, ( familial, familial adenomatous, adenomatous polyposis, polyposis ), ) ., . Most, Most sporadic, sporadic colorectal, colorectal cancers, cancers also, also have, have two, two APC, APC mutations, mutations ., . Clues, Clues from, from attenuated, attenuated polyposis, polyposis ,, , missense, missense germline, germline variants, variants with, with mild, mild disease, disease and, and the, the somatic, somatic mutation, mutation cluster, cluster region, region (, ( codons, codons 1, 1 ,, , 250-1, 250-1 ,, , 450, 450 ), ) indicate, indicate ,, , however, however ,, , that, that APC, APC mutations, mutations might, might not, not result, result in, in simple, simple loss, loss of, of protein, protein function, function ., . We, We have, have found, found that, that FAP, FAP patients, patients with, with germline, germline APC, APC mutations, mutations within, within a, a small, small region, region (, ( codons, codons 1, 1 ,, , 194-1, 194-1 ,, , 392, 392 at, at most, most ), ) mainly, mainly show, show allelic, allelic loss, loss in, in their, their colorectal, colorectal adenomas, adenomas ,, , in, in contrast, contrast to, to other, other FAP, FAP patients, patients ,, , whose, whose second, second hits, hits tend, tend to, to occur, occur by, by truncating, truncating mutations, mutations in, in the, the mutation, mutation cluster, cluster region, region ., . Our, Our results, results indicate, indicate that, that different, different APC, APC mutations, mutations provide, provide cells, cells with, with different, different selective, selective advantages, advantages ,, , with, with mutations, mutations close, close to, to codon, codon 1, 1 ,, , 300, 300 providing, providing the, the greatest, greatest advantage, advantage ., . Allelic, Allelic loss, loss is, is selected, selected strongly, strongly in, in cells, cells with, with one, one mutation, mutation near, near codon, codon 1, 1 ,, , 300, 300 ., . A, A different, different germline-somatic, germline-somatic APC, APC mutation, mutation association, association exists, exists in, in FAP, FAP desmoids, desmoids ., . APC, APC is, is not, not ,, , therefore, therefore ,, , a, a classical, classical tumor, tumor suppressor, suppressor ., . Our, Our findings, findings also, also indicate, indicate a, a new, new mechanism, mechanism for, for disease, disease severity, severity if, if a, a broader, broader spectrum, spectrum of, of mutations, mutations is, is selected, selected in, in tumors, tumors ,, , the, the somatic, somatic mutation, mutation rate, rate is, is effectively, effectively higher, higher and, and more, more tumors, tumors grow.., grow.. Mitochondrial, Mitochondrial very-long-chain, very-long-chain acyl-coenzyme, acyl-coenzyme A, A dehydrogenase, dehydrogenase (, ( VLCAD, VLCAD ), ) was, was purified, purified from, from human, human liver, liver ., . The, The molecular, molecular masses, masses of, of the, the native, native enzyme, enzyme and, and the, the subunit, subunit were, were estimated, estimated to, to be, be 154, 154 and, and 70, 70 kD, kD ,, , respectively, respectively ., . The, The enzyme, enzyme was, was found, found to, to catalyze, catalyze the, the major, major part, part of, of mitochondrial, mitochondrial palmitoylcoenzyme, palmitoylcoenzyme A, A dehydrogenation, dehydrogenation in, in liver, liver ,, , heart, heart ,, , skeletal, skeletal muscle, muscle ,, , and, and skin, skin fibroblasts, fibroblasts (, ( 89-97, 89-97 ,, , 86-99, 86-99 ,, , 96-99, 96-99 ,, , and, and 78-87, 78-87 %, % ,, , respectively, respectively ), ) ., . Skin, Skin fibroblasts, fibroblasts from, from 26, 26 patients, patients suspected, suspected of, of having, having a, a disorder, disorder of, of mitochondrial, mitochondrial beta-oxidation, beta-oxidation were, were analyzed, analyzed for, for VLCAD, VLCAD protein, protein using, using immunoblotting, immunoblotting ,, , and, and 7, 7 of, of them, them contained, contained undetectable, undetectable or, or trace, trace levels, levels of, of the, the enzyme, enzyme ., . The, The seven, seven deficient, deficient fibroblast, fibroblast lines, lines were, were characterized, characterized by, by measuring, measuring acyl-coenzyme, acyl-coenzyme A, A dehydrogenation, dehydrogenation activities, activities ,, , overall, overall palmitic, palmitic acid, acid oxidation, oxidation ,, , and, and VLCAD, VLCAD protein, protein synthesis, synthesis using, using pulse-chase, pulse-chase ,, , further, further confirming, confirming the, the diagnosis, diagnosis of, of VLCAD, VLCAD deficiency, deficiency ., . These, These results, results suggested, suggested the, the heterogenous, heterogenous nature, nature of, of the, the mutations, mutations causing, causing the, the deficiency, deficiency in, in the, the seven, seven patients, patients ., . Clinically, Clinically ,, , all, all patients, patients with, with VLCAD, VLCAD deficiency, deficiency exhibited, exhibited cardiac, cardiac disease, disease ., . At, At least, least four, four of, of them, them presented, presented with, with hypertrophic, hypertrophic cardiomyopathy, cardiomyopathy ., . This, This frequency, frequency (, ( >, > 57, 57 %, % ), ) was, was much, much higher, higher than, than that, that observed, observed in, in patients, patients with, with other, other disorders, disorders of, of mitochondrial, mitochondrial long-chain, long-chain fatty, fatty acid, acid oxidation, oxidation that, that may, may be, be accompanied, accompanied by, by cardiac, cardiac disease, disease in, in infants.., infants.. Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome caused, caused by, by a, a complete, complete deficiency, deficiency of, of hypoxanthine, hypoxanthine guanine, guanine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ), ) is, is the, the result, result of, of a, a heterogeneous, heterogeneous group, group of, of germ, germ line, line mutations, mutations ., . Identification, Identification of, of each, each mutant, mutant gene, gene provides, provides valuable, valuable information, information as, as to, to the, the type, type of, of mutation, mutation that, that occurs, occurs spontaneously, spontaneously ., . We, We report, report here, here a, a newly, newly identified, identified HPRT, HPRT mutation, mutation in, in a, a Japanese, Japanese patient, patient with, with Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . This, This gene, gene ,, , designated, designated HPRT, HPRT Tokyo, Tokyo ,, , had, had a, a single, single nucleotide, nucleotide change, change from, from G, G to, to A, A ,, , as, as identified, identified by, by sequencing, sequencing cDNA, cDNA amplified, amplified by, by the, the polymerase, polymerase chain, chain reaction, reaction ., . Allele, Allele specific, specific oligonucleotide, oligonucleotide hybridization, hybridization analysis, analysis using, using amplified, amplified genomic, genomic DNA, DNA showed, showed that, that the, the mutant, mutant gene, gene was, was transmitted, transmitted from, from the, the maternal, maternal germ, germ line, line ., . This, This mutation, mutation would, would lead, lead to, to an, an amino, amino acid, acid substitution, substitution of, of Asp, Asp for, for Gly, Gly at, at the, the amino, amino acid, acid position, position 140, 140 located, located within, within the, the putative, putative 5-phosphoribosyl-1-pyrophosphate, 5-phosphoribosyl-1-pyrophosphate (, ( PRPP, PRPP ), ) binding, binding region, region ., . Missense, Missense mutations, mutations in, in human, human HPRT, HPRT deficient, deficient patients, patients thus, thus far, far reported, reported tend, tend to, to accumulate, accumulate in, in this, this functionally, functionally active, active region, region ., . However, However ,, , a, a comparison, comparison of, of the, the data, data suggested, suggested that, that both, both missense, missense and, and synonymous, synonymous mutations, mutations can, can occur, occur at, at any, any coding, coding sequence, sequence of, of the, the human, human germ, germ line, line HPRT, HPRT gene, gene ,, , but, but that, that a, a limited, limited percentage, percentage of, of all, all the, the missense, missense mutations, mutations cause, cause disease, disease ., . The, The probability, probability that, that a, a mutation, mutation will, will cause, cause disease, disease tends, tends to, to be, be higher, higher when, when the, the missense, missense mutation, mutation is, is within, within a, a functionally, functionally important, important sequence.., sequence.. Mutations, Mutations at, at the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) locus, locus are, are the, the major, major cause, cause of, of hyperphenylalaninemia, hyperphenylalaninemia ., . We, We have, have previously, previously described, described four, four mutations, mutations (, ( M1V, M1V ,, , IVS12nt1, IVS12nt1 ,, , R408W, R408W ,, , and, and S349P, S349P ), ) at, at the, the PAH, PAH locus, locus in, in French, French Canadians, Canadians with, with ancestry, ancestry in, in eastern, eastern Quebec, Quebec ., . Here, Here we, we report, report (, ( 1, 1 ), ) identification, identification of, of another, another mutation, mutation ,, , on, on a, a haplotype, haplotype 9, 9 chromosome, chromosome ,, , which, which converts, converts codon, codon 65, 65 from, from isoleucine, isoleucine (, ( ATT, ATT ), ) to, to threonine, threonine (, ( ACT, ACT ), ) ,, , (, ( 2, 2 ), ) expression, expression analysis, analysis of, of the, the I65T, I65T mutation, mutation in, in COS, COS cells, cells demonstrating, demonstrating 75, 75 %, % loss, loss of, of both, both immunoreactive, immunoreactive protein, protein and, and enzyme, enzyme activity, activity ,, , and, and (, ( 3, 3 ), ) expression, expression analysis, analysis of, of the, the most, most prevalent, prevalent PKU, PKU allele, allele (, ( M1V, M1V ), ) in, in eastern, eastern Quebec, Quebec ,, , showing, showing nondetectable, nondetectable levels, levels of, of PAH, PAH protein, protein and, and activity, activity ,, , a, a finding, finding compatible, compatible with, with a, a mutation, mutation in, in the, the translation, translation initiation, initiation codon, codon ., . Homozygosity, Homozygosity for, for M1V, M1V and, and codominant, codominant inheritance, inheritance of, of I65T/R408W, I65T/R408W were, were both, both associated, associated with, with classical, classical phenylketonuria.., phenylketonuria.. The, The puzzling, puzzling linkage, linkage between, between genetic, genetic hemochromatosis, hemochromatosis and, and histocompatibility, histocompatibility loci, loci became, became even, even more, more so, so when, when the, the gene, gene involved, involved ,, , HFE, HFE ,, , was, was identified, identified ., . Indeed, Indeed ,, , within, within the, the well, well defined, defined ,, , mainly, mainly peptide-binding, peptide-binding ,, , MHC, MHC class, class I, I family, family of, of molecules, molecules ,, , HFE, HFE seems, seems to, to perform, perform an, an unusual, unusual yet, yet essential, essential function, function ., . As, As yet, yet ,, , our, our understanding, understanding of, of HFE, HFE function, function in, in iron, iron homeostasis, homeostasis is, is only, only partial, partial ;, ; an, an even, even more, more open, open question, question is, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "is its, its possible, possible role, role in, in the, the immune, immune system, system ., . To, To advance, advance on, on both, both of, of these, these avenues, avenues ,, , we, we report, report the, the deletion, deletion of, of HFE, HFE alpha1, alpha1 and, and alpha2, alpha2 putative, putative ligand, ligand binding, binding domains, domains in, in vivo, vivo ., . HFE-deficient, HFE-deficient animals, animals were, were analyzed, analyzed for, for a, a comprehensive, comprehensive set, set of, of metabolic, metabolic and, and immune, immune parameters, parameters ., . Faithfully, Faithfully mimicking, mimicking human, human hemochromatosis, hemochromatosis ,, , mice, mice homozygous, homozygous for, for this, this deletion, deletion develop, develop iron, iron overload, overload ,, , characterized, characterized by, by a, a higher, higher plasma, plasma iron, iron content, content and, and a, a raised, raised transferrin, transferrin saturation, saturation as, as well, well as, as an, an elevated, elevated hepatic, hepatic iron, iron load, load ., . The, The primary, primary defect, defect could, could ,, , indeed, indeed ,, , be, be traced, traced to, to an, an augmented, augmented duodenal, duodenal iron, iron absorption, absorption ., . In, In parallel, parallel ,, , measurement, measurement of, of the, the gut, gut mucosal, mucosal iron, iron content, content as, as well, well as, as iron, iron regulatory, regulatory proteins, proteins allows, allows a, a more, more informed, informed evaluation, evaluation of, of various, various hypotheses, hypotheses regarding, regarding the, the precise, precise role, role of, of HFE, HFE in, in iron, iron homeostasis, homeostasis ., . Finally, Finally ,, , an, an extensive, extensive phenotyping, phenotyping of, of primary, primary and, and secondary, secondary lymphoid, lymphoid organs, organs including, including the, the gut, gut provides, provides no, no compelling, compelling evidence, evidence for, for an, an obvious, obvious immune-linked, immune-linked function, function for, for HFE.., HFE.. Examination, Examination on, on G6PD, G6PD deficiency, deficiency in, in 349, 349 patients, patients of, of Shekii, Shekii district, district hospital, hospital (, ( Azerbaijan, Azerbaijan ), ) revealed, revealed 16, 16 hemi-, hemi- ,, , 4, 4 homo-, homo- and, and 9, 9 heterozygotic, heterozygotic carriers, carriers of, of the, the defect, defect ., . Gd-, Gd- frequency, frequency ,, , calculated, calculated from, from the, the data, data obtained, obtained (, ( 7, 7 ., . 7, 7 %, % ), ) ,, , may, may be, be compared, compared to, to neighbouring, neighbouring regions, regions frequencies, frequencies (, ( 6-30, 6-30 %, % ), ) ., . Carriers, Carriers of, of G6PD, G6PD deficiency, deficiency are, are residents, residents of, of 11, 11 villages, villages located, located in, in Alasani-Aphtalan, Alasani-Aphtalan valley, valley ,, , highly, highly endemic, endemic with, with malaria, malaria in, in the, the past, past ;, ; nearly, nearly all, all marriages, marriages are, are endogamic, endogamic ., . Physico-chemical, Physico-chemical and, and kinetic, kinetic study, study of, of 10, 10 mutant, mutant forms, forms of, of G6PD, G6PD ,, , according, according to, to WHO, WHO program, program ,, , led, led to, to identification, identification of, of 5, 5 variants, variants of, of the, the II, II class, class (, ( Shekii, Shekii ,, , Bideiz, Bideiz ,, , Shirin-Bulakh, Shirin-Bulakh ,, , Okhut, Okhut I, I and, and Zakataly, Zakataly ), ) and, and 2, 2 variants, variants of, of the, the III, III class, class (, ( Okhut, Okhut II, II and, and Martinique-like, Martinique-like ), ) ., . Resemblance, Resemblance of, of the, the majority, majority of, of variants, variants in, in electrophoretic, electrophoretic mobility, mobility and, and the, the level, level of, of erythrocyte, erythrocyte enzyme, enzyme activity, activity permit, permit to, to suggest, suggest the, the existence, existence of, of a, a common, common parental, parental mutant, mutant G6PD, G6PD allele, allele distributed, distributed in, in this, this area, area ., . In, In 28, 28 families, families with, with G6PD, G6PD deficiency, deficiency living, living in, in 3, 3 settlements, settlements of, of Shekii, Shekii district, district of, of Azerbaijan, Azerbaijan 11, 11 G6PD, G6PD variants, variants of, of II, II and, and III, III classes, classes differing, differing by, by kinetic, kinetic properties, properties were, were identified, identified according, according WHO, WHO program, program ., . 9, 9 of, of them, them are, are characterized, characterized with, with the, the same, same electrophoretic, electrophoretic mobility, mobility ., . Comparison, Comparison of, of G6PD, G6PD spectra, spectra in, in two, two subpopulations, subpopulations and, and in, in a, a mixed, mixed group, group permits, permits to, to make, make a, a conclusion, conclusion about, about existence, existence of, of common, common and, and rare, rare G6PD, G6PD alleles, alleles in, in examined, examined population, population ., . They, They distribute, distribute by, by gene, gene drift, drift supported, supported by, by natural, natural selection, selection ., . Among, Among 7, 7 samples, samples of, of G6PD, G6PD with, with normal, normal and, and increased, increased activity, activity two, two new, new variants, variants of, of IV, IV class, class --, -- Nukha, Nukha and, and Bash-Kungut, Bash-Kungut --, -- were, were found.., found.. The, The Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) is, is caused, caused by, by defects, defects in, in the, the WAS, WAS protein, protein (, ( WASP, WASP ), ) gene, gene on, on the, the X, X chromosome, chromosome ., . Previous, Previous study, study disclosed, disclosed that, that flow, flow cytometric, cytometric analysis, analysis of, of intracellular, intracellular WASP, WASP expression, expression (, ( FCM-WASP, FCM-WASP analysis, analysis ), ) in, in lymphocytes, lymphocytes was, was useful, useful for, for the, the diagnosis, diagnosis of, of WAS, WAS patients, patients ., . Lymphocytes, Lymphocytes from, from all, all WAS, WAS patients, patients showed, showed WASPdim, WASPdim instead, instead of, of WASPbright, WASPbright ., . Here, Here we, we report, report that, that FCM-WASP, FCM-WASP analysis, analysis in, in monocytes, monocytes could, could be, be a, a useful, useful tool, tool for, for the, the WAS, WAS carrier, carrier diagnosis, diagnosis ., . Monocytes, Monocytes from, from all, all nine, nine WAS, WAS carriers, carriers showed, showed varied, varied population, population of, of WASPdim, WASPdim together, together with, with WASPbright, WASPbright ., . None, None of, of control, control individuals, individuals possessed, possessed the, the WASPdim, WASPdim population, population ., . In, In contrast, contrast ,, , lymphocytes, lymphocytes from, from all, all the, the carriers, carriers except, except two, two lacked, lacked the, the WASPdim, WASPdim population, population ., . The, The difference, difference of, of the, the WASPdim, WASPdim population, population in, in monocytes, monocytes and, and lymphocytes, lymphocytes observed, observed in, in WAS, WAS carriers, carriers suggests, suggests that, that WASP, WASP plays, plays a, a more, more critical, critical role, role in, in the, the development, development of, of lymphocytes, lymphocytes than, than in, in that, that of, of monocytes, monocytes ., . The, The present, present studies, studies suggest, suggest that, that a, a skewed, skewed X-chromosomal, X-chromosomal inactivation, inactivation pattern, pattern observed, observed in, in WAS, WAS carrier, carrier peripheral, peripheral blood, blood cells, cells is, is not, not fixed, fixed at, at the, the hemopoietic, hemopoietic stem, stem cell, cell level, level but, but progresses, progresses after, after the, the lineage, lineage commitment.., commitment.. We, We present, present a, a large, large kindred, kindred that, that contained, contained patients, patients with, with either, either adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) or, or adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) ., . The, The pedigree, pedigree clearly, clearly supported, supported the, the X-linked, X-linked mode, mode of, of inheritance, inheritance of, of the, the nonneonatal, nonneonatal form, form of, of ALD/AMN, ALD/AMN ., . Analysis, Analysis with, with DNA, DNA markers, markers at, at Xq28, Xq28 suggested, suggested segregation, segregation of, of both, both ALD, ALD and, and AMN, AMN with, with an, an identical, identical haplotype, haplotype ., . This, This indicated, indicated that, that nonneonatal, nonneonatal ALD, ALD and, and AMN, AMN are, are caused, caused by, by a, a mutation, mutation in, in the, the same, same gene, gene at, at Xq28, Xq28 ., . It, It showed, showed ,, , furthermore, furthermore ,, , that, that phenotypic, phenotypic differences, differences between, between ALD, ALD and, and AMN, AMN are, are not, not necessarily, necessarily the, the consequence, consequence of, of allelic, allelic heterogeneity, heterogeneity due, due to, to different, different mutations, mutations within, within the, the same, same gene, gene ., . The, The maximal, maximal lod, lod score, score for, for linkage, linkage of, of the, the ALD/AMN, ALD/AMN gene, gene and, and the, the multiallelic, multiallelic anonymous, anonymous DNA, DNA marker, marker at, at DXS52, DXS52 was, was 3, 3 ., . 0, 0 at, at a, a recombination, recombination fraction, fraction of, of 0, 0 ., . 00, 00 ., . This, This made, made a, a prenatal, prenatal or, or presymptomatic, presymptomatic diagnosis, diagnosis and, and heterozygote, heterozygote detection, detection by, by DNA, DNA analysis, analysis with, with this, this marker, marker reliable, reliable ., . In, In a, a previous, previous study, study we, we found, found that, that a, a Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) causing, causing mutation, mutation in, in the, the intron, intron 9, 9 donor, donor splice, splice site, site of, of the, the HEXA, HEXA gene, gene occurs, occurs at, at high, high frequency, frequency in, in non-Jewish, non-Jewish patients, patients and, and carriers, carriers from, from the, the British, British Isles, Isles ., . It, It was, was found, found more, more frequently, frequently in, in subjects, subjects of, of Irish, Irish ,, , Scottish, Scottish ,, , and, and Welsh, Welsh origin, origin compared, compared with, with English, English origin, origin (, ( 63, 63 %, % and, and 31, 31 %, % respectively, respectively ), ) ., . We, We have, have now, now tested, tested ,, , in, in a, a blind, blind study, study ,, , 26, 26 American, American TSD, TSD carriers, carriers and, and 28, 28 non-carriers, non-carriers who, who have, have British, British ancestry, ancestry for, for the, the intron, intron 9, 9 splice, splice site, site mutation, mutation ., . Six, Six of, of the, the carriers, carriers and, and none, none of, of the, the controls, controls were, were positive, positive for, for the, the mutation, mutation ., . All, All six, six had, had Irish, Irish ancestry, ancestry ,, , compared, compared with, with nine, nine of, of the, the 20, 20 other, other (, ( intron, intron 9, 9 mutation, mutation negative, negative ), ) TSD, TSD carriers, carriers (, ( p, p <, < 0, 0 ., . 05, 05 ), ) ., . These, These results, results confirm, confirm the, the previously, previously found, found high, high frequency, frequency of, of the, the intron, intron 9, 9 mutation, mutation in, in non-Jewish, non-Jewish TSD, TSD families, families of, of British, British Isles, Isles ,, , particularly, particularly Irish, Irish ,, , origin, origin ,, , and, and reinforce, reinforce the, the need, need to, to screen, screen such, such families, families for, for this, this mutation, mutation ., . Huntington, Huntington disease, disease (, ( HD, HD ), ) is, is a, a severe, severe autosomal, autosomal dominant, dominant neurodegenerative, neurodegenerative disorder, disorder associated, associated with, with a, a novel, novel gene, gene (, ( IT15, IT15 ), ) ., . Recently, Recently ,, , we, we reported, reported the, the cloning, cloning of, of Hdh, Hdh ,, , the, the murine, murine homologue, homologue of, of IT15, IT15 ., . Here, Here ,, , using, using an, an interspecific, interspecific backcross, backcross ,, , we, we have, have mapped, mapped both, both Hdh, Hdh and, and the, the mouse, mouse homologue, homologue of, of human, human alpha-adducin, alpha-adducin (, ( Add1, Add1 ), ) ,, , a, a membrane-associated, membrane-associated cytoskeletal, cytoskeletal protein, protein gene, gene ., . Both, Both of, of these, these genes, genes map, map in, in the, the same, same position, position on, on mouse, mouse chromosome, chromosome 5, 5 in, in a, a region, region associated, associated with, with ancestral, ancestral chromosomal, chromosomal rearrangements, rearrangements and, and show, show no, no recombination, recombination with, with D5H4S43, D5H4S43 ,, , D5H4S115, D5H4S115 ,, , and, and D5H4S62, D5H4S62 ,, , the, the murine, murine homologues, homologues of, of D4S43, D4S43 ,, , D4S115, D4S115 ,, , and, and D4S62, D4S62 ,, , respectively, respectively ., . Further, Further mapping, mapping studies, studies of, of humans, humans ,, , mice, mice ,, , and, and other, other mammalian, mammalian species, species should, should reveal, reveal the, the nature, nature of, of the, the rearrangements, rearrangements affecting, affecting this, this chromosomal, chromosomal segment, segment during, during mammalian, mammalian evolution.., evolution.. The, The gene, gene for, for human, human apolipoprotein, apolipoprotein C2, C2 (, ( APOC2, APOC2 ), ) ,, , situated, situated on, on the, the proximal, proximal long, long arm, arm of, of chromosome, chromosome 19, 19 ,, , is, is closely, closely linked, linked to, to the, the gene, gene for, for the, the most, most common, common form, form of, of adult, adult muscular, muscular dystrophy, dystrophy ,, , myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ., . Six, Six APOC2, APOC2 RFLPs, RFLPs (, ( TaqI, TaqI ,, , BglI, BglI ,, , BanI, BanI ,, , BamHI, BamHI ,, , NcoI, NcoI ,, , and, and AvaII, AvaII ), ) have, have been, been identified, identified to, to date, date ., . We, We have, have conducted, conducted a, a comprehensive, comprehensive DM, DM linkage, linkage study, study utilizing, utilizing all, all six, six RFLPs, RFLPs and, and involving, involving 50, 50 families, families and, and 372, 372 individuals, individuals ., . The, The most, most informative, informative RFLPs, RFLPs are, are ,, , in, in descending, descending order, order ,, , NcoI, NcoI (, ( lod, lod =, = 6, 6 ., . 64, 64 ,, , theta, theta =, = 0, 0 ., . 05, 05 ), ) ,, , BglI, BglI (, ( lod, lod =, = 6, 6 ., . 12, 12 ,, , theta, theta =, = 0, 0 ., . 05, 05 ), ) ,, , AvaII, AvaII (, ( lod, lod =, = 6, 6 ., . 02, 02 ,, , theta, theta =, = 0, 0 ., . 03, 03 ), ) ,, , BanI, BanI (, ( lod, lod =, = 5, 5 ., . 76, 76 ,, , theta, theta =, = 0, 0 ., . 04, 04 ), ) ,, , TaqI, TaqI (, ( lod, lod =, = 4, 4 ., . 29, 29 ,, , theta, theta =, = 0, 0 ., . 06, 06 ), ) ,, , and, and BamHI, BamHI (, ( lod, lod =, = 1, 1 ., . 75, 75 ,, , theta, theta =, = 0, 0 ., . 01, 01 ), ) ., . A, A substantial, substantial increase, increase in, in the, the lod, lod scores, scores over, over those, those seen, seen with, with the, the individual, individual RFLPs, RFLPs was, was obtained, obtained when, when the, the linkage, linkage of, of the, the entire, entire APOC2, APOC2 haplotype, haplotype (, ( composed, composed of, of the, the six, six RFLPs, RFLPs ), ) was, was studied, studied (, ( lod, lod =, = 17, 17 ., . 87, 87 ,, , theta, theta =, = 0, 0 ., . 04, 04 ), ) ., . We, We have, have observed, observed significant, significant inter-APOC2, inter-APOC2 RFLP, RFLP linkage, linkage disequilibrium, disequilibrium ., . Consequently, Consequently ,, , the, the three, three most, most informative, informative RFLPs, RFLPs have, have been, been found, found to, to be, be BanI, BanI ,, , TaqI, TaqI ,, , and, and either, either BglI, BglI ,, , AvaII, AvaII ,, , or, or NcoI, NcoI polymorphisms, polymorphisms ., . We, We also, also demonstrate, demonstrate linkage, linkage disequilibrium, disequilibrium between, between DM, DM and, and APOC2, APOC2 in, in our, our French-Canadian, French-Canadian population, population (, ( standardized, standardized disequilibrium, disequilibrium constant, constant phi, phi =, = ., . 22, 22 ,, , chi, chi 2, 2 =, = 5, 5 ., . 12, 12 ,, , df, df =, = 1, 1 ,, , P, P less, less than, than 0, 0 ., . 04, 04 ), ) ., . This, This represents, represents the, the first, first evidence, evidence of, of linkage, linkage disequilibrium, disequilibrium between, between APOC2, APOC2 and, and the, the DM, DM locus, locus ., . We, We have, have retrospectively, retrospectively analyzed, analyzed 837, 837 random, random anonymized, anonymized dried, dried blood, blood spot, spot (, ( DBS, DBS ), ) samples, samples from, from neonatal, neonatal screening, screening programs, programs in, in Scandinavia, Scandinavia for, for mutations, mutations in, in HFE, HFE ,, , the, the candidate, candidate gene, gene for, for hemochromatosis, hemochromatosis ., . We, We have, have found, found C282Y, C282Y allele, allele frequencies, frequencies of, of 2, 2 ., . 3, 3 %, % (, ( +, + 2, 2 ., . 0, 0 %, % ), ) (, ( -1, -1 ., . 3, 3 %, % ), ) in, in Greenland, Greenland ,, , 4, 4 ., . 5, 5 %, % +/-1, +/-1 ., . 9, 9 %, % in, in Iceland, Iceland ,, , 5, 5 ., . 1, 1 %, % +/-2, +/-2 ., . 3, 3 %, % in, in the, the Faeroe, Faeroe Islands, Islands ,, , and, and 8, 8 ., . 2, 2 %, % +/-2, +/-2 ., . 7, 7 %, % in, in Denmark, Denmark ., . The, The high, high prevalence, prevalence of, of HFE, HFE mutations, mutations in, in Denmark, Denmark suggests, suggests that, that population, population screening, screening for, for the, the C282Y, C282Y mutation, mutation could, could be, be highly, highly advantageous, advantageous in, in terms, terms of, of preventive, preventive health, health care, care ., . Long-term, Long-term follow-up, follow-up evaluation, evaluation of, of C282Y, C282Y homozygotes, homozygotes and, and H63D/C282Y, H63D/C282Y compound, compound heterozygotes, heterozygotes will, will give, give an, an indication, indication of, of the, the penetrance, penetrance of, of the, the mutations.Li-Fraumeni, mutations.Li-Fraumeni syndrome, syndrome is, is an, an autosomal, autosomal dominant, dominant disorder, disorder that, that is, is characterized, characterized by, by various, various types, types of, of cancer, cancer in, in childhood, childhood and, and adult, adult cases, cases ., . Although, Although hereditary, hereditary TP53, TP53 mutation, mutation is, is very, very rare, rare in, in different, different human, human cancers, cancers ,, , it, it has, has been, been frequently, frequently reported, reported in, in Li-Fraumeni, Li-Fraumeni syndrome, syndrome ., . On, On the, the other, other hand, hand ,, , hereditary, hereditary mutations, mutations of, of TP57KIP2, TP57KIP2 ,, , P15INK4B, P15INK4B ,, , and, and P16INK4A, P16INK4A ,, , which, which affect, affect the, the cell, cell cycle, cycle similar, similar to, to TP53, TP53 ,, , were, were observed, observed in, in some, some types, types of, of cancer, cancer ., . In, In a, a Turkish, Turkish family, family with, with the, the diagnosis, diagnosis of, of Li-Fraumeni, Li-Fraumeni syndrome, syndrome ,, , we, we analyzed, analyzed the, the mutation, mutation pattern, pattern of, of TP53, TP53 ,, , P57KIP2, P57KIP2 ,, , P15INK4B, P15INK4B ,, , and, and P16INK4A, P16INK4A in, in the, the peripheral, peripheral blood, blood ,, , and, and loss, loss of, of heterozygosity, heterozygosity (, ( homo/hemizygous, homo/hemizygous deletion, deletion ), ) pattern, pattern of, of TP53, TP53 and, and P15INK4B/P16INK4A, P15INK4B/P16INK4A in, in two, two tumor, tumor tissues, tissues ., . The, The propositus, propositus had, had a, a seminoma, seminoma ,, , his, his daughter, daughter a, a medulloblastoma, medulloblastoma ,, , and, and one, one of, of his, his healthy, healthy cousins, cousins ,, , a, a TP53, TP53 codon, codon 292, 292 missense, missense point, point mutation, mutation (, ( AAA, AAA --, -- >, > ATA, ATA ;, ; Lys, Lys --, -- >, > Ile, Ile ), ) in, in the, the peripheral, peripheral blood, blood cells, cells ., . Tumor, Tumor tissue, tissue obtained, obtained from, from the, the propositus, propositus with, with the, the seminoma, seminoma revealed, revealed loss, loss of, of heterozygosity, heterozygosity in, in the, the TP53, TP53 gene, gene ., . In, In the, the analyses, analyses of, of tumor, tumor tissues, tissues from, from the, the propositus, propositus and, and his, his daughter, daughter ,, , a, a P16INK4A, P16INK4A codon, codon 94, 94 missense, missense point, point mutation, mutation (, ( GCG, GCG --, -- >, > GAG, GAG ;, ; Ala, Ala --, -- >, > Glu, Glu ), ) was, was observed, observed with, with the, the hereditary, hereditary TP53, TP53 mutation, mutation ., . P16INK4A, P16INK4A codon, codon 94, 94 mutation, mutation observed, observed in, in our, our family, family is, is a, a novel, novel mutation, mutation in, in Li-Fraumeni, Li-Fraumeni syndrome, syndrome ., . No, No other, other gene, gene alteration, alteration in, in TP53, TP53 ,, , P57KIP2, P57KIP2 ,, , P15INK4B, P15INK4B ,, , and, and P16INK4A, P16INK4A was, was observed, observed ., . Existence, Existence of, of the, the P16INK4A, P16INK4A mutation, mutation and, and the, the hereditary, hereditary TP53, TP53 mutation, mutation with, with or, or without, without loss, loss of, of heterozygosity, heterozygosity in, in the, the TP53, TP53 gene, gene (, ( seminoma/medulloblastoma, seminoma/medulloblastoma ), ) may, may be, be evidence, evidence for, for a, a common, common mechanism, mechanism involved, involved in, in tumorogenesis, tumorogenesis ., . The, The gene, gene alterations, alterations in, in TP53, TP53 and, and P16INK4A, P16INK4A genes, genes may, may be, be used, used as, as tumor, tumor markers, markers in, in our, our family.., family.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is an, an autosomal, autosomal recessive, recessive human, human genetic, genetic disorder, disorder caused, caused by, by a, a deficiency, deficiency of, of hepatic, hepatic phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ,, , phenylalanine, phenylalanine 4-monooxygenase, 4-monooxygenase ,, , EC, EC 1, 1 ., . 14, 14 ., . 16, 16 ., . 1, 1 ), ) ., . PKU, PKU is, is a, a common, common inborn, inborn error, error of, of amino-acid, amino-acid metabolism, metabolism in, in caucasian, caucasian populations, populations and, and approximately, approximately 1, 1 in, in 50, 50 individuals, individuals are, are carriers, carriers of, of a, a PKU, PKU allele, allele ., . To, To define, define the, the molecular, molecular basis, basis of, of PKU, PKU ,, , we, we characterized, characterized twelve, twelve restriction, restriction fragment-length, fragment-length polymorphism, polymorphism (, ( RFLP, RFLP ), ) haplotypes, haplotypes of, of the, the PAH, PAH locus, locus in, in the, the northern, northern European, European population, population and, and observed, observed that, that 90, 90 %, % of, of the, the PKU, PKU alleles, alleles in, in this, this population, population are, are confined, confined to, to four, four common, common RFLP, RFLP haplotypes, haplotypes ., . We, We have, have recently, recently reported, reported a, a splicing, splicing mutation, mutation in, in the, the PAH, PAH gene, gene that, that is, is associated, associated with, with RFLP, RFLP haplotype, haplotype 3, 3 which, which is, is present, present at, at about, about 40, 40 %, % of, of mutant, mutant alleles, alleles ., . We, We now, now report, report the, the molecular, molecular lesion, lesion associated, associated with, with the, the RFLP, RFLP haplotype, haplotype 2, 2 mutant, mutant allele, allele ., . This, This defect, defect is, is caused, caused by, by a, a C-to-T, C-to-T transition, transition in, in exon, exon 12, 12 resulting, resulting in, in an, an amino-acid, amino-acid substitution, substitution (, ( Arg, Arg to, to Trp, Trp ), ) at, at residue, residue 408, 408 of, of PAH, PAH ., . Direct, Direct hybridization, hybridization analysis, analysis of, of the, the point, point mutation, mutation using, using a, a specific, specific oligonucleotide, oligonucleotide probe, probe demonstrated, demonstrated that, that this, this mutation, mutation is, is also, also in, in linkage, linkage disequilibrium, disequilibrium with, with RFLP, RFLP haplotype, haplotype 2, 2 alleles, alleles that, that make, make up, up about, about 20, 20 %, % of, of mutant, mutant PAH, PAH genes, genes PURPOSE, PURPOSE ., . The, The authors, authors earlier, earlier findings, findings of, of a, a negative, negative electroretinogram, electroretinogram (, ( ERG, ERG ), ) in, in a, a boy, boy with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) led, led them, them to, to investigate, investigate dystrophin, dystrophin gene, gene deletions, deletions and, and ERGs, ERGs in, in five, five boys, boys with, with DMD, DMD ., . The, The authors, authors wanted, wanted to, to determined, determined whether, whether there, there were, were similar, similar ERG, ERG findings, findings in, in an, an animal, animal model, model for, for DMD, DMD ,, , the, the mdx, mdx mouse, mouse ., . METHODS, METHODS ., . Ganzfeld, Ganzfeld ERGs, ERGs were, were recorded, recorded in, in five, five boys, boys with, with DMD, DMD after, after a, a complete, complete ophthalmic, ophthalmic examination, examination ., . The, The dystrophin, dystrophin gene, gene was, was analyzed, analyzed by, by Southern, Southern blot, blot hybridization, hybridization ., . ERGs, ERGs were, were recorded, recorded in, in anesthetized, anesthetized mdx, mdx and, and control, control mice, mice with, with a, a modified, modified Grass, Grass photostimulator, photostimulator (, ( Grass, Grass Instrument, Instrument Company, Company ,, , Quincy, Quincy ,, , MA, MA ), ) ., . RESULTS, RESULTS ., . Ophthalmic, Ophthalmic examinations, examinations in, in all, all five, five boys, boys had, had normal, normal findings, findings ,, , yet, yet an, an abnormal, abnormal negative, negative ERG, ERG was, was recorded, recorded for, for each, each subject, subject ., . The, The subjects, subjects gene, gene deletions, deletions were, were variable, variable ,, , ranging, ranging from, from large, large deletions, deletions to, to no, no detectable, detectable deletions, deletions ., . The, The ERGs, ERGs of, of the, the mdx, mdx mice, mice were, were normal, normal and, and did, did not, not differ, differ significantly, significantly from, from those, those of, of the, the control, control mice, mice ., . CONCLUSIONS, CONCLUSIONS ., . The, The authors, authors believe, believe the, the unique, unique ERG, ERG recorded, recorded for, for the, the human, human subjects, subjects is, is a, a manifestation, manifestation of, of DMD, DMD associated, associated with, with defects, defects at, at the, the dystrophin, dystrophin gene, gene locus, locus and, and represents, represents a, a new, new clinical, clinical entity, entity ., . The, The ERG, ERG of, of the, the mdx, mdx mouse, mouse may, may be, be spared, spared for, for several, several reasons, reasons ,, , including, including milder, milder effects, effects of, of the, the mouse, mouse gene, gene defect, defect ,, , differences, differences in, in muscle, muscle and, and retinal, retinal gene, gene product, product ,, , or, or species, species differences, differences in, in the, the biochemical, biochemical role, role of, of dystrophin, dystrophin ., . The, The ERG, ERG shows, shows promise, promise of, of becoming, becoming a, a noninvasive, noninvasive diagnostic, diagnostic tool, tool for, for DMD, DMD and, and its, its milder, milder allelic, allelic forms.., forms.. Familial, Familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) is, is a, a dominantly, dominantly inherited, inherited condition, condition predisposing, predisposing to, to colorectal, colorectal cancer, cancer ., . The, The recent, recent isolation, isolation of, of the, the responsible, responsible gene, gene (, ( adenomatous, adenomatous polyposis, polyposis coli, coli or, or APC, APC ), ) has, has facilitated, facilitated the, the search, search for, for germ, germ line, line mutations, mutations in, in affected, affected individuals, individuals ., . Previous, Previous authors, authors have, have used, used the, the RNase, RNase protection, protection assay, assay and, and the, the single-strand, single-strand conformation, conformation polymorphisms, polymorphisms procedure, procedure to, to screen, screen for, for mutations, mutations ., . In, In this, this study, study we, we used, used denaturing, denaturing gradient, gradient gel, gel electrophoresis, electrophoresis (, ( DGGE, DGGE ), ) ., . DGGE, DGGE analysis, analysis of, of 10, 10 APC, APC exons, exons (, ( 4, 4 ,, , 5, 5 ,, , 7, 7 ,, , 8, 8 ,, , 9, 9 ,, , 10, 10 ,, , 12, 12 ,, , 13, 13 ,, , 14, 14 ,, , and, and part, part of, of 15, 15 ), ) in, in 33, 33 unrelated, unrelated Dutch, Dutch FAP, FAP patients, patients has, has led, led to, to the, the identification, identification of, of eight, eight novel, novel germ, germ line, line mutations, mutations resulting, resulting in, in stop, stop codons, codons or, or frameshifts, frameshifts ., . The, The results, results reported, reported here, here indicate, indicate that, that (, ( 1, 1 ), ) familial, familial adenomatous, adenomatous polyposis, polyposis is, is caused, caused by, by an, an extremely, extremely heterogeneous, heterogeneous spectrum, spectrum of, of point, point mutations, mutations ;, ; (, ( 2, 2 ), ) all, all the, the mutations, mutations found, found in, in this, this study, study are, are chain, chain terminating, terminating ;, ; and, and (, ( 3, 3 ), ) DGGE, DGGE represents, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "represents a, a rapid, rapid and, and sensitive, sensitive technique, technique for, for the, the detection, detection of, of mutations, mutations in, in the, the unusually, unusually large, large APC, APC gene, gene ., . An, An extension, extension of, of the, the DGGE, DGGE analysis, analysis to, to the, the entire, entire coding, coding region, region in, in a, a sufficient, sufficient number, number of, of clinically, clinically well-characterized, well-characterized ,, , unrelated, unrelated patients, patients will, will facilitate, facilitate the, the establishment, establishment of, of genotype-phenotype, genotype-phenotype correlations, correlations ., . On, On the, the other, other hand, hand ,, , the, the occurrence, occurrence of, of an, an extremely, extremely heterogeneous, heterogeneous spectrum, spectrum of, of mutations, mutations spread, spread throughout, throughout the, the entire, entire length, length of, of the, the large, large APC, APC gene, gene among, among the, the FAP, FAP patients, patients indicates, indicates that, that this, this approach, approach may, may not, not be, be useful, useful as, as a, a rapid, rapid presymptomatic, presymptomatic diagnostic, diagnostic procedure, procedure in, in a, a routine, routine laboratory, laboratory ., . Nevertheless, Nevertheless ,, , the, the above, above DGGE, DGGE approach, approach has, has incidentally, incidentally led, led to, to the, the identification, identification of, of a, a common, common polymorphism, polymorphism in, in exon, exon 13, 13 ., . Such, Such intragenic, intragenic polymorphisms, polymorphisms offer, offer a, a practical, practical approach, approach to, to a, a more, more rapid, rapid procedure, procedure for, for presymptomatic, presymptomatic diagnosis, diagnosis of, of FAP, FAP by, by linkage, linkage analysis, analysis in, in informative, informative families.., families.. Juvenile, Juvenile retinoschisis, retinoschisis is, is an, an X-linked, X-linked recessive, recessive disease, disease caused, caused by, by mutations, mutations in, in the, the XLRS1, XLRS1 gene, gene ., . We, We screened, screened 31, 31 new, new unrelated, unrelated patients, patients and, and families, families for, for XLRS1, XLRS1 mutations, mutations in, in addition, addition to, to previously, previously reported, reported mutations, mutations for, for 60, 60 of, of our, our families, families (, ( Retinoschisis, Retinoschisis Consortium, Consortium ,, , Hum, Hum Mol, Mol Genet, Genet 1998, 1998 ;, ; 7, 7 1185-1192, 1185-1192 ), ) ., . Twenty-three, Twenty-three different, different mutations, mutations including, including 12, 12 novel, novel ones, ones were, were identified, identified in, in 28, 28 patients, patients ., . Mutations, Mutations identified, identified in, in this, this study, study include, include 19, 19 missense, missense mutations, mutations ,, , two, two nonsense, nonsense mutations, mutations ,, , one, one intragenic, intragenic deletion, deletion ,, , four, four microdeletions, microdeletions ,, , one, one insertion, insertion ,, , and, and one, one intronic, intronic sequence, sequence substitution, substitution that, that is, is likely, likely to, to result, result in, in a, a splice, splice site, site defect, defect ., . Two, Two novel, novel mutations, mutations ,, , c., c. 38T, 38T --, -- >, > C, C (, ( L13P, L13P ), ) and, and c., c. 667T, 667T --, -- >, > C, C (, ( C223R, C223R ), ) ,, , respectively, respectively ,, , present, present the, the first, first genetic, genetic evidence, evidence for, for the, the functional, functional significance, significance of, of the, the putative, putative leader, leader peptide, peptide sequence, sequence and, and for, for the, the functional, functional significance, significance at, at the, the carboxyl, carboxyl terminal, terminal of, of the, the XLRS1, XLRS1 protein, protein beyond, beyond the, the discoidin, discoidin domain, domain ., . Mutations, Mutations in, in 25, 25 of, of the, the families, families were, were localized, localized to, to exons, exons 4-6, 4-6 ,, , emphasizing, emphasizing the, the critical, critical functional, functional significance, significance of, of the, the discoidin, discoidin domain, domain of, of the, the XLRS1, XLRS1 protein, protein Seventy, Seventy families, families with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) known, known to, to the, the Institute, Institute of, of Child, Child Health, Health fall, fall into, into three, three categories, categories with, with respect, respect to, to potential, potential linkage, linkage analysis, analysis with, with the, the X, X chromosome, chromosome DNA, DNA markers, markers RC8, RC8 and, and L1, L1 ., . 28, 28 that, that bridge, bridge the, the DMD, DMD gene, gene ., . Families, Families in, in which, which there, there is, is at, at least, least one, one obligatory, obligatory female, female heterozygote, heterozygote (, ( n, n =, = 13, 13 ), ) ., . Here, Here prediction, prediction and, and exclusion, exclusion of, of DMD, DMD gene, gene transmission, transmission may, may be, be possible, possible ,, , the, the accuracy, accuracy being, being dependent, dependent on, on the, the closeness, closeness of, of the, the linkage, linkage of, of the, the DNA, DNA marker, marker (, ( s, s ), ) to, to the, the DMD, DMD gene, gene ;, ; an, an illustrative, illustrative case, case is, is reported, reported ., . Families, Families in, in which, which there, there is, is a, a single, single affected, affected boy, boy ,, , who, who also, also has, has one, one or, or more, more healthy, healthy brothers, brothers (, ( n, n =, = 26, 26 ), ) ., . Given, Given an, an informative, informative restriction, restriction fragment, fragment length, length polymorphism, polymorphism (, ( RFLP, RFLP ), ) ,, , the, the probability, probability that, that the, the boy, boy represents, represents a, a new, new mutation, mutation can, can be, be reassessed, reassessed ;, ; it, it is, is also, also possible, possible to, to exclude, exclude the, the DMD, DMD gene, gene in, in a, a sister, sister ., . Families, Families with, with a, a single, single affected, affected boy, boy with, with no, no brother, brother (, ( n, n =, = 30, 30 ), ) ., . Here, Here exclusion, exclusion of, of the, the DMD, DMD gene, gene in, in a, a sister, sister may, may be, be possible, possible ., . Only, Only in, in one, one family, family was, was there, there no, no possibility, possibility of, of useful, useful linkage, linkage analysis, analysis ., . The, The linkage, linkage analysis, analysis required, required is, is described, described ,, , and, and the, the need, need to, to check, check DMD, DMD families, families for, for informative, informative RFLPs, RFLPs is, is stressed, stressed ., . The, The underlying, underlying DNA, DNA changes, changes associated, associated with, with glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) -deficient, -deficient Asians, Asians have, have not, not been, been extensively, extensively investigated, investigated ., . To, To fill, fill this, this gap, gap ,, , we, we sequenced, sequenced the, the G6PD, G6PD gene, gene of, of 43, 43 G6PD-deficient, G6PD-deficient Chinese, Chinese whose, whose G6PD, G6PD was, was well, well characterized, characterized biochemically, biochemically ., . DNA, DNA samples, samples were, were obtained, obtained from, from peripheral, peripheral blood, blood of, of these, these individuals, individuals for, for sequencing, sequencing using, using a, a direct, direct polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) sequencing, sequencing procedure, procedure ., . From, From these, these 43, 43 samples, samples ,, , we, we have, have identified, identified five, five different, different types, types of, of nucleotide, nucleotide substitutions, substitutions in, in the, the G6PD, G6PD gene, gene at, at cDNA, cDNA 1388, 1388 from, from G, G to, to A, A (, ( Arg, Arg to, to His, His ), ) ;, ; at, at cDNA, cDNA 1376, 1376 from, from G, G to, to T, T (, ( Arg, Arg to, to Leu, Leu ), ) ;, ; at, at cDNA, cDNA 1024, 1024 from, from C, C to, to T, T (, ( Leu, Leu to, to Phe, Phe ), ) ;, ; at, at cDNA, cDNA 392, 392 from, from G, G to, to T, T (, ( Gly, Gly to, to Val, Val ), ) ;, ; at, at cDNA, cDNA 95, 95 from, from A, A to, to G, G (, ( His, His to, to Arg, Arg ), ) ., . These, These five, five nucleotide, nucleotide substitutions, substitutions account, account for, for over, over 83, 83 %, % of, of our, our 43, 43 G6PD-deficient, G6PD-deficient samples, samples and, and these, these substitutions, substitutions have, have not, not been, been reported, reported in, in non-Asians, non-Asians ., . The, The substitutions, substitutions found, found at, at cDNA, cDNA 392, 392 and, and cDNA, cDNA 1024, 1024 are, are new, new findings, findings ., . The, The substitutions, substitutions at, at cDNA, cDNA 1376, 1376 and, and 1388, 1388 account, account for, for over, over 50, 50 %, % of, of the, the 43, 43 samples, samples examined, examined indicating, indicating a, a high, high prevalence, prevalence of, of these, these two, two alleles, alleles among, among G6PD-deficient, G6PD-deficient Chinese, Chinese ., . Our, Our findings, findings add, add support, support to, to the, the notion, notion that, that diverse, diverse point, point mutations, mutations may, may account, account largely, largely for, for much, much of, of the, the phenotypic, phenotypic heterogeneity, heterogeneity of, of G6PD, G6PD deficiency.., deficiency.. Positional, Positional cloning, cloning experiments, experiments have, have resulted, resulted recently, recently in, in the, the isolation, isolation of, of a, a candidate, candidate gene, gene for, for Norrie, Norrie disease, disease (, ( pseudoglioma, pseudoglioma ;, ; NDP, NDP ), ) ,, , a, a severe, severe X-linked, X-linked neurodevelopmental, neurodevelopmental disorder, disorder ., . Here, Here we, we report, report the, the isolation, isolation and, and analysis, analysis of, of human, human genomic, genomic DNA, DNA clones, clones encompassing, encompassing the, the NDP, NDP gene, gene ., . The, The gene, gene spans, spans 28, 28 kb, kb and, and consists, consists of, of 3, 3 exons, exons ,, , the, the first, first of, of which, which is, is entirely, entirely contained, contained within, within the, the 5, 5 untranslated, untranslated region, region ., . Detailed, Detailed analysis, analysis of, of genomic, genomic deletions, deletions in, in Norrie, Norrie patients, patients shows, shows that, that they, they are, are heterogeneous, heterogeneous ,, , both, both in, in size, size and, and in, in position, position ., . By, By PCR, PCR analysis, analysis ,, , we, we found, found that, that expression, expression of, of the, the NDP, NDP gene, gene was, was not, not confined, confined to, to the, the eye, eye or, or to, to the, the brain, brain ., . An, An extensive, extensive DNA, DNA and, and protein, protein sequence, sequence comparison, comparison between, between the, the human, human NDP, NDP gene, gene and, and related, related genes, genes from, from the, the database, database revealed, revealed homology, homology with, with cysteine-rich, cysteine-rich protein-binding, protein-binding domains, domains of, of immediate, immediate --, -- early, early genes, genes implicated, implicated in, in the, the regulation, regulation of, of cell, cell proliferation, proliferation ., . We, We propose, propose that, that NDP, NDP is, is a, a molecule, molecule related, related in, in function, function to, to these, these genes, genes and, and may, may be, be involved, involved in, in a, a pathway, pathway that, that regulates, regulates neural, neural cell, cell differentiation, differentiation and, and proliferation.., proliferation.. Two, Two pregnancies, pregnancies at, at risk, risk for, for Wolman, Wolman disease, disease were, were monitored, monitored by, by assay, assay and, and electrophoresis, electrophoresis of, of acid, acid lipase, lipase in, in cultured, cultured amniotic-fluid, amniotic-fluid cells, cells ., . Cells, Cells from, from patient, patient 1, 1 had, had 5, 5 %, % of, of control, control levels, levels of, of acid, acid lipase, lipase ,, , using, using 14C-triolein, 14C-triolein as, as substrate, substrate ;, ; however, however ,, , when, when artificial, artificial substrates, substrates (, ( esters, esters of, of 4-methylumbelliferone, 4-methylumbelliferone and, and p-nitrophenol, p-nitrophenol ), ) were, were used, used to, to measure, measure acid, acid lipase, lipase ,, , these, these cells, cells had, had 30, 30 %, % of, of control, control levels, levels ., . Electrophoresis, Electrophoresis of, of cell, cell extracts, extracts revealed, revealed the, the absence, absence of, of the, the A, A form, form of, of acid, acid lipase, lipase ,, , consistent, consistent with, with the, the diagnosis, diagnosis of, of Wolman, Wolman disease, disease ., . Analysis, Analysis of, of fetal, fetal tissues, tissues following, following prostaglandin, prostaglandin termination, termination of, of this, this pregnancy, pregnancy confirmed, confirmed the, the diagnosis, diagnosis ., . Assay, Assay of, of fetal-skin, fetal-skin fibroblasts, fibroblasts with, with 14C-triolein, 14C-triolein ,, , as, as well, well as, as with, with artificial, artificial substrates, substrates ,, , showed, showed marked, marked deficiency, deficiency of, of acid, acid lipase, lipase activity, activity ., . Electrophoresis, Electrophoresis of, of fetal-tissue, fetal-tissue extracts, extracts also, also demonstrated, demonstrated the, the absence, absence of, of the, the A, A form, form of, of acid, acid lipase, lipase ., . Amniotic-fluid, Amniotic-fluid cells, cells from, from patient, patient 2, 2 showed, showed normal, normal levels, levels of, of acid, acid lipase, lipase with, with all, all substrates, substrates tested, tested ;, ; the, the electrophoretic, electrophoretic pattern, pattern of, of acid, acid lipase, lipase was, was normal, normal ., . The, The results, results suggest, suggest that, that the, the prenatal, prenatal diagnosis, diagnosis of, of Wolman, Wolman disease, disease be, be made, made using, using the, the radioassay, radioassay of, of acid, acid lipase, lipase and/or, and/or electrophoresis.., electrophoresis.. The, The BRCA1, BRCA1 gene, gene on, on chromosome, chromosome 17q21, 17q21 is, is responsible, responsible for, for an, an autosomal, autosomal dominant, dominant syndrome, syndrome of, of increased, increased susceptibility, susceptibility to, to breast, breast and, and ovarian, ovarian cancer, cancer but, but no, no somatic, somatic mutations, mutations in, in tumours, tumours have, have yet, yet been, been described, described ., . To, To study, study the, the potential, potential role, role of, of BRCA1, BRCA1 in, in sporadic, sporadic carcinogenesis, carcinogenesis ,, , we, we analysed, analysed the, the genomic, genomic DNA, DNA of, of tumour, tumour and, and normal, normal fractions, fractions of, of 47, 47 ovarian, ovarian cancers, cancers for, for mutations, mutations in, in BRCA1, BRCA1 using, using the, the single-strand, single-strand conformation, conformation polymorphism, polymorphism technique, technique ., . We, We now, now describe, describe somatic, somatic mutations, mutations in, in the, the DNA, DNA of, of four, four tumours, tumours which, which also, also had, had loss, loss of, of heterozygosity, heterozygosity (, ( LOH, LOH ), ) at, at a, a BRCA1, BRCA1 intragenic, intragenic marker, marker ., . Our, Our data, data support, support a, a tumour, tumour suppressor, suppressor mechanism, mechanism for, for BRCA1, BRCA1 ;, ; somatic, somatic mutations, mutations and, and LOH, LOH may, may result, result in, in inactivation, inactivation of, of BRCA1, BRCA1 in, in at, at least, least a, a small, small number, number of, of ovarian, ovarian cancers.., cancers.. One, One of, of female, female MZ, MZ twins, twins presented, presented with, with muscular, muscular dystrophy, dystrophy ., . Physical, Physical examination, examination ,, , creatine, creatine phosphokinase, phosphokinase levels, levels ,, , and, and muscle, muscle biopsy, biopsy were, were consistent, consistent with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . However, However ,, , because, because of, of her, her sex, sex she, she was, was diagnosed, diagnosed as, as having, having limb-girdle, limb-girdle muscular, muscular dystrophy, dystrophy ., . With, With cDNA, cDNA probes, probes to, to the, the DMD, DMD gene, gene ,, , a, a gene, gene deletion, deletion was, was detected, detected in, in the, the twins, twins and, and their, their mother, mother ., . The, The de, de novo, novo mutation, mutation which, which arose, arose in, in the, the mother, mother was, was shown, shown by, by novel, novel junction, junction fragments, fragments generated, generated by, by HindIII, HindIII ,, , PstI, PstI ,, , or, or TaqI, TaqI when, when probed, probed with, with cDNA8, cDNA8 ., . Additional, Additional evidence, evidence of, of a, a large, large gene, gene deletion, deletion was, was given, given by, by novel, novel SfiI, SfiI junction, junction fragments, fragments detected, detected by, by probes, probes p20, p20 ,, , J-Bir, J-Bir ,, , and, and J-66, J-66 on, on pulsed-field, pulsed-field gel, gel electrophoresis, electrophoresis (, ( PFGE, PFGE ), ) ., . Immunoblot, Immunoblot analysis, analysis of, of muscle, muscle from, from the, the affected, affected twin, twin showed, showed dystrophin, dystrophin of, of normal, normal size, size but, but of, of reduced, reduced amount, amount ., . Immunofluorescent, Immunofluorescent visualization, visualization of, of dystrophin, dystrophin revealed, revealed foci, foci of, of dystrophin-positive, dystrophin-positive fibers, fibers adjacent, adjacent to, to foci, foci of, of dystrophin-negative, dystrophin-negative fibers, fibers ., . These, These data, data indicate, indicate that, that the, the affected, affected twin, twin is, is a, a manifesting, manifesting carrier, carrier of, of an, an abnormal, abnormal DMD, DMD gene, gene ,, , her, her myopathy, myopathy being, being a, a direct, direct result, result of, of underexpression, underexpression of, of dystrophin, dystrophin ., . Cytogenetic, Cytogenetic analysis, analysis revealed, revealed normal, normal karyotypes, karyotypes ,, , eliminating, eliminating the, the possibility, possibility of, of a, a translocation, translocation affecting, affecting DMD, DMD gene, gene function, function ., . Both, Both linkage, linkage analysis, analysis and, and DNA, DNA fingerprint, fingerprint analysis, analysis revealed, revealed that, that each, each twin, twin has, has two, two different, different X, X chromosomes, chromosomes ,, , eliminating, eliminating the, the possibility, possibility of, of uniparental, uniparental disomy, disomy as, as a, a mechanism, mechanism for, for DMD, DMD expression, expression ., . On, On the, the basis, basis of, of methylation, methylation differences, differences of, of the, the paternal, paternal and, and maternal, maternal X, X chromosomes, chromosomes in, in these, these MZ, MZ twins, twins ,, , we, we propose, propose uneven, uneven lyonization, lyonization (, ( X, X chromosome, chromosome inactivation, inactivation ), ) as, as the, the underlying, underlying mechanism, mechanism for, for disease, disease expression, expression in, in the, the affected, affected female.., female.. A, A 24, 24 year, year old, old male, male with, with a, a history, history of, of eczema, eczema ,, , recurrent, recurrent mild, mild infections, infections ,, , and, and thrombocytopenia, thrombocytopenia consistent, consistent with, with the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) presented, presented with, with a, a mediastinal, mediastinal mass, mass ,, , generalized, generalized lymphadenopathy, lymphadenopathy ,, , splenomegaly, splenomegaly ,, , and, and severe, severe thrombocytopenia, thrombocytopenia ., . Studies, Studies of, of immune, immune function, function including, including immunoglobulin, immunoglobulin levels, levels and, and T-cell, T-cell subsets, subsets were, were normal, normal ., . Furthermore, Furthermore ,, , his, his T, T lymphocytes, lymphocytes proliferated, proliferated normally, normally in, in response, response to, to phytohemagglutinin, phytohemagglutinin ,, , concanavalin, concanavalin A, A ,, , and, and the, the combination, combination of, of neuraminidase/galactose, neuraminidase/galactose oxidase, oxidase ., . However, However ,, , their, their proliferative, proliferative responses, responses to, to anti-CD43, anti-CD43 antibody, antibody and, and periodate, periodate were, were diminished, diminished ,, , consistent, consistent with, with the, the clinical, clinical diagnosis, diagnosis of, of WAS, WAS ., . An, An initial, initial inguinal, inguinal lymph, lymph node, node biopsy, biopsy surprisingly, surprisingly revealed, revealed Kaposi, Kaposi sarcoma, sarcoma ., . However, However ,, , following, following splenectomy, splenectomy to, to increase, increase the, the platelet, platelet count, count ,, , biopsy, biopsy of, of the, the mediastinal, mediastinal mass, mass revealed, revealed T-cell, T-cell large, large cell, cell lymphoma, lymphoma ., . Studies, Studies of, of biopsied, biopsied tissue, tissue for, for the, the presence, presence of, of Epstein-Barr, Epstein-Barr virus, virus and, and cytomegalovirus, cytomegalovirus were, were negative, negative ,, , as, as were, were studies, studies of, of blood, blood ,, , including, including the, the polymerase, polymerase chain, chain reaction, reaction ,, , for, for the, the presence, presence of, of the, the human, human immunodeficiency, immunodeficiency virus, virus (, ( HIV, HIV ), ) ., . This, This is, is the, the first, first report, report of, of Kaposi, Kaposi sarcoma, sarcoma arising, arising in, in a, a patient, patient with, with a, a congenital, congenital immunodeficiency, immunodeficiency syndrome, syndrome ., . Although, Although Kaposi, Kaposi sarcoma, sarcoma can, can arise, arise in, in the, the face, face of, of the, the severe, severe immunosuppression, immunosuppression that, that follows, follows allograft, allograft transplantation, transplantation and, and in, in patients, patients infected, infected with, with HIV, HIV ,, , we, we postulate, postulate that, that longevity, longevity in, in the, the face, face of, of mild, mild immunosuppression, immunosuppression was, was the, the major, major factor, factor in, in the, the development, development of, of Kaposi, Kaposi sarcoma, sarcoma in, in this, this patient.., patient.. Treatments, Treatments by, by oral, oral administration, administration of, of chenodeoxycholic, chenodeoxycholic acid, acid (, ( CDCA, CDCA ), ) alone, alone ,, , 3-hydroxy-3-methylglutaryl, 3-hydroxy-3-methylglutaryl (, ( HMG, HMG ), ) CoA, CoA reductase, reductase inhibitor, inhibitor (, ( pravastatin, pravastatin ), ) alone, alone ,, , and, and combination, combination of, of the, the two, two drugs, drugs were, were attempted, attempted for, for 7, 7 patients, patients with, with cerebrotendinous, cerebrotendinous xanthomatosis, xanthomatosis (, ( CTX, CTX ), ) ., . CDCA, CDCA treatment, treatment at, at a, a dose, dose of, of 300, 300 mg/day, mg/day reduced, reduced serum, serum cholestanol, cholestanol (, ( 67, 67 ., . 3, 3 %, % reduction, reduction ), ) ,, , lathosterol, lathosterol (, ( 50, 50 ., . 8, 8 %, % ), ) ,, , campesterol, campesterol (, ( 61, 61 ., . 7, 7 %, % ), ) and, and sitosterol, sitosterol (, ( 12, 12 ., . 7, 7 %, % ), ) ., . However, However ,, , the, the sera, sera of, of the, the patients, patients changed, changed to, to be, be ``, `` atherogenic, atherogenic ``, `` ;, ; total, total cholesterol, cholesterol ,, , triglyceride, triglyceride and, and low-density, low-density lipoprotein, lipoprotein (, ( LDL, LDL ), ) -cholesterol, -cholesterol were, were increased, increased ,, , while, while high-density, high-density lipoprotein, lipoprotein (, ( HDL, HDL ), ) -cholesterol, -cholesterol was, was decreased, decreased ., . Contrarily, Contrarily ,, , pravastatin, pravastatin at, at a, a dose, dose of, of 10, 10 mg/day, mg/day improved, improved the, the sera, sera of, of the, the patients, patients to, to be, be markedly, markedly ``, `` anti-atherogenic, anti-atherogenic ``, `` ,, , but, but the, the reductions, reductions of, of cholestanol, cholestanol (, ( 30, 30 ., . 4, 4 %, % ), ) ,, , lathosterol, lathosterol (, ( 44, 44 ., . 0, 0 %, % ), ) ,, , campesterol, campesterol (, ( 22, 22 ., . 9, 9 %, % ), ) and, and sitosterol, sitosterol (, ( 9, 9 ., . 6, 6 %, % ), ) were, were inadequate, inadequate ., . Combined, Combined treatment, treatment with, with CDCA, CDCA and, and pravastatin, pravastatin showed, showed good, good overlapping, overlapping of, of the, the effects, effects of, of each, each drug, drug alone, alone ., . The, The sera, sera of, of the, the patients, patients were, were apparently, apparently more, more ``, `` anti-atherogenic, anti-atherogenic ``, `` than, than those, those after, after CDCA, CDCA treatment, treatment ., . Serum, Serum cholestanol, cholestanol concentration, concentration was, was still, still 2, 2 ., . 7, 7 times, times higher, higher than, than in, in controls, controls ,, , but, but the, the serum, serum lathosterol, lathosterol level, level was, was within, within the, the normal, normal range, range ,, , indicating, indicating that, that the, the enhancement, enhancement of, of overall, overall cholesterol, cholesterol synthesis, synthesis in, in the, the patients, patients was, was sufficiently, sufficiently suppressed, suppressed ., . Plant, Plant sterol, sterol levels, levels were, were also, also within, within the, the normal, normal range, range ., . The, The combination, combination of, of CDCA, CDCA and, and pravastatin, pravastatin was, was a, a good, good treatment, treatment for, for CTX, CTX ,, , based, based on, on the, the improvement, improvement of, of serum, serum lipoprotein, lipoprotein metabolism, metabolism ,, , the, the suppression, suppression of, of cholesterol, cholesterol synthesis, synthesis ,, , and, and reductions, reductions of, of cholestanol, cholestanol and, and plant, plant sterol, sterol levels, levels ., . In, In all, all of, of 7, 7 patients, patients ,, , the, the progression, progression of, of disease, disease was, was arrested, arrested ,, , but, but dramatic, dramatic effects, effects on, on clinical, clinical manifestations, manifestations ,, , xanthoma, xanthoma ,, , and, and electrophysiological, electrophysiological findings, findings could, could not, not be, be found, found after, after the, the treatment, treatment of, of these, these drugs, drugs By, By routine, routine screening, screening of, of sera, sera ,, , a, a subject, subject was, was discovered, discovered who, who showed, showed a, a sub-total, sub-total deficiency, deficiency of, of C6, C6 and, and C7, C7 ., . No, No clinical, clinical disease, disease was, was associated, associated with, with this, this deficiency, deficiency which, which was, was transmitted, transmitted through, through the, the subjects, subjects family, family as, as a, a single, single genetic, genetic characteristic, characteristic ,, , the, the C6, C6 deficiency, deficiency being, being associated, associated with, with a, a silent, silent allele, allele at, at the, the structural, structural locus, locus ., . The, The propositus, propositus was, was found, found to, to have, have low, low quantities, quantities of, of an, an abnormal, abnormal C6, C6 which, which was, was both, both antigenically, antigenically deficient, deficient and, and smaller, smaller in, in size, size than, than normal, normal C6, C6 (, ( 110, 110 ,, , 000, 000 daltons, daltons compared, compared with, with 140, 140 ,, , 000, 000 daltons, daltons ), ) and, and small, small quantities, quantities of, of apparently, apparently normal, normal C7, C7 ., . It, It is, is concluded, concluded that, that the, the most, most likely, likely explanation, explanation for, for this, this defect, defect is, is that, that the, the subject, subject has, has a, a structural, structural mutation, mutation in, in his, his C6, C6 gene, gene which, which produces, produces hyopsynthesis, hyopsynthesis not, not only, only of, of C6, C6 but, but also, also of, of the, the closely, closely linked, linked gene, gene for, for C7, C7 ., . These, These findings, findings suggest, suggest the, the possibility, possibility that, that C6, C6 and, and C7, C7 may, may function, function as, as a, a single, single genetic, genetic unit, unit and, and that, that the, the primary, primary transcript, transcript copied, copied from, from the, the genome, genome includes, includes information, information for, for both, both proteins.., proteins.. We, We report, report two, two de, de novo, novo cases, cases of, of del, del (, ( 8, 8 ), ) (, ( pter, pter --, -- --, -- q24, q24 ., . 1, 1 ), ) with, with breakpoints, breakpoints involving, involving the, the distal, distal part, part of, of band, band 8q24, 8q24 ., . 1, 1 1, 1 ., . The, The clinical, clinical features, features were, were similar, similar and, and there, there were, were no, no obvious, obvious stigmata, stigmata of, of Langer-Giedion, Langer-Giedion syndrome, syndrome (, ( LGS, LGS ), ) ., . There, There are, are three, three other, other cases, cases reported, reported with, with a, a deletion, deletion of, of chromosome, chromosome 8, 8 at, at approximately, approximately the, the same, same breakpoint, breakpoint ,, , one, one without, without LGS, LGS and, and some, some similarities, similarities to, to our, our cases, cases ,, , the, the other, other two, two with, with LGS, LGS ., . Our, Our findings, findings would, would support, support the, the observation, observation that, that the, the critical, critical segment, segment for, for the, the assignment, assignment of, of LGS, LGS is, is proximal, proximal to, to or, or involves, involves the, the proximal, proximal part, part of, of 8q24, 8q24 ., . 1, 1 ,, , but, but a, a review, review of, of published, published reports, reports suggests, suggests that, that the, the aetiology, aetiology of, of LGS, LGS may, may be, be a, a more, more complex, complex issue, issue Frataxin, Frataxin deficiency, deficiency is, is the, the primary, primary cause, cause of, of Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) ,, , an, an autosomal, autosomal recessive, recessive cardiodegenerative, cardiodegenerative and, and neurodegenerative, neurodegenerative disease, disease ., . Frataxin, Frataxin is, is a, a nuclear-encoded, nuclear-encoded mitochondrial, mitochondrial protein, protein that, that is, is widely, widely conserved, conserved among, among eukaryotes, eukaryotes ., . Genetic, Genetic inactivation, inactivation of, of the, the yeast, yeast frataxin, frataxin homologue, homologue (, ( Yfh1p, Yfh1p ), ) results, results in, in mitochondrial, mitochondrial iron, iron accumulation, accumulation and, and hypersensitivity, hypersensitivity to, to oxidative, oxidative stress, stress ., . Increased, Increased iron, iron deposition, deposition and, and evidence, evidence of, of oxidative, oxidative damage, damage have, have also, also been, been observed, observed in, in cardiac, cardiac tissue, tissue and, and cultured, cultured fibroblasts, fibroblasts from, from patients, patients with, with FRDA, FRDA ., . These, These findings, findings indicate, indicate that, that frataxin, frataxin is, is essential, essential for, for mitochondrial, mitochondrial iron, iron homeostasis, homeostasis and, and protection, protection from, from iron-induced, iron-induced formation, formation of, of free, free radicals, radicals ., . The, The functional, functional mechanism, mechanism of, of frataxin, frataxin ,, , however, however ,, , is, is still, still unknown, unknown ., . We, We have, have expressed, expressed the, the mature, mature form, form of, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "of Yfh1p, Yfh1p (, ( mYfh1p, mYfh1p ), ) in, in Escherichia, Escherichia coli, coli and, and have, have analyzed, analyzed its, its function, function in, in vitro, vitro ., . Isolated, Isolated mYfh1p, mYfh1p is, is a, a soluble, soluble monomer, monomer (, ( 13, 13 ,, , 783, 783 Da, Da ), ) that, that contains, contains no, no iron, iron and, and shows, shows no, no significant, significant tendency, tendency to, to self-associate, self-associate ., . Aerobic, Aerobic addition, addition of, of ferrous, ferrous iron, iron to, to mYfh1p, mYfh1p results, results in, in assembly, assembly of, of regular, regular spherical, spherical multimers, multimers with, with a, a molecular, molecular mass, mass of, of approximately, approximately 1, 1 ., . 1, 1 MDa, MDa (, ( megadaltons, megadaltons ), ) and, and a, a diameter, diameter of, of 13, 13 +/-2, +/-2 nm, nm ., . Each, Each multimer, multimer consists, consists of, of approximately, approximately 60, 60 subunits, subunits and, and can, can sequester, sequester >, > 3, 3 ,, , 000, 000 atoms, atoms of, of iron, iron ., . Titration, Titration of, of mYfh1p, mYfh1p with, with increasing, increasing iron, iron concentrations, concentrations supports, supports a, a stepwise, stepwise mechanism, mechanism of, of multimer, multimer assembly, assembly ., . Sequential, Sequential addition, addition of, of an, an iron, iron chelator, chelator and, and a, a reducing, reducing agent, agent results, results in, in quantitative, quantitative iron, iron release, release with, with concomitant, concomitant disassembly, disassembly of, of the, the multimer, multimer ,, , indicating, indicating that, that mYfh1p, mYfh1p sequesters, sequesters iron, iron in, in an, an available, available form, form ., . In, In yeast, yeast mitochondria, mitochondria ,, , native, native mYfh1p, mYfh1p exists, exists as, as monomer, monomer and, and a, a higher-order, higher-order species, species with, with a, a molecular, molecular weight, weight >, > 600, 600 ,, , 000, 000 ., . After, After addition, addition of, of (, ( 55, 55 ), ) Fe, Fe to, to the, the medium, medium ,, , immunoprecipitates, immunoprecipitates of, of this, this species, species contain, contain >, > 16, 16 atoms, atoms of, of (, ( 55, 55 ), ) Fe, Fe per, per molecule, molecule of, of mYfh1p, mYfh1p ., . We, We propose, propose that, that iron-dependent, iron-dependent self-assembly, self-assembly of, of recombinant, recombinant mYfh1p, mYfh1p reflects, reflects a, a physiological, physiological role, role for, for frataxin, frataxin in, in mitochondrial, mitochondrial iron, iron sequestration, sequestration and, and bioavailability.., bioavailability.. Glucose, Glucose 6-phosphate, 6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) is, is a, a cytosolic, cytosolic enzyme, enzyme encoded, encoded by, by a, a housekeeping, housekeeping X-linked, X-linked gene, gene whose, whose main, main function, function is, is to, to produce, produce NADPH, NADPH ,, , a, a key, key electron, electron donor, donor in, in the, the defense, defense against, against oxidizing, oxidizing agents, agents and, and in, in reductive, reductive biosynthetic, biosynthetic reactions, reactions ., . Inherited, Inherited G6PD, G6PD deficiency, deficiency is, is associated, associated with, with either, either episodic, episodic hemolytic, hemolytic anemia, anemia (, ( triggered, triggered by, by fava, fava beans, beans or, or other, other agents, agents ), ) or, or life-long, life-long hemolytic, hemolytic anemia, anemia ., . We, We show, show here, here that, that an, an evolutionary, evolutionary analysis, analysis is, is a, a key, key to, to understanding, understanding the, the biology, biology of, of a, a housekeeping, housekeeping gene, gene ., . From, From the, the alignment, alignment of, of the, the amino, amino acid, acid (, ( aa, aa ), ) sequence, sequence of, of 52, 52 glucose, glucose 6-phosphate, 6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) species, species from, from 42, 42 different, different organisms, organisms ,, , we, we found, found a, a striking, striking correlation, correlation between, between the, the aa, aa replacements, replacements that, that cause, cause G6PD, G6PD deficiency, deficiency in, in humans, humans and, and the, the sequence, sequence conservation, conservation of, of G6PD, G6PD two-thirds, two-thirds of, of such, such replacements, replacements are, are in, in highly, highly and, and moderately, moderately conserved, conserved (, ( 50-99, 50-99 %, % ), ) aa, aa ;, ; relatively, relatively few, few are, are in, in fully, fully conserved, conserved aa, aa (, ( where, where they, they might, might be, be lethal, lethal ), ) or, or in, in poorly, poorly conserved, conserved aa, aa ,, , where, where presumably, presumably they, they simply, simply would, would not, not cause, cause G6PD, G6PD deficiency, deficiency ., . This, This is, is consistent, consistent with, with the, the notion, notion that, that all, all human, human mutants, mutants have, have residual, residual enzyme, enzyme activity, activity and, and that, that null, null mutations, mutations are, are lethal, lethal at, at some, some stage, stage of, of development, development ., . Comparing, Comparing the, the distribution, distribution of, of mutations, mutations in, in a, a human, human housekeeping, housekeeping gene, gene with, with evolutionary, evolutionary conservation, conservation is, is a, a useful, useful tool, tool for, for pinpointing, pinpointing amino, amino acid, acid residues, residues important, important for, for the, the stability, stability or, or the, the function, function of, of the, the corresponding, corresponding protein, protein ., . In, In view, view of, of the, the current, current explosive, explosive increase, increase in, in full, full genome, genome sequencing, sequencing projects, projects ,, , this, this tool, tool will, will become, become rapidly, rapidly available, available for, for numerous, numerous other, other genes.., genes.. Germline, Germline mutation, mutation in, in APC, APC at, at 5q21-22, 5q21-22 results, results in, in the, the dominantly, dominantly inherited, inherited syndrome, syndrome adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) ., . Somatic, Somatic mutation, mutation in, in this, this gene, gene is, is an, an early, early event, event in, in colorectal, colorectal tumourigenesis, tumourigenesis ., . Both, Both types, types of, of mutation, mutation are, are concentrated, concentrated in, in the, the 5, 5 half, half of, of exon, exon 15, 15 ., . We, We have, have used, used single, single strand, strand conformational, conformational polymorphism, polymorphism (, ( SSCP, SSCP ), ) and, and heteroduplex, heteroduplex analysis, analysis to, to screen, screen for, for variants, variants in, in this, this region, region of, of the, the gene, gene in, in a, a total, total of, of 45, 45 affected, affected but, but unrelated, unrelated individuals, individuals ., . Eighteen, Eighteen patients, patients had, had no, no family, family history, history of, of the, the disease, disease ;, ; of, of these, these 11, 11 were, were classified, classified as, as having, having a, a severe, severe phenotype, phenotype ,, , based, based on, on an, an early, early age, age at, at presentation, presentation or, or cancer, cancer development, development ., . This, This compared, compared with, with 6, 6 of, of 27, 27 familial, familial cases, cases ., . A, A 5, 5 bp, bp deletion, deletion at, at codon, codon 1309, 1309 reported, reported to, to occur, occur in, in 10-15, 10-15 %, % of, of unselected, unselected APC, APC patients, patients worldwide, worldwide ,, , was, was found, found in, in 5, 5 of, of the, the 18, 18 new, new mutation, mutation cases, cases and, and 4, 4 of, of the, the 27, 27 familial, familial cases, cases all, all nine, nine were, were classed, classed as, as severe, severe ., . A, A further, further 3, 3 new, new mutations, mutations and, and 1, 1 familial, familial mutation, mutation were, were located, located downstream, downstream from, from codon, codon 1309, 1309 ,, , these, these individuals, individuals similarly, similarly being, being classed, classed as, as phenotypically, phenotypically severe, severe ., . In, In contrast, contrast all, all of, of the, the APC, APC mutations, mutations detected, detected in, in affected, affected individuals, individuals with, with an, an average, average phenotype, phenotype were, were located, located prior, prior to, to codon, codon 1309, 1309 ., . The, The frequent, frequent association, association of, of a, a severe, severe phenotype, phenotype with, with fresh, fresh mutation, mutation may, may explain, explain the, the apparent, apparent conflict, conflict of, of a, a high, high mutation, mutation rate, rate (, ( 20-30, 20-30 %, % ), ) in, in a, a condition, condition ,, , which, which on, on average, average ,, , is, is lethal, lethal at, at a, a post-reproductive, post-reproductive age.., age.. We, We recently, recently showed, showed that, that alkaptonuria, alkaptonuria (, ( AKU, AKU ), ) is, is caused, caused by, by loss-of-function, loss-of-function mutations, mutations in, in the, the homogentisate, homogentisate 1, 1 ,, , 2, 2 dioxygenase, dioxygenase gene, gene (, ( HGO, HGO ), ) ., . Herein, Herein we, we describe, describe haplotype, haplotype and, and mutational, mutational analyses, analyses of, of HGO, HGO in, in seven, seven new, new AKU, AKU pedigrees, pedigrees ., . These, These analyses, analyses identified, identified two, two novel, novel single-nucleotide, single-nucleotide polymorphisms, polymorphisms (, ( INV4, INV4 +, + 31A, 31A --, -- >, > G, G and, and INV11, INV11 +, + 18A, 18A --, -- >, > G, G ), ) and, and six, six novel, novel AKU, AKU mutations, mutations (, ( INV1-1G, INV1-1G --, -- >, > A, A ,, , W60G, W60G ,, , Y62C, Y62C ,, , A122D, A122D ,, , P230T, P230T ,, , and, and D291E, D291E ), ) ,, , which, which further, further illustrates, illustrates the, the remarkable, remarkable allelic, allelic heterogeneity, heterogeneity found, found in, in AKU, AKU ., . Reexamination, Reexamination of, of all, all 29, 29 mutations, mutations and, and polymorphisms, polymorphisms thus, thus far, far described, described in, in HGO, HGO shows, shows that, that these, these nucleotide, nucleotide changes, changes are, are not, not randomly, randomly distributed, distributed ;, ; the, the CCC, CCC sequence, sequence motif, motif and, and its, its inverted, inverted complement, complement ,, , GGG, GGG ,, , are, are preferentially, preferentially mutated, mutated ., . These, These analyses, analyses also, also demonstrated, demonstrated that, that the, the nucleotide, nucleotide substitutions, substitutions in, in HGO, HGO do, do not, not involve, involve CpG, CpG dinucleotides, dinucleotides ,, , which, which illustrates, illustrates important, important differences, differences between, between HGO, HGO and, and other, other genes, genes for, for the, the occurrence, occurrence of, of mutation, mutation at, at specific, specific short-sequence, short-sequence motifs, motifs ., . Because, Because the, the CCC, CCC sequence, sequence motifs, motifs comprise, comprise a, a significant, significant proportion, proportion (, ( 34, 34 ., . 5, 5 %, % ), ) of, of all, all mutated, mutated bases, bases that, that have, have been, been observed, observed in, in HGO, HGO ,, , we, we conclude, conclude that, that the, the CCC, CCC triplet, triplet is, is a, a mutational, mutational hot, hot spot, spot in, in HGO, HGO ., . Four, Four new, new G6PD, G6PD variants, variants have, have been, been characterized, characterized in, in individuals, individuals from, from Papua, Papua New, New Guinea, Guinea ., . This, This study, study demonstrates, demonstrates that, that the, the previously, previously reported, reported Markham, Markham variant, variant and, and the, the newly, newly characterized, characterized Salata, Salata variant, variant may, may be, be widely, widely distributed, distributed in, in Papua, Papua New, New Guinea, Guinea ., . Th, Th data, data presented, presented here, here together, together with, with those, those of, of previously, previously published, published studies, studies demonstrate, demonstrate a, a degree, degree of, of heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency that, that is, is much, much higher, higher than, than that, that in, in other, other regions, regions of, of the, the world, world where, where G6PD, G6PD deficiency, deficiency is, is common.., common.. Aspartylglucosaminuria, Aspartylglucosaminuria (, ( AGU, AGU ), ) is, is a, a lysosomal, lysosomal storage, storage disorder, disorder caused, caused by, by deficiency, deficiency of, of aspartylglucosaminidase, aspartylglucosaminidase (, ( AGA, AGA ), ) ., . The, The main, main symptom, symptom is, is progressive, progressive mental, mental retardation, retardation ., . A, A spectrum, spectrum of, of different, different mutations, mutations has, has been, been reported, reported in, in this, this disease, disease ,, , one, one missense, missense mutation, mutation (, ( Cys163Ser, Cys163Ser ), ) being, being responsible, responsible for, for the, the majority, majority of, of Finnish, Finnish cases, cases ., . We, We were, were able, able to, to examine, examine 66, 66 Finnish, Finnish AGU, AGU patients, patients for, for changes, changes in, in the, the oral, oral mucosa, mucosa and, and 44, 44 of, of these, these for, for changes, changes in, in facial, facial skin, skin ., . Biopsy, Biopsy specimens, specimens of, of 16, 16 oral, oral lesions, lesions ,, , 12, 12 of, of them, them associated, associated with, with the, the teeth, teeth ,, , plus, plus two, two facial, facial lesions, lesions were, were studied, studied histologically, histologically ., . Immunohistochemical, Immunohistochemical staining, staining for, for AGA, AGA was, was performed, performed on, on 15, 15 oral, oral specimens, specimens ., . Skin, Skin was, was seborrhoeic, seborrhoeic in, in adolescent, adolescent and, and adult, adult patients, patients ,, , with, with erythema, erythema of, of the, the facial, facial skin, skin already, already common, common in, in childhood, childhood ., . Of, Of 44, 44 patients, patients ,, , nine, nine (, ( 20, 20 %, % ), ) had, had facial, facial angiofibromas, angiofibromas ,, , tumours, tumours primarily, primarily occurring, occurring in, in association, association with, with tuberous, tuberous sclerosis, sclerosis ., . Oedemic, Oedemic buccal, buccal mucosa, mucosa (, ( leucoedema, leucoedema ), ) and, and gingival, gingival overgrowths, overgrowths were, were more, more frequent, frequent in, in AGU, AGU patients, patients than, than in, in controls, controls (, ( p, p <, < 0, 0 ., . 001, 001 ), ) ., . Of, Of 16, 16 oral, oral mucosal, mucosal lesions, lesions studied, studied histologically, histologically ,, , 15, 15 represented, represented fibroepithelial, fibroepithelial or, or epithelial, epithelial hyperplasias, hyperplasias and, and were, were reactive, reactive in, in nature, nature ., . Cytoplasmic, Cytoplasmic vacuolisation, vacuolisation was, was evident, evident in, in four, four ., . Immunohistochemically, Immunohistochemically ,, , expression, expression of, of AGA, AGA in, in AGU, AGU patients, patients mucosal, mucosal lesions, lesions did, did not, not differ, differ from, from that, that seen, seen in, in corresponding, corresponding lesions, lesions of, of normal, normal subjects, subjects ., . Thus, Thus ,, , the, the high, high frequency, frequency of, of mucosal, mucosal overgrowth, overgrowth in, in AGU, AGU patients, patients does, does not, not appear, appear to, to be, be directly, directly associated, associated with, with lysosomal, lysosomal storage, storage or, or with, with alterations, alterations in, in the, the level, level of, of AGA, AGA expression, expression ., . We, We characterized, characterized two, two novel, novel mutations, mutations of, of the, the galactose-1-phosphate, galactose-1-phosphate uridyltransferase, uridyltransferase (, ( GALT, GALT ), ) gene, gene in, in two, two Japanese, Japanese patients, patients with, with GALT, GALT deficiency, deficiency and, and identified, identified N314D, N314D and, and R333W, R333W mutations, mutations ,, , previously, previously found, found in, in Caucasians, Caucasians ., . One, One novel, novel missense, missense mutation, mutation was, was an, an G-to-A, G-to-A transition, transition in, in exon, exon 8, 8 ,, , resulting, resulting in, in the, the substitution, substitution of, of arginine, arginine by, by histidine, histidine at, at the, the codon, codon 231, 231 (, ( R231H, R231H ), ) ., . GALT, GALT activity, activity of, of the, the R231H, R231H mutant, mutant construct, construct was, was reduced, reduced to, to 15, 15 %, % of, of normal, normal controls, controls in, in a, a COS, COS cell, cell expression, expression system, system ., . The, The other, other was, was a, a splicing, splicing mutation, mutation ,, , an, an A-to-G, A-to-G transition, transition at, at the, the 38th, 38th nucleotide, nucleotide in, in exon, exon 3, 3 (, ( 318A, 318A --, -- >, > G, G ), ) ,, , resulting, resulting in, in a, a 38-bp, 38-bp deletion, deletion in, in the, the GALT, GALT cDNA, cDNA by, by activating, activating a, a cryptic, cryptic splice, splice acceptor, acceptor site, site ., . In, In seven, seven Japanese, Japanese families, families (, ( 14, 14 alleles, alleles for, for classic, classic form, form and, and one, one allele, allele for, for Duarte, Duarte variant, variant ), ) with, with GALT, GALT deficiency, deficiency ,, , the, the R231H, R231H and, and 318A, 318A --, -- >, > G, G mutations, mutations were, were found, found only, only on, on both, both alleles, alleles of, of the, the proband, proband ., . The, The N314D, N314D and, and R333W, R333W mutations, mutations were, were found, found on, on one, one allele, allele each, each ., . The, The Q188R, Q188R was, was prevalent, prevalent in, in the, the United, United States, States but, but not, not in, in Japanese, Japanese patients, patients ., . The, The N314D, N314D mutation, mutation was, was associated, associated with, with the, the Duarte, Duarte variant, variant in, in Japanese, Japanese persons, persons ,, , as, as well, well as, as in, in the, the United, United States, States ., . We, We speculate, speculate that, that classic, classic galactosemia, galactosemia mutations, mutations appear, appear to, to differ, differ between, between Japanese, Japanese and, and Caucasian, Caucasian patients, patients ., . Our, Our limited, limited data, data set, set on, on galactosemia, galactosemia mutations, mutations in, in Japanese, Japanese suggests, suggests that, that the, the N314D, N314D GALT, GALT mutation, mutation encoding, encoding the, the Duarte, Duarte variant, variant arose, arose before, before Asian, Asian and, and Caucasian, Caucasian people, people diverged, diverged and, and that, that classic, classic galactosemia, galactosemia mutations, mutations arose, arose and/or, and/or accumulated, accumulated after, after the, the divergence, divergence of, of Asian, Asian and, and Caucasian, Caucasian populations.., populations.. Linkage, Linkage disequilibrium, disequilibrium mapping, mapping in, in isolated, isolated populations, populations provides, provides a, a powerful, powerful tool, tool for, for fine, fine structure, structure localization, localization of, of disease, disease genes, genes ., . Here, Here ,, , Luria, Luria and, and Delbrucks, Delbrucks classical, classical methods, methods for, for analysing, analysing bacterial, bacterial cultures, cultures are, are adapted, adapted to, to the, the study, study of, of human, human isolated, isolated founder, founder populations, populations in, in order, order to, to estimate, estimate (, ( i, i ), ) the, the recombination, recombination fraction, fraction between, between a, a disease, disease locus, locus and, and a, a marker, marker ;, ; (, ( ii, ii ), ) the, the expected, expected degree, degree of, of allelic, allelic homogeneity, homogeneity in, in a, a population, population ;, ; and, and (, ( iii, iii ), ) the, the mutation, mutation rate, rate of, of marker, marker loci, loci ., . Using, Using these, these methods, methods ,, , we, we report, report striking, striking linkage, linkage disequilibrium, disequilibrium for, for diastrophic, diastrophic dysplasia, dysplasia (, ( DTD, DTD ), ) in, in Finland, Finland indicating, indicating that, that the, the DTD, DTD gene, gene should, should lie, lie within, within 0, 0 ., . 06, 06 centimorgans, centimorgans (, ( or, or about, about 60, 60 kilobases, kilobases ), ) of, of the, the CSF1R, CSF1R gene, gene ., . Predictions, Predictions about, about allelic, allelic homogeneity, homogeneity in, in Finland, Finland and, and mutation, mutation rates, rates in, in simple, simple sequence, sequence repeats, repeats are, are confirmed, confirmed by, by independent, independent observations, observations ., . Familial, Familial expansile, expansile osteolysis, osteolysis (, ( FEO, FEO ,, , MIM, MIM 174810, 174810 ), ) is, is a, a rare, rare ,, , autosomal, autosomal dominant, dominant bone, bone disorder, disorder characterized, characterized by, by focal, focal areas, areas of, of increased, increased bone, bone remodelling, remodelling ., . The, The osteolytic, osteolytic lesions, lesions ,, , which, which develop, develop usually, usually in, in the, the long, long bones, bones during, during early, early adulthood, adulthood ,, , show, show increased, increased osteoblast, osteoblast and, and osteoclast, osteoclast activity, activity ., . Our, Our previous, previous linkage, linkage studies, studies mapped, mapped the, the gene, gene responsible, responsible for, for FEO, FEO to, to an, an interval, interval of, of less, less than, than 5, 5 cM, cM between, between D18S64, D18S64 and, and D18S51, D18S51 on, on chromosome, chromosome 18q21, 18q21 ., . 2-21, 2-21 2-21, 2-21 ., . 3, 3 in, in a, a large, large Northern, Northern Irish, Irish family, family ., . The, The gene, gene encoding, encoding receptor, receptor activator, activator of, of nuclear, nuclear factor-kappa, factor-kappa B, B (, ( RANK, RANK ;, ; ref, ref ., . 5, 5 ), ) ,, , TNFRSF11A, TNFRSF11A ,, , maps, maps to, to this, this region, region ., . RANK, RANK is, is essential, essential in, in osteoclast, osteoclast formation, formation ., . We, We identified, identified two, two heterozygous, heterozygous insertion, insertion mutations, mutations in, in exon, exon 1, 1 of, of TNFRSF11A, TNFRSF11A in, in affected, affected members, members of, of four, four families, families with, with FEO, FEO or, or familial, familial Paget, Paget disease, disease of, of bone, bone (, ( PDB, PDB ), ) ., . One, One was, was a, a duplication, duplication of, of 18, 18 bases, bases and, and the, the other, other a, a duplication, duplication of, of 27, 27 bases, bases ,, , both, both of, of which, which affected, affected the, the signal, signal peptide, peptide region, region of, of the, the RANK, RANK molecule, molecule ., . Expression, Expression of, of recombinant, recombinant forms, forms of, of the, the mutant, mutant RANK, RANK proteins, proteins revealed, revealed perturbations, perturbations in, in expression, expression levels, levels and, and lack, lack of, of normal, normal cleavage, cleavage of, of the, the signal, signal peptide, peptide ., . Both, Both mutations, mutations caused, caused an, an increase, increase in, in RANK-mediated, RANK-mediated nuclear, nuclear factor-kappaB, factor-kappaB (, ( NF-kappaB, NF-kappaB ), ) signalling, signalling in, in vitro, vitro ,, , consistent, consistent with, with the, the presence, presence of, of an, an activating, activating mutation.Inherited, mutation.Inherited defects, defects in, in the, the peroxisomal, peroxisomal ATP-binding, ATP-binding cassette, cassette (, ( ABC, ABC ), ) transporter, transporter adrenoleukodystrophy, adrenoleukodystrophy protein, protein (, ( ALDP, ALDP ), ) lead, lead to, to the, the lethal, lethal peroxisomal, peroxisomal disorder, disorder X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( X-ALD, X-ALD ), ) ,, , for, for which, which no, no efficient, efficient treatment, treatment has, has been, been established, established so, so far, far ., . Three, Three other, other peroxisomal, peroxisomal ABC, ABC transporters, transporters currently, currently are, are known, known adrenoleukodystrophy-related, adrenoleukodystrophy-related protein, protein (, ( ALDRP, ALDRP ), ) ,, , 70, 70 kDa, kDa peroxisomal, peroxisomal membrane, membrane protein, protein (, ( PMP70, PMP70 ), ) and, and PMP70-, PMP70- related, related protein, protein ., . By, By using, using transient, transient and, and stable, stable overexpression, overexpression of, of human, human cDNAs, cDNAs encoding, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "encoding ALDP, ALDP and, and its, its closest, closest relative, relative ALDRP, ALDRP ,, , we, we could, could restore, restore the, the impaired, impaired peroxisomal, peroxisomal beta-oxidation, beta-oxidation in, in fibroblasts, fibroblasts of, of X-ALD, X-ALD patients, patients ., . The, The pathognomonic, pathognomonic accumulation, accumulation of, of very, very long, long chain, chain fatty, fatty acids, acids could, could also, also be, be prevented, prevented by, by overexpression, overexpression of, of ALDRP, ALDRP in, in immortalized, immortalized X-ALD, X-ALD cells, cells ., . Immunofluorescence, Immunofluorescence analysis, analysis demonstrated, demonstrated that, that the, the functional, functional replacement, replacement of, of ALDP, ALDP by, by ALDRP, ALDRP was, was not, not due, due to, to stabilization, stabilization of, of the, the mutated, mutated ALDP, ALDP itself, itself ., . Moreover, Moreover ,, , we, we were, were able, able to, to restore, restore the, the peroxisomal, peroxisomal beta-oxidation, beta-oxidation defect, defect in, in the, the liver, liver of, of ALDP-deficient, ALDP-deficient mice, mice by, by stimulation, stimulation of, of ALDRP, ALDRP and, and PMP70, PMP70 gene, gene expression, expression through, through a, a dietary, dietary treatment, treatment with, with the, the peroxisome, peroxisome proliferator, proliferator fenofibrate, fenofibrate ., . These, These results, results suggest, suggest that, that a, a correction, correction of, of the, the biochemical, biochemical defect, defect in, in X-ALD, X-ALD could, could be, be possible, possible by, by drug-induced, drug-induced overexpression, overexpression or, or ectopic, ectopic expression, expression of, of ALDRP.., ALDRP.. We, We evaluated, evaluated the, the hypothesis, hypothesis that, that Huntington, Huntington disease, disease (, ( HD, HD ), ) is, is influenced, influenced by, by the, the normal, normal HD, HD allele, allele by, by comparing, comparing transmission, transmission patterns, patterns of, of genetically, genetically linked, linked markers, markers at, at the, the D4S10, D4S10 locus, locus in, in the, the normal, normal parent, parent against, against age, age at, at onset, onset in, in the, the affected, affected offspring, offspring ., . Analysis, Analysis of, of information, information from, from 21, 21 sibships, sibships in, in 14, 14 kindreds, kindreds showed, showed a, a significant, significant tendency, tendency for, for sibs, sibs who, who have, have similar, similar onset, onset ages, ages to, to share, share the, the same, same D4S10, D4S10 allele, allele from, from the, the normal, normal parent, parent ., . Affected, Affected sibs, sibs who, who inherited, inherited different, different D4S10, D4S10 alleles, alleles from, from the, the normal, normal parent, parent tended, tended to, to have, have more, more variable, variable ages, ages at, at onset, onset ., . These, These findings, findings suggest, suggest that, that the, the expression, expression of, of HD, HD is, is modulated, modulated by, by the, the normal, normal HD, HD allele, allele or, or by, by a, a closely, closely linked, linked locus.., locus.. Most, Most fragile, fragile X, X syndrome, syndrome patients, patients have, have expansion, expansion of, of a, a (, ( CGG, CGG ), ) (, ( n, n ), ) sequence, sequence with, with >, > 200, 200 repeats, repeats (, ( full, full mutation, mutation ), ) in, in the, the FMR1, FMR1 gene, gene responsible, responsible for, for this, this condition, condition ., . Hypermethylation, Hypermethylation of, of the, the expanded, expanded repeat, repeat and, and of, of the, the FMR1, FMR1 promoter, promoter is, is almost, almost always, always present, present and, and apparently, apparently suppresses, suppresses transcription, transcription ,, , resulting, resulting in, in absence, absence of, of the, the FMR1, FMR1 protein, protein ., . We, We recently, recently showed, showed that, that transcriptional, transcriptional reactivation, reactivation of, of FMR1, FMR1 full, full mutations, mutations can, can be, be achieved, achieved by, by inducing, inducing DNA, DNA demethylation, demethylation with, with 5-azadeoxycytidine, 5-azadeoxycytidine (, ( 5-azadC, 5-azadC ), ) ., . The, The level, level of, of histone, histone acetylation, acetylation is, is another, another important, important factor, factor in, in regulating, regulating gene, gene expression, expression ;, ; therefore, therefore ,, , we, we treated, treated lymphoblastoid, lymphoblastoid cell, cell lines, lines of, of non-mosaic, non-mosaic full, full mutation, mutation patients, patients with, with three, three drugs, drugs capable, capable of, of inducing, inducing histone, histone hyperacetylation, hyperacetylation ., . We, We observed, observed a, a consistent, consistent ,, , although, although modest, modest ,, , reactivation, reactivation of, of the, the FMR1, FMR1 gene, gene with, with 4-phenylbutyrate, 4-phenylbutyrate ,, , sodium, sodium butyrate, butyrate and, and trichostatin, trichostatin A, A ,, , as, as shown, shown by, by RT-PCR, RT-PCR ., . However, However ,, , we, we report, report that, that combining, combining these, these drugs, drugs with, with 5-azadC, 5-azadC results, results in, in a, a 2-, 2- to, to 5-fold, 5-fold increase, increase in, in FMR1, FMR1 mRNA, mRNA levels, levels obtained, obtained with, with 5-azadC, 5-azadC alone, alone ,, , thus, thus showing, showing a, a marked, marked synergistic, synergistic effect, effect of, of histone, histone hyperacetylation, hyperacetylation and, and DNA, DNA demethylation, demethylation in, in the, the reactivation, reactivation of, of FMR1, FMR1 full, full mutations.., mutations.. The, The AMELX, AMELX gene, gene located, located at, at Xp22, Xp22 ., . 1-p22, 1-p22 ., . 3, 3 encodes, encodes for, for the, the enamel, enamel protein, protein amelogenin, amelogenin and, and has, has been, been implicated, implicated as, as the, the gene, gene responsible, responsible for, for the, the inherited, inherited dental, dental abnormality, abnormality X-linked, X-linked amelogenesis, amelogenesis imperfecta, imperfecta (, ( XAI, XAI ), ) ., . Three, Three families, families with, with XAI, XAI have, have been, been investigated, investigated using, using polymorphic, polymorphic DNA, DNA markers, markers flanking, flanking the, the position, position of, of AMELX, AMELX ., . Using, Using two-point, two-point linkage, linkage analysis, analysis ,, , linkage, linkage was, was established, established between, between XAI, XAI and, and several, several of, of these, these markers, markers in, in two, two families, families ,, , with, with a, a combined, combined lod, lod score, score of, of 6, 6 ., . 05, 05 for, for DXS16, DXS16 at, at theta, theta =, = 0, 0 ., . 04, 04 04, 04 ., . This, This supports, supports the, the involvement, involvement of, of AMELX, AMELX ,, , located, located close, close to, to DXS16, DXS16 ,, , in, in the, the XAI, XAI disease, disease process, process (, ( AIH1, AIH1 ), ) in, in those, those families, families ., . Using, Using multipoint, multipoint linkage, linkage analysis, analysis ,, , the, the combined, combined maximum, maximum lod, lod score, score for, for these, these two, two families, families was, was 7, 7 ., . 30, 30 for, for a, a location, location of, of AIH1, AIH1 at, at 2, 2 cM, cM distal, distal to, to DXS16, DXS16 ., . The, The support, support interval, interval around, around this, this location, location extended, extended about, about 8, 8 cM, cM proximal, proximal to, to DXS92, DXS92 ,, , and, and the, the AIH1, AIH1 location, location could, could not, not be, be precisely, precisely defined, defined by, by multipoint, multipoint mapping, mapping ., . Study, Study of, of recombination, recombination events, events indicated, indicated that, that AIH1, AIH1 lies, lies in, in the, the interval, interval between, between DXS143, DXS143 and, and DXS85, DXS85 ., . There, There was, was significant, significant evidence, evidence against, against linkage, linkage to, to this, this region, region in, in the, the third, third family, family ,, , indicating, indicating locus, locus heterogeneity, heterogeneity in, in XAI, XAI ., . Further, Further analysis, analysis with, with markers, markers on, on the, the long, long arm, arm of, of the, the X, X chromosome, chromosome showed, showed evidence, evidence of, of linkage, linkage to, to DXS144E, DXS144E and, and F9, F9 with, with no, no recombination, recombination with, with either, either of, of these, these markers, markers ., . Two-point, Two-point analysis, analysis gave, gave a, a peak, peak lod, lod score, score at, at DXS144E, DXS144E with, with a, a maximum, maximum lod, lod score, score of, of 2, 2 ., . 83, 83 at, at theta, theta =, = 0, 0 ,, , with, with a, a peak, peak lod, lod score, score in, in multipoint, multipoint linkage, linkage analysis, analysis of, of 2, 2 ., . 84, 84 at, at theta, theta =, = 0, 0 ., . The, The support, support interval, interval extended, extended 9, 9 cM, cM proximal, proximal to, to DXS144E, DXS144E and, and 14, 14 cM, cM distal, distal to, to F9, F9 ., . (, ( ABSTRACT, ABSTRACT TRUNCATED, TRUNCATED AT, AT 250, 250 WORDS, WORDS ), ) .The, .The hemochromatosis, hemochromatosis gene, gene (, ( HFE, HFE ), ) maps, maps to, to 6p21, 6p21 ., . 3, 3 and, and is, is less, less than, than 1, 1 cM, cM from, from the, the HLA, HLA class, class I, I genes, genes ;, ; however, however ,, , the, the precise, precise physical, physical location, location of, of the, the gene, gene has, has remained, remained elusive, elusive and, and controversial, controversial ., . The, The unambiguous, unambiguous identification, identification of, of a, a crossover, crossover event, event within, within hemochromatosis, hemochromatosis families, families is, is very, very difficult, difficult ;, ; it, it is, is particularly, particularly hampered, hampered by, by the, the variability, variability of, of the, the phenotypic, phenotypic expression, expression as, as well, well as, as by, by the, the sex-, sex- and, and age-related, age-related penetrance, penetrance of, of the, the disease, disease ., . For, For these, these practical, practical considerations, considerations ,, , traditional, traditional linkage, linkage analysis, analysis could, could prove, prove of, of limited, limited value, value in, in further, further refining, refining the, the extrapolated, extrapolated physical, physical position, position of, of HFE, HFE ., . We, We therefore, therefore embarked, embarked upon, upon a, a linkage-disequilibrium, linkage-disequilibrium analysis, analysis of, of HFE, HFE and, and normal, normal chromosomes, chromosomes from, from the, the Brittany, Brittany population, population ., . In, In the, the present, present report, report ,, , 66, 66 hemochromatosis, hemochromatosis families, families yielding, yielding 151, 151 hemochromatosis, hemochromatosis chromosomes, chromosomes and, and 182, 182 normal, normal chromosomes, chromosomes were, were RFLP-typed, RFLP-typed with, with a, a battery, battery of, of probes, probes ,, , including, including two, two newly, newly derived, derived polymorphic, polymorphic markers, markers from, from the, the 6, 6 ., . 7, 7 and, and HLA-F, HLA-F loci, loci located, located 150, 150 and, and 250, 250 kb, kb telomeric, telomeric to, to HLA-A, HLA-A ,, , respectively, respectively ., . The, The results, results suggest, suggest a, a strong, strong peak, peak of, of existing, existing linkage, linkage disequilibrium, disequilibrium focused, focused within, within the, the i82-to-6, i82-to-6 ., . 7, 7 interval, interval (, ( approximately, approximately 250, 250 kb, kb ), ) ., . The, The zone, zone of, of linkage, linkage disequilibrium, disequilibrium is, is flanked, flanked by, by the, the i97, i97 locus, locus ,, , positioned, positioned 30, 30 kb, kb proximal, proximal to, to i82, i82 ,, , and, and the, the HLA-F, HLA-F gene, gene ,, , found, found 250, 250 kb, kb distal, distal to, to HLA-A, HLA-A ,, , markers, markers of, of which, which display, display no, no significant, significant association, association with, with HFE, HFE ., . These, These data, data support, support the, the possibility, possibility that, that HFE, HFE resides, resides within, within the, the 400-kb, 400-kb expanse, expanse of, of DNA, DNA between, between i97, i97 and, and HLA-F., HLA-F. Alternatively, Alternatively ,, , the, the very, very tight, tight association, association of, of HLA-A3, HLA-A3 and, and allele, allele 1, 1 of, of the, the 6, 6 ., . 7, 7 locus, locus ,, , both, both of, of which, which are, are comprised, comprised by, by the, the major, major ancestral, ancestral or, or founder, founder HFE, HFE haplotype, haplotype in, in Brittany, Brittany ,, , supports, supports the, the possibility, possibility that, that the, the disease, disease gene, gene may, may reside, reside immediately, immediately telomeric, telomeric to, to the, the 6, 6 ., . 7, 7 locus, locus within, within the, the linkage-disequilibrium, linkage-disequilibrium zone, zone ., . Additionally, Additionally ,, , hemochromatosis, hemochromatosis haplotypes, haplotypes possessing, possessing HLA-A11, HLA-A11 and, and the, the low-frequency, low-frequency HLA-F, HLA-F polymorphism, polymorphism (, ( allele, allele 2, 2 ), ) are, are supportive, supportive of, of a, a separate, separate founder, founder chromosome, chromosome containing, containing a, a second, second ,, , independently, independently arising, arising mutant, mutant allele, allele ., . Overall, Overall ,, , the, the establishment, establishment of, of a, a likely, likely ``, `` hemochromatosis, hemochromatosis critical, critical region, region ``, `` centromeric, centromeric boundary, boundary and, and the, the identification, identification of, of a, a linkage-disequilibrium, linkage-disequilibrium zone, zone both, both significantly, significantly contribute, contribute to, to a, a reduction, reduction in, in the, the amount, amount of, of DNA, DNA required, required to, to be, be searched, searched for, for novel, novel coding, coding sequences, sequences constituting, constituting the, the HFE, HFE defect, defect Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency ,, , the, the most, most common, common enzymopathy, enzymopathy of, of humans, humans ,, , affects, affects over, over 400, 400 million, million people, people ., . The, The geographical, geographical correlation, correlation of, of its, its distribution, distribution with, with the, the historical, historical endemicity, endemicity of, of malaria, malaria suggests, suggests that, that this, this disorder, disorder has, has risen, risen in, in frequency, frequency through, through natural, natural selection, selection by, by malaria, malaria ., . However, However ,, , attempts, attempts to, to confirm, confirm that, that G6PD, G6PD deficiency, deficiency is, is protective, protective in, in case-control, case-control studies, studies of, of malaria, malaria have, have yielded, yielded conflicting, conflicting results, results ., . Hence, Hence ,, , for, for this, this X-linked, X-linked disorder, disorder ,, , it, it is, is unclear, unclear whether, whether both, both male, male hemizygotes, hemizygotes and, and female, female heterozygotes, heterozygotes are, are protected, protected or, or ,, , as, as frequently, frequently suggested, suggested ,, , only, only females, females ., . Furthermore, Furthermore ,, , how, how much, much protection, protection may, may be, be afforded, afforded is, is unknown, unknown ., . Here, Here we, we report, report that, that ,, , in, in two, two large, large case-control, case-control studies, studies of, of over, over 2, 2 ,, , 000, 000 African, African children, children ,, , the, the common, common African, African form, form of, of G6PD, G6PD deficiency, deficiency (, ( G6PD, G6PD A-, A- ), ) is, is associated, associated with, with a, a 46-58, 46-58 %, % reduction, reduction in, in risk, risk of, of severe, severe malaria, malaria for, for both, both female, female heterozygotes, heterozygotes and, and male, male hemizygotes, hemizygotes ., . A, A mathematical, mathematical model, model incorporating, incorporating the, the measured, measured selective, selective advantage, advantage against, against malaria, malaria suggests, suggests that, that a, a counterbalancing, counterbalancing selective, selective disadvantage, disadvantage ,, , associated, associated with, with this, this enzyme, enzyme deficiency, deficiency ,, , has, has retarded, retarded its, its rise, rise in, in frequency, frequency in, in malaria-endemic, malaria-endemic regions, regions ., . Although, Although G6PD, G6PD deficiency, deficiency is, is now, now regarded, regarded as, as a, a generally, generally benign, benign disorder, disorder ,, , in, in earlier, earlier environmental, environmental conditions, conditions it, it could, could have, have been, been significantly, significantly disadvantageous.., disadvantageous.. A, A chromosome, chromosome 15, 15 anomaly, anomaly was, was observed, observed in, in 12, 12 of, of 20, 20 patients, patients ,, , 17, 17 of, of whom, whom were, were clinically, clinically suspected, suspected of, of having, having Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . The, The clinical, clinical features, features of, of eight, eight cases, cases with, with 15q11-12, 15q11-12 deletion, deletion were, were very, very similar, similar to, to those, those originally, originally described, described in, in PWS, PWS ., . On, On the, the other, other hand, hand ,, , the, the group, group of, of normal, normal karyotype, karyotype patients, patients is, is heterogeneous, heterogeneous ,, , and, and their, their features, features do, do not, not strictly, strictly correspond, correspond to, to the, the clinical, clinical definition, definition of, of PWS, PWS ., . However, However ,, , the, the hypothesis, hypothesis that, that PWS, PWS is, is associated, associated with, with deletion, deletion of, of 15q11-12, 15q11-12 can, can neither, neither explain, explain the, the apparently, apparently balanced, balanced translocations, translocations of, of chromosome, chromosome 15, 15 nor, nor account, account for, for the, the small, small supernumerary, supernumerary metacentric, metacentric chromosomes, chromosomes corresponding, corresponding to, to an, an isochromosome, isochromosome 15, 15 for, for band, band 15q11, 15q11 observed, observed in, in some, some cases.., cases.. Mutations, Mutations in, in the, the human, human phenylalanine, phenylalanine hydroxylase, hydroxylase gene, gene producing, producing phenylketonuria, phenylketonuria or, or hyperphenylalaninemia, hyperphenylalaninemia have, have now, now been, been identified, identified in, in many, many patients, patients from, from various, various ethnic, ethnic groups, groups ., . These, These mutations, mutations all, all exhibit, exhibit a, a high, high degree, degree of, of association, association with, with specific, specific restriction, restriction fragment-length, fragment-length polymorphism, polymorphism haplotypes, haplotypes at, at the, the PAH, PAH locus, locus ., . About, About 50, 50 of, of these, these mutations, mutations are, are single-base, single-base substitutions, substitutions ,, , including, including six, six nonsense, nonsense mutations, mutations and, and eight, eight splicing, splicing mutations, mutations ,, , with, with the, the remainder, remainder being, being missense, missense mutations, mutations ., . One, One splicing, splicing mutation, mutation results, results in, in a, a 3, 3 amino, amino acid, acid in-frame, in-frame insertion, insertion ., . Two, Two or, or 3, 3 large, large deletions, deletions ,, , 2, 2 single, single codon, codon deletions, deletions ,, , and, and 2, 2 single, single base, base deletions, deletions have, have been, been found, found ., . Twelve, Twelve of, of the, the missense, missense mutations, mutations apparently, apparently result, result from, from the, the methylation, methylation and, and subsequent, subsequent deamination, deamination of, of highly, highly mutagenic, mutagenic CpG, CpG dinucleotides, dinucleotides ., . Recurrent, Recurrent mutation, mutation has, has been, been observed, observed at, at several, several of, of these, these sites, sites ,, , producing, producing associations, associations with, with different, different haplotypes, haplotypes in, in different, different populations, populations ., . About, About half, half of, of all, all missense, missense mutations, mutations have, have been, been examined, examined by, by in, in vitro, vitro expression, expression analysis, analysis ,, , and, and a, a significant, significant correlation, correlation has, has been, been observed, observed between, between residual, residual PAH, PAH activity, activity and, and disease, disease phenotype, phenotype ., . Since, Since continuing, continuing advances, advances in, in molecular, molecular methodologies, methodologies have, have dramatically, dramatically accelerated, accelerated the, the rate, rate in, in which, which new, new mutations, mutations are, are being, being identified, identified and, and characterized, characterized ,, , this, this register, register of, of mutations, mutations will, will be, be updated, updated periodically.., periodically.. Mutations, Mutations at, at the, the hexosaminidase, hexosaminidase A, A (, ( HEXA, HEXA ), ) gene, gene which, which cause, cause Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) have, have elevated, elevated frequency, frequency in, in the, the Ashkenazi, Ashkenazi Jewish, Jewish and, and French-Canadian, French-Canadian populations, populations ., . We, We report, report a, a novel, novel TSD, TSD allele, allele in, in the, the French-Canadian, French-Canadian population, population associated, associated with, with the, the infantile, infantile form, form of, of the, the disease, disease ., . The, The mutation, mutation ,, , a, a G, G --, -- >, > A, A transition, transition at, at the, the +, + 1, 1 position, position of, of intron, intron 7, 7 ,, , abolishes, abolishes the, the donor, donor splice, splice site, site ., . Cultured, Cultured human, human fibroblasts, fibroblasts from, from a, a compound, compound heterozygote, heterozygote for, for this, this transition, transition (, ( and, and for, for a, a deletion, deletion mutation, mutation ), ) produce, produce no, no detectable, detectable HEXA, HEXA mRNA, mRNA ., . The, The intron, intron 7, 7 +, + 1, 1 mutation, mutation occurs, occurs in, in the, the base, base adjacent, adjacent to, to the, the site, site of, of the, the adult-onset, adult-onset TSD, TSD mutation, mutation (, ( G805A, G805A ), ) ., . In, In both, both mutations, mutations a, a restriction, restriction site, site for, for the, the endonuclease, endonuclease EcoRII, EcoRII is, is abolished, abolished ., . Unambiguous, Unambiguous diagnosis, diagnosis ,, , therefore, therefore ,, , requires, requires allele-specific, allele-specific oligonucleotide, oligonucleotide hybridization, hybridization to, to distinguish, distinguish between, between these, these two, two mutant, mutant alleles, alleles ., . The, The intron, intron 7, 7 +, + 1, 1 mutation, mutation has, has been, been detected, detected in, in three, three unrelated, unrelated families, families ., . Obligate, Obligate heterozygotes, heterozygotes for, for the, the intron, intron 7, 7 +, + 1, 1 mutation, mutation were, were born, born in, in the, the Saguenay-Lac-St-Jean, Saguenay-Lac-St-Jean region, region of, of Quebec, Quebec ., . The, The most, most recent, recent ancestors, ancestors common, common to, to obligate, obligate carriers, carriers of, of this, this mutation, mutation were, were from, from the, the Charlevoix, Charlevoix region, region of, of the, the province, province of, of Quebec, Quebec ., . This, This mutation, mutation thus, thus has, has a, a different, different geographic, geographic centre, centre of, of diffusion, diffusion and, and is, is probably, probably less, less common, common than, than the, the exon, exon 1, 1 deletion, deletion TSD, TSD mutation, mutation in, in French, French Canadians, Canadians ., . Neither, Neither mutation, mutation has, has been, been detected, detected in, in France, France ,, , the, the ancestral, ancestral homeland, homeland of, of French, French Canada.., Canada.. We, We have, have observed, observed over, over 25, 25 different, different mutations, mutations in, in the, the diastrophic, diastrophic dysplasia, dysplasia sulphate, sulphate transporter, transporter gene, gene (, ( DTDST, DTDST ), ) in, in association, association with, with the, the recessive, recessive disorders, disorders achondrogenesis, achondrogenesis 1B, 1B ,, , atelosteogenesis, atelosteogenesis 2, 2 ,, , and, and diastrophic, diastrophic dysplasia, dysplasia ., . The, The c862t, c862t (, ( R279W, R279W ), ) transition, transition is, is the, the most, most common, common mutation, mutation in, in non-Finnish, non-Finnish patients, patients ,, , but, but in, in these, these disorders, disorders it, it is, is usually, usually combined, combined with, with other, other DTDST, DTDST mutations, mutations ., . We, We had, had not, not seen, seen a, a case, case of, of homozygosity, homozygosity for, for c862t, c862t (, ( R279W, R279W ), ) until, until we, we analysed, analysed DNA, DNA from, from a, a 36, 36 year, year old, old male, male with, with tall-normal, tall-normal stature, stature (, ( 180, 180 cm, cm ), ) who, who asked, asked for, for genetic, genetic counselling, counselling for, for suspected, suspected multiple, multiple epiphyseal, epiphyseal dysplasia, dysplasia ., . He, He was, was treated, treated for, for club, club foot, foot and, and hip, hip dysplasia, dysplasia at, at birth, birth ., . Skeletal, Skeletal changes, changes consistent, consistent with, with multiple, multiple epiphyseal, epiphyseal dysplasia, dysplasia ,, , with, with the, the peculiar, peculiar finding, finding of, of a, a double, double layered, layered patella, patella ,, , were, were recognised, recognised during, during childhood, childhood ., . Cleft, Cleft palate, palate ,, , swelling, swelling of, of the, the ear, ear pinna, pinna ,, , and, and hitch, hitch hiker, hiker thumb, thumb were, were absent, absent ., . He, He was, was found, found to, to be, be homozygous, homozygous ,, , and, and both, both healthy, healthy parents, parents heterozygous, heterozygous ,, , for, for the, the R279W, R279W mutation, mutation in, in DTDST, DTDST ,, , and, and his, his fibroblasts, fibroblasts showed, showed a, a sulphate, sulphate incorporation, incorporation defect, defect typical, typical of, of DTDST, DTDST disorders, disorders ., . Counselling, Counselling was, was given, given for, for a, a recessive, recessive disorder, disorder ,, , thereby, thereby considerably, considerably reducing, reducing the, the probability, probability of, of affected, affected offspring, offspring ., . Multiple, Multiple epiphyseal, epiphyseal dysplasia, dysplasia is, is more, more frequently, frequently caused, caused by, by dominant, dominant mutations, mutations in, in the, the COMP, COMP (, ( EDM1, EDM1 ,, , McKusick, McKusick 132400, 132400 ), ) and, and COL9A2, COL9A2 genes, genes (, ( EDM2, EDM2 ,, , McKusick, McKusick 600204, 600204 ), ) ., . A, A few, few other, other patients, patients and, and families, families with, with features, features similar, similar to, to our, our proband, proband have, have been, been described, described previously, previously and, and considered, considered to, to have, have autosomal, autosomal recessive, recessive MED, MED (, ( EDM4, EDM4 ,, , McKusick, McKusick 226900, 226900 ), ) ., . This, This observation, observation confirms, confirms the, the existence, existence of, of this, this entity, entity and, and assigns, assigns it, it to, to the, the phenotypic, phenotypic spectrum, spectrum associated, associated with, with mutations, mutations at, at the, the DTDST, DTDST locus.., locus.. Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is a, a progressive, progressive neuromuscular, neuromuscular disorder, disorder which, which results, results from, from elongations, elongations of, of an, an unstable, unstable (, ( CTG, CTG ), ) n, n repeat, repeat ,, , located, located in, in the, the 3, 3 untranslated, untranslated region, region of, of the, the DM, DM gene, gene ., . A, A correlation, correlation has, has been, been demonstrated, demonstrated between, between the, the increase, increase in, in the, the repeat, repeat number, number of, of this, this sequence, sequence and, and the, the severity, severity of, of the, the disease, disease ., . However, However ,, , the, the clinical, clinical status, status of, of patients, patients can, can not, not be, be unambiguously, unambiguously ascertained, ascertained solely, solely on, on the, the basis, basis of, of the, the number, number of, of CTG, CTG repeats, repeats ., . Moreover, Moreover ,, , the, the exclusive, exclusive maternal, maternal inheritance, inheritance of, of the, the congenital, congenital form, form remains, remains unexplained, unexplained ., . Our, Our observation, observation of, of differently, differently sized, sized repeats, repeats in, in various, various DM, DM tissues, tissues from, from the, the same, same individual, individual may, may explain, explain why, why the, the size, size of, of the, the mutation, mutation observed, observed in, in lymphocytes, lymphocytes does, does not, not necessarily, necessarily correlate, correlate with, with the, the severity, severity and, and nature, nature of, of symptoms, symptoms ., . Through, Through a, a molecular, molecular and, and genetic, genetic study, study of, of 142, 142 families, families including, including 418, 418 DM, DM patients, patients ,, , we, we have, have investigated, investigated the, the dynamics, dynamics of, of the, the CTG, CTG repeat, repeat meiotic, meiotic instability, instability ., . A, A positive, positive correlation, correlation between, between the, the size, size of, of the, the repeat, repeat and, and the, the intergenerational, intergenerational enlargement, enlargement was, was observed, observed similarly, similarly through, through male, male and, and female, female meioses, meioses for, for <, < or, or =, = 0, 0 ., . 5-kb, 5-kb CTG, CTG sequences, sequences ., . Beyond, Beyond 0, 0 ., . 5, 5 kb, kb ,, , the, the intergenerational, intergenerational variation, variation was"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", was more, more important, important through, through female, female meioses, meioses ,, , whereas, whereas a, a tendency, tendency to, to compression, compression was, was observed, observed almost, almost exclusively, exclusively in, in male, male meioses, meioses ,, , for, for >, > or, or =, = 1, 1 ., . 5-kb, 5-kb fragments, fragments ., . This, This implies, implies a, a size-, size- and, and sex-dependent, sex-dependent meiotic, meiotic instability, instability ., . Moreover, Moreover ,, , segregation, segregation analysis, analysis supports, supports the, the hypothesis, hypothesis of, of a, a maternal, maternal as, as well, well as, as a, a familial, familial predisposition, predisposition for, for the, the occurrence, occurrence of, of the, the congenital, congenital form, form ., . Finally, Finally ,, , this, this analysis, analysis reveals, reveals a, a significant, significant excess, excess of, of transmitting, transmitting grandfathers, grandfathers partially, partially accounted, accounted for, for by, by increased, increased fertility, fertility in, in affected, affected males, males Although, Although pyoderma, pyoderma gangrenosum, gangrenosum (, ( PG, PG ), ) is, is often, often associated, associated with, with systemic, systemic diseases, diseases ,, , it, it has, has not, not been, been reported, reported in, in association, association with, with congenital, congenital complement, complement deficiencies, deficiencies ., . We, We describe, describe an, an aggressive, aggressive and, and ultimately, ultimately fatal, fatal case, case of, of PG, PG in, in a, a patient, patient with, with a, a congenital, congenital C7, C7 deficiency, deficiency ., . Deficiencies, Deficiencies of, of C7, C7 can, can be, be associated, associated with, with decreased, decreased neutrophil, neutrophil chemotaxis, chemotaxis ,, , phagocytosis, phagocytosis ,, , and, and opsonization, opsonization ,, , similar, similar to, to the, the immunologic, immunologic abnormalities, abnormalities described, described in, in patients, patients with, with PG, PG ., . Our, Our patients, patients decreased, decreased complement, complement level, level ,, , if, if not, not directly, directly related, related to, to the, the development, development of, of PG, PG ,, , may, may have, have contributed, contributed to, to the, the aggressive, aggressive nature, nature of, of her, her disease.., disease.. Mutations, Mutations in, in the, the STA, STA gene, gene at, at the, the Xq28, Xq28 locus, locus have, have been, been found, found in, in patients, patients with, with X-linked, X-linked Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EDMD, EDMD ), ) ., . This, This gene, gene encodes, encodes a, a hitherto, hitherto unknown, unknown protein, protein named, named emerin, emerin ., . To, To elucidate, elucidate the, the subcellular, subcellular localization, localization of, of emerin, emerin ,, , we, we raised, raised two, two antisera, antisera against, against synthetic, synthetic peptide, peptide fragments, fragments predicted, predicted from, from emerin, emerin cDNA, cDNA ., . Using, Using both, both antisera, antisera ,, , we, we found, found positive, positive nuclear, nuclear membrane, membrane staining, staining in, in skeletal, skeletal ,, , cardiac, cardiac and, and smooth, smooth muscles, muscles in, in the, the normal, normal controls, controls and, and in, in patients, patients with, with neuromuscular, neuromuscular diseases, diseases other, other than, than EDMD, EDMD ., . In, In contrast, contrast ,, , a, a deficiency, deficiency in, in immunofluorescent, immunofluorescent staining, staining of, of skeletal, skeletal and, and cardiac, cardiac muscle, muscle from, from EDMD, EDMD patients, patients was, was observed, observed ., . A, A 34, 34 kD, kD protein, protein is, is immunoreactive, immunoreactive with, with the, the antisera, antisera --, -- the, the protein, protein is, is equivalent, equivalent to, to that, that predicted, predicted for, for emerin, emerin ., . Together, Together ,, , our, our findings, findings suggest, suggest the, the specific, specific deficiency, deficiency of, of emerin, emerin in, in the, the nuclear, nuclear membrane, membrane of, of muscle, muscle cells, cells in, in patients, patients with, with EDMD.., EDMD.. A, A mutated, mutated cyclin-dependent, cyclin-dependent kinase, kinase 4, 4 (, ( CDK4, CDK4 ), ) was, was identified, identified as, as a, a tumor-specific, tumor-specific antigen, antigen recognized, recognized by, by HLA-A2, HLA-A2 ., . 1-restricted, 1-restricted autologous, autologous cytolytic, cytolytic T, T lymphocytes, lymphocytes (, ( CTLs, CTLs ), ) in, in a, a human, human melanoma, melanoma ., . The, The mutated, mutated CDK4, CDK4 allele, allele was, was present, present in, in autologous, autologous cultured, cultured melanoma, melanoma cells, cells and, and metastasis, metastasis tissue, tissue ,, , but, but not, not in, in the, the patients, patients lymphocytes, lymphocytes ., . The, The mutation, mutation ,, , an, an arginine-to-cysteine, arginine-to-cysteine exchange, exchange at, at residue, residue 24, 24 ,, , was, was part, part of, of the, the CDK4, CDK4 peptide, peptide recognized, recognized by, by CTLs, CTLs and, and prevented, prevented binding, binding of, of the, the CDK4, CDK4 inhibitor, inhibitor p16INK4a, p16INK4a ,, , but, but not, not of, of p21, p21 or, or of, of p27KIP1, p27KIP1 ., . The, The same, same mutation, mutation was, was found, found in, in one, one additional, additional melanoma, melanoma among, among 28, 28 melanomas, melanomas analyzed, analyzed ., . These, These results, results suggest, suggest that, that mutation, mutation of, of CDK4, CDK4 can, can create, create a, a tumor-specific, tumor-specific antigen, antigen and, and can, can disrupt, disrupt the, the cell-cycle, cell-cycle regulation, regulation exerted, exerted by, by the, the tumor, tumor suppressor, suppressor p16INK4a.., p16INK4a.. Familial, Familial neurohypophyseal, neurohypophyseal diabetes, diabetes insipidus, insipidus (, ( FNDI, FNDI ), ) is, is an, an inherited, inherited deficiency, deficiency of, of the, the hormone, hormone arginine, arginine vasopressin, vasopressin (, ( AVP, AVP ), ) and, and is, is transmitted, transmitted as, as an, an autosomal, autosomal dominant, dominant trait, trait ., . In, In the, the present, present study, study we, we have, have analyzed, analyzed the, the AVP-neurophysin, AVP-neurophysin II, II (, ( AVP-NPII, AVP-NPII ), ) gene, gene in, in a, a Spanish, Spanish kindred, kindred ., . Studies, Studies were, were performed, performed on, on seven, seven members, members (, ( four, four clinically, clinically affected, affected ), ) of, of the, the family, family ., . Patients, Patients were, were diagnosed, diagnosed at, at the, the Hospital, Hospital Universitario, Universitario Gregorio, Gregorio Maranon, Maranon (, ( Madrid, Madrid ,, , Spain, Spain ), ) ., . The, The entire, entire coding, coding region, region of, of the, the AVP-NPII, AVP-NPII gene, gene of, of all, all family, family members, members was, was amplified, amplified by, by PCR, PCR and, and sequenced, sequenced ., . All, All affected, affected individuals, individuals presented, presented a, a missense, missense mutation, mutation (, ( G1757, G1757 --, -- >, > A, A ), ) that, that replaces, replaces glycine, glycine at, at position, position 23, 23 with, with arginine, arginine within, within the, the NPII, NPII domain, domain ., . The, The substitution, substitution was, was confirmed, confirmed by, by restriction, restriction endonuclease, endonuclease analysis, analysis and, and was, was present, present in, in heterozygosis, heterozygosis ., . Additionally, Additionally ,, , one, one of, of the, the asymptomatic, asymptomatic relatives, relatives (, ( a, a girl, girl 8, 8 months, months old, old at, at the, the time, time of, of study, study ), ) was, was identified, identified as, as carrier, carrier of, of the, the same, same mutation, mutation and, and developed, developed the, the disease, disease 3, 3 months, months later, later ., . The, The alteration, alteration found, found in, in the, the second, second exon, exon of, of the, the gene, gene in, in this, this family, family seems, seems to, to be, be responsible, responsible for, for the, the disease, disease ,, , as, as all, all individuals, individuals harboring, harboring the, the mutation, mutation had, had been, been previously, previously diagnosed, diagnosed or, or have, have eventually, eventually developed, developed FNDI, FNDI ., . Identification, Identification of, of the, the molecular, molecular defect, defect underlying, underlying FNDI, FNDI in, in affected, affected families, families is, is a, a powerful, powerful tool, tool for, for early, early asymptomatic, asymptomatic diagnosis, diagnosis in, in infants.., infants.. The, The mAb, mAb L10, L10 was, was used, used to, to determine, determine the, the distribution, distribution and, and the, the function, function of, of sialophorin, sialophorin ,, , the, the heavily, heavily glycosylated, glycosylated surface, surface molecule, molecule that, that is, is deficient/defective, deficient/defective in, in lymphocytes, lymphocytes of, of patients, patients with, with the, the X-linked, X-linked immunodeficiency, immunodeficiency Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome ., . Dual-parameter, Dual-parameter FACS, FACS analysis, analysis indicated, indicated that, that sialophorin, sialophorin is, is expressed, expressed on, on CD4, CD4 +, + and, and CD8, CD8 +, + lymphocytes, lymphocytes ,, , on, on a, a subpopulation, subpopulation of, of peripheral, peripheral blood, blood B, B lymphocytes, lymphocytes ,, , on, on all, all thymocytes, thymocytes ,, , and, and on, on a, a subpopulation, subpopulation of, of bone, bone marrow, marrow cells, cells ., . Functional, Functional studies, studies demonstrated, demonstrated that, that L10, L10 mAb, mAb stimulates, stimulates the, the proliferation, proliferation of, of peripheral, peripheral blood, blood T, T lymphocytes, lymphocytes as, as measured, measured by, by stimulation, stimulation of, of [, [ 3H, 3H ], ] thymidine, thymidine incorporation, incorporation ., . The, The time, time course, course and, and magnitude, magnitude of, of increased, increased [, [ 3H, 3H ], ] thymidine, thymidine incorporation, incorporation by, by T, T lymphocytes, lymphocytes in, in response, response to, to L10, L10 mAb, mAb paralleled, paralleled that, that induced, induced by, by anti-CD3, anti-CD3 mAb, mAb ., . Effective, Effective stimulation, stimulation was, was dependent, dependent on, on the, the presence, presence of, of monocytes, monocytes and, and the, the Fc, Fc portion, portion of, of L10, L10 mAb, mAb ., . Stimulation, Stimulation of, of lymphocytes, lymphocytes by, by L10, L10 ,, , like, like stimulation, stimulation by, by anti-CD3, anti-CD3 mAb, mAb ,, , involves, involves increased, increased expression, expression of, of 4F2, 4F2 ,, , HLA-DR, HLA-DR ,, , and, and IL-2-R, IL-2-R ., . These, These observations, observations suggest, suggest that, that sialophorin, sialophorin functions, functions in, in T, T cell, cell activation.., activation.. Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) belongs, belongs to, to a, a group, group of, of clinically, clinically and, and genetically, genetically heterogeneous, heterogeneous neurodegenerative, neurodegenerative disorders, disorders characterized, characterized by, by progressive, progressive cerebellar, cerebellar ataxia, ataxia ., . The, The disease-causing, disease-causing mutation, mutation has, has recently, recently been, been identified, identified as, as an, an unstable, unstable and, and expanded, expanded (, ( CAG, CAG ), ) n, n trinucleotide, trinucleotide repeat, repeat in, in a, a novel, novel gene, gene of, of unknown, unknown function, function ., . In, In Caucasians, Caucasians ,, , repeat, repeat expansions, expansions in, in the, the MJD1, MJD1 gene, gene have, have also, also been, been found, found in, in patients, patients with, with the, the clinically, clinically distinct, distinct autosomal, autosomal dominant, dominant spinocerebellar, spinocerebellar ataxia, ataxia type, type 3, 3 (, ( SCA3, SCA3 ), ) ., . In, In order, order to, to gain, gain insight, insight into, into the, the biology, biology of, of the, the MJD1/SCA3, MJD1/SCA3 gene, gene we, we cloned, cloned the, the rat, rat homologue, homologue and, and studied, studied its, its expression, expression ., . The, The rat, rat and, and human, human ataxin-3, ataxin-3 genes, genes are, are highly, highly homologous, homologous with, with an, an overall, overall sequence, sequence identity, identity of, of approximately, approximately 88, 88 %, % ., . However, However ,, , the, the C-terminal, C-terminal end, end of, of the, the putative, putative protein, protein differs, differs strongly, strongly from, from the, the published, published human, human sequence, sequence ., . The, The (, ( CAG, CAG ), ) n, n block, block in, in the, the rat, rat cDNA, cDNA consists, consists of, of just, just three, three interrupted, interrupted units, units suggesting, suggesting that, that a, a long, long polyglutamine, polyglutamine stretch, stretch is, is not, not essential, essential for, for the, the normal, normal function, function of, of the, the ataxin-3, ataxin-3 protein, protein in, in rodents, rodents ., . The, The expression, expression pattern, pattern of, of the, the SCA3, SCA3 gene, gene in, in various, various rat, rat and, and human, human tissues, tissues was, was investigated, investigated by, by Northern, Northern blot, blot analyses, analyses ., . The, The mature, mature transcript, transcript is, is approximately, approximately 6, 6 kb, kb in, in length, length ., . In, In rat, rat testis, testis ,, , a, a smaller, smaller transcript, transcript of, of 1, 1 ., . 3, 3 kb, kb was, was identified, identified ., . Transcription, Transcription of, of rsca3, rsca3 was, was detected, detected in, in most, most rat, rat tissues, tissues including, including brain, brain ., . Analyzing, Analyzing the, the expression, expression level, level of, of the, the SCA3, SCA3 gene, gene in, in several, several human, human brain, brain sections, sections revealed, revealed no, no significant, significant higher, higher mRNA, mRNA level, level in, in regions, regions predominantly, predominantly affected, affected in, in MJD, MJD ., . Thus, Thus additional, additional molecules, molecules and/or, and/or regulatory, regulatory events, events are, are necessary, necessary to, to explain, explain the, the exclusive, exclusive degeneration, degeneration of, of certain, certain brain, brain areas, areas ., . Chimeric, Chimeric transcription, transcription factors, factors ,, , created, created by, by gene, gene fusions, fusions as, as the, the result, result of, of chromosomal, chromosomal translocations, translocations ,, , have, have been, been implicated, implicated in, in the, the pathogenesis, pathogenesis of, of several, several pathologically, pathologically disparate, disparate solid, solid tumors, tumors ., . The, The PAX3/FKHR, PAX3/FKHR fusion, fusion gene, gene ,, , formed, formed by, by a, a t, t (, ( 2, 2 ;, ; 13, 13 ), ) (, ( q35, q35 ;, ; q14, q14 ), ) in, in alveolar, alveolar rhabdomyosarcoma, rhabdomyosarcoma ,, , encodes, encodes a, a hybrid, hybrid protein, protein that, that contains, contains both, both PAX3, PAX3 DNA, DNA binding, binding domains, domains ,, , the, the paired, paired box, box and, and homeodomain, homeodomain ,, , linked, linked to, to the, the bisected, bisected DNA, DNA binding, binding domain, domain of, of FKHR, FKHR ,, , a, a member, member of, of the, the forkhead, forkhead family, family of, of transcription, transcription factors, factors ., . Here, Here we, we report, report that, that PAX3, PAX3 and, and PAX3/FKHR, PAX3/FKHR display, display similar, similar ,, , but, but not, not identical, identical transactivation, transactivation activities, activities when, when tested, tested with, with model, model Pax, Pax recognition, recognition sequences, sequences ., . No, No functional, functional role, role could, could be, be ascribed, ascribed solely, solely to, to the, the residual, residual FKHR, FKHR binding, binding domain, domain present, present in, in the, the fusion, fusion protein, protein ,, , but, but FKHR, FKHR was, was found, found to, to contribute, contribute a, a strong, strong carboxyl, carboxyl terminal, terminal activation, activation domain, domain replacing, replacing the, the one, one located, located in, in the, the unrearranged, unrearranged PAX3, PAX3 gene, gene ., . We, We show, show that, that the, the native, native PAX3/FKHR, PAX3/FKHR protein, protein present, present in, in tumor, tumor cells, cells with, with this, this translocation, translocation has, has transcriptional, transcriptional characteristics, characteristics similar, similar to, to the, the in, in vitro, vitro expressed, expressed protein, protein ., . The, The ability, ability of, of the, the PAX3/FKHR, PAX3/FKHR hybrid, hybrid protein, protein to, to bind, bind DNA, DNA in, in a, a sequence, sequence specific, specific manner, manner and, and to, to transactivate, transactivate the, the expression, expression of, of artificial, artificial reporter, reporter genes, genes suggests, suggests that, that its, its aberrant, aberrant expression, expression could, could subvert, subvert the, the transcriptional, transcriptional programs, programs that, that normally, normally control, control the, the growth, growth ,, , differentiation, differentiation ,, , and, and survival, survival of, of primitive, primitive myogenic, myogenic precursors, precursors in, in vivo.., vivo.. The, The group, group of, of dominant, dominant non-dystrophic, non-dystrophic myotonias, myotonias ,, , comprising, comprising disorders, disorders characterized, characterized by, by clinically, clinically similar, similar forms, forms of, of myogenic, myogenic muscle, muscle stiffness, stiffness ,, , is, is genetically, genetically inhomogeneous, inhomogeneous ., . Dominant, Dominant myotonia, myotonia congenita, congenita (, ( Thomsens, Thomsens disease, disease ), ) is, is linked, linked to, to CLCN1, CLCN1 ,, , the, the gene, gene encoding, encoding the, the major, major muscle, muscle chloride, chloride channel, channel ,, , localized, localized on, on chromosome, chromosome 7q35, 7q35 ., . In, In contrast, contrast ,, , dominant, dominant myotonias, myotonias sensitive, sensitive to, to potassium, potassium are, are caused, caused by, by point, point mutations, mutations in, in SCN4A, SCN4A on, on chromosome, chromosome 17q, 17q ,, , the, the gene, gene for, for the, the alpha, alpha subunit, subunit of, of the, the adult, adult skeletal, skeletal muscle, muscle sodium, sodium channel, channel ., . No, No linkage, linkage or, or molecular, molecular genetic, genetic data, data are, are as, as yet, yet available, available on, on myotonia, myotonia levior, levior characterized, characterized by, by milder, milder symptoms, symptoms and, and later, later onset, onset of, of myotonia, myotonia than, than in, in Thomsens, Thomsens disease, disease ,, , and, and absence, absence of, of muscle, muscle hypertrophy, hypertrophy ., . We, We report, report a, a CLCN1, CLCN1 Gln-552-Arg, Gln-552-Arg substitution, substitution for, for a, a family, family with, with dominant, dominant inheritance, inheritance previously, previously diagnosed, diagnosed to, to have, have myotonia, myotonia levior, levior ., . Thus, Thus ,, , this, this disorder, disorder appears, appears as, as a, a variant, variant of, of Thomsens, Thomsens disease, disease due, due to, to mutations, mutations leading, leading to, to low, low clinical, clinical expressivity, expressivity ., . In, In addition, addition ,, , we, we report, report a, a novel, novel Ile-290-Met, Ile-290-Met CLCN1, CLCN1 mutation, mutation for, for a, a typical, typical Thomsen, Thomsen pedigree, pedigree ., . In, In another, another family, family previously, previously diagnosed, diagnosed as, as having, having Thomsens, Thomsens disease, disease ,, , we, we unexpectedly, unexpectedly found, found a, a CLCN1, CLCN1 14, 14 bp, bp deletion, deletion known, known to, to cause, cause recessive, recessive myotonia, myotonia ,, , and, and a, a rare, rare Trp-118-Gly, Trp-118-Gly polymorphism.., polymorphism.. Classic, Classic (, ( complete, complete ), ) lecithin, lecithin cholesterol, cholesterol acyltransferase, acyltransferase (, ( LCAT, LCAT ), ) deficiency, deficiency and, and Fish-eye, Fish-eye disease, disease (, ( partial, partial LCAT, LCAT deficiency, deficiency ), ) are, are genetic, genetic syndromes, syndromes associated, associated with, with markedly, markedly decreased, decreased plasma, plasma levels, levels of, of high, high density, density lipoprotein, lipoprotein (, ( HDL, HDL ), ) cholesterol, cholesterol but, but not, not with, with an, an increased, increased risk, risk of, of atherosclerotic, atherosclerotic cardiovascular, cardiovascular disease, disease ., . We, We investigated, investigated the, the metabolism, metabolism of, of the, the HDL, HDL apolipoproteins, apolipoproteins (, ( apo, apo ), ) apoA-I, apoA-I and, and apoA-II, apoA-II in, in a, a total, total of, of five, five patients, patients with, with LCAT, LCAT deficiency, deficiency ,, , one, one with, with classic, classic LCAT, LCAT deficiency, deficiency and, and four, four with, with Fish-eye, Fish-eye disease, disease ., . Plasma, Plasma levels, levels of, of apoA-II, apoA-II were, were decreased, decreased to, to a, a proportionately, proportionately greater, greater extent, extent (, ( 23, 23 %, % of, of normal, normal ), ) than, than apoA-I, apoA-I (, ( 30, 30 %, % of, of normal, normal ), ) ., . In, In addition, addition ,, , plasma, plasma concentrations, concentrations of, of HDL, HDL particles, particles containing, containing both, both apoA-I, apoA-I and, and apoA-II, apoA-II (, ( LpA-I, LpA-I A-II, A-II ), ) were, were much, much lower, lower (, ( 18, 18 %, % of, of normal, normal ), ) than, than those, those of, of particles, particles containing, containing only, only apoA-I, apoA-I (, ( LpA-I, LpA-I ), ) (, ( 51, 51 %, % of, of normal, normal ), ) ., . The, The metabolic, metabolic basis, basis for, for the, the low, low levels, levels of, of apoA-II, apoA-II and, and LpA-I, LpA-I A-II, A-II was, was investigated, investigated in, in all, all five, five patients, patients using, using both, both exogenous, exogenous radiotracer, radiotracer and, and endogenous, endogenous stable, stable isotope, isotope labeling, labeling techniques, techniques ., . The, The mean, mean plasma, plasma residence, residence time, time of, of apoA-I, apoA-I was, was decreased, decreased at, at 2, 2 ., . 08, 08 +/-, +/- 0, 0 ., . 27, 27 d, d (, ( controls, controls 4, 4 ., . 74, 74 +/-, +/- 0, 0 ., . 65, 65 days, days ), ) ;, ; however, however ,, , the, the residence, residence time, time of, of apoA-II, apoA-II was, was even, even shorter, shorter at, at 1, 1 ., . 66, 66 +/-, +/- 0, 0 ., . 24, 24 d, d (, ( controls, controls 5, 5 ., . 25, 25 +/-, +/- 0, 0 ., . 61, 61 d, d ), ) ., . In, In addition, addition ,, , the, the catabolism, catabolism of, of apoA-I, apoA-I in, in LpA-I, LpA-I A-II, A-II was, was substantially, substantially faster, faster than, than that, that of, of apoA-I, apoA-I in, in LpA-I, LpA-I ., . In, In summary, summary ,, , genetic, genetic syndromes, syndromes of, of either, either complete, complete or, or partial, partial LCAT, LCAT deficiency, deficiency result, result in, in low, low levels, levels of, of HDL, HDL through, through preferential, preferential hypercatabolism, hypercatabolism of, of apoA-II, apoA-II and, and HDL, HDL particles, particles containing, containing apoA-II, apoA-II ., . Because, Because LpA-I, LpA-I has, has been, been proposed, proposed to, to be, be more, more protective, protective than, than LpA-I, LpA-I A-II, A-II against, against atherosclerosis, atherosclerosis ,, , this, this selective, selective effect, effect on, on the, the metabolism, metabolism of, of LpA-I, LpA-I A-II, A-II may, may provide, provide a, a potential, potential explanation, explanation why, why patients, patients with, with classic, classic LCAT, LCAT deficiency, deficiency and, and Fish-eye, Fish-eye disease, disease are, are not, not at, at increased, increased risk, risk for, for premature, premature atherosclerosis, atherosclerosis despite, despite markedly, markedly decreased, decreased levels, levels of, of HDL, HDL cholesterol, cholesterol and, and apoA-I, apoA-I Inherited, Inherited mutations, mutations of, of the, the APC, APC gene, gene predispose, predispose carriers, carriers to, to multiple, multiple adenomatous, adenomatous polyps, polyps of, of the, the colon, colon and, and rectum, rectum and, and to, to colorectal, colorectal cancer, cancer ., . Mutations, Mutations located, located at, at the, the extreme, extreme 5, 5 end, end of, of the, the APC, APC gene, gene ,, , however, however ,, , are, are associated, associated with, with a, a less, less severe, severe disease, disease known, known as, as attenuated, attenuated adenomatous, adenomatous polyposis, polyposis coli, coli (, ( AAPC, AAPC ), ) ., . Many, Many individuals, individuals with, with AAPC, AAPC develop, develop relatively, relatively few, few colorectal, colorectal polyps, polyps but, but are, are still, still at, at high, high risk, risk for, for colorectal, colorectal cancer, cancer ., . We, We report, report here, here the, the identification, identification of, of a, a 5, 5 APC, APC germline, germline mutation, mutation in, in five, five separately, separately ascertained, ascertained AAPC, AAPC families, families from, from Newfoundland, Newfoundland ,, , Canada, Canada ., . This, This disease-causing, disease-causing mutation, mutation is, is a, a single, single basepair, basepair change, change (, ( G, G to, to A, A ), ) in, in the, the splice-acceptor, splice-acceptor region, region of, of APC, APC intron, intron 3, 3 that, that creates, creates a, a mutant, mutant RNA, RNA without, without exon, exon 4, 4 of, of APC, APC ., . The, The observation, observation of, of the, the same, same APC, APC mutation, mutation in, in five, five families, families from, from the, the same, same geographic, geographic area, area demonstrates, demonstrates a, a founder, founder effect, effect ., . Furthermore, Furthermore ,, , the, the identification, identification of, of this, this germline, germline mutation, mutation strengthens, strengthens the, the correlation, correlation between, between the, the 5, 5 location, location of, of an, an APC, APC disease-causing, disease-causing mutation, mutation and, and the, the attenuated, attenuated polyposis, polyposis phenotype.., phenotype.. Aspartylglucosaminuria, Aspartylglucosaminuria (, ( AGU, AGU ), ) is, is caused, caused by, by deficient, deficient activity, activity of, of the, the enzyme, enzyme aspartylglucosaminidase, aspartylglucosaminidase (, ( AGA, AGA ), ) ., . The, The structural, structural gene, gene for, for AGA, AGA has, has been, been assigned, assigned to, to the, the region, region 4q21-qter, 4q21-qter of, of chromosome, chromosome 4, 4 ., . We, We have, have studied, studied the, the map, map position, position of, of the, the AGU, AGU locus, locus in, in relation, relation to, to other, other marker, marker loci, loci on, on the, the long, long arm, arm of, of chromosome, chromosome 4, 4 using, using linkage, linkage analyses, analyses ., . Restriction, Restriction fragment, fragment length, length polymorphism, polymorphism alleles, alleles for, for the, the ADH2, ADH2 ,, , ADH3, ADH3 ,, , EGF, EGF ,, , FG, FG alpha, alpha and, and FG, FG beta, beta loci, loci and, and blood, blood group, group antigens, antigens for, for the, the MNS, MNS locus, locus were, were determined, determined in, in a, a panel, panel of, of 12, 12 Finnish, Finnish AGU, AGU families, families ., . The, The heterozygous, heterozygous family, family members, members were, were identified, identified by, by reduced, reduced activity, activity of, of AGA, AGA in, in lymphocytes, lymphocytes ., . Linkage, Linkage studies, studies were, were performed, performed using, using both, both pairwise, pairwise and, and multipoint, multipoint analyses, analyses ., . Loose, Loose linkage, linkage of, of the, the AGU, AGU locus, locus to, to the, the FG, FG and, and MNS, MNS loci, loci was, was observed, observed (, ( z, z =, = 1, 1 ., . 16, 16 ,, , z, z =, = 1, 1 ., . 39, 39 ,, , respectively, respectively ), ) ., . Multipoint, Multipoint analysis, analysis to, to the, the fixed, fixed map, map [, [ ADH-, ADH- (, ( 0, 0 ., . 03, 03 ), ) -EGF-, -EGF- (, ( 0, 0 ., . 35, 35 ), ) -FG-, -FG- (, ( 0, 0 ., . 11, 11 ), ) -MNS, -MNS ], ] suggests, suggests that, that the, the location, location of, of the, the AGU, AGU locus, locus is, is 0, 0 ., . 05-0, 05-0 ., . 30, 30 recombination, recombination units, units distal, distal to, to MNS, MNS (, ( z, z =, = 3, 3 ., . 03, 03 ), ) ., . The, The order, order cen-ADH-EGF-FG-MNS-AGU, cen-ADH-EGF-FG-MNS-AGU is, is 35, 35 times, times more, more likely, likely than, than the, the next, next best, best order, order cen-ADH-EGF-AGU-FG-MNS, cen-ADH-EGF-AGU-FG-MNS ., . We, We have, have performed, performed linkage, linkage analysis, analysis with, with the, the DNA, DNA markers, markers DXS52, DXS52 and, and the, the clotting, clotting factor, factor VIII, VIII gene, gene (, ( F8C, F8C ), ) ,, , in, in several, several large, large families, families with, with X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) ., . The, The tight, tight linkage, linkage to, to DXS52, DXS52 could, could be, be extended, extended giving, giving a, a maximal, maximal LOD, LOD score, score of, of 22, 22 ., . 5, 5 at, at 1, 1 cM, cM ., . F8C, F8C was, was also, also tightly, tightly linked, linked to, to ALD, ALD with, with a, a maximal, maximal LOD, LOD score, score of, of 7, 7 ., . 8, 8 without, without recombination, recombination ., . Multipoint, Multipoint linkage, linkage analysis, analysis with, with the, the markers, markers DXS304, DXS304 ,, , DXS52, DXS52 ,, , and, and F8C, F8C indicated, indicated that, that both, both the, the gene, gene for, for ALD, ALD and, and for, for F8C, F8C are, are distal, distal to, to DXS52, DXS52 ., . In, In four, four patients, patients with, with ALD, ALD ,, , no, no major, major structural, structural rearrangement, rearrangement in, in the, the Xqter, Xqter region, region was, was observed, observed ;, ; in, in particular, particular ,, , there, there were, were no, no abnormalities, abnormalities in, in the, the vision, vision blindness, blindness genes, genes ., . DNA, DNA analysis, analysis appeared, appeared to, to be, be of, of use, use in, in determination, determination of, of the, the carrier, carrier status, status of, of females, females at, at risk, risk ,, , for, for the, the determination, determination of, of the, the origin, origin of, of the, the mutation, mutation in, in a, a particular, particular family, family ,, , and, and for, for prenatal, prenatal diagnosis.Genetic, diagnosis.Genetic hemochromatosis, hemochromatosis (, ( GH, GH ), ) is, is believed, believed to, to be, be a, a disease, disease restricted, restricted to, to those, those of, of European, European ancestry, ancestry ., . In, In northwestern, northwestern Europe, Europe ,, , >, > 80, 80 %, % of, of GH, GH patients, patients are, are homozygous, homozygous for, for one, one mutation, mutation ,, , the, the substitution, substitution of, of tyrosine, tyrosine for, for cysteine, cysteine at, at position, position 282, 282 (, ( C282Y, C282Y ), ) in, in the, the unprocessed"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", unprocessed protein, protein ., . In, In a, a proportion, proportion of, of GH, GH patients, patients ,, , two, two mutations, mutations are, are present, present ,, , C282Y, C282Y and, and H63D, H63D ., . The, The clinical, clinical significance, significance of, of this, this second, second mutation, mutation is, is such, such that, that it, it appears, appears to, to predispose, predispose 1, 1 %, % -2, -2 %, % of, of compound, compound heterozygotes, heterozygotes to, to expression, expression of, of the, the disease, disease ., . The, The distribution, distribution of, of the, the two, two mutations, mutations differ, differ ,, , C282Y, C282Y being, being limited, limited to, to those, those of, of northwestern, northwestern European, European ancestry, ancestry and, and H63D, H63D being, being found, found at, at allele, allele frequencies, frequencies >, > 5, 5 %, % ,, , in, in Europe, Europe ,, , in, in countries, countries bordering, bordering the, the Mediterranean, Mediterranean ,, , in, in the, the Middle, Middle East, East ,, , and, and in, in the, the Indian, Indian subcontinent, subcontinent ., . The, The C282Y, C282Y mutation, mutation occurs, occurs on, on a, a haplotype, haplotype that, that extends, extends <, < /=, /= 6, 6 Mb, Mb ,, , suggesting, suggesting that, that this, this mutation, mutation has, has arisen, arisen during, during the, the past, past 2, 2 ,, , 000, 000 years, years ., . The, The H63D, H63D mutation, mutation is, is older, older and, and does, does not, not occur, occur on, on such, such a, a large, large extended, extended haplotype, haplotype ,, , the, the haplotype, haplotype in, in this, this case, case extending, extending <, < /=, /= 700, 700 kb, kb ., . Here, Here we, we report, report the, the finding, finding of, of the, the H63D, H63D and, and C282Y, C282Y mutations, mutations on, on new, new haplotypes, haplotypes ., . In, In Sri, Sri Lanka, Lanka we, we have, have found, found H63D, H63D on, on three, three new, new haplotypes, haplotypes and, and have, have found, found C282Y, C282Y on, on one, one new, new haplotype, haplotype ,, , demonstrating, demonstrating that, that these, these mutations, mutations have, have arisen, arisen independently, independently on, on this, this island, island ., . These, These results, results suggest, suggest that, that the, the HFE, HFE gene, gene has, has been, been the, the subject, subject of, of selection, selection pressure, pressure ., . These, These selection, selection pressures, pressures could, could be, be due, due to, to infectious, infectious diseases, diseases ,, , environmental, environmental conditions, conditions ,, , or, or other, other genetic, genetic disorders, disorders such, such as, as anemia.Many, anemia.Many mutations, mutations leading, leading to, to human, human disease, disease are, are the, the result, result of, of single, single DNA, DNA base, base pair, pair changes, changes that, that can, can not, not be, be identified, identified by, by Southern, Southern analysis, analysis ., . This, This has, has prompted, prompted the, the development, development of, of alternative, alternative assays, assays for, for point, point mutation, mutation detection, detection ., . The, The recently, recently described, described ribonuclease, ribonuclease A, A cleavage, cleavage procedure, procedure ,, , with, with a, a polyuridylic, polyuridylic acid-paper, acid-paper affinity, affinity chromatography, chromatography step, step ,, , has, has been, been used, used to, to identify, identify the, the mutational, mutational lesions, lesions in, in the, the hypoxanthine, hypoxanthine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ), ) messenger, messenger RNAs, RNAs of, of patients, patients with, with Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . Distinctive, Distinctive ribonuclease, ribonuclease A, A cleavage, cleavage patterns, patterns were, were identified, identified in, in messenger, messenger RNA, RNA from, from 5, 5 of, of 14, 14 Lesch-Nyhan, Lesch-Nyhan patients, patients who, who were, were chosen, chosen because, because no, no HPRT, HPRT Southern, Southern or, or Northern, Northern blotting, blotting pattern, pattern changes, changes had, had been, been found, found ., . This, This approach, approach now, now allows, allows HPRT, HPRT mutation, mutation detection, detection in, in 50, 50 percent, percent of, of the, the cases, cases of, of Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . The, The polyuridylic, polyuridylic acid-paper, acid-paper affinity, affinity procedure, procedure provides, provides a, a general, general method, method for, for analysis, analysis of, of low, low abundance, abundance messenger, messenger RNAs.., RNAs.. Familial, Familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) is, is a, a recessively, recessively inherited, inherited disorder, disorder that, that is, is common, common in, in patients, patients of, of Armenian, Armenian ancestry, ancestry ., . To, To date, date ,, , its, its diagnosis, diagnosis ,, , which, which can, can be, be made, made only, only retrospectively, retrospectively ,, , is, is one, one of, of exclusion, exclusion ,, , based, based entirely, entirely on, on nonspecific, nonspecific clinical, clinical signs, signs that, that result, result from, from serosal, serosal inflammation, inflammation and, and that, that may, may lead, lead to, to unnecessary, unnecessary surgery, surgery ., . Renal, Renal amyloidosis, amyloidosis ,, , prevented, prevented by, by colchicine, colchicine ,, , is, is the, the most, most severe, severe complication, complication of, of FMF, FMF ,, , a, a disorder, disorder associated, associated with, with mutations, mutations in, in the, the MEFV, MEFV gene, gene ., . To, To evaluate, evaluate the, the diagnostic, diagnostic and, and prognostic, prognostic value, value of, of MEFV-gene, MEFV-gene analysis, analysis ,, , we, we investigated, investigated 90, 90 Armenian, Armenian FMF, FMF patients, patients from, from 77, 77 unrelated, unrelated families, families that, that were, were not, not selected, selected through, through genetic-linkage, genetic-linkage analysis, analysis ., . Eight, Eight mutations, mutations ,, , one, one of, of which, which (, ( R408Q, R408Q ), ) is, is new, new ,, , were, were found, found to, to account, account for, for 93, 93 %, % of, of the, the 163, 163 independent, independent FMF, FMF alleles, alleles ,, , with, with both, both FMF, FMF alleles, alleles identified, identified in, in 89, 89 %, % of, of the, the patients, patients ., . In, In several, several instances, instances ,, , family, family studies, studies provided, provided molecular, molecular evidence, evidence for, for pseudodominant, pseudodominant transmission, transmission and, and incomplete, incomplete penetrance, penetrance of, of the, the disease, disease phenotype, phenotype ., . The, The M694V, M694V homozygous, homozygous genotype, genotype was, was found, found to, to be, be associated, associated with, with a, a higher, higher prevalence, prevalence of, of renal, renal amyloidosis, amyloidosis and, and arthritis, arthritis ,, , compared, compared with, with other, other genotypes, genotypes (, ( P, P =, = ., . 0002, 0002 and, and P, P =, = ., . 006, 006 ,, , respectively, respectively ), ) ., . The, The demonstration, demonstration of, of both, both the, the diagnostic, diagnostic and, and prognostic, prognostic value, value of, of MEFV, MEFV analysis, analysis and, and particular, particular modes, modes of, of inheritance, inheritance should, should lead, lead to, to new, new ways, ways for, for management, management of, of FMF-including, FMF-including genetic, genetic counseling, counseling and, and therapeutic, therapeutic decisions, decisions in, in affected, affected families.The, families.The Huntington, Huntington disease, disease (, ( HD, HD ), ) phenotype, phenotype is, is associated, associated with, with expansion, expansion of, of a, a trinucleotide, trinucleotide repeat, repeat in, in the, the IT15, IT15 gene, gene ,, , which, which is, is predicted, predicted to, to encode, encode a, a 348-kDa, 348-kDa protein, protein named, named huntington, huntington ., . We, We used, used polyclonal, polyclonal and, and monoclonal, monoclonal anti-fusion, anti-fusion protein, protein antibodies, antibodies to, to identify, identify native, native huntingtin, huntingtin in, in rat, rat ,, , monkey, monkey ,, , and, and human, human ., . Western, Western blots, blots revealed, revealed a, a protein, protein with, with the, the expected, expected molecular, molecular weight, weight which, which is, is present, present in, in the, the soluble, soluble fraction, fraction of, of rat, rat and, and monkey, monkey brain, brain tissues, tissues and, and lymphoblastoid, lymphoblastoid cells, cells from, from control, control cases, cases ., . In, In lymphoblastoid, lymphoblastoid cell, cell lines, lines from, from juvenile-onset, juvenile-onset heterozygote, heterozygote HD, HD cases, cases ,, , both, both normal, normal and, and mutant, mutant huntingtin, huntingtin are, are expressed, expressed ,, , and, and increasing, increasing repeat, repeat expansion, expansion leads, leads to, to lower, lower levels, levels of, of the, the mutant, mutant protein, protein ., . Immunocytochemistry, Immunocytochemistry indicates, indicates that, that huntingtin, huntingtin is, is located, located in, in neurons, neurons throughout, throughout the, the brain, brain ,, , with, with the, the highest, highest levels, levels evident, evident in, in larger, larger neurons, neurons ., . In, In the, the human, human striatum, striatum ,, , huntingtin, huntingtin is, is enriched, enriched in, in a, a patch-like, patch-like distribution, distribution ,, , potentially, potentially corresponding, corresponding to, to the, the first, first areas, areas affected, affected in, in HD, HD ., . Subcellular, Subcellular localization, localization of, of huntingtin, huntingtin is, is consistent, consistent with, with a, a cytosolic, cytosolic protein, protein primarily, primarily found, found in, in somatodendritic, somatodendritic regions, regions ., . Huntingtin, Huntingtin appears, appears to, to particularly, particularly associate, associate with, with microtubules, microtubules ,, , although, although some, some is, is also, also associated, associated with, with synaptic, synaptic vesicles, vesicles ., . On, On the, the basis, basis of, of the, the localization, localization of, of huntingtin, huntingtin in, in association, association with, with microtubules, microtubules ,, , we, we speculate, speculate that, that the, the mutation, mutation impairs, impairs the, the cytoskeletal, cytoskeletal anchoring, anchoring or, or transport, transport of, of mitochondria, mitochondria ,, , vesicles, vesicles ,, , or, or other, other organelles, organelles or, or molecules.., molecules.. Recently, Recently we, we have, have isolated, isolated the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene which, which causes, causes familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) ,, , and, and its, its germ-line, germ-line mutations, mutations in, in a, a substantial, substantial number, number of, of FAP, FAP patients, patients have, have been, been identified, identified ., . On, On the, the basis, basis of, of this, this information, information ,, , we, we compared, compared the, the location, location of, of germ-line, germ-line mutations, mutations in, in the, the APC, APC gene, gene in, in 22, 22 unrelated, unrelated patients, patients (, ( 12, 12 of, of whom, whom have, have been, been reported, reported previously, previously ), ) with, with the, the number, number of, of colorectal, colorectal polyps, polyps developed, developed in, in FAP, FAP patients, patients ;, ; 17, 17 were, were sparse, sparse types, types and, and five, five were, were profuse, profuse types, types ., . All, All but, but one, one of, of the, the mutations, mutations were, were considered, considered to, to cause, cause truncation, truncation of, of the, the gene, gene product, product by, by frame-shift, frame-shift due, due to, to deletion, deletion (, ( 14, 14 cases, cases ), ) or, or nonsense, nonsense mutation, mutation (, ( seven, seven cases, cases ), ) ., . The, The location, location of, of the, the germ-line, germ-line mutations, mutations seems, seems to, to correlate, correlate with, with the, the two, two clinical, clinical types, types ;, ; germ-line, germ-line mutations, mutations in, in five, five FAP, FAP patients, patients with, with profuse, profuse polyps, polyps were, were observed, observed between, between codon, codon 1250, 1250 and, and codon, codon 1464, 1464 ,, , whereas, whereas mutations, mutations in, in 17, 17 FAP, FAP patients, patients with, with fewer, fewer polyps, polyps were, were observed, observed in, in the, the other, other regions, regions of, of the, the APC, APC gene, gene ., . The, The result, result suggests, suggests that, that the, the number, number of, of colorectal, colorectal polyps, polyps in, in FAP, FAP patients, patients may, may be, be associated, associated with, with a, a difference, difference in, in the, the stability, stability or, or biological, biological function, function of, of the, the truncated, truncated APC, APC protein.., protein.. The, The dark-adapted, dark-adapted electroretinogram, electroretinogram (, ( ERG, ERG ), ) of, of patients, patients with, with Duchenne, Duchenne and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( DMD/BMD, DMD/BMD ), ) shows, shows a, a marked, marked reduction, reduction in, in b-wave, b-wave amplitude, amplitude ., . Genotype-phenotype, Genotype-phenotype studies, studies of, of mouse, mouse models, models for, for DMD, DMD show, show position-specific, position-specific effects, effects of, of the, the mutations, mutations upon, upon the, the phenotype, phenotype mice, mice with, with 5, 5 defects, defects of, of dystrophin, dystrophin have, have normal, normal ERGs, ERGs ,, , those, those with, with defects, defects in, in the, the central, central region, region have, have a, a normal, normal b-wave, b-wave amplitude, amplitude associated, associated with, with prolonged, prolonged implicit, implicit times, times for, for both, both the, the b-wave, b-wave and, and oscillatory, oscillatory potentials, potentials ,, , and, and mice, mice with, with 3, 3 defects, defects have, have a, a phenotype, phenotype similar, similar to, to that, that seen, seen in, in DMD/BMD, DMD/BMD patients, patients ., . The, The mouse, mouse studies, studies suggest, suggest a, a key, key role, role for, for the, the carboxyl, carboxyl terminal, terminal dystrophin, dystrophin isoform, isoform ,, , Dp260, Dp260 ,, , in, in retinal, retinal electrophysiology, electrophysiology ., . We, We have, have undertaken, undertaken a, a systematic, systematic evaluation, evaluation of, of DMD/BMD, DMD/BMD patients, patients through, through clinical, clinical examination, examination and, and review, review of, of the, the literature, literature in, in order, order to, to determine, determine whether, whether the, the position-specific, position-specific effects, effects of, of mutations, mutations noted, noted in, in the, the mouse, mouse are, are present, present in, in man, man ., . We, We have, have found, found that, that ,, , in, in man, man ,, , a, a wider, wider variation, variation of, of DMD, DMD defects, defects correlate, correlate with, with reductions, reductions in, in the, the b-wave, b-wave amplitude, amplitude ., . Individuals, Individuals with, with normal, normal ERGs, ERGs have, have mutations, mutations predominantly, predominantly located, located 5, 5 of, of the, the transcript, transcript initiation, initiation site, site of, of Dp260, Dp260 ., . Our, Our results, results suggest, suggest that, that the, the most, most important, important determinant, determinant in, in the, the ERG, ERG b-wave, b-wave phenotype, phenotype is, is the, the mutation, mutation position, position ,, , rather, rather than, than muscle, muscle disease, disease severity, severity ., . Forty-six, Forty-six per, per cent, cent of, of patients, patients with, with mutations, mutations 5, 5 of, of the, the Dp260, Dp260 transcript, transcript start, start site, site have, have abnormal, abnormal ERGs, ERGs ,, , as, as opposed, opposed to, to 94, 94 %, % with, with more, more distal, distal mutations, mutations ., . The, The human, human genotype-phenotype, genotype-phenotype correlations, correlations are, are consistent, consistent with, with a, a role, role for, for Dp260, Dp260 in, in normal, normal retinal, retinal electrophysiology, electrophysiology and, and may, may also, also reflect, reflect the, the expression, expression of, of other, other C-terminal, C-terminal dystrophin, dystrophin isoforms, isoforms and, and their, their contributions, contributions to, to retinal, retinal signal, signal transmission.., transmission.. We, We report, report here, here the, the molecular, molecular characterization, characterization of, of two, two galactosemia, galactosemia mutations, mutations ,, , L74P, L74P and, and F171S, F171S ,, , and, and one, one polymorphism, polymorphism ,, , S135L, S135L ,, , in, in human, human galactose-1-phosphate, galactose-1-phosphate uridyltransferase, uridyltransferase (, ( GALT, GALT ), ) ., . Both, Both galactosemia, galactosemia mutations, mutations result, result in, in reduced, reduced enzymatic, enzymatic activity, activity when, when reconstructed, reconstructed in, in the, the cDNA, cDNA and, and overexpressed, overexpressed ., . The, The polymorphism, polymorphism ,, , in, in contrast, contrast ,, , has, has near, near normal, normal activity, activity ., . Both, Both mutations, mutations affect, affect evolutionarily, evolutionarily conserved, conserved residues, residues ,, , suggesting, suggesting that, that they, they are, are functionally, functionally important, important ,, , while, while the, the polymorphism, polymorphism occurs, occurs in, in a, a nonconserved, nonconserved domain, domain which, which is, is presumably, presumably not, not critical, critical for, for enzymatic, enzymatic function, function ., . The, The F171S, F171S mutation, mutation is, is close, close to, to the, the putative, putative active-site, active-site nucleophile, nucleophile ., . Our, Our data, data further, further support, support the, the notion, notion of, of molecular, molecular heterogeneity, heterogeneity of, of galactosemia, galactosemia and, and suggest, suggest that, that galactosemia, galactosemia mutations, mutations and, and GALT, GALT polymorphisms, polymorphisms may, may be, be useful, useful tools, tools in, in highlighting, highlighting different, different functional, functional domains, domains in, in human, human GALT.., GALT.. Type, Type 1, 1 Gaucher, Gaucher disease, disease (, ( GD, GD ), ) ,, , a, a non-neuronopathic, non-neuronopathic lysosomal, lysosomal storage, storage disorder, disorder ,, , results, results from, from the, the deficient, deficient activity, activity of, of acid, acid beta-glucosidase, beta-glucosidase (, ( GBA, GBA ), ) ., . Type, Type 1, 1 disease, disease is, is panethnic, panethnic but, but is, is more, more prevalent, prevalent in, in individuals, individuals of, of Ashkenazi, Ashkenazi Jewish, Jewish (, ( AJ, AJ ), ) descent, descent ., . Of, Of the, the causative, causative GBA, GBA mutations, mutations ,, , N370S, N370S is, is particularly, particularly frequent, frequent in, in the, the AJ, AJ population, population ,, , (, ( q, q approximately, approximately ., . 03, 03 ), ) ,, , whereas, whereas the, the 84GG, 84GG insertion, insertion (, ( q, q approximately, approximately ., . 003, 003 ), ) occurs, occurs exclusively, exclusively in, in the, the Ashkenazim, Ashkenazim ., . To, To investigate, investigate the, the genetic, genetic history, history of, of these, these mutations, mutations in, in the, the AJ, AJ population, population ,, , short, short tandem, tandem repeat, repeat (, ( STR, STR ), ) markers, markers were, were used, used to, to map, map a, a 9, 9 ., . 3-cM, 3-cM region, region containing, containing the, the GBA, GBA locus, locus and, and to, to genotype, genotype 261, 261 AJ, AJ N370S, N370S chromosomes, chromosomes ,, , 60, 60 European, European non-Jewish, non-Jewish N370S, N370S chromosomes, chromosomes ,, , and, and 62, 62 AJ, AJ 84GG, 84GG chromosomes, chromosomes ., . A, A highly, highly conserved, conserved haplotype, haplotype at, at four, four markers, markers flanking, flanking GBA, GBA (, ( PKLR, PKLR ,, , D1S1595, D1S1595 ,, , D1S2721, D1S2721 ,, , and, and D1S2777, D1S2777 ), ) was, was observed, observed on, on both, both the, the AJ, AJ chromosomes, chromosomes and, and the, the non-Jewish, non-Jewish N370S, N370S chromosomes, chromosomes ,, , suggesting, suggesting the, the occurrence, occurrence of, of a, a founder, founder common, common to, to both, both populations, populations ., . Of, Of note, note ,, , the, the presence, presence of, of different, different divergent, divergent haplotypes, haplotypes suggested, suggested the, the occurrence, occurrence of, of de, de novo, novo ,, , recurrent, recurrent N370S, N370S mutations, mutations ., . In, In contrast, contrast ,, , a, a different, different conserved, conserved haplotype, haplotype at, at these, these markers, markers was, was identified, identified on, on the, the 84GG, 84GG chromosomes, chromosomes ,, , which, which was, was unique, unique to, to the, the AJ, AJ population, population ., . On, On the, the basis, basis of, of the, the linkage, linkage disequilibrium, disequilibrium (, ( LD, LD ), ) delta, delta values, values ,, , the, the non-Jewish, non-Jewish European, European N370S, N370S chromosomes, chromosomes had, had greater, greater haplotype, haplotype diversity, diversity and, and less, less LD, LD at, at the, the markers, markers flanking, flanking the, the conserved, conserved haplotype, haplotype than, than did, did the, the AJ, AJ N370S, N370S chromosomes, chromosomes ., . This, This finding, finding is, is consistent, consistent with, with the, the presence, presence of, of the, the N370S, N370S mutation, mutation in, in the, the non-Jewish, non-Jewish European, European population, population prior, prior to, to the, the founding, founding of, of the, the AJ, AJ population, population ., . Coalescence, Coalescence analyses, analyses for, for the, the N370S, N370S and, and 84GG, 84GG mutations, mutations estimated, estimated similar, similar coalescence, coalescence times, times ,, , of, of 48, 48 and, and 55.5, 55.5 generations, generations ago, ago ,, , respectively, respectively ., . The, The results, results of, of these, these studies, studies are, are consistent, consistent with, with a, a significant, significant bottleneck, bottleneck occurring, occurring in, in the, the AJ, AJ population, population during, during the, the first, first millennium, millennium ,, , when, when the, the population, population became, became established, established in, in Europe, Europe ., . A, A survey, survey instrument, instrument is, is used, used to, to assess, assess temperature, temperature regulation, regulation characteristics, characteristics in, in children, children with, with Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) compared, compared to, to 3, 3 control, control groups, groups sibs, sibs of, of PWS, PWS patients, patients (, ( SIB, SIB ), ) ,, , neurodevelopmentally, neurodevelopmentally handicapped, handicapped children, children (, ( ND, ND ), ) ,, , and, and age, age and, and gender, gender matched, matched well, well children, children (, ( WC, WC ), ) ., . Significant, Significant differences, differences were, were found, found between, between PWS, PWS patients, patients ,, , SIB, SIB controls, controls ,, , and, and WC, WC controls, controls in, in the, the prevalence, prevalence of, of febrile, febrile convulsions, convulsions ,, , fever-associated, fever-associated symptoms, symptoms ,, , and, and temperature, temperature less, less than, than 94, 94 degrees, degrees F., F. No, No differences, differences were, were noted, noted in, in any, any variable, variable between, between the, the PWS, PWS patients, patients and, and the, the ND, ND controls, controls ,, , suggesting, suggesting that, that these, these abnormalities, abnormalities are, are not, not unique, unique to, to PWS, PWS ,, , but, but can, can occur, occur in, in any, any neurodevelopmentally, neurodevelopmentally handicapped, handicapped individual, individual ,, , further, further suggesting, suggesting these, these do, do not, not necessarily, necessarily reflect, reflect syndrome-specific, syndrome-specific hypothalamic, hypothalamic abnormalities.., abnormalities.. The, The plasma, plasma lipoprotein, lipoprotein profiles, profiles and, and high, high density, density lipoproteins, lipoproteins (, ( HDL, HDL ), ) were, were characterized, characterized in, in patients, patients with, with the, the genetic, genetic disease, disease cerebrotendinous, cerebrotendinous xanthomatosis, xanthomatosis (, ( CTX, CTX ), ) ., . Abnormalities, Abnormalities in, in the, the HDL, HDL may, may contribute, contribute to, to their, their increased, increased atherogenesis, atherogenesis and, and excessive, excessive deposits, deposits of, of tissue, tissue sterols, sterols in, in the, the presence, presence of, of low, low or, or low-normal, low-normal concentrations, concentrations of, of plasma, plasma cholesterol, cholesterol (, ( 165, 165 +/-, +/- 25, 25 mg/dl, mg/dl ), ) and, and low, low density, density lipoproteins, lipoproteins (, ( LDL, LDL ), ) ., . The, The mean, mean HDL-cholesterol, HDL-cholesterol concentration, concentration in, in the, the CTX, CTX plasmas, plasmas was, was 14, 14 ., . 5, 5 +/-, +/- 3, 3 ., . 2, 2 mg/dl, mg/dl ,, , about, about one-third, one-third the, the normal, normal value, value ., . The, The low, low HDL-cholesterol, HDL-cholesterol reflects, reflects a, a low, low concentration, concentration and, and an, an abnormal, abnormal lipid, lipid composition, composition of, of the, the plasma, plasma HDL, HDL ., . Relative, Relative to, to normal, normal HDL, HDL ,, , the, the cholesteryl, cholesteryl esters, esters are, are low, low ,, , free, free cholesterol, cholesterol and, and phospholipids, phospholipids essentially, essentially normal, normal ,, , and, and triglycerides, triglycerides increased, increased ., . The, The ratio, ratio of, of apoprotein, apoprotein (, ( apo, apo ), ) to, to total, total cholesterol, cholesterol in, in the, the HDL, HDL of, of CTX, CTX was, was two, two to, to three, three times, times greater, greater than, than normal, normal ., . In, In the, the CTX, CTX HDL, HDL ,, , the, the ratio, ratio of, of apoAI, apoAI to, to apoAII, apoAII was, was high, high ,, , the, the proportion, proportion of, of apoC, apoC low, low ,, , and, and a, a normally, normally minor, minor form, form of, of apoAI, apoAI increased, increased relative, relative to, to other, other forms, forms ., . The, The HDL, HDL in, in electron, electron micrographs, micrographs appeared, appeared normal, normal morphologically, morphologically and, and in, in particle, particle size, size ., . The, The abnormalities, abnormalities in, in lipoprotein, lipoprotein distribution, distribution profile, profile and, and composition, composition of, of the, the plasma, plasma HDL, HDL result, result from, from metabolic, metabolic defects, defects that, that are, are not, not understood, understood but, but may, may be, be linked, linked to, to the, the genetic, genetic defect, defect in, in bile, bile acid, acid synthesis, synthesis in, in CTX, CTX ., . As, As a, a consequence, consequence ,, , it, it is, is probable, probable that, that the, the normal, normal functions, functions of, of the, the HDL, HDL ,, , possibly, possibly including, including modulation, modulation of, of LDL-cholesterol, LDL-cholesterol uptake, uptake and, and the, the removal, removal of, of excess, excess cholesterol, cholesterol from, from peripheral, peripheral tissues, tissues ,, , are, are perturbed, perturbed significantly, significantly in, in this, this disease.Mutations, disease.Mutations resulting, resulting in, in defective, defective splicing, splicing constitute, constitute a, a significant, significant proportion, proportion (, ( 30/62, 30/62 [, [ 48, 48 %, % ], ] ), ) of, of a, a new, new series, series of, of mutations, mutations in, in the, the ATM, ATM gene, gene in, in patients, patients with, with ataxia-telangiectasia, ataxia-telangiectasia (, ( AT, AT ), ) that, that were, were detected, detected by, by the, the protein-truncation, protein-truncation assay, assay followed, followed by, by sequence, sequence analysis, analysis of, of genomic, genomic DNA, DNA ., . Fewer, Fewer than, than half, half of, of the, the splicing, splicing mutations, mutations involved, involved the, the canonical, canonical AG, AG splice-acceptor, splice-acceptor site, site or, or GT, GT splice-donor, splice-donor site, site ., . A, A higher, higher percentage, percentage of, of mutations, mutations occurred, occurred at, at less, less stringently, stringently conserved, conserved sites, sites ,, , including, including silent, silent mutations, mutations of, of the, the last, last nucleotide, nucleotide of, of exons, exons ,, , mutations, mutations in, in nucleotides, nucleotides other, other than, than the, the conserved, conserved AG, AG and, and GT, GT in, in the, the consensus, consensus splice, splice sites, sites ,, , and, and creation, creation of, of splice-acceptor, splice-acceptor or, or splice-donor, splice-donor sites, sites in, in either, either introns, introns or, or exons, exons ., . These, These splicing, splicing mutations, mutations led, led to, to a, a variety, variety of, of consequences, consequences ,, , including, including exon, exon skipping, skipping and, and ,, , to, to a, a lesser, lesser degree, degree ,, , intron, intron retention, retention ,, , activation, activation of, of cryptic, cryptic splice, splice sites, sites ,, , or, or creation, creation of, of new, new splice, splice sites, sites ., . In, In addition, addition ,, , 5, 5 of, of 12, 12 nonsense, nonsense mutations, mutations and, and 1, 1 missense, missense mutation, mutation were, were associated, associated with, with deletion, deletion in, in the, the cDNA, cDNA of, of the, the exons, exons in, in which, which the, the mutations, mutations occurred, occurred ., . No, No ATM, ATM protein, protein was, was detected, detected by, by western, western blotting, blotting in, in any, any AT, AT cell, cell line, line in, in which, which splicing, splicing mutations, mutations were, were identified, identified ., . Several, Several cases, cases of, of exon, exon skipping, skipping in, in both, both normal, normal controls, controls and, and patients, patients for, for whom, whom no, no underlying, underlying defect, defect could, could be, be found, found in, in genomic, genomic DNA, DNA were, were also, also observed, observed ,, , suggesting, suggesting caution, caution in, in the, the interpretation, interpretation of, of exon, exon deletions, deletions observed, observed in, in ATM, ATM cDNA, cDNA when, when there, there is, is no, no accompanying, accompanying identification, identification of, of genomic, genomic mutations.., mutations.. Papillon-Lefevre, Papillon-Lefevre syndrome, syndrome (, ( PLS, PLS ), ) is, is an, an autosomal, autosomal recessive, recessive disorder, disorder characterised, characterised by, by palmoplantar, palmoplantar hyperkeratosis, hyperkeratosis and, and severe, severe early, early onset, onset periodontitis, periodontitis that, that results, results in, in the, the premature, premature loss, loss of, of the, the primary, primary and, and secondary, secondary dentitions, dentitions ., . A, A major, major gene, gene locus, locus for, for PLS, PLS has, has been, been mapped, mapped to, to a, a 2, 2 ., . 8, 8 cM, cM interval, interval on, on chromosome, chromosome 11q14, 11q14 ., . Correlation, Correlation of, of physical, physical and, and genetic, genetic maps, maps of, of this, this interval, interval indicate, indicate it, it includes, includes at, at least, least 40, 40 ESTs, ESTs and, and six, six known, known genes, genes including, including the, the lysosomal, lysosomal protease, protease cathepsin, cathepsin C, C gene, gene (, ( CTSC, CTSC ), ) ., . The, The CTSC, CTSC message, message is, is expressed, expressed at, at high, high levels, levels in, in a, a variety, variety of, of immune, immune cells, cells including, including polymorphonuclear, polymorphonuclear leucocytes, leucocytes ,, , macrophages, macrophages ,, , and, and their, their precursors, precursors ., . By, By RT-PCR, RT-PCR ,, , we, we found, found CTSC, CTSC is, is also, also expressed, expressed in, in epithelial, epithelial regions, regions commonly, commonly affected, affected by, by PLS, PLS ,, , including, including the, the palms, palms ,, , soles, soles ,, , knees, knees ,, , and, and oral, oral keratinised, keratinised gingiva, gingiva ., . The, The 4, 4 ., . 7, 7 kb, kb CTSC, CTSC gene, gene consists, consists of, of two, two exons, exons ., . Sequence, Sequence analysis, analysis of, of CTSC, CTSC from, from subjects, subjects affected, affected with, with PLS, PLS from, from five, five consanguineous, consanguineous Turkish, Turkish families, families identified, identified four, four different, different mutations, mutations ., . An, An exon, exon 1, 1 nonsense, nonsense mutation, mutation (, ( 856C, 856C --, -- >, > T, T ), ) introduces, introduces a, a premature, premature stop, stop codon, codon at, at amino, amino acid, acid 286, 286 ., . Three, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Three exon, exon 2, 2 mutations, mutations were, were identified, identified ,, , including, including a, a single, single nucleotide, nucleotide deletion, deletion (, ( 2692delA, 2692delA ), ) of, of codon, codon 349, 349 introducing, introducing a, a frameshift, frameshift and, and premature, premature termination, termination codon, codon ,, , a, a 2, 2 bp, bp deletion, deletion (, ( 2673-2674delCT, 2673-2674delCT ), ) that, that results, results in, in introduction, introduction of, of a, a stop, stop codon, codon at, at amino, amino acid, acid 343, 343 ,, , and, and a, a G, G --, -- >, > A, A substitution, substitution in, in codon, codon 429, 429 (, ( 2931G, 2931G --, -- >, > A, A ), ) introducing, introducing a, a premature, premature termination, termination codon, codon ., . All, All PLS, PLS patients, patients were, were homozygous, homozygous for, for cathepsin, cathepsin C, C mutations, mutations inherited, inherited from, from a, a common, common ancestor, ancestor ., . Parents, Parents and, and sibs, sibs heterozygous, heterozygous for, for cathepsin, cathepsin C, C mutations, mutations do, do not, not show, show either, either the, the palmoplantar, palmoplantar hyperkeratosis, hyperkeratosis or, or severe, severe early, early onset, onset periodontitis, periodontitis characteristic, characteristic of, of PLS, PLS ., . A, A more, more complete, complete understanding, understanding of, of the, the functional, functional physiology, physiology of, of cathepsin, cathepsin C, C carries, carries significant, significant implications, implications for, for understanding, understanding normal, normal and, and abnormal, abnormal skin, skin development, development and, and periodontal, periodontal disease, disease susceptibility, susceptibility Complete, Complete deficiency, deficiency of, of hypoxanthine-guanine, hypoxanthine-guanine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ), ) causes, causes the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . Previous, Previous characterization, characterization of, of a, a mutant, mutant form, form of, of HPRT, HPRT ,, , HPRTYale, HPRTYale ,, , from, from a, a subject, subject with, with the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome revealed, revealed normal, normal mRNA, mRNA and, and protein, protein concentrations, concentrations ,, , no, no residual, residual catalytic, catalytic activity, activity ,, , and, and cathodal, cathodal migration, migration upon, upon PAGE, PAGE ., . We, We have, have cloned, cloned and, and sequenced, sequenced HPRTYale, HPRTYale cDNA, cDNA ., . The, The nucleotide, nucleotide sequence, sequence of, of full-length, full-length HPRTYale, HPRTYale cDNA, cDNA revealed, revealed a, a single, single nucleotide, nucleotide substitution, substitution compared, compared with, with normal, normal HPRT, HPRT cDNA, cDNA G, G --, -- --, -- C, C at, at nucleotide, nucleotide position, position 211, 211 ., . This, This transversion, transversion predicts, predicts substitution, substitution of, of arginine, arginine for, for glycine, glycine at, at amino, amino acid, acid position, position 71, 71 ,, , explaining, explaining the, the cathodal, cathodal migration, migration of, of HPRTYale, HPRTYale ., . Chou-Fasman, Chou-Fasman secondary, secondary structure, structure analysis, analysis predicts, predicts a, a change, change in, in the, the probability, probability of, of beta-turn, beta-turn formation, formation in, in the, the region, region containing, containing the, the mutation, mutation ., . Inclusion, Inclusion of, of the, the bulky, bulky arginine, arginine side, side chain, chain in, in place, place of, of glycine, glycine probably, probably disrupts, disrupts protein, protein folding, folding as, as well, well ., . Cloning, Cloning mutant, mutant forms, forms of, of cDNA, cDNA allows, allows identification, identification of, of specific, specific mutations, mutations ,, , provides, provides insight, insight into, into mutational, mutational mechanisms, mechanisms ,, , and, and facilitates, facilitates structure-function, structure-function analysis, analysis of, of mutant, mutant proteins.., proteins.. A, A candidate, candidate DNA, DNA sequence, sequence with, with many, many of, of the, the properties, properties predicted, predicted for, for the, the retinoblastoma, retinoblastoma susceptibility, susceptibility (, ( RB1, RB1 ), ) locus, locus has, has been, been cloned, cloned (, ( S., S. H., H. Friend, Friend ,, , R., R. Bernards, Bernards ,, , S., S. Rogelj, Rogelj ,, , R., R. A., A. Weinberg, Weinberg ,, , J., J. M., M. Rapaport, Rapaport ,, , D., D. M., M. Albert, Albert ,, , and, and T., T. P., P. Dryja, Dryja ,, , Nature, Nature [, [ London, London ], ] 323, 323 643-645, 643-645 ,, , 1986, 1986 ), ) ., . The, The large, large size, size of, of this, this gene, gene (, ( ca, ca ., . 200, 200 kilobases, kilobases [, [ kb, kb ], ] ), ) and, and its, its multiple, multiple dispersed, dispersed exons, exons (, ( Wiggs, Wiggs et, et al., al. ,, , N., N. Engl, Engl ., . J., J. Med, Med ., . 318, 318 151-157, 151-157 ,, , 1988, 1988 ), ) complicate, complicate molecular, molecular screening, screening strategies, strategies important, important in, in prenatal, prenatal and, and presymptomatic, presymptomatic diagnosis, diagnosis and, and in, in carrier, carrier detection, detection ., . Here, Here we, we used, used field, field inversion, inversion gel, gel electrophoresis, electrophoresis (, ( FIGE, FIGE ), ) to, to construct, construct a, a restriction, restriction map, map of, of approximately, approximately 1, 1 ,, , 000, 000 kb, kb of, of DNA, DNA surrounding, surrounding the, the RB1, RB1 locus, locus and, and to, to detect, detect the, the translocation, translocation breakpoints, breakpoints in, in three, three retinoblastoma, retinoblastoma patients, patients ., . DNA, DNA probes, probes from, from either, either the, the 5, 5 or, or 3, 3 end, end of, of the, the gene, gene were, were used, used to, to detect, detect a, a 250-kb, 250-kb EagI, EagI restriction, restriction fragment, fragment in, in DNA, DNA from, from unaffected, unaffected individuals, individuals ., . Both, Both probes, probes identified, identified an, an additional, additional hybridizing, hybridizing fragment, fragment in, in the, the DNA, DNA from, from each, each patient, patient ,, , permitting, permitting the, the breakpoints, breakpoints in, in all, all three, three to, to be, be mapped, mapped within, within the, the cloned, cloned RB1, RB1 gene, gene ., . Analysis, Analysis of, of the, the breakpoint, breakpoint in, in one, one translocation, translocation cell, cell line, line allowed, allowed the, the RB1, RB1 gene, gene to, to be, be oriented, oriented with, with its, its 5, 5 end, end toward, toward the, the centromere, centromere ., . The, The 5, 5 end, end of, of the, the gene, gene also, also appeared, appeared to, to be, be associated, associated with, with a, a clustering, clustering of, of sites, sites for, for several, several infrequently, infrequently cleaving, cleaving restriction, restriction enzymes, enzymes ,, , indicating, indicating the, the presence, presence of, of an, an HpaII, HpaII tiny, tiny fragment, fragment island, island ., . The, The detection, detection and, and mapping, mapping of, of the, the translocation, translocation breakpoints, breakpoints of, of all, all three, three retinoblastoma, retinoblastoma patients, patients to, to within, within the, the putative, putative RB1, RB1 gene, gene substantiated, substantiated the, the authenticity, authenticity of, of this, this candidate, candidate sequence, sequence and, and demonstrated, demonstrated the, the utility, utility of, of FIGE, FIGE in, in detecting, detecting chromosomal, chromosomal rearrangements, rearrangements affecting, affecting this, this locus, locus ., . The, The Denys-Drash, Denys-Drash syndrome, syndrome is, is characterised, characterised by, by a, a typical, typical nephropathy, nephropathy ,, , genital, genital abnormalities, abnormalities and, and also, also predisposes, predisposes to, to the, the development, development of, of Wilms, Wilms tumor, tumor ., . These, These patients, patients eventually, eventually go, go into, into end, end stage, stage renal, renal failure, failure ., . A, A candidate, candidate Wilms, Wilms tumor, tumor gene, gene ,, , WT1, WT1 ,, , from, from the, the 11p13, 11p13 chromosome, chromosome region, region has, has recently, recently been, been cloned, cloned ., . We, We have, have analysed, analysed the, the DNA, DNA sequence, sequence in, in constitutional, constitutional cells, cells from, from eight, eight patients, patients and, and have, have shown, shown heterozygous, heterozygous mutations, mutations in, in six, six of, of them, them ., . Four, Four of, of the, the mutations, mutations were, were in, in exon, exon 9, 9 ,, , all, all resulting, resulting in, in missense, missense mutations, mutations ., . Three, Three were, were at, at nucleotide, nucleotide position, position 1180, 1180 resulting, resulting in, in an, an arg, arg >, > trp, trp amino, amino acid, acid change, change ., . The, The other, other was, was at, at position, position 1186, 1186 converting, converting an, an asp, asp >, > asn, asn in, in the, the predicted, predicted resultant, resultant protein, protein ., . One, One patient, patient had, had a, a missense, missense mutation, mutation in, in exon, exon 8, 8 ,, , converting, converting an, an arg, arg >, > his, his ., . A, A single, single base, base pair, pair insertion, insertion at, at nucleotide, nucleotide position, position 821, 821 in, in exon, exon 6, 6 resulted, resulted in, in the, the generation, generation of, of a, a premature, premature stop, stop codon, codon in, in the, the last, last patient, patient ., . We, We were, were unable, unable to, to find, find a, a mutation, mutation in, in one, one patient, patient despite, despite complete, complete sequencing, sequencing of, of the, the genomic, genomic sequence, sequence of, of the, the gene, gene ., . The, The last, last patient, patient carried, carried a, a constitutional, constitutional deletion, deletion of, of the, the 11p13, 11p13 region, region and, and no, no additional, additional mutation, mutation was, was found, found ., . There, There was, was no, no obvious, obvious correlation, correlation between, between the, the type, type of, of mutation, mutation and, and phenotypic, phenotypic expression, expression ., . These, These results, results further, further demonstrate, demonstrate that, that the, the WT1, WT1 gene, gene is, is important, important in, in both, both the, the development, development of, of the, the kidney, kidney and, and the, the genito-urinary, genito-urinary system.., system.. Mutations, Mutations at, at the, the PEPD, PEPD locus, locus cause, cause prolidase, prolidase deficiency, deficiency (, ( McKusick, McKusick 170100, 170100 ), ) ,, , a, a rare, rare autosomal, autosomal recessive, recessive disorder, disorder characterized, characterized by, by iminodipeptiduria, iminodipeptiduria ,, , skin, skin ulcers, ulcers ,, , mental, mental retardation, retardation ,, , and, and recurrent, recurrent infections, infections ., . Four, Four PEPD, PEPD mutations, mutations from, from five, five severely, severely affected, affected individuals, individuals were, were characterized, characterized by, by analysis, analysis of, of reverse-transcribed, reverse-transcribed ,, , PCR-amplified, PCR-amplified (, ( RT-PCR, RT-PCR ), ) cDNA, cDNA ., . We, We used, used SSCP, SSCP analysis, analysis on, on four, four overlapping, overlapping cDNA, cDNA fragments, fragments covering, covering the, the entire, entire coding, coding region, region of, of the, the PEPD, PEPD gene, gene and, and detected, detected abnormal, abnormal SSCP, SSCP bands, bands for, for the, the fragment, fragment spanning, spanning all, all or, or part, part of, of exons, exons 13-15, 13-15 in, in three, three of, of the, the probands, probands ., . Direct, Direct sequencing, sequencing of, of the, the mutant, mutant cDNAs, cDNAs showed, showed a, a G, G --, -- >, > A, A ,, , 1342, 1342 substitution, substitution (, ( G448R, G448R ), ) in, in two, two patients, patients and, and a, a 3-bp, 3-bp deletion, deletion (, ( delta, delta E452, E452 or, or delta, delta E453, E453 ), ) in, in another, another ., . In, In the, the other, other two, two probands, probands the, the amplified, amplified products, products were, were of, of reduced, reduced size, size ., . Direct, Direct sequencing, sequencing of, of these, these mutant, mutant cDNAs, cDNAs revealed, revealed a, a deletion, deletion of, of exon, exon 5, 5 in, in one, one patient, patient and, and of, of exon, exon 7, 7 in, in the, the other, other ., . Intronic, Intronic sequences, sequences flanking, flanking exons, exons 5, 5 and, and 7, 7 were, were identified, identified using, using inverse, inverse PCR, PCR followed, followed by, by direct, direct sequencing, sequencing ., . Conventional, Conventional PCR, PCR and, and direct, direct sequencing, sequencing then, then established, established the, the intron-exon, intron-exon borders, borders of, of the, the mutant, mutant genomic, genomic DNA, DNA revealing, revealing two, two splice, splice acceptor, acceptor mutations, mutations a, a G, G --, -- >, > C, C substitution, substitution at, at position, position -1, -1 of, of intron, intron 4, 4 and, and an, an A, A --, -- >, > G, G substitution, substitution at, at position, position -2, -2 of, of intron, intron 6, 6 ., . Our, Our results, results indicate, indicate that, that the, the severe, severe form, form of, of prolidase, prolidase deficiency, deficiency is, is caused, caused by, by multiple, multiple PEPD, PEPD alleles, alleles ., . In, In this, this report, report we, we attempt, attempt to, to begin, begin the, the process, process of, of describing, describing these, these alleles, alleles and, and cataloging, cataloging their, their phenotypic, phenotypic expression.., expression.. A, A father, father and, and daughter, daughter with, with isolated, isolated aniridia, aniridia were, were observed, observed to, to have, have an, an apparently, apparently balanced, balanced ,, , reciprocal, reciprocal translocation, translocation involving, involving chromosomes, chromosomes 5, 5 and, and 11, 11 [, [ t, t (, ( 5, 5 ;, ; 11, 11 ), ) (, ( q13, q13 ., . 1, 1 ;, ; p13, p13 ), ) ], ] ., . No, No other, other clinical, clinical characteristics, characteristics often, often associated, associated with, with the, the deletion, deletion of, of 11p13, 11p13 were, were observed, observed in, in this, this family, family ., . This, This finding, finding ,, , in, in association, association with, with 3, 3 other, other instances, instances of, of single, single breaks, breaks at, at 11p13, 11p13 and, and aniridia, aniridia ,, , supports, supports the, the assignment, assignment of, of AN2, AN2 to, to 11p13, 11p13 ., . Direct, Direct sequencing, sequencing of, of the, the emerin, emerin gene, gene in, in 22, 22 families, families with, with Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EMD, EMD ), ) revealed, revealed mutations, mutations in, in 21, 21 (, ( 95, 95 %, % ), ) ,, , confirming, confirming that, that emerin, emerin mutations, mutations can, can be, be identified, identified in, in the, the majority, majority of, of families, families with, with X-linked, X-linked EMD, EMD ., . Most, Most emerin, emerin mutations, mutations result, result in, in absence, absence of, of the, the protein, protein ., . In, In this, this study, study three, three mutations, mutations (, ( a, a missense, missense mutation, mutation Pro183Thr, Pro183Thr and, and two, two in-frame, in-frame deletions, deletions removing, removing residues, residues 95-99, 95-99 and, and 236-241, 236-241 ,, , respectively, respectively ), ) were, were unusual, unusual in, in being, being associated, associated with, with expression, expression of, of mutant, mutant protein, protein ., . The, The phenotype, phenotype in, in these, these families, families was, was compared, compared in, in detail, detail with, with the, the clinical, clinical features, features in, in cases, cases with, with typical, typical null, null mutations, mutations ., . For, For the, the in-frame, in-frame deletions, deletions there, there were, were no, no significant, significant differences, differences ., . In, In the, the family, family with, with the, the missense, missense mutation, mutation the, the phenotype, phenotype was, was milder, milder ., . Age, Age at, at onset, onset was, was later, later for, for first, first symptoms, symptoms and, and for, for development, development of, of ankle, ankle contractures, contractures and, and muscle, muscle weakness, weakness ., . These, These findings, findings have, have diagnostic, diagnostic implications, implications as, as well, well as, as pointing, pointing to, to functionally, functionally important, important regions, regions of, of the, the emerin, emerin protein.., protein.. The, The adenomatous, adenomatous polyposis, polyposis coli, coli gene, gene (, ( APC, APC ), ) is, is mutated, mutated in, in familial, familial adenomatous, adenomatous polyposis, polyposis and, and in, in sporadic, sporadic colorectal, colorectal tumors, tumors ., . Here, Here the, the APC, APC gene, gene product, product is, is shown, shown to, to bind, bind through, through its, its armadillo, armadillo repeat, repeat domain, domain to, to a, a Rac-specific, Rac-specific guanine, guanine nucleotide, nucleotide exchange, exchange factor, factor (, ( GEF, GEF ), ) ,, , termed, termed Asef, Asef ., . Endogenous, Endogenous APC, APC colocalized, colocalized with, with Asef, Asef in, in mouse, mouse colon, colon epithelial, epithelial cells, cells and, and neuronal, neuronal cells, cells ., . Furthermore, Furthermore ,, , APC, APC enhanced, enhanced the, the GEF, GEF activity, activity of, of Asef, Asef and, and stimulated, stimulated Asef-mediated, Asef-mediated cell, cell flattening, flattening ,, , membrane, membrane ruffling, ruffling ,, , and, and lamellipodia, lamellipodia formation, formation in, in MDCK, MDCK cells, cells ., . These, These results, results suggest, suggest that, that the, the APC-Asef, APC-Asef complex, complex may, may regulate, regulate the, the actin, actin cytoskeletal, cytoskeletal network, network ,, , cell, cell morphology, morphology and, and migration, migration ,, , and, and neuronal, neuronal function.., function.. Recent, Recent progress, progress has, has resulted, resulted in, in part, part of, of the, the gene, gene mutated, mutated in, in Duchenne, Duchenne and, and the, the milder, milder Becker, Becker muscular, muscular dystrophies, dystrophies being, being cloned, cloned and, and has, has suggested, suggested that, that the, the gene, gene itself, itself extends, extends over, over 1, 1 ,, , 000, 000 to, to 2, 2 ,, , 000, 000 kilobases, kilobases (, ( kb, kb ), ) ., . To, To study, study how, how mutations, mutations in, in this, this gene, gene affect, affect muscle, muscle development, development and, and integrity, integrity ,, , it, it would, would be, be of, of interest, interest to, to have, have available, available a, a mouse, mouse model, model of, of the, the human, human disease, disease ., . The, The mouse, mouse mdx, mdx mutation, mutation affects, affects muscle, muscle and, and confers, confers a, a mild, mild dystrophic, dystrophic syndrome, syndrome ,, , but, but it, it is, is not, not clear, clear whether, whether this, this mutation, mutation is, is equivalent, equivalent to, to Duchenne/Becker, Duchenne/Becker muscular, muscular dystrophy, dystrophy in, in man, man ., . Here, Here we, we describe, describe the, the use, use of, of two, two sequences, sequences from, from the, the human, human Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene that, that cross-hybridize, cross-hybridize to, to mouse, mouse X-linked, X-linked sequences, sequences to, to localize, localize the, the gene, gene homologous, homologous to, to DMD, DMD in, in the, the mouse, mouse ., . Both, Both sequences, sequences map, map to, to the, the region, region of, of 10, 10 centimorgan, centimorgan lying, lying between, between the, the Tabby, Tabby (, ( Ta, Ta ), ) and, and St14-1, St14-1 (, ( DxPas8, DxPas8 ), ) loci, loci ,, , close, close to, to the, the phosphorylase, phosphorylase b, b kinase, kinase locus, locus (, ( Phk, Phk ), ) ., . By, By analogy, analogy with, with the, the human, human X-chromosome, X-chromosome ,, , we, we conclude, conclude that, that the, the region, region in, in the, the mouse, mouse around, around the, the G6pd, G6pd and, and St14-1, St14-1 loci, loci may, may contain, contain two, two genes, genes corresponding, corresponding to, to distinct, distinct human, human myopathies, myopathies Emery, Emery Dreifuss, Dreifuss muscular, muscular dystrophy, dystrophy which, which is, is known, known to, to be, be closely, closely linked, linked to, to St14-1, St14-1 in, in man, man and, and the, the DMD, DMD homologue, homologue described, described here.., here.. Following, Following the, the birth, birth of, of two, two infants, infants with, with Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) ,, , a, a non-Jewish, non-Jewish ,, , Pennsylvania, Pennsylvania Dutch, Dutch kindred, kindred was, was screened, screened for, for TSD, TSD carriers, carriers using, using the, the biochemical, biochemical assay, assay ., . A, A high, high frequency, frequency of, of individuals, individuals who, who appeared, appeared to, to be, be TSD, TSD heterozygotes, heterozygotes was, was detected, detected (, ( Kelly, Kelly et, et al., al. ,, , 1975, 1975 ), ) ., . Clinical, Clinical and, and biochemical, biochemical evidence, evidence suggested, suggested that, that the, the increased, increased carrier, carrier frequency, frequency was, was due, due to, to at, at least, least two, two altered, altered alleles, alleles for, for the, the hexosaminidase, hexosaminidase A, A alpha-subunit, alpha-subunit ., . We, We now, now report, report two, two mutant, mutant alleles, alleles in, in this, this Pennsylvania, Pennsylvania Dutch, Dutch kindred, kindred ,, , and, and one, one polymorphism, polymorphism ., . One, One allele, allele ,, , reported, reported originally, originally in, in a, a French, French TSD, TSD patient, patient (, ( Akli, Akli et, et al., al. ,, , 1991, 1991 ), ) ,, , is, is a, a GT, GT --, -- >, > AT, AT transition, transition at, at the, the donor, donor splice-site, splice-site of, of intron, intron 9, 9 ., . The, The second, second ,, , a, a C, C --, -- >, > T, T transition, transition at, at nucleotide, nucleotide 739, 739 (, ( Arg247Trp, Arg247Trp ), ) ,, , has, has been, been shown, shown by, by Triggs-Raine, Triggs-Raine et, et al, al ., . (, ( 1992, 1992 ), ) to, to be, be a, a clinically, clinically benign, benign ``, `` pseudodeficient, pseudodeficient ``, `` allele, allele associated, associated with, with reduced, reduced enzyme, enzyme activity, activity against, against artificial, artificial substrate, substrate ., . Finally, Finally ,, , a, a polymorphism, polymorphism [, [ G, G --, -- >, > A, A (, ( 759, 759 ), ) ], ] ,, , which, which leaves, leaves valine, valine at, at codon, codon 253, 253 unchanged, unchanged ,, , is, is described, described .Phenylketonuria, .Phenylketonuria (, ( PKU, PKU ), ) is, is caused, caused by, by a, a genetic, genetic deficiency, deficiency of, of the, the enzyme, enzyme phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . A, A full-length, full-length complementary, complementary DNA, DNA clone, clone of, of human, human PAH, PAH was, was inserted, inserted into, into a, a eukaryotic, eukaryotic expression, expression vector, vector and, and transferred, transferred into, into mouse, mouse NIH3T3, NIH3T3 cells, cells which, which do, do not, not normally, normally express, express PAH, PAH ., . The, The transformed, transformed mouse, mouse cells, cells expressed, expressed PAH, PAH messenger, messenger RNA, RNA ,, , immunoreactive, immunoreactive protein, protein ,, , and, and enzymatic, enzymatic activity, activity that, that are, are characteristic, characteristic of, of the, the normal, normal human, human liver, liver products, products ,, , demonstrating, demonstrating that, that a, a single, single gene, gene contains, contains all, all of, of the, the necessary, necessary genetic, genetic information, information to, to code, code for, for functional, functional PAH, PAH ., . These, These results, results support, support the, the use, use of, of the, the human, human PAH, PAH probe, probe in, in prenatal, prenatal diagnosis, diagnosis and, and detection, detection of, of carriers, carriers ,, , to, to provide, provide new, new opportunities, opportunities for, for the, the biochemical, biochemical characterization, characterization of, of normal, normal and, and mutant, mutant enzymes, enzymes ,, , and, and in, in the, the investigation, investigation of, of alternative, alternative genetic, genetic therapies, therapies for, for PKU.., PKU.. BACKGROUND, BACKGROUND Recently, Recently ,, , mutations, mutations in, in the, the retinal, retinal degeneration, degeneration slow, slow (, ( rds, rds ), ) gene, gene which, which codes, codes for, for peripherin-rds, peripherin-rds have, have been, been implicated, implicated as, as a, a cause, cause of, of autosomal, autosomal dominant, dominant retinitis, retinitis pigmentosa, pigmentosa ., . Because, Because this, this gene, gene is, is expressed, expressed in, in both, both rods, rods and, and cones, cones ,, , mutations, mutations in, in the, the rds, rds gene, gene might, might be, be expected, expected to, to cause, cause degeneration, degeneration affecting, affecting either, either the, the scotopic, scotopic or, or photopic, photopic systems, systems ., . Mutations, Mutations at, at codon, codon 172, 172 of, of the, the rds, rds gene, gene have, have been, been identified, identified in, in three, three families, families with, with autosomal, autosomal dominantly, dominantly inherited, inherited ,, , progressive, progressive macular, macular dystrophy, dystrophy ., . METHODS, METHODS Affected, Affected individuals, individuals underwent, underwent ophthalmic, ophthalmic examination, examination ,, , scotopic, scotopic perimetry, perimetry ,, , dark, dark adaptometry, adaptometry ,, , measurement, measurement of, of color-contrast, color-contrast sensitivity, sensitivity ,, , and, and electroretinography, electroretinography to, to characterize, characterize the, the photoreceptor, photoreceptor dysfunction, dysfunction ., . RESULTS, RESULTS In, In all, all but, but one, one affected, affected member, member ,, , symptoms, symptoms of, of progressive, progressive central, central visual, visual loss, loss developed, developed in, in the, the third, third or, or fourth, fourth decade, decade of, of life, life accompanied, accompanied by, by central, central scotoma, scotoma and, and well-demarcated, well-demarcated atrophy, atrophy of, of the, the retinal, retinal pigment, pigment epithelium, epithelium and, and choriocapillaris, choriocapillaris of, of the, the macula, macula ., . In, In general, general ,, , cone, cone and, and rod, rod thresholds, thresholds were, were elevated, elevated ,, , and, and color-contrast, color-contrast sensitivity, sensitivity was, was absent, absent in, in the, the central, central visual, visual field, field ., . Peripherally, Peripherally ,, , the, the scotopic, scotopic sensitivities, sensitivities were, were normal, normal ,, , as, as was, was the, the recovery, recovery from, from bleach, bleach ., . Cone, Cone electroretinograms, electroretinograms were, were diminished, diminished in, in amplitude, amplitude ,, , and, and delayed, delayed in, in all, all affected, affected adults, adults except, except one, one ., . Rod, Rod electroretinograms, electroretinograms were, were normal, normal or, or near, near normal, normal in, in amplitude, amplitude ,, , and, and had, had normal, normal implicit, implicit times, times ., . Affected, Affected asymptomatic, asymptomatic children, children had, had macular, macular changes, changes ,, , abnormal, abnormal color-contrast, color-contrast sensitivity, sensitivity ,, , and, and reduced, reduced pattern, pattern and, and cone, cone electroretinograms, electroretinograms ., . CONCLUSION, CONCLUSION These, These results, results indicate, indicate that, that mutations, mutations in, in the, the rds, rds gene, gene can, can be, be expressed, expressed as, as a, a macular, macular dystrophy, dystrophy ,, , with, with evidence, evidence of, of primary, primary cone, cone dysfunction, dysfunction and, and preservation, preservation of, of peripheral, peripheral rod, rod function.., function.. Two, Two male, male subjects, subjects are, are described, described ,, , with, with unusual, unusual clinical, clinical presentations, presentations and, and with, with hitherto, hitherto undescribed, undescribed G6PD, G6PD variants, variants ., . The, The first, first ,, , of, of Italian, Italian extraction, extraction ,, , suffered, suffered from, from severe, severe neonatal, neonatal jaundice, jaundice following, following maternal, maternal ingestion, ingestion of, of fresh, fresh broad, broad beans, beans (, ( Vicia, Vicia fava, fava ), ) both, both prenatally, prenatally and, and postnatally, postnatally the, the expression, expression of, of the, the enzymatic, enzymatic defect, defect was, was much, much more, more severe, severe in, in the, the neonatal, neonatal period, period than, than on, on retesting, retesting in, in adolescence, adolescence ,, , when, when biochemical, biochemical characterization, characterization showed, showed unique, unique features, features which, which justify, justify designation, designation as, as a, a new, new variant, variant Gd, Gd (, ( +, + ), ) Alexandra, Alexandra ., . The, The second, second patient, patient ,, , a, a boy, boy of, of Maltese, Maltese extraction, extraction who, who was, was found, found to, to have, have bilateral, bilateral lamellar, lamellar cataracts, cataracts at, at the, the age, age of, of 4, 4 years, years ,, , was, was identified, identified as, as G6PD, G6PD deficient, deficient only, only as, as a, a result, result of, of a, a survey, survey of, of children, children of, of Mediterranean, Mediterranean origin, origin with, with unexplained, unexplained cataract, cataract formation, formation ;, ; he, he has, has approximately, approximately 15, 15 %, % of, of normal, normal enzyme, enzyme activity, activity ,, , with, with another, another unique, unique combination, combination of, of biochemical, biochemical characteristics, characteristics which, which has, has led, led to, to its, its designation, designation as, as Gd, Gd (, ( -, - ), ) Camperdown, Camperdown ., . Although, Although this, this association, association may, may be, be coincidental, coincidental ,, , it, it prompts, prompts further, further attention, attention to, to the, the possibility, possibility that, that under, under certain, certain circumstances, circumstances G6PD, G6PD deficiency, deficiency may, may favor, favor cataract, cataract formation, formation ., . The, The two, two cases, cases illustrate, illustrate the, the value, value of, of characterization, characterization of, of the, the mutant, mutant enzyme, enzyme whenever, whenever unexpected, unexpected clinical, clinical or, or laboratory, laboratory results, results are, are obtained.., obtained.. The, The alpha, alpha 1-protease, 1-protease inhibitor, inhibitor ,, , or, or alpha-antitrypsin, alpha-antitrypsin (, ( AAT, AAT ), ) ,, , a, a major, major plasma, plasma inhibitor, inhibitor of, of leukocyte, leukocyte elastase, elastase and, and bacterial, bacterial proteases, proteases ,, , is, is encoded, encoded at, at the, the PI, PI locus, locus on, on chromosome, chromosome 14, 14 (, ( 14q24, 14q24 ., . 3-q32, 3-q32 ., . 1, 1 ), ) ., . A, A deficiency, deficiency of, of AAT, AAT in, in individuals, individuals homozygous, homozygous for, for the, the PI, PI Z, Z allele, allele occurs, occurs in, in about, about 1, 1 in, in 2, 2 ,, , 000-8, 000-8 ,, , 000, 000 caucasians, caucasians and, and is, is associated, associated with, with an, an increased, increased risk, risk of, of early, early adult, adult onset, onset emphysema, emphysema and, and liver, liver disease, disease in, in childhood, childhood ., . We, We have, have now, now used, used DNA, DNA polymorphisms, polymorphisms associated, associated with, with the, the AAT, AAT gene, gene to, to investigate, investigate the, the origin, origin of, of the, the PI, PI Z, Z allele, allele ., . Using, Using two, two genomic, genomic probes, probes extending, extending into, into the, the 5, 5 and, and 3, 3 flanking, flanking regions, regions ,, , respectively, respectively ,"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", , we, we have, have identified, identified eight, eight polymorphic, polymorphic restriction, restriction sites, sites ., . Extensive, Extensive linkage, linkage disequilibrium, disequilibrium occurs, occurs throughout, throughout the, the probed, probed region, region with, with the, the PI, PI Z, Z allele, allele ,, , but, but not, not with, with normal, normal PI, PI M, M alleles, alleles ., . The, The Z, Z allele, allele occurs, occurs mainly, mainly with, with one, one haplotype, haplotype ,, , indicating, indicating a, a single, single ,, , relatively, relatively recent, recent ,, , origin, origin in, in caucasians, caucasians Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) ,, , the, the most, most common, common form, form of, of muscular, muscular dystrophy, dystrophy in, in adult, adult humans, humans ,, , results, results from, from expansion, expansion of, of a, a CTG, CTG repeat, repeat in, in the, the 3, 3 untranslated, untranslated region, region of, of the, the DMPK, DMPK gene, gene ., . The, The mutant, mutant DMPK, DMPK messenger, messenger RNA, RNA (, ( mRNA, mRNA ), ) contains, contains an, an expanded, expanded CUG, CUG repeat, repeat and, and is, is retained, retained in, in the, the nucleus, nucleus ., . We, We have, have expressed, expressed an, an untranslated, untranslated CUG, CUG repeat, repeat in, in an, an unrelated, unrelated mRNA, mRNA in, in transgenic, transgenic mice, mice ., . Mice, Mice that, that expressed, expressed expanded, expanded CUG, CUG repeats, repeats developed, developed myotonia, myotonia and, and myopathy, myopathy ,, , whereas, whereas mice, mice expressing, expressing a, a nonexpanded, nonexpanded repeat, repeat did, did not, not ., . Thus, Thus ,, , transcripts, transcripts with, with expanded, expanded CUG, CUG repeats, repeats are, are sufficient, sufficient to, to generate, generate a, a DM, DM phenotype, phenotype ., . This, This result, result supports, supports a, a role, role for, for RNA, RNA gain, gain of, of function, function in, in disease, disease pathogenesis.., pathogenesis.. The, The Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) critical, critical region, region on, on 15q11-q13, 15q11-q13 is, is subject, subject to, to imprinting, imprinting ., . PWS, PWS becomes, becomes apparent, apparent when, when genes, genes on, on the, the paternally, paternally inherited, inherited chromosome, chromosome are, are not, not expressed, expressed ., . Familial, Familial PWS, PWS is, is rare, rare ., . We, We report, report on, on a, a family, family in, in which, which a, a male, male and, and a, a female, female paternal, paternal first, first cousin, cousin both, both have, have PWS, PWS with, with cytogenetically, cytogenetically normal, normal karyotypes, karyotypes ., . Fluorescence, Fluorescence in, in situ, situ hybridization, hybridization (, ( FISH, FISH ), ) analysis, analysis shows, shows a, a submicroscopic, submicroscopic deletion, deletion of, of SNRPN, SNRPN ,, , but, but not, not the, the closely, closely associated, associated loci, loci D15S10, D15S10 ,, , D15S11, D15S11 ,, , D15S63, D15S63 ,, , and, and GABRB3, GABRB3 ., . The, The cousins, cousins fathers, fathers and, and two, two paternal, paternal aunts, aunts have, have the, the same, same deletion, deletion and, and are, are clinically, clinically normal, normal ., . The, The grandmother, grandmother of, of the, the cousins, cousins is, is deceased, deceased and, and not, not available, available for, for study, study ,, , and, and their, their grandfather, grandfather is, is not, not deleted, deleted for, for SNRPN, SNRPN ., . DNA, DNA methylation, methylation analysis, analysis of, of D15S63, D15S63 is, is consistent, consistent with, with an, an abnormality, abnormality of, of the, the imprinting, imprinting center, center associated, associated with, with PWS., PWS. ``, `` Grandmatrilineal, Grandmatrilineal ``, `` inheritance, inheritance occurs, occurs when, when a, a woman, woman with, with deletion, deletion of, of an, an imprinted, imprinted ,, , paternally, paternally expressed, expressed gene, gene is, is at, at risk, risk of, of having, having affected, affected grandchildren, grandchildren through, through her, her sons, sons ., . In, In this, this case, case ,, , PWS, PWS does, does not, not become, become evident, evident as, as long, long as, as the, the deletion, deletion is, is passed, passed through, through the, the matrilineal, matrilineal line, line ., . This, This represents, represents a, a unique, unique inheritance, inheritance pattern, pattern due, due to, to imprinting.., imprinting.. Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) is, is caused, caused by, by the, the loss, loss of, of expression, expression of, of imprinted, imprinted genes, genes in, in chromosome, chromosome 15q11-q13, 15q11-q13 ., . Affected, Affected individuals, individuals exhibit, exhibit neonatal, neonatal hypotonia, hypotonia ,, , developmental, developmental delay, delay and, and childhood-onset, childhood-onset obesity, obesity ., . Necdin, Necdin ,, , a, a protein, protein implicated, implicated in, in the, the terminal, terminal differentiation, differentiation of, of neurons, neurons ,, , is, is the, the only, only PWS, PWS candidate, candidate gene, gene to, to reduce, reduce viability, viability when, when disrupted, disrupted in, in a, a mouse, mouse model, model ., . In, In this, this study, study ,, , we, we have, have characterized, characterized MAGEL2, MAGEL2 (, ( also, also known, known as, as NDNL1, NDNL1 ), ) ,, , a, a gene, gene with, with 51, 51 %, % amino, amino acid, acid sequence, sequence similarity, similarity to, to necdin, necdin and, and located, located 41, 41 kb, kb distal, distal to, to NDN, NDN in, in the, the PWS, PWS deletion, deletion region, region ., . MAGEL2, MAGEL2 is, is expressed, expressed predominantly, predominantly in, in brain, brain ,, , the, the primary, primary tissue, tissue affected, affected in, in PWS, PWS and, and in, in several, several fetal, fetal tissues, tissues as, as shown, shown by, by northern, northern blot, blot analysis, analysis ., . MAGEL2, MAGEL2 is, is imprinted, imprinted with, with monoallelic, monoallelic expression, expression in, in control, control brain, brain ,, , and, and paternal-only, paternal-only expression, expression in, in the, the central, central nervous, nervous system, system as, as demonstrated, demonstrated by, by its, its lack, lack of, of expression, expression in, in brain, brain from, from a, a PWS-affected, PWS-affected individual, individual ., . The, The orthologous, orthologous mouse, mouse gene, gene (, ( Magel2, Magel2 ), ) is, is located, located within, within 150, 150 kb, kb of, of NDN, NDN ,, , is, is imprinted, imprinted with, with paternal-only, paternal-only expression, expression and, and is, is expressed, expressed predominantly, predominantly in, in late, late developmental, developmental stages, stages and, and adult, adult brain, brain as, as shown, shown by, by northern, northern blotting, blotting ,, , RT-PCR, RT-PCR and, and whole-mount, whole-mount RNA, RNA in, in situ, situ hybridization, hybridization ., . Magel2, Magel2 distribution, distribution partially, partially overlaps, overlaps that, that of, of NDN, NDN ,, , with, with strong, strong expression, expression being, being detected, detected in, in the, the central, central nervous, nervous system, system in, in mid-gestation, mid-gestation mouse, mouse embryos, embryos by, by in, in situ, situ hybridization, hybridization ., . We, We hypothesize, hypothesize that, that ,, , although, although loss, loss of, of necdin, necdin expression, expression may, may be, be important, important in, in the, the neonatal, neonatal presentation, presentation of, of PWS, PWS ,, , loss, loss of, of MAGEL2, MAGEL2 may, may be, be critical, critical to, to abnormalities, abnormalities in, in brain, brain development, development and, and dysmorphic, dysmorphic features, features in, in individuals, individuals with, with PWS.., PWS.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is a, a metabolic, metabolic disease, disease caused, caused by, by recessive, recessive mutations, mutations of, of the, the gene, gene encoding, encoding the, the hepatic, hepatic enzyme, enzyme phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . The, The incidence, incidence of, of PKU, PKU varies, varies widely, widely across, across different, different geographic, geographic areas, areas ,, , and, and is, is highest, highest (, ( about, about 1, 1 in, in 5, 5 ,, , 000, 000 live, live births, births ), ) in, in Ireland, Ireland and, and western, western Scotland, Scotland ,, , and, and among, among Yemenite, Yemenite Jews, Jews ., . A, A limited, limited number, number of, of point, point mutations, mutations account, account for, for most, most of, of the, the PKU, PKU cases, cases in, in the, the European, European population, population ., . Here, Here we, we report, report that, that a, a single, single molecular, molecular defect, defect --, -- a, a deletion, deletion spanning, spanning the, the third, third exon, exon of, of the, the PAH, PAH gene, gene --, -- is, is responsible, responsible for, for all, all the, the PKU, PKU cases, cases among, among the, the Yemenite, Yemenite Jews, Jews ., . Examination, Examination of, of a, a random, random sample, sample of, of Yemenite, Yemenite Jews, Jews using, using a, a molecular, molecular probe, probe that, that detects, detects the, the carriers, carriers of, of this, this deletion, deletion indicated, indicated a, a high, high frequency, frequency of, of the, the defective, defective gene, gene in, in this, this community, community ., . Although, Although the, the deleted, deleted PAH, PAH gene, gene was, was traced, traced to, to 25, 25 different, different locations, locations throughout, throughout Yemen, Yemen ,, , family, family histories, histories and, and official, official documents, documents of, of the, the Yemenite, Yemenite Jewish, Jewish community, community showed, showed that, that the, the common, common ancestor, ancestor of, of all, all the, the carriers, carriers of, of this, this genetic, genetic defect, defect lived, lived in, in Sana, Sana ,, , the, the capital, capital of, of Yemen, Yemen ,, , before, before the, the eighteenth, eighteenth century.., century.. The, The mutation, mutation causing, causing myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) has, has been, been identified, identified as, as an, an amplification, amplification of, of an, an unstable, unstable trinucleotide, trinucleotide (, ( CTG, CTG ), ) n, n repeat, repeat in, in over, over 99, 99 %, % of, of the, the global, global DM, DM population, population ., . It, It is, is in, in complete, complete linkage, linkage disequilibrium, disequilibrium with, with an, an Alu, Alu element, element polymorphism, polymorphism within, within the, the DM, DM kinase, kinase gene, gene ,, , suggesting, suggesting that, that DM, DM is, is a, a consequence, consequence of, of one, one or, or few, few ancestral, ancestral mutations, mutations ., . A, A recent, recent analysis, analysis utilizing, utilizing this, this polymorphism, polymorphism as, as well, well as, as a, a flanking, flanking dinucleotide, dinucleotide marker, marker ,, , suggested, suggested that, that similar, similar to, to Fragile, Fragile X, X syndrome, syndrome ,, , DM, DM exhibited, exhibited a, a founder, founder effect, effect (, ( Imbert, Imbert et, et al., al. ,, , 1993, 1993 Nature, Nature Genet, Genet ., . 4, 4 ,, , 72-76, 72-76 ), ) ., . In, In contrast, contrast ,, , the, the low, low reproductive, reproductive fitness, fitness of, of individuals, individuals with, with congenital, congenital DM, DM (, ( the, the endpoint, endpoint of, of genetic, genetic anticipation, anticipation in, in myotonic, myotonic dystrophy, dystrophy ), ) suggests, suggests a, a higher, higher rate, rate of, of new, new mutations, mutations ., . We, We present, present a, a high, high resolution, resolution genetic, genetic analysis, analysis of, of the, the DM, DM locus, locus using, using PCR, PCR based, based assays, assays of, of nine, nine polymorphisms, polymorphisms ,, , spanning, spanning a, a physical, physical distance, distance of, of 30, 30 kb, kb ,, , within, within and, and immediately, immediately flanking, flanking the, the DM, DM kinase, kinase gene, gene ., . The, The persistent, persistent complete, complete allelic, allelic association, association of, of the, the DM, DM mutation, mutation with, with all, all these, these polymorphisms, polymorphisms provides, provides further, further support, support to, to previous, previous observations, observations and, and suggests, suggests more, more strongly, strongly that, that the, the DM, DM mutation, mutation occurred, occurred on, on the, the background, background of, of a, a particular, particular haplotype, haplotype in, in which, which the, the (, ( CTG, CTG ), ) n, n repeat, repeat became, became inherently, inherently unstable, unstable and, and therefore, therefore predisposed, predisposed to, to amplification, amplification ., . Infantile, Infantile Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) is, is caused, caused by, by mutations, mutations in, in the, the HEXA, HEXA gene, gene that, that result, result in, in the, the complete, complete absence, absence of, of beta-hexosaminidase, beta-hexosaminidase A, A activity, activity ., . It, It is, is well, well known, known that, that an, an elevated, elevated frequency, frequency of, of TSD, TSD mutations, mutations exists, exists among, among Ashkenazi, Ashkenazi Jews, Jews ., . More, More recently, recently it, it has, has become, become apparent, apparent that, that elevated, elevated carrier, carrier frequencies, frequencies for, for TSD, TSD also, also occur, occur in, in several, several other, other ethnic, ethnic groups, groups ,, , including, including Moroccan, Moroccan Jews, Jews ,, , a, a subgroup, subgroup of, of Sephardic, Sephardic Jews, Jews ., . Elsewhere, Elsewhere we, we reported, reported an, an in-frame, in-frame deletion, deletion of, of one, one of, of the, the two, two adjacent, adjacent phenylalanine, phenylalanine codons, codons at, at position, position 304, 304 or, or 305, 305 (, ( delta, delta F304/305, F304/305 ), ) in, in one, one HEXA, HEXA allele, allele of, of a, a Moroccan, Moroccan Jewish, Jewish TSD, TSD patient, patient and, and in, in three, three obligate, obligate carriers, carriers from, from six, six unrelated, unrelated Moroccan, Moroccan Jewish, Jewish families, families ., . We, We have, have now, now identified, identified two, two additional, additional mutations, mutations within, within exon, exon 5, 5 of, of the, the HEXA, HEXA gene, gene that, that account, account for, for the, the remaining, remaining TSD, TSD alleles, alleles in, in the, the patient, patient and, and carriers, carriers ., . One, One of, of the, the mutations, mutations is, is a, a novel, novel C-to-G, C-to-G transversion, transversion ,, , resulting, resulting in, in a, a replacement, replacement of, of Tyr180, Tyr180 by, by a, a stop, stop codon, codon ., . The, The other, other mutation, mutation is, is a, a G-to-A, G-to-A transition, transition resulting, resulting in, in an, an Arg170-to-Gln, Arg170-to-Gln substitution, substitution ., . This, This mutation, mutation is, is at, at a, a CpG, CpG site, site in, in a, a Japanese, Japanese infant, infant with, with Tay-Sachs, Tay-Sachs disease, disease and, and was, was described, described elsewhere, elsewhere ., . Analysis, Analysis of, of nine, nine obligate, obligate carriers, carriers from, from seven, seven unrelated, unrelated families, families showed, showed that, that four, four harbor, harbor the, the delta, delta F304/305, F304/305 mutation, mutation ,, , two, two the, the Arg170, Arg170 --, -- --, -- Gln, Gln mutation, mutation ,, , and, and one, one the, the Tyr180, Tyr180 --, -- --, -- Stop, Stop mutation, mutation ., . We, We also, also have, have developed, developed rapid, rapid ,, , nonradioactive, nonradioactive assays, assays for, for the, the detection, detection of, of each, each mutation, mutation ,, , which, which should, should be, be helpful, helpful for, for carrier, carrier screening.., screening.. ATP7B, ATP7B ,, , the, the gene, gene altered, altered in, in Wilson, Wilson disease, disease (, ( WD, WD ), ) patients, patients ,, , lies, lies in, in a, a block, block of, of homology, homology shared, shared between, between human, human chromosome, chromosome 13q14, 13q14 and, and the, the central, central region, region of, of mouse, mouse chromosome, chromosome 14, 14 ., . However, However ,, , we, we have, have mapped, mapped the, the murine, murine homologue, homologue of, of ATP7B, ATP7B (, ( Atp7b, Atp7b ), ) to, to mouse, mouse chromosome, chromosome 8, 8 by, by somatic, somatic cell, cell hybrid, hybrid analysis, analysis ., . Analysis, Analysis of, of 80, 80 interspecific, interspecific backcross, backcross offspring, offspring was, was used, used to, to position, position Atp7b, Atp7b close, close to, to D8Mit3, D8Mit3 and, and another, another ATPase, ATPase locus, locus ,, , Atp4b, Atp4b ,, , on, on mouse, mouse chromosome, chromosome 8, 8 ., . ATP4B, ATP4B lies, lies in, in 13q34, 13q34 and, and is, is separated, separated from, from ATP7B, ATP7B by, by several, several loci, loci whose, whose mouse, mouse homologues, homologues map, map to, to mouse, mouse chromosome, chromosome 14, 14 ., . The, The assignment, assignment of, of Atp7b, Atp7b to, to mouse, mouse chromosome, chromosome 8, 8 identifies, identifies a, a previously, previously unrecognized, unrecognized region, region of, of homology, homology between, between this, this chromosome, chromosome and, and human, human chromosome, chromosome 13, 13 ., . This, This assignment, assignment suggests, suggests a, a possible, possible location, location for, for the, the toxic, toxic milk, milk mutation, mutation in, in the, the mouse, mouse ,, , which, which has, has been, been proposed, proposed as, as a, a homologue, homologue of, of WD.., WD.. In, In myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ,, , the, the size, size of, of a, a CTG, CTG repeat, repeat in, in the, the DM, DM kinase, kinase gene, gene generally, generally increases, increases in, in successive, successive generations, generations with, with clinical, clinical evidence, evidence of, of anticipation, anticipation ., . However, However ,, , there, there have, have also, also been, been cases, cases with, with an, an intergenerational, intergenerational contraction, contraction of, of the, the repeat, repeat ., . We, We examined, examined 1, 1 ,, , 489, 489 DM, DM parent-offspring, parent-offspring pairs, pairs ,, , of, of which, which 95, 95 (, ( 6, 6 ., . 4, 4 %, % ), ) showed, showed such, such contractions, contractions in, in peripheral, peripheral blood, blood leukocytes, leukocytes (, ( PBL, PBL ), ) ., . In, In 56, 56 of, of the, the 95, 95 pairs, pairs ,, , clinical, clinical data, data allowed, allowed an, an analysis, analysis of, of their, their anticipation, anticipation status, status ., . It, It is, is surprising, surprising that, that anticipation, anticipation occurred, occurred in, in 27, 27 (, ( 48, 48 %, % ), ) of, of these, these 56, 56 pairs, pairs ,, , while, while none, none clearly, clearly showed, showed a, a later, later onset, onset of, of DM, DM in, in the, the symptomatic, symptomatic offspring, offspring ., . The, The contraction, contraction occurred, occurred in, in 76, 76 (, ( 10, 10 %, % ), ) of, of 753, 753 paternal, paternal transmissions, transmissions and, and in, in 19, 19 (, ( 3, 3 %, % ), ) of, of 736, 736 maternal, maternal transmissions, transmissions ., . Anticipation, Anticipation was, was observed, observed more, more frequently, frequently in, in maternal, maternal (, ( 85, 85 %, % ), ) than, than in, in paternal, paternal (, ( 37, 37 %, % ), ) transmissions, transmissions (, ( P, P <, < ., . 001, 001 ), ) ., . The, The parental, parental repeat, repeat size, size correlated, correlated with, with the, the size, size of, of intergenerational, intergenerational contraction, contraction (, ( r2, r2 =, = ., . 50, 50 ,, , P, P <, < <, < ., . 001, 001 ), ) ,, , and, and the, the slope, slope of, of linear, linear regression, regression was, was steeper, steeper in, in paternal, paternal (, ( -, - ., . 62, 62 ), ) than, than in, in maternal, maternal (, ( -, - ., . 30, 30 ), ) transmissions, transmissions (, ( P, P <, < <, < ., . 001, 001 ), ) ., . Sixteen, Sixteen DM, DM parents, parents had, had multiple, multiple DM, DM offspring, offspring with, with the, the CTG, CTG repeat, repeat contractions, contractions ., . This, This frequency, frequency was, was higher, higher than, than the, the frequency, frequency expected, expected from, from the, the probability, probability of, of the, the repeat, repeat contractions, contractions (, ( 6, 6 ., . 4, 4 %, % ), ) and, and the, the size, size of, of DM, DM sib, sib population, population (, ( 1, 1 ., . 54, 54 DM, DM offspring, offspring per, per DM, DM parent, parent ,, , in, in 968, 968 DM, DM parents, parents ), ) ., . We, We conclude, conclude that, that (, ( 1, 1 ), ) intergenerational, intergenerational contractions, contractions of, of the, the CTG, CTG repeat, repeat in, in leukocyte, leukocyte DNA, DNA frequently, frequently accompanies, accompanies apparent, apparent anticipation, anticipation ,, , especially, especially when, when DM, DM is, is maternally, maternally transmitted, transmitted ,, , and, and (, ( 2, 2 ), ) the, the paternal, paternal origin, origin of, of the, the repeat, repeat and, and the, the presence, presence of, of the, the repeat, repeat contraction, contraction in, in a, a sibling, sibling increase, increase the, the probability, probability of, of the, the CTG, CTG repeat, repeat contraction, contraction Pendred, Pendred syndrome, syndrome is, is a, a recessive, recessive inherited, inherited disorder, disorder that, that consists, consists of, of developmental, developmental abnormalities, abnormalities of, of the, the cochlea, cochlea ,, , sensorineural, sensorineural hearing, hearing loss, loss ,, , and, and diffuse, diffuse thyroid, thyroid enlargement, enlargement (, ( goiter, goiter ), ) ., . This, This disorder, disorder may, may account, account for, for up, up to, to 10, 10 %, % of, of cases, cases of, of hereditary, hereditary deafness, deafness ., . The, The disease, disease gene, gene (, ( PDS, PDS ), ) has, has been, been mapped, mapped to, to chromosome, chromosome 7q22-q31, 7q22-q31 ,, , and, and encodes, encodes a, a chloride-iodide, chloride-iodide transport, transport protein, protein ., . We, We performed, performed mutation, mutation analysis, analysis of, of individual, individual exons, exons of, of the, the PDS, PDS gene, gene in, in one, one Spanish, Spanish family, family that, that shows, shows intrafamilial, intrafamilial variability, variability of, of the, the deafness, deafness phenotype, phenotype (, ( two, two patients, patients with, with profound, profound and, and one, one with, with moderate-severe, moderate-severe deafness, deafness ), ) ., . We, We identified, identified a, a new, new splice-site, splice-site mutation, mutation affecting, affecting intron, intron 4, 4 of, of the, the PDS, PDS gene, gene ,, , at, at nucleotide, nucleotide position, position 639, 639 +, + 7, 7 ., . RNA, RNA analysis, analysis from, from lymphocytes, lymphocytes of, of the, the affected, affected patients, patients showed, showed that, that mutation, mutation 639, 639 +, + 7A, 7A --, -- >, > G, G generates, generates a, a new, new donor, donor splice, splice site, site ,, , leading, leading to, to an, an mRNA, mRNA with, with an, an insertion, insertion of, of six, six nucleotides, nucleotides from, from intron, intron 4, 4 of, of PDS, PDS ., . Since, Since the, the newly, newly created, created donor, donor splice, splice site, site is, is likely, likely to, to compete, compete with, with the, the normal, normal one, one ,, , variations, variations of, of the, the levels, levels of, of normal, normal and, and aberrant, aberrant transcripts, transcripts of, of the, the PDS, PDS gene, gene in, in the, the cochlea, cochlea may, may explain, explain the, the variability, variability in, in the, the deafness, deafness presentation.., presentation.. Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is an, an autosomal, autosomal dominant, dominant disorder, disorder characterized, characterized by, by skeletal, skeletal muscle, muscle wasting, wasting ,, , myotonia, myotonia ,, , cardiac, cardiac arrhythmia, arrhythmia ,, , hyperinsulinaemia, hyperinsulinaemia ,, , mental, mental retardation, retardation and, and ocular, ocular cataracts, cataracts ., . The, The genetic, genetic defect, defect in, in DM, DM is, is a, a CTG, CTG repeat, repeat expansion, expansion located, located in, in the, the 3, 3 untranslated, untranslated region, region of, of DMPK, DMPK and, and 5, 5 of, of a, a homeodomain-encoding, homeodomain-encoding gene, gene ,, , SIX5, SIX5 (, ( formerly, formerly DMAHP, DMAHP ;, ; refs, refs 2-5, 2-5 ), ) ., . There, There are, are three, three mechanisms, mechanisms by, by which, which CTG, CTG expansion, expansion can, can result, result in, in DM, DM ., . First, First ,, , repeat, repeat expansion, expansion may, may alter, alter the, the processing, processing or, or transport, transport of, of the, the mutant, mutant DMPK, DMPK mRNA, mRNA and, and consequently, consequently reduce, reduce DMPK, DMPK levels, levels ., . Second, Second ,, , CTG, CTG expansion, expansion may"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", may establish, establish a, a region, region of, of heterochromatin, heterochromatin 3, 3 of, of the, the repeat, repeat sequence, sequence and, and decrease, decrease SIX5, SIX5 transcription, transcription ., . Third, Third ,, , toxic, toxic effects, effects of, of the, the repeat, repeat expansion, expansion may, may be, be intrinsic, intrinsic to, to the, the repeated, repeated elements, elements at, at the, the level, level of, of DNA, DNA or, or RNA, RNA (, ( refs, refs 10, 10 ,, , 11, 11 ), ) ., . Previous, Previous studies, studies have, have demonstrated, demonstrated that, that a, a dose-dependent, dose-dependent loss, loss of, of Dm15, Dm15 (, ( the, the mouse, mouse DMPK, DMPK homologue, homologue ), ) in, in mice, mice produces, produces a, a partial, partial DM, DM phenotype, phenotype characterized, characterized by, by decreased, decreased development, development of, of skeletal, skeletal muscle, muscle force, force and, and cardiac, cardiac conduction, conduction disorders, disorders ., . To, To test, test the, the role, role of, of Six5, Six5 loss, loss in, in DM, DM ,, , we, we have, have analysed, analysed a, a strain, strain of, of mice, mice in, in which, which Six5, Six5 was, was deleted, deleted ., . Our, Our results, results demonstrate, demonstrate that, that the, the rate, rate and, and severity, severity of, of cataract, cataract formation, formation is, is inversely, inversely related, related to, to Six5, Six5 dosage, dosage and, and is, is temporally, temporally progressive, progressive ., . Six5, Six5 +/-, +/- and, and Six5-/-, Six5-/- mice, mice show, show increased, increased steady-state, steady-state levels, levels of, of the, the Na, Na +/K, +/K +, + -ATPase, -ATPase alpha-1, alpha-1 subunit, subunit and, and decreased, decreased Dm15, Dm15 mRNA, mRNA levels, levels ., . Thus, Thus ,, , altered, altered ion, ion homeostasis, homeostasis within, within the, the lens, lens may, may contribute, contribute to, to cataract, cataract formation, formation ., . As, As ocular, ocular cataracts, cataracts are, are a, a characteristic, characteristic feature, feature of, of DM, DM ,, , these, these results, results demonstrate, demonstrate that, that decreased, decreased SIX5, SIX5 transcription, transcription is, is important, important in, in the, the aetiology, aetiology of, of DM, DM ., . Our, Our data, data support, support the, the hypothesis, hypothesis that, that DM, DM is, is a, a contiguous, contiguous gene, gene syndrome, syndrome associated, associated with, with the, the partial, partial loss, loss of, of both, both DMPK, DMPK and, and SIX5.., SIX5.. The, The mutation, mutation causing, causing myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) has, has been, been identified, identified as, as a, a CTG, CTG expansion, expansion in, in the, the 3-untranslated, 3-untranslated region, region (, ( 3-UTR, 3-UTR ), ) of, of the, the DM, DM protein, protein kinase, kinase gene, gene (, ( DMPK, DMPK ), ) ,, , but, but the, the mechanism, mechanism (, ( s, s ), ) of, of pathogenesis, pathogenesis remain, remain unknown, unknown ., . Studies, Studies using, using DM, DM patient, patient materials, materials have, have often, often produced, produced confusing, confusing results, results ., . Therefore, Therefore ,, , to, to study, study the, the effects, effects of, of the, the DM, DM mutation, mutation in, in a, a controlled, controlled environment, environment ,, , we, we have, have established, established a, a cell, cell culture, culture model, model system, system using, using C2C12, C2C12 mouse, mouse myoblasts, myoblasts ., . By, By expressing, expressing chimeric, chimeric reporter, reporter constructs, constructs containing, containing a, a reporter, reporter gene, gene fused, fused to, to a, a human, human DMPK, DMPK 3-UTR, 3-UTR ,, , we, we identified, identified both, both cis, cis and, and trans, trans effects, effects that, that are, are mediated, mediated by, by the, the DM, DM mutation, mutation ., . Our, Our data, data show, show that, that a, a mutant, mutant DMPK, DMPK 3-UTR, 3-UTR ,, , with, with as, as few, few as, as 57, 57 CTGs, CTGs ,, , had, had a, a negative, negative cis, cis effect, effect on, on protein, protein expression, expression and, and resulted, resulted in, in the, the aggregation, aggregation of, of reporter, reporter transcripts, transcripts into, into discrete, discrete nuclear, nuclear foci, foci ., . We, We determined, determined by, by deletion, deletion analysis, analysis that, that an, an expanded, expanded (, ( CTG, CTG ), ) (, ( n, n ), ) tract, tract alone, alone was, was sufficient, sufficient to, to mediate, mediate these, these cis, cis effects, effects ., . Furthermore, Furthermore ,, , in, in contrast, contrast to, to the, the normal, normal DMPK, DMPK 3-UTR, 3-UTR mRNA, mRNA ,, , a, a mutant, mutant DMPK, DMPK 3-UTR, 3-UTR mRNA, mRNA with, with (, ( CUG, CUG ), ) (, ( 200, 200 ), ) selectively, selectively inhibited, inhibited myogenic, myogenic differentiation, differentiation of, of C2C12, C2C12 myoblasts, myoblasts ., . Genetic, Genetic analysis, analysis and, and the, the Cre-, Cre- loxP, loxP system, system were, were used, used to, to clearly, clearly demonstrate, demonstrate that, that the, the myoblast, myoblast fusion, fusion defect, defect could, could be, be rescued, rescued by, by eliminating, eliminating the, the expression, expression of, of the, the mutant, mutant DMPK, DMPK 3-UTR, 3-UTR transcript, transcript ., . Characterization, Characterization of, of spontaneous, spontaneous deletion, deletion events, events mapped, mapped the, the inhibitory, inhibitory effect, effect to, to the, the (, ( CTG, CTG ), ) (, ( n, n ), ) expansion, expansion and/or, and/or the, the 3, 3 end, end of, of the, the DMPK, DMPK 3-UTR, 3-UTR ., . These, These results, results provide, provide evidence, evidence that, that the, the DM, DM mutation, mutation acts, acts in, in cis, cis to, to reduce, reduce protein, protein production, production (, ( consistent, consistent with, with DMPK, DMPK haploinsufficiency, haploinsufficiency ), ) and, and in, in trans, trans as, as a, a riboregulator, riboregulator to, to inhibit, inhibit myogenesis.., myogenesis.. An, An abbreviated, abbreviated Wechsler, Wechsler Adult, Adult Intelligence, Intelligence Scale, Scale Revised, Revised (, ( WAIS-R, WAIS-R ), ) was, was used, used to, to assess, assess verbal, verbal and, and arithmetical, arithmetical cognitive, cognitive performance, performance in, in 55, 55 subjects, subjects with, with myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ,, , covering, covering all, all grades, grades of, of disease, disease severity, severity ,, , and, and 31, 31 controls, controls at, at 50, 50 %, % risk, risk of, of inheriting, inheriting DM, DM ., . Scaled, Scaled scores, scores from, from the, the assessment, assessment were, were converted, converted into, into an, an intelligence, intelligence quotient, quotient (, ( IQ, IQ ), ) estimation, estimation on, on each, each person, person ., . Significant, Significant IQ, IQ differences, differences were, were found, found between, between (, ( 1, 1 ), ) all, all 55, 55 DM, DM subjects, subjects (, ( mean, mean 90, 90 ., . 2, 2 ,, , SD, SD 16, 16 ., . 1, 1 ), ) and, and 31, 31 controls, controls (, ( 102, 102 ., . 6, 6 ,, , SD, SD 9, 9 ., . 4, 4 ), ) ,, , with, with no, no sex, sex differences, differences in, in either, either group, group ;, ; (, ( 2, 2 ), ) 15, 15 affected, affected parents, parents (, ( 99, 99 ., . 3, 3 ,, , SD, SD 12, 12 ., . 2, 2 ), ) and, and their, their affected, affected children, children (, ( 88, 88 ., . 1, 1 ,, , SD, SD 17, 17 ., . 2, 2 ), ) ,, , where, where significance, significance was, was dependent, dependent on, on parental, parental sex, sex being, being female, female ;, ; and, and (, ( 3, 3 ), ) 15, 15 pairs, pairs of, of affected, affected sibs, sibs (, ( 89, 89 ., . 6, 6 ,, , SD, SD 13, 13 ., . 2, 2 ), ) and, and their, their normal, normal sibs, sibs (, ( 100, 100 ., . 2, 2 ,, , SD, SD 7, 7 ., . 6, 6 ), ) ., . IQ, IQ steadily, steadily declined, declined as, as (, ( 1, 1 ), ) the, the age, age of, of onset, onset of, of signs, signs and, and symptoms, symptoms decreased, decreased ,, , and, and (, ( 2, 2 ), ) the, the CTG, CTG expansion, expansion size, size increased, increased ., . The, The correlation, correlation appeared, appeared to, to be, be more, more linear, linear with, with age, age of, of onset, onset ., . The, The correlation, correlation of, of IQ, IQ difference, difference and, and CTG, CTG expansion, expansion difference, difference in, in both, both the, the DM, DM parent-child, parent-child pairs, pairs and, and normal, normal sib-affected, sib-affected sib, sib pairs, pairs was, was poor, poor ,, , indicating, indicating that, that CTG, CTG expansion, expansion is, is not, not a, a reliable, reliable predictor, predictor of, of IQ, IQ either, either in, in individual, individual persons, persons or, or families, families ., . Further, Further analysis, analysis of, of cognitive, cognitive function, function in, in DM, DM is, is required, required to, to clarify, clarify specific, specific deficits, deficits characteristic, characteristic of, of this, this patient, patient group, group Inherited, Inherited complement, complement deficiencies, deficiencies are, are associated, associated with, with a, a variety, variety of, of connective, connective tissue, tissue diseases, diseases ., . A, A family, family with, with inherited, inherited deficiency, deficiency of, of complement, complement factor, factor 2, 2 (, ( C2, C2 ), ) is, is described, described in, in which, which two, two family, family members, members with, with homozygous, homozygous C2, C2 deficiency, deficiency developed, developed cutaneous, cutaneous vasculitis, vasculitis and, and sicca, sicca syndrome, syndrome ., . The, The other, other family, family members, members had, had heterozygous, heterozygous C2, C2 deficiency, deficiency and, and each, each member, member had, had the, the HLA-A25, HLA-A25 ,, , B18, B18 ,, , DR2, DR2 (, ( w15, w15 ), ) haplotype, haplotype ., . The, The mother, mother had, had seropositive, seropositive rheumatoid, rheumatoid arthritis, arthritis ., . Further, Further studies, studies showed, showed the, the presence, presence of, of cryoglobulins, cryoglobulins ,, , antibodies, antibodies against, against endothelial, endothelial cells, cells ,, , and, and anticardiolipin, anticardiolipin antibodies.., antibodies.. The, The retinoblastoma-predisposition, retinoblastoma-predisposition gene, gene ,, , RB1, RB1 ,, , segregates, segregates as, as an, an autosomal, autosomal dominant, dominant trait, trait with, with high, high (, ( 90, 90 %, % ), ) penetrance, penetrance ., . Certain, Certain families, families ,, , however, however ,, , show, show an, an unusual, unusual low-penetrance, low-penetrance phenotype, phenotype with, with many, many individuals, individuals being, being unaffected, unaffected ,, , unilaterally, unilaterally affected, affected ,, , or, or with, with evidence, evidence of, of spontaneously, spontaneously regressed, regressed tumors, tumors ., . We, We have, have used, used single-strand, single-strand conformation, conformation polymorphism, polymorphism analysis, analysis and, and PCR, PCR sequencing, sequencing to, to study, study two, two such, such families, families ., . Mutations, Mutations were, were found, found in, in exon, exon 20, 20 of, of RB1, RB1 in, in both, both cases, cases ., . In, In one, one family, family a, a C, C --, -- --, -- T, T transition, transition in, in codon, codon 661, 661 converts, converts an, an arginine, arginine (, ( CGG, CGG ), ) to, to a, a tryptophan, tryptophan (, ( TGG, TGG ), ) codon, codon ., . In, In this, this family, family ,, , incomplete, incomplete penetrance, penetrance and, and mild, mild phenotypic, phenotypic expression, expression were, were observed, observed in, in virtually, virtually all, all patients, patients ,, , possibly, possibly indicating, indicating that, that single, single amino, amino acid, acid changes, changes may, may modify, modify protein, protein structure/function, structure/function such, such that, that tumorigenesis, tumorigenesis is, is not, not inevitable, inevitable ., . In, In the, the second, second family, family the, the mutation, mutation in, in codon, codon 675, 675 is, is a, a G, G --, -- --, -- T, T transversion, transversion that, that converts, converts a, a glutamine, glutamine (, ( GAA, GAA ), ) to, to a, a stop, stop (, ( TAA, TAA ), ) codon, codon ., . However, However ,, , this, this mutation, mutation also, also occurs, occurs near, near a, a potential, potential cryptic, cryptic splice, splice acceptor, acceptor site, site ,, , raising, raising the, the possibility, possibility of, of alternative, alternative splicing, splicing resulting, resulting in, in a, a less, less severely, severely disrupted, disrupted protein.., protein.. Argininemia, Argininemia is, is a, a rare, rare autossomal, autossomal recessive, recessive disorder, disorder caused, caused by, by deficiency, deficiency in, in the, the cytosolic, cytosolic liver-type, liver-type arginase, arginase enzyme, enzyme (, ( L-arginine, L-arginine urea-hydrolase, urea-hydrolase ;, ; E., E. C., C. 3, 3 ., . 5, 5 ., . 3, 3 ., . 1, 1 ), ) ., . In, In order, order to, to investigate, investigate the, the molecular, molecular basis, basis for, for argininemia, argininemia in, in four, four unrelated, unrelated Portuguese, Portuguese patients, patients (, ( two, two from, from northern, northern Portugal, Portugal and, and two, two from, from Madeira, Madeira Island, Island ), ) we, we performed, performed a, a DNA, DNA sequence, sequence analysis, analysis of, of all, all the, the exons, exons and, and exon/intron, exon/intron boundaries, boundaries of, of the, the liver-type, liver-type arginase, arginase gene, gene (, ( ARG1, ARG1 ), ) ., . All, All patients, patients were, were found, found to, to be, be homozygous, homozygous for, for a, a newly, newly identified, identified C, C -, - >, > T, T transition, transition in, in codon, codon 21, 21 (, ( exon, exon 2, 2 ), ) substituting, substituting arginine, arginine for, for a, a premature, premature stop, stop codon, codon (, ( R21X, R21X CGA, CGA to, to TGA, TGA ), ) and, and generating, generating a, a NlaIII, NlaIII restriction, restriction site, site ., . Restriction, Restriction digestion, digestion following, following PCR, PCR amplification, amplification of, of ARG1, ARG1 exon, exon 2, 2 confirmed, confirmed the, the presence, presence of, of the, the mutation.Aarskog-Scott, mutation.Aarskog-Scott Syndrome, Syndrome (, ( AAS, AAS ), ) is, is an, an X-linked, X-linked disorder, disorder characterised, characterised by, by short, short stature, stature and, and multiple, multiple facial, facial ,, , limb, limb and, and genital, genital abnormalities, abnormalities ., . A, A gene, gene ,, , FGD1, FGD1 ,, , altered, altered in, in a, a patient, patient with, with AAS, AAS phenotype, phenotype ,, , has, has been, been identified, identified and, and found, found to, to encode, encode a, a protein, protein with, with homology, homology to, to Rho/Rac, Rho/Rac guanine, guanine nucleotide, nucleotide exchange, exchange factors, factors (, ( Rho/Rac, Rho/Rac GEF, GEF ), ) ., . However, However ,, , since, since this, this original, original report, report on, on identification, identification of, of a, a mutated, mutated FGD1, FGD1 gene, gene in, in an, an AAS, AAS patient, patient ,, , no, no additional, additional mutations, mutations in, in the, the FGD1, FGD1 gene, gene have, have been, been described, described ., . We, We analysed, analysed 13, 13 independent, independent patients, patients with, with clinical, clinical diagnosis, diagnosis of, of AAS, AAS ., . One, One patient, patient presented, presented a, a mutation, mutation that, that results, results in, in a, a nucleotide, nucleotide change, change in, in exon, exon 10, 10 of, of the, the FGD1, FGD1 gene, gene (, ( G2559, G2559 >, > A, A ), ) substituting, substituting a, a Gln, Gln for, for Arg, Arg in, in position, position 610, 610 ., . The, The mutation, mutation was, was found, found to, to segregate, segregate with, with the, the AAS, AAS phenotype, phenotype in, in affected, affected males, males and, and carrier, carrier females, females in, in the, the family, family of, of this, this patient, patient ., . Interestingly, Interestingly ,, , Arg-610, Arg-610 is, is located, located within, within one, one of, of the, the two, two pleckstrin, pleckstrin homology, homology (, ( PH, PH ), ) domains, domains of, of the, the FGD1, FGD1 gene, gene and, and it, it corresponds, corresponds to, to a, a highly, highly conserved, conserved residue, residue which, which has, has been, been involved, involved in, in InsP, InsP binding, binding in, in PH, PH domains, domains of, of other, other proteins, proteins ., . The, The same, same residue, residue is, is often, often mutated, mutated in, in the, the Brutons, Brutons tyrosine, tyrosine kinase, kinase (, ( Btk, Btk ), ) gene, gene in, in patients, patients with, with an, an X-linked, X-linked agammaglobulinemia, agammaglobulinemia ., . The, The Arg610Gln, Arg610Gln mutation, mutation represents, represents the, the first, first case, case of, of a, a mutation, mutation in, in the, the PH, PH domain, domain of, of the, the FGD1, FGD1 gene, gene and, and additional, additional evidence, evidence that, that mutations, mutations in, in PH, PH domains, domains can, can be, be associated, associated to, to human, human diseases.., diseases.. The, The human, human gene, gene for, for histidase, histidase (, ( histidine, histidine ammonia-lyase, ammonia-lyase ;, ; HAL, HAL ), ) ,, , the, the enzyme, enzyme deficient, deficient in, in histidinemia, histidinemia ,, , was, was assigned, assigned to, to human, human chromosome, chromosome 12, 12 by, by Southern, Southern blot, blot analysis, analysis of, of human, human X, X mouse, mouse somatic, somatic cell, cell hybrid, hybrid DNA, DNA ., . The, The gene, gene was, was sublocalized, sublocalized to, to region, region 12q22, 12q22 --, -- --, -- q24, q24 ., . 1, 1 by, by in, in situ, situ hybridization, hybridization ,, , using, using a, a human, human histidase, histidase cDNA, cDNA ., . The, The homologous, homologous locus, locus in, in the, the mouse, mouse (, ( Hal, Hal ), ) was, was mapped, mapped to, to region, region 10C2, 10C2 --, -- --, -- D1, D1 by, by in, in situ, situ hybridization, hybridization ,, , using, using a, a cell, cell line, line from, from a, a mouse, mouse homozygous, homozygous for, for a, a 1, 1 ., . 10, 10 Robertsonian, Robertsonian translocation, translocation ., . These, These assignments, assignments extend, extend the, the conserved, conserved syntenic, syntenic region, region between, between human, human chromosome, chromosome 12, 12 and, and mouse, mouse chromosome, chromosome 10, 10 that, that includes, includes the, the genes, genes for, for phenylalanine, phenylalanine hydroxylase, hydroxylase ,, , gamma, gamma interferon, interferon ,, , peptidase, peptidase ,, , and, and citrate, citrate synthase, synthase ., . The, The localization, localization of, of histidase, histidase to, to mouse, mouse chromosome, chromosome 10, 10 suggests, suggests that, that the, the histidase, histidase regulatory, regulatory locus, locus (, ( Hsd, Hsd ), ) and, and the, the histidinemia, histidinemia mutation, mutation (, ( his, his ), ) ,, , which, which are, are both, both known, known to, to be, be on, on chromosome, chromosome 10, 10 ,, , may, may be, be alleles, alleles of, of the, the histidase, histidase structural, structural gene, gene locus.Identification, locus.Identification of, of the, the FMR1, FMR1 gene, gene and, and the, the repeat-amplification, repeat-amplification mechanism, mechanism causing, causing fragile, fragile X, X syndrome, syndrome led, led to, to development, development of, of reliable, reliable DNA-based, DNA-based diagnostic, diagnostic methods, methods ,, , including, including Southern, Southern blot, blot hybridization, hybridization and, and PCR, PCR ., . Both, Both methods, methods are, are performed, performed on, on DNA, DNA isolated, isolated from, from peripheral, peripheral blood, blood cells, cells and, and measure, measure the, the repeat, repeat size, size in, in FMR1, FMR1 ., . Using, Using an, an immunocytochemical, immunocytochemical technique, technique on, on blood, blood smears, smears ,, , we, we recently, recently developed, developed a, a novel, novel test, test for, for identification, identification of, of patients, patients with, with fragile, fragile X, X syndrome, syndrome ., . This, This method, method ,, , also, also called, called ``, `` antibody, antibody test, test ,, , ``, `` uses, uses monoclonal, monoclonal antibodies, antibodies against, against the, the FMR1, FMR1 gene, gene product, product (, ( FMRP, FMRP ), ) and, and is, is based, based on, on absence, absence of, of FMRP, FMRP in, in patients, patients cells, cells ., . Here, Here we, we describe, describe a, a new, new diagnostic, diagnostic test, test to, to identify, identify male, male patients, patients with, with fragile, fragile X, X syndrome, syndrome ,, , on, on the, the basis, basis of, of lack, lack of, of FMRP, FMRP in, in their, their hair, hair roots, roots ., . Expression, Expression of, of FMRP, FMRP in, in hair, hair roots, roots was, was studied, studied by, by use, use of, of an, an FMRP-specific, FMRP-specific antibody, antibody test, test ,, , and, and the, the percentage, percentage of, of FMRP-expressing, FMRP-expressing hair, hair roots, roots in, in controls, controls and, and in, in male, male fragile, fragile X, X patients, patients was, was determined, determined ., . Control, Control individuals, individuals showed, showed clear, clear expression, expression of, of FMRP, FMRP in, in nearly, nearly every, every hair, hair root, root ,, , whereas, whereas male, male fragile, fragile X, X patients, patients lacked, lacked expression, expression of, of FMRP, FMRP in, in almost, almost all, all their, their hair, hair roots, roots ., . Mentally, Mentally retarded, retarded female, female patients, patients with, with a, a full, full mutation, mutation showed, showed FMRP, FMRP expression, expression in, in only, only some, some of, of their, their hair, hair roots, roots (, ( <, < 55, 55 %, % ), ) ,, , and, and no, no overlap, overlap with, with normal, normal female, female controls, controls was, was observed, observed ., . The, The advantages, advantages of, of this, this test, test are, are (, ( 1, 1 ), ) plucking, plucking of, of hair, hair follicles, follicles does, does no, no appreciable, appreciable harm, harm to, to the, the mentally, mentally retarded, retarded patient, patient ,, , (, ( 2, 2 ), ) hairs, hairs can, can be, be sent, sent in, in a, a simple, simple envelope, envelope to, to a, a diagnostic, diagnostic center, center ,, , and, and (, ( 3, 3 ), ) the, the result, result of, of the, the test, test is, is available, available within, within 5, 5 h, h of, of plucking, plucking ., . In, In addition, addition ,, , this, this test, test enabled, enabled us, us to, to identify, identify two, two fragile, fragile X, X patients, patients who, who did, did not, not show, show the, the full, full mutation, mutation by, by analysis, analysis of, of DNA, DNA isolated, isolated from, from blood, blood cells.., cells.. A, A family, family with, with an, an apparent, apparent history, history of, of X-linked, X-linked Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease presented, presented for, for genetic, genetic counseling, counseling ,, , requesting, requesting carrier, carrier detection, detection and, and prenatal, prenatal diagnosis, diagnosis ., . RFLP, RFLP analysis, analysis using, using the, the proteolipid, proteolipid protein, protein (, ( PLP, PLP ), ) gene, gene probe, probe was, was uninformative, uninformative in, in this, this family, family ., . A, A prenatal, prenatal diagnosis, diagnosis on, on a, a chorionic, chorionic villus, villus sample, sample (, ( CVS, CVS ), ) was, was carried, carried out, out using, using single-strand, single-strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) analysis, analysis of, of a, a variant, variant in, in exon, exon 4, 4 of, of the, the PLP, PLP gene, gene ., . The, The fetus, fetus was, was predicted, predicted to, to be, be unaffected, unaffected ., . Sequencing, Sequencing of, of the, the exon, exon from, from the, the CVS, CVS ,, , the, the predicted-carrier, predicted-carrier mother, mother ,, , and, and the, the obligate-carrier, obligate-carrier grandmother, grandmother revealed, revealed an, an A-to-C, A-to-C change, change at, at nucleotide, nucleotide 541, 541 in, in the, the two, two women, women but, but not, not in, in the, the fetus, fetus ., . As, As this, this change, change results, results in, in a, a Thr-to-Pro, Thr-to-Pro change, change at, at amino, amino acid, acid 181, 181 in, in a, a region, region of, of the, the gene, gene predicted, predicted to, to be, be part, part of, of a, a transmembrane, transmembrane segment, segment ,, , it, it was, was concluded, concluded that, that this, this was, was the, the mutation, mutation causing, causing the, the disease, disease in, in this, this family, family ., . In, In addition, addition ,, , in, in a, a second, second family, family ,, , an, an exon, exon 5, 5 variant, variant band, band pattern, pattern on, on SSCP, SSCP analysis, analysis was, was shown, shown by, by sequencing, sequencing to, to be, be due, due to, to a, a T-to-C, T-to-C change, change at, at nucleotide, nucleotide 668, 668 ., . This, This results, results in, in a, a Leu-to-Pro, Leu-to-Pro change, change in, in a, a carrier, carrier mother, mother and, and in, in her, her two, two affected, affected sons, sons ., . These, These results, results provide, provide further, further examples, examples of, of mutations, mutations in, in PLP, PLP that, that cause, cause Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease and, and illustrate, illustrate the, the value, value of, of SSCP, SSCP in, in genetic, genetic analysis.., analysis.. We, We describe, describe two, two brothers, brothers with, with identical, identical inherited, inherited deletions, deletions of, of one, one single, single exon, exon within, within the, the middle, middle of, of the, the DMD, DMD gene, gene ;, ; one, one brother, brother has, has Becker, Becker muscular, muscular dystrophy, dystrophy diagnosed, diagnosed at, at 11, 11 years, years of, of age, age ,, , whereas, whereas the, the older, older brother, brother is, is normal, normal at, at 18, 18 ., . These, These results, results have, have implications, implications for, for genetic, genetic counselling, counselling and, and prenatal, prenatal diagnosis, diagnosis in, in families, families with, with Becker, Becker muscular, muscular dystrophy.., dystrophy.. Kniest, Kniest dysplasia, dysplasia is, is a, a moderately, moderately severe, severe type, type II, II collagenopathy, collagenopathy ,, , characterized, characterized by, by short, short trunk, trunk and, and limbs, limbs ,, , kyphoscoliosis, kyphoscoliosis ,, , midface, midface hypoplasia, hypoplasia ,, , severe, severe myopia, myopia ,, , and, and hearing, hearing loss, loss ., . Mutations, Mutations in, in the, the gene, gene that, that encodes, encodes type, type II, II collagen, collagen (, ( COL2A1, COL2A1 ), ) ,, , the, the predominant, predominant protein, protein of, of cartilage, cartilage ,, , have, have been, been identified, identified in, in a, a number, number of, of individuals, individuals with, with Kniest, Kniest dysplasia, dysplasia ., . All, All but, but two, two of, of these, these previously, previously described, described mutations, mutations cause, cause in-frame, in-frame deletions, deletions in, in type, type II, II collagen, collagen ,, , either, either by, by small, small deletions, deletions in, in the, the gene, gene or, or splice, splice site, site alterations, alterations ., . Furthermore, Furthermore ,, , all, all but, but one, one of, of these, these mutations, mutations is, is located, located between, between exons, exons 12, 12 and, and 24, 24 in, in the, the COL2A1, COL2A1 gene, gene ., . We, We used, used heteroduplex, heteroduplex analysis, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "analysis to, to identify, identify sequence, sequence anomalies, anomalies in, in five, five individuals, individuals with, with Kniest, Kniest dysplasia, dysplasia ., . Sequencing, Sequencing of, of the, the index, index patients, patients genomic, genomic DNA, DNA identified, identified four, four new, new dominant, dominant mutations, mutations in, in COL2A1, COL2A1 that, that result, result in, in Kniest, Kniest dysplasia, dysplasia a, a 21-bp, 21-bp deletion, deletion in, in exon, exon 16, 16 ,, , an, an 18-bp, 18-bp deletion, deletion in, in exon, exon 19, 19 ,, , and, and 4-bp, 4-bp deletions, deletions in, in the, the splice, splice donor, donor sites, sites of, of introns, introns 14, 14 and, and 20, 20 ., . A, A previously, previously described, described 28-bp, 28-bp deletion, deletion at, at the, the COL2A1, COL2A1 exon, exon 12-intron, 12-intron 12, 12 junction, junction ,, , deleting, deleting the, the splice, splice donor, donor site, site ,, , was, was identified, identified in, in the, the fifth, fifth case, case ., . The, The latter, latter three, three mutations, mutations are, are predicted, predicted to, to result, result in, in exon, exon skipping, skipping in, in the, the mRNA, mRNA encoded, encoded from, from the, the mutant, mutant allele, allele ., . These, These data, data suggest, suggest that, that Kniest, Kniest dysplasia, dysplasia results, results from, from shorter, shorter type, type II, II collagen, collagen monomers, monomers ,, , and, and support, support the, the hypothesis, hypothesis that, that alteration, alteration of, of a, a specific, specific COL2A1, COL2A1 domain, domain ,, , which, which may, may span, span from, from exons, exons 12, 12 to, to 24, 24 ,, , leads, leads to, to the, the Kniest, Kniest dysplasia, dysplasia phenotype.., phenotype.. We, We present, present the, the clinical, clinical and, and laboratory, laboratory findings, findings in, in an, an institutionalised, institutionalised adult, adult patient, patient originally, originally referred, referred for, for autism, autism ., . A, A high, high risk, risk of, of colorectal, colorectal cancer, cancer was, was predicted, predicted when, when an, an interstitial, interstitial deletion, deletion of, of the, the long, long arm, arm of, of chromosome, chromosome 5, 5 ,, , del, del (, ( 5, 5 ), ) (, ( q15q22, q15q22 ., . 3, 3 ), ) ,, , was, was detected, detected in, in her, her lymphocytes, lymphocytes and, and deletion, deletion of, of the, the MCC, MCC and, and APC, APC genes, genes confirmed, confirmed by, by molecular, molecular analysis, analysis ., . Adenomatous, Adenomatous polyposis, polyposis coli, coli and, and carcinoma, carcinoma of, of the, the rectum, rectum were, were subsequently, subsequently diagnosed, diagnosed in, in the, the patient, patient ., . She, She was, was profoundly, profoundly mentally, mentally retarded, retarded ,, , autistic, autistic ,, , and, and had, had minor, minor dysmorphic, dysmorphic features, features consistent, consistent with, with those, those of, of previous, previous patients, patients with, with similar, similar deletions, deletions ., . The, The deletion, deletion arose, arose as, as a, a result, result of, of recombination, recombination within, within the, the small, small insertion, insertion loop, loop formed, formed at, at meiosis, meiosis by, by the, the direct, direct insertion, insertion (, ( dir, dir ins, ins (, ( 5, 5 ), ) (, ( q22, q22 ., . 3q14, 3q14 ., . 2q15, 2q15 ), ) ), ) found, found in, in the, the patients, patients mother, mother ., . This, This family, family further, further confirms, confirms the, the cytogenetic, cytogenetic mapping, mapping of, of both, both MCC, MCC and, and APC, APC genes, genes to, to 5q22, 5q22 and, and comparison, comparison with, with other, other recent, recent cases, cases suggests, suggests that, that both, both genes, genes and, and their, their closely, closely linked, linked markers, markers lie, lie within, within the, the 5q22, 5q22 ., . 1, 1 subband, subband We, We examined, examined somatic, somatic mutations, mutations of, of the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene in, in 63, 63 colorectal, colorectal tumors, tumors (, ( 16, 16 adenomas, adenomas and, and 47, 47 carcinomas, carcinomas ), ) developed, developed in, in familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) and, and non-FAP, non-FAP patients, patients ., . In, In addition, addition to, to loss, loss of, of heterozygosity, heterozygosity (, ( LOH, LOH ), ) at, at the, the APC, APC locus, locus in, in 30, 30 tumors, tumors ,, , 43, 43 other, other somatic, somatic mutations, mutations were, were detected, detected ., . Twenty-one, Twenty-one of, of them, them were, were point, point mutations, mutations ;, ; 16, 16 nonsense, nonsense and, and two, two missense, missense mutations, mutations ,, , and, and three, three occurred, occurred in, in introns, introns at, at the, the splicing, splicing site, site ., . Twenty-two, Twenty-two tumors, tumors had, had frameshift, frameshift mutations, mutations due, due to, to deletion, deletion or, or insertion, insertion ;, ; nineteen, nineteen of, of them, them were, were deletions, deletions of, of one, one to, to 31, 31 bp, bp and, and three, three were, were a, a 1-bp, 1-bp insertion, insertion ., . One, One tumor, tumor had, had a, a 1-bp, 1-bp deletion, deletion in, in an, an intron, intron near, near the, the splicing, splicing site, site ., . Hence, Hence ,, , 41, 41 (, ( 95, 95 %, % ), ) of, of 43, 43 mutations, mutations resulted, resulted in, in truncation, truncation of, of the, the APC, APC protein, protein ., . Over, Over 60, 60 %, % of, of the, the somatic, somatic mutations, mutations in, in the, the APC, APC gene, gene were, were clustered, clustered within, within a, a small, small region, region of, of exon, exon 15, 15 ,, , designated, designated as, as MCR, MCR (, ( mutation, mutation cluster, cluster region, region ), ) ,, , which, which accounted, accounted for, for less, less than, than 10, 10 %, % of, of the, the coding, coding region, region ., . Combining, Combining these, these data, data and, and the, the results, results of, of LOH, LOH ,, , more, more than, than 80, 80 %, % of, of tumors, tumors (, ( 14, 14 adenomas, adenomas and, and 39, 39 carcinomas, carcinomas ), ) had, had at, at least, least one, one mutation, mutation in, in the, the APC, APC gene, gene ,, , of, of which, which more, more than, than 60, 60 %, % (, ( 9, 9 adenomas, adenomas and, and 23, 23 carcinomas, carcinomas ), ) had, had two, two mutations, mutations ., . These, These results, results strongly, strongly suggest, suggest that, that somatic, somatic mutations, mutations of, of the, the APC, APC gene, gene are, are associated, associated with, with development, development of, of a, a great, great majority, majority of, of colorectal, colorectal tumors.., tumors.. Tay-Sachs, Tay-Sachs disease, disease is, is an, an autosomal, autosomal recessive, recessive genetic, genetic disorder, disorder resulting, resulting from, from mutation, mutation of, of the, the HEXA, HEXA gene, gene encoding, encoding the, the alpha-subunit, alpha-subunit of, of the, the lysosomal, lysosomal enzyme, enzyme ,, , beta-N-acetylhexosaminidase, beta-N-acetylhexosaminidase A, A (, ( ref, ref ., . 1, 1 ), ) ., . A, A relatively, relatively high, high frequency, frequency of, of carriers, carriers (, ( 1/27, 1/27 ), ) of, of a, a lethal, lethal ,, , infantile, infantile form, form of, of the, the disease, disease is, is found, found in, in the, the Ashkenazi, Ashkenazi Jewish, Jewish population, population ,, , but, but it, it is, is not, not yet, yet evident, evident whether, whether this, this has, has resulted, resulted from, from a, a founder, founder effect, effect and, and random, random genetic, genetic drift, drift or, or from, from a, a selective, selective advantage, advantage of, of heterozygotes, heterozygotes ., . We, We have, have identified, identified a, a single-base, single-base mutation, mutation in, in a, a cloned, cloned fragment, fragment of, of the, the HEXA, HEXA gene, gene from, from an, an Ashkenazi, Ashkenazi Jewish, Jewish patient, patient ., . This, This change, change ,, , the, the substitution, substitution of, of a, a C, C for, for G, G in, in the, the first, first nucleotide, nucleotide of, of intron, intron 12, 12 is, is expected, expected to, to result, result in, in defective, defective splicing, splicing of, of the, the messenger, messenger RNA, RNA ., . A, A test, test for, for the, the mutant, mutant allele, allele based, based on, on amplification, amplification of, of DNA, DNA by, by the, the polymerase, polymerase chain, chain rection, rection and, and cleavage, cleavage of, of a, a DdeI, DdeI restriction, restriction site, site generated, generated by, by the, the mutation, mutation revealed, revealed that, that this, this case, case and, and two, two other, other cases, cases of, of the, the Ashkenazi, Ashkenazi ,, , infantile, infantile form, form of, of Tay-Sachs, Tay-Sachs disease, disease are, are heterozygous, heterozygous for, for two, two different, different mutations, mutations ., . The, The occurrence, occurrence of, of multiple, multiple mutant, mutant alleles, alleles warrants, warrants further, further examination, examination of, of the, the selective, selective advantage, advantage hypothesis.., hypothesis.. Coats, Coats disease, disease is, is characterized, characterized by, by abnormal, abnormal retinal, retinal vascular, vascular development, development (, ( so-called, so-called retinal, retinal telangiectasis, telangiectasis ), ) which, which results, results in, in massive, massive intraretinal, intraretinal and, and subretinal, subretinal lipid, lipid accumulation, accumulation (, ( exudative, exudative retinal, retinal detachment, detachment ), ) ., . The, The classical, classical form, form of, of Coats, Coats disease, disease is, is almost, almost invariably, invariably isolated, isolated ,, , unilateral, unilateral and, and seen, seen in, in males, males ., . A, A female, female with, with a, a unilateral, unilateral variant, variant of, of Coats, Coats disease, disease gave, gave birth, birth to, to a, a son, son affected, affected by, by Norrie, Norrie disease, disease ., . Both, Both carried, carried a, a missense, missense mutation, mutation within, within the, the NDP, NDP gene, gene on, on chromosome, chromosome Xp11, Xp11 ., . 2, 2 2, 2 ., . Subsequently, Subsequently analysis, analysis of, of the, the retinas, retinas of, of nine, nine enucleated, enucleated eyes, eyes from, from males, males with, with Coats, Coats disease, disease demonstrated, demonstrated in, in one, one a, a somatic, somatic mutation, mutation in, in the, the NDP, NDP gene, gene which, which was, was not, not present, present within, within non-retinal, non-retinal tissue, tissue ., . We, We suggest, suggest that, that Coats, Coats telangiectasis, telangiectasis is, is secondary, secondary to, to somatic, somatic mutation, mutation in, in the, the NDP, NDP gene, gene which, which results, results in, in a, a deficiency, deficiency of, of norrin, norrin (, ( the, the protein, protein product, product of, of the, the NDP, NDP gene, gene ), ) within, within the, the developing, developing retina, retina ., . This, This supports, supports recent, recent observations, observations that, that the, the protein, protein is, is critical, critical for, for normal, normal retinal, retinal vasculogenesis, vasculogenesis ., . Uniparental, Uniparental disomy, disomy has, has recently, recently been, been recognized, recognized to, to cause, cause human, human disorders, disorders ,, , including, including Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . We, We describe, describe a, a particularly, particularly instructive, instructive case, case which, which raises, raises important, important issues, issues concerning, concerning the, the mechanisms, mechanisms producing, producing uniparental, uniparental disomy, disomy and, and whose, whose evaluation, evaluation provides, provides evidence, evidence that, that trisomy, trisomy may, may precede, precede uniparental, uniparental disomy, disomy in, in a, a fetus, fetus ., . Chorionic, Chorionic villus, villus sampling, sampling performed, performed for, for advanced, advanced maternal, maternal age, age revealed, revealed trisomy, trisomy 15, 15 in, in all, all direct, direct and, and cultured, cultured cells, cells ,, , though, though the, the fetus, fetus appeared, appeared normal, normal ., . Chromosome, Chromosome analysis, analysis of, of amniocytes, amniocytes obtained, obtained at, at 15, 15 wk, wk was, was normal, normal in, in over, over 100, 100 cells, cells studied, studied ., . The, The child, child was, was hypotonic, hypotonic at, at birth, birth ,, , and, and high-resolution, high-resolution banding, banding failed, failed to, to reveal, reveal the, the deletion, deletion of, of 15q11-13, 15q11-13 ,, , a, a deletion, deletion which, which is, is found, found in, in 50, 50 %, % -70, -70 %, % of, of patients, patients with, with PWS, PWS ., . Over, Over time, time ,, , typical, typical features, features of, of PWS, PWS developed, developed ., . Molecular, Molecular genetic, genetic analysis, analysis using, using probes, probes for, for chromosome, chromosome 15, 15 revealed, revealed maternal, maternal disomy, disomy ., . Maternal, Maternal nondisjunction, nondisjunction with, with fertilization, fertilization of, of a, a disomic, disomic egg, egg by, by a, a normal, normal sperm, sperm ,, , followed, followed by, by loss, loss of, of the, the paternal, paternal 15, 15 ,, , is, is a, a likely, likely cause, cause of, of confined, confined placental, placental mosaicism, mosaicism and, and uniparental, uniparental disomy, disomy in, in this, this case, case of, of PWS, PWS ,, , and, and advanced, advanced maternal, maternal age, age may, may be, be a, a predisposing, predisposing factor.., factor.. A, A genetic, genetic deficiency, deficiency of, of the, the fifth, fifth (, ( C5, C5 ), ) component, component of, of complement1-3, complement1-3 ,, , a, a serum, serum glycoprotein, glycoprotein of, of molecular, molecular weight, weight (, ( MW, MW ), ) 220, 220 ,, , 000, 000 (, ( ref, ref ., . 4, 4 ), ) ,, , has, has been, been found, found in, in 39, 39 %, % of, of inbred, inbred strains, strains of, of mice3, mice3 ., . Sera, Sera of, of deficient, deficient mice, mice lack, lack detectable, detectable C5, C5 activity, activity and, and protein2, protein2 ,, , 3, 3 ., . In, In addition, addition deficient, deficient mice, mice produce, produce antibody, antibody to, to mouse, mouse C5, C5 when, when injected, injected with, with sera, sera from, from C5, C5 sufficient, sufficient (, ( normal, normal ), ) strains, strains ., . Levy, Levy et, et al, al ., . 5, 5 showed, showed that, that somatic, somatic cell, cell hybrids, hybrids between, between C5, C5 deficient, deficient (, ( B10, B10 ., . D2/old, D2/old line, line ), ) macrophages, macrophages and, and either, either C5, C5 sufficient, sufficient (, ( B10, B10 ., . D2/new, D2/new line, line ), ) mouse, mouse kidney, kidney or, or chicken, chicken erythroblasts, erythroblasts secreted, secreted haemolytically, haemolytically active, active mouse, mouse C5, C5 in, in vitro, vitro ., . Several, Several possible, possible molecular, molecular mechanisms, mechanisms to, to account, account for, for the, the findings, findings were, were considered, considered ,, , but, but insufficient, insufficient direct, direct data, data were, were available, available to, to choose, choose among, among them, them ., . We, We recently, recently reported, reported that, that mouse, mouse (, ( CD, CD ., . 1, 1 strain, strain ), ) peritoneal, peritoneal cells, cells in, in culture, culture synthesise, synthesise and, and secrete, secrete a, a single, single chain, chain precursor, precursor ,, , pro-C5, pro-C5 (, ( MW, MW approximately, approximately 210, 210 ,, , 000, 000 ), ) ,, , of, of the, the two-chain, two-chain (, ( alpha, alpha chain, chain ,, , 125, 125 ,, , 000, 000 and, and beta, beta chain, chain 83, 83 ,, , 000, 000 MW, MW ), ) C5, C5 protein6, protein6 ., . Radiolabelled, Radiolabelled precursor, precursor C5, C5 was, was contained, contained within, within the, the cells, cells and, and was, was secreted, secreted into, into the, the tissue, tissue culture, culture media, media ., . Using, Using similar, similar methods, methods ,, , we, we now, now find, find that, that C5, C5 deficiency, deficiency in, in each, each of, of five, five different, different mouse, mouse strains, strains (, ( AKR, AKR ,, , SWR, SWR ,, , DBA/2J8, DBA/2J8 A/HeJ, A/HeJ and, and B10, B10 ., . D2/old, D2/old line, line ), ) is, is due, due to, to a, a failure, failure in, in secretion, secretion of, of C5, C5 protein, protein and, and not, not to, to a, a failure, failure in, in biosynthesis, biosynthesis of, of pro-C5, pro-C5 The, The WASP, WASP gene, gene has, has been, been recently, recently cloned, cloned from, from Xp11, Xp11 ., . 23, 23 and, and shown, shown to, to be, be mutated, mutated in, in three, three patients, patients with, with the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) ., . We, We have, have developed, developed a, a screening, screening protocol, protocol for, for identifying, identifying WASP, WASP gene, gene alterations, alterations in, in genomic, genomic DNA, DNA and, and have, have identified, identified a, a spectrum, spectrum of, of novel, novel mutations, mutations in, in 12, 12 additional, additional unrelated, unrelated families, families ., . These, These missense, missense ,, , nonsense, nonsense and, and frameshift, frameshift mutations, mutations involve, involve eight, eight of, of the, the 12, 12 exons, exons of, of the, the gene, gene ., . Two, Two mutations, mutations creating, creating premature, premature termination, termination codons, codons were, were associated, associated with, with lack, lack of, of detectable, detectable mRNA, mRNA on, on Northern, Northern blots, blots ., . Four, Four amino, amino acid, acid substitutions, substitutions ,, , Leu27Phe, Leu27Phe ,, , Thr48Ile, Thr48Ile ,, , Val75Met, Val75Met and, and Arg477Lys, Arg477Lys ,, , were, were found, found in, in patients, patients with, with congenital, congenital thrombocytopenia, thrombocytopenia and, and no, no clinically, clinically evident, evident immune, immune defect, defect indicating, indicating that, that the, the WASP, WASP gene, gene is, is the, the site, site for, for mutations, mutations in, in X-linked, X-linked thrombocytopenia, thrombocytopenia as, as well, well as, as in, in WAS, WAS ., . A, A T-cell, T-cell line, line from, from a, a WAS, WAS patient, patient contained, contained two, two independent, independent DNA, DNA alterations, alterations ,, , a, a constitutional, constitutional frameshift, frameshift mutation, mutation ,, , also, also present, present in, in peripheral, peripheral blood, blood leukocytes, leukocytes from, from the, the patient, patient ,, , and, and compensatory, compensatory splice, splice site, site mutation, mutation unique, unique to, to the, the cell, cell line, line ., . The, The distribution, distribution of, of eight, eight missense, missense mutations, mutations provides, provides valuable, valuable information, information on, on amino, amino acids, acids which, which are, are essential, essential for, for normal, normal protein, protein function, function ,, , and, and suggests, suggests that, that sites, sites in, in the, the first, first two, two exons, exons are, are hot-spots, hot-spots for, for mutation, mutation ., . A, A combination, combination of, of multiplex, multiplex PCR, PCR with, with the, the single, single strand, strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) technique, technique was, was employed, employed to, to screen, screen for, for point, point mutations, mutations in, in the, the human, human dystrophin, dystrophin gene, gene ., . Co-amplification, Co-amplification of, of 11, 11 exons, exons from, from genomic, genomic DNA, DNA of, of Duchenne, Duchenne and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( DMD/BMD, DMD/BMD ), ) patients, patients with, with no, no deletion, deletion or, or duplication, duplication was, was performed, performed and, and the, the samples, samples subjected, subjected to, to multiple, multiple SSCP, SSCP analysis, analysis ., . We, We report, report the, the case, case of, of a, a nonsense, nonsense mutation, mutation in, in a, a Duchenne, Duchenne patient, patient identified, identified by, by this, this approach, approach ., . The, The mutation, mutation introduces, introduces a, a termination, termination codon, codon within, within exon, exon 8, 8 of, of the, the dystrophin, dystrophin gene, gene ., . It, It is, is predicted, predicted to, to cause, cause a, a very, very premature, premature translational, translational termination, termination accounting, accounting for, for the, the severe, severe phenotype, phenotype observed, observed ., . The, The patient, patient inherited, inherited this, this mutation, mutation from, from his, his mother, mother ., . In, In addition, addition the, the analysis, analysis revealed, revealed 5, 5 polymorphisms, polymorphisms useful, useful for, for internal, internal control.., control.. The, The RB1, RB1 gene, gene from, from 12, 12 human, human retinoblastoma, retinoblastoma tumors, tumors has, has been, been analyzed, analyzed exon-by-exon, exon-by-exon with, with the, the single-strand, single-strand conformation, conformation polymorphism, polymorphism technique, technique ., . Mutations, Mutations were, were found, found in, in all, all tumors, tumors ,, , and, and one-third, one-third of, of the, the tumors, tumors had, had independent, independent mutations, mutations in, in both, both alleles, alleles neither, neither of, of which, which were, were found, found in, in the, the germ, germ line, line ,, , confirming, confirming their, their true, true sporadic, sporadic nature, nature ., . In, In the, the remaining, remaining two-thirds, two-thirds of, of the, the tumors, tumors only, only one, one mutation, mutation was, was found, found ,, , consistent, consistent with, with the, the loss-of-heterozygosity, loss-of-heterozygosity theory, theory of, of tumorigenesis, tumorigenesis ., . Point, Point mutations, mutations ,, , the, the majority, majority of, of which, which were, were C, C --, -- >, > T, T transitions, transitions ,, , were, were the, the most, most common, common abnormality, abnormality and, and usually, usually resulted, resulted in, in the, the conversion, conversion of, of an, an arginine, arginine codon, codon to, to a, a stop, stop codon, codon ., . Small, Small deletions, deletions were, were the, the second, second most, most common, common abnormality, abnormality and, and most, most often, often created, created a, a downstream, downstream stop, stop codon, codon as, as the, the result, result of, of a, a reading, reading frameshift, frameshift ., . Deletions, Deletions and, and point, point mutations, mutations also, also affected, affected splice, splice junctions, junctions ., . Direct, Direct repeats, repeats were, were present, present at, at the, the breakpoint, breakpoint junctions, junctions in, in the, the majority, majority of, of deletions, deletions ,, , supporting, supporting a, a slipped-mispairing, slipped-mispairing mechanism, mechanism ., . Point, Point mutations, mutations generally, generally produced, produced DNA, DNA sequences, sequences which, which resulted, resulted in, in perfect, perfect homology, homology with, with endogenous, endogenous sequences, sequences which, which lay, lay within, within 14, 14 bp.., bp.. The, The human, human eye, eye malformation, malformation aniridia, aniridia results, results from, from haploinsufficiency, haploinsufficiency of, of PAX6, PAX6 ,, , a, a paired, paired box, box DNA-binding, DNA-binding protein, protein ., . To, To study, study this, this dosage, dosage effect, effect ,, , we, we characterized, characterized two, two PAX6, PAX6 mutations, mutations in, in a, a family, family segregating, segregating aniridia, aniridia and, and a, a milder, milder syndrome, syndrome consisting, consisting of, of congenital, congenital cataracts, cataracts and, and late, late onset, onset corneal, corneal dystrophy, dystrophy ., . The, The nonsense, nonsense mutations, mutations ,, , at, at codons, codons 103, 103 and, and 353, 353 ,, , truncate, truncate PAX6, PAX6 within, within the, the N-terminal, N-terminal paired, paired and, and C-terminal, C-terminal PST, PST domains, domains ,, , respectively, respectively ., . The, The wild-type, wild-type PST, PST domain, domain activates, activates transcription, transcription autonomously, autonomously and, and the, the mutant, mutant form, form has, has partial, partial activity, activity ., . A, A compound, compound heterozygote, heterozygote had, had severe, severe craniofacial, craniofacial and, and central, central nervous, nervous system, system defects, defects and, and no, no eyes, eyes ., . The, The pattern, pattern of, of malformations, malformations is, is similar, similar to, to that, that in, in homozygous, homozygous Sey, Sey mice, mice and, and suggests, suggests a, a critical, critical role, role for, for PAX6, PAX6 in, in controlling, controlling the, the migration, migration and, and differentiation, differentiation of, of specific, specific neuronal, neuronal progenitor, progenitor cells, cells in, in the, the brain.., brain.. The, The serum, serum of, of a, a 44-yr-old, 44-yr-old woman, woman of, of French-Canadian, French-Canadian descent, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "descent having, having a, a B-27, B-27 positive, positive ankylosing, ankylosing spondylitis, spondylitis was, was deficient, deficient in, in the, the seventh, seventh component, component of, of complement, complement (, ( C7, C7 ), ) as, as determined, determined by, by hemolytic, hemolytic and, and immunochemical, immunochemical methods, methods ., . No, No inhibitor, inhibitor against, against C7, C7 was, was detected, detected ,, , and, and the, the levels, levels of, of all, all other, other complement, complement components, components were, were normal, normal ., . No, No deficiency, deficiency in, in the, the opsonic, opsonic activity, activity of, of the, the serum, serum was, was found, found ,, , and, and the, the results, results of, of basic, basic coagulation, coagulation studies, studies of, of the, the plasma, plasma were, were normal, normal ., . On, On investigation, investigation of, of the, the patients, patients family, family ,, , two, two sisters, sisters were, were found, found to, to have, have the, the same, same deficiency, deficiency but, but were, were otherwise, otherwise in, in good, good health, health ., . The, The seven, seven other, other siblings, siblings were, were heterozygous, heterozygous for, for C7, C7 deficiency, deficiency ,, , while, while the, the paternal, paternal aunt, aunt had, had a, a normal, normal C7, C7 level, level ., . In, In the, the third, third generation, generation ,, , six, six children, children of, of the, the three, three homozygous, homozygous sisters, sisters and, and five, five children, children of, of heterozygotes, heterozygotes were, were available, available for, for testing, testing ., . Studies, Studies of, of the, the HLA, HLA antigens, antigens in, in all, all the, the 22, 22 subjects, subjects and, and in, in three, three spouses, spouses indicated, indicated no, no close, close linkage, linkage between, between the, the CM, CM deficienty, deficienty and, and the, the HLA, HLA system, system ., . In, In addition, addition ,, , the, the simultaneous, simultaneous occurrence, occurrence of, of two, two hereditary, hereditary complement, complement deficiencies, deficiencies (, ( C2, C2 and, and C7, C7 ), ) was, was discovered, discovered in, in one, one family, family of, of this, this remarkable, remarkable kindred.., kindred.. Alstrom, Alstrom syndrome, syndrome is, is a, a rare, rare autosomal, autosomal recessive, recessive disorder, disorder characterized, characterized by, by retinal, retinal degeneration, degeneration ,, , sensorineural, sensorineural hearing, hearing loss, loss ,, , early-onset, early-onset obesity, obesity ,, , and, and non-insulin-dependent, non-insulin-dependent diabetes, diabetes mellitus, mellitus ., . The, The gene, gene for, for Alstrom, Alstrom syndrome, syndrome (, ( ALMS1, ALMS1 ), ) has, has been, been previously, previously localized, localized to, to human, human chromosome, chromosome 2p13, 2p13 by, by homozygosity, homozygosity mapping, mapping in, in two, two distinct, distinct isolated, isolated populations, populations -, - French, French Acadian, Acadian and, and North, North African, African ., . Pair-wise, Pair-wise analyses, analyses resulted, resulted in, in maximum, maximum lod, lod (, ( logarithm, logarithm of, of the, the odds, odds ratio, ratio ), ) scores, scores of, of 3, 3 ., . 84, 84 and, and 2, 2 ., . 9, 9 ,, , respectively, respectively ., . To, To confirm, confirm these, these findings, findings ,, , a, a large, large linkage, linkage study, study was, was performed, performed in, in twelve, twelve additional, additional families, families segregating, segregating for, for Alstrom, Alstrom syndrome, syndrome ., . A, A maximum, maximum two-point, two-point lod, lod score, score of, of 7, 7 ., . 13, 13 (, ( theta, theta =, = 0, 0 ., . 00, 00 ), ) for, for marker, marker D2S2110, D2S2110 and, and a, a maximum, maximum cumulative, cumulative multipoint, multipoint lod, lod score, score of, of 9, 9 ., . 16, 16 for, for marker, marker D2S2110, D2S2110 were, were observed, observed ,, , further, further supporting, supporting linkage, linkage to, to chromosome, chromosome 2p13, 2p13 ., . No, No evidence, evidence of, of genetic, genetic heterogeneity, heterogeneity was, was observed, observed in, in these, these families, families ., . Meiotic, Meiotic recombination, recombination events, events have, have localized, localized the, the critical, critical region, region containing, containing ALMS1, ALMS1 to, to a, a 6, 6 ., . 1-cM, 1-cM interval, interval flanked, flanked by, by markers, markers D2S327, D2S327 and, and D2S286, D2S286 ., . A, A fine, fine resolution, resolution radiation, radiation hybrid, hybrid map, map of, of 31, 31 genes, genes and, and markers, markers has, has been, been constructed.Multipoint, constructed.Multipoint linkage, linkage analysis, analysis of, of choroideremia, choroideremia (, ( TCD, TCD ), ) and, and seven, seven X, X chromosomal, chromosomal restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms (, ( RFLPs, RFLPs ), ) was, was carried, carried out, out in, in 18, 18 Finnish, Finnish TCD, TCD families, families ., . The, The data, data place, place TCD, TCD distal, distal to, to PGK, PGK and, and DXS72, DXS72 ,, , very, very close, close to, to DXYS1, DXYS1 and, and DXYS5, DXYS5 (, ( Zmax, Zmax =, = 24, 24 at, at theta, theta =, = 0, 0 ), ) and, and proximal, proximal to, to DXYS4, DXYS4 and, and DXYS12, DXYS12 ., . This, This agrees, agrees with, with the, the data, data obtained, obtained from, from other, other linkage, linkage studies, studies and, and from, from physical, physical mapping, mapping ., . All, All the, the TCD, TCD males, males and, and carrier, carrier females, females studied, studied have, have the, the same, same DXYS1, DXYS1 allele, allele in, in coupling, coupling with, with TCD, TCD ., . In, In Northeastern, Northeastern Finland, Finland ,, , 66/69, 66/69 chromosomes, chromosomes carrying, carrying TCD, TCD had, had the, the same, same haplotype, haplotype at, at loci, loci DXS72, DXS72 ,, , DXYS1, DXYS1 ,, , DXYS4, DXYS4 ,, , and, and DXYS12, DXYS12 ., . The, The same, same haplotype, haplotype is, is seen, seen in, in only, only 15/99, 15/99 chromosomes, chromosomes not, not carrying, carrying TCD, TCD ., . Moreover, Moreover ,, , in, in 71/104, 71/104 non-TCD, non-TCD chromosomes, chromosomes ,, , the, the haplotype, haplotype at, at six, six marker, marker loci, loci is, is different, different from, from those, those seen, seen in, in any, any of, of the, the 76, 76 TCD, TCD chromosomes, chromosomes ., . This, This supports, supports the, the previously, previously described, described hypothesis, hypothesis that, that the, the large, large Northern, Northern Finnish, Finnish choroideremia, choroideremia pedigrees, pedigrees ,, , comprising, comprising a, a total, total of, of over, over 80, 80 living, living patients, patients representing, representing more, more than, than a, a fifth, fifth of, of all, all TCD, TCD patients, patients described, described worldwide, worldwide ,, , carry, carry the, the same, same mutation, mutation ., . These, These linkage, linkage and, and haplotype, haplotype data, data provide, provide improved, improved opportunities, opportunities for, for prenatal, prenatal diagnosis, diagnosis based, based on, on RFLP, RFLP studies.., studies.. Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) has, has been, been analyzed, analyzed by, by gel, gel electrophoresis, electrophoresis and, and by, by quantitative, quantitative assay, assay in, in an, an unselected, unselected sample, sample of, of 1524, 1524 schoolboys, schoolboys from, from the, the province, province of, of Matera, Matera (, ( Lucania, Lucania ), ) in, in southern, southern Italy, Italy ., . We, We have, have identified, identified 43, 43 subjects, subjects with, with a, a G6PD, G6PD variant, variant ., . Of, Of these, these ,, , 31, 31 had, had severe, severe G6PD, G6PD deficiency, deficiency ,, , nine, nine had, had mild, mild to, to moderate, moderate deficiency, deficiency ,, , and, and three, three had, had a, a non-deficient, non-deficient electrophoretic, electrophoretic variant, variant ., . The, The overall, overall rate, rate of, of G6PD, G6PD deficiency, deficiency was, was 2, 2 ., . 6, 6 %, % ., . The, The frequency, frequency of, of G6PD, G6PD deficiency, deficiency ,, , ranging, ranging from, from 7, 7 ., . 2, 2 %, % on, on the, the Ionian, Ionian Coast, Coast to, to zero, zero on, on the, the eastern, eastern side, side of, of the, the Lucanian, Lucanian Apennines, Apennines ,, , appears, appears to, to be, be inversely, inversely related, related to, to the, the distance, distance of, of each, each town, town examined, examined from, from the, the Ionian, Ionian Coast, Coast ,, , suggesting, suggesting that, that this, this geographic, geographic distribution, distribution may, may reflect, reflect ,, , at, at least, least in, in part, part ,, , gene, gene flow, flow from, from Greek, Greek settlers, settlers ., . Biochemical, Biochemical characterization, characterization has, has shown, shown that, that most, most of, of the, the G6PD, G6PD deficiency, deficiency in, in this, this population, population is, is accounted, accounted for, for by, by G6PD, G6PD Mediterranean, Mediterranean ., . In, In addition, addition ,, , we, we have, have found, found several, several examples, examples of, of two, two other, other known, known polymorphic, polymorphic variants, variants (, ( G6PD, G6PD Cagliari, Cagliari and, and G6PD, G6PD A-, A- ), ) ;, ; three, three new, new polymorphic, polymorphic variants, variants ,, , G6PD, G6PD Metaponto, Metaponto (, ( class, class III, III ), ) ,, , G6PD, G6PD Montalbano, Montalbano (, ( class, class III, III ), ) ,, , and, and G6PD, G6PD Pisticci, Pisticci (, ( class, class IV, IV ), ) ;, ; and, and two, two sporadic, sporadic variants, variants ,, , G6PD, G6PD Tursi, Tursi (, ( class, class III, III ), ) and, and G6PD, G6PD Ferrandina, Ferrandina (, ( class, class II, II ), ) ., . These, These data, data provide, provide further, further evidence, evidence for, for the, the marked, marked genetic, genetic heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency within, within a, a relatively, relatively narrow, narrow geographic, geographic area, area and, and they, they prove, prove the, the presence, presence in, in the, the Italian, Italian peninsula, peninsula of, of a, a gene, gene (, ( GdA-, GdA- ), ) regarded, regarded as, as characteristically, characteristically African.Cytotoxic, African.Cytotoxic T, T lymphocyte-associated, lymphocyte-associated antigen, antigen 4, 4 (, ( CTLA-4, CTLA-4 ,, , also, also known, known as, as CD152, CD152 ), ) has, has been, been shown, shown to, to play, play a, a major, major role, role in, in the, the regulation, regulation of, of T, T cell, cell activation, activation ., . Its, Its membrane, membrane expression, expression is, is highly, highly regulated, regulated by, by endocytosis, endocytosis and, and trafficking, trafficking through, through the, the secretory, secretory lysosome, lysosome pathway, pathway ., . Chediak-Higashi, Chediak-Higashi syndrome, syndrome (, ( CHS, CHS ), ) is, is an, an inherited, inherited disorder, disorder caused, caused by, by mutations, mutations in, in the, the lysosomal, lysosomal trafficking, trafficking regulator, regulator gene, gene ,, , LYST, LYST ., . It, It results, results in, in defective, defective membrane, membrane targeting, targeting of, of the, the proteins, proteins present, present in, in secretory, secretory lysosomes, lysosomes ,, , and, and it, it is, is associated, associated with, with a, a variety, variety of, of features, features ,, , including, including a, a lymphoproliferative, lymphoproliferative syndrome, syndrome with, with hemophagocytosis, hemophagocytosis ., . The, The murine, murine equivalent, equivalent of, of CHS, CHS ,, , beige, beige mice, mice ,, , present, present similar, similar characteristics, characteristics but, but do, do not, not develop, develop the, the lymphoproliferative, lymphoproliferative syndrome, syndrome ., . We, We show, show herein, herein that, that CTLA-4, CTLA-4 is, is present, present in, in enlarged, enlarged ,, , abnormal, abnormal vesicles, vesicles in, in CHS, CHS T, T cells, cells and, and is, is not, not properly, properly expressed, expressed at, at the, the cell, cell surface, surface after, after T, T cell, cell activation, activation ,, , whereas, whereas its, its surface, surface expression, expression is, is not, not impaired, impaired ., . It, It is, is therefore, therefore proposed, proposed that, that the, the defective, defective surface, surface expression, expression of, of CTLA-4, CTLA-4 by, by CHS, CHS T, T cells, cells is, is involved, involved in, in the, the generation, generation of, of lymphoproliferative, lymphoproliferative disease, disease ., . This, This observation, observation may, may provide, provide insight, insight into, into the, the role, role of, of CTLA-4, CTLA-4 in, in humans.., humans.. Hepatoblastoma, Hepatoblastoma is, is a, a rare, rare malignant, malignant tumor, tumor of, of the, the liver, liver that, that occurs, occurs in, in children, children at, at an, an average, average age, age of, of 2, 2 to, to 3, 3 years, years ., . Epidemiologic, Epidemiologic studies, studies have, have shown, shown an, an increased, increased frequency, frequency of, of this, this tumor, tumor type, type in, in families, families affected, affected by, by adenomatous, adenomatous polyposis, polyposis coli, coli ., . In, In addition, addition to, to the, the epidemiologic, epidemiologic data, data ,, , molecular, molecular genetic, genetic studies, studies suggest, suggest that, that inactivation, inactivation of, of the, the APC, APC tumor, tumor suppressor, suppressor may, may be, be involved, involved in, in hepatoblastoma, hepatoblastoma tumorigenesis, tumorigenesis ., . A, A major, major function, function of, of APC, APC is, is the, the downregulation, downregulation of, of beta-catenin, beta-catenin ,, , a, a transcription-activating, transcription-activating protein, protein with, with oncogenic, oncogenic potential, potential ., . In, In an, an ongoing, ongoing immunohistochemical, immunohistochemical study, study of, of beta-catenin, beta-catenin expression, expression in, in sporadic, sporadic cases, cases of, of tumor, tumor types, types that, that are, are associated, associated with, with adenomatous, adenomatous polyposis, polyposis coli, coli ,, , we, we observed, observed increased, increased beta-catenin, beta-catenin levels, levels in, in the, the cytoplasm, cytoplasm and, and in, in the, the nuclei, nuclei of, of three, three investigated, investigated hepatoblastomas, hepatoblastomas ., . Sequencing, Sequencing of, of exon, exon 3, 3 of, of the, the beta-catenin, beta-catenin gene, gene (, ( CTNNB1, CTNNB1 ), ) revealed, revealed an, an activating, activating mutation, mutation in, in one, one of, of the, the tumor, tumor samples, samples ., . Our, Our data, data indicate, indicate for, for the, the first, first time, time that, that beta-catenin, beta-catenin accumulation, accumulation may, may play, play a, a role, role in, in the, the development, development of, of hepatoblastoma, hepatoblastoma and, and that, that activating, activating mutations, mutations of, of the, the beta-catenin, beta-catenin gene, gene may, may substitute, substitute biallelic, biallelic APC, APC inactivation, inactivation in, in this, this tumor, tumor type, type ., . Genes, Genes Chromosomes, Chromosomes Cancer, Cancer 25, 25 399-402, 399-402 ,, , 1999.., 1999.. The, The rapid, rapid identification, identification of, of mutations, mutations causing, causing Tay-Sachs, Tay-Sachs disease, disease requires, requires the, the capacity, capacity to, to readily, readily screen, screen the, the regions, regions of, of the, the HEXA, HEXA gene, gene most, most likely, likely to, to be, be affected, affected by, by mutation, mutation ., . We, We have, have sequenced, sequenced the, the portions, portions of, of the, the introns, introns flanking, flanking each, each of, of the, the 14, 14 HEXA, HEXA exons, exons in, in order, order to, to specify, specify oligonucleotide, oligonucleotide primers, primers for, for the, the PCR-dependent, PCR-dependent amplification, amplification of, of each, each exon, exon and, and splice-junction, splice-junction sequence, sequence ., . The, The amplified, amplified products, products were, were analyzed, analyzed ,, , by, by electrophoresis, electrophoresis in, in nondenaturing, nondenaturing polyacrylamide, polyacrylamide gels, gels ,, , for, for the, the presence, presence of, of either, either heteroduplexes, heteroduplexes ,, , derived, derived from, from the, the annealing, annealing of, of normal, normal and, and mutant, mutant DNA, DNA strands, strands ,, , or, or single-strand, single-strand conformational, conformational polymorphisms, polymorphisms (, ( SSCP, SSCP ), ) ,, , derived, derived from, from the, the renaturation, renaturation of, of single-stranded, single-stranded DNA, DNA ., . Five, Five novel, novel mutations, mutations from, from Tay-Sachs, Tay-Sachs disease, disease patients, patients were, were detected, detected a, a 5-bp, 5-bp deletion, deletion of, of TCTCC, TCTCC in, in IVS-9, IVS-9 ;, ; a, a 2-bp, 2-bp deletion, deletion of, of TG, TG in, in exon, exon 5, 5 ;, ; G78, G78 to, to A, A ,, , giving, giving a, a stop, stop codon, codon in, in exon, exon 1, 1 ;, ; G533, G533 to, to T, T in, in exon, exon 5, 5 ,, , producing, producing the, the third, third amino, amino acid, acid substitution, substitution detected, detected at, at this, this site, site ;, ; and, and G, G to, to C, C at, at position, position 1, 1 of, of IVS-2, IVS-2 ,, , expected, expected to, to produce, produce abnormal, abnormal splicing, splicing ., . In, In addition, addition ,, , two, two mutations, mutations ,, , (, ( G1496, G1496 to, to A, A in, in exon, exon 13, 13 and, and a, a 4-bp, 4-bp insertion, insertion in, in exon, exon 11, 11 ), ) that, that have, have previously, previously been, been reported, reported were, were identified.., identified.. The, The HMGI, HMGI family, family of, of proteins, proteins consists, consists of, of three, three members, members ,, , HMGIC, HMGIC ,, , HMGI, HMGI and, and HMGI, HMGI (, ( Y, Y ), ) ,, , that, that function, function as, as architectural, architectural factors, factors and, and are, are essential, essential components, components of, of the, the enhancesome, enhancesome ., . HMGIC, HMGIC is, is predominantly, predominantly expressed, expressed in, in proliferating, proliferating ,, , undifferentiated, undifferentiated mesenchymal, mesenchymal cells, cells and, and is, is not, not detected, detected in, in adult, adult tissues, tissues ., . It, It is, is disrupted, disrupted and, and misexpressed, misexpressed in, in a, a number, number of, of mesenchymal, mesenchymal tumour, tumour cell, cell types, types ,, , including, including fat-cell, fat-cell tumours, tumours (, ( lipomas, lipomas ), ) ., . In, In addition, addition Hmgic-/-, Hmgic-/- mice, mice have, have a, a deficiency, deficiency in, in fat, fat tissue, tissue ., . To, To study, study its, its role, role in, in adipogenesis, adipogenesis and, and obesity, obesity ,, , we, we examined, examined Hmgic, Hmgic expression, expression in, in the, the adipose, adipose tissue, tissue of, of adult, adult ,, , obese, obese mice, mice ., . Mice, Mice with, with a, a partial, partial or, or complete, complete deficiency, deficiency of, of Hmgic, Hmgic resisted, resisted diet-induced, diet-induced obesity, obesity ., . Disruption, Disruption of, of Hmgic, Hmgic caused, caused a, a reduction, reduction in, in the, the obesity, obesity induced, induced by, by leptin, leptin deficiency, deficiency (, ( Lepob/Lepob, Lepob/Lepob ), ) in, in a, a gene-dose-dependent, gene-dose-dependent manner, manner ., . Our, Our studies, studies implicate, implicate a, a role, role for, for HMGIC, HMGIC in, in fat-cell, fat-cell proliferation, proliferation ,, , indicating, indicating that, that it, it may, may be, be an, an adipose-specific, adipose-specific target, target for, for the, the treatment, treatment of, of obesity.., obesity.. A, A diagnosis, diagnosis of, of Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease (, ( MIM, MIM 312080, 312080 ), ) was, was made, made in, in a, a young, young boy, boy ., . No, No mutation, mutation in, in the, the coding, coding region, region of, of the, the proteolipid, proteolipid protein, protein (, ( PLP, PLP ), ) gene, gene had, had been, been found, found ., . The, The boys, boys maternal, maternal aunt, aunt came, came for, for prenatal, prenatal diagnosis, diagnosis when, when 16, 16 +, + weeks, weeks pregnant, pregnant and, and carrying, carrying a, a male, male fetus, fetus ., . Samples, Samples were, were tested, tested for, for duplication, duplication of, of the, the PLP, PLP gene, gene ,, , by, by interphase, interphase FISH, FISH ,, , in, in lymphocyte, lymphocyte preparations, preparations from, from the, the proband, proband ,, , his, his aunt, aunt and, and an, an amniotic, amniotic fluid, fluid cell, cell preparation, preparation from, from the, the fetus, fetus ., . The, The proband, proband was, was found, found to, to carry, carry the, the duplication, duplication ,, , thus, thus confirming, confirming the, the diagnosis, diagnosis of, of Pelizaeus, Pelizaeus Merzbacher, Merzbacher disease, disease ,, , but, but neither, neither the, the aunt, aunt nor, nor the, the fetus, fetus carried, carried a, a duplication.., duplication.. Ataxia-telangiectasia, Ataxia-telangiectasia is, is a, a rare, rare genetic, genetic disorder, disorder associated, associated with, with immune, immune deficiency, deficiency ,, , chromosome, chromosome instability, instability ,, , and, and a, a predisposition, predisposition to, to lymphoid, lymphoid malignancy, malignancy ., . We, We have, have detected, detected chromosomally, chromosomally anomalous, anomalous clones, clones of, of lymphocytes, lymphocytes in, in eight, eight patients, patients with, with this, this disorder, disorder ., . Chromosome, Chromosome banding, banding disclosed, disclosed that, that the, the clones, clones are, are consistently, consistently marked, marked by, by structural, structural rearrangement, rearrangement of, of the, the long, long arm, arm (, ( q, q ), ) of, of chromosome, chromosome 14, 14 ., . A, A translocation, translocation involving, involving 14q, 14q was, was found, found in, in clones, clones obtained, obtained from, from seven, seven of, of the, the eight, eight patients, patients whereas, whereas a, a ring, ring 14, 14 chromosome, chromosome was, was found, found in, in a, a clone, clone obtained, obtained from, from the, the other, other ., . These, These findings, findings as, as well, well as, as data, data obtained, obtained by, by others, others for, for patients, patients with, with ataxia-telangiectasia, ataxia-telangiectasia suggest, suggest that, that structural, structural rearrangement, rearrangement of, of 14q, 14q is, is the, the initial, initial chromosomal, chromosomal change, change in, in lymphocyte, lymphocyte clones, clones of, of patients, patients with, with this, this disorder, disorder ., . Chromosomes, Chromosomes of, of lymphocytes, lymphocytes from, from one, one of, of the, the patients, patients were, were studied, studied before, before and, and after, after the, the onset, onset of, of chronic, chronic lymphocytic, lymphocytic leukemia, leukemia ., . Before, Before leukemia, leukemia was, was diagnosed, diagnosed ,, , the, the patient, patient had, had a, a lymphocyte, lymphocyte clone, clone with, with a, a 14q, 14q translocation, translocation ., . This, This clone, clone appears, appears to, to have, have given, given rise, rise to, to the, the leukemic, leukemic cells, cells ., . We, We hypothesize, hypothesize that, that structural, structural rearrangement, rearrangement of, of 14q, 14q is, is directly, directly related, related to, to abnormal, abnormal growth, growth of, of lymphocytes, lymphocytes and, and that, that it, it may, may be, be a, a step, step toward, toward the, the development, development of, of lymphoid, lymphoid malignancies, malignancies ., . Increasing, Increasing evidence, evidence ,, , provided, provided by, by others, others ,, , for, for the, the nonrandom, nonrandom involvement, involvement of, of 14q, 14q in, in African-type, African-type Burkitts, Burkitts lymphoma, lymphoma and, and other, other lymphoid, lymphoid neoplasms, neoplasms further, further strengthens, strengthens this, this hypothesis.., hypothesis.. The, The genetic, genetic defects, defects responsible, responsible for, for most, most phenylketonuria, phenylketonuria (, ( PKU, PKU ), ) and, and hyperphenylalaninemia, hyperphenylalaninemia (, ( HPA, HPA ), ) cases, cases are, are located, located in, in the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) gene, gene ., . Approximately, Approximately 50-60, 50-60 mutations, mutations have, have been, been reported, reported in, in Caucasians, Caucasians and, and are, are reflected, reflected in, in a, a wide, wide range, range of, of clinical, clinical severities, severities ., . Most, Most mutations, mutations are, are linked, linked to, to specific, specific haplotypes, haplotypes ,, , as, as defined, defined by, by eight, eight polymorphic, polymorphic restriction, restriction sites, sites in, in the, the PAH, PAH gene, gene ., . We, We hypothesized, hypothesized that, that there, there is, is at, at least, least one, one mild, mild mutation, mutation linked, linked to, to haplotype, haplotype 12, 12 in, in the, the Swedish, Swedish PKU/HPA, PKU/HPA population, population ,, , since, since 7, 7 of, of 8, 8 patients, patients carrying, carrying haplotype, haplotype 12, 12 had, had mild, mild HPA, HPA ., . Sequence, Sequence analysis, analysis revealed, revealed a, a C-to-G, C-to-G transversion, transversion at, at the, the second, second base, base of, of codon, codon 322, 322 ,, , resulting, resulting in, in a, a substitution, substitution of, of glycine, glycine for, for alanine, alanine ,, , in, in four, four mutant, mutant haplotype, haplotype 12, 12 genes, genes ,, , and, and a, a G-to-A, G-to-A transition, transition at, at the, the second, second base, base of, of codon, codon 408, 408 ,, , resulting, resulting in, in a, a substitution, substitution of, of glutamine, glutamine for, for arginine, arginine ,, , in, in another, another three, three mutant, mutant haplotype, haplotype 12, 12 genes, genes ., . These, These mutations, mutations segregated, segregated with, with mutant, mutant haplotype, haplotype 12, 12 alleles, alleles in, in nuclear, nuclear families, families but, but were, were not, not present, present on, on normal, normal or, or other, other mutant, mutant alleles, alleles ., . Both, Both mutations, mutations were, were tested, tested in, in a, a eukaryotic, eukaryotic expression, expression system, system in, in which, which enzyme, enzyme activities, activities of, of different, different mutant, mutant PAH, PAH enzymes, enzymes reflect, reflect the, the relative, relative severities, severities of, of the, the mutations, mutations ,, , although, although these, these in, in vitro, vitro activities, activities can, can not, not be, be translated, translated directly, directly into, into in, in vivo, vivo hepatic, hepatic activities, activities ., . The, The A322G, A322G mutant, mutant PAH, PAH had, had about, about 75, 75 %, % and, and the, the R408Q, R408Q mutant, mutant PAH, PAH about, about 55, 55 %, % of, of the, the wild-type, wild-type PAH, PAH enzyme, enzyme activity, activity ., . These, These in, in vitro, vitro activities, activities are, are the, the highest, highest reported, reported for, for mutant, mutant PAH, PAH enzymes, enzymes produced, produced in, in the, the same, same expression, expression system, system ., . (, ( ABSTRACT, ABSTRACT TRUNCATED, TRUNCATED AT, AT 250, 250 WORDS, WORDS ), ) ., . Adrenoleukodystrophy, Adrenoleukodystrophy (, ( ALD, ALD ), ) ,, , the, the most, most frequent, frequent peroxisomal, peroxisomal disorder, disorder ,, , is, is a, a severe, severe neurodegenerative, neurodegenerative disease, disease associated, associated with, with an, an impairment, impairment of, of very, very long, long chain, chain fatty, fatty acids, acids beta-oxidation, beta-oxidation ., . We, We have, have recently, recently identified, identified by, by positional, positional cloning, cloning the, the gene, gene responsible, responsible for, for ALD, ALD ,, , located, located in, in Xq28, Xq28 ., . It, It encodes, encodes a, a new, new member, member of, of the, the ``, `` ABC, ABC ``, `` superfamily, superfamily of, of membrane-associated, membrane-associated transporters, transporters that, that shows, shows ,, , in, in particular, particular ,, , significant, significant homology, homology to, to the, the 70-kDa, 70-kDa peroxisomal, peroxisomal membrane, membrane protein, protein (, ( PMP70, PMP70 ), ) ., . We, We report, report here, here a, a detailed, detailed characterization, characterization of, of the, the ALD, ALD gene, gene structure, structure ., . It, It extends, extends over, over 21, 21 kb, kb and, and consists, consists of, of 10, 10 exons, exons ., . To, To facilitate, facilitate the, the detection, detection of, of mutations, mutations in, in ALD, ALD patients, patients ,, , we, we have, have determined, determined the, the intronic, intronic sequences, sequences flanking, flanking the, the exons, exons as, as well, well as, as the, the sequence, sequence of, of the, the 3, 3 untranslated, untranslated region, region and, and of, of the, the immediate, immediate 5, 5 promoter, promoter region, region ., . Sequences, Sequences present, present in, in distal, distal exons, exons cross-hybridize, cross-hybridize strongly, strongly to, to additional, additional sequences, sequences in, in the, the human, human genome, genome ., . The, The ALD, ALD gene, gene has, has been, been positioned, positioned on, on a, a pulsed-field, pulsed-field map, map between, between DXS15, DXS15 and, and the, the L1CAM, L1CAM gene, gene ,, , about, about 650, 650 kb, kb upstream, upstream from, from the, the color, color pigment, pigment genes, genes ., . The, The frequent, frequent occurrence, occurrence of, of color, color vision, vision anomalies, anomalies observed, observed in, in patients, patients with, with adrenomyeloneuropathy, adrenomyeloneuropathy (, ( the, the adult, adult onset, onset form, form of, of ALD, ALD ), ) thus, thus does, does not, not represent, represent a, a contiguous, contiguous gene, gene syndrome, syndrome but, but a, a secondary, secondary manifestation, manifestation of, of ALD.., ALD.. Germ-line, Germ-line mutations, mutations in, in the, the BRCA1, BRCA1 tumor-suppressor, tumor-suppressor gene, gene are, are associated, associated with, with an, an increased, increased susceptibility, susceptibility to, to breast, breast and, and ovarian, ovarian cancer, cancer ., . BRCA1, BRCA1 contains, contains a, a carboxyl-terminal, carboxyl-terminal domain, domain ("
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", ( BRCT, BRCT ), ) that, that is, is shared, shared with, with several, several other, other proteins, proteins involved, involved in, in maintaining, maintaining genome, genome integrity, integrity ., . In, In an, an effort, effort to, to understand, understand the, the function, function of, of BRCA1, BRCA1 ,, , we, we sought, sought to, to isolate, isolate proteins, proteins that, that interact, interact with, with the, the BRCT, BRCT domain, domain ., . Purified, Purified BRCT, BRCT polypeptide, polypeptide was, was used, used as, as a, a probe, probe to, to screen, screen a, a human, human placenta, placenta cDNA, cDNA expression, expression library, library by, by Far, Far Western, Western analysis, analysis ., . Here, Here we, we report, report that, that BRCA1, BRCA1 interacts, interacts in, in vivo, vivo and, and in, in vitro, vitro with, with the, the Rb-binding, Rb-binding proteins, proteins ,, , RbAp46, RbAp46 and, and RbAp48, RbAp48 ,, , as, as well, well as, as with, with Rb, Rb ., . Moreover, Moreover ,, , the, the BRCT, BRCT domain, domain associates, associates with, with the, the histone, histone deacetylases, deacetylases HDAC1, HDAC1 and, and HDAC2, HDAC2 ., . These, These results, results demonstrate, demonstrate that, that BRCA1, BRCA1 interacts, interacts with, with components, components of, of the, the histone, histone deacetylase, deacetylase complex, complex ,, , and, and therefore, therefore may, may explain, explain the, the involvement, involvement of, of BRCA1, BRCA1 in, in multiple, multiple processes, processes such, such as, as transcription, transcription ,, , DNA, DNA repair, repair ,, , and, and recombination.., recombination.. We, We have, have previously, previously shown, shown that, that human, human piebaldism, piebaldism results, results from, from mutations, mutations of, of the, the KIT, KIT gene, gene ,, , which, which encodes, encodes the, the receptor, receptor for, for the, the mast/stem, mast/stem cell, cell growth, growth factor, factor and, and is, is located, located in, in chromosome, chromosome segment, segment 4q12, 4q12 ., . Using, Using DNA, DNA of, of a, a patient, patient with, with piebaldism, piebaldism ,, , mental, mental retardation, retardation ,, , and, and multiple, multiple congenital, congenital anomalies, anomalies associated, associated with, with a, a 46, 46 ,, , XY, XY ,, , del, del (, ( 4, 4 ), ) (, ( q12q21, q12q21 ., . 1, 1 ), ) karyotype, karyotype ,, , we, we carried, carried out, out quantitative, quantitative Southern, Southern blot, blot hybridization, hybridization analyses, analyses of, of the, the KIT, KIT gene, gene and, and the, the adjacent, adjacent PDGFRA, PDGFRA (, ( platelet-derived, platelet-derived growth, growth factor, factor receptor, receptor alpha, alpha subunit, subunit ), ) genes, genes ., . The, The patient, patient was, was hemizygous, hemizygous for, for both, both the, the KIT, KIT and, and PDGFRA, PDGFRA genes, genes ,, , indicating, indicating that, that both, both of, of these, these genes, genes are, are included, included within, within the, the deleted, deleted region, region ., . Therefore, Therefore ,, , deletion, deletion of, of the, the KIT, KIT and, and PDGFRA, PDGFRA genes, genes may, may account, account for, for the, the piebald, piebald phenotype, phenotype in, in this, this patient, patient ., . Erythrocyte, Erythrocyte glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) was, was characterized, characterized in, in blood, blood samples, samples obtained, obtained from, from 97, 97 randomly, randomly selected, selected males, males with, with enzyme, enzyme deficiency, deficiency from, from various, various regions, regions of, of Guangdong, Guangdong Province, Province ,, , China, China ., . Nine, Nine new, new variants, variants (, ( Gd, Gd Kaiping, Kaiping ,, , Gd, Gd Boluo, Boluo ,, , Gd, Gd Huiyang, Huiyang ,, , Gd, Gd Gaomin, Gaomin ,, , Gd, Gd Qing-Baijiang, Qing-Baijiang ,, , Gd, Gd Gaozhou, Gaozhou ,, , Gd, Gd Huazhou, Huazhou ,, , Gd, Gd Nanhai, Nanhai ,, , and, and Gd, Gd Guangzhou, Guangzhou ), ) were, were identified, identified ., . Of, Of the, the 31, 31 variants, variants found, found in, in this, this province, province ,, , Gd, Gd Kaiping, Kaiping ,, , Gd, Gd Taiwan-Hakka, Taiwan-Hakka ,, , Gd, Gd Haad, Haad Yai, Yai ,, , Gd, Gd Haad, Haad Yai-like, Yai-like and, and Gd, Gd Huiyang, Huiyang occurred, occurred most, most frequently, frequently ., . The, The frequency, frequency of, of each, each variant, variant was, was calculated, calculated ., . The, The results, results demonstrated, demonstrated that, that the, the genetic, genetic heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency was, was high, high in, in this, this area.., area.. The, The chromosome, chromosome 22q11, 22q11 region, region is, is susceptible, susceptible to, to rearrangements, rearrangements that, that are, are associated, associated with, with congenital, congenital anomaly, anomaly disorders, disorders and, and malignant, malignant tumors, tumors ., . Three, Three congenital, congenital anomaly, anomaly disorders, disorders ,, , cat-eye, cat-eye syndrome, syndrome ,, , der, der (, ( ), ) syndrome, syndrome and, and velo-cardio-facial, velo-cardio-facial syndrome/DiGeorge, syndrome/DiGeorge syndrome, syndrome (, ( VCFS/DGS, VCFS/DGS ), ) are, are associated, associated with, with tetrasomy, tetrasomy ,, , trisomy, trisomy or, or monosomy, monosomy ,, , respectively, respectively ,, , for, for part, part of, of chromosome, chromosome 22q11, 22q11 ., . VCFS/DGS, VCFS/DGS is, is the, the most, most common, common syndrome, syndrome associated, associated with, with 22q11, 22q11 rearrangements, rearrangements ., . In, In order, order to, to determine, determine whether, whether there, there are, are particular, particular regions, regions on, on 22q11, 22q11 that, that are, are prone, prone to, to rearrangements, rearrangements ,, , the, the deletion, deletion end-points, end-points in, in a, a large, large number, number of, of VCFS/DGS, VCFS/DGS patients, patients were, were defined, defined by, by haplotype, haplotype analysis, analysis ., . Most, Most VCFS/DGS, VCFS/DGS patients, patients have, have a, a similar, similar 3, 3 Mb, Mb deletion, deletion ,, , some, some have, have a, a nested, nested distal, distal deletion, deletion breakpoint, breakpoint resulting, resulting in, in a, a 1, 1 ., . 5, 5 Mb, Mb deletion, deletion and, and a, a few, few rare, rare patients, patients have, have unique, unique deletions, deletions or, or translocations, translocations ., . The, The high, high prevalence, prevalence of, of the, the disorder, disorder in, in the, the population, population and, and the, the fact, fact that, that most, most cases, cases occur, occur sporadically, sporadically suggest, suggest that, that sequences, sequences at, at or, or near, near the, the breakpoints, breakpoints confer, confer susceptibility, susceptibility to, to chromosome, chromosome rearrangements, rearrangements ., . To, To investigate, investigate this, this hypothesis, hypothesis ,, , we, we developed, developed hamster-human, hamster-human somatic, somatic hybrid, hybrid cell, cell lines, lines from, from VCFS/DGS, VCFS/DGS patients, patients with, with all, all three, three classes, classes of, of deletions, deletions and, and we, we now, now show, show that, that the, the breakpoints, breakpoints occur, occur within, within similar, similar low, low copy, copy repeats, repeats ,, , termed, termed LCR22s, LCR22s ., . To, To support, support this, this idea, idea further, further ,, , we, we identified, identified a, a family, family that, that carries, carries an, an interstitial, interstitial duplication, duplication of, of the, the same, same 3, 3 Mb, Mb region, region that, that is, is deleted, deleted in, in VCFS/DGS, VCFS/DGS patients, patients ., . We, We present, present models, models to, to explain, explain how, how the, the LCR22s, LCR22s can, can mediate, mediate different, different homologous, homologous recombination, recombination events, events ,, , thereby, thereby generating, generating a, a number, number of, of rearrangements, rearrangements that, that are, are associated, associated with, with congenital, congenital anomaly, anomaly disorders, disorders ., . We, We identified, identified five, five additional, additional copies, copies of, of the, the LCR22, LCR22 on, on 22q11, 22q11 that, that may, may mediate, mediate other, other rearrangements, rearrangements leading, leading to, to disease, disease ., . Three, Three children, children are, are reported, reported with, with typical, typical cat, cat eye, eye syndrome, syndrome (, ( CES, CES ), ) and, and three, three more, more children, children with, with partial, partial CES, CES because, because of, of absence, absence of, of coloboma, coloboma ,, , in, in which, which the, the supernumerary, supernumerary marker, marker chromosome, chromosome was, was studied, studied by, by FISH, FISH ., . Using, Using a, a genomic, genomic library, library ,, , and, and also, also a, a centromeric, centromeric and, and particularly, particularly a, a cosmid, cosmid probe, probe of, of 22q11, 22q11 ,, , partial, partial tetrasomy, tetrasomy was, was shown, shown in, in all, all cases.., cases.. We, We report, report familial, familial adenomatous, adenomatous polyposis, polyposis coli, coli (, ( FAPC, FAPC ), ) with, with epidermoid, epidermoid cysts, cysts ,, , osteomata, osteomata ,, , and, and areas, areas of, of congenital, congenital hypertrophy, hypertrophy of, of the, the retinal, retinal pigment, pigment epithelium, epithelium (, ( CHRPEs, CHRPEs ), ) in, in a, a male, male patient, patient and, and his, his maternal, maternal aunt, aunt ,, , both, both of, of whom, whom suffered, suffered a, a mild, mild to, to moderate, moderate degree, degree of, of mental, mental handicap, handicap ., . Both, Both had, had an, an interstitial, interstitial deletion, deletion of, of the, the long, long arm, arm of, of chromosome, chromosome 5, 5 (, ( del, del (, ( 5, 5 ), ) (, ( q22q23, q22q23 ., . 2, 2 ), ) ), ) ., . Two, Two other, other normal, normal family, family members, members had, had the, the underlying, underlying direct, direct insertion, insertion of, of chromosome, chromosome 5, 5 (, ( dir, dir ins, ins (, ( 5, 5 ), ) (, ( q31, q31 ., . 3q22q23, 3q22q23 3q22q23, 3q22q23 ., . 2, 2 ), ) ), ) ., . Molecular, Molecular genetic, genetic and, and fluorescent, fluorescent hybridisation, hybridisation studies, studies have, have shown, shown that, that loci, loci D5S37, D5S37 and, and D5S98, D5S98 are, are outside, outside the, the deletion, deletion whereas, whereas loci, loci detected, detected by, by probes, probes EF5, EF5 ., . 44, 44 and, and YN5, YN5 ., . 48, 48 are, are lost, lost ., . As, As expected, expected ,, , the, the molecular, molecular analyses, analyses indicate, indicate loss, loss of, of one, one allele, allele at, at the, the MCC, MCC and, and APC, APC loci, loci ., . The, The APC, APC gene, gene is, is located, located within, within band, band 5q22, 5q22 ., . Familial, Familial direct, direct insertions, insertions should, should be, be considered, considered as, as a, a cause, cause of, of recurrent, recurrent microdeletion, microdeletion syndromes.The, syndromes.The gene, gene responsible, responsible for, for Huntington, Huntington disease, disease has, has been, been localized, localized to, to a, a 2, 2 ., . 5, 5 million, million base, base pair, pair (, ( Mb, Mb ), ) region, region between, between the, the loci, loci D4S10, D4S10 and, and D4S168, D4S168 on, on the, the short, short arm, arm of, of chromosome, chromosome 4, 4 ., . As, As part, part of, of a, a strategy, strategy to, to clone, clone the, the HD, HD gene, gene on, on the, the basis, basis of, of its, its chromosomal, chromosomal location, location ,, , we, we isolated, isolated genomic, genomic DNA, DNA from, from the, the HD, HD region, region as, as a, a set, set of, of overlapping, overlapping yeast, yeast artificial, artificial chromosome, chromosome (, ( YAC, YAC ), ) clones, clones ., . Twenty-eight, Twenty-eight YAC, YAC clones, clones were, were identified, identified by, by screening, screening human, human YAC, YAC libraries, libraries with, with twelve, twelve PCR-based, PCR-based sequence-tagged, sequence-tagged sites, sites (, ( STSs, STSs ), ) from, from the, the region, region ., . We, We assembled, assembled the, the YAC, YAC clones, clones into, into overlapping, overlapping sets, sets by, by hybridizing, hybridizing them, them to, to a, a large, large number, number of, of DNA, DNA probes, probes from, from the, the HD, HD region, region ,, , including, including the, the STSs, STSs ., . In, In addition, addition ,, , we, we isolated, isolated the, the ends, ends of, of the, the human, human DNA, DNA inserts, inserts of, of most, most of, of the, the YAC, YAC clones, clones to, to assist, assist in, in the, the construction, construction of, of the, the contig, contig ., . Although, Although almost, almost half, half of, of the, the YACs, YACs appear, appear to, to contain, contain chimeric, chimeric inserts, inserts and, and several, several contain, contain internal, internal deletions, deletions or, or other, other rearrangements, rearrangements ,, , we, we were, were able, able to, to obtain, obtain over, over 2, 2 ., . 2, 2 Mb, Mb of, of the, the HD, HD region, region in, in YACs, YACs ,, , including, including one, one continuous, continuous segment, segment of, of 2, 2 ., . 0, 0 Mb, Mb covering, covering the, the region, region that, that most, most likely, likely contains, contains the, the HD, HD gene, gene ., . Ten, Ten of, of the, the twenty, twenty eight, eight YAC, YAC clones, clones comprise, comprise a, a minimal, minimal set, set spanning, spanning the, the 2, 2 ., . 2, 2 Mb, Mb ., . These, These clones, clones provide, provide reagents, reagents for, for the, the complete, complete characterization, characterization of, of this, this region, region of, of the, the genome, genome and, and for, for the, the eventual, eventual isolation, isolation of, of the, the HD, HD gene, gene ., . A, A panel, panel of, of eight, eight unrelated, unrelated subjects, subjects with, with inherited, inherited type, type I, I protein, protein S, S deficiency, deficiency was, was screened, screened for, for mutations, mutations in, in the, the PROS1, PROS1 gene, gene ., . In, In five, five subjects, subjects an, an abnormality, abnormality was, was found, found but, but mutations, mutations were, were not, not detected, detected in, in the, the remaining, remaining three, three subjects, subjects ., . Two, Two subjects, subjects shared, shared a, a G, G --, -- >, > A, A transition, transition at, at position, position +, + 5, 5 of, of the, the donor, donor splice, splice site, site consensus, consensus sequence, sequence of, of intron, intron 10, 10 ., . Also, Also in, in two, two subjects, subjects an, an A, A --, -- >, > T, T transversion, transversion was, was detected, detected in, in the, the stopcodon, stopcodon of, of the, the PROS1, PROS1 gene, gene ;, ; this, this transversion, transversion predicts, predicts a, a protein, protein S, S molecule, molecule that, that is, is extended, extended by, by 14, 14 amino, amino acids, acids ., . The, The fifth, fifth subject, subject was, was found, found to, to possess, possess two, two sequence, sequence abnormalities, abnormalities ., . One, One allele, allele carried, carried a, a G, G --, -- >, > A, A transition, transition near, near the, the donor, donor splice, splice junction, junction of, of intron, intron 2, 2 ,, , but, but this, this abnormality, abnormality is, is probably, probably neutral, neutral ,, , since, since it, it was, was inherited, inherited from, from the, the parent, parent with, with normal, normal protein, protein S, S antigen, antigen levels, levels ., . In, In the, the other, other allele, allele a, a single, single T, T insertion, insertion in, in codon, codon -25, -25 was, was found, found ., . Analysis, Analysis of, of platelet, platelet RNA, RNA showed, showed that, that only, only the, the mRNA, mRNA with, with the, the A, A --, -- >, > T, T mutation, mutation in, in the, the stopcodon, stopcodon is, is present, present in, in amounts, amounts comparable, comparable to, to wildtype, wildtype RNA, RNA ., . mRNA, mRNA from, from the, the alleles, alleles with, with the, the other, other two, two mutations, mutations was, was either, either undetectable, undetectable or, or present, present in, in greatly, greatly reduced, reduced amounts, amounts ., . The, The latter, latter indicates, indicates that, that a, a mRNA, mRNA based, based approach, approach is, is not, not feasible, feasible for, for the, the genetic, genetic analysis, analysis of, of protein, protein S, S deficiency, deficiency type, type I.., I.. The, The human, human Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome is, is a, a rare, rare neurological, neurological and, and behavioural, behavioural disorder, disorder ,, , affecting, affecting only, only males, males ,, , which, which is, is caused, caused by, by an, an inherited, inherited deficiency, deficiency in, in the, the level, level of, of activity, activity of, of the, the purine, purine salvage, salvage enzyme, enzyme hypoxanthine-guanosine, hypoxanthine-guanosine phosphoribosyl, phosphoribosyl transferase, transferase (, ( HPRT, HPRT ), ) ., . How, How the, the resulting, resulting alterations, alterations in, in purine, purine metabolism, metabolism lead, lead to, to the, the severe, severe symptoms, symptoms characteristic, characteristic of, of Lesch-Nyhan, Lesch-Nyhan patients, patients is, is still, still not, not understood, understood ., . No, No mutations, mutations at, at the, the Hprt, Hprt locus, locus leading, leading to, to loss, loss of, of activity, activity have, have been, been described, described in, in laboratory, laboratory animals, animals ., . To, To derive, derive an, an animal, animal model, model for, for the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ,, , we, we have, have used, used cultured, cultured mouse, mouse embryonic, embryonic stem, stem cells, cells ,, , mutagenized, mutagenized by, by retroviral, retroviral insertion, insertion and, and selected, selected for, for loss, loss of, of HPRT, HPRT activity, activity ,, , to, to construct, construct chimaeric, chimaeric mice, mice ., . Two, Two clonal, clonal lines, lines carrying, carrying different, different mutant, mutant Hprt, Hprt alleles, alleles have, have given, given rise, rise to, to germ, germ cells, cells in, in chimaeras, chimaeras ,, , allowing, allowing the, the derivation, derivation of, of strains, strains of, of mutant, mutant mice, mice having, having the, the same, same biochemical, biochemical defect, defect as, as Lesch-Nyhan, Lesch-Nyhan patients, patients ., . Male, Male mice, mice carrying, carrying the, the mutant, mutant alleles, alleles are, are viable, viable and, and analysis, analysis of, of their, their cells, cells shows, shows a, a total, total lack, lack of, of HPRT, HPRT activity.., activity.. Partial, Partial gene, gene deletion, deletion is, is the, the major, major cause, cause of, of mutation, mutation leading, leading to, to Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( BMD, BMD ), ) ., . Partial, Partial gene, gene duplication, duplication has, has also, also been, been recognized, recognized in, in a, a few, few cases, cases ., . We, We have, have conducted, conducted a, a survey, survey for, for duplication, duplication in, in 72, 72 unrelated, unrelated nondeletion, nondeletion patients, patients ,, , analyzed, analyzed by, by Southern, Southern blot, blot hybridization, hybridization with, with clones, clones representing, representing the, the entire, entire DMD, DMD cDNA, cDNA ., . With, With careful, careful quantitative, quantitative analysis, analysis of, of hybridization, hybridization band, band intensity, intensity ,, , 10, 10 cases, cases were, were found, found to, to carry, carry a, a duplication, duplication of, of part, part of, of the, the gene, gene ,, , a, a frequency, frequency of, of 14, 14 %, % for, for nondeletion, nondeletion cases, cases (, ( 10/72, 10/72 ), ) ,, , or, or 6, 6 %, % for, for all, all cases, cases (, ( 10/181, 10/181 ), ) ., . The, The extent, extent of, of these, these duplications, duplications has, has been, been characterized, characterized according, according to, to the, the published, published exon-containing, exon-containing HindIII, HindIII fragment, fragment map, map ,, , and, and in, in six, six of, of the, the 10, 10 duplications, duplications a, a novel, novel restriction, restriction fragment, fragment that, that spanned, spanned the, the duplication, duplication junction, junction was, was detected, detected ., . The, The resulting, resulting translational, translational reading, reading frame, frame of, of mRNA, mRNA has, has been, been predicted, predicted for, for nine, nine duplications, duplications ., . A, A shift, shift of, of the, the reading, reading frame, frame was, was predicted, predicted in, in four, four of, of the, the six, six DMD, DMD cases, cases and, and in, in one, one of, of the, the two, two intermediate, intermediate cases, cases ,, , while, while the, the reading, reading frame, frame remained, remained uninterrupted, uninterrupted in, in both, both BMD, BMD cases, cases ., . RFLP, RFLP and, and quantitative, quantitative Southern, Southern blot, blot analyses, analyses revealed, revealed a, a grandpaternal, grandpaternal origin, origin of, of duplication, duplication in, in four, four families, families and, and grandmaternal, grandmaternal origin, origin in, in one, one family, family ., . In, In all, all five, five families, families ,, , the, the duplication, duplication was, was found, found to, to originate, originate from, from a, a single, single X, X chromosome, chromosome ., . Unequal, Unequal sister-chromatid, sister-chromatid exchange, exchange is, is proposed, proposed to, to be, be the, the mechanism, mechanism for, for the, the formation, formation of, of these, these duplications.., duplications.. Hypoxanthine-guanine, Hypoxanthine-guanine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ;, ; EC2, EC2 ., . 4, 4 ., . 2, 2 ., . 8, 8 ), ) ,, , which, which functions, functions in, in the, the metabolic, metabolic salvage, salvage of, of purines, purines ,, , is, is encoded, encoded by, by an, an X-linked, X-linked gene, gene in, in man, man ., . Partial, Partial HPRT, HPRT deficiencies, deficiencies are, are associated, associated with, with gouty, gouty arthritis, arthritis ,, , while, while absence, absence of, of activity, activity results, results in, in Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome (, ( L-N, L-N ), ) ., . L-N, L-N patients, patients fail, fail to, to reproduce, reproduce and, and the, the heterozygous, heterozygous state, state appears, appears to, to confer, confer no, no selective, selective advantage, advantage ., . Thus, Thus ,, , Haldanes, Haldanes principle, principle predicts, predicts that, that new, new mutations, mutations at, at the, the hprt, hprt locus, locus must, must occur, occur frequently, frequently in, in order, order for, for L-N, L-N syndrome, syndrome to, to be, be maintained, maintained in, in the, the population, population ., . This, This constant, constant introduction, introduction of, of new, new mutations, mutations would, would be, be expected, expected to, to result, result in, in a, a heterogeneous, heterogeneous collection, collection of, of genetic, genetic lesions, lesions ,, , some, some of, of which, which may, may be, be novel, novel ., . As, As we, we report, report here, here ,, , the, the mutations, mutations in, in the, the hprt, hprt gene, gene of, of seven, seven L-N, L-N patients, patients ,, , selected, selected from, from an, an initial, initial survey, survey of, of 28, 28 patients, patients ,, , have, have been, been characterized, characterized and, and all, all were, were found, found to, to be, be distinctly, distinctly different, different ,, , as, as predicted, predicted ., . The, The origin, origin of, of one, one unusual, unusual mutation, mutation has, has been, been identified, identified by, by analysis, analysis of, of DNA, DNA from, from four, four generations, generations of, of family, family members, members ., . Further, Further molecular, molecular analysis, analysis of, of the, the origin, origin of, of new, new mutations, mutations at, at the, the hprt, hprt locus, locus should, should aid, aid in, in resolving, resolving the, the issue, issue of, of an, an apparent, apparent difference, difference in, in the, the frequency, frequency of, of hprt, hprt mutations, mutations in, in males, males and, and females, females The, The recent, recent discovery, discovery of, of sequences, sequences at, at the, the site, site of, of the, the Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene in, in humans, humans has, has opened, opened up, up the, the possibility, possibility of, of a, a detailed, detailed molecular, molecular analysis, analysis of, of the, the genes, genes in, in humans, humans and, and in, in related, related mammalian, mammalian species, species ., . Until, Until relatively, relatively recently, recently ,, , there, there was, was no, no obvious, obvious mouse, mouse model, model of, of this, this genetic, genetic disease, disease for, for the, the development, development of, of therapeutic, therapeutic strategies, strategies ., . The, The identification, identification of, of a, a mouse, mouse X-linked, X-linked mutant, mutant showing, showing muscular, muscular dystrophy, dystrophy ,, , mdx, mdx ,, , has, has provided, provided a, a candidate, candidate mouse, mouse genetic, genetic homologue, homologue to, to the, the DMD, DMD locus, locus ;, ; the, the relatively, relatively mild, mild pathological, pathological features, features of, of mdx, mdx suggest, suggest it, it may, may have, have more, more in, in common, common with, with mutations, mutations of, of the, the Becker, Becker muscular, muscular dystrophy, dystrophy type, type at, at the, the same, same human, human locus, locus ,, , however, however ., . But, But the, the close, close genetic, genetic linkage, linkage of, of mdx, mdx to, to G6PD, G6PD and, and Hprt, Hprt on, on the, the mouse, mouse X, X chromosome, chromosome ,, , coupled, coupled with, with its, its comparatively, comparatively mild, mild pathology, pathology ,, , have, have suggested, suggested that, that the, the mdx, mdx mutation, mutation may, may instead, instead correspond, correspond to, to Emery, Emery Dreifuss, Dreifuss muscular, muscular dystrophy, dystrophy which, which itself, itself is, is closely, closely linked, linked to, to DNA, DNA markers, markers at, at Xq28-qter, Xq28-qter in, in the, the region, region of, of G6PD, G6PD on, on the, the human, human X, X chromosome, chromosome ., . Using, Using an, an interspecific, interspecific mouse, mouse domesticus/spretus, domesticus/spretus cross, cross ,, , segregating, segregating for, for a, a variety, variety of, of markers, markers on, on the, the mouse, mouse X, X chromosome, chromosome ,, , we, we have, have positioned, positioned on, on the, the mouse, mouse X, X chromosome, chromosome sequences, sequences homologous, homologous to, to a, a DMD, DMD cDNA, cDNA clone, clone ., . These, These sequences, sequences map, map provocatively, provocatively close, close to, to the, the mdx, mdx mutation, mutation and, and unexpectedly, unexpectedly distant, distant from, from sparse, sparse fur, fur ,, , spf, spf ,, , the, the mouse, mouse homologue, homologue of, of OTC, OTC (, ( ornithine, ornithine transcarbamylase, transcarbamylase ), ) which, which is, is closely, closely linked, linked to, to DMD, DMD on, on the, the human, human X, X chromosome.., chromosome.. Alkaptonuria, Alkaptonuria (, ( aku, aku ), ) ,, , an"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", an inborn, inborn error, error of, of metabolism, metabolism caused, caused by, by the, the loss, loss of, of homogentisate, homogentisate 1, 1 ,, , 2-dioxygenase, 2-dioxygenase (, ( HGD, HGD ), ) ,, , has, has been, been described, described in, in a, a mouse, mouse model, model created, created by, by ethylnitrosourea, ethylnitrosourea mutagenesis, mutagenesis but, but the, the mutation, mutation in, in these, these mice, mice has, has not, not previously, previously been, been identified, identified ., . We, We used, used RT-PCR, RT-PCR to, to amplify, amplify the, the Hgd, Hgd cDNA, cDNA from, from Hgd, Hgd (, ( aku, aku ), ) /Hgd, /Hgd (, ( aku, aku ), ) mice, mice ., . Two, Two products, products shorter, shorter than, than the, the wild-type, wild-type product, product were, were amplified, amplified ., . Restriction, Restriction mapping, mapping and, and DNA, DNA sequencing, sequencing were, were then, then used, used to, to identify, identify the, the Hgd, Hgd (, ( aku, aku ), ) mouse, mouse mutation, mutation ,, , found, found to, to be, be a, a single, single base, base change, change in, in a, a splice, splice donor, donor consensus, consensus sequence, sequence ,, , causing, causing exon, exon skipping, skipping and, and frame-shifted, frame-shifted products, products ., . This, This base, base change, change allowed, allowed us, us to, to create, create a, a non-radioactive, non-radioactive genotyping, genotyping assay, assay for, for this, this allele, allele ., . Reciprocal, Reciprocal chromosome, chromosome translocations, translocations are, are common, common de, de novo, novo rearrangements, rearrangements that, that occur, occur randomly, randomly throughout, throughout the, the human, human genome, genome ., . To, To learn, learn about, about causative, causative mechanisms, mechanisms ,, , we, we have, have cloned, cloned and, and sequenced, sequenced the, the breakpoints, breakpoints of, of a, a cytologically, cytologically balanced, balanced constitutional, constitutional reciprocal, reciprocal translocation, translocation ,, , t, t (, ( X, X ;, ; 4, 4 ), ) (, ( p21, p21 ., . 2, 2 ;, ; q31, q31 ., . 22, 22 ), ) ,, , present, present in, in a, a girl, girl with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . Physical, Physical mapping, mapping of, of the, the derivative, derivative chromosomes, chromosomes ,, , after, after their, their separation, separation in, in somatic, somatic cell, cell hybrids, hybrids ,, , reveals, reveals that, that the, the translocation, translocation disrupts, disrupts the, the DMD, DMD gene, gene in, in Xp21, Xp21 within, within the, the 18-kb, 18-kb intron, intron 16, 16 ., . Restriction, Restriction mapping, mapping and, and sequencing, sequencing of, of clones, clones that, that span, span both, both translocation, translocation breakpoints, breakpoints as, as well, well as, as the, the corresponding, corresponding normal, normal regions, regions indicate, indicate the, the loss, loss of, of approximately, approximately 5, 5 kb, kb in, in the, the formation, formation of, of the, the derivative, derivative X, X chromosome, chromosome ,, , with, with 4-6, 4-6 bp, bp deleted, deleted from, from chromosome, chromosome 4, 4 ., . RFLP, RFLP and, and Southern, Southern analyses, analyses indicate, indicate that, that the, the de, de novo, novo translocation, translocation is, is a, a paternal, paternal origin, origin and, and that, that the, the fathers, fathers X, X chromosome, chromosome contains, contains the, the DNA, DNA that, that is, is deleted, deleted in, in the, the derivative, derivative X, X ., . Most, Most likely, likely ,, , deletion, deletion and, and translation, translation arose, arose simultaneously, simultaneously from, from a, a complex, complex rearrangement, rearrangement event, event that, that involves, involves three, three chromosomal, chromosomal breakpoints, breakpoints ., . Short, Short regions, regions of, of sequence, sequence homology, homology were, were present, present at, at the, the three, three sites, sites ., . A, A 5-bp, 5-bp sequence, sequence ,, , GGAAT, GGAAT ,, , found, found exactly, exactly at, at the, the translocation, translocation breakpoints, breakpoints on, on both, both normal, normal chromosomes, chromosomes X, X and, and 4, 4 ,, , has, has been, been preserved, preserved only, only on, on the, the der, der (, ( 4, 4 ), ) chromosome, chromosome ., . It, It is, is likely, likely that, that the, the X-derived, X-derived sequence, sequence GGAATCA, GGAATCA has, has been, been lost, lost in, in the, the formation, formation of, of the, the der, der (, ( X, X ), ) chromosome, chromosome ,, , as, as it, it matches, matches an, an inverted, inverted GAATCA, GAATCA sequence, sequence present, present on, on the, the opposite, opposite strand, strand exactly, exactly at, at the, the other, other end, end of, of the, the deleted, deleted 5-kb, 5-kb fragment, fragment ., . Germline, Germline mutations, mutations are, are the, the major, major source, source of, of genetic, genetic variation, variation that, that allows, allows a, a species, species to, to evolve, evolve over, over time, time but, but at, at the, the cost, cost of, of Mendelian, Mendelian disease, disease and, and genetic, genetic predisposition, predisposition to, to multifactorial, multifactorial diseases, diseases ., . Previous, Previous analyses, analyses have, have revealed, revealed that, that the, the pattern, pattern of, of germline, germline mutations, mutations in, in the, the factor, factor IX, IX gene, gene (, ( F9, F9 ), ) is, is similar, similar among, among a, a variety, variety of, of ethnically, ethnically and, and geographically, geographically diverse, diverse populations, populations and, and compatible, compatible with, with the, the ancient, ancient pattern, pattern that, that has, has shaped, shaped the, the mammalian, mammalian genome, genome ., . Here, Here ,, , we, we compare, compare the, the pattern, pattern of, of germline, germline mutation, mutation in, in a, a population, population of, of hemophilia, hemophilia B, B patients, patients from, from Mainland, Mainland China, China (, ( n, n =, = 66, 66 ), ) to, to that, that in, in U., U. S., S. Caucasians, Caucasians ,, , Blacks, Blacks ,, , and, and Mexican, Mexican Hispanics, Hispanics and, and stratify, stratify by, by disease, disease severity, severity and, and ethnicity, ethnicity ., . The, The similar, similar pattern, pattern of, of germline, germline mutation, mutation in, in all, all ethnic, ethnic groups, groups studied, studied to, to date, date provides, provides additional, additional data, data compatible, compatible with, with the, the inference, inference that, that endogenous, endogenous processes, processes predominate, predominate in, in germline, germline mutations, mutations ., . We, We report, report on, on two, two clinically, clinically ,, , neurologically, neurologically normal, normal relatives, relatives of, of a, a boy, boy affected, affected by, by adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) ;, ; they, they were, were found, found repeatedly, repeatedly to, to have, have the, the biochemical, biochemical defect, defect of, of an, an ALD, ALD hemizygote, hemizygote ., . The, The assay, assay consisted, consisted in, in the, the determination, determination of, of very-long-chain, very-long-chain fatty, fatty acids, acids in, in lyophilized, lyophilized and, and reconstituted, reconstituted plasma, plasma ., . While, While no, no evidence, evidence of, of neurologic, neurologic disease, disease (, ( leukodystrophy, leukodystrophy or, or myeloneuropathy, myeloneuropathy ), ) was, was present, present in, in these, these hemizygotes, hemizygotes ,, , adrenocortical, adrenocortical insufficiency, insufficiency provoking, provoking compensatory, compensatory high, high ACTH, ACTH release, release was, was found, found in, in both, both ., . These, These findings, findings should, should be, be taken, taken into, into consideration, consideration when, when counseling, counseling families, families in, in which, which cases, cases with, with clinically, clinically expressed, expressed ALD, ALD are, are represented, represented in, in several, several generations.., generations.. Wilson, Wilson disease, disease (, ( WD, WD ), ) is, is an, an autosomal, autosomal recessive, recessive disorder, disorder characterized, characterized by, by copper, copper accumulation, accumulation in, in the, the liver, liver ,, , brain, brain ,, , kidneys, kidneys ,, , and, and corneas, corneas ,, , and, and culminating, culminating in, in copper, copper toxication, toxication in, in these, these organs, organs ., . In, In this, this study, study ,, , we, we analyzed, analyzed mutations, mutations of, of the, the responsible, responsible gene, gene ,, , ATP7B, ATP7B ,, , in, in four, four Japanese, Japanese patients, patients with, with WD, WD ., . By, By direct, direct sequencing, sequencing ,, , we, we identified, identified five, five mutations, mutations ,, , of, of which, which two, two were, were novel, novel ,, , and, and 16, 16 polymorphisms, polymorphisms ,, , of, of which, which 6, 6 were, were novel, novel ., . The, The mutations, mutations 2871delC, 2871delC and, and 2513delA, 2513delA shift, shift the, the reading, reading frame, frame so, so that, that truncated, truncated abnormal, abnormal protein, protein is, is expected, expected ., . In, In contrast, contrast to, to these, these mutations, mutations found, found in, in patients, patients with, with hepatic-type, hepatic-type of, of early, early onset, onset ,, , the, the mutations, mutations A874V, A874V ,, , R778L, R778L ,, , and, and 3892delGTC, 3892delGTC were, were either, either missense, missense mutations, mutations or, or in, in frame, frame 1-amino, 1-amino acid, acid deletion, deletion ,, , and, and occurred, occurred in, in the, the patients, patients with, with hepato-neurologic, hepato-neurologic type, type of, of late, late onset, onset ., . The, The mutations, mutations 2871delC, 2871delC and, and R778L, R778L have, have been, been previously, previously reported, reported in, in a, a relatively, relatively large, large number, number of, of Japanese, Japanese patients, patients ., . In, In particular, particular ,, , R778L, R778L is, is known, known to, to be, be more, more prevalent, prevalent in, in Asian, Asian countries, countries than, than in, in other, other countries, countries of, of the, the world, world ., . Our, Our data, data are, are compatible, compatible with, with the, the hypothesis, hypothesis that, that the, the mutations, mutations tend, tend to, to occur, occur in, in a, a population-specific, population-specific manner, manner ., . Therefore, Therefore ,, , the, the accumulation, accumulation of, of the, the types, types of, of mutations, mutations in, in Japanese, Japanese patients, patients with, with WD, WD will, will facilitate, facilitate the, the fast, fast and, and effective, effective genetic, genetic diagnosis, diagnosis of, of WD, WD in, in Japanese, Japanese patients.., patients.. We, We have, have previously, previously cloned, cloned and, and characterized, characterized the, the murine, murine homologue, homologue of, of the, the Huntington, Huntington disease, disease (, ( HD, HD ), ) gene, gene and, and shown, shown that, that it, it maps, maps to, to mouse, mouse chromosome, chromosome 5, 5 within, within a, a region, region of, of conserved, conserved synteny, synteny with, with human, human chromosome, chromosome 4p16, 4p16 ., . 3, 3 3, 3 ., . Here, Here we, we present, present a, a detailed, detailed comparison, comparison of, of the, the sequence, sequence of, of the, the putative, putative promoter, promoter and, and the, the organization, organization of, of the, the 5, 5 genomic, genomic region, region of, of the, the murine, murine (, ( Hdh, Hdh ), ) and, and human, human HD, HD genes, genes encompassing, encompassing the, the first, first five, five exons, exons ., . We, We show, show that, that in, in this, this region, region these, these two, two genes, genes share, share identical, identical exon, exon boundaries, boundaries ,, , but, but have, have different-size, different-size introns, introns ., . Two, Two dinucleotide, dinucleotide (, ( CT, CT ), ) and, and one, one trinucleotide, trinucleotide intronic, intronic polymorphism, polymorphism in, in Hdh, Hdh and, and an, an intronic, intronic CA, CA polymorphism, polymorphism in, in the, the HD, HD gene, gene were, were identified, identified ., . Comparison, Comparison of, of 940-bp, 940-bp sequence, sequence 5, 5 to, to the, the putative, putative translation, translation start, start site, site reveals, reveals a, a highly, highly conserved, conserved region, region (, ( 78, 78 ., . 8, 8 %, % nucleotide, nucleotide identity, identity ), ) between, between Hdh, Hdh and, and the, the HD, HD gene, gene from, from nucleotide, nucleotide -56, -56 to, to -206, -206 (, ( of, of Hdh, Hdh ), ) ., . Neither, Neither Hdh, Hdh nor, nor the, the HD, HD gene, gene have, have typical, typical TATA, TATA or, or CCAAT, CCAAT elements, elements ,, , but, but both, both show, show one, one putative, putative AP2, AP2 binding, binding site, site and, and numerous, numerous potential, potential Sp1, Sp1 binding, binding sites, sites ., . The, The high, high sequence, sequence identity, identity between, between Hdh, Hdh and, and the, the HD, HD gene, gene for, for approximately, approximately 200, 200 bp, bp 5, 5 to, to the, the putative, putative translation, translation start, start site, site indicates, indicates that, that these, these sequences, sequences may, may play, play a, a role, role in, in regulating, regulating expression, expression of, of the, the Huntington, Huntington disease, disease gene, gene A, A family, family is, is described, described in, in which, which three, three children, children had, had homozygous, homozygous deficiency, deficiency of, of C3, C3 and, and in, in which, which both, both parents, parents and, and two, two other, other children, children were, were heterozygous, heterozygous for, for the, the C3, C3 null, null gene, gene ., . One, One child, child with, with heterozygous, heterozygous C3, C3 deficiency, deficiency was, was found, found to, to have, have membranoproliferative, membranoproliferative glomerulonephritis, glomerulonephritis ;, ; proteinuria, proteinuria and/or, and/or microscopical, microscopical haematuria, haematuria was, was present, present in, in all, all three, three homozygous, homozygous C3-deficient, C3-deficient children, children ., . All, All children, children with, with homozygous, homozygous or, or heterozygous, heterozygous C3, C3 deficiency, deficiency were, were ,, , to, to a, a varying, varying degree, degree ,, , susceptible, susceptible to, to infection, infection ., . The, The only, only child, child of, of the, the family, family with, with normal, normal complement, complement had, had no, no increased, increased risk, risk of, of infection, infection and, and no, no renal, renal disease, disease ., . This, This family, family study, study provides, provides further, further support, support for, for the, the proposal, proposal that, that C3, C3 deficiency, deficiency predisposes, predisposes to, to nephritis.., nephritis.. Chromosomal, Chromosomal studies, studies were, were performed, performed on, on peripheral, peripheral blood, blood lymphocytes, lymphocytes and, and cultured, cultured skin, skin fibroblasts, fibroblasts from, from five, five Israeli-Moroccan, Israeli-Moroccan families, families with, with ataxia-telangiectasia, ataxia-telangiectasia ., . A, A total, total of, of 24, 24 individuals, individuals ,, , including, including seven, seven propositi, propositi ,, , was, was investigated, investigated ., . Among, Among the, the probands, probands ,, , significantly, significantly elevated, elevated rates, rates of, of chromosome, chromosome damage, damage were, were observed, observed in, in both, both blood, blood and, and skin, skin ., . Skin, Skin fibroblasts, fibroblasts of, of affected, affected individuals, individuals showed, showed several, several orders, orders of, of magnitude, magnitude more, more chromosome, chromosome breakage, breakage than, than lymphocytes, lymphocytes ., . Increased, Increased rates, rates of, of chromosome, chromosome damage, damage were, were also, also observed, observed in, in the, the fibroblasts, fibroblasts of, of some, some phenotypically, phenotypically normal, normal family, family members, members (, ( obligate, obligate heterozygotes, heterozygotes and, and sibs, sibs ), ) when, when compared, compared to, to normal, normal controls, controls ., . An, An apparent, apparent abnormal, abnormal clone, clone of, of cells, cells ,, , possessing, possessing a, a large, large acrocentric, acrocentric marker, marker chromosome, chromosome (, ( 14q, 14q +, + ), ) ,, , was, was observed, observed in, in varying, varying proportions, proportions among, among cells, cells of, of all, all the, the propositi, propositi (, ( 2-5, 2-5 %, % of, of lymphocytes, lymphocytes ;, ; 1-9, 1-9 %, % of, of fibroblasts, fibroblasts ), ) .., .. X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( X-ALD, X-ALD ), ) is, is an, an inherited, inherited disorder, disorder of, of peroxisomal, peroxisomal beta-oxidation, beta-oxidation associated, associated with, with accumulation, accumulation of, of saturated, saturated very, very long-chain, long-chain fatty, fatty acids, acids ,, , which, which results, results in, in central, central and, and peripheral, peripheral demyelination, demyelination and, and in, in impaired, impaired function, function of, of adrenal, adrenal cortex, cortex and, and testes, testes ., . The, The phenotypic, phenotypic expression, expression is, is highly, highly variable, variable ,, , childhood, childhood cerebral, cerebral ALD, ALD (, ( CCALD, CCALD ), ) and, and adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) being, being the, the main, main variants, variants ., . We, We explored, explored the, the 30, 30 Dutch, Dutch kindreds, kindreds well, well known, known to, to the, the Dutch, Dutch X-ALD/AMN, X-ALD/AMN Study, Study Group, Group and, and phenotyped, phenotyped 77, 77 male, male patients, patients 35, 35 (, ( 46, 46 %, % ), ) had, had AMN, AMN and, and 24, 24 (, ( 31, 31 %, % ), ) CCALD, CCALD or, or adolescent, adolescent cerebral, cerebral ALD, ALD (, ( AdolCALD, AdolCALD ), ) ., . These, These percentages, percentages differ, differ significantly, significantly from, from previous, previous reports, reports ,, , in, in which, which 25, 25 to, to 28, 28 %, % of, of the, the patients, patients developed, developed AMN, AMN and, and 53, 53 to, to 57, 57 %, % CCALD, CCALD or, or AdolCALD, AdolCALD ., . Our, Our findings, findings indicate, indicate that, that --, -- at, at least, least in, in the, the Netherlands, Netherlands --, -- AMN, AMN may, may be, be the, the most, most frequent, frequent phenotype, phenotype of, of X-ALD.., X-ALD.. Aniridia, Aniridia (, ( iris, iris hypoplasia, hypoplasia ), ) is, is an, an autosomal, autosomal dominant, dominant congenital, congenital disorder, disorder of, of the, the eye, eye ., . Mutations, Mutations in, in the, the human, human aniridia, aniridia (, ( PAX6, PAX6 ), ) gene, gene have, have now, now been, been identified, identified in, in many, many patients, patients from, from various, various ethnic, ethnic groups, groups ., . In, In the, the study, study reported, reported here, here we, we describe, describe PAX6, PAX6 mutations, mutations in, in one, one sporadic, sporadic and, and five, five familial, familial cases, cases with, with aniridia, aniridia ., . Of, Of the, the four, four different, different mutations, mutations identified, identified ,, , one, one was, was identical, identical to, to a, a previously, previously reported, reported mutation, mutation (, ( C, C --, -- >, > T, T transition, transition at, at codon, codon 240, 240 ), ) ,, , and, and three, three were, were novel, novel two, two in, in the, the glycine-rich, glycine-rich region, region and, and one, one in, in the, the proline/serine/threonine-rich, proline/serine/threonine-rich (, ( PST, PST ), ) region, region ., . One, One PAX6, PAX6 mutation, mutation found, found in, in the, the PST, PST region, region was, was associated, associated with, with cataracts, cataracts in, in an, an aniridia, aniridia family, family ., . Another, Another splice, splice mutation, mutation in, in the, the PST, PST domain, domain occurred, occurred in, in an, an aniridia, aniridia patient, patient with, with anosmia, anosmia (, ( inability, inability to, to smell, smell ), ) ., . The, The six, six new, new aniridia, aniridia cases, cases reported, reported here, here have, have mutations, mutations predicted, predicted to, to generate, generate incomplete, incomplete PAX6, PAX6 proteins, proteins ., . These, These results, results support, support the, the theory, theory that, that human, human aniridia, aniridia is, is caused, caused by, by haploinsufficiency, haploinsufficiency of, of PAX6.., PAX6.. Hepatoblastoma, Hepatoblastoma is, is a, a rare, rare neoplasm, neoplasm of, of infants, infants and, and children, children only, only recently, recently documented, documented in, in association, association with, with hereditary, hereditary adenomatous, adenomatous polyposis, polyposis of, of the, the colon, colon [, [ Kingston, Kingston et, et al., al. ,, , 1983, 1983 ], ] ., . We, We report, report four, four children, children with, with hepatoblastoma, hepatoblastoma from, from four, four unrelated, unrelated families, families with, with Gardner, Gardner syndrome, syndrome (, ( GS, GS ), ) ., . One, One child, child ,, , now, now 19, 19 years, years old, old ,, , survived, survived after, after a, a resection, resection of, of a, a hepatoblastoma, hepatoblastoma in, in infancy, infancy and, and recently, recently was, was found, found to, to have, have GS, GS ., . He, He has, has an, an associated, associated odontoma, odontoma and, and pigmented, pigmented ocular, ocular fundus, fundus lesions, lesions ,, , both, both of, of which, which have, have been, been shown, shown to, to be, be clinical, clinical markers, markers of, of GS, GS ., . Many, Many individuals, individuals in, in these, these four, four GS, GS families, families ,, , both, both affected, affected and, and at, at risk, risk ,, , have, have osteomatous, osteomatous jaw, jaw lesions, lesions and, and pigmented, pigmented ocular, ocular fundus, fundus lesions, lesions ., . A, A search, search for, for colonic, colonic polyps, polyps should, should be, be made, made in, in families, families of, of infants, infants and, and children, children with, with hepatoblastoma, hepatoblastoma ., . If, If the, the child, child survives, survives ,, , he, he or, or she, she should, should be, be monitored, monitored for, for the, the later, later appearance, appearance of, of colonic, colonic polyps, polyps ., . The, The finding, finding of, of jaw, jaw lesions, lesions and/or, and/or pigmented, pigmented ocular, ocular fundus, fundus lesions, lesions in, in relatives, relatives at, at risk, risk are, are indications, indications of, of the, the possible, possible presence, presence of, of the, the GS, GS gene, gene ., . The, The recent, recent isolation, isolation of, of the, the complete, complete open, open reading, reading frame, frame of, of the, the choroideremia, choroideremia (, ( CHM, CHM ), ) gene, gene and, and the, the characterization, characterization of, of the, the exon-intron, exon-intron boundaries, boundaries has, has paved, paved the, the way, way to, to mutation, mutation detection, detection in, in patients, patients with, with classical, classical choroideremia, choroideremia ., . We, We have, have performed, performed mutation, mutation screening, screening in, in patients, patients from, from 15, 15 Danish, Danish and, and Swedish, Swedish families, families by, by using, using Southern, Southern blot, blot hybridization, hybridization and, and the, the polymerase, polymerase chain, chain reaction, reaction single-strand, single-strand conformation, conformation polymorphism, polymorphism (, ( PCR-SSCP, PCR-SSCP ), ) technique, technique ., . Causative, Causative mutations, mutations in, in the, the CHM, CHM gene, gene were, were detected, detected in, in at, at least, least 12, 12 families, families ,, , indicating, indicating that, that a, a substantial, substantial part, part of, of the, the mutations, mutations can, can be, be identified, identified by, by this, this approach, approach ., . In, In four, four of, of these, these families, families deletions, deletions of, of different, different sizes, sizes were, were found, found ., . Thus, Thus ,, , in, in one, one patient, patient ,, , the, the deletion, deletion resulted, resulted in, in the, the absence, absence of, of only, only one, one exon, exon ,, , while, while in, in another, another the, the deletion, deletion comprised, comprised the, the entire, entire CHM, CHM gene, gene ., . Mapping, Mapping of, of the, the deletion, deletion endpoints, endpoints in, in these, these four, four patients, patients and, and in, in another, another 11, 11 male, male patients, patients with, with sizeable, sizeable deletions, deletions enabled, enabled us, us to, to construct, construct a, a very, very detailed, detailed map, map of, of intervals, intervals 2, 2 and, and 3, 3 of, of Xq21, Xq21 ., . In, In the, the remaining, remaining 11, 11 Danish, Danish and, and Swedish, Swedish families, families at, at least, least 8, 8 causative, causative mutations, mutations were, were found, found by, by PCR-SSCP, PCR-SSCP analysis, analysis and, and direct, direct sequencing, sequencing ., . Interestingly, Interestingly ,, , all, all CHM, CHM gene, gene mutations, mutations detected, detected thus, thus far, far in, in choroideremia, choroideremia patients, patients give, give rise, rise to, to the, the introduction, introduction of, of a, a premature, premature stop, stop codon.., codon.. Glucose-6-PHOSPHATE, Glucose-6-PHOSPHATE dehydrogenase, dehydrogenase (, ( G6PD, G6PD ;, ; EC, EC 1.1, 1.1 ., . 1, 1 ., . 49, 49 ), ) deficiency, deficiency is, is the, the most, most common, common human, human enzymopathy, enzymopathy ,, , affecting, affecting more, more than, than 200, 200 million, million people, people worldwide, worldwide ., . Although, Although greater, greater than, than 400, 400 variants, variants have, have been, been described, described based, based on, on clinical, clinical and, and biochemical, biochemical criteria, criteria ,, , little, little is, is known, known about, about the, the molecular, molecular basis, basis of, of these, these G6PD, G6PD deficiencies, deficiencies ., . Recently, Recently ,, , the, the gene, gene that, that encodes, encodes human, human G6PD, G6PD has, has been, been cloned, cloned and, and sequenced, sequenced ,, , which, which enables, enables us, us to, to examine, examine directly, directly the, the heterogeneity, heterogeneity of, of G6PD, G6PD at, at the, the DNA, DNA level, level ., . During, During the, the past, past 10, 10 years, years ,, , we, we examined, examined the, the G6PD, G6PD activity, activity in, in 21, 21 ,, , 271, 271 newborn, newborn Chinese, Chinese infants, infants (, ( 11, 11 ,, , 400, 400 males, males and, and 9, 9 ,, , 871, 871 females, females ), ) and, and identified, identified 314, 314 (, ( 2, 2 ., . 8, 8 %, % ), ) males, males and, and 246, 246 (, ( 2, 2 ., . 5, 5 %, % ), ) females, females having, having low, low G6PD, G6PD activity, activity ., . The, The G6PD, G6PD gene, gene from, from 10, 10 randomly, randomly selected, selected affected, affected individuals, individuals and, and their, their relatives, relatives was, was polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) amplified, amplified ,, , subcloned, subcloned ,, , and, and sequenced, sequenced ., . Our, Our results, results indicate, indicate that, that at, at least, least four, four types, types of, of mutation, mutation are, are responsible, responsible for, for the, the G6PD, G6PD polymorphism, polymorphism in, in Taiwan, Taiwan ., . The, The first, first type, type of, of mutation, mutation (, ( 487, 487 G, G --, -- --, -- A, A ), ) was, was found, found in, in an, an affected, affected Chinese, Chinese with, with a, a G, G to, to A, A change, change at, at nucleotide, nucleotide 487, 487 ,, , which, which results, results in, in a, a (, ( 163, 163 ), ) Gly, Gly to, to Ser, Ser substitution, substitution ., . The, The second, second type, type of, of mutation, mutation (, ( 493, 493 A, A --, -- --, -- G, G ), ) is, is a, a novel, novel mutation, mutation that, that has, has not, not been, been reported, reported in, in any, any other, other ethnic, ethnic group, group and, and was, was identified, identified in, in two, two affected, affected Chinese, Chinese ., . This, This mutation, mutation causes, causes an, an A, A to, to G, G change, change at, at nucleotide, nucleotide position, position 493, 493 ,, , producing, producing an, an (, ( 165, 165 ), ) Asn, Asn to, to Asp, Asp substitution, substitution ., . Interestingly, Interestingly ,, , the, the 487, 487 G, G --, -- --, -- A, A and, and 493, 493 A, A --, -- --, -- G, G mutations, mutations create, create Alu, Alu I, I and, and Ava, Ava II, II recognition, recognition sites, sites ,, , respectively, respectively ,, , which, which enabled, enabled us, us to, to rapidly, rapidly detect, detect these, these two, two mutations, mutations by, by PCR/restriction, PCR/restriction enzyme, enzyme (, ( RE, RE ), ) digestion, digestion method, method ., . The, The third, third mutation, mutation (, ( 1376, 1376 G, G --, -- --, -- T, T ), ) was, was found, found in, in four, four affected, affected Chinese, Chinese ., . This, This mutation, mutation causes, causes a, a G, G to, to T, T change, change at, at nucleotide, nucleotide position, position 1376, 1376 that, that results, results in, in an, an (, ( 459, 459 ), ) Arg, Arg to, to Leu, Leu substitution, substitution ., . The, The 1376, 1376 G, G --, -- --, -- T, T mutation, mutation seems, seems to, to be, be the, the dominant, dominant allele, allele that, that causes, causes G6PD, G6PD deficiency, deficiency in, in Taiwan, Taiwan ., . Finally, Finally ,, , two, two affected, affected Chinese, Chinese were, were identified, identified as, as having, having the, the fourth, fourth mutation, mutation (, ( 1388, 1388 G, G --, -- --, -- A, A ), ) ., . This, This mutation, mutation causes, causes a, a G, G to, to A, A change, change at, at nucleotide, nucleotide 1388, 1388 that, that produces, produces an, an (, ( 463, 463 ), ) Arg, Arg to, to His, His substitution, substitution ., . Our, Our studies, studies provide, provide the, the direct, direct proof, proof of, of the, the genetic, genetic heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency in, in the, the Chinese, Chinese populations, populations of, of Taiwan, Taiwan and, and the, the PCR/RE, PCR/RE digestion, digestion method, method is, is suitable, suitable for, for simultaneous, simultaneous detection, detection of, of the, the 487, 487 G, G --, -- --, -- A, A and, and 493, 493 A, A --, -- --, -- G, G mutations.Heterozygous, mutations.Heterozygous mutations, mutations encoding, encoding abnormal, abnormal forms, forms of, of the, the death, death receptor, receptor Fas, Fas dominantly, dominantly interfere, interfere with, with Fas-induced, Fas-induced lymphocyte, lymphocyte apoptosis, apoptosis in, in human, human autoimmune, autoimmune lymphoproliferative, lymphoproliferative syndrome, syndrome ., . This, This effect, effect ,, , rather, rather than, than depending, depending on, on ligand-induced, ligand-induced receptor, receptor oligomerization, oligomerization ,, , was, was found, found to, to stem, stem from, from ligand-, ligand- independent, independent interaction, interaction of, of wild-type, wild-type and, and mutant, mutant Fas, Fas receptors, receptors through, through a, a specific, specific region, region in, in the, the extracellular, extracellular domain, domain ., . Preassociated, Preassociated Fas, Fas complexes, complexes were, were found, found in, in living, living cells, cells by, by means, means of, of fluorescence, fluorescence resonance, resonance energy, energy transfer, transfer between, between variants, variants of, of green, green fluorescent, fluorescent protein, protein ., . These, These results, results show, show that, that formation, formation of, of preassociated, preassociated receptor, receptor complexes, complexes is, is necessary, necessary for, for Fas, Fas signaling, signaling and, and dominant, dominant interference, interference in, in human, human disease.., disease.. In, In order, order to, to demonstrate, demonstrate the, the effect, effect of, of prophylactic, prophylactic colchicine, colchicine treatment, treatment on, on the, the natural, natural history, history of, of familial, familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) ,, , a, a family, family is, is presented, presented with, with 6, 6 out, out of, of 9, 9 siblings, siblings affected, affected by, by FMF, FMF ., . Each, Each patient, patient represents, represents a, a different, different stage, stage of, of the, the amyloidotic, amyloidotic kidney, kidney disease, disease of, of FMF, FMF and, and the, the effect, effect of, of continuous, continuous colchicine, colchicine treatment, treatment on, on its, its course, course ., . Considered, Considered together, together ,, , the, the members, members of, of this, this family, family present, present an, an almost, almost complete, complete clinical, clinical ,, , genetic, genetic ,, , and, and behavioral, behavioral picture, picture of, of the, the disease.., disease.. Fragments, Fragments of, of the, the arylsulfatase, arylsulfatase A, A (, ( ARSA, ARSA ), ) gene, gene from, from a, a patient, patient with, with juvenile-onset, juvenile-onset metachromatic, metachromatic leukodystrophy, leukodystrophy (, ( MLD, MLD ), ) were, were amplified, amplified by, by PCR, PCR and, and ligated, ligated into, into MP13, MP13 cloning, cloning vectors, vectors ., . Clones, Clones hybridizing, hybridizing with, with cDNA, cDNA for, for human, human ARSA, ARSA were, were selected, selected ,, , examined, examined for, for appropriate, appropriate size, size inserts, inserts ,, , and, and used, used to, to prepare, prepare single-stranded, single-stranded phage, phage DNA, DNA ., . Examination, Examination of, of the, the entire, entire coding, coding and, and most, most of, of the, the intronic, intronic sequence, sequence revealed, revealed two, two putative, putative disease-related, disease-related mutations, mutations ., . One, One ,, , a, a point, point mutation, mutation in, in exon, exon 3, 3 ,, , resulted, resulted in, in the, the substitution, substitution of, of isoleucine, isoleucine by, by serine, serine ., . Introduction, Introduction of, of this, this alteration, alteration into, into the, the normal, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "normal ARSA, ARSA cDNA, cDNA sequence, sequence resulted, resulted in, in a, a substantial, substantial decrease, decrease in, in ARSA, ARSA activity, activity on, on transient, transient expression, expression in, in cultured, cultured baby, baby hamster, hamster kidney, kidney cells, cells ., . About, About 5, 5 %, % of, of the, the control, control expression, expression was, was observed, observed ,, , suggesting, suggesting a, a small, small residual, residual activity, activity in, in the, the mutated, mutated ARSA, ARSA ., . The, The second, second mutation, mutation ,, , a, a G-to-A, G-to-A transition, transition ,, , occurred, occurred in, in the, the other, other allele, allele and, and resulted, resulted in, in an, an altered, altered splice-recognition, splice-recognition sequence, sequence between, between exon, exon 7, 7 and, and the, the following, following intron, intron ., . The, The mutation, mutation also, also resulted, resulted in, in the, the loss, loss of, of a, a restriction, restriction site, site ., . Apparently, Apparently normal, normal levels, levels of, of mRNA, mRNA were, were generated, generated from, from this, this allele, allele ,, , but, but no, no ARSA, ARSA activity, activity or, or immuno-cross-reactive, immuno-cross-reactive material, material could, could be, be detected, detected ., . A, A collection, collection of, of DNA, DNA samples, samples from, from known, known or, or suspected, suspected MLD, MLD patients, patients ,, , members, members of, of their, their families, families ,, , and, and normal, normal controls, controls was, was screened, screened for, for these, these mutations, mutations ., . Four, Four additional, additional individuals, individuals carrying, carrying each, each of, of the, the mutations, mutations were, were found, found among, among the, the nearly, nearly 100, 100 MLD, MLD patients, patients in, in the, the sample, sample ., . Gene, Gene segregation, segregation in, in the, the original, original patients, patients family, family was, was consistent, consistent with, with available, available clinical, clinical and, and biochemical, biochemical data, data ., . No, No individuals, individuals homozygous, homozygous for, for either, either of, of these, these two, two mutations, mutations were, were identified, identified ., . However, However ,, , combinations, combinations with, with other, other MLD, MLD mutations, mutations suggest, suggest that, that the, the point, point mutation, mutation in, in exon, exon 3, 3 does, does result, result in, in some, some residual, residual enzyme, enzyme activity, activity and, and is, is associated, associated with, with late-onset, late-onset forms, forms of, of the, the disease, disease ., . The, The splice-site, splice-site mutation, mutation following, following exon, exon 7, 7 produces, produces late-infantile, late-infantile MLD, MLD when, when combined, combined with, with other, other enzyme-null, enzyme-null mutations, mutations ,, , implying, implying that, that it, it is, is completely, completely silent, silent enzymatically.., enzymatically.. The, The Atp7b, Atp7b protein, protein is, is a, a copper-transporting, copper-transporting ATPase, ATPase expressed, expressed predominantly, predominantly in, in the, the liver, liver and, and to, to a, a lesser, lesser extent, extent in, in most, most other, other tissues, tissues ., . Mutations, Mutations in, in the, the ATP7B, ATP7B gene, gene lead, lead to, to Wilson, Wilson disease, disease ,, , a, a copper, copper toxicity, toxicity disorder, disorder characterized, characterized by, by dramatic, dramatic build-up, build-up of, of intracellular, intracellular hepatic, hepatic copper, copper with, with subsequent, subsequent hepatic, hepatic and, and neuro-logical, neuro-logical abnormalities, abnormalities ., . Using, Using homologous, homologous recombination, recombination to, to disrupt, disrupt the, the normal, normal translation, translation of, of ATP7B, ATP7B ,, , we, we have, have generated, generated a, a strain, strain of, of mice, mice that, that are, are homozygous, homozygous mutants, mutants (, ( null, null ), ) for, for the, the Wilson, Wilson disease, disease gene, gene ., . The, The ATP7B, ATP7B null, null mice, mice display, display a, a gradual, gradual accumulation, accumulation of, of hepatic, hepatic copper, copper that, that increases, increases to, to a, a level, level 60-fold, 60-fold greater, greater than, than normal, normal by, by 5, 5 months, months of, of age, age ., . An, An increase, increase in, in copper, copper concentration, concentration was, was also, also observed, observed in, in the, the kidney, kidney ,, , brain, brain ,, , placenta, placenta and, and lactating, lactating mammary, mammary glands, glands of, of homo-zygous, homo-zygous mutants, mutants ,, , although, although milk, milk from, from the, the mutant, mutant glands, glands was, was copper, copper deficient, deficient ., . Morphological, Morphological abnormalities, abnormalities resembling, resembling cirrhosis, cirrhosis developed, developed in, in the, the majority, majority of, of the, the livers, livers from, from homozygous, homozygous mutants, mutants older, older than, than 7, 7 months, months of, of age, age ., . Progeny, Progeny of, of the, the homozygous, homozygous mutant, mutant females, females demonstrated, demonstrated neurological, neurological abnormalities, abnormalities and, and growth, growth retardation, retardation characteristic, characteristic of, of copper, copper deficiency, deficiency ., . Copper, Copper concentration, concentration in, in the, the livers, livers of, of the, the newborn, newborn homozygous, homozygous null, null mutants, mutants was, was decreased, decreased dramatically, dramatically ., . In, In summary, summary ,, , inactivation, inactivation of, of the, the murine, murine ATP7B, ATP7B gene, gene produces, produces a, a form, form of, of cirrhotic, cirrhotic liver, liver disease, disease that, that resembles, resembles Wilson, Wilson disease, disease in, in humans, humans and, and the, the toxic, toxic milk, milk phenotype, phenotype in, in the, the mouse.., mouse.. Four, Four cases, cases of, of adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) and, and one, one case, case of, of adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) have, have developed, developed in, in a, a kindred, kindred over, over three, three generations, generations demonstrating, demonstrating that, that AMN, AMN is, is a, a clinical, clinical variant, variant of, of ALD, ALD ., . Pituitary-adrenal, Pituitary-adrenal function, function studies, studies were, were performed, performed in, in 10, 10 family, family members, members ,, , including, including two, two affected, affected males, males and, and four, four females, females identified, identified as, as carriers, carriers of, of ALD/AMN, ALD/AMN ., . No, No pituitary-adrenal, pituitary-adrenal abnormality, abnormality was, was found, found in, in the, the carriers, carriers ., . However, However ,, , basal, basal morning, morning plasma, plasma adrenocorticotropic, adrenocorticotropic hormone, hormone (, ( ACTH, ACTH ), ) levels, levels were, were markedly, markedly elevated, elevated in, in the, the two, two males, males with, with ALD, ALD and, and AMN, AMN ,, , despite, despite the, the fact, fact that, that they, they had, had no, no clinical, clinical signs, signs of, of adrenal, adrenal insufficiency, insufficiency and, and that, that morning, morning plasma, plasma cortisol, cortisol levels, levels and, and their, their response, response to, to maximal, maximal exogenous, exogenous ACTH, ACTH stimulation, stimulation appeared, appeared to, to be, be normal, normal ., . In, In addition, addition ,, , the, the integrated, integrated 24-hour, 24-hour response, response to, to the, the administration, administration were, were also, also subnormal, subnormal in, in these, these two, two cases, cases ., . Thus, Thus ,, , people, people with, with ALD, ALD and, and AMN, AMN may, may have, have subclinical, subclinical partial, partial adrenocrotical, adrenocrotical insufficiency, insufficiency ., . No, No other, other endocrinologic, endocrinologic dysfunction, dysfunction was, was identified.., identified.. Adrenoleukodystrophy, Adrenoleukodystrophy (, ( ALD, ALD ), ) ,, , an, an X-linked, X-linked inherited, inherited metabolic, metabolic disorder, disorder ,, , is, is the, the most, most frequent, frequent inborn, inborn peroxisomal, peroxisomal disease, disease ., . It, It leads, leads to, to demyelination, demyelination in, in the, the central, central and, and peripheral, peripheral nervous, nervous system, system ., . Defective, Defective beta-oxidation, beta-oxidation of, of saturated, saturated very, very long, long chain, chain fatty, fatty acids, acids (, ( VLCFAs, VLCFAs ;, ; C22, C22 0-C26, 0-C26 0, 0 ), ) in, in peroxisomes, peroxisomes has, has been, been shown, shown to, to lead, lead to, to an, an accumulation, accumulation of, of VLCFAs, VLCFAs in, in leukoid, leukoid areas, areas of, of the, the central, central nervous, nervous system, system ,, , peripheral, peripheral nerves, nerves ,, , adrenal, adrenal gland, gland ,, , and, and blood, blood ., . The, The ALD, ALD gene, gene has, has been, been recently, recently identified, identified and, and encodes, encodes a, a 745-amino-acid, 745-amino-acid protein, protein ., . We, We screened, screened patients, patients with, with adrenoleukodystrophy/adrenomyeloneuropathy, adrenoleukodystrophy/adrenomyeloneuropathy (, ( ALD/AMN, ALD/AMN ), ) from, from 20, 20 kindreds, kindreds for, for mutations, mutations in, in the, the ALD, ALD gene, gene ., . Eleven, Eleven missense, missense and, and two, two nonsense, nonsense mutations, mutations ,, , five, five deletions, deletions ,, , and, and one, one insertion, insertion were, were detected, detected by, by direct, direct sequencing, sequencing of, of eight, eight reverse, reverse transcribed, transcribed fragments, fragments of, of the, the ALD-gene, ALD-gene mRNA, mRNA ., . Four, Four mutations, mutations could, could be, be shown, shown to, to be, be de, de novo, novo ., . All, All mutations, mutations could, could be, be confirmed, confirmed in, in carriers, carriers by, by sequencing, sequencing genomic, genomic DNA, DNA ., . No, No correlation, correlation between, between the, the type, type of, of mutation, mutation and, and the, the severity, severity of, of the, the phenotype, phenotype could, could be, be observed, observed ., . The, The mutations, mutations were, were not, not detected, detected in, in the, the ALD, ALD gene, gene of, of 30, 30 healthy, healthy persons.., persons.. Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is caused, caused by, by abnormal, abnormal expansion, expansion of, of a, a polymorphic, polymorphic (, ( CTG, CTG ), ) n, n repeat, repeat ,, , located, located in, in the, the DM, DM protein, protein kinase, kinase gene, gene ., . We, We determined, determined the, the (, ( CTG, CTG ), ) n, n repeat, repeat lengths, lengths in, in a, a broad, broad range, range of, of tissue, tissue DNAs, DNAs from, from patients, patients with, with mild, mild ,, , classical, classical ,, , or, or congenital, congenital manifestation, manifestation of, of DM, DM ., . Differences, Differences in, in the, the repeat, repeat length, length were, were seen, seen in, in somatic, somatic tissues, tissues from, from single, single DM, DM individuals, individuals and, and twins, twins ., . Repeats, Repeats appeared, appeared to, to expand, expand to, to a, a similar, similar extent, extent in, in tissues, tissues originating, originating from, from the, the same, same embryonal, embryonal origin, origin ., . In, In most, most male, male patients, patients carrying, carrying intermediate-, intermediate- or, or small-sized, small-sized expansions, expansions in, in blood, blood ,, , the, the repeat, repeat lengths, lengths covered, covered a, a markedly, markedly wider, wider range, range in, in sperm, sperm ., . In, In contrast, contrast ,, , male, male patients, patients with, with large, large allele, allele expansions, expansions in, in blood, blood (, ( >, > 700, 700 CTGs, CTGs ), ) had, had similar, similar or, or smaller, smaller repeats, repeats in, in sperm, sperm ,, , when, when detectable, detectable ., . Sperm, Sperm alleles, alleles with, with >, > 1, 1 ,, , 000, 000 CTGs, CTGs were, were not, not seen, seen ., . We, We conclude, conclude that, that DM, DM patients, patients can, can be, be considered, considered gonosomal, gonosomal mosaics, mosaics ,, , i., i. e, e e., e. ,, , combined, combined somatic, somatic and, and germ-line, germ-line tissue, tissue mosaics, mosaics ., . Most, Most remarkably, remarkably ,, , we, we observed, observed multiple, multiple cases, cases where, where the, the length, length distributions, distributions of, of intermediate-, intermediate- or, or small-sized, small-sized alleles, alleles in, in fathers, fathers sperm, sperm were, were significantly, significantly different, different from, from that, that in, in their, their offsprings, offsprings blood, blood ., . Our, Our combined, combined findings, findings indicate, indicate that, that intergenerational, intergenerational length, length changes, changes in, in the, the unstable, unstable CTG, CTG repeat, repeat are, are most, most likely, likely to, to occur, occur during, during early, early embryonic, embryonic mitotic, mitotic divisions, divisions in, in both, both somatic, somatic and, and germ-line, germ-line tissue, tissue formation, formation ., . Both, Both the, the initial, initial CTG, CTG length, length ,, , the, the overall, overall number, number of, of cell, cell divisions, divisions involved, involved in, in tissue, tissue formation, formation ,, , and, and perhaps, perhaps a, a specific, specific selection, selection process, process in, in spermatogenesis, spermatogenesis may, may influence, influence the, the dynamics, dynamics of, of this, this process, process ., . A, A model, model explaining, explaining mitotic, mitotic instability, instability and, and sex-dependent, sex-dependent segregation, segregation phenomena, phenomena in, in DM, DM manifestation, manifestation is, is discussed, discussed A, A previous, previous linkage, linkage study, study provided, provided evidence, evidence for, for a, a prostate, prostate cancer-susceptibility, cancer-susceptibility locus, locus at, at 1q24-25, 1q24-25 ., . Subsequent, Subsequent reports, reports in, in additional, additional collections, collections of, of families, families have, have yielded, yielded conflicting, conflicting results, results ., . In, In addition, addition ,, , evidence, evidence for, for locus, locus heterogeneity, heterogeneity has, has been, been provided, provided by, by the, the identification, identification of, of other, other putative, putative hereditary, hereditary prostate, prostate cancer, cancer loci, loci on, on Xq27-28, Xq27-28 ,, , 1q42-43, 1q42-43 ,, , and, and 1p36, 1p36 ., . The, The present, present study, study describes, describes a, a combined, combined analysis, analysis for, for six, six markers, markers in, in the, the 1q24-25, 1q24-25 region, region in, in 772, 772 families, families affected, affected by, by hereditary, hereditary prostate, prostate cancer, cancer and, and ascertained, ascertained by, by the, the members, members of, of the, the International, International Consortium, Consortium for, for Prostate, Prostate Cancer, Cancer Genetics, Genetics (, ( ICPCG, ICPCG ), ) from, from North, North America, America ,, , Australia, Australia ,, , Finland, Finland ,, , Norway, Norway ,, , Sweden, Sweden ,, , and, and the, the United, United Kingdom, Kingdom ., . Overall, Overall ,, , there, there was, was some, some evidence, evidence for, for linkage, linkage ,, , with, with a, a peak, peak parametric, parametric multipoint, multipoint LOD, LOD score, score assuming, assuming heterogeneity, heterogeneity (, ( HLOD, HLOD ), ) of, of 1, 1 ., . 40, 40 (, ( P, P =, = ., . 01, 01 ), ) at, at D1S212, D1S212 ., . The, The estimated, estimated proportion, proportion of, of families, families (, ( alpha, alpha ), ) linked, linked to, to the, the locus, locus was, was ., . 06, 06 (, ( 1-LOD, 1-LOD support, support interval, interval ., . 01-, 01- ., . 12, 12 ), ) ., . This, This evidence, evidence was, was not, not observed, observed by, by a, a nonparametric, nonparametric approach, approach ,, , presumably, presumably because, because of, of the, the extensive, extensive heterogeneity, heterogeneity ., . Further, Further parametric, parametric analysis, analysis revealed, revealed a, a significant, significant effect, effect of, of the, the presence, presence of, of male-to-male, male-to-male disease, disease transmission, transmission within, within the, the families, families ., . In, In the, the subset, subset of, of 491, 491 such, such families, families ,, , the, the peak, peak HLOD, HLOD was, was 2, 2 ., . In, In the, the subset, subset of, of 491, 491 such, such families, families ,, , the, the peak, peak HLOD, HLOD was, was 2, 2 ., . 56, 56 (, ( P, P =, = ., . 0006, 0006 ), ) and, and alpha, alpha =, = ., . 11, 11 (, ( 1-LOD, 1-LOD support, support interval, interval ., . 04-, 04- ., . 19, 19 ), ) ,, , compared, compared with, with HLODs, HLODs of, of 0, 0 in, in the, the remaining, remaining 281, 281 families, families ., . Within, Within the, the families, families with, with male-to-male, male-to-male disease, disease transmission, transmission ,, , alpha, alpha increased, increased with, with the, the early, early mean, mean age, age at, at diagnosis, diagnosis (, ( <, < 65, 65 years, years ,, , alpha, alpha =, = ., . 19, 19 ,, , with, with 1-LOD, 1-LOD support, support interval, interval ., . 06-, 06- ., . 34, 34 ), ) and, and the, the number, number of, of affected, affected family, family members, members (, ( five, five or, or more, more family, family members, members ,, , alpha, alpha =, = ., . 15, 15 ,, , with, with 1-LOD, 1-LOD support, support interval, interval ., . 04-, 04- ., . 28, 28 ), ) ., . The, The highest, highest value, value of, of alpha, alpha was, was observed, observed for, for the, the 48, 48 families, families that, that met, met all, all three, three criteria, criteria (, ( peak, peak HLOD, HLOD =, = 2, 2 ., . 25, 25 ,, , P, P =, = ., . 001, 001 ,, , alpha, alpha =, = ., . 29, 29 ,, , with, with 1-LOD, 1-LOD support, support interval, interval ., . 08-, 08- ., . 53, 53 ), ) ., . These, These results, results support, support the, the finding, finding of, of a, a prostate, prostate cancer-susceptibility, cancer-susceptibility gene, gene linked, linked to, to 1q24-25, 1q24-25 ,, , albeit, albeit in, in a, a defined, defined subset, subset of, of prostate, prostate cancer, cancer families, families ., . Although, Although HPC1, HPC1 accounts, accounts for, for only, only a, a small, small proportion, proportion of, of all, all families, families affected, affected by, by hereditary, hereditary prostate, prostate cancer, cancer ,, , it, it appears, appears to, to play, play a, a more, more prominent, prominent role, role in, in the, the subset, subset of, of families, families with, with several, several members, members affected, affected at, at an, an early, early age, age and, and with, with male-to-male, male-to-male disease, disease transmission.Palmitoyl-CoA, transmission.Palmitoyl-CoA dehydrogenase, dehydrogenase activity, activity in, in skin, skin fibroblasts, fibroblasts from, from seven, seven patients, patients with, with unidentified, unidentified defects, defects of, of fatty, fatty acid, acid oxidation, oxidation was, was measured, measured in, in the, the presence, presence and, and absence, absence of, of antibodies, antibodies against, against medium-chain, medium-chain ,, , long-chain, long-chain ,, , and, and very-long-chain, very-long-chain acyl-CoA, acyl-CoA dehydrogenases, dehydrogenases (, ( VLCAD, VLCAD ), ) ., . Two, Two of, of the, the patients, patients ,, , 4-5, 4-5 month, month old, old boys, boys ,, , were, were found, found to, to have, have a, a novel, novel disease, disease ,, , VLCAD, VLCAD deficiency, deficiency ,, , as, as judged, judged from, from the, the results, results of, of very, very low, low palmitoyl-CoA, palmitoyl-CoA dehydrogenase, dehydrogenase activity, activity and, and the, the lack, lack of, of immunoreactivity, immunoreactivity toward, toward antibody, antibody raised, raised to, to purified, purified VLCAD.., VLCAD.. Patients, Patients with, with the, the Denys-Drash, Denys-Drash syndrome, syndrome (, ( Wilms, Wilms tumor, tumor ,, , genital, genital anomalies, anomalies ,, , and, and nephropathy, nephropathy ), ) have, have been, been demonstrated, demonstrated to, to carry, carry de, de novo, novo constitutional, constitutional mutations, mutations in, in WT1, WT1 ,, , the, the Wilms, Wilms tumor, tumor gene, gene at, at chromosome, chromosome 11p13, 11p13 ., . We, We report, report three, three new, new cases, cases ,, , two, two carrying, carrying a, a previously, previously described, described WT1, WT1 exon, exon 9, 9 mutation, mutation and, and one, one with, with a, a novel, novel WT1, WT1 exon, exon 8, 8 mutation, mutation ., . However, However ,, , unlike, unlike patients, patients in, in previous, previous reports, reports ,, , one, one of, of our, our three, three patients, patients inherited, inherited the, the affected, affected allele, allele from, from his, his phenotypically, phenotypically unaffected, unaffected father, father ., . This, This observation, observation indicates, indicates that, that the, the WT1, WT1 exon, exon 9, 9 mutation, mutation affecting, affecting 394Arg, 394Arg demonstrated, demonstrated in, in over, over one-half, one-half of, of the, the patients, patients with, with the, the Denys-Drash, Denys-Drash syndrome, syndrome may, may exhibit, exhibit incomplete, incomplete penetrance, penetrance ., . Consequently, Consequently ,, , familial, familial studies, studies in, in patients, patients affected, affected by, by this, this syndrome, syndrome are, are recommended.., recommended.. Glucose/galactose, Glucose/galactose malabsorption, malabsorption (, ( GGM, GGM ), ) is, is an, an autosomal, autosomal recessive, recessive disease, disease manifesting, manifesting within, within the, the first, first weeks, weeks of, of life, life and, and characterized, characterized by, by a, a selective, selective failure, failure to, to absorb, absorb dietary, dietary glucose, glucose and, and galactose, galactose from, from the, the intestine, intestine ., . The, The consequent, consequent severe, severe diarrhoea, diarrhoea and, and dehydration, dehydration are, are usually, usually fatal, fatal unless, unless these, these sugars, sugars are, are eliminated, eliminated from, from the, the diet, diet ., . Intestinal, Intestinal biopsies, biopsies of, of GGM, GGM patients, patients have, have revealed, revealed a, a specific, specific defect, defect in, in Na, Na (, ( +, + ), ) -dependent, -dependent absorption, absorption of, of glucose, glucose in, in the, the brush, brush border, border ., . Normal, Normal glucose, glucose absorption, absorption is, is mediated, mediated by, by the, the Na, Na +/glucose, +/glucose cotransporter, cotransporter in, in the, the brush, brush border, border membrane, membrane of, of the, the intestinal, intestinal epithelium, epithelium ., . Cellular, Cellular influx, influx is, is driven, driven by, by the, the transmembrane, transmembrane Na, Na +, + electrochemical, electrochemical potential, potential gradient, gradient ;, ; thereafter, thereafter the, the sugar, sugar moves, moves to, to the, the blood, blood across, across the, the basolateral, basolateral membrane, membrane via, via the, the facilitated, facilitated glucose, glucose carrier, carrier ., . We, We have, have previously, previously cloned, cloned and, and sequenced, sequenced a, a Na, Na +/glucose, +/glucose cotransporter, cotransporter from, from normal, normal human, human ileum, ileum and, and shown, shown that, that this, this gene, gene ,, , SGLT1, SGLT1 ,, , resides, resides on, on the, the distal, distal q, q arm, arm of, of chromosome, chromosome 22, 22 ., . We, We have, have now, now amplified, amplified SGLT1, SGLT1 complementary, complementary DNA, DNA and, and genomic, genomic DNA, DNA from, from members, members of, of a, a family, family affected, affected with, with GGM, GGM by, by the, the polymerase, polymerase chain, chain reaction, reaction ., . Sequence, Sequence analysis, analysis of, of the, the amplified, amplified products, products has, has revealed, revealed a, a single, single missense, missense mutation, mutation in, in SGLT1, SGLT1 which, which cosegregates, cosegregates with, with the, the GGM, GGM phenotype, phenotype and, and results, results in, in a, a complete, complete loss, loss of, of Na, Na (, ( +, + ), ) -dependent, -dependent glucose, glucose transport, transport in, in Xenopus, Xenopus oocytes, oocytes injected, injected with, with this, this complementary, complementary RNA.., RNA.. Ataxia-telangiectasia, Ataxia-telangiectasia is, is a, a hereditary, hereditary multisystemic, multisystemic disease, disease resulting, resulting from, from mutations, mutations of, of ataxia, ataxia telangiectasia, telangiectasia ,, , mutated, mutated (, ( ATM, ATM ), ) and, and is, is characterized, characterized by, by neurodegeneration, neurodegeneration ,, , cancer, cancer ,, , immune, immune defects, defects ,, , and, and hypersensitivity, hypersensitivity to, to ionizing, ionizing radiation, radiation ., . The, The molecular, molecular details, details of, of ATM, ATM function, function in, in the, the nervous, nervous system, system are, are unclear, unclear ,, , although, although the, the neurological, neurological lesion, lesion in, in ataxia-telangiectasia, ataxia-telangiectasia becomes, becomes apparent, apparent early, early in, in life, life ,, , suggesting, suggesting a, a developmental, developmental origin, origin ., . The, The central, central nervous, nervous system, system (, ( CNS, CNS ), ) of, of Atm-null, Atm-null mice, mice shows, shows a, a pronounced, pronounced defect, defect in, in apoptosis, apoptosis induced, induced by, by genotoxic, genotoxic stress, stress ,, , suggesting, suggesting ATM, ATM functions, functions to, to eliminate, eliminate neurons, neurons with, with excessive, excessive genomic, genomic damage, damage ., . Here, Here ,, , we, we report, report that, that the, the death, death effector, effector Bax, Bax is, is required, required for, for a, a large, large proportion, proportion of, of Atm-dependent, Atm-dependent apoptosis, apoptosis in, in the, the developing, developing CNS, CNS after, after ionizing, ionizing radiation, radiation (, ( IR, IR ), ) ., . Although, Although many, many of, of the, the same, same regions, regions of, of the, the CNS, CNS in, in both, both Bax-/-, Bax-/- and, and Atm-/-, Atm-/- mice, mice were, were radioresistant, radioresistant ,, , mice, mice nullizygous, nullizygous for, for both, both Bax, Bax and, and Atm, Atm showed, showed additional, additional reduction, reduction in, in IR-induced, IR-induced apoptosis, apoptosis in, in the, the CNS, CNS ., . Therefore, Therefore ,, , although, although the, the major, major IR-induced, IR-induced apoptotic, apoptotic pathway, pathway in, in the, the CNS, CNS requires, requires Atm, Atm and, and Bax, Bax ,, , a, a p53-dependent, p53-dependent collateral, collateral pathway, pathway exists, exists that, that has, has both, both Atm-, Atm- and, and Bax-independent, Bax-independent branches, branches ., . Further, Further ,, , Atm-, Atm- and, and Bax-dependent, Bax-dependent apoptosis, apoptosis in, in the, the CNS, CNS also, also required, required caspase-3, caspase-3 activation, activation ., . These, These data, data implicate, implicate Bax, Bax and, and caspase-3, caspase-3 as, as death, death effectors, effectors in, in neurodegenerative, neurodegenerative pathways.., pathways.. We, We describe, describe three, three HEXA, HEXA mutations, mutations associated, associated with, with infantile, infantile Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) in, in three, three unrelated, unrelated nonconsanguineous, nonconsanguineous Chinese, Chinese families, families ., . Novel, Novel mutations, mutations were, were found, found in, in two, two of, of these, these families, families ., . The, The third, third is, is a, a previously, previously reported, reported mutation, mutation (, ( G, G --, -- >, > A, A transition, transition at, at nt, nt 1444, 1444 ), ) (, ( Nakano, Nakano et, et al., al. ,, , 1988, 1988 ), ) ., . Direct, Direct sequencing, sequencing of, of PCR, PCR products, products identified, identified a, a novel, novel insertion, insertion of, of an, an A, A after, after nt, nt 547, 547 in, in family, family 1, 1 ., . This, This change, change generates, generates an, an early, early termination, termination codon, codon 6, 6 bp, bp downstream, downstream from, from the, the insertion, insertion site, site ., . Allele-specific, Allele-specific oligonucleotide, oligonucleotide hybridization, hybridization confirmed, confirmed homozygosity, homozygosity in, in the, the proband, proband ., . Single, Single strand, strand conformational, conformational polymorphism, polymorphism analysis, analysis and, and direct, direct sequencing, sequencing of, of amplified, amplified exon, exon 13, 13 revealed, revealed a, a T, T --, -- >, > C, C transition, transition at, at nt, nt 1453, 1453 with, with the, the corresponding, corresponding amino, amino acid, acid substitution, substitution W485R, W485R in, in the, the second, second family, family ., . This, This mutation, mutation creates, creates an, an Fnu4HI, Fnu4HI restriction, restriction site, site ., . The, The proband, proband is, is homozygous, homozygous for, for this, this allele, allele ., . When, When the, the site-specific, site-specific mutagenized, mutagenized alpha, alpha cDNA, cDNA carrying, carrying the, the T, T --, -- >, > C, C transition, transition at, at nt, nt 1453, 1453 was, was expressed, expressed in, in COS, COS 1, 1 cells, cells hexosaminidase, hexosaminidase S, S activity, activity was, was not, not detectable, detectable above, above background, background ., . A, A G, G --, -- >, > A, A transition, transition at, at nt, nt 1444, 1444 (, ( exon, exon 13, 13 ), ) corresponding, corresponding to, to the, the E482K, E482K substitution, substitution was, was found, found in, in the, the third, third family, family ., . This, This mutation, mutation occurs, occurs at, at a, a CpG, CpG dinucleotide, dinucleotide ., . It, It has, has been, been reported, reported in, in an, an Italian, Italian TSD, TSD proband, proband and, and causes, causes defective, defective intracellular, intracellular transport, transport of, of the, the alpha-subunit, alpha-subunit from, from the, the rough, rough endoplasmic, endoplasmic reticulum, reticulum to, to the, the Golgi, Golgi apparatus, apparatus ., . We, We have, have evaluated, evaluated the, the hypothesis, hypothesis of, of a, a negative, negative association, association between, between glucose, glucose 6-phosphate, 6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency and, and cancer, cancer in, in a, a cohort, cohort of, of 481, 481 Sardinian, Sardinian males, males with, with hematological, hematological malignancies, malignancies ., . The, The frequency, frequency of, of G6PD, G6PD deficiency, deficiency in, in the, the patients, patients was, was not, not different, different from, from the, the incidence, incidence in, in a, a group, group of, of 16, 16 ,, , 219, 219 controls, controls ., . The, The same, same conclusion, conclusion resulted, resulted from, from the, the comparison, comparison of, of the, the frequency, frequency of"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", of expression, expression of, of the, the GdB, GdB gene, gene in, in 23, 23 heterozygous, heterozygous women, women having, having a, a clonal, clonal hematologic, hematologic disease, disease and, and a, a control, control group, group of, of 37, 37 healthy, healthy heterozygotes, heterozygotes ., . Therefore, Therefore at, at present, present there, there is, is no, no evidence, evidence that, that G6PD, G6PD deficiency, deficiency has, has a, a protective, protective effect, effect against, against development, development of, of hematologic, hematologic neoplasms.., neoplasms.. We, We have, have constructed, constructed a, a physical, physical map, map of, of a, a 4, 4 cM, cM region, region on, on chromosome, chromosome 17q12-21, 17q12-21 that, that contains, contains the, the hereditary, hereditary breast, breast and, and ovarian, ovarian cancer, cancer gene, gene BRCA1, BRCA1 ., . The, The map, map comprises, comprises a, a contig, contig of, of 137, 137 overlapping, overlapping yeast, yeast artificial, artificial chromosomes, chromosomes and, and P1, P1 clones, clones ,, , onto, onto which, which we, we have, have placed, placed 112, 112 PCR, PCR markers, markers ., . We, We have, have localized, localized more, more than, than 20, 20 genes, genes on, on this, this map, map ,, , ten, ten of, of which, which had, had not, not been, been mapped, mapped to, to the, the region, region previously, previously ,, , and, and have, have isolated, isolated 30, 30 cDNA, cDNA clones, clones representing, representing partial, partial sequences, sequences of, of as, as yet, yet unidentified, unidentified genes, genes ., . Two, Two genes, genes that, that lie, lie within, within a, a narrow, narrow region, region defined, defined by, by meiotic, meiotic breakpoints, breakpoints in, in BRCA1, BRCA1 patients, patients have, have been, been sequenced, sequenced in, in breast, breast cancer, cancer patients, patients without, without revealing, revealing any, any deleterious, deleterious mutations, mutations ., . These, These new, new reagents, reagents should, should facilitate, facilitate the, the identification, identification of, of BRCA1.., BRCA1.. Pendred, Pendred syndrome, syndrome is, is the, the most, most common, common form, form of, of syndromic, syndromic deafness, deafness ,, , characterized, characterized by, by dyshormonogenic, dyshormonogenic goiter, goiter associated, associated with, with sensory-neural, sensory-neural deafness, deafness ., . The, The gene, gene responsible, responsible for, for the, the disease, disease (, ( PDS, PDS ), ) has, has been, been cloned, cloned ,, , but, but its, its function, function is, is as, as yet, yet unknown, unknown and, and the, the connection, connection between, between thyroid, thyroid goiter, goiter and, and sensory-neural, sensory-neural deafness, deafness remains, remains an, an enigma, enigma ., . PDS, PDS codes, codes for, for a, a novel, novel protein, protein ,, , pendrin, pendrin ,, , which, which is, is closely, closely related, related to, to a, a number, number of, of sufate, sufate transporters, transporters ., . Mechanisms, Mechanisms by, by which, which abnormal, abnormal sulfate, sulfate transport, transport could, could deleteriously, deleteriously affect, affect iodide, iodide organification, organification have, have been, been proposed, proposed ., . We, We tested, tested sulfate, sulfate transport, transport in, in thyrocytes, thyrocytes obtained, obtained from, from Pendred, Pendred syndrome, syndrome patients, patients and, and found, found that, that it, it was, was not, not defective, defective ., . This, This suggests, suggests that, that pendrin, pendrin in, in fact, fact may, may not, not be, be a, a sulfate, sulfate transporter, transporter ,, , and, and emphasizes, emphasizes the, the importance, importance of, of functional, functional studies, studies on, on this, this novel, novel protein.., protein.. We, We describe, describe seven, seven Dutch, Dutch patients, patients from, from six, six families, families with, with a, a slowly, slowly progressive, progressive ,, , mainly, mainly spinal, spinal cord, cord syndrome, syndrome that, that remained, remained for, for many, many years, years the, the sole, sole expression, expression of, of cerebrotendinous, cerebrotendinous xanthomatosis, xanthomatosis (, ( CTX, CTX ), ) ., . MRI, MRI demonstrated, demonstrated white, white matter, matter abnormalities, abnormalities in, in the, the lateral, lateral and, and dorsal, dorsal columns, columns of, of the, the spinal, spinal cord, cord ., . Post-mortem, Post-mortem examination, examination of, of one, one of, of the, the patients, patients showed, showed extensive, extensive myelin, myelin loss, loss in, in these, these columns, columns ., . An, An array, array of, of genotypes, genotypes was, was found, found in, in these, these patients, patients ., . We, We conclude, conclude that, that spinal, spinal xanthomatosis, xanthomatosis is, is a, a clinical, clinical and, and radiological, radiological separate, separate entity, entity of, of CTX, CTX that, that should, should be, be included, included in, in the, the differential, differential diagnosis, diagnosis of, of chronic, chronic myelopathy.., myelopathy.. Recently, Recently ,, , a, a 6-kb, 6-kb duplication, duplication of, of exon, exon 13, 13 ,, , which, which creates, creates a, a frameshift, frameshift in, in the, the coding, coding sequence, sequence of, of the, the BRCA1, BRCA1 gene, gene ,, , has, has been, been described, described in, in three, three unrelated, unrelated U, U ., . S, S S., S. families, families of, of European, European ancestry, ancestry and, and in, in one, one Portuguese, Portuguese family, family ., . Here, Here ,, , our, our goal, goal was, was to, to estimate, estimate the, the frequency, frequency and, and geographic, geographic diversity, diversity of, of carriers, carriers of, of this, this duplication, duplication ., . To, To do, do this, this ,, , a, a collaborative, collaborative screening, screening study, study was, was set, set up, up that, that involved, involved 39, 39 institutions, institutions from, from 19, 19 countries, countries and, and included, included 3, 3 ,, , 580, 580 unrelated, unrelated individuals, individuals with, with a, a family, family history, history of, of the, the disease, disease and, and 934, 934 early-onset, early-onset breast, breast and/or, and/or ovarian, ovarian cancer, cancer cases, cases ., . A, A total, total of, of 11, 11 additional, additional families, families carrying, carrying this, this mutation, mutation were, were identified, identified in, in Australia, Australia (, ( 1, 1 ), ) ,, , Belgium, Belgium (, ( 1, 1 ), ) ,, , Canada, Canada (, ( 1, 1 ), ) ,, , Great, Great Britain, Britain (, ( 6, 6 ), ) ,, , and, and the, the United, United States, States (, ( 2, 2 ), ) ., . Haplotyping, Haplotyping showed, showed that, that they, they are, are likely, likely to, to derive, derive from, from a, a common, common ancestor, ancestor ,, , possibly, possibly of, of northern, northern British, British origin, origin ., . Our, Our results, results demonstrate, demonstrate that, that it, it is, is strongly, strongly advisable, advisable ,, , for, for laboratories, laboratories carrying, carrying out, out screening, screening either, either in, in English-speaking, English-speaking countries, countries or, or in, in countries, countries with, with historical, historical links, links with, with Britain, Britain ,, , to, to include, include within, within their, their BRCA1, BRCA1 screening, screening protocols, protocols the, the polymerase, polymerase chain, chain reaction-based, reaction-based assay, assay described, described in, in this, this report, report ., . Mutations, Mutations in, in the, the BRCA1, BRCA1 gene, gene ,, , discovered, discovered in, in 1994, 1994 ,, , are, are associated, associated with, with an, an 80-90, 80-90 %, % lifetime, lifetime risk, risk of, of breast, breast cancer, cancer ., . We, We have, have analysed, analysed 60, 60 families, families with, with a, a history, history of, of breast, breast and/or, and/or ovarian, ovarian cancer, cancer for, for germline, germline mutations, mutations in, in BRCA1, BRCA1 ., . Twenty-two, Twenty-two different, different mutations, mutations were, were detected, detected in, in 32, 32 families, families (, ( 53, 53 %, % ), ) ,, , of, of which, which 14, 14 are, are previously, previously unreported, unreported ., . We, We observed, observed a, a significant, significant correlation, correlation between, between the, the location, location of, of the, the mutation, mutation in, in the, the gene, gene and, and the, the ratio, ratio of, of breast, breast to, to ovarian, ovarian cancer, cancer incidence, incidence within, within each, each family, family ., . Our, Our data, data suggest, suggest a, a transition, transition in, in risk, risk such, such that, that mutations, mutations in, in the, the 3, 3 third, third of, of the, the gene, gene are, are associated, associated with, with a, a lower, lower proportion, proportion of, of ovarian, ovarian cancer, cancer ., . Haplotype, Haplotype analysis, analysis supports, supports previous, previous data, data which, which suggest, suggest some, some BRCA1, BRCA1 mutation, mutation carriers, carriers have, have common, common ancestors, ancestors ;, ; however, however ,, , we, we have, have found, found at, at least, least two, two examples, examples where, where recurrent, recurrent mutations, mutations appear, appear to, to have, have arisen, arisen independently.., independently.. Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) ,, , the, the most, most common, common autosomal, autosomal recessive, recessive ataxia, ataxia ,, , is, is caused, caused in, in almost, almost all, all cases, cases by, by homozygous, homozygous intronic, intronic expansions, expansions resulting, resulting in, in the, the loss, loss of, of frataxin, frataxin ,, , a, a mitochondrial, mitochondrial protein, protein conserved, conserved through, through evolution, evolution ,, , and, and involved, involved in, in mitochondrial, mitochondrial iron, iron homeostasis, homeostasis ., . Yeast, Yeast knockout, knockout models, models ,, , and, and histological, histological and, and biochemical, biochemical data, data from, from patient, patient heart, heart biopsies, biopsies or, or autopsies, autopsies indicate, indicate that, that the, the frataxin, frataxin defect, defect causes, causes a, a specific, specific iron-sulfur, iron-sulfur protein, protein deficiency, deficiency and, and mitochondrial, mitochondrial iron, iron accumulation, accumulation leading, leading to, to the, the pathological, pathological changes, changes ., . Affected, Affected human, human tissues, tissues are, are rarely, rarely available, available to, to further, further examine, examine this, this hypothesis, hypothesis ., . To, To study, study the, the mechanism, mechanism of, of the, the disease, disease ,, , we, we generated, generated a, a mouse, mouse model, model by, by deletion, deletion of, of exon, exon 4, 4 leading, leading to, to inactivation, inactivation of, of the, the Frda, Frda gene, gene product, product ., . We, We show, show that, that homozygous, homozygous deletions, deletions cause, cause embryonic, embryonic lethality, lethality a, a few, few days, days after, after implantation, implantation ,, , demonstrating, demonstrating an, an important, important role, role for, for frataxin, frataxin during, during early, early development, development ., . These, These results, results suggest, suggest that, that the, the milder, milder phenotype, phenotype in, in humans, humans is, is due, due to, to residual, residual frataxin, frataxin expression, expression associated, associated with, with the, the expansion, expansion mutations, mutations ., . Surprisingly, Surprisingly ,, , in, in the, the frataxin, frataxin knockout, knockout mouse, mouse ,, , no, no iron, iron accumulation, accumulation was, was observed, observed during, during embryonic, embryonic resorption, resorption ,, , suggesting, suggesting that, that cell, cell death, death could, could be, be due, due to, to a, a mechanism, mechanism independent, independent of, of iron, iron accumulation.., accumulation.. The, The mutation, mutation causing, causing juvenile, juvenile Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) in, in two, two sibs, sibs of, of Lebanese-Maronite, Lebanese-Maronite origin, origin is, is described, described ., . An, An mRNA-containing, mRNA-containing extract, extract of, of cultured, cultured fibroblasts, fibroblasts obtained, obtained from, from one, one of, of the, the probands, probands was, was used, used as, as a, a template, template to, to amplify, amplify the, the coding, coding sequence, sequence of, of the, the hexosaminidase, hexosaminidase A, A (, ( Hex, Hex A, A ), ) alpha-subunit, alpha-subunit ., . Sequencing, Sequencing of, of amplified, amplified cDNA, cDNA fragments, fragments revealed, revealed a, a single, single alteration, alteration ,, , guanine, guanine to, to adenine, adenine at, at nt, nt 749, 749 creating, creating a, a G250D, G250D mutation, mutation ., . The, The mutation, mutation introduces, introduces a, a new, new recognition, recognition site, site for, for the, the restriction, restriction enzyme, enzyme Eco, Eco RV, RV ,, , permitting, permitting identification, identification of, of heterozygotes, heterozygotes for, for this, this allele, allele following, following PCR, PCR amplification, amplification and, and Eco, Eco RV, RV digestion, digestion of, of exon, exon 7, 7 sequences, sequences from, from genomic, genomic DNA, DNA templates, templates ., . In, In order, order to, to test, test the, the effect, effect of, of this, this substitution, substitution ,, , an, an in, in vitro, vitro mutagenized, mutagenized cDNA, cDNA construct, construct was, was introduced, introduced into, into a, a mammalian, mammalian expression, expression vector, vector and, and transfected, transfected into, into monkey, monkey Cos-1, Cos-1 cells, cells separately, separately or, or along, along with, with a, a beta-cDNA, beta-cDNA expression, expression vector, vector ., . When, When the, the mutant, mutant alpha-cDNA, alpha-cDNA was, was the, the only, only gene, gene introduced, introduced into, into COS, COS cells, cells no, no enzymatic, enzymatic activity, activity above, above endogenous, endogenous COS, COS cell, cell activity, activity was, was detected, detected ., . Cotransfection, Cotransfection of, of normal, normal alpha-cDNA, alpha-cDNA and, and beta-cDNA, beta-cDNA followed, followed by, by immunoprecipitation, immunoprecipitation of, of human, human Hex, Hex A, A resulted, resulted in, in 20-fold, 20-fold increase, increase in, in the, the ratio, ratio between, between positive, positive and, and negative, negative (, ( mock, mock transfection, transfection ), ) control, control values, values ., . This, This allowed, allowed the, the detection, detection of, of some, some residual, residual activity, activity (, ( 12, 12 %, % of, of the, the positive, positive control, control ), ) when, when the, the mutant, mutant alpha-cDNA, alpha-cDNA replaced, replaced its, its wild-type, wild-type counterpart, counterpart ., . The, The predicted, predicted protein, protein environment, environment in, in which, which the, the mutation, mutation occurs, occurs is, is compared, compared to, to that, that of, of the, the adult-onset, adult-onset Tay-Sachs, Tay-Sachs disease, disease mutation, mutation caused, caused by, by a, a Gly269, Gly269 --, -- >, > Ser, Ser substitution, substitution in, in exon, exon 7, 7 ., . (, ( ABSTRACT, ABSTRACT TRUNCATED, TRUNCATED AT, AT 250, 250 WORDS, WORDS ), ) ., . In, In humans, humans ,, , alteration, alteration of, of the, the tumor, tumor suppressor, suppressor gene, gene ,, , APC, APC ,, , causes, causes adenomatous, adenomatous polyposis, polyposis coli, coli ,, , a, a condition, condition causing, causing predisposition, predisposition to, to colorectal, colorectal cancer, cancer ., . The, The syndrome, syndrome inconsistently, inconsistently associates, associates characteristic, characteristic patches, patches of, of congenital, congenital hypertrophy, hypertrophy of, of the, the retinal, retinal pigment, pigment epithelium, epithelium (, ( CHRPE, CHRPE ), ) ., . Ocular, Ocular examination, examination revealed, revealed that, that patients, patients expressing, expressing CHRPE, CHRPE tend, tend to, to cluster, cluster within, within specific, specific families, families ., . The, The exact, exact APC, APC mutation, mutation was, was identified, identified in, in 42, 42 unrelated, unrelated patients, patients ., . In, In all, all cases, cases these, these mutations, mutations were, were predicted, predicted to, to lead, lead to, to the, the synthesis, synthesis of, of a, a truncated, truncated protein, protein ., . The, The extent, extent of, of CHRPE, CHRPE was, was found, found to, to be, be dependent, dependent on, on the, the position, position of, of the, the mutation, mutation along, along the, the coding, coding sequence, sequence ., . CHRPE, CHRPE lesions, lesions are, are almost, almost always, always absent, absent if, if the, the mutation, mutation occurs, occurs before, before exon, exon 9, 9 ,, , but, but are, are systematically, systematically present, present if, if it, it occurs, occurs after, after this, this exon, exon ., . Thus, Thus ,, , the, the range, range of, of phenotypic, phenotypic expression, expression observed, observed among, among affected, affected patients, patients may, may result, result in, in part, part from, from different, different allelic, allelic manifestations, manifestations of, of APC, APC mutations.., mutations.. We, We have, have examined, examined 26, 26 Canadian, Canadian families, families with, with hereditary, hereditary breast, breast or, or ovarian, ovarian cancer, cancer for, for linkage, linkage to, to markers, markers flanking, flanking the, the BRCA1, BRCA1 gene, gene on, on chromosome, chromosome 17q12-q21, 17q12-q21 ., . Of, Of the, the 15, 15 families, families that, that contain, contain cases, cases of, of ovarian, ovarian cancer, cancer ,, , 94, 94 %, % were, were estimated, estimated to, to be, be linked, linked to, to BRCA1, BRCA1 ., . In, In contrast, contrast ,, , there, there was, was no, no overall, overall evidence, evidence of, of linkage, linkage in, in the, the group, group of, of 10, 10 families, families with, with breast, breast cancer, cancer without, without ovarian, ovarian cancer, cancer ., . A, A genetic, genetic recombinant, recombinant in, in a, a breast-ovarian, breast-ovarian cancer, cancer family, family indicates, indicates a, a placement, placement of, of BRCA1, BRCA1 telomeric, telomeric to, to D17S776, D17S776 ,, , and, and helps, helps to, to define, define the, the region, region of, of assignment, assignment of, of the, the cancer, cancer susceptibility, susceptibility gene, gene ., . Other, Other cancers, cancers of, of interest, interest that, that appeared, appeared in, in the, the BRCA1-linked, BRCA1-linked families, families included, included primary, primary peritoneal, peritoneal cancer, cancer ,, , cancer, cancer of, of the, the fallopian, fallopian tube, tube ,, , and, and malignant, malignant melanoma.., melanoma.. Ataxia-telangiectasia, Ataxia-telangiectasia (, ( A-T, A-T ), ) is, is an, an autosomal, autosomal recessive, recessive syndrome, syndrome associated, associated with, with a, a greatly, greatly increased, increased incidence, incidence of, of malignant, malignant neoplasms, neoplasms in, in homozygous, homozygous affected, affected individuals, individuals ., . Heterozygotes, Heterozygotes for, for the, the gene, gene for, for A-T, A-T are, are thought, thought to, to comprise, comprise about, about 1, 1 %, % of, of the, the general, general population, population and, and ,, , therefore, therefore ,, , it, it is, is important, important to, to know, know whether, whether this, this gene, gene also, also predisposes, predisposes the, the heterozygous, heterozygous carrier, carrier to, to cancers, cancers ., . Heterozygous, Heterozygous carriers, carriers of, of this, this gene, gene are, are common, common among, among the, the close, close relatives, relatives of, of patients, patients with, with A-T, A-T ,, , although, although individual, individual carriers, carriers can, can not, not be, be identified, identified by, by any, any clinical, clinical criterion, criterion or, or laboratory, laboratory test, test ., . For, For this, this reason, reason ,, , we, we compared, compared the, the incidence, incidence of, of death, death from, from malignant, malignant neoplasms, neoplasms in, in 2, 2 families, families of, of patients, patients with, with A-T, A-T to, to that, that expected, expected in, in a, a random, random sample, sample of, of the, the general, general population, population ., . There, There were, were 59, 59 deaths, deaths from, from malignant, malignant neoplasms, neoplasms in, in relatives, relatives dying, dying before, before age, age 75, 75 ,, , compared, compared to, to 42, 42 ., . 6, 6 expected, expected (, ( p, p less, less than, than 0, 0 ., . 02, 02 ), ) ., . For, For A-T, A-T heterozygotes, heterozygotes younger, younger than, than age, age 45, 45 ,, , the, the risk, risk of, of dying, dying from, from a, a malignant, malignant neoplasm, neoplasm was, was estimated, estimated to, to be, be greater, greater than, than 5, 5 times, times the, the risk, risk for, for the, the general, general population, population ., . A-T, A-T heterozygotes, heterozygotes may, may comprise, comprise more, more than, than 5, 5 %, % of, of all, all persons, persons dying, dying from, from a, a cancer, cancer before, before age, age 45, 45 ., . The, The incidence, incidence of, of ovarian, ovarian ,, , gastric, gastric ,, , and, and biliary, biliary system, system carcinomas, carcinomas and, and of, of leukemia, leukemia and, and lymphoma, lymphoma was, was increased, increased in, in these, these A-T, A-T families, families ., . Other, Other neoplasms, neoplasms that, that may, may be, be associated, associated with, with this, this gene, gene in, in heterozygotes, heterozygotes include, include pancreatic, pancreatic ,, , basal, basal cell, cell ,, , colonic, colonic ,, , breast, breast ,, , and, and cervical, cervical carcinomas.Phenylketonuria, carcinomas.Phenylketonuria (, ( PKU, PKU ), ) is, is a, a genetic, genetic disorder, disorder secondary, secondary to, to a, a deficiency, deficiency of, of hepatic, hepatic phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . Several, Several mutations, mutations in, in the, the PAH, PAH gene, gene have, have recently, recently been, been reported, reported ,, , and, and linkage, linkage disequilibrium, disequilibrium was, was observed, observed between, between RFLP, RFLP haplotypes, haplotypes and, and specific, specific mutations, mutations ., . A, A new, new molecular, molecular lesion, lesion has, has been, been identified, identified in, in exon, exon 7, 7 of, of the, the PAH, PAH gene, gene in, in a, a Hungarian, Hungarian PKU, PKU patient, patient by, by direct, direct sequencing, sequencing of, of PCR-amplified, PCR-amplified DNA, DNA ., . The, The C-to-T, C-to-T transition, transition causes, causes the, the substitution, substitution of, of Arg243, Arg243 to, to a, a termination, termination codon, codon ,, , and, and the, the mutant, mutant allele, allele is, is associated, associated with, with haplotype, haplotype 4, 4 of, of the, the PAH, PAH gene, gene ., . The, The mutation, mutation is, is present, present in, in two, two of, of nine, nine mutant, mutant haplotype, haplotype 4, 4 alleles, alleles among, among Eastern, Eastern Europeans, Europeans and, and is, is not, not present, present among, among Western, Western Europeans, Europeans and, and Asians, Asians ., . The, The rarity, rarity of, of this, this mutant, mutant allele, allele and, and its, its restricted, restricted geographic, geographic distribution, distribution suggest, suggest that, that the, the mutational, mutational event, event occurred, occurred recently, recently on, on a, a normal, normal haplotype, haplotype 4, 4 background, background in, in Eastern, Eastern Europe.., Europe.. The, The BRCA1, BRCA1 gene, gene is, is in, in large, large part, part responsible, responsible for, for hereditary, hereditary human, human breast, breast and, and ovarian, ovarian cancer, cancer ., . Here, Here we, we report, report the, the isolation, isolation of, of the, the murine, murine Brca1, Brca1 homologue, homologue cDNA, cDNA clones, clones ., . In, In addition, addition ,, , we, we identified, identified genomic, genomic P1, P1 clones, clones that, that contain, contain most, most ,, , if, if not, not all, all ,, , of, of the, the mouse, mouse Brca1, Brca1 locus, locus ., . DNA, DNA sequence, sequence analysis, analysis revealed, revealed that, that the, the mouse, mouse and, and human, human coding, coding regions, regions are, are 75, 75 %, % identical, identical at, at the, the nucleotide, nucleotide level, level while, while the, the predicted, predicted amino, amino acid, acid identity, identity is, is only, only 58, 58 %, % ., . A, A DNA, DNA sequence, sequence variant, variant in, in the, the Brca1, Brca1 locus, locus was, was identified, identified and, and used, used to, to map, map this, this gene, gene on, on a, a (, ( Mus, Mus m., m. musculus, musculus Czech, Czech II, II x, x C57BL/KsJ, C57BL/KsJ ), ) F1, F1 x, x C57BL/KsJ, C57BL/KsJ intersubspecific, intersubspecific backcross, backcross to, to distal, distal mouse, mouse chromosome, chromosome 11, 11 ., . The, The mapping, mapping of, of this, this gene, gene to, to a, a region, region highly, highly syntenic, syntenic with, with human, human chromosome, chromosome 17, 17 ,, , coupled, coupled with, with Southern, Southern and, and Northern, Northern analyses, analyses ,, , confirms, confirms that, that we, we isolated, isolated the, the murine, murine Brca1, Brca1 homologue, homologue rather, rather than, than a, a related, related RING, RING finger, finger gene, gene ., . The, The isolation, isolation of, of the, the mouse, mouse Brca1, Brca1 homologue, homologue will, will facilitate, facilitate the, the creation, creation of, of mouse, mouse models, models for, for germline, germline BRCA1, BRCA1 defects.., defects.. A, A case, case of, of human, human complete, complete C6, C6 deficiency, deficiency is, is reported, reported ., . The, The patient, patient ,, , a, a 31, 31 year, year old, old white, white male, male ,, , was, was seen, seen on, on the, the occasion, occasion of, of an, an isolated, isolated episode, episode of, of meningococcal, meningococcal meningitis, meningitis ., . Serum, Serum complement, complement hemolytic, hemolytic and, and bactericidal, bactericidal activities, activities were, were lacking, lacking and, and could, could be, be restored, restored to, to normal, normal by, by addition, addition of, of appropriate, appropriate amounts, amounts of, of purified, purified C6, C6 ., . No, No hemostatic, hemostatic abnormalities, abnormalities were, were observed.., observed.. The, The Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) has, has previously, previously been, been mapped, mapped to, to the, the proximal, proximal short, short arm, arm of, of the, the X, X chromosome, chromosome between, between the, the DXS14, DXS14 and, and DXS7, DXS7 loci, loci ., . In, In this, this study, study ,, , further, further segregation, segregation analysis, analysis has, has been, been performed, performed using, using a, a newly, newly identified, identified WAS, WAS family, family as, as well, well as, as an, an additional, additional marker, marker probe, probe ,, , HOATL1, HOATL1 ., . The, The results, results indicate, indicate close, close linkage, linkage between, between the, the WAS, WAS and, and OATL1, OATL1 loci, loci (, ( Z, Z =, = 6, 6 ., . 08, 08 at, at theta, theta =, = 0, 0 ., . 00, 00 ), ) and, and localize, localize the, the TIMP, TIMP ,, , OATL1, OATL1 ,, , DXS255, DXS255 ,, , and, and WAS, WAS loci, loci distal, distal to, to DXS146, DXS146 and, and the, the OATL1, OATL1 and, and WAS, WAS loci, loci proximal, proximal to, to TIMP, TIMP ., . These, These linkage, linkage data, data narrow, narrow the, the boundaries, boundaries within, within which, which the, the WAS, WAS locus, locus maps, maps to, to the, the chromosomal, chromosomal region, region bracketed, bracketed by, by TIMP, TIMP and, and DXS146, DXS146 and, and support, support the, the loci, loci order, order Xpter-DXS7-TIMP-, Xpter-DXS7-TIMP- (, ( OATL1, OATL1 ,, , WAS, WAS ,, , DXS255, DXS255 ), ) -DXS146.A, -DXS146.A previously, previously well, well 34-month-old, 34-month-old male, male presenting, presenting with, with fever, fever ,, , skin, skin rash, rash ,, , and, and arthralgias, arthralgias was, was found, found to, to lack, lack C3, C3 by, by immunochemical, immunochemical (, ( undetectable, undetectable ), ) and, and hemolytic, hemolytic (, ( 1, 1 %, % normal, normal ), ) assays, assays ., . No, No infectious, infectious agent, agent could, could be, be demonstrated, demonstrated ., . Protein, Protein levels, levels of, of Clq, Clq ., . C4, C4 ,, , C5, C5 ,, , properdin, properdin ,, , and, and C3b-INA, C3b-INA and, and hemolytic, hemolytic activities, activities of, of complement, complement components, components C1, C1 to, to C9, C9 except, except C3, C3 were, were normal, normal or, or elevated, elevated ;, ; total, total hemolytic, hemolytic complement, complement activity, activity was, was 13, 13 %, % of, of normal, normal and, and was, was reconstituted, reconstituted by, by purified, purified C3, C3 ., . Properdin, Properdin factor, factor B, B was, was 702, 702 (, ( normal, normal 175, 175 to, to 275, 275 ), ) mug/ml, mug/ml ,, , and, and was, was not, not cleaver, cleaver upon, upon addition, addition of, of zymosan, zymosan or, or cobra, cobra venom, venom factor, factor ., . The, The serum, serum had, had normal, normal immune, immune adherence, adherence activity, activity ,, , but, but was, was deficient, deficient in, in ability, ability to, to opsonize, opsonize Candida, Candida albicans, albicans for, for uptake, uptake and, and Escherichia, Escherichia coli, coli for, for killing, killing by, by neurophils, neurophils ,, , generate, generate neutrophil, neutrophil chemotactic, chemotactic factors, factors and, and inhibit, inhibit the, the growth, growth of, of E., E. coli, coli ;, ; these, these activities, activities were, were restored, restored by, by purified, purified C3, C3 ., . A, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "A transfusion, transfusion of, of 320, 320 ml, ml 1-hour-old, 1-hour-old normal, normal whole, whole blood, blood on, on the, the fifty-second, fifty-second day, day resulted, resulted in, in transitory, transitory elevation, elevation of, of the, the C3, C3 level, level to, to 25, 25 mg/dl, mg/dl with, with a, a fall-off, fall-off (, ( approximately, approximately 2, 2 1/2, 1/2 %, % per, per hour, hour ), ) to, to undetectable, undetectable levels, levels by, by 69, 69 hours, hours ;, ; it, it was, was followed, followed by, by disappearance, disappearance of, of the, the skin, skin rash, rash and, and arthralgias, arthralgias and, and return, return to, to normal, normal of, of the, the previously, previously elevated, elevated temperature, temperature and, and CRP, CRP levels, levels ., . C3, C3 levels, levels in, in family, family members, members (, ( seven, seven of, of 24, 24 half-normal, half-normal ), ) ,, , lack, lack of, of anti-C3, anti-C3 activity, activity ,, , normal, normal C3b-INA, C3b-INA levels, levels and, and a, a normal, normal rate, rate of, of catabolism, catabolism of, of transfused, transfused C3, C3 indicated, indicated that, that the, the deficiency, deficiency was, was inherited, inherited with, with autosomal, autosomal codominance, codominance and, and involved, involved decreased, decreased synthesis, synthesis of, of C3, C3 ., . Thus, Thus ,, , this, this child, child is, is a, a unique, unique individual, individual with, with inherited, inherited C3, C3 deficiency, deficiency presenting, presenting with, with absence, absence of, of repeated, repeated infections, infections ,, , whose, whose symptoms, symptoms of, of fever, fever ,, , skin, skin rash, rash ,, , and, and arthralgia, arthralgia were, were abated, abated by, by whole, whole blood, blood transfusion.., transfusion.. Chromosome, Chromosome translocations, translocations involving, involving 11p13, 11p13 have, have been, been associated, associated with, with familial, familial aniridia, aniridia in, in two, two kindreds, kindreds highlighting, highlighting the, the chromosomal, chromosomal localization, localization of, of the, the AN2, AN2 locus, locus ., . This, This locus, locus is, is also, also part, part of, of the, the WAGR, WAGR complex, complex (, ( Wilms, Wilms tumor, tumor ,, , aniridia, aniridia ,, , genitourinary, genitourinary abnormalities, abnormalities ,, , and, and mental, mental retardation, retardation ), ) ., . In, In one, one kindred, kindred ,, , the, the translocation, translocation is, is associated, associated with, with a, a deletion, deletion ,, , and, and probes, probes for, for this, this region, region were, were used, used to, to identify, identify and, and clone, clone the, the breakpoints, breakpoints of, of the, the translocation, translocation in, in the, the second, second kindred, kindred ., . Comparison, Comparison of, of phage, phage restriction, restriction maps, maps exclude, exclude the, the presence, presence of, of any, any sizable, sizable deletion, deletion in, in this, this case, case ., . Sequences, Sequences at, at the, the chromosome, chromosome 11, 11 breakpoint, breakpoint are, are conserved, conserved in, in multiple, multiple species, species ,, , suggesting, suggesting that, that the, the translocation, translocation falls, falls within, within the, the AN2, AN2 gene.., gene.. Benign, Benign familial, familial infantile, infantile convulsions, convulsions (, ( BFIC, BFIC ), ) is, is a, a rare, rare autosomal, autosomal dominant, dominant epilepsy, epilepsy syndrome, syndrome ., . This, This syndrome, syndrome has, has been, been recently, recently described, described in, in Italian, Italian and, and French, French pedigrees, pedigrees ., . Patients, Patients present, present with, with partial, partial ,, , then, then generalized, generalized seizures, seizures ,, , with, with onset, onset at, at age, age three, three months, months ., . The, The seizures, seizures usually, usually spontaneously, spontaneously cease, cease after, after one, one year, year without, without treatment, treatment ,, , leaving, leaving no, no neurological, neurological abnormalities, abnormalities ., . We, We have, have mapped, mapped BFIC, BFIC to, to chromosome, chromosome 19q, 19q in, in five, five Italian, Italian pedigrees, pedigrees ., . The, The sodium, sodium channel, channel beta1, beta1 subunit, subunit gene, gene (, ( SCN1B, SCN1B ), ) maps, maps to, to this, this candidate, candidate region, region and, and has, has been, been shown, shown to, to be, be involved, involved in, in one, one Australian, Australian pedigree, pedigree with, with generalized, generalized epilepsy, epilepsy and, and febrile, febrile seizures, seizures ``, `` plus, plus ``, `` (, ( GEFS, GEFS +, + ), ) ., . In, In this, this family, family ,, , a, a missense, missense mutation, mutation in, in SCN1B, SCN1B cosegregates, cosegregates with, with the, the GEFS, GEFS +, + phenotype, phenotype ., . BFIC, BFIC and, and GEFS, GEFS +, + have, have clinical, clinical features, features in, in common, common ,, , therefore, therefore SCN1B, SCN1B is, is a, a candidate, candidate gene, gene for, for BFIC, BFIC ., . We, We studied, studied SCN1B, SCN1B exons, exons 1, 1 ,, , 2, 2 ,, , 3, 3 ,, , 4, 4 ,, , and, and 5, 5 ,, , using, using four, four SSCP, SSCP methods, methods in, in 10, 10 Caucasian, Caucasian BFIC, BFIC probands, probands of, of Western, Western Europe, Europe ., . We, We found, found no, no exon, exon variants, variants ., . One, One variant, variant was, was identified, identified in, in intron, intron 5, 5 (, ( IVS5-10C, IVS5-10C >, > G, G ), ) ,, , which, which did, did not, not segregate, segregate with, with BFIC, BFIC and, and was, was observed, observed in, in 9, 9 ., . 2, 2 %, % controls, controls ., . A, A second, second variant, variant in, in intron, intron 5, 5 was, was identified, identified (, ( IVS5, IVS5 +, + 30G, 30G >, > A, A ), ) ., . It, It was, was rare, rare ,, , as, as not, not observed, observed in, in controls, controls ,, , but, but not, not segregating, segregating with, with the, the BFIC, BFIC phenotype, phenotype ., . Abnormal, Abnormal amplification, amplification of, of a, a CTG, CTG repeat, repeat on, on chromosome, chromosome 19, 19 is, is the, the molecular, molecular basis, basis of, of myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ., . Expansion, Expansion of, of the, the repeat, repeat has, has been, been correlated, correlated with, with severity, severity of, of several, several clinical, clinical features, features of, of the, the disease, disease ., . We, We performed, performed extensive, extensive cognitive, cognitive testing, testing ,, , cerebral, cerebral magnetic, magnetic resonance, resonance imaging, imaging (, ( MRI, MRI ), ) and, and a, a molecular, molecular analysis, analysis in, in 28, 28 cases, cases of, of DM, DM to, to determine, determine the, the relationship, relationship between, between the, the molecular, molecular defect, defect and, and brain, brain disease, disease ., . Performance, Performance in, in two, two or, or more, more cognitive, cognitive tests, tests was, was pathological, pathological in, in 10, 10 cases, cases ., . Fourteen, Fourteen patients, patients had, had subcortical, subcortical white, white matter, matter lesions, lesions on, on MRI, MRI ,, , 14, 14 had, had cerebral, cerebral atrophy, atrophy ., . Amplification, Amplification of, of the, the CTG, CTG repeat, repeat showed, showed a, a strong, strong correlation, correlation with, with cognitive, cognitive test, test deficits, deficits when, when exceeding, exceeding a, a length, length of, of over, over 1000, 1000 trinucleotides, trinucleotides ., . MRI, MRI lesions, lesions were, were associated, associated with, with impaired, impaired psychometric, psychometric performance, performance ,, , but, but MRI, MRI and, and molecular, molecular findings, findings were, were only, only weakly, weakly related, related ., . Disease, Disease duration, duration influenced, influenced the, the appearance, appearance and, and amount, amount of, of white, white matter, matter lesions, lesions on, on MRI, MRI ., . Quantification, Quantification of, of CTG, CTG repeat, repeat size, size may, may allow, allow an, an early, early estimate, estimate on, on the, the probability, probability of, of brain, brain involvement, involvement in, in DM, DM ;, ; cognitive, cognitive dysfunction, dysfunction is, is associated, associated with, with white, white matter, matter lesions, lesions and, and cerebral, cerebral atrophy, atrophy later, later on, on in, in the, the course.., course.. The, The hereditary, hereditary breast, breast and, and ovarian, ovarian cancer, cancer syndrome, syndrome is, is associated, associated with, with a, a high, high frequency, frequency of, of BRCA1, BRCA1 mutations, mutations ., . However, However ,, , the, the widespread, widespread use, use of, of BRCA1, BRCA1 testing, testing has, has been, been limited, limited to, to date, date by, by three, three principal, principal concerns, concerns the, the fear, fear of, of loss, loss of, of health, health and, and life, life insurance, insurance ,, , the, the uncertain, uncertain clinical, clinical value, value of, of a, a positive, positive test, test result, result ,, , and, and the, the current, current lack, lack of, of an, an inexpensive, inexpensive and, and sensitive, sensitive screening, screening test, test for, for BRCA1, BRCA1 mutations, mutations ., . We, We have, have developed, developed an, an inexpensive, inexpensive system, system for, for gene, gene mutational, mutational scanning, scanning ,, , based, based on, on a, a combination, combination of, of extensive, extensive multiplex, multiplex PCR, PCR amplification, amplification and, and two, two dimensional, dimensional electrophoresis, electrophoresis ., . The, The efficiency, efficiency of, of this, this system, system ,, , as, as a, a screening, screening test, test for, for BRCA1, BRCA1 mutations, mutations ,, , was, was evaluated, evaluated in, in a, a panel, panel of, of 60, 60 samples, samples from, from high, high risk, risk women, women ,, , 14, 14 of, of which, which contained, contained a, a previously, previously identified, identified mutation, mutation in, in BRCA1, BRCA1 ., . All, All 14, 14 mutations, mutations were, were identified, identified ,, , as, as well, well as, as an, an additional, additional five, five that, that had, had previously, previously escaped, escaped detection, detection ., . In, In addition, addition to, to the, the 19, 19 mutations, mutations ,, , a, a total, total of, of 15, 15 different, different polymorphic, polymorphic variants, variants were, were scored, scored ,, , most, most of, of which, which were, were recurring, recurring ., . All, All were, were confirmed, confirmed by, by nucleotide, nucleotide sequencing, sequencing ., . The, The cost, cost of, of screening, screening per, per sample, sample was, was calculated, calculated to, to be, be approximately, approximately US, US $, $ 70, 70 for, for the, the manual, manual technique, technique used, used in, in this, this study, study ,, , and, and may, may be, be reduced, reduced to, to approximately, approximately US, US $, $ 10, 10 with, with the, the introduction, introduction of, of commercially, commercially available, available PCR, PCR robotics, robotics and, and fluorescent, fluorescent imaging, imaging ., . Implementation, Implementation of, of this, this method, method of, of mutation, mutation screening, screening in, in the, the research, research and, and clinical, clinical setting, setting should, should permit, permit rapid, rapid accrual, accrual of, of quantitative, quantitative data, data on, on genotype-phenotype, genotype-phenotype associations, associations for, for the, the evaluation, evaluation of, of diagnostic, diagnostic testing.., testing.. We, We extensively, extensively analyzed, analyzed genomic, genomic DNA, DNA and, and messenger, messenger RNA, RNA (, ( mRNA, mRNA ), ) from, from 62, 62 unrelated, unrelated Korean, Korean patients, patients with, with familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) for, for identification, identification of, of germline, germline adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene mutations, mutations ., . We, We adopted, adopted both, both single-strand, single-strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) analysis, analysis and, and a, a method, method of, of analysis, analysis involving, involving the, the reverse, reverse transcription-polymerase, transcription-polymerase chain, chain reaction, reaction (, ( RT-PCR, RT-PCR ), ) followed, followed by, by a, a protein, protein truncation, truncation test, test (, ( PTT, PTT ), ) ., . DNA, DNA sequencing, sequencing confirmed, confirmed all, all alterations, alterations represented, represented by, by aberrant, aberrant bands, bands ., . Germline, Germline mutations, mutations were, were identified, identified in, in 38, 38 patients, patients (, ( 61, 61 %, % ), ) ., . Nineteen, Nineteen of, of the, the detected, detected mutations, mutations were, were presumed, presumed to, to be, be novel, novel ,, , thus, thus emphasizing, emphasizing the, the heterogeneity, heterogeneity of, of the, the mutational, mutational spectrum, spectrum in, in Korean, Korean FAP, FAP patients, patients ., . In, In the, the initial, initial 48, 48 patients, patients ,, , SSCP, SSCP analysis, analysis was, was followed, followed by, by PTT, PTT for, for those, those patients, patients for, for whom, whom no, no detectable, detectable mutations, mutations were, were found, found by, by SSCP, SSCP ., . Using, Using this, this combined, combined approach, approach ,, , we, we identified, identified germline, germline APC, APC gene, gene mutations, mutations in, in 29, 29 of, of the, the 48, 48 FAP, FAP patients, patients (, ( 60, 60 %, % ), ) ,, , including, including 6, 6 patients, patients in, in whom, whom SSCP, SSCP analysis, analysis failed, failed to, to distinguish, distinguish the, the mutant, mutant allele, allele ., . In, In the, the 14, 14 later, later patients, patients ,, , we, we identified, identified truncating, truncating mutations, mutations in, in 9, 9 patients, patients (, ( 64, 64 %, % ), ) using, using PTT, PTT only, only ., . Our, Our results, results confirm, confirm that, that the, the mutation, mutation detection, detection rate, rate with, with PTT, PTT was, was superior, superior to, to that, that with, with SSCP, SSCP ,, , and, and suggest, suggest that, that PTT, PTT would, would be, be a, a more, more practical, practical screening, screening method, method to, to detect, detect germline, germline mutations, mutations of, of the, the APC, APC gene, gene in, in FAP, FAP patients.A, patients.A syndrome, syndrome of, of microcephaly, microcephaly ,, , progressive, progressive postnatal, postnatal growth, growth deficiency, deficiency ,, , and, and mental, mental retardation, retardation was, was observed, observed in, in two, two brothers, brothers and, and their, their cousin, cousin from, from a, a multiply, multiply consanguineous, consanguineous kindred, kindred of, of Lebanese, Lebanese descent, descent ., . Hypotonia, Hypotonia ,, , chorioretinal, chorioretinal dystrophy, dystrophy ,, , and, and myopia, myopia were, were also, also identified, identified ., . The, The severity, severity of, of the, the condition, condition varied, varied among, among the, the closely, closely related, related patients, patients ., . Because, Because of, of absence, absence of, of a, a distinctive, distinctive facial, facial appearance, appearance ,, , the, the degree, degree of, of mental, mental retardation, retardation ,, , and, and short, short stature, stature ,, , the, the initially, initially considered, considered clinical, clinical diagnosis, diagnosis of, of Cohen, Cohen syndrome, syndrome was, was withdrawn, withdrawn and, and a, a novel, novel genetic, genetic entity, entity was, was assumed, assumed ., . Homozygosity, Homozygosity mapping, mapping in, in this, this family, family assigned, assigned the, the gene, gene to, to a, a 26, 26 ., . 8-cM, 8-cM region, region on, on the, the chromosome, chromosome band, band 8q21, 8q21 ., . 3, 3 -22, -22 ., . 1, 1 ,, , between, between the, the microsatellites, microsatellites at, at D8S270, D8S270 and, and D8S514, D8S514 ., . The, The maximum, maximum two-point, two-point LOD, LOD score, score was, was found, found for, for marker, marker at, at D8S267, D8S267 (, ( Zmax, Zmax =, = 3.., 3.. 237, 237 at, at Omax, Omax =, = 0, 0 ., . 00, 00 ), ) ., . Intriguingly, Intriguingly enough, enough ,, , the, the identified, identified gene, gene region, region overlaps, overlaps the, the refined, refined gene, gene region, region for, for Cohen, Cohen syndrome, syndrome (, ( COH1, COH1 ), ) [, [ Kolehmainen, Kolehmainen et, et al., al. ,, , 1997, 1997 Euro, Euro J, J Hum, Hum Genet, Genet 5, 5 206-213, 206-213 ], ] ., . This, This fact, fact encourages, encourages the, the hypothesis, hypothesis that, that the, the described, described kindred, kindred segregates, segregates for, for a, a variant, variant of, of Cohen, Cohen syndrome, syndrome and, and suggests, suggests a, a redefinition, redefinition of, of its, its phenotype, phenotype Molecular, Molecular analysis, analysis of, of an, an unusual, unusual patient, patient with, with the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome has, has suggested, suggested that, that the, the mutation, mutation is, is due, due to, to a, a partial, partial HPRT, HPRT gene, gene duplication, duplication ., . We, We now, now report, report the, the cloning, cloning and, and sequencing, sequencing of, of the, the mutant, mutant HPRT, HPRT cDNA, cDNA which, which shows, shows the, the precise, precise duplication, duplication of, of exons, exons 2, 2 and, and 3, 3 ., . This, This mutation, mutation is, is the, the result, result of, of an, an internal, internal duplication, duplication of, of 16-20, 16-20 kilobases, kilobases of, of the, the gene, gene ., . The, The structure, structure of, of the, the mutant, mutant gene, gene suggests, suggests that, that the, the duplication, duplication was, was not, not generated, generated by, by a, a single, single unequal, unequal crossing-over, crossing-over event, event between, between two, two normal, normal HPRT, HPRT alleles, alleles ., . Growth, Growth of, of Epstein-Barr, Epstein-Barr virus-transformed, virus-transformed lymphoblasts, lymphoblasts from, from this, this patient, patient in, in selective, selective medium, medium has, has permitted, permitted isolation, isolation of, of spontaneous, spontaneous HPRT, HPRT +, + revertants, revertants of, of this, this mutation, mutation ., . The, The reversion, reversion event, event involves, involves a, a second, second major, major HPRT, HPRT gene, gene rearrangement, rearrangement where, where most, most or, or all, all of, of the, the duplicated, duplicated portion, portion of, of the, the mutant, mutant gene, gene is, is deleted, deleted ., . The, The original, original mutation, mutation therefore, therefore has, has the, the potential, potential for, for spontaneous, spontaneous somatic, somatic reversion, reversion ., . This, This may, may explain, explain the, the relatively, relatively mild, mild symptoms, symptoms of, of the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome exhibited, exhibited by, by this, this patient.., patient.. Nephropathy, Nephropathy was, was detected, detected in, in five, five of, of 32, 32 patients, patients with, with the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome who, who were, were participating, participating in, in a, a study, study of, of transfer, transfer factor, factor (, ( TF, TF ), ) therapy, therapy ., . In, In two, two patients, patients ,, , nephropathy, nephropathy was, was present, present before, before TF, TF and, and did, did not, not appear, appear changed, changed by, by TF, TF therapy, therapy ., . One, One of, of these, these patients, patients subsequently, subsequently developed, developed progressive, progressive renal, renal failure, failure requiring, requiring dialysis, dialysis beginning, beginning 5, 5 1/2, 1/2 years, years after, after TF, TF therapy, therapy ., . In, In two, two patients, patients ,, , decreased, decreased renal, renal function, function appeared, appeared very, very soon, soon after, after the, the administration, administration of, of TF, TF ., . One, One patient, patient showed, showed gradually, gradually decreasing, decreasing renal, renal function, function beginning, beginning after, after two, two years, years of, of TF, TF therapy, therapy ., . An, An additional, additional patient, patient was, was identified, identified who, who died, died with, with renal, renal failure, failure without, without having, having received, received TF, TF ., . The, The results, results suggest, suggest that, that renal, renal failure, failure occurs, occurs in, in the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome more, more frequently, frequently than, than generally, generally recognized, recognized and, and that, that administration, administration of, of TF, TF may, may precipitate, precipitate or, or accelerate, accelerate the, the renal, renal disease, disease in, in patients, patients with, with this, this syndrome.., syndrome.. Current, Current evidence, evidence suggests, suggests that, that aniridia, aniridia (, ( absence, absence of, of iris, iris ), ) is, is caused, caused by, by loss, loss of, of function, function of, of one, one copy, copy of, of the, the PAX6, PAX6 gene, gene ,, , which, which maps, maps to, to 11p13, 11p13 ., . We, We present, present the, the further, further characterisation, characterisation of, of two, two aniridia, aniridia pedigrees, pedigrees in, in which, which the, the disease, disease segregates, segregates with, with chromosomal, chromosomal rearrangements, rearrangements which, which involve, involve 11p13, 11p13 but, but do, do not, not disrupt, disrupt the, the PAX6, PAX6 gene, gene ., . We, We have, have isolated, isolated three, three human, human YAC, YAC clones, clones which, which encompass, encompass the, the PAX6, PAX6 locus, locus and, and we, we have, have used, used these, these to, to show, show that, that in, in both, both cases, cases the, the chromosomal, chromosomal breakpoint, breakpoint is, is at, at least, least 85, 85 kb, kb distal, distal of, of the, the 3, 3 end, end of, of PAX6, PAX6 ., . In, In addition, addition ,, , the, the open, open reading, reading frame, frame of, of PAX6, PAX6 is, is apparently, apparently free, free of, of mutations, mutations ., . We, We propose, propose that, that the, the PAX6, PAX6 gene, gene on, on the, the rearranged, rearranged chromosome, chromosome 11, 11 is, is in, in an, an inappropriate, inappropriate chromatin, chromatin environment, environment for, for normal, normal expression, expression and, and therefore, therefore that, that a, a position, position effect, effect is, is the, the underlying, underlying mechanism, mechanism of, of disease, disease in, in these, these families.., families.. Genetic, Genetic determinants, determinants of, of HDL, HDL cholesterol, cholesterol (, ( HDL-C, HDL-C ), ) levels, levels in, in the, the general, general population, population are, are poorly, poorly understood, understood ., . We, We previously, previously described, described plasma, plasma cholesteryl, cholesteryl ester, ester transfer, transfer protein, protein (, ( CETP, CETP ), ) deficiency, deficiency due, due to, to an, an intron, intron 14, 14 G, G (, ( +, + 1, 1 ), ) -to-A, -to-A mutation, mutation (, ( Int14, Int14 A, A ), ) in, in several, several families, families with, with very, very high, high HDL-C, HDL-C levels, levels in, in Japan, Japan ., . Subjects, Subjects with, with HDL-C, HDL-C >, > or, or =, = 100, 100 mg/dl, mg/dl (, ( n, n =, = 130, 130 ), ) were, were screened, screened by, by PCR, PCR single, single strand, strand conformational, conformational polymorphism, polymorphism analysis, analysis of, of the, the CETP, CETP gene, gene ., . Two, Two other, other mutations, mutations were, were identified, identified by, by DNA, DNA sequencing, sequencing or, or primer-mediated, primer-mediated restriction, restriction map, map modification, modification of, of PCR, PCR products, products a, a novel, novel intron, intron 14, 14 splice, splice donor, donor site, site mutation, mutation caused, caused by, by a, a T, T insertion, insertion at, at position, position +, + 3, 3 from, from the, the exon14/intron14, exon14/intron14 boundary, boundary (, ( Int14, Int14 T, T ), ) and, and a, a missense, missense mutation, mutation (, ( Asp442, Asp442 to, to Gly, Gly ), ) within, within exon, exon 15, 15 (, ( D442G, D442G ), ) ., . The, The Int14, Int14 T, T mutation, mutation was, was only, only found, found in, in one, one family, family ., . However, However ,, , the, the D442G, D442G and, and Int14, Int14 A, A mutations, mutations were, were highly, highly prevalent, prevalent in, in subjects, subjects with, with HDL-C, HDL-C >, > or, or =, = 60, 60 mg/dl, mg/dl ,, , with, with combined, combined allele, allele frequencies, frequencies of, of 9, 9 %, % ,, , 12, 12 %, % ,, , 21, 21 %, % and, and 43, 43 %, % for, for HDL-C, HDL-C 60-79, 60-79 ,, , 80-99, 80-99 ,, , 100-119, 100-119 ,, , and, and >, > or, or =, = 120, 120 mg/dl, mg/dl ,, , respectively, respectively ., . Furthermore, Furthermore ,, , prevalences, prevalences of, of the, the D442G, D442G and, and Int14, Int14 A, A mutations, mutations were, were extremely, extremely high, high in, in a, a general, general sample, sample of, of Japanese, Japanese men, men (, ( n, n =, = 236, 236 ), ) ,, , with, with heterozygote, heterozygote frequencies, frequencies of, of 7, 7 %, % and, and 2, 2 %, % ,, , respectively, respectively ., . These, These two, two mutations, mutations accounted, accounted for, for about, about 10, 10 %, % of, of the, the total, total variance, variance of, of HDL-C, HDL-C in, in this, this population, population ., . The, The phenotype, phenotype in, in a, a genetic, genetic compound, compound heterozygote, heterozygote (, ( Int14, Int14 T, T and, and Int14, Int14 A, A ), ) was, was similar, similar to, to that, that of, of Int14, Int14 A, A homozygotes, homozygotes (, ( no, no detectable, detectable CETP, CETP and, and markedly, markedly increased, increased HDL-C, HDL-C ), ) ,, , indicating, indicating that, that the, the Int14, Int14 T, T produces, produces a, a null, null allele, allele ., . In, In four, four D442G, D442G homozygotes, homozygotes ,, , mean, mean HDL-C, HDL-C levels, levels (, ( 86, 86 +/-, +/- 26, 26 mg/dl, mg/dl ), ) were, were lower, lower than, than in, in Int14, Int14 A, A homozygotes, homozygotes (, ( 158, 158 +/-, +/- 35, 35 mg/dl, mg/dl ), ) ,, , reflecting, reflecting residual, residual CETP, CETP activity, activity in, in plasma, plasma ., . In, In 47, 47 D442G, D442G heterozygotes, heterozygotes ,, , mean, mean HDL-C, HDL-C levels, levels were, were 91, 91 +/-, +/- 23, 23 mg/dl, mg/dl ,, , similar, similar to, to the, the level, level in, in D442G, D442G homozygotes, homozygotes ,, , and, and significantly, significantly greater, greater than, than mean, mean HDL-C, HDL-C levels, levels in, in Int14, Int14 A, A heterozygotes, heterozygotes (, ( 69, 69 +/-, +/- 15, 15 mg/dl, mg/dl ), ) ., . Thus, Thus ,, , the, the D442G, D442G mutation, mutation acts, acts differently, differently to, to the, the null, null mutations, mutations with, with weaker, weaker effects, effects on, on HDL, HDL in, in the, the homozygous, homozygous state, state and, and stronger, stronger effects, effects in, in the, the heterozygotes, heterozygotes ,, , suggesting, suggesting dominant, dominant expression, expression of, of a, a partially, partially defective, defective allele, allele ., . CETP, CETP deficiency, deficiency ,, , reflecting, reflecting two, two prevalent, prevalent mutations, mutations (, ( D442G, D442G and, and Int14, Int14 A, A ), ) ,, , is, is the, the first, first example, example of, of a, a genetic, genetic deficiency, deficiency state, state which, which is, is sufficiently, sufficiently common, common to, to explain, explain a, a significant, significant fraction, fraction of, of the, the variation, variation in, in HDL-C, HDL-C in, in the, the general, general population.., population.. A, A mouse, mouse with, with X-linked, X-linked glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency has, has been, been recovered, recovered in, in offspring, offspring of, of 1-ethyl-1-nitrosourea-treated, 1-ethyl-1-nitrosourea-treated male, male mice, mice ., . The, The activity, activity alteration, alteration was, was detected, detected in, in blood, blood but, but can, can also, also be, be observed, observed in, in other, other tissue, tissue extracts, extracts ., . Hemizygous, Hemizygous ,, , heterozygous, heterozygous ,, , and, and homozygous, homozygous mutants, mutants have, have ,, , respectively, respectively ,, , about, about 15, 15 ,, , 60, 60 ,, , and, and 15, 15 %, % G6PD, G6PD remaining, remaining activity, activity in, in the, the blood, blood as, as compared, compared to, to the, the wild, wild type, type ., . Erythrocyte, Erythrocyte indices, indices did, did not, not show, show differences, differences between, between mutants, mutants and, and wild, wild types, types ., . The, The mutation, mutation does, does not, not affect, affect the, the electrophoretic, electrophoretic migration, migration ,, , the, the isoelectric, isoelectric point, point ,, , or, or the, the thermal, thermal stability, stability ., . Kinetic, Kinetic properties, properties ,, , such, such as, as the, the Km, Km for, for glucose-6-phosphate, glucose-6-phosphate or, or for, for NADP, NADP and, and the, the relative, relative utilization, utilization of, of substrate, substrate analogues, analogues ,, , showed, showed no, no differences, differences between, between wild, wild types, types and, and mutants, mutants with, with the, the exception, exception of, of the, the relative, relative utilization, utilization of, of deamino-NADP, deamino-NADP which, which was, was significantly, significantly lower, lower in, in mutants, mutants ., . This, This is, is presently, presently the, the only, only animal, animal model, model for, for X-linked, X-linked G6PD, G6PD deficiency, deficiency in, in humans.., humans.. Mutations, Mutations in, in the, the glycine, glycine decarboxylase, decarboxylase gene, gene (, ( GLDC, GLDC ), ) cause, cause nonketotic, nonketotic hyperglycinemia, hyperglycinemia (, ( NKH, NKH ), ) ,, , an, an in-born, in-born error, error of, of metabolism, metabolism characterized, characterized by, by severe, severe neurological, neurological disturbance, disturbance ., . We, We have, have determined, determined the, the structure, structure of, of GLDC, GLDC and, and of, of its, its pseudogene, pseudogene (, ( psiGLDC, psiGLDC ), ) and, and studied, studied their, their expression, expression for, for a, a molecular, molecular analysis, analysis of, of NKH, NKH ., . The, The GLDC, GLDC gene, gene spans, spans at, at least, least 135, 135 kb, kb and, and consists, consists of, of 25, 25 exons, exons ., . All, All donor, donor and, and acceptor, acceptor sites, sites adhere, adhere to, to the, the canonical, canonical GT-AG, GT-AG rule, rule ,, , except, except for, for the, the donor, donor site, site of, of intron, intron 21, 21 ,, , where, where a, a variant, variant form, form GC, GC is, is used, used instead, instead of, of GT, GT ., . The, The transcription, transcription initiation, initiation site, site has, has been, been assigned, assigned to, to a, a residue, residue 163, 163 bp, bp upstream, upstream from, from the, the translation, translation initiation, initiation triplet, triplet by, by primer, primer extension, extension analysis, analysis ., . The, The psiGLDC, psiGLDC gene, gene has, has no, no intron, intron and, and shares, shares 97, 97 ., . 5, 5 %, % homology, homology with, with the, the coding, coding region, region of, of functional, functional GLDC, GLDC ,, , suggesting, suggesting that, that psiGLDC, psiGLDC is, is a, a processed, processed pseudogene, pseudogene that, that arose, arose from, from the, the GLDC, GLDC transcript, transcript about, about 4-8, 4-8 million, million years, years ago, ago ., . RNA, RNA blotting, blotting analysis, analysis has, has revealed, revealed that, that GLDC, GLDC is, is expressed, expressed in, in human, human liver, liver ,, , kidney, kidney ,, , brain, brain ,, , and, and placenta, placenta ., . We, We have, have also, also examined, examined a, a patient, patient with, with NKH, NKH with, with no, no detectable, detectable GLDC, GLDC mRNA, mRNA in, in his, his lymphoblasts, lymphoblasts ., . Exons, Exons 1-3, 1-3 of, of the, the functional, functional GLDC, GLDC gene"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", gene from, from this, this patient, patient are, are not, not amplified, amplified by, by polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) ,, , whereas, whereas those, those from, from control, control subjects, subjects are, are ., . These, These results, results suggest, suggest a, a large, large homozygous, homozygous deletion, deletion (, ( at, at least, least 30, 30 kb, kb ), ) in, in the, the patient, patient ., . Furthermore, Furthermore ,, , we, we have, have devised, devised a, a semi-quantitative, semi-quantitative PCR, PCR to, to estimate, estimate the, the number, number of, of GLDC, GLDC alleles, alleles by, by using, using psiGLDC, psiGLDC as, as an, an internal, internal control, control and, and have, have confirmed, confirmed the, the homozygosity, homozygosity and, and heterozygosity, heterozygosity of, of the, the deletion, deletion in, in the, the patient, patient and, and his, his parents, parents ,, , respectively, respectively ., . Structural, Structural information, information of, of GLDC, GLDC and, and psiGLDC, psiGLDC should, should facilitate, facilitate the, the molecular, molecular analysis, analysis of, of NKH, NKH ., . Inherited, Inherited mutations, mutations in, in BRCA1, BRCA1 predispose, predispose to, to breast, breast and, and ovarian, ovarian cancer, cancer ,, , but, but the, the role, role of, of BRCA1, BRCA1 in, in sporadic, sporadic breast, breast and, and ovarian, ovarian cancer, cancer has, has previously, previously been, been elusive, elusive ., . Here, Here ,, , we, we show, show that, that retroviral, retroviral transfer, transfer of, of the, the wild-type, wild-type BRCA1, BRCA1 gene, gene inhibits, inhibits growth, growth in, in vitro, vitro of, of all, all breast, breast and, and ovarian, ovarian cancer, cancer cell, cell lines, lines tested, tested ,, , but, but not, not colon, colon or, or lung, lung cancer, cancer cells, cells or, or fibroblasts, fibroblasts ., . Mutant, Mutant BRCA1, BRCA1 has, has no, no effect, effect on, on growth, growth of, of breast, breast cancer, cancer cells, cells ;, ; ovarian, ovarian cancer, cancer cell, cell growth, growth is, is not, not affected, affected by, by BRCA1, BRCA1 mutations, mutations in, in the, the 5, 5 portion, portion of, of the, the gene, gene ,, , but, but is, is inhibited, inhibited by, by 3, 3 BRCA1, BRCA1 mutations, mutations ., . Development, Development of, of MCF-7, MCF-7 tumours, tumours in, in nude, nude mice, mice is, is inhibited, inhibited when, when MCF-7, MCF-7 cells, cells are, are transfected, transfected with, with wild-type, wild-type ,, , but, but not, not mutant, mutant ,, , BRCA1, BRCA1 ., . Most, Most importantly, importantly ,, , among, among mice, mice with, with established, established MCF-7, MCF-7 tumours, tumours ,, , peritoneal, peritoneal treatment, treatment with, with a, a retroviral, retroviral vector, vector expressing, expressing wild-type, wild-type BRCA1, BRCA1 significantly, significantly inhibits, inhibits tumour, tumour growth, growth and, and increased, increased survival.., survival.. Ankylosing, Ankylosing spondylitis, spondylitis is, is diagnosed, diagnosed once, once or, or twice, twice in, in each, each 1000, 1000 males, males and, and one, one tenth, tenth as, as frequently, frequently in, in females, females ,, , but, but the, the true, true prevalence, prevalence is, is unknown, unknown ., . Indentification, Indentification of, of genetic, genetic marker, marker ,, , HL-A, HL-A W27, W27 ,, , for, for susceptible, susceptible persons, persons has, has provided, provided a, a tool, tool facilitating, facilitating epidemiologic, epidemiologic studies, studies and, and allowing, allowing identification, identification of, of ``, `` control, control ``, `` populations, populations without, without the, the marker, marker ., . Evaluation, Evaluation by, by postal, postal questionnaires, questionnaires ,, , and, and pelvic, pelvic radiography, radiography of, of 78, 78 HL-A, HL-A 27W-positive, 27W-positive blood, blood donors, donors selected, selected from, from a, a group, group of, of apparently, apparently healthy, healthy subjects, subjects revealed, revealed 14, 14 who, who satisfied, satisfied the, the criteria, criteria for, for definite, definite ankylosing, ankylosing spondylitis, spondylitis ., . The, The prevalence, prevalence was, was similar, similar in, in both, both sexes, sexes ., . One, One hundred, hundred and, and twenty-six, twenty-six W27-negative, W27-negative controls, controls matched, matched for, for race, race ,, , sex, sex ,, , and, and age, age failed, failed to, to yield, yield a, a single, single case, case ., . For, For a, a person, person of, of either, either sex, sex with, with HL-A, HL-A W27, W27 ,, , there, there appears, appears to, to be, be about, about a, a 20, 20 per, per cent, cent chance, chance that, that ankylosing, ankylosing spondylitis, spondylitis will, will develop, develop ,, , suggesting, suggesting a, a prevalence, prevalence of, of 10, 10 to, to 15, 15 per, per thousand, thousand ., . Hitherto, Hitherto accepted, accepted figures, figures may, may underestimate, underestimate the, the frequency, frequency by, by a, a factor, factor of, of 10, 10 to, to 20.., 20.. More, More than, than 75, 75 %, % of, of the, the reported, reported mutations, mutations in, in the, the hereditary, hereditary breast, breast and, and ovarian, ovarian cancer, cancer gene, gene ,, , BRCA1, BRCA1 ,, , result, result in, in truncated, truncated proteins, proteins ., . We, We have, have used, used the, the protein, protein truncation, truncation test, test (, ( PTT, PTT ), ) to, to screen, screen for, for mutations, mutations in, in exon, exon 11, 11 ,, , which, which encodes, encodes 61, 61 %, % of, of BRCA1, BRCA1 ., . In, In 45, 45 patients, patients from, from breast, breast and/or, and/or ovarian, ovarian cancer, cancer families, families we, we found, found six, six novel, novel mutations, mutations two, two single, single nucleotide, nucleotide insertions, insertions ,, , three, three small, small deletions, deletions (, ( 1-5, 1-5 bp, bp ), ) and, and a, a nonsense, nonsense mutation, mutation identified, identified two, two unrelated, unrelated families, families ., . Furthermore, Furthermore ,, , we, we were, were able, able to, to amplify, amplify the, the remaining, remaining coding, coding region, region by, by RT-PCR, RT-PCR using, using lymphocyte, lymphocyte RNA, RNA ., . Combined, Combined with, with PTT, PTT ,, , we, we detected, detected aberrantly, aberrantly spliced, spliced products, products affecting, affecting exons, exons 5, 5 and, and 6, 6 in, in one, one of, of two, two BRCA1-linked, BRCA1-linked families, families examined, examined ., . The, The protein, protein truncation, truncation test, test promises, promises to, to become, become a, a valuable, valuable technique, technique in, in detecting, detecting BRCA1, BRCA1 mutations.., mutations.. A, A C, C --, -- greater, greater than, than G, G transversion, transversion has, has been, been found, found in, in exon, exon 3, 3 of, of the, the PLP, PLP gene, gene of, of affected, affected males, males and, and their, their mother, mother in, in a, a single, single sibship, sibship with, with Pelizaeus-merzbacher, Pelizaeus-merzbacher disease, disease (, ( PMD, PMD ), ) ., . The, The transversion, transversion should, should not, not result, result in, in an, an amino, amino acid, acid change, change in, in the, the protein, protein but, but it, it does, does result, result in, in the, the loss, loss of, of a, a HaeIII, HaeIII restriction, restriction endonuclease, endonuclease cleavage, cleavage site, site ., . It, It is, is concordant, concordant with, with the, the disease, disease in, in this, this family, family ., . One-hundred-ten, One-hundred-ten unrelated, unrelated X, X chromosomes, chromosomes are, are negative, negative for, for this, this mutation, mutation ., . No, No other, other sequence, sequence defect, defect was, was found, found in, in the, the PLP, PLP exons, exons of, of the, the affected, affected males, males ., . The, The cause, cause of, of disease, disease in, in this, this family, family remains, remains unknown, unknown ,, , but, but the, the association, association between, between this, this rare, rare mutation, mutation and, and PMD, PMD is, is intriguing, intriguing ., . The, The mutation, mutation can, can serve, serve as, as a, a marker, marker for, for following, following segregation, segregation of, of the, the PLP, PLP gene.., gene.. Ten, Ten variants, variants of, of erythrocyte, erythrocyte glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase were, were identified, identified in, in 22, 22 patients, patients with, with G6PD, G6PD deficiency, deficiency from, from three, three districts, districts of, of Bulgaria, Bulgaria ., . Corinth-like, Corinth-like and, and Fayoum-like, Fayoum-like variants, variants were, were the, the most, most frequent, frequent ;, ; Mediterranean, Mediterranean ,, , Ohut, Ohut II, II ,, , Kilgore, Kilgore ,, , Boston, Boston ,, , Poznan, Poznan ,, , and, and Panay, Panay variants, variants and, and two, two new, new variants, variants ,, , Petrich, Petrich and, and Gotze, Gotze Delchev, Delchev ,, , were, were each, each found, found in, in one, one or, or two, two carriers, carriers ., . No, No correlation, correlation was, was revealed, revealed between, between clinical, clinical and, and biochemical, biochemical polymorphism.., polymorphism.. Targeted, Targeted mutagenesis, mutagenesis was, was used, used to, to produce, produce two, two mutations, mutations in, in the, the murine, murine hemochromatosis, hemochromatosis gene, gene (, ( Hfe, Hfe ), ) locus, locus ., . The, The first, first mutation, mutation deletes, deletes a, a large, large portion, portion of, of the, the coding, coding sequence, sequence ,, , generating, generating a, a null, null allele, allele ., . The, The second, second mutation, mutation introduces, introduces a, a missense, missense mutation, mutation (, ( C282Y, C282Y ), ) into, into the, the Hfe, Hfe locus, locus ,, , but, but otherwise, otherwise leaves, leaves the, the gene, gene intact, intact ., . This, This mutation, mutation is, is identical, identical to, to the, the disease-causing, disease-causing mutation, mutation in, in patients, patients with, with hereditary, hereditary hemochromatosis, hemochromatosis ., . Mice, Mice carrying, carrying each, each of, of the, the two, two mutations, mutations were, were bred, bred and, and analyzed, analyzed ., . Homozygosity, Homozygosity for, for either, either mutation, mutation results, results in, in postnatal, postnatal iron, iron loading, loading ., . The, The effects, effects of, of the, the null, null mutation, mutation are, are more, more severe, severe than, than the, the effects, effects of, of the, the C282Y, C282Y mutation, mutation ., . Mice, Mice heterozygous, heterozygous for, for either, either mutation, mutation accumulate, accumulate more, more iron, iron than, than normal, normal controls, controls ., . Interestingly, Interestingly ,, , although, although liver, liver iron, iron stores, stores are, are greatly, greatly increased, increased ,, , splenic, splenic iron, iron is, is decreased, decreased ., . We, We conclude, conclude that, that the, the C282Y, C282Y mutation, mutation does, does not, not result, result in, in a, a null, null allele.., allele.. We, We have, have previously, previously assigned, assigned the, the Friedreich, Friedreich ataxia, ataxia locus, locus (, ( FRDA, FRDA ), ) to, to chromosome, chromosome 9, 9 ;, ; the, the current, current maximal, maximal lod, lod score, score between, between FRDA, FRDA and, and MCT112, MCT112 (, ( D9S15, D9S15 ), ) is, is greater, greater than, than 50, 50 at, at a, a recombination, recombination fraction, fraction of, of theta, theta =, = 0, 0 ., . The, The physical, physical assignment, assignment of, of the, the locus, locus defined, defined by, by MCT112, MCT112 ,, , and, and hence, hence FRDA, FRDA ,, , has, has not, not been, been determined, determined ,, , although, although linkage, linkage analysis, analysis of, of MCT112, MCT112 with, with other, other chromosome, chromosome 9, 9 markers, markers inferred, inferred a, a location, location close, close to, to the, the centromere, centromere ., . We, We have, have used, used in, in situ, situ hybridisation, hybridisation with, with MCT112, MCT112 ,, , a, a corresponding, corresponding cosmid, cosmid MJ1, MJ1 ,, , and, and DR47, DR47 (, ( D9S5, D9S5 ), ) ,, , coupled, coupled with, with mapping, mapping studies, studies on, on hybrid, hybrid cell, cell panels, panels ,, , to, to define, define more, more precisely, precisely the, the location, location of, of the, the disease, disease locus, locus ., . The, The in, in situ, situ location, location of, of all, all three, three probes, probes is, is 9q13, 9q13 --, -- --, -- q21, q21 ., . 1, 1 ,, , distal, distal to, to the, the variable, variable heterochromatin, heterochromatin region, region ., . Physical, Physical assignment, assignment of, of FRDA, FRDA will, will allow, allow us, us to, to identify, identify hybrid, hybrid cell, cell lines, lines containing, containing the, the mutated, mutated gene, gene ., . Mxi1, Mxi1 is, is thought, thought to, to negatively, negatively regulate, regulate Myc, Myc function, function and, and may, may therefore, therefore be, be a, a potential, potential tumor, tumor suppressor, suppressor gene, gene ., . Little, Little effort, effort has, has yet, yet been, been made, made to, to find, find alterations, alterations involving, involving this, this gene, gene in, in human, human solid, solid tumors, tumors ., . We, We screened, screened 31, 31 human, human gastric, gastric cancers, cancers ,, , 7, 7 esophageal, esophageal cancers, cancers ,, , 85, 85 bone, bone and, and soft, soft tissue, tissue tumors, tumors of, of various, various types, types ,, , including, including 4, 4 neurofibrosarcomas, neurofibrosarcomas ., . We, We also, also examined, examined 29, 29 human, human tumor, tumor cell, cell lines, lines consisting, consisting of, of 12, 12 esophageal, esophageal cancers, cancers ,, , 7, 7 glioma/glioblastomas, glioma/glioblastomas and, and 10, 10 others, others for, for Mxi1, Mxi1 mutations, mutations in, in exons, exons 1, 1 ,, , 2, 2 ,, , 4, 4 (, ( HLH, HLH domain, domain ), ) ,, , 5, 5 and, and 6, 6 ., . Polymerase, Polymerase chain, chain reaction-single-strand, reaction-single-strand conformation, conformation polymorphism, polymorphism (, ( PCR-SSCP, PCR-SSCP ), ) and, and subsequent, subsequent sequencing, sequencing revealed, revealed three, three distinct, distinct polymorphisms, polymorphisms in, in the, the intron-exon, intron-exon boundary, boundary upstream, upstream from, from exon, exon 6, 6 ., . We, We discovered, discovered a, a missense, missense mutation, mutation ,, , GCA, GCA to, to GTA, GTA (, ( Ala, Ala 54, 54 Val, Val ), ) ,, , in, in exon, exon 2, 2 in, in a, a neurofibrosarcoma, neurofibrosarcoma patient, patient (, ( case, case 1, 1 ), ) ,, , two, two missense, missense mutations, mutations ,, , AAA, AAA to, to CAA, CAA (, ( Lys, Lys 118, 118 Gln, Gln ), ) and, and GAA, GAA to, to GGA, GGA (, ( Glu, Glu 154, 154 Gly, Gly ), ) in, in exon, exon 5, 5 of, of another, another neurofibrosarcoma, neurofibrosarcoma patient, patient (, ( case, case 2, 2 ), ) ,, , and, and 3, 3 amino, amino acid, acid substitutions, substitutions ,, , GTG, GTG to, to GCG, GCG (, ( Val, Val 179, 179 Ala, Ala ), ) ,, , GTT, GTT to, to GCT, GCT (, ( Val, Val 181, 181 Ala, Ala ), ) and, and TTC, TTC to, to CTC, CTC (, ( Phe, Phe 186, 186 Leu, Leu ), ) ,, , in, in a, a third, third neurofibrosarcoma, neurofibrosarcoma patient, patient (, ( case, case 3, 3 ), ) ., . In, In case, case 3, 3 ,, , loss, loss of, of heterozygosity, heterozygosity was, was also, also demonstrated, demonstrated by, by informative, informative (, ( TTC, TTC ), ) 3/, 3/ (, ( TTC, TTC ), ) 2, 2 polymorphism, polymorphism ., . Our, Our data, data demonstrate, demonstrate that, that mutations, mutations occur, occur in, in the, the Mxi1, Mxi1 gene, gene in, in neurofibrosarcoma, neurofibrosarcoma ., . Missense, Missense mutations, mutations in, in the, the functional, functional domain, domain of, of Mxi1, Mxi1 in, in these, these cases, cases may, may be, be involved, involved in, in the, the pathogenesis, pathogenesis of, of neurofibrosarcoma.., neurofibrosarcoma.. Essential, Essential fructosuria, fructosuria is, is one, one of, of the, the oldest, oldest known, known inborn, inborn errors, errors of, of metabolism, metabolism ., . It, It is, is a, a benign, benign condition, condition which, which is, is believed, believed to, to result, result from, from deficiency, deficiency of, of hepatic, hepatic fructokinase, fructokinase (, ( ketohexokinase, ketohexokinase ,, , KHK, KHK ,, , E., E. C., C. 2, 2 ., . 7, 7 ., . 1, 1 ., . 3, 3 ), ) ., . This, This enzyme, enzyme catalyses, catalyses the, the first, first step, step of, of metabolism, metabolism of, of dietary, dietary fructose, fructose ,, , conversion, conversion of, of fructose, fructose to, to fructose-1-phosphate, fructose-1-phosphate ., . Despite, Despite the, the early, early recognition, recognition of, of this, this disorder, disorder ,, , the, the primary, primary structure, structure of, of human, human KHK, KHK and, and the, the molecular, molecular basis, basis of, of essential, essential fructosuria, fructosuria have, have not, not been, been previously, previously defined, defined ., . In, In this, this report, report ,, , the, the isolation, isolation and, and sequencing, sequencing of, of full-length, full-length cDNA, cDNA clones, clones encoding, encoding human, human ketohexokinase, ketohexokinase are, are described, described ., . Alternative, Alternative mRNA, mRNA species, species and, and alternative, alternative KHK, KHK isozymes, isozymes are, are produced, produced by, by alternative, alternative polyadenylation, polyadenylation and, and splicing, splicing of, of the, the KHK, KHK gene, gene ., . The, The KHK, KHK proteins, proteins show, show a, a high, high level, level of, of sequence, sequence conservation, conservation relative, relative to, to rat, rat KHK, KHK ., . Direct, Direct evidence, evidence that, that mutation, mutation of, of the, the KHK, KHK structural, structural gene, gene is, is the, the cause, cause of, of essential, essential fructosuria, fructosuria was, was also, also obtained, obtained ., . In, In a, a well-characterized, well-characterized family, family ,, , in, in which, which three, three of, of eight, eight siblings, siblings have, have fructosuria, fructosuria ,, , all, all affected, affected individuals, individuals are, are compound, compound heterozygotes, heterozygotes for, for two, two mutations, mutations Gly40Arg, Gly40Arg and, and Ala43Thr, Ala43Thr ., . Both, Both mutations, mutations result, result from, from G, G --, -- >, > A, A transitions, transitions ,, , and, and each, each alters, alters the, the same, same conserved, conserved region, region of, of the, the KHK, KHK protein, protein ., . Neither, Neither mutation, mutation was, was seen, seen in, in a, a sample, sample of, of 52, 52 unrelated, unrelated control, control individuals, individuals ., . An, An additional, additional conservative, conservative amino, amino acid, acid change, change (, ( Val49IIe, Val49IIe ), ) was, was present, present on, on the, the KHK, KHK allele, allele bearing, bearing Ala43Thr, Ala43Thr Ataxia-telangiectasia, Ataxia-telangiectasia (, ( A-T, A-T ), ) is, is characterized, characterized by, by a, a markedly, markedly increased, increased sensitivity, sensitivity to, to ionizing, ionizing radiation, radiation ,, , increased, increased incidence, incidence of, of cancer, cancer ,, , and, and neurodegeneration, neurodegeneration ,, , especially, especially of, of the, the cerebellar, cerebellar Purkinje, Purkinje cells, cells ., . Ionizing, Ionizing radiation, radiation oxidizes, oxidizes macromolecules, macromolecules and, and causes, causes tissue, tissue damage, damage through, through the, the generation, generation of, of reactive, reactive oxygen, oxygen species, species (, ( ROS, ROS ), ) ., . We, We therefore, therefore hypothesized, hypothesized that, that A-T, A-T is, is due, due to, to oxidative, oxidative damage, damage resulting, resulting from, from loss, loss of, of function, function of, of the, the A-T, A-T gene, gene product, product ., . To, To assess, assess this, this hypothesis, hypothesis ,, , we, we employed, employed an, an animal, animal model, model of, of A-T, A-T ,, , the, the mouse, mouse with, with a, a disrupted, disrupted Atm, Atm gene, gene ., . We, We show, show that, that organs, organs which, which develop, develop pathologic, pathologic changes, changes in, in the, the Atm-deficient, Atm-deficient mice, mice are, are targets, targets of, of oxidative, oxidative damage, damage ,, , and, and that, that cerebellar, cerebellar Purkinje, Purkinje cells, cells are, are particularly, particularly affected, affected ., . These, These observations, observations provide, provide a, a mechanistic, mechanistic basis, basis for, for the, the A-T, A-T phenotype, phenotype and, and lay, lay a, a rational, rational foundation, foundation for, for therapeutic, therapeutic intervention.., intervention.. The, The results, results of, of segregation, segregation analyses, analyses in, in 75, 75 families, families where, where the, the proband, proband had, had ankylosing, ankylosing spondylitis, spondylitis ,, , are, are presented, presented ., . Of, Of the, the 278, 278 adult, adult ,, , living, living first, first degree, degree relatives, relatives ,, , approximately, approximately 85, 85 %, % cooperated, cooperated in, in the, the study, study ., . Clinical, Clinical and, and radiographical, radiographical examinations, examinations were, were performed, performed and, and HLA, HLA typing, typing was, was conducted, conducted ., . The, The results, results were, were in, in agreement, agreement with, with our, our hypothesis, hypothesis that, that ankylosing, ankylosing spondylitis, spondylitis is, is part, part of, of a, a syndrome, syndrome where, where different, different genetic, genetic factors, factors interact, interact ., . Such, Such known, known factors, factors are, are HLA, HLA B27, B27 associated, associated disease, disease susceptibility, susceptibility ,, , susceptibility, susceptibility to, to psoriatic, psoriatic arthropathy, arthropathy and, and susceptibility, susceptibility to, to entero-arthropathy, entero-arthropathy ., . Radiographical, Radiographical sacro-iliitis, sacro-iliitis was, was restricted, restricted to, to HLA, HLA B27, B27 positive, positive relatives, relatives ,, , and, and was, was more, more frequently, frequently found, found in, in relatives, relatives to, to probands, probands with, with psoriasis, psoriasis than, than in, in relatives, relatives to, to probands, probands without, without psoriasis, psoriasis ., . Environmental, Environmental factors, factors (, ( intestinal, intestinal bacteria, bacteria ), ) are, are known, known to, to trigger, trigger the, the disease, disease at, at least, least in, in some, some persons, persons ,, , and, and we, we have, have postulated, postulated that, that all, all or, or most, most of, of them, them have, have the, the predisposition, predisposition to, to develop, develop disease, disease ., . Thus, Thus ,, , the, the syndrome, syndrome has, has a, a multifactorial, multifactorial etiology, etiology ., . The, The phenotypic, phenotypic expressions, expressions of, of the, the different, different genetic, genetic predispositions, predispositions involved, involved ,, , include, include sacro-iliitis, sacro-iliitis ,, , psoriasis, psoriasis ,, , acute, acute anterior, anterior uveitis, uveitis ,, , peripheral, peripheral arthropathy, arthropathy and, and inflammatory, inflammatory bowel, bowel disease, disease ., . We, We suggest, suggest the, the descriptive, descriptive name, name HEREDITARY, HEREDITARY MULTIFOCAL, MULTIFOCAL RELAPSING, RELAPSING INFLAMMATION, INFLAMMATION (, ( HEMRI, HEMRI ), ) for, for this, this syndrome, syndrome ., . Ankylosing, Ankylosing spondylitis, spondylitis ,, , psoriatic, psoriatic arthropathy, arthropathy and, and entero-arthropathy, entero-arthropathy may, may be, be regarded, regarded as, as clinical, clinical sub-types, sub-types of, of the, the syndrome.., syndrome.. The, The retinal, retinal degeneration, degeneration mouse, mouse (, ( gene, gene symbol, symbol ,, , rd, rd ), ) is, is an, an animal, animal model, model for, for certain, certain forms, forms of, of human, human hereditary, hereditary retinopathies, retinopathies ., . Recent, Recent findings, findings of"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", of a, a nonsense, nonsense mutation, mutation in, in the, the rd, rd mouse, mouse PDE, PDE beta-subunit, beta-subunit gene, gene (, ( Pdeb, Pdeb ), ) prompted, prompted us, us to, to investigate, investigate the, the chromosome, chromosome locations, locations of, of the, the mouse, mouse and, and human, human genes, genes ., . We, We have, have utilized, utilized backcross, backcross analysis, analysis in, in mice, mice to, to verify, verify and, and define, define more, more precisely, precisely the, the location, location of, of the, the Pdeb, Pdeb locus, locus 6, 6 ., . 1, 1 +/-, +/- 2, 2 ., . 3, 3 cM, cM distal, distal of, of Mgsa, Mgsa on, on mouse, mouse chromosome, chromosome 5, 5 ., . We, We have, have determined, determined that, that the, the human, human gene, gene (, ( PDEB, PDEB ), ) maps, maps to, to 4p16, 4p16 ., . 3, 3 ,, , very, very close, close to, to the, the Huntington, Huntington disease, disease (, ( HD, HD ), ) region, region ., . Analysis, Analysis of, of the, the comparative, comparative map, map for, for mice, mice and, and humans, humans shows, shows that, that the, the mouse, mouse homologue, homologue of, of the, the HD, HD gene, gene will, will reside, reside on, on chromosome, chromosome 5, 5 ., . Linkage, Linkage of, of the, the mouse, mouse Pdeb, Pdeb locus, locus with, with other, other homologues, homologues in, in the, the human, human 4p16, 4p16 ., . 3, 3 region, region is, is maintained, maintained but, but gene, gene order, order is, is not, not ,, , suggesting, suggesting at, at least, least three, three possible, possible sites, sites for, for the, the corresponding, corresponding mouse, mouse HD, HD gene.The, gene.The first, first known, known human, human kindred, kindred with, with hereditary, hereditary deficiency, deficiency of, of the, the fifth, fifth component, component of, of complement, complement (, ( C5, C5 ), ) was, was documented, documented in, in the, the accompanying, accompanying report, report ., . This, This study, study examines, examines several, several biological, biological properties, properties of, of C5-deficient, C5-deficient (, ( C5D, C5D ), ) human, human serum, serum ,, , particularly, particularly sera, sera obtained, obtained from, from two, two C5D, C5D homozygotes, homozygotes ., . The, The proband, proband ,, , who, who has, has inactive, inactive systemic, systemic lupus, lupus erythematosus, erythematosus is, is completely, completely lacking, lacking C5, C5 ,, , while, while her, her healthy, healthy half-sister, half-sister has, has 1-2, 1-2 %, % of, of normal, normal levels, levels ., . Both, Both sera, sera were, were severely, severely impaired, impaired in, in their, their ability, ability to, to generate, generate chemotactic, chemotactic activity, activity for, for normal, normal human, human neutrophils, neutrophils upon, upon incubation, incubation with, with aggregated, aggregated human, human gamma-globulin, gamma-globulin or, or Escherichia, Escherichia coli, coli endotoxin, endotoxin ., . This, This function, function was, was fully, fully restored, restored in, in the, the siblings, siblings serum, serum ,, , and, and substantially, substantially improved, improved in, in the, the probands, probands serum, serum ,, , by, by addition, addition of, of highly, highly purified, purified human, human C5, C5 to, to normal, normal serum, serum concentrations, concentrations ., . Sera, Sera from, from eight, eight family, family members, members who, who were, were apparently, apparently heterozygous, heterozygous for, for C5, C5 deficiency, deficiency gave, gave normal, normal chemotactic, chemotactic scores, scores ., . The, The ability, ability of, of C5D, C5D serum, serum to, to opsonize, opsonize Saccharomyces, Saccharomyces cerevisiae, cerevisiae (, ( bakers, bakers yeast, yeast ), ) or, or Candida, Candida albicans, albicans for, for ingestion, ingestion by, by normal, normal neutrophils, neutrophils was, was completely, completely normal, normal ., . In, In addition, addition ,, , C5D, C5D serum, serum was, was capable, capable of, of promoting, promoting normal, normal phagocytosis, phagocytosis and, and intracellular, intracellular killing, killing of, of Staphylococcus, Staphylococcus aureus, aureus ., . The, The probands, probands serum, serum was, was incapable, incapable of, of mediating, mediating lysis, lysis of, of erythrocytes, erythrocytes from, from a, a patient, patient with, with paroxysmal, paroxysmal nocturnal, nocturnal hemoglobinuria, hemoglobinuria in, in both, both the, the sucrose, sucrose hemolysia, hemolysia and, and acid, acid hemolysis, hemolysis tests, tests ,, , and, and also, also lacked, lacked bactericidal, bactericidal activity, activity against, against sensitized, sensitized or, or unsensitized, unsensitized Salmonella, Salmonella typhi, typhi ., . The, The siblings, siblings serum, serum ,, , containing, containing only, only 1-2, 1-2 %, % of, of normal, normal C5, C5 ,, , effectively, effectively lysed, lysed S., S. typhi, typhi ,, , but, but only, only at, at eightfold, eightfold lower, lower serum, serum dilutions, dilutions as, as compared, compared to, to normals, normals ., . These, These findings, findings underscore, underscore the, the critical, critical role, role of, of C5, C5 in, in the, the generation, generation of, of chemotactic, chemotactic activity, activity and, and in, in cytolytic, cytolytic reactions, reactions ,, , as, as opposed, opposed to, to a, a nonobligatory, nonobligatory or, or minimal, minimal role, role in, in opsonization, opsonization ,, , at, at least, least for, for the, the organisms, organisms under, under study.., study.. Familial, Familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) is, is a, a recessive, recessive disorder, disorder characterized, characterized by, by episodes, episodes of, of fever, fever and, and neutrophil-mediated, neutrophil-mediated serosal, serosal inflammation, inflammation ., . We, We recently, recently identified, identified the, the gene, gene causing, causing FMF, FMF ,, , designated, designated MEFV, MEFV ,, , and, and found, found it, it to, to be, be expressed, expressed in, in mature, mature neutrophils, neutrophils ,, , suggesting, suggesting that, that it, it functions, functions as, as an, an inflammatory, inflammatory regulator, regulator ., . To, To facilitate, facilitate our, our understanding, understanding of, of the, the normal, normal function, function of, of MEFV, MEFV ,, , we, we extended, extended our, our previous, previous studies, studies ., . MEFV, MEFV messenger, messenger RNA, RNA was, was detected, detected by, by reverse, reverse transcriptase-polymerase, transcriptase-polymerase chain, chain reaction, reaction in, in bone, bone marrow, marrow leukocytes, leukocytes ,, , with, with differential, differential expression, expression observed, observed among, among cells, cells by, by in, in situ, situ hybridization, hybridization ., . CD34, CD34 hematopoietic, hematopoietic stem-cell, stem-cell cultures, cultures induced, induced toward, toward the, the granulocytic, granulocytic lineage, lineage expressed, expressed MEFV, MEFV at, at the, the myelocyte, myelocyte stage, stage ,, , concurrently, concurrently with, with lineage, lineage commitment, commitment ., . The, The prepromyelocytic, prepromyelocytic cell, cell line, line HL60, HL60 expressed, expressed MEFV, MEFV only, only at, at granulocytic, granulocytic and, and monocytic, monocytic differentiation, differentiation ., . MEFV, MEFV was, was also, also expressed, expressed in, in the, the monocytic, monocytic cell, cell lines, lines U937, U937 and, and THP-1, THP-1 ., . Among, Among peripheral, peripheral blood, blood leukocytes, leukocytes ,, , MEFV, MEFV expression, expression was, was detected, detected in, in neutrophils, neutrophils ,, , eosinophils, eosinophils ,, , and, and to, to varying, varying degrees, degrees ,, , monocytes, monocytes ., . Consistent, Consistent with, with the, the tissue, tissue specificity, specificity of, of expression, expression ,, , complete, complete sequencing, sequencing and, and analysis, analysis of, of upstream, upstream regulatory, regulatory regions, regions of, of MEFV, MEFV revealed, revealed homology, homology to, to myeloid-specific, myeloid-specific promoters, promoters and, and to, to more, more broadly, broadly expressed, expressed inflammatory, inflammatory promoter, promoter elements, elements ., . In, In vitro, vitro stimulation, stimulation of, of monocytes, monocytes with, with the, the proinflammatory, proinflammatory agents, agents interferon, interferon (, ( IFN, IFN ), ) gamma, gamma ,, , tumor, tumor necrosis, necrosis factor, factor ,, , and, and lipopolysaccharide, lipopolysaccharide induced, induced MEFV, MEFV expression, expression ,, , whereas, whereas the, the antiinflammatory, antiinflammatory cytokines, cytokines interleukin, interleukin (, ( IL, IL ), ) 4, 4 ,, , IL-10, IL-10 ,, , and, and transforming, transforming growth, growth factor, factor beta, beta inhibited, inhibited such, such expression, expression ., . Induction, Induction by, by IFN-gamma, IFN-gamma occurred, occurred rapidly, rapidly and, and was, was resistant, resistant to, to cycloheximide, cycloheximide ., . IFN-alpha, IFN-alpha also, also induced, induced MEFV, MEFV expression, expression ., . In, In granulocytes, granulocytes ,, , MEFV, MEFV was, was up-regulated, up-regulated by, by IFN-gamma, IFN-gamma and, and the, the combination, combination of, of IFN-alpha, IFN-alpha and, and colchicine, colchicine ., . These, These results, results refine, refine understanding, understanding of, of MEFV, MEFV by, by placing, placing the, the gene, gene in, in the, the myelomonocytic-specific, myelomonocytic-specific proinflammatory, proinflammatory pathway, pathway and, and identifying, identifying it, it as, as an, an IFN-gamma, IFN-gamma immediate, immediate early, early gene.., gene.. The, The hSNF5/INI1, hSNF5/INI1 gene, gene which, which encodes, encodes a, a member, member of, of the, the SWI/SNF, SWI/SNF chromatin, chromatin ATP-dependent, ATP-dependent remodeling, remodeling complex, complex ,, , is, is a, a new, new tumor, tumor suppressor, suppressor gene, gene localized, localized on, on chromosome, chromosome 22q11, 22q11 ., . 2, 2 and, and recently, recently shown, shown to, to be, be mutated, mutated in, in malignant, malignant rhabdoid, rhabdoid tumors, tumors ., . We, We have, have searched, searched for, for hSNF5/INI1, hSNF5/INI1 mutations, mutations in, in 229, 229 tumors, tumors of, of various, various origins, origins using, using a, a screening, screening method, method based, based on, on denaturing, denaturing high-performance, high-performance liquid, liquid chromatography, chromatography ., . A, A total, total of, of 31, 31 homozygous, homozygous deletions, deletions and, and 36, 36 point, point alterations, alterations were, were identified, identified ., . Point, Point mutations, mutations were, were scattered, scattered along, along the, the coding, coding sequence, sequence and, and included, included 15, 15 nonsense, nonsense ,, , 15, 15 frameshift, frameshift ,, , three, three splice, splice site, site ,, , two, two missense, missense and, and one, one editing, editing mutations, mutations ., . Mutations, Mutations were, were retrieved, retrieved in, in most, most rhabdoid, rhabdoid tumors, tumors ,, , whatever, whatever their, their sites, sites of, of occurrence, occurrence ,, , indicating, indicating the, the common, common pathogenetic, pathogenetic origin, origin of, of these, these tumors, tumors ., . Recurrent, Recurrent hSNF5/INI1, hSNF5/INI1 alterations, alterations were, were also, also observed, observed in, in choroid, choroid plexus, plexus carcinomas, carcinomas and, and in, in a, a subset, subset of, of central, central primitive, primitive neuroectodermal, neuroectodermal tumors, tumors (, ( cPNETs, cPNETs ), ) and, and medulloblastomas, medulloblastomas ., . In, In contrast, contrast ,, , hSNF5/INI1, hSNF5/INI1 point, point mutations, mutations were, were not, not detected, detected in, in breast, breast cancers, cancers ,, , Wilms, Wilms tumors, tumors ,, , gliomas, gliomas ,, , ependymomas, ependymomas ,, , sarcomas, sarcomas and, and other, other tumor, tumor types, types ,, , even, even though, though most, most analyzed, analyzed cases, cases harbored, harbored loss, loss of, of heterozygosity, heterozygosity at, at 22q11, 22q11 ., . 2, 2 loci, loci ., . These, These results, results suggest, suggest that, that rhabdoid, rhabdoid tumors, tumors ,, , choroid, choroid plexus, plexus carcinomas, carcinomas and, and a, a subset, subset of, of medulloblastomas, medulloblastomas and, and cPNETs, cPNETs share, share common, common pathways, pathways of, of oncogenesis, oncogenesis related, related to, to hSNF5/INI1, hSNF5/INI1 alteration, alteration and, and that, that hSNF5/INI1, hSNF5/INI1 mutations, mutations define, define a, a genetically, genetically homogeneous, homogeneous family, family of, of highly, highly aggressive, aggressive cancers, cancers mainly, mainly occurring, occurring in, in young, young children, children and, and frequently, frequently ,, , but, but not, not always, always ,, , exhibiting, exhibiting a, a rhabdoid, rhabdoid phenotype, phenotype Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency was, was found, found in, in 3, 3 ., . 2, 2 %, % of, of the, the male, male population, population living, living in, in the, the urban, urban area, area of, of Algiers, Algiers ., . The, The deficient, deficient subjects, subjects originated, originated from, from multiple, multiple geographic, geographic regions, regions of, of Northern, Northern Algeria, Algeria ,, , with, with prevalence, prevalence of, of individuals, individuals of, of Berber-Kabyle, Berber-Kabyle origin, origin ., . Red, Red blood, blood cell, cell G6PD, G6PD was, was partially, partially purified, purified and, and characterized, characterized in, in deficient, deficient males, males from, from 17, 17 families, families ,, , and, and six, six different, different variants, variants were, were found, found ., . Among, Among them, them ,, , only, only one, one ,, , the, the Gd, Gd (, ( -, - ), ) Kabyle, Kabyle variant, variant ,, , had, had been, been previously, previously described, described ., . It, It was, was detected, detected in, in nine, nine families, families ., . The, The other, other five, five variants, variants were, were new, new Gd, Gd (, ( -, - ), ) Laghouat, Laghouat (, ( four, four cases, cases ), ) ,, , Gd, Gd (, ( -, - ), ) Blida, Blida (, ( one, one case, case ), ) ,, , Gd, Gd (, ( -, - ), ) Thenia, Thenia (, ( one, one case, case ), ) ,, , Gd, Gd (, ( -, - ), ) Titteri, Titteri (, ( one, one case, case ), ) ,, , and, and Gd, Gd (, ( -, - ), ) Alger, Alger (, ( two, two brothers, brothers ), ) ., . Strikingly, Strikingly ,, , the, the common, common Mediterranean, Mediterranean variant, variant was, was not, not found, found ., . G6PD, G6PD deficiency, deficiency is, is heterogeneous, heterogeneous in, in northern, northern Algeria, Algeria where, where autochtonous, autochtonous variants, variants seem, seem to, to prevail, prevail ., . The, The Kabyle, Kabyle variant, variant may, may be, be common, common in, in this, this country, country ., . We, We describe, describe a, a patient, patient with, with typical, typical clinical, clinical features, features of, of the, the fragile, fragile X, X syndrome, syndrome ,, , but, but without, without cytogenetic, cytogenetic expression, expression of, of the, the fragile, fragile X, X or, or an, an amplified, amplified CCG, CCG trinucleotide, trinucleotide repeat, repeat fragment, fragment ., . The, The patient, patient has, has a, a previously, previously uncharacterized, uncharacterized submicroscopic, submicroscopic deletion, deletion encompassing, encompassing the, the CCG, CCG repeat, repeat ,, , the, the entire, entire FMR1, FMR1 gene, gene and, and about, about 2, 2 ., . 5, 5 megabases, megabases of, of flanking, flanking sequences, sequences ., . This, This finding, finding confirms, confirms that, that the, the fragile, fragile X, X phenotype, phenotype can, can exist, exist ,, , without, without amplification, amplification of, of the, the CCG, CCG repeat, repeat or, or cytogenetic, cytogenetic expression, expression of, of the, the fragile, fragile X, X ,, , and, and that, that fragile, fragile X, X syndrome, syndrome is, is a, a genetically, genetically homogeneous, homogeneous disorder, disorder involving, involving FMR1, FMR1 ., . We, We also, also found, found random, random X-inactivation, X-inactivation in, in the, the mother, mother of, of the, the patient, patient who, who was, was shown, shown to, to be, be a, a carrier, carrier of, of this, this deletion, deletion ., . Van, Van der, der Woude, Woude syndrome, syndrome (, ( VWS, VWS ), ) is, is an, an autosomal, autosomal dominant, dominant craniofacial, craniofacial disorder, disorder with, with high, high penetrance, penetrance and, and variable, variable expression, expression ., . Its, Its clinical, clinical features, features are, are variably, variably expressed, expressed ,, , but, but include, include cleft, cleft lip, lip and/or, and/or cleft, cleft palate, palate ,, , lip, lip pits, pits and, and hypodontia, hypodontia ., . All, All VWS, VWS families, families studied, studied to, to date, date map, map the, the disease, disease gene, gene to, to a, a <, < 2, 2 cM, cM region, region of, of chromosome, chromosome 1q32, 1q32 ,, , with, with no, no evidence, evidence of, of locus, locus heterogeneity, heterogeneity ., . The, The aim, aim of, of this, this study, study is, is to, to refine, refine the, the localization, localization of, of the, the VWS, VWS gene, gene and, and to, to further, further assess, assess possible, possible heterogeneity, heterogeneity ., . We, We analyzed, analyzed four, four multiplex, multiplex VWS, VWS families, families ., . All, All available, available members, members were, were clinically, clinically assessed, assessed and, and genotyped, genotyped for, for 19, 19 short, short tandem, tandem repeat, repeat markers, markers on, on chromosome, chromosome 1, 1 in, in the, the VWS, VWS candidate, candidate gene, gene region, region ., . We, We performed, performed two-point, two-point and, and multipoint, multipoint limit, limit of, of detection, detection (, ( LOD, LOD ), ) score, score analyses, analyses using, using a, a high, high penetrance, penetrance autosomal, autosomal dominant, dominant model, model ., . All, All families, families showed, showed positive, positive LOD, LOD scores, scores without, without any, any recombination, recombination in, in the, the candidate, candidate region, region ., . The, The largest, largest two-point, two-point LOD, LOD score, score was, was 5, 5 ., . 87, 87 87, 87 ., . Our, Our assay, assay method, method for, for short, short tandem, tandem repeat, repeat (, ( STR, STR ), ) markers, markers provided, provided highly, highly accurate, accurate size, size estimation, estimation of, of marker, marker allele, allele fragment, fragment sizes, sizes ,, , and, and therefore, therefore enabled, enabled us, us to, to determine, determine the, the specific, specific alleles, alleles segregating, segregating with, with the, the VWS, VWS gene, gene in, in each, each of, of our, our four, four families, families ., . We, We observed, observed a, a striking, striking pattern, pattern of, of STR, STR allele, allele sharing, sharing at, at several, several closely, closely linked, linked loci, loci among, among our, our four, four Caucasian, Caucasian VWS, VWS families, families recruited, recruited at, at three, three different, different locations, locations in, in the, the US, US ., . These, These results, results suggest, suggest the, the possibility, possibility of, of a, a unique, unique origin, origin for, for a, a mutation, mutation responsible, responsible for, for many, many or, or most, most cases, cases of, of VWS, VWS ., . Since, Since BRCA1, BRCA1 ,, , the, the first, first major, major gene, gene responsible, responsible for, for inherited, inherited breast, breast cancer, cancer ,, , was, was cloned, cloned ,, , more, more than, than 50, 50 unique, unique mutations, mutations have, have been, been detected, detected in, in the, the germline, germline of, of individuals, individuals with, with breast, breast and, and ovarian, ovarian cancer, cancer ., . In, In high-risk, high-risk pedigrees, pedigrees ,, , female, female carriers, carriers of, of BRCA1, BRCA1 mutations, mutations have, have an, an 80-90, 80-90 %, % lifetime, lifetime risk, risk of, of breast, breast cancer, cancer ,, , and, and a, a 40-50, 40-50 %, % risk, risk of, of ovarian, ovarian cancer, cancer ., . However, However ,, , the, the mutation, mutation stats, stats of, of individuals, individuals unselected, unselected for, for breast, breast or, or ovarian, ovarian cancer, cancer has, has not, not been, been determined, determined ,, , and, and it, it is, is not, not known, known whether, whether mutations, mutations in, in such, such individuals, individuals confer, confer the, the same, same risk, risk of, of cancer, cancer as, as in, in individuals, individuals from, from the, the high-risk, high-risk families, families studied, studied so, so far, far ., . Following, Following the, the finding, finding of, of a, a 185delAG, 185delAG frameshift, frameshift mutation, mutation in, in several, several Ashkenazi, Ashkenazi Jewish, Jewish breast/ovarian, breast/ovarian families, families ,, , we, we have, have determined, determined the, the frequency, frequency of, of this, this mutation, mutation in, in 858, 858 Ashkenazim, Ashkenazim seeking, seeking genetic, genetic testing, testing for, for conditions, conditions unrelated, unrelated to, to cancer, cancer ,, , and, and in, in 815, 815 reference, reference individuals, individuals not, not selected, selected for, for ethnic, ethnic origin, origin ., . We, We observed, observed the, the 185delAG, 185delAG mutation, mutation in, in 0, 0 ., . 9, 9 %, % of, of Ashkenazim, Ashkenazim (, ( 95, 95 %, % confidence, confidence limit, limit ,, , 0, 0 ., . 4-1, 4-1 ., . 8, 8 %, % ), ) and, and in, in none, none of, of the, the reference, reference samples, samples ., . Our, Our results, results suggest, suggest that, that one, one in, in a, a hundred, hundred women, women of, of Ashkenazi, Ashkenazi descent, descent may, may be, be at, at especially, especially high, high risk, risk of, of developing, developing breast, breast and/or, and/or ovarian, ovarian cancer.Familial, cancer.Familial hypobetalipoproteinemia, hypobetalipoproteinemia is, is an, an autosomal, autosomal codominant, codominant disorder, disorder resulting, resulting in, in a, a dramatic, dramatic reduction, reduction in, in plasma, plasma concentrations, concentrations of, of apolipoprotein, apolipoprotein (, ( apo, apo ), ) B, B ,, , cholesterol, cholesterol ,, , and, and beta-migrating, beta-migrating lipoproteins, lipoproteins ., . A, A benefit, benefit of, of hypobetalipoproteinemia, hypobetalipoproteinemia is, is that, that mildly, mildly affected, affected individuals, individuals may, may be, be protected, protected from, from coronary, coronary vascular, vascular disease, disease ., . We, We have, have used, used gene, gene targeting, targeting to, to generate, generate mice, mice with, with a, a modified, modified Apob, Apob allele, allele ., . Mice, Mice containing, containing this, this allele, allele display, display all, all of, of the, the hallmarks, hallmarks of, of human, human hypobetalipoproteinemia, hypobetalipoproteinemia they, they produce, produce a, a truncated, truncated apoB, apoB protein, protein ,, , apoB70, apoB70 ,, , and, and have, have markedly, markedly decreased, decreased plasma, plasma concentrations, concentrations of, of apoB, apoB ,, , beta-lipoproteins, beta-lipoproteins ,, , and, and total, total cholesterol, cholesterol ., . In, In addition, addition ,, , the, the mice, mice manifest, manifest several, several characteristics, characteristics that, that are, are occasionally, occasionally observed, observed in, in human, human hypobetalipoproteinemia, hypobetalipoproteinemia ,, , including, including reduced, reduced plasma, plasma triglyceride, triglyceride concentrations, concentrations ,, , fasting, fasting chylomicronemia, chylomicronemia ,, , and, and reduced, reduced high, high density, density lipoprotein, lipoprotein cholesterol, cholesterol ., . An, An unexpected, unexpected finding, finding is, is that, that the, the modified, modified Apob, Apob allele, allele is, is strongly, strongly associated, associated with, with exencephalus, exencephalus and, and hydrocephalus, hydrocephalus ., . These, These mice, mice should, should help, help increase, increase our, our understanding, understanding of, of hypobetalipoproteinemia, hypobetalipoproteinemia ,, , atherogenesis, atherogenesis ,, , and, and the, the etiology, etiology of, of exencephalus, exencephalus and, and hydrocephalus.., hydrocephalus.. BACKGROUND, BACKGROUND Families, Families with, with a, a high, high incidence, incidence of, of hereditary, hereditary breast, breast cancer, cancer ,, , and, and subsequently, subsequently shown, shown to, to have, have terminating, terminating mutations, mutations in, in BRCA1, BRCA1 or, or BRCA2, BRCA2 ,, , appear, appear to, to have, have a, a higher, higher incidence, incidence of, of prostate, prostate cancer, cancer among, among male, male relatives, relatives ., . We, We aimed, aimed to, to determine, determine whether, whether the, the common, common germline, germline mutations, mutations of, of BRCA1, BRCA1 or, or BRCA2, BRCA2 in, in Ashkenazi, Ashkenazi Jewish, Jewish men, men predisposed, predisposed them, them to, to prostate, prostate cancer, cancer ., . METHODS, METHODS We, We examined, examined genomic, genomic DNA, DNA from, from 83, 83 (, ( for, for BRCA1, BRCA1 185delAG, 185delAG ), ) or, or 82, 82 (, ( for, for BRCA2, BRCA2 6174delT, 6174delT ), ) Ashkenazi, Ashkenazi Jewish, Jewish prostate, prostate cancer, cancer patients, patients ,, , most, most of, of whom, whom were, were treated, treated at, at a, a relatively, relatively young, young age, age ,, , for, for the, the most, most common, common germline, germline mutation, mutation in, in each, each gene, gene seen, seen in, in the, the Ashkenazi, Ashkenazi population, population ., . RESULTS, RESULTS Our, Our study, study should, should have, have been, been able, able to, to detect, detect a, a 4-5-fold, 4-5-fold increase, increase in, in the, the risk, risk of, of prostate, prostate cancer, cancer due, due to, to mutation, mutation of, of BRCA1, BRCA1 or, or BRCA2, BRCA2 ., . However, However ,, , only, only one, one (, ( 1, 1 ., . 15, 15 %, % ;, ; 95, 95 %, % confidence, confidence interval, interval ,, , 0-3, 0-3 ., . 6, 6 %, % ), ) of, of the, the patients, patients was, was heterozygous, heterozygous for, for the, the BRCA1, BRCA1 mutant, mutant allele, allele ,, , and, and only, only two, two were, were heterozygous, heterozygous for, for the, the BRCA2, BRCA2 mutation, mutation (, ( 2, 2 ., . 4, 4 %, % ;, ; 95, 95 %, % confidence, confidence interval, interval ,, , 0-6, 0-6 ., . 2, 2 %, % ), ) ., . CONCLUSIONS, CONCLUSIONS The, The incidence, incidence of, of each, each of, of the, the germline, germline mutations, mutations in, in these, these prostate, prostate cancer, cancer patients, patients closely, closely matched, matched their, their incidence, incidence (, ( about, about 1, 1 %, % ), ) in, in the, the general, general Ashkenazi, Ashkenazi Jewish, Jewish population, population ., . This, This suggests, suggests that, that unlike, unlike cases, cases of, of breast, breast and, and ovarian, ovarian cancers, cancers ,, , mutations, mutations in, in BRCA1, BRCA1 or, or BRCA2, BRCA2 do, do not, not significantly, significantly predispose, predispose men, men to, to prostate, prostate cancer, cancer Two, Two new, new deficient, deficient variants, variants of, of glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) causing, causing hereditary, hereditary nonspherocytic, nonspherocytic hemolytic, hemolytic anemia, anemia (, ( HNSHA, HNSHA ), ) are, are described, described ., . Both, Both of, of these, these are, are unique, unique and, and they, they have, have been, been named, named G6PD, G6PD Wayne, Wayne and, and G6PD, G6PD Huron, Huron ., . Patients, Patients with, with G6PD, G6PD Wayne, Wayne underwent, underwent splenectomy, splenectomy and, and no, no objective, objective improvement, improvement was, was noted, noted ., . The, The patients, patients with, with G6PD, G6PD Huron, Huron were, were under, under medical, medical observation, observation for, for a, a considerable, considerable period, period of, of time, time without, without the, the diagnosis, diagnosis of, of G6PD, G6PD deficiency, deficiency being, being entertained, entertained because, because the, the family, family was, was of, of Northern, Northern European, European origin, origin ., . Since, Since sporadic, sporadic variants, variants of, of G6PD, G6PD causing, causing HNSHA, HNSHA show, show no, no special, special racial, racial predilection, predilection ,, , the, the diagnosis, diagnosis of, of G6PD, G6PD deficiency, deficiency should, should always, always be, be considered, considered in, in patients, patients with, with this, this syndrome.., syndrome.. From, From data, data collected, collected in, in a, a North, North American, American Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) heterozygote, heterozygote screening, screening program, program ,, , the, the TSD, TSD carrier, carrier frequency, frequency among, among 46, 46 ,, , 304, 304 Jewish, Jewish individuals, individuals was, was found, found to, to be, be ., . 0324, 0324 (, ( 1, 1 in, in 31, 31 individuals, individuals ), ) ., . This, This frequency, frequency is, is consistent, consistent with, with earlier, earlier estimates, estimates based, based on, on TSD, TSD incidence, incidence data, data ., . TSD, TSD carrier, carrier frequencies, frequencies were, were then, then examined, examined by, by single, single country, country and, and single, single region, region of, of origin, origin in, in 28, 28 ,, , 029, 029 Jews, Jews within, within this, this sample, sample for, for whom, whom such, such data, data were, were available, available for, for analysis, analysis ., . Jews, Jews with, with Polish, Polish and/or, and/or Russian, Russian ancestry, ancestry constituted, constituted 88, 88 %, % of, of this, this sample, sample and, and had, had a, a TSD, TSD carrier, carrier frequency, frequency of, of ., . 0327, 0327 ., . No, No TSD, TSD carriers, carriers were, were observed, observed among, among the, the 166, 166 Jews, Jews of, of Near, Near Eastern, Eastern origins, origins ., . Relative, Relative to, to Jews, Jews of, of Polish, Polish and, and Russian, Russian origins, origins ,, , there, there was, was at, at least, least a, a twofold, twofold increase, increase in, in the, the TSD, TSD carrier, carrier frequency, frequency in, in Jews, Jews of, of Austrian, Austrian ,, , Hungarian, Hungarian ,, , and, and Czechoslovakian, Czechoslovakian origins, origins (, ( P, P less, less than, than ., . 005, 005 ), ) ., . These, These findings, findings suggest, suggest that, that the, the TSD, TSD gene, gene proliferated, proliferated among, among the, the antecedents, antecedents of, of modern, modern Ashkenazi, Ashkenazi Jewry, Jewry after, after the, the Second, Second Diaspora, Diaspora (, ( 70, 70 A., A. D., D. ), ) and, and before, before their, their major, major migrations, migrations to, to regions, regions of, of Poland, Poland and, and Russia, Russia (, ( before, before 1100, 1100 A., A. D., D. ), ) ., . Thirty-seven, Thirty-seven families, families with, with four, four or, or more, more cases, cases of, of breast, breast cancer, cancer or, or breast, breast and, and ovarian, ovarian cancer, cancer were, were analyzed, analyzed for, for mutations, mutations in, in BRCA1, BRCA1 ., . Twelve, Twelve different, different germ-line, germ-line mutations, mutations ,, , four, four novel, novel and, and eight, eight previously, previously observed, observed ,, , were, were detected, detected in, in 16, 16 families, families ., . Five, Five families, families of, of Ashkenazi, Ashkenazi Jewish, Jewish descent, descent carried, carried the, the 185delAG, 185delAG mutation, mutation and, and shared, shared the, the same, same haplotype, haplotype at, at eight, eight polymorphic, polymorphic markers, markers spanning, spanning approximately, approximately 850, 850 kb, kb at, at BRCA1, BRCA1 ., . Expressivity, Expressivity of, of 185delAG, 185delAG in, in these, these families, families varied, varied ,, , from, from early-onset, early-onset breast, breast cancer, cancer without, without ovarian, ovarian cancer"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", cancer ., . Mutation, Mutation 4184delTCAA, 4184delTCAA occurred, occurred independently, independently in, in two, two families, families ., . In, In one, one family, family ,, , penetrance, penetrance was, was complete, complete ,, , with, with females, females developing, developing early-onset, early-onset breast, breast cancer, cancer or, or ovarian, ovarian cancer, cancer and, and the, the male, male carrier, carrier developing, developing prostatic, prostatic cancer, cancer ,, , whereas, whereas ,, , in, in the, the other, other family, family ,, , penetrance, penetrance was, was incomplete, incomplete and, and only, only breast, breast cancer, cancer occurred, occurred ,, , diagnosed, diagnosed at, at ages, ages 38-81, 38-81 years, years ., . Two, Two novel, novel nonsense, nonsense mutations, mutations led, led to, to the, the loss, loss of, of mutant, mutant BRCA1, BRCA1 transcript, transcript in, in families, families with, with 10, 10 and, and 6, 6 cases, cases of, of early-onset, early-onset breast, breast cancer, cancer and, and ovarian, ovarian cancer, cancer ., . A, A 665-nt, 665-nt segment, segment of, of the, the BRCA1, BRCA1 3-UTR, 3-UTR and, and 1, 1 ., . 3, 3 kb, kb of, of genomic, genomic sequence, sequence including, including the, the putative, putative promoter, promoter region, region were, were invariant, invariant by, by single-strand, single-strand conformation, conformation analysis, analysis in, in 13, 13 families, families without, without coding-sequence, coding-sequence mutations, mutations ., . Overall, Overall in, in our, our series, series ,, , BRCA1, BRCA1 mutations, mutations have, have been, been detected, detected in, in 26, 26 families, families 16, 16 with, with positive, positive BRCA1, BRCA1 lod, lod scores, scores ,, , 7, 7 with, with negative, negative lod, lod scores, scores (, ( reflecting, reflecting multiple, multiple sporadic, sporadic breast, breast cancers, cancers ), ) ,, , and, and 3, 3 not, not tested, tested for, for linkage, linkage ., . Three, Three other, other families, families have, have positive, positive lod, lod scores, scores for, for linkage, linkage to, to BRCA2, BRCA2 ,, , but, but 13, 13 families, families without, without detected, detected BRCA1, BRCA1 mutations, mutations have, have negative, negative lod, lod scores, scores for, for both, both BRCA1, BRCA1 and, and BRCA2, BRCA2 ., . Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is caused, caused by, by a, a CTG, CTG repeat, repeat expansion, expansion in, in the, the 3UTR, 3UTR of, of the, the DM, DM protein, protein kinase, kinase (, ( DMPK, DMPK ), ) gene, gene ., . A, A very, very high, high level, level of, of instability, instability is, is observed, observed through, through successive, successive generations, generations and, and the, the size, size of, of the, the repeat, repeat is, is generally, generally correlated, correlated with, with the, the severity, severity of, of the, the disease, disease and, and with, with age, age at, at onset, onset ., . Furthermore, Furthermore ,, , tissues, tissues from, from DM, DM patients, patients exhibit, exhibit somatic, somatic mosaicism, mosaicism that, that increases, increases with, with age, age ., . We, We generated, generated transgenic, transgenic mice, mice carrying, carrying large, large human, human genomic, genomic sequences, sequences with, with 20, 20 ,, , 55, 55 or, or >, > 300, 300 CTG, CTG ,, , cloned, cloned from, from patients, patients from, from the, the same, same affected, affected DM, DM family, family ., . Using, Using large, large human, human flanking, flanking sequences, sequences and, and a, a large, large amplification, amplification ,, , we, we demonstrate, demonstrate that, that the, the intergenerational, intergenerational CTG, CTG repeat, repeat instability, instability is, is reproduced, reproduced in, in mice, mice ,, , with, with a, a strong, strong bias, bias towards, towards expansions, expansions and, and with, with the, the same, same sex-, sex- and, and size-dependent, size-dependent characteristics, characteristics as, as in, in humans, humans ., . Moreover, Moreover ,, , a, a high, high level, level of, of instability, instability ,, , increasing, increasing with, with age, age ,, , can, can be, be observed, observed in, in tissues, tissues and, and in, in sperm, sperm ., . Although, Although we, we did, did not, not observe, observe dramatic, dramatic expansions, expansions (, ( or, or big, big jumps, jumps over, over several, several hundred, hundred CTG, CTG repeats, repeats ), ) as, as in, in congenital, congenital forms, forms of, of DM, DM ,, , our, our model, model carrying, carrying >, > 300, 300 CTG, CTG is, is the, the first, first to, to show, show instability, instability so, so close, close to, to the, the human, human DM, DM situation, situation ., . Our, Our three, three models, models carrying, carrying different, different sizes, sizes of, of CTG, CTG repeat, repeat provide, provide insight, insight on, on the, the different, different factors, factors modulating, modulating the, the CTG, CTG repeat, repeat instability.., instability.. Close, Close linkage, linkage between, between HL-A, HL-A and, and C2, C2 deficiency, deficiency was, was first, first reported, reported by, by FU, FU and, and co-workers, co-workers in, in 1974, 1974 ., . We, We present, present here, here a, a pedigree, pedigree of, of a, a 31-year-old, 31-year-old C2-deficient, C2-deficient individual, individual with, with clinical, clinical manifestations, manifestations of, of Hodgkins, Hodgkins disease, disease ., . The, The following, following markers, markers were, were tested, tested C2, C2 levels, levels ,, , factor, factor B, B polymorphism, polymorphism ,, , blood, blood groups, groups ,, , and, and enzyme, enzyme typing, typing ., . In, In addition, addition to, to close, close linkage, linkage between, between HL-A, HL-A and, and C2, C2 deficiency, deficiency ,, , both, both parents, parents were, were heterozygous, heterozygous for, for Bf, Bf (, ( HL-A, HL-A linked, linked ,, , electrophoretic, electrophoretic variation, variation of, of B, B ), ) ., . The, The two, two HL-A, HL-A haplotypes, haplotypes closely, closely linked, linked to, to C2, C2 deficiency, deficiency are, are different, different 2, 2 ,, , W18, W18 and, and W24, W24 ,, , W18, W18 ., . They, They share, share ,, , however, however ,, , the, the SD2, SD2 antigen, antigen W18, W18 and, and the, the LD, LD type, type 7a.., 7a.. Age, Age of, of onset, onset (, ( AO, AO ), ) of, of Huntington, Huntington disease, disease (, ( HD, HD ), ) is, is known, known to, to be, be correlated, correlated with, with the, the length, length of, of an, an expanded, expanded CAG, CAG repeat, repeat in, in the, the HD, HD gene, gene ., . Apolipoprotein, Apolipoprotein E, E (, ( APOE, APOE ), ) genotype, genotype ,, , in, in turn, turn ,, , is, is known, known to, to influence, influence AO, AO in, in Alzheimer, Alzheimer disease, disease ,, , rendering, rendering the, the APOE, APOE gene, gene a, a likely, likely candidate, candidate to, to affect, affect AO, AO in, in other, other neurological, neurological diseases, diseases too, too ., . We, We therefore, therefore determined, determined APOE, APOE genotype, genotype and, and normal, normal CAG, CAG repeat, repeat length, length in, in the, the HD, HD gene, gene for, for 138, 138 HD, HD patients, patients who, who were, were previously, previously analysed, analysed with, with respect, respect to, to CAG, CAG repeat, repeat length, length ., . Genotyping, Genotyping for, for APOE, APOE was, was performed, performed blind, blind to, to clinical, clinical information, information ., . In, In addition, addition to, to highlighting, highlighting the, the effect, effect of, of the, the normal, normal repeat, repeat length, length upon, upon AO, AO in, in maternally, maternally inherited, inherited HD, HD and, and in, in male, male patients, patients ,, , we, we show, show that, that the, the APOE, APOE epsilon2epsilon3, epsilon2epsilon3 genotype, genotype is, is associated, associated with, with significantly, significantly earlier, earlier AO, AO in, in males, males than, than in, in females, females ., . Such, Such a, a sex, sex difference, difference in, in AO, AO was, was not, not apparent, apparent for, for any, any of, of the, the other, other APOE, APOE genotypes, genotypes ., . Our, Our findings, findings suggest, suggest that, that subtle, subtle differences, differences in, in the, the course, course of, of the, the neurodegeneration, neurodegeneration in, in HD, HD may, may allow, allow interacting, interacting genes, genes to, to exert, exert gender, gender specific, specific effects, effects upon, upon AO.A, AO.A genetic, genetic linkage, linkage map, map of, of six, six polymorphic, polymorphic DNA, DNA markers, markers close, close to, to the, the gene, gene (, ( APC, APC ), ) for, for familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) on, on chromosome, chromosome 5q, 5q is, is reported, reported ., . One, One hundred, hundred fifty-five, fifty-five typed, typed members, members of, of nine, nine FAP, FAP kindred, kindred provided, provided more, more than, than 90, 90 meioses, meioses for, for linkage, linkage analysis, analysis ., . A, A number, number of, of crucial, crucial recombination, recombination events, events have, have been, been identified, identified which, which are, are informative, informative at, at three, three or, or more, more loci, loci ,, , allowing, allowing confident, confident ordering, ordering of, of parts, parts of, of the, the map, map ., . There, There was, was no, no evidence, evidence of, of genetic, genetic heterogeneity, heterogeneity ,, , with, with all, all families, families showing, showing linkage, linkage of, of at, at least, least one, one chromosome, chromosome 5, 5 marker, marker to, to the, the gene, gene ., . Recombination, Recombination data, data and, and two-point, two-point linkage, linkage analysis, analysis support, support a, a locus, locus order, order of, of centromere-pi, centromere-pi 227-C11P11-ECB27-L5, 227-C11P11-ECB27-L5 ., . 62-APC-EF5, 62-APC-EF5 62-APC-EF5, 62-APC-EF5 ., . 44-YN5, 44-YN5 44-YN5, 44-YN5 ., . 48-telomer, 48-telomer e, e ,, , although, although EF5, EF5 ., . 44, 44 could, could lie, lie in, in the, the interval, interval L5, L5 ., . 62-APC, 62-APC or, or ECB27-L5, ECB27-L5 ., . 62, 62 ., . No, No recombinants, recombinants were, were identified, identified between, between APC, APC and, and either, either EF5, EF5 ., . 44, 44 or, or YN5, YN5 ., . 48, 48 ,, , but, but published, published deletion, deletion mapping, mapping in, in colorectal, colorectal carcinomas, carcinomas and, and linkage, linkage analysis, analysis in, in FAP, FAP suggest, suggest that, that YN5, YN5 ., . 48, 48 is, is 1-3, 1-3 cM, cM from, from APC, APC ., . The, The present, present study, study suggests, suggests that, that YN5, YN5 ., . 48, 48 and, and L5, L5 ., . 62, 62 delineate, delineate a, a small, small region, region of, of chromosome, chromosome 5, 5 within, within which, which the, the EF5, EF5 ., . 44, 44 locus, locus lies, lies very, very close, close to, to the, the APC, APC gene, gene ., . These, These data, data not, not only, only allow, allow use, use of, of flanking, flanking markers, markers for, for presymptomatic, presymptomatic diagnosis, diagnosis of, of FAP, FAP but, but also, also provide, provide a, a high-density, high-density map, map of, of the, the region, region for, for isolation, isolation of, of the, the APC, APC gene, gene itself, itself and, and for, for further, further assessment, assessment of, of the, the role, role of, of chromosome, chromosome 5, 5 deletions, deletions in, in the, the biology, biology of, of sporadic, sporadic colorectal, colorectal cancer.Autosomal, cancer.Autosomal dominant, dominant neurohypophyseal, neurohypophyseal diabetes, diabetes insipidus, insipidus is, is a, a familial, familial form, form of, of diabetes, diabetes insipidus, insipidus ., . This, This disorder, disorder is, is associated, associated with, with variable, variable levels, levels of, of arginine, arginine vasopressin, vasopressin (, ( AVP, AVP ), ) and, and diabetes, diabetes insipidus, insipidus of, of varying, varying severity, severity ,, , which, which responds, responds to, to exogenous, exogenous AVP, AVP ., . To, To determine, determine the, the molecular, molecular basis, basis of, of autosomal, autosomal dominant, dominant neurohypophyseal, neurohypophyseal diabetes, diabetes insipidus, insipidus ,, , the, the AVP, AVP genes, genes of, of members, members of, of a, a large, large kindred, kindred were, were analyzed, analyzed ., . A, A new, new method, method ,, , called, called dideoxy, dideoxy fingerprinting, fingerprinting ,, , was, was used, used to, to detect, detect an, an AVP, AVP mutation, mutation that, that was, was characterized, characterized by, by DNA, DNA sequencing, sequencing ., . The, The novel, novel defect, defect found, found changes, changes the, the last, last codon, codon of, of the, the AVP, AVP signal, signal peptide, peptide from, from alanine, alanine to, to threonine, threonine ,, , which, which should, should perturb, perturb cleavage, cleavage of, of mature, mature AVP, AVP from, from its, its precursor, precursor protein, protein and, and inhibit, inhibit its, its secretion, secretion or, or action.., action.. Mutations, Mutations of, of APC, APC appear, appear to, to initiate, initiate sporadic, sporadic and, and inherited, inherited forms, forms of, of human, human colorectal, colorectal cancer, cancer ., . Although, Although these, these mutations, mutations have, have been, been well, well characterized, characterized ,, , little, little is, is known, known about, about the, the function, function of, of the, the APC, APC gene, gene product, product ., . Two, Two cellular, cellular proteins, proteins that, that associate, associate with, with APC, APC were, were identified, identified by, by nucleotide, nucleotide sequence, sequence analysis, analysis and, and peptide, peptide mapping, mapping as, as the, the E-cadherin-associated, E-cadherin-associated proteins, proteins alpha-, alpha- and, and beta-catenin, beta-catenin ., . A, A 27-residue, 27-residue fragment, fragment of, of APC, APC containing, containing a, a 15-amino, 15-amino acid, acid repeat, repeat was, was sufficient, sufficient for, for the, the interaction, interaction with, with the, the catenins, catenins ., . These, These results, results suggest, suggest an, an important, important link, link between, between tumor, tumor initiation, initiation and, and cell, cell adhesion.., adhesion.. We, We have, have studied, studied genetic, genetic linkage, linkage between, between the, the gene, gene for, for creatine, creatine kinase, kinase muscle, muscle type, type (, ( CKMM, CKMM ), ) and, and the, the gene, gene for, for myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) ., . In, In a, a panel, panel of, of 65, 65 myotonic, myotonic dystrophy, dystrophy families, families from, from Canada, Canada and, and the, the Netherlands, Netherlands ,, , a, a maximum, maximum lod, lod score, score (, ( Zmax, Zmax ), ) of, of 22, 22 ., . 8, 8 at, at a, a recombination, recombination frequency, frequency (, ( theta, theta ), ) of, of 0, 0 ., . 03, 03 was, was obtained, obtained ., . Tight, Tight linkage, linkage was, was also, also demonstrated, demonstrated for, for CKMM, CKMM and, and the, the gene, gene for, for apolipoprotein, apolipoprotein C2, C2 (, ( ApoC2, ApoC2 ), ) ., . This, This establishes, establishes CKMM, CKMM as, as a, a useful, useful marker, marker for, for myotonic, myotonic dystrophy, dystrophy A, A myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) family, family is, is described, described in, in which, which discordant, discordant DM, DM phenotypes, phenotypes were, were found, found in, in the, the children, children of, of two, two affected, affected sisters, sisters with, with similar, similar CTG, CTG expansion, expansion and, and clinical, clinical manifestations, manifestations ., . In, In this, this family, family ,, , congenital, congenital as, as well, well as, as early, early severe, severe childhood, childhood and, and later, later childhood, childhood onset, onset DM, DM coexist, coexist ., . This, This observation, observation strengthens, strengthens the, the limited, limited ability, ability of, of lymphocytes, lymphocytes CTG, CTG repeat, repeat number, number analysis, analysis in, in predicting, predicting genotype-phenotype, genotype-phenotype correlations, correlations in, in DM, DM patients.., patients.. von, von Hippel-Lindau, Hippel-Lindau (, ( VHL, VHL ), ) disease, disease is, is an, an autosomal, autosomal dominantly, dominantly inherited, inherited cancer, cancer syndrome, syndrome predisposing, predisposing to, to a, a variety, variety of, of tumor, tumor types, types that, that include, include retinal, retinal hemangioblastomas, hemangioblastomas ,, , hemangioblastomas, hemangioblastomas of, of the, the central, central nervous, nervous system, system ,, , renal, renal cell, cell carcinomas, carcinomas ,, , pancreatic, pancreatic cysts, cysts and, and tumors, tumors ,, , pheochromocytomas, pheochromocytomas ,, , endolymphatic, endolymphatic sac, sac tumors, tumors ,, , and, and epididymal, epididymal cystadenomas, cystadenomas [, [ W., W. M., M. Linehan, Linehan et, et al., al. ,, , J, J ., . Am, Am ., . Med, Med ., . Assoc., Assoc. ,, , 273, 273 564-570, 564-570 ,, , 1995, 1995 ;, ; E., E. A., A. Maher, Maher and, and W., W. G., G. Kaelin, Kaelin ,, , Jr., Jr. ,, , Medicine, Medicine (, ( Baltimore, Baltimore ), ) ,, , 76, 76 381-391, 381-391 ,, , 1997, 1997 ;, ; W., W. M., M. Linehan, Linehan and, and R., R. D., D. Klausner, Klausner ,, , In, In B., B. Vogelstein, Vogelstein and, and K., K. Kinzler, Kinzler (, ( eds, eds ., . ), ) ,, , The, The Genetic, Genetic Basis, Basis of, of Human, Human Cancer, Cancer ,, , pp, pp ., . 455-473, 455-473 ,, , McGraw-Hill, McGraw-Hill ,, , 1998, 1998 ], ] ., . The, The VHL, VHL gene, gene was, was localized, localized to, to chromosome, chromosome 3p25-26, 3p25-26 and, and cloned, cloned [, [ F., F. Latif, Latif et, et al., al. ,, , Science, Science (, ( Washington, Washington DC, DC ), ) ,, , 260, 260 1317-1320, 1317-1320 ,, , 1993, 1993 ], ] ., . Germline, Germline mutations, mutations in, in the, the VHL, VHL gene, gene have, have been, been detected, detected in, in the, the majority, majority of, of VHL, VHL kindreds, kindreds ., . The, The reported, reported frequency, frequency of, of detection, detection of, of VHL, VHL germline, germline mutations, mutations has, has varied, varied from, from 39, 39 to, to 80, 80 %, % (, ( J., J. M., M. Whaley, Whaley et, et al., al. ,, , Am, Am ., . J., J. Hum, Hum ., . Genet., Genet. ,, , 55, 55 1092-1102, 1092-1102 ,, , 1994, 1994 ;, ; Clinical, Clinical Research, Research Group, Group for, for Japan, Japan ,, , Hum, Hum ., . Mol, Mol ., . Genet., Genet. ,, , 4, 4 2233-2237, 2233-2237 ,, , 1995, 1995 ;, ; F., F. Chen, Chen et, et al., al. ,, , Hum, Hum ., . Mutat., Mutat. ,, , 5, 5 66-75, 66-75 ,, , 1995, 1995 ;, ; E., E. R., R. Maher, Maher et, et al., al. ,, , J., J. Med, Med ., . Genet., Genet. ,, , 33, 33 328-332, 328-332 ,, , 1996, 1996 ;, ; B., B. Zbar, Zbar ,, , Cancer, Cancer Surv., Surv. ,, , 25, 25 219-232, 219-232 ,, , 1995, 1995 ), ) ., . Recently, Recently a, a quantitative, quantitative Southern, Southern blotting, blotting procedure, procedure was, was found, found to, to improve, improve this, this frequency, frequency (, ( C., C. Stolle, Stolle et, et al., al. ,, , Hum, Hum ., . Mutat., Mutat. ,, , 12, 12 417-423, 417-423 ,, , 1998, 1998 ), ) ., . In, In the, the present, present study, study ,, , we, we report, report the, the use, use of, of fluorescence, fluorescence in, in situ, situ hybridization, hybridization (, ( FISH, FISH ), ) as, as a, a method, method to, to detect, detect and, and characterize, characterize VHL, VHL germline, germline deletions, deletions ., . We, We reexamined, reexamined a, a group, group of, of VHL, VHL patients, patients shown, shown previously, previously by, by single-strand, single-strand conformation, conformation and, and sequencing, sequencing analysis, analysis not, not to, to harbor, harbor point, point mutations, mutations in, in the, the VHL, VHL locus, locus ., . We, We found, found constitutional, constitutional deletions, deletions in, in 29, 29 of, of 30, 30 VHL, VHL patients, patients in, in this, this group, group using, using cosmid, cosmid and, and P1, P1 probes, probes that, that cover, cover the, the VHL, VHL locus, locus ., . We, We then, then tested, tested six, six phenotypically, phenotypically normal, normal offspring, offspring from, from four, four of, of these, these VHL, VHL families, families two, two were, were found, found to, to carry, carry the, the deletion, deletion and, and the, the other, other four, four were, were deletion-free, deletion-free ., . In, In addition, addition ,, , germline, germline mosaicism, mosaicism of, of the, the VHL, VHL gene, gene was, was identified, identified in, in one, one family, family ., . In, In sum, sum ,, , FISH, FISH was, was found, found to, to be, be a, a simple, simple and, and reliable, reliable method, method to, to detect, detect VHL, VHL germline, germline deletions, deletions and, and practically, practically useful, useful in, in cases, cases where, where other, other methods, methods of, of screening, screening have, have failed, failed to, to detect, detect a, a VHL, VHL gene, gene abnormality, abnormality The, The BRCA1, BRCA1 gene, gene product, product was, was identified, identified as, as a, a 220-kilodalton, 220-kilodalton nuclear, nuclear phosphoprotein, phosphoprotein in, in normal, normal cells, cells ,, , including, including breast, breast ductal, ductal epithelial, epithelial cells, cells ,, , and, and in, in 18, 18 of, of 20, 20 tumor, tumor cell, cell lines, lines derived, derived from, from tissues, tissues other, other than, than breast, breast and, and ovary, ovary ., . In, In 16, 16 of, of 17, 17 breast, breast and, and ovarian, ovarian cancer, cancer lines, lines and, and 17, 17 of, of 17, 17 samples, samples of, of cells, cells obtained, obtained from, from malignant, malignant effusions, effusions ,, , however, however ,, , BRCA1, BRCA1 localized, localized mainly, mainly in, in cytoplasm, cytoplasm ., . Absence, Absence of, of BRCA1, BRCA1 or, or aberrant, aberrant subcellular, subcellular location, location was, was also, also observed, observed to, to a, a variable, variable extent, extent in, in histological, histological sections, sections of, of many, many breast, breast cancer, cancer biopsies, biopsies ., . These, These findings, findings suggest, suggest that, that BRCA1, BRCA1 abnormalities, abnormalities may, may be, be involved, involved in, in the, the pathogenesis, pathogenesis of, of many, many breast, breast cancers, cancers ,, , sporadic, sporadic as, as well, well as, as familial.., familial.. One, One hundred, hundred and, and twenty-eight, twenty-eight of, of 145, 145 patients, patients with, with ankylosing, ankylosing spondylitis, spondylitis (, ( AS, AS ), ) were, were found, found to, to be, be HLA, HLA B27, B27 positive, positive ., . Five, Five patients, patients had, had evidence, evidence of, of a, a sero-negative, sero-negative peripheral, peripheral arthritis, arthritis resembling, resembling peripheral, peripheral psoriatic, psoriatic arthritis, arthritis and, and 3, 3 of, of these, these were, were B27, B27 negative, negative ., . One, One further, further B27, B27 negative, negative patients, patients had, had a, a sister, sister with, with ankylosing, ankylosing spondylitis, spondylitis and, and ulcerative, ulcerative colitis, colitis and, and a, a mother, mother with, with ulcerative, ulcerative colitis, colitis ., . There, There was, was evidence, evidence of, of a, a somewhat, somewhat later, later age, age of, of onset, onset of, of symptoms, symptoms in, in B27, B27 negative, negative patients, patients ., . These, These findings, findings are, are interpreted, interpreted as, as suggesting, suggesting some, some degree, degree of, of clinical, clinical and, and genetic, genetic heterogeneity, heterogeneity in, in ankylosing, ankylosing spondylitis, spondylitis with, with genes, genes for, for psoriasis, psoriasis and, and inflammatory, inflammatory bowel, bowel disease, disease being, being important, important in, in some, some individuals, individuals ,, , particularly, particularly those, those who, who are, are B27, B27 negative, negative ., . Twenty-five, Twenty-five first-degree, first-degree relatives, relatives with, with ankylosing, ankylosing spondylitis, spondylitis were, were all, all B27, B27 positive, positive ., . The, The only, only instance, instance of, of disassociation, disassociation of, of B27, B27 and, and spondylitis, spondylitis in, in a, a family, family was, was where, where the, the proband, proband had, had ulcerative, ulcerative colitis, colitis as, as well, well as, as spondylitis, spondylitis ., . Of, Of 13, 13 B27, B27 positive, positive fathers, fathers 3, 3 could, could be, be diagnosed, diagnosed as, as having, having definite, definite ankylosing, ankylosing spondylitis, spondylitis (, ( 23, 23 %, % ), ) ., . These, These findings, findings are, are thought, thought to, to provide, provide evidence, evidence against, against the, the concept, concept that, that the, the gene, gene for, for ankylosing, ankylosing spondylitis, spondylitis is, is not, not B27, B27 but, but a, a closely, closely linked, linked gene, gene and, and favour, favour the, the occurrence, occurrence of, of an, an environmental, environmental event, event affecting, affecting approximately, approximately one-fifth, one-fifth of, of B27, B27 positive, positive males, males to, to result, result in, in disease.., disease.. Metachromatic, Metachromatic Leukodystrophy, Leukodystrophy (, ( MLD, MLD ), ) is, is a, a neurodegenerative, neurodegenerative disease, disease in, in which, which the, the lysosomal, lysosomal enzyme, enzyme ,, , Aryl, Aryl sulfatase, sulfatase A, A (, ( ARSA, ARSA ), ) is, is deficient, deficient ., . The, The disease, disease is, is inherited, inherited as, as an, an autosomal, autosomal recessive, recessive trait, trait and, and its, its frequency, frequency is, is estimated, estimated to, to be, be 1/40, 1/40 ,, , 000, 000 live, live births, births ., . The, The gene, gene of, of ARSA, ARSA has, has been, been cloned, cloned and, and up, up to, to now, now eight, eight mutations, mutations causing, causing MLD, MLD have, have been, been reported, reported ., . Another, Another mutation, mutation ,, , PD, PD ,, , leads, leads to, to the, the deficiency, deficiency of, of the, the enzyme, enzyme in, in vitro, vitro (, ( pseudodeficiency, pseudodeficiency ), ) without, without any, any known, known clinical, clinical effect, effect ., . The, The PD, PD mutation, mutation is, is frequent, frequent in, in all, all populations, populations ., . In, In Israel, Israel ,, , late, late infantile, infantile MLD, MLD was, was found, found to, to be, be very, very frequent, frequent in, in a, a small, small Jewish, Jewish isolate, isolate ,, , the, the Habbanite, Habbanite Jews, Jews (, ( 1/75, 1/75 live, live births, births ), ) ., . The, The molecular, molecular analysis, analysis demonstrated, demonstrated that, that in, in the, the Habbanite, Habbanite population, population ,, , the, the mutation, mutation occurred, occurred on, on an, an allele, allele with, with the, the PD, PD mutation, mutation ., . The, The loss, loss of, of ARSA, ARSA activity, activity is, is due, due to, to a, a point, point mutation, mutation C, C >, > T, T leading, leading to, to a, a change, change of, of proline, proline to, to leucine, leucine ., . MLD, MLD is, is also, also frequent, frequent among, among Moslem, Moslem Arabs, Arabs in, in Jerusalem, Jerusalem ., . The, The mutation, mutation is, is a, a transition, transition G, G >, > A, A destroying, destroying the, the splice, splice donor, donor site, site of, of exon, exon 2, 2 ., . This, This mutation, mutation has, has been, been reported, reported in, in patients, patients with, with the, the late, late infantile, infantile MLD, MLD from, from different, different ethnic, ethnic groups, groups ., . The, The Christian, Christian Arabs, Arabs in, in Israel, Israel also, also have, have a, a high, high incidence, incidence of, of the, the disease, disease (, ( 1/10, 1/10 ,, , 000, 000 live, live births, births ), ) ;, ; the, the mutation, mutation in, in this, this population, population is, is still, still unknown, unknown ., . Knowledge, Knowledge of, of the, the different, different mutations, mutations causing, causing MLD, MLD in, in these, these defined, defined populations, populations will, will allow, allow a, a carrier, carrier screening, screening program, program to, to be, be carried, carried out, out and, and prevent, prevent the, the birth"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", birth of, of additional, additional affected, affected children.., children.. Germline, Germline mutations, mutations of, of the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) tumor-suppressor, tumor-suppressor gene, gene result, result in, in the, the hereditary, hereditary colorectal, colorectal cancer, cancer syndrome, syndrome familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) ., . Almost, Almost all, all APC, APC mutations, mutations that, that have, have been, been identified, identified are, are single-nucleotide, single-nucleotide alterations, alterations ,, , small, small insertions, insertions ,, , or, or small, small deletions, deletions that, that would, would truncate, truncate the, the protein, protein product, product of, of the, the gene, gene ., . No, No well-characterized, well-characterized intragenic, intragenic rearrangement, rearrangement of, of APC, APC has, has been, been described, described ,, , and, and the, the prevalence, prevalence of, of this, this type, type of, of mutation, mutation in, in FAP, FAP patients, patients is, is not, not clear, clear ., . We, We screened, screened 49, 49 potential, potential FAP, FAP families, families and, and identified, identified 26, 26 different, different germline, germline APC, APC mutations, mutations in, in 30, 30 families, families ., . Four, Four of, of these, these mutations, mutations were, were genomic, genomic rearrangements, rearrangements resulting, resulting from, from homologous, homologous and, and nonhomologous, nonhomologous recombinations, recombinations mediated, mediated by, by Alu, Alu elements, elements ., . Two, Two of, of these, these four, four rearrangements, rearrangements were, were complex, complex ,, , involving, involving deletion, deletion and, and insertion, insertion of, of nucleotides, nucleotides ., . Of, Of these, these four, four rearrangements, rearrangements ,, , one, one resulted, resulted in, in the, the deletion, deletion of, of exons, exons 11, 11 and, and 12, 12 and, and two, two others, others resulted, resulted in, in either, either complete, complete or, or partial, partial deletion, deletion of, of exon, exon 14, 14 ., . The, The fourth, fourth rearrangement, rearrangement grossly, grossly altered, altered the, the sequence, sequence within, within intron, intron 14, 14 ., . Although, Although this, this rearrangement, rearrangement did, did not, not affect, affect any, any coding, coding sequence, sequence of, of APC, APC at, at the, the genomic, genomic DNA, DNA level, level ,, , it, it caused, caused inappropriate, inappropriate splicing, splicing of, of exon, exon 14, 14 ., . These, These rearrangements, rearrangements were, were initially, initially revealed, revealed by, by analyzing, analyzing cDNAs, cDNAs and, and could, could not, not have, have been, been identified, identified by, by using, using mutation, mutation detection, detection methods, methods that, that screened, screened each, each exon, exon individually, individually ., . The, The identification, identification of, of a, a rearrangement, rearrangement that, that did, did not, not alter, alter any, any coding, coding exons, exons yet, yet affected, affected the, the splicing, splicing further, further underscores, underscores the, the importance, importance of, of using, using cDNA, cDNA for, for mutation, mutation analysis, analysis ., . The, The identification, identification of, of four, four genomic, genomic rearrangements, rearrangements among, among 30, 30 mutations, mutations suggests, suggests that, that genomic, genomic rearrangements, rearrangements are, are frequent, frequent germline, germline APC, APC mutations.., mutations.. Breast, Breast cancer, cancer in, in men, men is, is about, about a, a hundredfold, hundredfold less, less common, common than, than in, in women, women and, and this, this has, has hindered, hindered research, research into, into its, its genetic, genetic basis, basis ., . We, We have, have examined, examined 22, 22 families, families with, with at, at least, least one, one case, case of, of male, male breast, breast cancer, cancer for, for linkage, linkage to, to the, the hereditary, hereditary breast, breast and, and ovarian, ovarian cancer, cancer locus, locus ,, , BRCA1, BRCA1 ,, , on, on chromosome, chromosome 17q, 17q ., . We, We found, found strong, strong evidence, evidence against, against linkage, linkage to, to BRCA1, BRCA1 (, ( lod, lod score-16, score-16 ., . 63, 63 ), ) and, and the, the best, best estimate, estimate of, of the, the proportion, proportion of, of linked, linked families, families was, was 0, 0 %, % (, ( 95, 95 %, % CI, CI 0-18, 0-18 %, % ), ) ., . Our, Our results, results indicate, indicate that, that there, there is, is a, a gene, gene (, ( s, s ), ) other, other than, than BRCA1, BRCA1 which, which predisposes, predisposes to, to early-onset, early-onset breast, breast cancer, cancer in, in women, women and, and which, which confers, confers a, a higher, higher risk, risk of, of male, male breast, breast cancer, cancer ., . Identification, Identification of, of additional, additional pedigrees, pedigrees that, that include, include cases, cases of, of male, male breast, breast cancer, cancer may, may therefore, therefore facilitate, facilitate the, the mapping, mapping and, and isolation, isolation of, of this, this gene, gene ., . The, The size, size of, of the, the (, ( CAG, CAG ), ) n, n repeat, repeat array, array in, in the, the 3, 3 ', ' end, end of, of the, the MJD1, MJD1 gene, gene and, and the, the haplotype, haplotype at, at a, a series, series of, of microsatellite, microsatellite markers, markers surrounding, surrounding the, the MJD1, MJD1 gene, gene were, were examined, examined in, in a, a large, large cohort, cohort of, of Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects affected, affected with, with Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) ., . Our, Our data, data provide, provide five, five novel, novel observations, observations ., . First, First ,, , MJD, MJD is, is associated, associated with, with expansion, expansion fo, fo the, the array, array from, from the, the normal, normal range, range of, of 14-37, 14-37 repeats, repeats to, to 68-84, 68-84 repeats, repeats in, in most, most Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects ,, , but, but no, no subjects, subjects were, were observed, observed with, with expansions, expansions intermediate, intermediate in, in size, size between, between those, those of, of the, the normal, normal and, and MJD, MJD affected, affected groups, groups ., . Second, Second ,, , the, the expanded, expanded allele, allele associated, associated with, with MJD, MJD displays, displays inter-generational, inter-generational instability, instability ,, , particularly, particularly in, in male, male meioses, meioses ,, , and, and this, this instability, instability was, was associated, associated with, with the, the clinical, clinical phenomenon, phenomenon of, of anticipation, anticipation ., . Third, Third ,, , the, the size, size of, of the, the expanded, expanded allele, allele is, is not, not only, only inversely, inversely correlated, correlated with, with the, the age-of-onset, age-of-onset of, of MJD, MJD (, ( r, r =, = -0.738, -0.738 ,, , p, p <, < 0.001, 0.001 ), ) ,, , but, but is, is also, also correlated, correlated with, with the, the frequency, frequency of, of other, other clinical, clinical features, features [, [ e.g, e.g ., . pseudoexophthalmos, pseudoexophthalmos and, and pyramidal, pyramidal signs, signs were, were more, more frequent, frequent in, in subjects, subjects with, with large, large repeats, repeats (, ( p, p <, < 0.001, 0.001 and, and p, p <, < 0.05, 0.05 respectively, respectively ), ) ], ] ., . Fourth, Fourth ,, , the, the disease, disease phenotype, phenotype is, is significantly, significantly more, more severe, severe and, and had, had an, an early, early age, age of, of onset, onset (, ( 16, 16 years, years ), ) in, in a, a subject, subject homozygous, homozygous for, for the, the expanded, expanded allele, allele ,, , which, which contrasts, contrasts with, with Huntington, Huntington disease, disease and, and suggests, suggests that, that the, the expanded, expanded allele, allele in, in the, the MJD1, MJD1 gene, gene could, could exert, exert its, its effect, effect either, either by, by a, a dominant, dominant negative, negative effect, effect (, ( putatively, putatively excluded, excluded in, in HD, HD ), ) or, or by, by a, a gain, gain of, of function, function effect, effect as, as proposed, proposed for, for HD, HD ., . Finally, Finally ,, , Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects affected, affected with, with MJD, MJD share, share haplotypes, haplotypes at, at several, several markers, markers surrounding, surrounding the, the MJD1, MJD1 gene, gene ,, , which, which are, are uncommon, uncommon in, in the, the normal, normal Japanese, Japanese and, and Caucasian, Caucasian population, population ,, , and, and which, which suggests, suggests the, the existence, existence either, either of, of common, common founders, founders in, in these, these populations, populations or, or of, of chromosomes, chromosomes susceptible, susceptible to, to pathologic, pathologic expansion, expansion of, of the, the CAG, CAG repeat, repeat in, in the, the MJD1, MJD1 gene.We, gene.We report, report on, on 4, 4 sibs, sibs (, ( 2F, 2F ,, , 2M, 2M ), ) with, with Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . Diagnosis, Diagnosis was, was made, made clinically, clinically on, on the, the basis, basis of, of history, history ,, , behavior, behavior ,, , and, and physical, physical findings, findings in, in 3, 3 of, of the, the sibs, sibs ., . The, The other, other child, child had, had died, died at, at age, age 10, 10 months, months with, with a, a history, history and, and clinical, clinical findings, findings typical, typical of, of first, first phase, phase of, of PWS, PWS ., . Results, Results of, of chromosome, chromosome studies, studies on, on the, the parents, parents and, and surviving, surviving sibs, sibs were, were normal, normal ., . The, The implications, implications of, of this, this unusual, unusual familial, familial occurrence, occurrence for, for our, our understanding, understanding of, of PWS, PWS are, are discussed.., discussed.. We, We searched, searched for, for criteria, criteria that, that could, could indicate, indicate breast, breast cancer, cancer families, families with, with a, a high, high prior, prior probability, probability of, of being, being caused, caused by, by the, the breast/ovarian, breast/ovarian cancer, cancer susceptibility, susceptibility locus, locus BRCA1, BRCA1 on, on chromosome, chromosome 17, 17 ., . To, To this, this end, end ,, , we, we performed, performed a, a linkage, linkage study, study with, with 59, 59 consecutively, consecutively collected, collected Dutch, Dutch breast, breast cancer, cancer families, families ,, , including, including 16, 16 with, with at, at least, least one, one case, case of, of ovarian, ovarian cancer, cancer ., . We, We used, used an, an intake, intake cut-off, cut-off of, of at, at least, least three, three first-degree, first-degree relatives, relatives with, with breast, breast and/or, and/or ovarian, ovarian cancer, cancer at, at any, any age, age ., . Significant, Significant evidence, evidence for, for linkage, linkage was, was found, found only, only among, among the, the 13, 13 breast, breast cancer, cancer families, families with, with a, a mean, mean age, age at, at diagnosis, diagnosis of, of less, less than, than 45, 45 years, years ., . An, An unexpectedly, unexpectedly low, low proportion, proportion of, of the, the breast-ovarian, breast-ovarian cancer, cancer families, families were, were estimated, estimated to, to be, be linked, linked to, to BRCA1, BRCA1 ,, , which, which could, could be, be due, due to, to a, a founder, founder effect, effect in, in the, the Dutch, Dutch population, population ., . Given, Given the, the expected, expected logistical, logistical problems, problems in, in clinical, clinical management, management now, now that, that BRCA1, BRCA1 has, has been, been identified, identified ,, , we, we propose, propose an, an interim, interim period, period in, in which, which only, only families, families with, with a, a strong, strong positive, positive family, family history, history for, for early, early onset, onset breast, breast and/or, and/or ovarian, ovarian cancer, cancer will, will be, be offered, offered BRCA1, BRCA1 mutation, mutation testing.., testing.. Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency appears, appears to, to be, be fairly, fairly common, common in, in Mexico, Mexico ., . We, We have, have now, now examined, examined the, the DNA, DNA of, of three, three previously, previously reported, reported electrophoretically, electrophoretically fast, fast Mexican, Mexican G6PD, G6PD variants, variants ,, , -G6PD, -G6PD Distrito, Distrito Federal, Federal ,, , G6PD, G6PD Tepic, Tepic ,, , and, and G6PD, G6PD Castilla, Castilla ., . All, All three, three of, of these, these variants, variants ,, , believed, believed on, on the, the basis, basis of, of biochemical, biochemical characterization, characterization and, and population, population origin, origin to, to be, be unique, unique ,, , have, have the, the G, G --, -- --, -- A, A transition, transition at, at nucleotide, nucleotide 202, 202 and, and the, the A, A --, -- --, -- G, G transition, transition at, at nucleotide, nucleotide 376, 376 ,, , mutations, mutations that, that we, we now, now recognize, recognize to, to be, be characteristic, characteristic of, of G6PD, G6PD A-, A- ., . Two, Two other, other Mexican, Mexican males, males with, with G6PD, G6PD deficiency, deficiency were, were found, found to, to have, have the, the same, same mutation, mutation ., . All, All five, five have, have the, the (, ( NlaIII/FokI/PvuII/PstI, NlaIII/FokI/PvuII/PstI ), ) haplotype, haplotype characteristic, characteristic of, of G6PD, G6PD A, A -in, -in Africa, Africa ., . Since, Since the, the PvuII, PvuII +, + genotype, genotype seems, seems to, to be, be rare, rare in, in Europe, Europe ,, , we, we conclude, conclude that, that all, all of, of these, these G6PD, G6PD A, A -, - genes, genes had, had their, their ancient, ancient origin, origin in, in Africa, Africa ,, , although, although in, in many, many of, of the, the Mexican, Mexican patients, patients with, with G6PD, G6PD A, A -202A/376G, -202A/376G the, the gene, gene may, may have, have been, been imported, imported more, more recently, recently from, from Spain, Spain ,, , where, where this, this variant, variant ,, , formerly, formerly known, known as, as G6PD, G6PD Betica, Betica ,, , is, is also, also prevalent.., prevalent.. Germline, Germline mutations, mutations of, of the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) tumor-suppressor, tumor-suppressor gene, gene result, result in, in familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) ., . Patients, Patients with, with FAP, FAP typically, typically develop, develop hundreds, hundreds to, to thousands, thousands of, of benign, benign colorectal, colorectal tumors, tumors and, and early-onset, early-onset colorectal, colorectal cancer, cancer ., . A, A subset, subset of, of germline, germline APC, APC mutations, mutations results, results in, in an, an attenuated, attenuated FAP, FAP (, ( AFAP, AFAP ), ) phenotype, phenotype ,, , in, in which, which patients, patients develop, develop fewer, fewer tumors, tumors and, and develop, develop them, them at, at an, an older, older age, age ., . Although, Although a, a genotype-phenotype, genotype-phenotype correlation, correlation between, between the, the locations, locations of, of APC, APC germline, germline mutations, mutations and, and the, the development, development of, of AFAP, AFAP has, has been, been well, well documented, documented ,, , the, the mechanism, mechanism for, for AFAP, AFAP has, has not, not been, been well, well defined, defined ., . We, We investigated, investigated the, the mechanism, mechanism for, for AFAP, AFAP in, in patients, patients carrying, carrying a, a mutant, mutant APC, APC allele, allele (, ( APC, APC (, ( AS9, AS9 ), ) ), ) that, that has, has a, a mutation, mutation in, in the, the alternatively, alternatively spliced, spliced region, region of, of exon, exon 9, 9 ., . APC, APC (, ( AS9, AS9 ), ) was, was found, found to, to down-regulate, down-regulate beta-catenin-regulated, beta-catenin-regulated transcription, transcription ,, , the, the major, major tumor-suppressor, tumor-suppressor function, function of, of APC, APC ,, , as, as did, did the, the wild-type, wild-type APC, APC ., . Mutation, Mutation analysis, analysis showed, showed that, that both, both APC, APC (, ( AS9, AS9 ), ) and, and the, the wild-type, wild-type APC, APC alleles, alleles were, were somatically, somatically mutated, mutated in, in most, most colorectal, colorectal tumors, tumors from, from these, these patients, patients ., . Functional, Functional analysis, analysis showed, showed that, that 4666insA, 4666insA ,, , a, a common, common somatic, somatic mutation, mutation in, in APC, APC (, ( AS9, AS9 ), ) in, in these, these tumors, tumors ,, , did, did not, not inactivate, inactivate the, the wild-type, wild-type APC, APC ., . Our, Our results, results indicate, indicate that, that carriers, carriers of, of APC, APC (, ( AS9, AS9 ), ) develop, develop fewer, fewer colorectal, colorectal tumors, tumors than, than do, do typical, typical patients, patients with, with FAP, FAP because, because somatic, somatic inactivation, inactivation of, of both, both APC, APC alleles, alleles is, is necessary, necessary for, for colorectal, colorectal tumorigenesis, tumorigenesis ., . However, However ,, , these, these patients, patients develop, develop colorectal, colorectal tumors, tumors more, more frequently, frequently than, than does, does the, the general, general population, population because, because APC, APC (, ( AS9, AS9 ), ) is, is inactivated, inactivated by, by mutations, mutations that, that do, do not, not inactivate, inactivate the, the wild-type, wild-type APC.., APC.. Fluorescence, Fluorescence in, in situ, situ hybridization, hybridization (, ( FISH, FISH ), ) with, with biotin-labeled, biotin-labeled probes, probes mapping, mapping to, to 11p13, 11p13 has, has been, been used, used for, for the, the molecular, molecular analysis, analysis of, of deletions, deletions of, of the, the WAGR, WAGR (, ( Wilms, Wilms tumor, tumor ,, , aniridia, aniridia ,, , genitourinary, genitourinary abnormalities, abnormalities ,, , and, and mental, mental retardation, retardation ), ) locus, locus ., . We, We have, have detected, detected a, a submicroscopic, submicroscopic 11p13, 11p13 deletion, deletion in, in a, a child, child with, with inherited, inherited aniridia, aniridia who, who subsequently, subsequently presented, presented with, with Wilms, Wilms tumor, tumor in, in a, a horseshoe, horseshoe kidney, kidney ,, , only, only revealed, revealed at, at surgery, surgery ., . The, The mother, mother ,, , who, who has, has aniridia, aniridia ,, , was, was also, also found, found to, to carry, carry a, a deletion, deletion including, including both, both the, the aniridia, aniridia candidate, candidate gene, gene (, ( AN2, AN2 ), ) and, and the, the Wilms, Wilms tumor, tumor predisposition, predisposition gene, gene (, ( WT1, WT1 ), ) ., . This, This is, is therefore, therefore a, a rare, rare case, case of, of an, an inherited, inherited WAGR, WAGR deletion, deletion ., . Wilms, Wilms tumor, tumor has, has so, so far, far only, only been, been associated, associated with, with sporadic, sporadic de, de novo, novo aniridia, aniridia cases, cases ., . We, We have, have shown, shown that, that a, a cosmid, cosmid probe, probe for, for a, a candidate, candidate aniridia, aniridia gene, gene ,, , homologous, homologous to, to the, the mouse, mouse Pax-6, Pax-6 gene, gene ,, , is, is deleted, deleted in, in cell, cell lines, lines from, from aniridia, aniridia patients, patients with, with previously, previously characterized, characterized deletions, deletions at, at 11p13, 11p13 ,, , while, while another, another cosmid, cosmid marker, marker mapping, mapping between, between two, two aniridia-associated, aniridia-associated translocation, translocation breakpoints, breakpoints (, ( and, and hence, hence a, a second, second candidate, candidate marker, marker ), ) is, is present, present on, on both, both chromosomes, chromosomes ., . These, These results, results support, support the, the Pax-6, Pax-6 homologue, homologue as, as a, a strong, strong candidate, candidate for, for the, the AN2, AN2 gene, gene ., . FISH, FISH with, with cosmid, cosmid probes, probes has, has proved, proved to, to be, be a, a fast, fast and, and reliable, reliable technique, technique for, for the, the molecular, molecular analysis, analysis of, of deletions, deletions ., . It, It can, can be, be used, used with, with limited, limited amounts, amounts of, of material, material and, and has, has strong, strong potential, potential for, for clinical, clinical applications.., applications.. In, In 51, 51 families, families with, with Wilson, Wilson disease, disease ,, , we, we have, have studied, studied DNA, DNA haplotypes, haplotypes of, of dinucleotide, dinucleotide repeat, repeat polymorphisms, polymorphisms (, ( CA, CA repeats, repeats ), ) in, in the, the 13q14, 13q14 ., . 3, 3 region, region ,, , to, to examine, examine these, these markers, markers for, for association, association with, with the, the Wilson, Wilson disease, disease gene, gene (, ( WND, WND ), ) ., . In, In addition, addition to, to a, a marker, marker (, ( D13S133, D13S133 ), ) described, described elsewhere, elsewhere ,, , we, we have, have developed, developed three, three new, new highly, highly polymorphic, polymorphic markers, markers (, ( D13S314, D13S314 ,, , D13S315, D13S315 ,, , and, and D13S316, D13S316 ), ) close, close to, to the, the WND, WND locus, locus ., . We, We have, have examined, examined the, the distribution, distribution of, of marker, marker alleles, alleles at, at the, the loci, loci studied, studied and, and have, have found, found that, that D13S314, D13S314 ,, , D13S133, D13S133 ,, , and, and D13S316, D13S316 each, each show, show nonrandom, nonrandom distribution, distribution on, on chromosomes, chromosomes carrying, carrying the, the WND, WND mutation, mutation ., . We, We have, have studied, studied haplotypes, haplotypes of, of these, these three, three markers, markers and, and have, have found, found that, that there, there are, are highly, highly significant, significant differences, differences between, between WND, WND and, and normal, normal haplotypes, haplotypes in, in northern, northern European, European families, families ., . These, These findings, findings have, have important, important implications, implications for, for mutation, mutation detection, detection and, and molecular, molecular diagnosis, diagnosis in, in families, families with, with Wilson, Wilson disease, disease ., . We, We studied, studied whether, whether the, the beneficial, beneficial effects, effects of, of growth, growth hormone, hormone (, ( GH, GH ), ) treatment, treatment on, on growth, growth and, and body, body composition, composition in, in PWS, PWS are, are accompanied, accompanied by, by an, an improvement, improvement in, in respiratory, respiratory function, function ., . We, We measured, measured resting, resting ventilation, ventilation ,, , airway, airway occlusion, occlusion pressure, pressure (, ( P, P (, ( 0, 0 ., . 1, 1 ), ) ), ) and, and ventilatory, ventilatory response, response to, to CO, CO (, ( 2, 2 ), ) in, in nine, nine children, children ,, , aged, aged 7-14, 7-14 years, years ,, , before, before and, and 6-9, 6-9 months, months after, after the, the start, start of, of GH, GH treatment, treatment ., . During, During GH, GH treatment, treatment ,, , resting, resting ventilation, ventilation increased, increased by, by 26, 26 %, % ,, , P, P (, ( 0, 0 ., . 1, 1 ), ) by, by 72, 72 %, % and, and the, the response, response to, to CO, CO (, ( 2, 2 ), ) by, by 65, 65 %, % (, ( P, P <, < 0, 0 ., . 002, 002 ,, , <, < 0, 0 ., . 04, 04 and, and <, < 0, 0 ., . 02, 02 ,, , respectively, respectively ), ) ., . This, This observed, observed increase, increase in, in ventilatory, ventilatory output, output was, was not, not correlated, correlated to, to changes, changes in, in body, body mass, mass index, index ., . CONCLUSION, CONCLUSION Treatment, Treatment of, of children, children with, with Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) seems, seems to, to have, have a, a stimulatory, stimulatory effect, effect on, on central, central respiratory, respiratory structures, structures ., . The, The observed, observed increase, increase in, in ventilation, ventilation and, and inspiratory, inspiratory drive, drive may, may contribute, contribute to, to the, the improved, improved activity, activity level, level reported, reported by, by parents, parents of, of PWS, PWS children, children during, during growth, growth hormone, hormone therapy, therapy Papillary, Papillary cystadenoma, cystadenoma of, of the, the epididymis, epididymis is, is an, an uncommon, uncommon benign, benign lesion, lesion that, that may, may occur, occur sporadically, sporadically or, or as, as a, a manifestation, manifestation of, of von, von Hippel-Lindau, Hippel-Lindau (, ( VHL, VHL ), ) disease, disease ., . Neither, Neither immunohistochemical, immunohistochemical studies, studies nor, nor molecular, molecular genetic, genetic analyses, analyses of, of the, the VHL, VHL gene, gene have, have been, been reported, reported previously, previously for, for this, this lesion, lesion ., . The, The authors, authors describe, describe two, two cases, cases of, of clear, clear cell, cell papillary, papillary cystadenoma, cystadenoma of, of the, the epididymis, epididymis ,, , both, both of, of which, which were, were initially, initially confused, confused with, with metastatic, metastatic renal, renal cell, cell carcinoma, carcinoma ., . Both, Both lesions, lesions showed, showed positive, positive immunohistochemical, immunohistochemical staining, staining for, for low, low and, and intermediate, intermediate molecular, molecular weight, weight keratins, keratins (, ( Cam, Cam 5, 5 ., . 2, 2 and, and AE1/AE3, AE1/AE3 ), ) ,, , EMA, EMA ,, , vimentin, vimentin ,, , alpha, alpha 1-antitrypsin, 1-antitrypsin ,, , and, and alpha, alpha 1-antichymotrypsin, 1-antichymotrypsin ., . Each, Each was, was negative, negative for, for CEA, CEA ., . Because, Because clear, clear cell, cell papillary, papillary cystadenoma, cystadenoma is, is similar, similar to, to renal, renal cell, cell carcinoma, carcinoma histologically, histologically ,, , and, and because, because both, both occur, occur as, as components, components of, of the, the von, von Hippel-Lindau, Hippel-Lindau disease, disease complex, complex ,, , the, the authors, authors analyzed, analyzed both, both cases, cases for, for the, the presence, presence of, of mutations, mutations in, in the, the VHL, VHL gene, gene ., . A, A somatic, somatic VHL, VHL gene, gene mutation, mutation was, was detected, detected in, in one, one of, of the, the two, two tumors, tumors by, by polymerase, polymerase chain, chain reaction, reaction followed, followed by, by single-strand, single-strand conformation, conformation polymorphism, polymorphism analysis, analysis ., . Direct, Direct sequencing, sequencing revealed, revealed a, a cytosine, cytosine to, to thymine, thymine transition, transition at, at nucleotide, nucleotide 694, 694 ,, , resulting, resulting in, in the, the replacement, replacement of, of an, an arginine, arginine with, with a, a stop, stop codon, codon after, after the, the sixth, sixth amino, amino acid, acid of, of exon, exon 3, 3 ., . As, As the, the VHL, VHL gene, gene is, is believed, believed to, to function, function as, as a, a tumor, tumor suppressor, suppressor gene, gene ,, , VHL, VHL gene, gene mutations, mutations may, may play, play a, a role, role in, in the, the initiation, initiation of, of tumorigenesis, tumorigenesis in, in sporadic, sporadic cystadenomas, cystadenomas of, of the, the epididymis, epididymis ., . The, The breast-ovary, breast-ovary cancer-family, cancer-family syndrome, syndrome is, is a, a dominant, dominant predisposition, predisposition to, to cancer, cancer of, of the, the breast, breast and, and ovaries, ovaries which, which has, has been, been mapped, mapped to, to chromosome, chromosome region, region 17q12-q21, 17q12-q21 ., . The, The majority, majority ,, , but, but not, not all, all ,, , of, of breast-ovary, breast-ovary cancer, cancer families, families show, show linkage, linkage to, to this, this susceptibility, susceptibility locus, locus ,, , designated, designated BRCA1, BRCA1 ., . We, We report, report here, here the, the results, results of, of a, a linkage, linkage analysis, analysis of, of 145, 145 families, families with, with both, both breast, breast and, and ovarian, ovarian cancer, cancer ., . These, These families, families contain, contain either, either a, a total, total of, of three, three or, or more, more cases, cases of, of early-onset, early-onset (, ( before, before age, age 60, 60 years, years ), ) breast, breast cancer, cancer or, or ovarian, ovarian cancer, cancer ., . All, All families, families contained, contained at, at least, least one, one case, case of, of ovarian, ovarian cancer, cancer ., . Overall, Overall ,, , an, an estimated, estimated 76, 76 %, % of, of the, the 145, 145 families, families are, are linked, linked to, to the, the BRCA1, BRCA1 locus, locus ., . None, None of, of the, the 13, 13 families, families with, with cases, cases of, of male, male breast, breast cancer, cancer appear, appear to, to be, be linked, linked ,, , but, but it, it is, is estimated, estimated that, that 92, 92 %, % (, ( 95, 95 %, % confidence, confidence interval, interval 76, 76 %, % -100, -100 %, % ), ) of, of families, families with, with no, no male, male breast, breast cancer, cancer and, and with, with two, two or, or more, more ovarian, ovarian cancers, cancers are, are linked, linked to, to BRCA1, BRCA1 ., . These, These data, data suggest, suggest that, that the, the breast-ovarian, breast-ovarian cancer-family, cancer-family syndrome, syndrome is, is genetically, genetically heterogeneous, heterogeneous ., . However, However ,, , the, the large, large majority, majority of, of families, families with, with early-onset, early-onset breast, breast cancer, cancer and, and with, with two, two or, or more, more cases, cases of, of ovarian, ovarian cancer, cancer are, are likely, likely to, to be, be due, due to, to BRCA1, BRCA1 mutations.., mutations.. We, We have, have brought, brought together, together information, information on, on 864, 864 affected, affected individuals, individuals in, in 164, 164 families, families (, ( including, including three, three new, new pedigrees, pedigrees ), ) reported, reported in, in the, the 137, 137 year, year period, period since, since 1845, 1845 when, when Demarquay, Demarquay first, first described, described a, a family, family with, with what, what was, was later, later called, called van, van der, der Woude, Woude syndrome, syndrome (, ( VWS, VWS ), ) ., . Both, Both types, types of, of oral, oral cleft, cleft ,, , cleft, cleft palate, palate (, ( CP, CP ), ) and, and cleft, cleft lip, lip with, with or, or without, without CP, CP (, ( CLP, CLP ), ) ,, , segregate, segregate in, in these, these families, families together, together with, with lower, lower lip, lip pits, pits or, or fistulae, fistulae in, in an, an autosomal, autosomal dominant, dominant mode, mode with, with high, high penetrance, penetrance estimated, estimated to, to be, be K, K =, = ., . 89, 89 and, and ., . 99, 99 by, by different, different methods, methods ., . Cleft"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", Cleft types, types (, ( CLP, CLP and, and CP, CP ), ) occur, occur in, in VWS, VWS in, in the, the same, same proportions, proportions as, as in, in the, the general, general non-VWS, non-VWS population, population ,, , ie, ie ,, , about, about twice, twice as, as many, many cleft-bearing, cleft-bearing individuals, individuals have, have CLP, CLP as, as have, have CP, CP ., . On, On the, the other, other hand, hand ,, , we, we do, do not, not find, find the, the usually, usually observed, observed excess, excess of, of females, females with, with CP, CP and, and excess, excess of, of males, males with, with CLP, CLP ;, ; in, in VWS, VWS the, the sex, sex ratios, ratios are, are more, more nearly, nearly equal, equal ., . Lip, Lip pits, pits also, also are, are equally, equally distributed, distributed between, between the, the sexes, sexes ., . Affected, Affected males, males and, and females, females are, are equally, equally likely, likely to, to transmit, transmit VWS, VWS ., . However, However ,, , there, there is, is an, an excess, excess of, of less, less severely, severely affected, affected individuals, individuals among, among transmitters, transmitters and, and a, a deficiency, deficiency of, of more, more severely, severely affected, affected ,, , brought, brought about, about by, by a, a proband, proband bias, bias and, and differential, differential fecundity, fecundity ., . The, The expression, expression of, of VWS, VWS is, is significantly, significantly modified, modified by, by the, the genetic, genetic background, background More, More extreme, extreme phenotypes, phenotypes in, in parents, parents tend, tend to, to produce, produce more, more extreme, extreme expression, expression in, in their, their children, children ., . For, For a, a VWS, VWS gene, gene carrier, carrier the, the relative, relative risk, risk of, of transmitting, transmitting a, a cleft, cleft is, is 26, 26 ., . 45, 45 %, % ;, ; that, that of, of transmitting, transmitting lower, lower lip, lip pits, pits is, is 23, 23 ., . 55, 55 %, % ., . Three, Three pedigrees, pedigrees of, of lip, lip pits, pits in, in the, the literature, literature show, show no, no clefts, clefts among, among a, a significant, significant number, number of, of affected, affected individuals, individuals ., . Control, Control of, of gene, gene expression, expression in, in VWS, VWS in, in the, the three, three target, target tissues, tissues appears, appears to, to be, be independent, independent and, and separately, separately designated, designated ., . Mutation, Mutation rate, rate of, of the, the VWS, VWS gene, gene is, is calculated, calculated to, to be, be 1, 1 ., . 8, 8 X, X 10, 10 (, ( -5, -5 ), ) Eighty, Eighty unrelated, unrelated individuals, individuals with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) or, or Becker, Becker muscular, muscular dystrophy, dystrophy (, ( BMD, BMD ), ) were, were found, found to, to have, have deletions, deletions in, in the, the major, major deletion-rich, deletion-rich region, region of, of the, the DMD, DMD locus, locus ., . This, This region, region includes, includes the, the last, last five, five exons, exons detected, detected by, by cDNA5b-7, cDNA5b-7 ,, , all, all exons, exons detected, detected by, by cDNA8, cDNA8 ,, , and, and the, the first, first two, two exons, exons detected, detected by, by cDNA9, cDNA9 ., . These, These 80, 80 individuals, individuals account, account for, for approximately, approximately 75, 75 %, % of, of 109, 109 deletions, deletions of, of the, the gene, gene ,, , detected, detected among, among 181, 181 patients, patients analyzed, analyzed with, with the, the entire, entire dystrophin, dystrophin cDNA, cDNA ., . Endpoints, Endpoints for, for many, many of, of these, these deletions, deletions were, were further, further characterized, characterized using, using two, two genomic, genomic probes, probes ,, , p20, p20 (, ( DXS269, DXS269 ;, ; Wapenaar, Wapenaar et, et al, al ., . ), ) and, and GMGX11, GMGX11 (, ( DXS239, DXS239 ;, ; present, present paper, paper ), ) ., . Clinical, Clinical findings, findings are, are presented, presented for, for all, all 80, 80 patients, patients allowing, allowing a, a correlation, correlation of, of phenotypic, phenotypic severity, severity with, with the, the genotype, genotype ., . Thirty-eight, Thirty-eight independent, independent patients, patients were, were old, old enough, enough to, to be, be classified, classified as, as DMD, DMD ,, , BMD, BMD ,, , or, or intermediate, intermediate phenotype, phenotype and, and had, had deletions, deletions of, of exons, exons with, with sequenced, sequenced intron/exon, intron/exon boundaries, boundaries ., . Of, Of these, these ,, , eight, eight BMD, BMD patients, patients and, and one, one intermediate, intermediate patient, patient had, had gene, gene deletions, deletions predicted, predicted to, to leave, leave the, the reading, reading frame, frame intact, intact ,, , while, while 21, 21 DMD, DMD patients, patients ,, , 7, 7 intermediate, intermediate patients, patients ,, , and, and 1, 1 BMD, BMD patient, patient had, had gene, gene deletions, deletions predicted, predicted to, to disrupt, disrupt the, the reading, reading frame, frame ., . Thus, Thus ,, , with, with two, two exceptions, exceptions ,, , frameshift, frameshift deletions, deletions of, of the, the gene, gene resulted, resulted in, in more, more severe, severe phenotype, phenotype than, than did, did in-frame, in-frame deletions, deletions ., . This, This is, is in, in agreement, agreement with, with recent, recent findings, findings by, by Baumbach, Baumbach et, et al, al ., . and, and Koenig, Koenig et, et al, al ., . but, but is, is in, in contrast, contrast to, to findings, findings ,, , by, by Malhotra, Malhotra et, et al, al ., . at, at the, the 5, 5 ', ' end, end of, of the, the gene.Pelizaeus-Merzbacher, gene.Pelizaeus-Merzbacher Disease, Disease (, ( PMD, PMD ), ) is, is an, an X-linked, X-linked developmental, developmental defect, defect of, of myelination, myelination affecting, affecting the, the central, central nervous, nervous system, system and, and segregating, segregating with, with the, the proteolipoprotein, proteolipoprotein (, ( PLP, PLP ), ) locus, locus ., . Investigating, Investigating 82, 82 strictly, strictly selected, selected sporadic, sporadic cases, cases of, of PMD, PMD ,, , we, we found, found PLP, PLP mutations, mutations in, in 77, 77 %, % ;, ; complete, complete PLP-gene, PLP-gene duplications, duplications were, were the, the most, most frequent, frequent abnormality, abnormality (, ( 62, 62 %, % ), ) ,, , whereas, whereas point, point mutations, mutations in, in coding, coding or, or splice-site, splice-site regions, regions of, of the, the gene, gene were, were involved, involved less, less frequently, frequently (, ( 38, 38 %, % ), ) ., . We, We analyzed, analyzed the, the maternal, maternal status, status of, of 56, 56 cases, cases to, to determine, determine the, the origin, origin of, of both, both types, types of, of PLP, PLP mutation, mutation ,, , since, since this, this is, is relevant, relevant to, to genetic, genetic counseling, counseling ., . In, In the, the 22, 22 point, point mutations, mutations ,, , 68, 68 %, % of, of mothers, mothers were, were heterozygous, heterozygous for, for the, the mutation, mutation ,, , a, a value, value identical, identical to, to the, the two-thirds, two-thirds of, of carrier, carrier mothers, mothers that, that would, would be, be expected, expected if, if there, there were, were an, an equal, equal mutation, mutation rate, rate in, in male, male and, and female, female germ, germ cells, cells ., . In, In sharp, sharp contrast, contrast ,, , among, among the, the 34, 34 duplicated, duplicated cases, cases ,, , 91, 91 %, % of, of mothers, mothers were, were carriers, carriers ,, , a, a value, value significantly, significantly (, ( chi2, chi2 =, = 9, 9 ., . 20, 20 ,, , P, P <, < ., . 01, 01 ), ) in, in favor, favor of, of a, a male, male bias, bias ,, , with, with an, an estimation, estimation of, of the, the male/female, male/female mutation, mutation frequency, frequency (, ( k, k ), ) of, of 9, 9 ., . 3, 3 3, 3 ., . Moreover, Moreover ,, , we, we observed, observed the, the occurrence, occurrence of, of de, de novo, novo mutations, mutations between, between parental, parental and, and grandparental, grandparental generations, generations in, in 17, 17 three-generation, three-generation families, families ,, , which, which allowed, allowed a, a direct, direct estimation, estimation of, of the, the k, k value, value (, ( k, k =, = 11, 11 ), ) ., . Again, Again ,, , a, a significant, significant male, male mutation, mutation imbalance, imbalance was, was observed, observed only, only for, for the, the duplications, duplications ., . We, We have, have estimated, estimated the, the haplotype, haplotype distribution, distribution of, of mutant, mutant and, and normal, normal phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) alleles, alleles for, for 17, 17 Turkish, Turkish phenylketonuria, phenylketonuria (, ( PKU, PKU ), ) families, families 20, 20 normal, normal and, and 27, 27 mutated, mutated PAH, PAH alleles, alleles could, could be, be identified, identified ., . Of, Of the, the latter, latter ,, , the, the most, most prevalent, prevalent were, were associated, associated with, with haplotype, haplotype 6, 6 (, ( 29, 29 ., . 6, 6 %, % ), ) ,, , 1, 1 (, ( 18, 18 ., . 5, 5 %, % ), ) and, and 36, 36 (, ( 11, 11 ., . 1, 1 %, % ), ) ,, , while, while the, the normal, normal alleles, alleles were, were preferentially, preferentially associated, associated with, with haplotype, haplotype 1, 1 (, ( 20, 20 %, % ), ) ., . Of, Of the, the 19, 19 different, different haplotypes, haplotypes observed, observed ,, , 5, 5 have, have not, not been, been described, described previously, previously ., . The, The haplotype, haplotype distribution, distribution differed, differed significantly, significantly from, from that, that of, of the, the Northern, Northern European, European population, population ., . Two, Two of, of the, the eight, eight polymorphic, polymorphic sites, sites were, were in, in association, association with, with PKU, PKU ., . No, No deletions, deletions of, of exon, exon sequences, sequences were, were found, found in, in the, the families, families analysed.Two, analysed.Two overlapping, overlapping cDNA, cDNA clones, clones (, ( 1, 1 ,, , 991, 991 bp, bp and, and 736, 736 bp, bp ,, , respectively, respectively ), ) encoding, encoding the, the precursor, precursor of, of human, human mitochondrial, mitochondrial very-long-chain, very-long-chain acyl-coenzyme, acyl-coenzyme A, A dehydrogenase, dehydrogenase (, ( VLCAD, VLCAD ), ) were, were cloned, cloned and, and sequenced, sequenced ., . The, The cDNA, cDNA inserts, inserts of, of these, these clones, clones together, together encompass, encompass a, a region, region of, of 2, 2 ,, , 177, 177 bases, bases ,, , encoding, encoding the, the entire, entire protein, protein of, of 655, 655 amino, amino acids, acids ,, , including, including a, a 40-amino, 40-amino acid, acid leader, leader peptide, peptide and, and a, a 615-amino, 615-amino acid, acid mature, mature polypeptide, polypeptide ., . PCR-amplified, PCR-amplified VLCAD, VLCAD cDNAs, cDNAs were, were sequenced, sequenced in, in cultured, cultured fibroblasts, fibroblasts from, from two, two VLCAD-deficient, VLCAD-deficient patients, patients ., . In, In both, both patients, patients ,, , a, a 105-bp, 105-bp deletion, deletion encompassing, encompassing bases, bases 1078-1182, 1078-1182 in, in VLCAD, VLCAD cDNA, cDNA was, was identified, identified ., . The, The deletion, deletion seems, seems to, to occur, occur due, due to, to exon, exon skipping, skipping during, during processing, processing of, of VLCAD, VLCAD pre-mRNA, pre-mRNA ., . This, This is, is the, the first, first demonstration, demonstration of, of a, a mutation, mutation causing, causing VLCAD, VLCAD deficiency, deficiency ., . Quantitative, Quantitative cDNA, cDNA expression, expression of, of normal, normal human, human VLCAD, VLCAD was, was performed, performed in, in the, the patients, patients fibroblasts, fibroblasts ,, , using, using vaccinia, vaccinia viral, viral system, system ,, , which, which demonstrated, demonstrated that, that the, the deficiency, deficiency of, of the, the normal, normal VLCAD, VLCAD protein, protein causes, causes impaired, impaired long-chain, long-chain fatty, fatty acid, acid beta-oxidation, beta-oxidation activity, activity in, in the, the patients, patients fibroblasts, fibroblasts ., . In, In patient, patient fibroblasts, fibroblasts ,, , raising, raising VLCAD, VLCAD activity, activity to, to approximately, approximately 20, 20 %, % of, of normal, normal control, control fibroblast, fibroblast activity, activity raised, raised palmitic, palmitic acid, acid beta-oxidation, beta-oxidation flux, flux to, to the, the level, level found, found in, in control, control fibroblasts, fibroblasts ,, , which, which may, may offer, offer important, important information, information for, for the, the rational, rational design, design of, of future, future somatic, somatic gene, gene therapy, therapy for, for VLCAD, VLCAD deficiency.., deficiency.. Inactivation, Inactivation of, of both, both alleles, alleles of, of the, the RB1, RB1 gene, gene during, during normal, normal retinal, retinal development, development initiates, initiates the, the formation, formation of, of a, a retinoblastoma, retinoblastoma (, ( RB, RB ), ) tumor, tumor ., . To, To identify, identify the, the mutations, mutations which, which inactivate, inactivate RB1, RB1 ,, , 21, 21 RB, RB tumors, tumors isolated, isolated from, from 19, 19 patients, patients were, were analyzed, analyzed with, with the, the polymerase, polymerase chain, chain reaction, reaction or, or an, an RNase, RNase protection, protection assay, assay or, or both, both ., . Mutations, Mutations were, were identified, identified in, in 13, 13 of, of 21, 21 RB, RB tumors, tumors ;, ; in, in 8, 8 tumors, tumors ,, , the, the precise, precise errors, errors in, in nucleotide, nucleotide sequence, sequence were, were characterized, characterized ., . Each, Each of, of four, four germ, germ line, line mutations, mutations involved, involved a, a small, small deletion, deletion or, or duplication, duplication ,, , while, while three, three somatic, somatic mutations, mutations were, were point, point mutations, mutations leading, leading to, to splice, splice alterations, alterations and, and loss, loss of, of an, an exon, exon from, from the, the mature, mature RB1, RB1 mRNA, mRNA ., . We, We were, were unable, unable to, to detect, detect expression, expression of, of the, the mutant, mutant allele, allele in, in lymphoblasts, lymphoblasts of, of three, three bilaterally, bilaterally affected, affected patients, patients ,, , although, although the, the mutation, mutation was, was present, present in, in the, the genomic, genomic DNA, DNA and, and transcripts, transcripts containing, containing the, the mutations, mutations were, were obvious, obvious in, in the, the RB, RB tumors, tumors in, in the, the absence, absence of, of a, a normal, normal RB1, RB1 allele, allele ., . The, The variations, variations in, in the, the level, level of, of expression, expression of, of mutant, mutant transcripts, transcripts suggest, suggest deregulation, deregulation of, of RB1, RB1 transcription, transcription in, in the, the absence, absence of, of a, a functional, functional RB1, RB1 gene, gene product.., product.. Two, Two distinct, distinct loci, loci have, have been, been proposed, proposed for, for aniridia, aniridia ;, ; AN1, AN1 for, for autosomal, autosomal dominant, dominant aniridia, aniridia on, on chromosome, chromosome 2p, 2p and, and AN2, AN2 for, for the, the aniridia, aniridia in, in the, the WAGR, WAGR contiguous, contiguous gene, gene syndrome, syndrome on, on chromosome, chromosome 11p13, 11p13 ., . In, In this, this report, report ,, , the, the kindred, kindred segregating, segregating for, for autosomal, autosomal dominant, dominant aniridia, aniridia ,, , which, which suggested, suggested linkage, linkage to, to acid, acid phosphatase-1, phosphatase-1 (, ( ACP1, ACP1 ), ) and, and led, led to, to the, the assignment, assignment of, of the, the AN1, AN1 locus, locus on, on chromosome, chromosome 2p, 2p ,, , has, has been, been updated, updated and, and expanded, expanded ., . Linkage, Linkage analysis, analysis between, between the, the aniridia, aniridia phenotype, phenotype and, and ACP1, ACP1 does, does not, not support, support the, the original, original linkage, linkage results, results ,, , excluding, excluding linkage, linkage up, up to, to theta, theta =, = 0, 0 ., . 17, 17 with, with Z, Z =, = -2, -2 ., . Tests, Tests for, for linkage, linkage to, to other, other chromosome, chromosome 2p, 2p markers, markers ., . APOB, APOB ,, , D2S71, D2S71 ,, , D2S5, D2S5 ,, , and, and D2S1, D2S1 ,, , also, also excluded, excluded linkage, linkage to, to aniridia, aniridia ., . Markers, Markers that, that have, have been, been isolated, isolated from, from the, the chromosome, chromosome 11p13, 11p13 region, region were, were then, then analyzed, analyzed in, in this, this aniridia, aniridia family, family ., . Two, Two RFLPs, RFLPs at, at the, the D11S323, D11S323 locus, locus give, give significant, significant evidence, evidence for, for linkage, linkage ., . The, The PvuII, PvuII polymorphism, polymorphism detected, detected by, by probe, probe p5S1, p5S1 ., . 6, 6 detects, detects no, no recombinants, recombinants ,, , with, with a, a maximum, maximum lod, lod score, score of, of Z, Z =, = 6, 6 ., . 97, 97 at, at theta, theta =, = 0, 0 ., . 00, 00 00, 00 ., . The, The HaeIII, HaeIII polymorphism, polymorphism detected, detected by, by the, the probe, probe p5BE1, p5BE1 ., . 2, 2 gives, gives a, a maximum, maximum lod, lod score, score of, of Z, Z =, = 2, 2 ., . 57, 57 at, at theta, theta =, = 0, 0 ., . 00, 00 00, 00 ., . Locus, Locus D11S325, D11S325 gives, gives a, a lod, lod score, score of, of Z, Z =, = 1, 1 ., . 53, 53 at, at theta, theta =, = 0, 0 ., . 00, 00 00, 00 ., . These, These data, data suggest, suggest that, that a, a locus, locus for, for aniridia, aniridia (, ( AN1, AN1 ), ) on, on chromosome, chromosome 2p, 2p has, has been, been misassigned, misassigned and, and that, that this, this autosomal, autosomal dominant, dominant aniridia, aniridia family, family is, is segregating, segregating for, for an, an aniridia, aniridia mutation, mutation linked, linked to, to markers, markers in, in the, the 11p13, 11p13 region.Classical, region.Classical Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is an, an autosomal, autosomal recessive, recessive human, human genetic, genetic disorder, disorder caused, caused by, by a, a deficiency, deficiency of, of hepatic, hepatic phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . We, We isolated, isolated several, several mutant, mutant PAH, PAH cDNA, cDNA clones, clones from, from a, a PKU, PKU carrier, carrier individual, individual and, and showed, showed that, that they, they contained, contained an, an internal, internal 116, 116 base, base pair, pair deletion, deletion ,, , corresponding, corresponding precisely, precisely to, to exon, exon 12, 12 of, of the, the human, human chromosomal, chromosomal PAH, PAH gene, gene ., . The, The deletion, deletion causes, causes the, the synthesis, synthesis of, of a, a truncated, truncated protein, protein lacking, lacking the, the C-terminal, C-terminal 52, 52 amino, amino acids, acids ., . Gene, Gene transfer, transfer and, and expression, expression studies, studies using, using the, the mutant, mutant PAH, PAH cDNA, cDNA indicated, indicated that, that the, the deletion, deletion abolishes, abolishes PAH, PAH activity, activity in, in the, the cell, cell as, as a, a result, result of, of protein, protein instability, instability ., . To, To determine, determine the, the molecular, molecular basis, basis of, of the, the deletion, deletion ,, , the, the mutant, mutant chromosomal, chromosomal PAH, PAH gene, gene was, was isolated, isolated from, from this, this individual, individual and, and shown, shown to, to contain, contain a, a GT, GT --, -- greater, greater than, than AT, AT substitution, substitution at, at the, the 5, 5 splice, splice donor, donor site, site of, of intron, intron 12, 12 ., . Thus, Thus ,, , the, the consequence, consequence of, of the, the splice, splice donor, donor site, site mutation, mutation in, in the, the human, human liver, liver is, is the, the skipping, skipping of, of the, the preceding, preceding exon, exon during, during RNA, RNA splicing.., splicing.. Wolfram, Wolfram syndrome, syndrome is, is an, an autosomal, autosomal recessive, recessive neurodegenerative, neurodegenerative disorder, disorder characterized, characterized by, by juvenile-onset, juvenile-onset diabetes, diabetes mellitus, mellitus and, and progressive, progressive optic, optic atrophy, atrophy ., . mtDNA, mtDNA deletions, deletions have, have been, been described, described ,, , and, and a, a gene, gene (, ( WFS1, WFS1 ), ) recently, recently has, has been, been identified, identified ,, , on, on chromosome, chromosome 4p16, 4p16 ,, , encoding, encoding a, a predicted, predicted 890, 890 amino, amino acid, acid transmembrane, transmembrane protein, protein ., . Direct, Direct DNA, DNA sequencing, sequencing was, was done, done to, to screen, screen the, the entire, entire coding, coding region, region of, of the, the WFS1, WFS1 gene, gene in, in 30, 30 patients, patients from, from 19, 19 British, British kindreds, kindreds with, with Wolfram, Wolfram syndrome, syndrome ., . DNA, DNA was, was also, also screened, screened for, for structural, structural rearrangements, rearrangements (, ( deletions, deletions and, and duplications, duplications ), ) and, and point, point mutations, mutations in, in mtDNA, mtDNA ., . No, No pathogenic, pathogenic mtDNA, mtDNA mutations, mutations were, were found, found in, in our, our cohort, cohort ., . We, We identified, identified 24, 24 mutations, mutations in, in the, the WFS1, WFS1 gene, gene 8, 8 nonsense, nonsense mutations, mutations ,, , 8, 8 missense, missense mutations, mutations ,, , 3, 3 in-frame, in-frame deletions, deletions ,, , 1, 1 in-frame, in-frame insertion, insertion ,, , and, and 4, 4 frameshift, frameshift mutations, mutations ., . Of, Of these, these ,, , 23, 23 were, were novel, novel mutations, mutations ,, , and, and most, most occurred, occurred in, in exon, exon 8, 8 ., . The, The majority, majority of, of patients, patients were, were compound, compound heterozygotes, heterozygotes for, for two, two mutations, mutations ,, , and, and there, there was, was no, no common, common founder, founder mutation, mutation ., . The, The data, data were, were also, also analyzed, analyzed for, for genotype-phenotype, genotype-phenotype relationships, relationships ., . Although, Although some, some interesting, interesting cases, cases were, were noted, noted ,, , consideration, consideration of, of the, the small, small sample, sample size, size and, and frequency, frequency of, of each, each mutation, mutation indicated, indicated no, no clear-cut, clear-cut correlations, correlations between, between any, any of, of the, the observed, observed mutations, mutations and, and disease, disease severity, severity ., . There, There were, were no, no obvious, obvious mutation, mutation hot, hot spots, spots or, or clusters, clusters ., . Hence, Hence ,, , molecular, molecular screening, screening for, for Wolfram, Wolfram syndrome, syndrome in, in affected, affected families, families and, and for, for Wolfram, Wolfram syndrome-carrier, syndrome-carrier status, status in, in subjects, subjects with, with psychiatric, psychiatric disorders, disorders or, or diabetes, diabetes mellitus, mellitus will, will require, require complete, complete analysis, analysis of, of exon, exon 8, 8 and, and upstream, upstream exons.., exons.. We, We report, report on, on a, a boy, boy with, with a, a maternal, maternal uniparental, uniparental disomy, disomy for, for chromosome, chromosome 14, 14 (, ( UPD, UPD (, ( 14, 14 ), ) ), ) ., . At, At 7, 7 years, years of, of age, age he, he was, was referred, referred to, to us, us by, by the, the paediatrician, paediatrician because, because of, of symptoms, symptoms of, of Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . He, He showed, showed short, short stature, stature ,, , obesity, obesity ,, , mild, mild developmental, developmental delay, delay ,, , cryptorchidism, cryptorchidism ,, , and, and some, some mild, mild dysmorphic, dysmorphic features, features ., . The, The history, history further, further indicated, indicated intrauterine, intrauterine growth, growth retardation, retardation at, at the, the end, end of, of the, the pregnancy, pregnancy ., . His, His mother, mother was, was 44, 44 years, years of, of age, age at, at the, the time, time of, of his, his birth, birth ., . After, After birth, birth he, he showed, showed hypotonia, hypotonia with, with poor, poor sucking, sucking ,, , for, for which, which gavage, gavage feeding, feeding was, was needed, needed ., . Motor, Motor development, development was, was delayed, delayed ., . After, After 1, 1 year, year he, he became, became obese, obese despite, despite a, a normal, normal appetite, appetite ., . Recurrent, Recurrent middle, middle ear, ear infections, infections ,, , a, a high, high pain, pain threshold, threshold ,, , and, and a, a great, great skill, skill with, with jigsaw, jigsaw puzzles, puzzles were, were reported, reported ., . There, There were, were no, no behavioural, behavioural problems, problems or, or sleep, sleep disturbance, disturbance ., . Chromosomal, Chromosomal analysis, analysis was, was normal, normal (, ( 46, 46 ,, , XY, XY ), ) ., . DNA, DNA analysis, analysis for, for Prader-Willi, Prader-Willi syndrome, syndrome showed, showed no, no abnormalities, abnormalities ., . Two, Two years, years later, later he, he was, was re-examined, re-examined because, because we, we thought, thought his, his features, features fitted, fitted the, the PWS-like, PWS-like phenotype, phenotype associated, associated with, with maternal, maternal UPD, UPD (, ( 14, 14 ), ) ., . At, At that, that time, time precocious, precocious puberty, puberty was, was evident, evident ., . DNA, DNA analysis, analysis showed, showed maternal, maternal heterodisomy, heterodisomy for, for chromosome, chromosome 14, 14 ., . In, In all, all the, the previously, previously described, described 11, 11 cases, cases with, with maternal, maternal UPD, UPD (, ( 14, 14 ), ) ,, , a, a Robertsonian, Robertsonian translocation, translocation involving, involving chromosome, chromosome 14, 14 was, was detected, detected cytogenetically, cytogenetically before, before DNA, DNA analysis, analysis ., . This, This is, is the, the first, first report, report of, of diagnosis, diagnosis of, of maternal, maternal UPD, UPD (, ( 14, 14 ), ) based, based on, on clinical, clinical features, features ., . This, This finding, finding underlines, underlines the, the importance, importance of, of DNA, DNA analysis, analysis for, for maternal, maternal UPD, UPD (, ( 14, 14 ), ) in, in patients, patients with, with a, a similar, similar PWS-like, PWS-like phenotype, phenotype even, even without, without previous, previous identification, identification of, of a, a Robertsonian, Robertsonian translocation, translocation involving, involving chromosome, chromosome 14.., 14.. Genetic, Genetic epidemiological, epidemiological evidence, evidence suggests, suggests that, that mutations, mutations in, in BRCA1, BRCA1 may, may be, be responsible, responsible for, for approximately, approximately one, one half, half of, of early, early onset, onset familial, familial breast, breast cancer, cancer and, and the, the majority, majority of, of familial, familial breast/ovarian, breast/ovarian cancer, cancer ., . The, The recent, recent cloning, cloning of, of BRCA1, BRCA1 allows, allows for, for the, the direct, direct detection, detection of, of mutations, mutations ,, , but, but the, the feasibility, feasibility of, of presymptomatic, presymptomatic screening, screening for, for cancer, cancer susceptibility, susceptibility is, is unknown, unknown ., . We, We analyzed, analyzed genomic, genomic DNA, DNA from, from one, one affected, affected individual, individual from, from each, each of, of 24, 24 families, families with, with at, at least, least three, three cases, cases of, of ovarian, ovarian or, or breast, breast cancer, cancer ,, , using, using SSCP, SSCP assays, assays ., . Variant, Variant SSCP, SSCP bands, bands were, were subcloned, subcloned and, and sequenced, sequenced ., . Allele-specific, Allele-specific oligonucleotide, oligonucleotide hybridization, hybridization was, was used, used to, to verify, verify sequence, sequence changes, changes and, and to, to screen, screen DNA, DNA from, from control, control individuals, individuals ., . Six, Six frameshift, frameshift and, and two, two missense, missense mutations, mutations were, were detected, detected in, in 10, 10 different, different families, families ., . A, A frameshift, frameshift mutation, mutation was, was detected, detected in, in a, a male, male proband, proband affected, affected with, with both, both breast, breast and, and prostate, prostate cancer, cancer ., . A, A 40-bp, 40-bp deletion, deletion was, was detected, detected in, in a, a patient, patient who, who developed, developed intra-abdominal, intra-abdominal carcinomatosis, carcinomatosis 1, 1 year, year after, after prophylactic, prophylactic oophorectomy, oophorectomy ., . Mutations, Mutations were, were detected, detected throughout, throughout the, the gene, gene ,, , and, and only, only one, one was, was detected, detected in, in more, more than, than a, a single, single family, family ., . These, These results, results provide, provide further, further evidence, evidence that, that inherited, inherited breast, breast and, and ovarian, ovarian cancer, cancer can, can occur, occur as, as a, a consequence, consequence of, of a, a wide, wide array, array of, of BRCA1, BRCA1 mutations, mutations ., . These, These results, results suggests, suggests that, that development, development of, of a, a screening, screening test, test for, for BRCA1, BRCA1 mutations, mutations will, will be, be technically, technically challenging, challenging ., . The, The finding, finding of, of a, a mutation, mutation in, in a, a family, family with, with male, male breast, breast cancer, cancer ,, , not, not previously, previously thought, thought to, to be, be related, related to, to BRCA1, BRCA1 ,, , also, also illustrates, illustrates the, the potential, potential difficulties, difficulties of, of genetic, genetic counseling, counseling for, for individuals, individuals known, known to, to carry, carry mutations.., mutations.. The, The relationship, relationship between, between abnormal, abnormal color, color vision, vision and, and adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) was, was investigated, investigated in, in 27, 27 AMN, AMN patients, patients and, and 31, 31 age-matched, age-matched controls, controls by, by using, using the, the Farnsworth-Munsell, Farnsworth-Munsell 100, 100 Hue, Hue test, test ., . Twelve, Twelve (, ( 44, 44 %, % ), ) of, of 27, 27 patients, patients showed, showed test, test scores, scores significantly, significantly above, above normal, normal ., . The, The axes, axes of, of bipolarity, bipolarity determined, determined by, by the, the testing, testing differed, differed widely, widely between, between the, the patients, patients with, with abnormal, abnormal scores, scores ,, , compatible, compatible with, with the, the notion, notion that, that different, different alterations, alterations in, in visual, visual pigment, pigment genes, genes occur, occur in, in different, different AMN, AMN kindreds, kindreds ., . These, These observations, observations confirm"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", confirm our, our earlier, earlier impression, impression that, that the, the frequency, frequency of, of abnormal, abnormal color, color vision, vision is, is increased, increased in, in these, these kindreds, kindreds ,, , and, and it, it supports, supports our, our contentions, contentions that, that (, ( 1, 1 ), ) AMN, AMN (, ( and, and its, its companion, companion ,, , adrenoleukodystrophy, adrenoleukodystrophy ), ) are, are very, very closely, closely linked, linked to, to the, the visual, visual pigment, pigment loci, loci at, at Xq28, Xq28 and, and (, ( 2, 2 ), ) this, this proximity, proximity might, might provide, provide the, the opportunity, opportunity to, to observe, observe contiguous, contiguous gene, gene defects.., defects.. A, A panel, panel of, of patients, patients with, with Duchenne, Duchenne and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( DMD, DMD and, and BMD, BMD ), ) has, has been, been screened, screened with, with the, the cDNA, cDNA probes, probes Cf56a, Cf56a and, and Cf23a, Cf23a ,, , which, which detect, detect exons, exons in, in the, the central, central part, part of, of the, the DMD, DMD gene, gene ., . One, One or, or more, more exons, exons were, were deleted, deleted in, in 60, 60 %, % of, of patients, patients ., . The, The deletions, deletions were, were mapped, mapped and, and prove, prove to, to be, be heterogeneous, heterogeneous in, in size, size and, and extent, extent ,, , particularly, particularly in, in DMD, DMD ., . Deletions, Deletions specific, specific to, to DMD, DMD and, and to, to BMD, BMD are, are described, described ., . Half, Half of, of all, all BMD, BMD patients, patients have, have a, a deletion, deletion of, of one, one particular, particular small, small group, group of, of exons, exons ;, ; smaller, smaller deletions, deletions within, within this, this same, same group, group produce, produce the, the more, more severe, severe DMD.., DMD.. The, The Long-Evans, Long-Evans Cinnamon, Cinnamon (, ( LEC, LEC ), ) rat, rat shows, shows similarity, similarity to, to Wilson, Wilson disease, disease in, in many, many clinical, clinical and, and biochemical, biochemical features, features ., . We, We have, have cloned, cloned cDNAs, cDNAs for, for the, the rat, rat gene, gene (, ( Atp7b, Atp7b ), ) homologous, homologous to, to the, the human, human Wilson, Wilson disease, disease gene, gene (, ( ATP7B, ATP7B ), ) and, and have, have used, used them, them to, to identify, identify a, a partial, partial deletion, deletion in, in the, the Atp7b, Atp7b gene, gene in, in the, the LEC, LEC rat, rat ., . The, The deletion, deletion removes, removes at, at least, least 900, 900 bp, bp of, of the, the coding, coding region, region at, at the, the 3, 3 end, end ,, , includes, includes the, the crucial, crucial ATP, ATP binding, binding domain, domain and, and extends, extends downstream, downstream of, of the, the gene, gene ., . Our, Our results, results provide, provide convincing, convincing evidence, evidence for, for defining, defining the, the LEC, LEC rat, rat as, as an, an animal, animal model, model for, for Wilson, Wilson disease, disease ., . This, This model, model will, will be, be important, important for, for studying, studying liver, liver pathophysiology, pathophysiology ,, , for, for developing, developing therapy, therapy for, for Wilson, Wilson disease, disease and, and for, for studying, studying the, the pathway, pathway of, of copper, copper transport, transport and, and its, its possible, possible interaction, interaction with, with other, other heavy, heavy metals.., metals.. Differential, Differential Alu, Alu PCR, PCR fingerprint, fingerprint cloning, cloning was, was used, used to, to isolate, isolate a, a DNA, DNA probe, probe from, from the, the Xp11, Xp11 ., . 4, 4 --, -- >, > p11, p11 ., . 21, 21 region, region of, of the, the human, human X, X chromosome, chromosome ., . This, This novel, novel sequence, sequence ,, , cpXr318, cpXr318 (, ( DXS742, DXS742 ), ) ,, , detects, detects a, a new, new submicroscopic, submicroscopic deletion, deletion interval, interval at, at the, the Norrie, Norrie disease, disease locus, locus (, ( NDP, NDP ), ) ., . Combining, Combining our, our data, data with, with the, the consensus, consensus genetic, genetic map, map of, of the, the proximal, proximal short, short arm, arm of, of the, the X, X chromosome, chromosome ,, , we, we propose, propose the, the physical, physical order, order Xcen-DXS14-DXS255-, Xcen-DXS14-DXS255- (, ( DXS426, DXS426 ,, , TIMP, TIMP ), ) -, - (, ( DXS742-, DXS742- (, ( [, [ MAOB-MAOA-DXS7, MAOB-MAOA-DXS7 ], ] ,, , NDP, NDP ), ) -DXS77-DXS228, -DXS77-DXS228 ), ) -DXS209-DXS148-DXS196-, -DXS209-DXS148-DXS196- +, + +, + +, + Xpter, Xpter ., . The, The cpXr318, cpXr318 probe, probe and, and a, a subclone, subclone from, from a, a cosmid, cosmid corresponding, corresponding to, to the, the DXS7, DXS7 locus, locus were, were converted, converted into, into sequence-tagged, sequence-tagged sites, sites ., . Finally, Finally ,, , DXS742, DXS742 ,, , DSX7, DSX7 ,, , DXS77, DXS77 ,, , and, and MAOA, MAOA were, were integrated, integrated into, into a, a physical, physical map, map spanning, spanning the, the Norrie, Norrie disease, disease locus, locus Normotriglyceridemic, Normotriglyceridemic abetalipoproteinemia, abetalipoproteinemia is, is a, a rare, rare familial, familial disorder, disorder characterized, characterized by, by an, an isolated, isolated deficiency, deficiency of, of apoB-100, apoB-100 ., . We, We have, have previously, previously reported, reported a, a patient, patient with, with this, this disease, disease ,, , who, who had, had normal, normal apoB-48, apoB-48 but, but no, no apoB-100, apoB-100 ., . To, To elucidate, elucidate the, the genetic, genetic abnormalities, abnormalities in, in this, this family, family ,, , we, we studied, studied the, the linkage, linkage of, of apoB, apoB gene, gene using, using three, three genetic, genetic markers, markers ., . The, The proband, proband and, and her, her affected, affected brother, brother showed, showed completely, completely different, different apoB, apoB gene, gene alleles, alleles ,, , suggesting, suggesting that, that the, the apoB, apoB gene, gene itself, itself is, is not, not related, related to, to this, this disorder, disorder in, in this, this family, family ., . By, By contrast, contrast ,, , an, an American, American case, case had, had a, a point, point substitution, substitution in, in the, the apoB, apoB gene, gene generating, generating an, an in-frame, in-frame stop, stop codon, codon ., . These, These results, results indicate, indicate that, that this, this disorder, disorder can, can be, be caused, caused by, by defect, defect (, ( s, s ), ) of, of either, either an, an apoB, apoB gene, gene or, or other, other genes.., genes.. We, We have, have undertaken, undertaken a, a hospital-based, hospital-based study, study ,, , to, to identify, identify possible, possible BRCA1, BRCA1 and, and BRCA2, BRCA2 founder, founder mutations, mutations in, in the, the Polish, Polish population, population ., . The, The study, study group, group consisted, consisted of, of 66, 66 Polish, Polish families, families with, with cancer, cancer who, who have, have at, at least, least three, three related, related females, females affected, affected with, with breast, breast or, or ovarian, ovarian cancer, cancer and, and who, who had, had cancer, cancer diagnosed, diagnosed ,, , in, in at, at least, least one, one of, of the, the three, three affected, affected females, females ,, , at, at age, age <, < 50, 50 years, years ., . A, A total, total of, of 26, 26 families, families had, had both, both breast, breast and, and ovarian, ovarian cancers, cancers ,, , 4, 4 families, families had, had ovarian, ovarian cancers, cancers only, only ,, , and, and 36, 36 families, families had, had breast, breast cancers, cancers only, only ., . Genomic, Genomic DNA, DNA was, was prepared, prepared from, from the, the peripheral, peripheral blood, blood leukocytes, leukocytes of, of at, at least, least one, one affected, affected woman, woman from, from each, each family, family ., . The, The entire, entire coding, coding region, region of, of BRCA1, BRCA1 and, and BRCA2, BRCA2 was, was screened, screened for, for the, the presence, presence of, of germline, germline mutations, mutations ,, , by, by use, use of, of SSCP, SSCP followed, followed by, by direct, direct sequencing, sequencing of, of observed, observed variants, variants ., . Mutations, Mutations were, were found, found in, in 35, 35 (, ( 53, 53 %, % ), ) of, of the, the 66, 66 families, families studied, studied ., . All, All but, but one, one of, of the, the mutations, mutations were, were detected, detected within, within the, the BRCA1, BRCA1 gene, gene ., . BRCA1, BRCA1 abnormalities, abnormalities were, were identified, identified in, in all, all four, four families, families with, with ovarian, ovarian cancer, cancer only, only ,, , in, in 67, 67 %, % of, of 27, 27 families, families with, with both, both breast, breast and, and ovarian, ovarian cancer, cancer ,, , and, and in, in 34, 34 %, % of, of 35, 35 families, families with, with breast, breast cancer, cancer only, only ., . The, The single, single family, family with, with a, a BRCA2, BRCA2 mutation, mutation had, had the, the breast-ovarian, breast-ovarian cancer, cancer syndrome, syndrome ., . Seven, Seven distinct, distinct mutations, mutations were, were identified, identified ;, ; five, five of, of these, these occurred, occurred in, in two, two or, or more, more families, families ., . In, In total, total ,, , recurrent, recurrent mutations, mutations were, were found, found in, in 33, 33 (, ( 94, 94 %, % ), ) of, of the, the 35, 35 families, families with, with detected, detected mutations, mutations ., . Three, Three BRCA1, BRCA1 abnormalities, abnormalities -, - 5382insC, 5382insC ,, , C61G, C61G ,, , and, and 4153delA, 4153delA -, - accounted, accounted for, for 51, 51 %, % ,, , 20, 20 %, % ,, , and, and 11, 11 %, % of, of the, the identified, identified mutations, mutations ,, , respectively.., respectively.. The, The association, association between, between normal, normal alleles, alleles at, at the, the CTG, CTG repeat, repeat and, and two, two nearby, nearby polymorphisms, polymorphisms in, in the, the myotonin, myotonin protein, protein kinase, kinase gene, gene ,, , the, the Alu, Alu insertion/deletion, insertion/deletion polymorphism, polymorphism and, and the, the myotonic, myotonic dystrophy, dystrophy kinase, kinase (, ( DMK, DMK ), ) (, ( G/T, G/T ), ) intron, intron 9/HinfI, 9/HinfI polymorphism, polymorphism ,, , has, has been, been analyzed, analyzed in, in South, South African, African Negroids, Negroids ,, , a, a population, population in, in which, which myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) has, has not, not been, been described, described ., . South, South African, African Negroids, Negroids have, have a, a CTG, CTG allelic, allelic distribution, distribution that, that is, is significantly, significantly different, different from, from that, that in, in Caucasoids, Caucasoids and, and Japanese, Japanese the, the CTG, CTG repeat, repeat lengths, lengths of, of >, > or, or =, = 19, 19 are, are very, very rare, rare ., . The, The striking, striking linkage, linkage disequilibrium, disequilibrium between, between specific, specific alleles, alleles at, at the, the Alu, Alu polymorphism, polymorphism (, ( Alu, Alu (, ( ins, ins ), ) and, and Alu, Alu (, ( del, del ), ) ), ) ,, , the, the HinfI, HinfI polymorphism, polymorphism (, ( HinfI-1, HinfI-1 and, and HinfI-2, HinfI-2 ), ) ,, , and, and the, the CTG, CTG repeat, repeat polymorphism, polymorphism seen, seen in, in Caucasoid, Caucasoid (, ( Europeans, Europeans and, and Canadians, Canadians ), ) populations, populations was, was also, also found, found in, in the, the South, South African, African Negroid, Negroid population, population ., . Numerous, Numerous haplotypes, haplotypes ,, , not, not previously, previously described, described in, in Europeans, Europeans ,, , were, were ,, , however, however ,, , found, found ., . It, It thus, thus seems, seems likely, likely that, that only, only a, a small, small number, number of, of these, these ``, `` African, African ``, `` chromosomes, chromosomes were, were present, present in, in the, the progenitors, progenitors of, of all, all non-African, non-African peoples, peoples ., . These, These data, data provide, provide support, support for, for the, the ``, `` out, out of, of Africa, Africa ``, `` model, model for, for the, the origin, origin of, of modern, modern humans, humans and, and suggest, suggest that, that the, the rare, rare ancestral, ancestral DM, DM mutation, mutation event, event may, may have, have occurred, occurred after, after the, the migration, migration from, from Africa, Africa ,, , hence, hence the, the absence, absence of, of DM, DM in, in sub-Saharan, sub-Saharan Negroid, Negroid peoples.., peoples.. The, The spinocerebellar, spinocerebellar ataxia, ataxia 3, 3 locus, locus (, ( SCA3, SCA3 ), ) for, for type, type I, I autosomal, autosomal dominant, dominant cerebellar, cerebellar ataxia, ataxia (, ( ADCA, ADCA type, type I, I ), ) ,, , a, a clinically, clinically and, and genetically, genetically heterogeneous, heterogeneous group, group of, of neurodegenerative, neurodegenerative disorders, disorders ,, , has, has been, been mapped, mapped to, to chromosome, chromosome 14q32, 14q32 ., . 1, 1 1, 1 ., . ADCA, ADCA type, type I, I patients, patients from, from families, families segregating, segregating SCA3, SCA3 share, share clinical, clinical features, features in, in common, common with, with those, those with, with Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) ,, , the, the gene, gene of, of which, which maps, maps to, to the, the same, same region, region ., . We, We show, show here, here that, that the, the disease, disease gene, gene segregating, segregating in, in each, each of, of three, three French, French ADCA, ADCA type, type I, I kindreds, kindreds and, and in, in a, a French, French family, family with, with neuropathological, neuropathological findings, findings suggesting, suggesting the, the ataxochoreic, ataxochoreic form, form of, of dentatorubropallidoluysian, dentatorubropallidoluysian atrophy, atrophy carries, carries an, an expanded, expanded CAG, CAG repeat, repeat sequence, sequence located, located at, at the, the same, same locus, locus as, as that, that for, for MJD, MJD ., . Analysis, Analysis of, of the, the mutation, mutation in, in these, these families, families shows, shows a, a strong, strong negative, negative correlation, correlation between, between size, size of, of the, the expanded, expanded CAG, CAG repeat, repeat and, and age, age at, at onset, onset of, of clinical, clinical disease, disease ., . Instability, Instability of, of the, the expanded, expanded triplet, triplet repeat, repeat was, was not, not found, found to, to be, be affected, affected by, by sex, sex of, of the, the parent, parent transmitting, transmitting the, the mutation, mutation ., . Evidence, Evidence was, was found, found for, for somatic, somatic and, and gonadal, gonadal mosaicism, mosaicism for, for alleles, alleles carrying, carrying expanded, expanded trinucleotide, trinucleotide repeats, repeats ., . Although, Although recent, recent data, data established, established that, that a, a specific, specific very-long-chain, very-long-chain fatty, fatty acyl-CoA, acyl-CoA synthetase, synthetase is, is defective, defective in, in X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) ,, , the, the ALD, ALD gene, gene is, is still, still unidentified, unidentified ., . The, The ALD, ALD locus, locus has, has been, been mapped, mapped to, to Xq28, Xq28 ,, , like, like the, the red, red and, and green, green color, color pigment, pigment genes, genes ., . Abnormal, Abnormal color, color vision, vision has, has been, been observed, observed in, in 12, 12 of, of 27, 27 patients, patients with, with adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) ,, , a, a milder, milder form, form of, of ALD, ALD ., . Furthermore, Furthermore ,, , rearrangements, rearrangements of, of the, the color, color vision, vision gene, gene cluster, cluster were, were found, found in, in four, four of, of eight, eight ALD, ALD kindreds, kindreds ., . This, This led, led us, us to, to propose, propose that, that a, a single, single DNA, DNA rearrangement, rearrangement could, could underlie, underlie both, both ALD, ALD and, and abnormal, abnormal color, color vision, vision in, in these, these patients, patients ., . Study, Study of, of 34, 34 French, French ALD, ALD patients, patients failed, failed to, to reveal, reveal a, a higher, higher than, than expected, expected frequency, frequency of, of green/red, green/red visual, visual pigment, pigment rearrangements, rearrangements 3, 3 to, to the, the red/green, red/green color, color vision, vision gene, gene complex, complex ., . The, The previous, previous report, report of, of such, such rearrangements, rearrangements was, was based, based on, on small, small numbers, numbers and, and lack, lack of, of knowledge, knowledge that, that the, the frequency, frequency of, of ``, `` abnormal, abnormal ``, `` color, color vision, vision arrays, arrays on, on molecular, molecular analysis, analysis was, was twice, twice as, as high, high as, as expected, expected on, on the, the basis, basis of, of the, the frequency, frequency of, of phenotypic, phenotypic color, color vision, vision defects, defects ., . The, The red/green, red/green color, color pigment, pigment (, ( R/GCP, R/GCP ), ) region, region was, was studied, studied by, by pulsed-field, pulsed-field gel, gel electrophoresis, electrophoresis in, in 14, 14 of, of these, these patients, patients ,, , and, and we, we did, did not, not find, find any, any fragment, fragment size, size difference, difference between, between the, the patients, patients and, and normal, normal individuals, individuals who, who have, have the, the same, same number, number of, of pigment, pigment genes, genes ., . The, The R/GCP, R/GCP region, region was, was also, also analyzed, analyzed in, in 29, 29 French, French and, and seven, seven North, North American, American ALD, ALD patients, patients by, by using, using six, six genomic, genomic DNA, DNA probes, probes ,, , isolated, isolated from, from a, a cosmid, cosmid walk, walk ,, , that, that flank, flank the, the color, color vision, vision genes, genes ., . No, No deletions, deletions were, were found, found with, with probes, probes that, that lie, lie 3, 3 of, of the, the green, green pigment, pigment genes, genes ., . One, One of, of the, the eight, eight previously, previously reported, reported ALD, ALD individuals, individuals has, has a, a long, long deletion, deletion 5, 5 of, of the, the red, red pigment, pigment gene, gene ,, , a, a deletion, deletion causing, causing blue, blue cone, cone monochromacy, monochromacy ., . This, This finding, finding and, and the, the previous, previous findings, findings of, of a, a 45, 45 %, % frequency, frequency of, of phenotypic, phenotypic color, color vision, vision defects, defects in, in patients, patients with, with AMN, AMN may, may suggest, suggest that, that the, the ALD/AMN, ALD/AMN gene, gene lies, lies 5, 5 to, to the, the red, red pigment, pigment gene, gene and, and that, that the, the frequent, frequent phenotypic, phenotypic color, color vision, vision anomalies, anomalies owe, owe their, their origin, origin to, to deleted, deleted DNA, DNA that, that includes, includes regulatory, regulatory genes, genes for, for color, color vision, vision ., . It, It is, is possible, possible ,, , however, however ,, , that, that phenotypic, phenotypic color, color vision, vision anomalies, anomalies in, in AMN, AMN may, may be, be phenocopies, phenocopies secondary, secondary to, to retinal, retinal or, or neural, neural involvement, involvement by, by the, the disease, disease ., . The, The single, single case, case of, of blue, blue cone, cone monochromacy, monochromacy may, may therefore, therefore be, be a, a fortuitous, fortuitous coincidence, coincidence of, of two, two diseases.., diseases.. Of, Of the, the many, many palmoplantar, palmoplantar keratoderma, keratoderma (, ( PPK, PPK ), ) conditions, conditions ,, , only, only Papillon-Lefevre, Papillon-Lefevre syndrome, syndrome (, ( PLS, PLS ), ) and, and Haim-Munk, Haim-Munk syndrome, syndrome (, ( HMS, HMS ), ) are, are associated, associated with, with premature, premature periodontal, periodontal destruction, destruction ., . Although, Although both, both PLS, PLS and, and HMS, HMS share, share the, the cardinal, cardinal features, features of, of PPK, PPK and, and severe, severe periodontitis, periodontitis ,, , a, a number, number of, of additional, additional findings, findings are, are reported, reported in, in HMS, HMS including, including arachnodactyly, arachnodactyly ,, , acro-osteolysis, acro-osteolysis ,, , atrophic, atrophic changes, changes of, of the, the nails, nails ,, , and, and a, a radiographic, radiographic deformity, deformity of, of the, the fingers, fingers ., . While, While PLS, PLS cases, cases have, have been, been identified, identified throughout, throughout the, the world, world ,, , HMS, HMS has, has only, only been, been described, described among, among descendants, descendants of, of a, a religious, religious isolate, isolate originally, originally from, from Cochin, Cochin ,, , India, India ., . Parental, Parental consanguinity, consanguinity is, is a, a characteristic, characteristic of, of many, many cases, cases of, of both, both conditions, conditions ., . Although, Although autosomal, autosomal recessive, recessive transmission, transmission of, of PLS, PLS is, is evident, evident ,, , a, a more, more ``, `` complex, complex ``, `` autosomal, autosomal recessive, recessive pattern, pattern of, of inheritance, inheritance with, with phenotypic, phenotypic influences, influences from, from a, a closely, closely linked, linked modifying, modifying locus, locus has, has been, been hypothesised, hypothesised for, for HMS, HMS ., . Recently, Recently ,, , mutations, mutations of, of the, the cathepsin, cathepsin C, C gene, gene have, have been, been identified, identified as, as the, the underlying, underlying genetic, genetic defect, defect in, in PLS, PLS ., . To, To determine, determine if, if a, a cathepsin, cathepsin C, C mutation, mutation is, is also, also responsible, responsible for, for HMS, HMS ,, , we, we sequenced, sequenced the, the gene, gene in, in affected, affected and, and unaffected, unaffected subjects, subjects from, from the, the Cochin, Cochin isolate, isolate in, in which, which both, both the, the PLS, PLS and, and HMS, HMS phenotypes, phenotypes appear, appear ., . Here, Here we, we report, report identification, identification of, of a, a mutation, mutation of, of cathepsin, cathepsin C, C (, ( exon, exon 6, 6 ,, , 2127A, 2127A --, -- >, > G, G ), ) that, that changes, changes a, a highly, highly conserved, conserved amino, amino acid, acid in, in the, the cathepsin, cathepsin C, C peptide, peptide ., . This, This mutation, mutation segregates, segregates with, with HMS, HMS in, in four, four nuclear, nuclear families, families ., . Additionally, Additionally ,, , the, the existence, existence of, of a, a shared, shared common, common haplotype, haplotype for, for genetic, genetic loci, loci flanking, flanking the, the cathepsin, cathepsin C, C gene, gene suggests, suggests that, that affected, affected subjects, subjects descended, descended from, from the, the Cochin, Cochin isolate, isolate are, are homozygous, homozygous for, for a, a mutation, mutation inherited, inherited ``, `` identical, identical by, by descent, descent ``, `` from, from a, a common, common ancestor, ancestor ., . This, This finding, finding supports, supports simple, simple autosomal, autosomal recessive, recessive inheritance, inheritance for, for HMS, HMS in, in these, these families, families ., . We, We also, also report, report a, a mutation, mutation of, of the, the same, same exon, exon 6, 6 CTSC, CTSC codon, codon (, ( 2126C, 2126C --, -- >, > T, T ), ) in, in a, a Turkish, Turkish family, family with, with classical, classical PLS, PLS ., . These, These findings, findings provide, provide evidence, evidence that, that PLS, PLS and, and HMS, HMS are, are allelic, allelic variants, variants of, of cathepsin, cathepsin C, C gene, gene mutations.., mutations.. A, A somatic, somatic mutation, mutation in, in the, the X, X linked, linked PIGA, PIGA gene, gene is, is responsible, responsible for, for the, the deficiency, deficiency of, of glycosyl, glycosyl phosphatidylinositol, phosphatidylinositol (, ( GPI, GPI ), ) -anchored, -anchored proteins, proteins on, on blood, blood cells, cells from, from patients, patients with, with paroxysmal, paroxysmal nocturnal, nocturnal hemoglobinuria, hemoglobinuria ., . No, No inherited, inherited form, form of, of GPI-anchor, GPI-anchor deficiency, deficiency has, has been, been described, described ., . Because, Because conventional, conventional Piga, Piga gene, gene knockout, knockout is, is associated, associated with, with high, high embryonic, embryonic lethality, lethality in, in chimeric, chimeric mice, mice ,, , we, we used, used the, the Cre/loxP, Cre/loxP system, system ., . We, We generated, generated mice, mice in, in which, which two, two loxP, loxP sites, sites flank, flank part, part of, of Piga, Piga exon, exon 2, 2 ., . After, After crossbreeding, crossbreeding with, with female, female mice, mice of, of the, the EIIa-cre, EIIa-cre strain, strain ,, , the, the floxed, floxed allele, allele undergoes, undergoes Cre-mediated, Cre-mediated recombination, recombination with, with high, high efficiency, efficiency during, during early, early embryonic, embryonic development, development ., . Because, Because of, of X, X chromosome, chromosome inactivation, inactivation ,, , female, female offspring, offspring are, are mosaic, mosaic for, for cells, cells that, that express, express or, or lack, lack GPI-linked, GPI-linked proteins, proteins ., . Analysis, Analysis of, of mosaic, mosaic mice, mice showed, showed that, that in, in heart, heart ,, , lung, lung ,, , kidney, kidney ,, , brain, brain ,, , and, and liver, liver ,, , mainly, mainly wild-type, wild-type Piga, Piga is, is active, active ,, , suggesting, suggesting that, that these, these tissues, tissues require, require GPI-linked, GPI-linked proteins, proteins ., . The, The salient, salient exceptions, exceptions were, were spleen, spleen ,, , thymus, thymus ,, , and, and red, red blood, blood cells, cells ,, , which, which had, had almost, almost equal, equal numbers, numbers of, of cells, cells expressing, expressing the, the wild-type, wild-type or, or the, the recombined, recombined allele, allele ,, , implying, implying that, that GPI-linked, GPI-linked proteins, proteins are, are not, not essential, essential for, for the, the derivation, derivation of, of these, these tissues, tissues ., . PIGA, PIGA (, ( -, - ), ) cells, cells had, had no, no growth, growth advantage, advantage ,, , suggesting, suggesting that, that other, other factors, factors are, are needed, needed for, for their, their clonal, clonal dominance, dominance in, in patients, patients with, with paroxysmal, paroxysmal nocturnal, nocturnal hemoglobinuria.., hemoglobinuria.. Norrie, Norrie disease, disease is, is a, a human, human X-linked, X-linked recessive, recessive disorder, disorder of, of unknown, unknown etiology, etiology characterized, characterized by, by congenital, congenital blindness, blindness ,, , sensory, sensory neural, neural deafness, deafness and, and mental, mental retardation, retardation ., . This, This disease, disease gene, gene was, was previously, previously linked, linked to, to the, the DXS7, DXS7 (, ( L1, L1 ., . 28, 28 ), ) locus, locus and, and the, the MAO, MAO genes, genes in, in band, band Xp11, Xp11 ., . 3, 3 3, 3 ., . We, We report, report here, here fine, fine physical, physical mapping, mapping of, of the, the obligate, obligate region, region containing, containing the, the Norrie, Norrie disease, disease gene, gene (, ( NDP, NDP ), ) defined, defined by, by a, a recombination, recombination and, and by, by the, the smallest, smallest submicroscopic, submicroscopic chromosomal, chromosomal deletion, deletion associated, associated with, with Norrie, Norrie disease, disease identified, identified to, to date, date ., . Analysis, Analysis ,, , using, using in, in addition, addition two, two overlapping, overlapping YAC, YAC clones, clones from, from this, this region, region ,, , allowed, allowed orientation, orientation of, of the, the MAOA, MAOA and, and MAOB, MAOB genes, genes in, in a, a 5-3-3-5, 5-3-3-5 configuration, configuration ., . A, A recombination, recombination event, event between, between a, a (, ( GT, GT ), ) n, n polymorphism, polymorphism in, in intron, intron 2, 2 of, of the, the MAOB, MAOB gene, gene and, and the, the NDP, NDP locus, locus ,, , in, in a, a family, family previously, previously reported, reported to, to have, have a, a recombination, recombination between, between DXS7, DXS7 and, and NDP, NDP ,, , delineates, delineates a, a flanking, flanking marker, marker telomeric, telomeric to, to this, this disease, disease gene, gene ., . An, An anonymous, anonymous DNA, DNA probe, probe ,, , dc12, dc12 ,, , present, present in, in one, one of, of the, the YACs, YACs and, and in, in a, a patient, patient with, with a, a submicroscopic, submicroscopic deletion, deletion which, which includes, includes MAOA, MAOA and, and MAOB, MAOB but, but not, not L1, L1 ., . 28, 28 ,, , serves, serves as, as a, a flanking, flanking marker, marker centromeric, centromeric to"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", to the, the disease, disease gene, gene ., . An, An Alu-PCR, Alu-PCR fragment, fragment from, from the, the right, right arm, arm of, of the, the MAO, MAO YAC, YAC (, ( YMAO, YMAO ., . AluR, AluR ), ) is, is not, not deleted, deleted in, in this, this patient, patient and, and also, also delineates, delineates the, the centromeric, centromeric extent, extent of, of the, the obligate, obligate disease, disease region, region ., . The, The apparent, apparent order, order of, of these, these loci, loci is, is telomere, telomere ., . DXS7-MAOA-MAOB-NDP-dc12-YMAO, DXS7-MAOA-MAOB-NDP-dc12-YMAO DXS7-MAOA-MAOB-NDP-dc12-YMAO, DXS7-MAOA-MAOB-NDP-dc12-YMAO ., . AluR, AluR ., . centromere, centromere ., . Together, Together these, these data, data define, define the, the obligate, obligate region, region containing, containing the, the NDP, NDP gene, gene to, to a, a chromosomal, chromosomal segment, segment less, less than, than 150, 150 kb.Glucose-6-phosphate, kb.Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ;, ; E., E. C., C. 1, 1 ., . 1, 1 ., . 1, 1 ., . 49, 49 ), ) deficiency, deficiency is, is the, the most, most common, common human, human enzymopathy, enzymopathy ;, ; more, more than, than 300, 300 different, different biochemical, biochemical variants, variants of, of the, the enzyme, enzyme have, have been, been described, described ., . In, In many, many parts, parts of, of the, the world, world the, the Mediterranean, Mediterranean type, type of, of G6PD, G6PD deficiency, deficiency is, is prevalent, prevalent ., . However, However ,, , G6PD, G6PD Mediterranean, Mediterranean has, has come, come to, to be, be regarded, regarded as, as a, a generic, generic term, term applied, applied to, to similar, similar G6PD, G6PD mutations, mutations thought, thought ,, , however, however ,, , to, to represent, represent a, a somewhat, somewhat heterogeneous, heterogeneous group, group ., . A, A C, C --, -- --, -- T, T mutation, mutation at, at nucleotide, nucleotide 563, 563 of, of G6PD, G6PD Mediterranean, Mediterranean has, has been, been identified, identified by, by Vulliamy, Vulliamy et, et al., al. ,, , and, and the, the same, same mutation, mutation has, has been, been found, found by, by De, De Vita, Vita et, et al, al ., . in, in G6PD, G6PD Mediterranean, Mediterranean ,, , G6PD, G6PD Sassari, Sassari ,, , and, and G6PD, G6PD Cagliari, Cagliari ., . The, The latter, latter subjects, subjects had, had an, an additional, additional mutation, mutation ,, , at, at nucleotide, nucleotide 1311, 1311 ,, , that, that did, did not, not produce, produce a, a coding, coding change, change ., . We, We have, have examined, examined genomic, genomic DNA, DNA of, of five, five patients, patients --, -- four, four of, of Spanish, Spanish origin, origin and, and one, one of, of Jewish, Jewish origin, origin --, -- having, having enzymatically, enzymatically documented, documented G6PD, G6PD Mediterranean, Mediterranean ., . All, All had, had both, both the, the mutation, mutation at, at nucleotide, nucleotide 563, 563 and, and that, that at, at nucleotide, nucleotide 1311, 1311 ., . A, A sixth, sixth sample, sample ,, , resembling, resembling G6PD, G6PD Mediterranean, Mediterranean kinetically, kinetically but, but with, with a, a slightly, slightly rapid, rapid electrophoretic, electrophoretic mobility, mobility ,, , was, was designated, designated G6PD, G6PD Andalus, Andalus and, and was, was found, found to, to have, have a, a different, different mutation, mutation ,, , a, a G, G --, -- --, -- A, A transition, transition at, at nucleotide, nucleotide 1361, 1361 ,, , producing, producing an, an arginine-to-histidine, arginine-to-histidine substitution, substitution ., . These, These studies, studies suggest, suggest that, that G6PD, G6PD Mediterranean, Mediterranean is, is ,, , after, after all, all ,, , relatively, relatively homogeneous.Prader-Willi, homogeneous.Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) is, is associated, associated with, with paternally, paternally derived, derived chromosomal, chromosomal deletions, deletions in, in region, region 15q11-13, 15q11-13 or, or with, with maternal, maternal disomy, disomy for, for chromosome, chromosome 15, 15 ., . Therefore, Therefore ,, , loss, loss of, of the, the expressed, expressed paternal, paternal alleles, alleles of, of maternally, maternally imprinted, imprinted genes, genes must, must be, be responsible, responsible for, for the, the PWS, PWS phenotype, phenotype ., . We, We have, have mapped, mapped the, the gene, gene encoding, encoding the, the small, small nuclear, nuclear RNA, RNA associated, associated polypeptide, polypeptide SmN, SmN (, ( SNRPN, SNRPN ), ) to, to human, human chromosome, chromosome 15q12, 15q12 and, and a, a processed, processed pseudogene, pseudogene SNRPNP1, SNRPNP1 to, to chromosome, chromosome region, region 6pter-p21, 6pter-p21 ., . Furthermore, Furthermore ,, , SNRPN, SNRPN was, was mapped, mapped to, to the, the minimal, minimal deletion, deletion interval, interval that, that is, is critical, critical for, for PWS, PWS ., . The, The fact, fact that, that the, the mouse, mouse Snrpn, Snrpn gene, gene is, is maternally, maternally imprinted, imprinted in, in brain, brain suggests, suggests that, that loss, loss of, of the, the paternally, paternally derived, derived SNRPN, SNRPN allele, allele may, may be, be involved, involved in, in the, the PWS, PWS phenotype.., phenotype.. OBJECTIVE, OBJECTIVE Previous, Previous reports, reports have, have suggested, suggested an, an increased, increased risk, risk of, of cancer, cancer among, among patients, patients with, with cartilage-hair, cartilage-hair hypoplasia, hypoplasia (, ( CHH, CHH ), ) ., . This, This study, study was, was carried, carried out, out to, to further, further evaluate, evaluate this, this risk, risk among, among patients, patients with, with CHH, CHH and, and their, their first-degree, first-degree relatives, relatives ., . STUDY, STUDY DESIGN, DESIGN One, One hundred, hundred twenty-two, twenty-two patients, patients with, with CHH, CHH were, were identified, identified through, through 2, 2 countrywide, countrywide epidemiologic, epidemiologic surveys, surveys in, in 1974, 1974 and, and in, in 1986, 1986 ., . Their, Their parents, parents and, and nonaffected, nonaffected siblings, siblings were, were identified, identified through, through the, the Population, Population Register, Register Center, Center ., . This, This cohort, cohort underwent, underwent follow-up, follow-up for, for cancer, cancer incidence, incidence through, through the, the Finnish, Finnish Cancer, Cancer Registry, Registry to, to the, the end, end of, of 1995, 1995 ., . RESULTS, RESULTS A, A statistically, statistically significant, significant excess, excess risk, risk of, of cancer, cancer was, was seen, seen among, among the, the patients, patients with, with CHH, CHH (, ( standardized, standardized incidence, incidence ratio, ratio 6, 6 ., . 9, 9 ,, , 95, 95 %, % confidence, confidence interval, interval 2, 2 ., . 3, 3 to, to 16, 16 ), ) ,, , which, which was, was mainly, mainly attributable, attributable to, to non-Hodgkins, non-Hodgkins lymphoma, lymphoma (, ( standardized, standardized incidence, incidence ratio, ratio 90, 90 ,, , 95, 95 %, % confidence, confidence interval, interval 18, 18 to, to 264, 264 ), ) ., . In, In addition, addition ,, , a, a significant, significant excess, excess risk, risk of, of basal, basal cell, cell carcinoma, carcinoma was, was seen, seen (, ( standardized, standardized incidence, incidence ratio, ratio 35, 35 ,, , 95, 95 %, % confidence, confidence interval, interval 7, 7 ., . 2, 2 to, to 102, 102 ), ) ., . The, The cancer, cancer incidence, incidence among, among the, the siblings, siblings or, or the, the parents, parents did, did not, not differ, differ from, from the, the average, average cancer, cancer incidence, incidence in, in the, the Finnish, Finnish population, population ., . CONCLUSIONS, CONCLUSIONS This, This study, study confirms, confirms an, an increased, increased risk, risk of, of cancer, cancer ,, , especially, especially non-Hodgkins, non-Hodgkins lymphoma, lymphoma ,, , probably, probably attributable, attributable to, to defective, defective immunity, immunity ,, , among, among patients, patients with, with CHH.Considerable, CHH.Considerable genetic, genetic heterogeneity, heterogeneity in, in G6PD, G6PD was, was found, found in, in the, the Bulgarian, Bulgarian population-14, population-14 G6PD, G6PD variants, variants isolated, isolated from, from 117, 117 hemizygous, hemizygous carriers, carriers of, of G6PD, G6PD deficiency, deficiency ., . Of, Of these, these ,, , G6PD, G6PD Mediterranean, Mediterranean type, type was, was a, a polymorphic, polymorphic variant, variant and, and G6PD, G6PD Corinth, Corinth occurred, occurred with, with high, high frequency, frequency ., . Two, Two new, new variants, variants were, were identified-G6PD, identified-G6PD Rudosem, Rudosem and, and G6PD, G6PD Nedelino, Nedelino ., . In, In a, a selected, selected group, group of, of 78, 78 subjects, subjects with, with clinical, clinical manifestations, manifestations ,, , four, four variants, variants were, were established, established G6PD, G6PD Mediterranian, Mediterranian ,, , G6PD, G6PD Corinth, Corinth ,, , G6PD, G6PD Seattle, Seattle and, and G6PD, G6PD Ohut, Ohut II.., II.. DiGeorge, DiGeorge syndrome, syndrome (, ( DGS, DGS ), ) ,, , a, a developmental, developmental field, field defect, defect of, of the, the third, third and, and fourth, fourth pharyngeal, pharyngeal pouches, pouches ,, , is, is characterized, characterized by, by aplasia, aplasia or, or hypoplasia, hypoplasia of, of the, the thymus, thymus and, and parathyroid, parathyroid glands, glands and, and by, by conotruncal, conotruncal cardiac, cardiac malformations, malformations ., . Cytogenetic, Cytogenetic studies, studies support, support the, the presence, presence of, of a, a DGS, DGS critical, critical region, region in, in band, band 22q11, 22q11 ., . In, In the, the present, present study, study ,, , we, we report, report the, the results, results of, of clinical, clinical ,, , cytogenetic, cytogenetic ,, , and, and molecular, molecular studies, studies of, of 14, 14 patients, patients with, with DGS, DGS ., . Chromosome, Chromosome analysis, analysis ,, , utilizing, utilizing high-resolution, high-resolution banding, banding techniques, techniques ,, , detected, detected interstitial, interstitial deletions, deletions in, in five, five probands, probands and, and was, was inconclusive, inconclusive for, for a, a deletion, deletion in, in three, three probands, probands ., . The, The remaining, remaining six, six patients, patients had, had normal, normal karyotypes, karyotypes ., . In, In contrast, contrast ,, , molecular, molecular analysis, analysis detected, detected DNA, DNA deletions, deletions in, in all, all 14, 14 probands, probands ., . Two, Two of, of 10, 10 loci, loci tested, tested ,, , D22S75, D22S75 and, and D22S259, D22S259 ,, , are, are deleted, deleted in, in all, all 14, 14 patients, patients ., . A, A third, third locus, locus ,, , D22S66, D22S66 ,, , is, is deleted, deleted in, in the, the eight, eight DGS, DGS probands, probands tested, tested ., . Physical, Physical mapping, mapping using, using somatic, somatic cell, cell hybrids, hybrids places, places D22S66, D22S66 between, between D22S75, D22S75 and, and D22S259, D22S259 ,, , suggesting, suggesting that, that it, it should, should be, be deleted, deleted in, in the, the remaining, remaining six, six cases, cases ., . Parent-of-origin, Parent-of-origin studies, studies were, were performed, performed in, in five, five families, families ., . Four, Four probands, probands failed, failed to, to inherit, inherit a, a maternal, maternal allele, allele ,, , and, and one, one failed, failed to, to inherit, inherit a, a paternal, paternal allele, allele ., . On, On the, the basis, basis of, of these, these families, families ,, , and, and of, of six, six maternally, maternally and, and five, five paternally, paternally derived, derived unbalanced-translocation, unbalanced-translocation DGS, DGS probands, probands in, in the, the literature, literature ,, , parent, parent of, of origin, origin or, or imprinting, imprinting does, does not, not appear, appear to, to play, play an, an important, important role, role in, in the, the pathogenesis, pathogenesis of, of DGS, DGS ., . Deletion, Deletion of, of the, the same, same three, three loci, loci in, in all, all 14, 14 DGS, DGS probands, probands begins, begins to, to delineate, delineate the, the region, region of, of chromosome, chromosome 22, 22 critical, critical for, for DGS, DGS and, and confirms, confirms the, the hypothesis, hypothesis that, that submicroscopic, submicroscopic deletions, deletions of, of 22q11, 22q11 are, are etiologic, etiologic in, in the, the vast, vast majority, majority of, of cases.., cases.. A, A new, new fragile, fragile site, site (, ( FRAXE, FRAXE ), ) in, in Xq28, Xq28 is, is described, described ., . It, It appears, appears to, to be, be a, a typical, typical folate, folate sensitive, sensitive fragile, fragile site, site ., . The, The fragile, fragile site, site is, is not, not associated, associated with, with mental, mental retardation, retardation ,, , it, it does, does not, not give, give abnormal, abnormal results, results when, when subjected, subjected to, to Southern, Southern analysis, analysis with, with probe, probe pfxa3, pfxa3 which, which detects, detects the, the unstable, unstable DNA, DNA sequence, sequence characteristic, characteristic of, of fragile, fragile X, X syndrome, syndrome ., . In, In situ, situ hybridization, hybridization mapping, mapping locates, locates the, the fragile, fragile site, site between, between 150, 150 kb, kb and, and 600, 600 kb, kb distal, distal to, to FRAXA, FRAXA ., . The, The distinction, distinction between, between the, the two, two fragile, fragile sites, sites is, is important, important clinically, clinically since, since cytogenetic, cytogenetic detection, detection of, of FRAXE, FRAXE ,, , without, without molecular, molecular analysis, analysis ,, , could, could result, result in, in misdiagnosis, misdiagnosis of, of fragile, fragile X, X syndrome.., syndrome.. Loss, Loss of, of heterozygosity, heterozygosity data, data from, from familial, familial tumors, tumors suggest, suggest that, that BRCA1, BRCA1 ,, , a, a gene, gene that, that confers, confers susceptibility, susceptibility to, to ovarian, ovarian and, and early-onset, early-onset breast, breast cancer, cancer ,, , encodes, encodes a, a tumor, tumor suppressor, suppressor ., . The, The BRCA1, BRCA1 region, region is, is also, also subject, subject to, to allelic, allelic loss, loss in, in sporadic, sporadic breast, breast and, and ovarian, ovarian cancers, cancers ,, , an, an indication, indication that, that BRCA1, BRCA1 mutations, mutations may, may occur, occur somatically, somatically in, in these, these tumors, tumors ., . The, The BRCA1, BRCA1 coding, coding region, region was, was examined, examined for, for mutations, mutations in, in primary, primary breast, breast and, and ovarian, ovarian tumors, tumors that, that show, show allele, allele loss, loss at, at the, the BRCA1, BRCA1 locus, locus ., . Mutations, Mutations were, were detected, detected in, in 3, 3 of, of 32, 32 breast, breast and, and 1, 1 of, of 12, 12 ovarian, ovarian carcinomas, carcinomas ;, ; all, all four, four mutations, mutations were, were germline, germline alterations, alterations and, and occurred, occurred in, in early-onset, early-onset cancers, cancers ., . These, These results, results suggest, suggest that, that mutation, mutation of, of BRCA1, BRCA1 may, may not, not be, be critical, critical in, in the, the development, development of, of the, the majority, majority of, of breast, breast and, and ovarian, ovarian cancers, cancers that, that arise, arise in, in the, the absence, absence of, of a, a mutant, mutant germline, germline allele.., allele.. The, The EWS, EWS gene, gene has, has been, been identified, identified based, based on, on its, its location, location at, at the, the chromosome, chromosome 22, 22 breakpoint, breakpoint of, of the, the t, t (, ( 11, 11 ;, ; 22, 22 ), ) (, ( q24, q24 ;, ; q12, q12 ), ) translocation, translocation that, that characterizes, characterizes Ewing, Ewing sarcoma, sarcoma and, and related, related neuroectodermal, neuroectodermal tumors, tumors ., . The, The EWS, EWS gene, gene spans, spans about, about 40, 40 kb, kb of, of DNA, DNA and, and is, is encoded, encoded by, by 17, 17 exons, exons ., . The, The nucleotide, nucleotide sequence, sequence of, of the, the exons, exons is, is identical, identical to, to that, that of, of the, the previously, previously described, described cDNA, cDNA ., . The, The first, first 7, 7 exons, exons encode, encode the, the N-terminal, N-terminal domain, domain of, of EWS, EWS ,, , which, which consists, consists of, of a, a repeated, repeated degenerated, degenerated polypeptide, polypeptide of, of 7, 7 to, to 12, 12 residues, residues rich, rich in, in tyrosine, tyrosine ,, , serine, serine ,, , threonine, threonine ,, , glycine, glycine ,, , and, and glutamine, glutamine ., . Exons, Exons 11, 11 ,, , 12, 12 ,, , and, and 13, 13 encode, encode the, the putative, putative RNA, RNA binding, binding domain, domain ., . The, The three, three glycine-, glycine- and, and arginine-rich, arginine-rich motifs, motifs of, of the, the gene, gene are, are mainly, mainly encoded, encoded by, by exons, exons 8-9, 8-9 ,, , 14, 14 ,, , and, and 16, 16 ., . The, The DNA, DNA sequence, sequence in, in the, the 5, 5 region, region of, of the, the gene, gene has, has features, features of, of a, a CpG-rich, CpG-rich island, island and, and lacks, lacks canonical, canonical promoter, promoter elements, elements ,, , such, such as, as TATA, TATA and, and CCAAT, CCAAT consensus, consensus sequences, sequences ., . Positions, Positions of, of the, the chromosome, chromosome 22, 22 breakpoints, breakpoints were, were determined, determined for, for 19, 19 Ewing, Ewing tumors, tumors ., . They, They were, were localized, localized in, in introns, introns 7, 7 or, or 8, 8 in, in 18, 18 cases, cases and, and in, in intron, intron 10, 10 in, in 1, 1 case.., case.. Aniridia, Aniridia is, is a, a congenital, congenital malformation, malformation of, of the, the eye, eye ,, , chiefly, chiefly characterised, characterised by, by iris, iris hypoplasia, hypoplasia ,, , which, which can, can cause, cause blindness, blindness ., . The, The PAX6, PAX6 gene, gene was, was isolated, isolated as, as a, a candidate, candidate aniridia, aniridia gene, gene by, by positional, positional cloning, cloning from, from the, the smallest, smallest region, region of, of overlap, overlap of, of aniridia-associated, aniridia-associated deletions, deletions ., . Subsequently, Subsequently PAX6, PAX6 intragenic, intragenic mutations, mutations were, were demonstrated, demonstrated in, in Smalleye, Smalleye ,, , a, a mouse, mouse mutant, mutant which, which is, is an, an animal, animal model, model for, for aniridia, aniridia ,, , and, and six, six human, human aniridia, aniridia patients, patients ., . In, In this, this paper, paper we, we describe, describe four, four additional, additional PAX6, PAX6 point, point mutations, mutations in, in aniridia, aniridia patients, patients ,, , both, both sporadic, sporadic and, and familial, familial ., . These, These mutations, mutations highlight, highlight regions, regions of, of the, the gene, gene which, which are, are essential, essential for, for normal, normal PAX6, PAX6 function, function ., . In, In addition, addition ,, , the, the frequency, frequency at, at which, which we, we have, have found, found PAX6, PAX6 mutations, mutations suggests, suggests that, that lesions, lesions in, in PAX6, PAX6 will, will account, account for, for most, most cases, cases of, of aniridia.., aniridia.. The, The 14, 14 exons, exons of, of the, the PAX6, PAX6 gene, gene have, have been, been analysed, analysed exon-by-exon, exon-by-exon using, using SSCP, SSCP in, in 6, 6 aniridia, aniridia families, families ., . In, In each, each family, family band, band shifts, shifts were, were observed, observed on, on the, the SSCP, SSCP gels, gels for, for only, only one, one exon, exon and, and direct, direct PCR-sequencing, PCR-sequencing revealed, revealed mutations, mutations in, in each, each case, case ., . Two, Two mutations, mutations involved, involved C, C --, -- >, > T, T transitions, transitions in, in CGAarg, CGAarg codons, codons in, in exons, exons 9, 9 and, and 11, 11 ., . Another, Another C, C --, -- >, > T, T transition, transition converted, converted a, a CAG-glutamine, CAG-glutamine to, to a, a TAG-stop, TAG-stop in, in exon, exon 7, 7 ., . Small, Small insertions, insertions created, created frameshifts, frameshifts which, which produced, produced downstream, downstream stop, stop codons, codons in, in another, another two, two patients, patients and, and an, an A, A --, -- >, > T, T mutation, mutation disrupted, disrupted the, the splice, splice donor, donor site, site of, of exon, exon 5, 5 in, in the, the remaining, remaining family, family ., . Thus, Thus ,, , complete, complete inactivation, inactivation of, of the, the PAX6, PAX6 gene, gene is, is predicted, predicted in, in all, all cases, cases ., . Analysis, Analysis of, of other, other affected, affected members, members of, of the, the families, families showed, showed that, that ,, , in, in each, each case, case ,, , all, all affected, affected individuals, individuals carried, carried the, the same, same family-specific, family-specific mutation, mutation ., . One, One polymorphism, polymorphism was, was found, found in, in exon, exon 7, 7 ., . This, This data, data strongly, strongly supports, supports the, the candidature, candidature of, of PAX6, PAX6 as, as the, the gene, gene responsible, responsible for, for hereditary, hereditary aniridia.., aniridia.. Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) is, is the, the most, most common, common form, form of, of autosomal, autosomal recessive, recessive ataxia, ataxia ., . The, The disease, disease locus, locus was, was assigned, assigned to, to chromosome, chromosome 9, 9 and, and the, the disease, disease gene, gene ,, , STM7/X25, STM7/X25 ,, , has, has been, been isolated, isolated ., . To, To date, date most, most data, data suggest, suggest locus, locus homogeneity, homogeneity in, in FRDA, FRDA ., . We, We now, now provide, provide strong, strong evidence, evidence of, of a, a second, second FRDA, FRDA locus, locus ., . Studying, Studying two, two siblings, siblings with, with FRDA, FRDA from, from two, two families, families we, we did, did not, not detect, detect a, a mutation, mutation in, in STM7/X25, STM7/X25 ., . Haplotype, Haplotype analysis, analysis of, of the, the STM7/X25, STM7/X25 region, region of, of chromosome, chromosome 9, 9 demonstrated, demonstrated that, that the, the relevant, relevant portion, portion of, of chromosome, chromosome 9, 9 differs, differs in, in the, the patients, patients ., . Although, Although the, the patients, patients studied, studied had, had typical, typical FRDA, FRDA ,, , one, one sibpair, sibpair had, had the, the uncommon, uncommon symptom, symptom of, of retained, retained tendon, tendon reflexes, reflexes ., . In, In order, order to, to investigate, investigate whether, whether retained, retained tendon, tendon reflexes, reflexes are, are characteristic, characteristic of, of FRDA, FRDA caused, caused by, by the, the second, second locus, locus ,, , FRDA2, FRDA2 ,, , we, we studied, studied an, an unrelated, unrelated FRDA, FRDA patient, patient with, with retained, retained tendon, tendon reflexes, reflexes ., . The, The observation, observation of, of typical, typical mutations, mutations in, in STM7/X25, STM7/X25 (, ( GAA, GAA expansions, expansions ), ) in, in this, this patient, patient demonstrates, demonstrates that, that the, the two, two genetically, genetically different, different forms, forms of, of FRDA, FRDA can, can not, not be, be distinguished, distinguished clinically.., clinically.. Anterior, Anterior segment, segment developmental, developmental disorders, disorders ,, , including, including Axenfeld-Rieger, Axenfeld-Rieger anomaly, anomaly (, ( ARA, ARA ), ) ,, , variably, variably associate, associate with, with harmfully, harmfully elevated, elevated intraocular, intraocular pressure, pressure (, ( IOP, IOP ), ) ,, , which, which causes, causes glaucoma, glaucoma ., . Clinically, Clinically observed, observed dysgenesis, dysgenesis does, does not, not correlate, correlate with, with IOP, IOP ,, , however, however ,, , and, and the, the etiology, etiology of, of glaucoma, glaucoma development, development is, is not, not understood, understood ., . The, The forkhead, forkhead transcription, transcription factor, factor genes, genes Foxc1, Foxc1 (, ( formerly, formerly Mf1, Mf1 ), ) and, and Foxc2, Foxc2 (, ( formerly, formerly Mfh1, Mfh1 ), ) are, are expressed, expressed in, in the, the mesenchyme, mesenchyme from, from which, which the, the ocular, ocular drainage, drainage structures, structures derive, derive ., . Mutations, Mutations in, in the, the human, human homolog, homolog of, of Foxc1, Foxc1 ,, , FKHL7, FKHL7 ,, , cause, cause dominant, dominant anterior, anterior segment, segment defects, defects and, and glaucoma, glaucoma in, in various, various families, families ., . We, We show, show that, that Foxc1, Foxc1 (, ( +/-, +/- ), ) mice, mice have, have anterior, anterior segment, segment abnormalities, abnormalities similar, similar to, to those, those reported, reported in, in human, human patients, patients ., . These, These abnormalities, abnormalities include, include small, small or, or absent, absent Schlemms, Schlemms canal, canal ,, , aberrantly, aberrantly developed, developed trabecular, trabecular meshwork, meshwork ,, , iris, iris hypoplasia, hypoplasia ,, , severely, severely eccentric, eccentric pupils, pupils and, and displaced, displaced Schwalbes, Schwalbes line, line ., . The, The penetrance, penetrance of, of clinically, clinically obvious, obvious abnormalities, abnormalities varies, varies with, with genetic, genetic background, background ., . In, In some, some affected, affected eyes, eyes ,, , collagen, collagen bundles, bundles were, were half, half normal, normal diameter, diameter ,, , or, or collagen, collagen and, and elastic, elastic tissue, tissue were, were very, very sparse, sparse ., . Thus, Thus ,, , abnormalities, abnormalities in, in extracellular, extracellular matrix, matrix synthesis, synthesis or, or organization, organization may, may contribute, contribute to, to development, development of, of the, the ocular, ocular phenotypes, phenotypes ., . Despite, Despite the, the abnormalities, abnormalities in, in ocular, ocular drainage, drainage structures, structures in, in Foxc1, Foxc1 (, ( +/-, +/- ), ) mice, mice ,, , IOP, IOP was, was normal, normal in, in almost, almost all, all mice, mice analyzed, analyzed ,, , on, on all, all genetic, genetic backgrounds, backgrounds and, and at, at all, all ages, ages ., . Similar, Similar abnormalities, abnormalities were, were found, found in, in Foxc2, Foxc2 (, ( +/-, +/- ), ) mice, mice ,, , but, but no, no disease-associated, disease-associated mutations, mutations were, were identified, identified in, in the, the human, human homolog, homolog FKHL14, FKHL14 in, in 32, 32 ARA, ARA patients, patients ., . Foxc1, Foxc1 (, ( +/-, +/- ), ) and, and Foxc2, Foxc2 (, ( +/-, +/- ), ) mice, mice are, are useful, useful models, models for, for studying, studying anterior, anterior segment, segment development, development and, and its, its anomalies, anomalies ,, , and, and may, may allow, allow identification, identification of, of genes, genes that, that interact, interact with, with Foxc1, Foxc1 and, and Foxc2, Foxc2 (, ( or, or FKHL7, FKHL7 and, and FKHL14, FKHL14 ), ) to, to produce, produce a, a phenotype, phenotype with, with elevated, elevated IOP, IOP and, and glaucoma.., glaucoma.. Dermatofibrosarcoma, Dermatofibrosarcoma protuberans, protuberans (, ( DFSP, DFSP ), ) displays, displays chromosomal, chromosomal rearrangements, rearrangements involving, involving chromosome, chromosome 17, 17 and, and 22, 22 ,, , which, which fuse, fuse the, the collagen, collagen type, type Ialpha1, Ialpha1 (, ( COLIA1, COLIA1 ), ) gene, gene to, to the, the platelet-derived, platelet-derived growth, growth factor, factor (, ( PDGF, PDGF ), ) B-chain, B-chain (, ( PDGFB, PDGFB ), ) gene, gene ., . To, To characterize, characterize the, the functional, functional and, and structural, structural properties, properties of, of the, the COLIA1/PDGFB, COLIA1/PDGFB fusion, fusion protein, protein ,, , we, we generated, generated a, a stable, stable NIH3T3, NIH3T3 cell, cell line, line that, that contained, contained a, a tumor-derived, tumor-derived chimeric, chimeric gene, gene resulting, resulting from, from a, a COIA1, COIA1 intron, intron 7-PDGFB, 7-PDGFB intron, intron 1, 1 fusion, fusion ., . Expression, Expression of, of the, the fusion, fusion protein, protein led, led to, to morphological, morphological transformation, transformation and, and increased, increased growth, growth rate, rate of, of these, these cells, cells ., . The, The PDGF, PDGF receptor, receptor kinase, kinase inhibitor, inhibitor CGP57148B, CGP57148B reversed, reversed the, the transformed, transformed phenotype, phenotype and, and reduced, reduced the, the growth, growth rate, rate of, of COLIA1/PDGFB-expressing, COLIA1/PDGFB-expressing cells, cells but, but had, had no, no effects, effects on, on control, control cells, cells ., . The, The presence, presence of, of dimeric, dimeric COLIA1/PDGFB, COLIA1/PDGFB precursors, precursors was, was demonstrated, demonstrated through, through PDGFB, PDGFB immunoprecipitations, immunoprecipitations of, of metabolically, metabolically labeled, labeled cells, cells and, and also, also by, by PDGFB, PDGFB immunoprecipitations, immunoprecipitations followed, followed by, by immunoblotting, immunoblotting with, with COLIA1, COLIA1 antibodies, antibodies ., . Pulse-chase, Pulse-chase studies, studies demonstrated, demonstrated that, that the, the COLIA1/PDGFB, COLIA1/PDGFB precursor, precursor was, was processed, processed to, to an, an end, end product, product that, that was, was indistinguishable, indistinguishable from, from wild-type, wild-type PDGF-BB, PDGF-BB ., . Finally, Finally ,, , COLIA1/PDGFB-expressing, COLIA1/PDGFB-expressing cells, cells generated, generated tumors, tumors after, after s., s. c, c c., c. injection, injection into, into nude, nude mice, mice ,, , and, and tumor, tumor growth, growth was, was reduced, reduced by, by treatment, treatment with, with CGP57148B, CGP57148B ., . We, We conclude"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", conclude that, that the, the COLIA1/PDGFB, COLIA1/PDGFB fusion, fusion associated, associated with, with DFSP, DFSP contributes, contributes to, to tumor, tumor development, development through, through ectopic, ectopic production, production of, of PDGF-BB, PDGF-BB and, and the, the formation, formation of, of an, an autocrine, autocrine loop, loop ., . Our, Our findings, findings ,, , thus, thus ,, , suggest, suggest that, that PDGF, PDGF receptors, receptors could, could be, be a, a target, target for, for pharmacological, pharmacological treatment, treatment of, of DFSP, DFSP and, and giant, giant cell, cell fibroblastoma, fibroblastoma ,, , e., e. g., g. ,, , through, through the, the use, use of, of PDGF, PDGF receptor, receptor kinase, kinase inhibitors, inhibitors such, such as, as CGP57148B.A, CGP57148B.A missense, missense mutation, mutation has, has been, been identified, identified in, in the, the human, human phenylalanine, phenylalanine hydroxylase, hydroxylase [, [ PAH, PAH ;, ; phenylalanine, phenylalanine 4-monooxygenase, 4-monooxygenase ;, ; L-phenylalanine, L-phenylalanine ,, , tetrahydrobiopterin, tetrahydrobiopterin oxygen, oxygen oxidoreductase, oxidoreductase (, ( 4-hydroxylating, 4-hydroxylating ), ) ,, , EC, EC 1, 1 ., . 14, 14 ., . 16, 16 ., . 1, 1 ], ] gene, gene in, in a, a Chinese, Chinese patient, patient with, with classic, classic phenylketonuria, phenylketonuria (, ( PKU, PKU ), ) ., . A, A G-to-C, G-to-C transition, transition at, at the, the second, second base, base of, of codon, codon 413, 413 in, in exon, exon 12, 12 of, of the, the gene, gene results, results in, in the, the substitution, substitution of, of Pro413, Pro413 for, for Arg413, Arg413 in, in the, the mutant, mutant protein, protein ., . This, This mutation, mutation (, ( R413P, R413P ), ) results, results in, in negligible, negligible enzymatic, enzymatic activity, activity when, when expressed, expressed in, in heterologous, heterologous mammalian, mammalian cells, cells and, and is, is compatible, compatible with, with a, a classic, classic PKU, PKU phenotype, phenotype in, in the, the patient, patient ., . Population, Population genetic, genetic studies, studies reveal, reveal that, that this, this mutation, mutation is, is tightly, tightly linked, linked to, to restriction, restriction fragment, fragment length, length polymorphism, polymorphism haplotype, haplotype 4, 4 ,, , which, which is, is the, the predominant, predominant haplotype, haplotype of, of the, the PAH, PAH locus, locus in, in the, the Oriental, Oriental population, population ., . It, It accounts, accounts for, for 13, 13 ., . 8, 8 %, % of, of northern, northern Chinese, Chinese and, and 27, 27 %, % of, of Japanese, Japanese PKU, PKU alleles, alleles ,, , but, but it, it is, is rare, rare in, in southern, southern Chinese, Chinese (, ( 2, 2 ., . 2, 2 %, % ), ) and, and is, is absent, absent in, in the, the Caucasian, Caucasian population, population ., . The, The data, data demonstrate, demonstrate unambiguously, unambiguously that, that the, the mutation, mutation occurred, occurred after, after racial, racial divergence, divergence of, of Orientals, Orientals and, and Caucasians, Caucasians and, and suggest, suggest that, that the, the allele, allele has, has spread, spread throughout, throughout the, the Orient, Orient by, by a, a founder, founder effect, effect ., . Previous, Previous protein, protein polymorphism, polymorphism studies, studies in, in eastern, eastern Asia, Asia have, have led, led to, to the, the hypothesis, hypothesis that, that ``, `` northern, northern Mongoloids, Mongoloids ``, `` represented, represented a, a founding, founding population, population in, in Asia, Asia ., . Our, Our results, results are, are compatible, compatible with, with this, this hypothesis, hypothesis in, in that, that the, the PKU, PKU mutation, mutation might, might have, have occurred, occurred in, in northern, northern Mongoloids, Mongoloids and, and subsequently, subsequently spread, spread to, to the, the Chinese, Chinese and, and Japanese, Japanese populations.To, populations.To determine, determine the, the prevalence, prevalence and, and characterize, characterize demographic, demographic ,, , clinical, clinical ,, , and, and genetic, genetic features, features of, of familial, familial Mediterranean, Mediterranean fever, fever (, ( FMF, FMF ), ) of, of late, late onset, onset ,, , all, all patients, patients experiencing, experiencing their, their first, first FMF, FMF attack, attack at, at age, age 40, 40 years, years or, or more, more were, were identified, identified using, using the, the computerized, computerized registry, registry of, of our, our FMF, FMF clinic, clinic ,, , and, and then, then thoroughly, thoroughly interviewed, interviewed and, and examined, examined ., . The, The control, control group, group consisted, consisted of, of 40, 40 consecutive, consecutive FMF, FMF patients, patients ,, , who, who arrived, arrived at, at the, the FMF, FMF clinic, clinic for, for their, their regular, regular follow-up, follow-up visit, visit and, and were, were 40, 40 years, years of, of age, age or, or older, older at, at the, the time, time of, of the, the examination, examination ., . The, The severity, severity of, of the, the disease, disease in, in patients, patients and, and controls, controls was, was determined, determined using, using a, a modified, modified score, score ,, , developed, developed previously, previously ., . Mutational, Mutational analysis, analysis in, in the, the FMF, FMF gene, gene was, was performed, performed using, using a, a commercial, commercial kit, kit ., . Only, Only 20, 20 of, of 4000, 4000 (, ( 0, 0 ., . 5, 5 %, % ), ) patients, patients had, had late-onset, late-onset FMF, FMF ., . These, These patients, patients were, were mostly, mostly men, men ,, , of, of non-North, non-North African, African origin, origin ,, , P, P <, < 0, 0 ., . 05, 05 compared, compared to, to controls, controls ., . All, All had, had abdominal, abdominal attacks, attacks and, and in, in most, most these, these were, were the, the only, only manifestation, manifestation of, of their, their disease, disease ,, , P, P <, < 0, 0 ., . 001, 001 001, 001 ., . None, None had, had chronic, chronic or, or prolonged, prolonged manifestations, manifestations of, of FMF, FMF ,, , for, for example, example ,, , amyloidosis, amyloidosis ,, , chronic, chronic arthritis, arthritis ,, , or, or protracted, protracted myalgia, myalgia ,, , P, P <, < 0, 0 ., . 001, 001 ., . The, The response, response to, to treatment, treatment was, was good, good despite, despite using, using low, low colchicine, colchicine dose, dose ,, , P, P <, < 0, 0 ., . 05, 05 ., . The, The overall, overall severity, severity score, score indicated, indicated a, a mild, mild disease, disease ,, , P, P <, < 0, 0 ., . 001, 001 ., . Mutational, Mutational analysis, analysis revealed, revealed absence, absence of, of M694V, M694V homozygosity, homozygosity ,, , P, P <, < 0, 0 ., . 01, 01 ,, , compared, compared to, to our, our regular, regular FMF, FMF population, population ., . We, We conclude, conclude that, that the, the onset, onset of, of FMF, FMF in, in a, a late, late age, age defines, defines a, a milder, milder form, form of, of disease, disease with, with typical, typical clinical, clinical ,, , demographic, demographic ,, , and, and molecular, molecular genetic, genetic characteristics, characteristics Intestinal, Intestinal uptake, uptake of, of dietary, dietary glucose, glucose and, and galactose, galactose is, is mediated, mediated by, by the, the SGLT1, SGLT1 Na, Na +/glucose, +/glucose cotransporter, cotransporter of, of the, the brush, brush border, border ., . An, An SGLT1, SGLT1 missense, missense mutation, mutation underlies, underlies hereditary, hereditary glucose/galactose, glucose/galactose malabsorption, malabsorption ,, , characterized, characterized by, by potentially, potentially fatal, fatal diarrhea, diarrhea ;, ; conversely, conversely ,, , oral, oral rehydration, rehydration therapy, therapy exploits, exploits normal, normal transport, transport to, to alleviate, alleviate life-threatening, life-threatening diarrhea, diarrhea of, of infectious, infectious origin, origin ., . We, We have, have mapped, mapped the, the entire, entire human, human SGLT1, SGLT1 Na, Na +/glucose, +/glucose cotransporter, cotransporter gene, gene from, from cosmid, cosmid and, and lambda, lambda phage, phage clones, clones representing, representing a, a genomic, genomic region, region of, of 112, 112 kilobases, kilobases ., . Transcription, Transcription initiation, initiation occurred, occurred from, from a, a site, site 27, 27 base, base pairs, pairs 3, 3 of, of a, a TATAA, TATAA sequence, sequence ., . All, All exon-flanking, exon-flanking regions, regions were, were sequenced, sequenced ,, , and, and the, the entire, entire 112-kilobase, 112-kilobase region, region mapped, mapped with, with four, four restriction, restriction enzymes, enzymes ., . SGLT1, SGLT1 is, is comprised, comprised of, of 15, 15 exons, exons (, ( spanning, spanning 72, 72 kilobases, kilobases ), ) ;, ; a, a possible, possible evolutionary, evolutionary origin, origin from, from a, a six-membrane-span, six-membrane-span ancestral, ancestral precursor, precursor via, via a, a gene, gene duplication, duplication event, event is, is suggested, suggested from, from comparison, comparison of, of exons, exons against, against protein, protein secondary, secondary structure, structure and, and from, from sequence, sequence considerations, considerations ., . A, A new, new missense, missense mutation, mutation in, in exon, exon 1, 1 causing, causing glucose/galactose, glucose/galactose malabsorption, malabsorption is, is also, also described, described ., . This, This is, is the, the first, first Na, Na (, ( +, + ), ) -dependent, -dependent cotransporter, cotransporter gene, gene structure, structure reported, reported ., . These, These data, data facilitate, facilitate the, the search, search for, for new, new glucose/galactose, glucose/galactose malabsorption-related, malabsorption-related mutations, mutations in, in this, this important, important gene, gene and, and provide, provide a, a basis, basis for, for future, future evolutionary, evolutionary comparisons, comparisons with, with other, other Na, Na (, ( +, + ), ) -dependent, -dependent cotransporters.., cotransporters.. The, The rare, rare diseases, diseases ataxia-telangiectasia, ataxia-telangiectasia (, ( AT, AT ), ) ,, , caused, caused by, by mutations, mutations in, in the, the ATM, ATM gene, gene ,, , and, and Nijmegen, Nijmegen breakage, breakage syndrome, syndrome (, ( NBS, NBS ), ) ,, , with, with mutations, mutations in, in the, the p95/nbs1, p95/nbs1 gene, gene ,, , share, share a, a variety, variety of, of phenotypic, phenotypic abnormalities, abnormalities such, such as, as chromosomal, chromosomal instability, instability ,, , radiation, radiation sensitivity, sensitivity and, and defects, defects in, in cell-cycle, cell-cycle checkpoints, checkpoints in, in response, response to, to ionizing, ionizing radiation, radiation ., . The, The ATM, ATM gene, gene encodes, encodes a, a protein, protein kinase, kinase that, that is, is activated, activated by, by ionizing, ionizing radiation, radiation or, or radiomimetic, radiomimetic drugs, drugs ,, , whereas, whereas p95/nbs1, p95/nbs1 is, is part, part of, of a, a protein, protein complex, complex that, that is, is involved, involved in, in responses, responses to, to DNA, DNA double-strand, double-strand breaks, breaks ., . Here, Here ,, , because, because of, of the, the similarities, similarities between, between AT, AT and, and NBS, NBS ,, , we, we evaluated, evaluated the, the functional, functional interactions, interactions between, between ATM, ATM and, and p95/nbs1, p95/nbs1 ., . Activation, Activation of, of the, the ATM, ATM kinase, kinase by, by ionizing, ionizing radiation, radiation and, and induction, induction of, of ATM-dependent, ATM-dependent responses, responses in, in NBS, NBS cells, cells indicated, indicated that, that p95/nbs1, p95/nbs1 may, may not, not be, be required, required for, for signalling, signalling to, to ATM, ATM after, after ionizing, ionizing radiation, radiation ., . However, However ,, , p95/nbs1, p95/nbs1 was, was phosphorylated, phosphorylated on, on serine, serine 343, 343 in, in an, an ATM-dependent, ATM-dependent manner, manner in, in vitro, vitro and, and in, in vivo, vivo after, after ionizing, ionizing radiation, radiation ., . A, A p95/nbs1, p95/nbs1 construct, construct mutated, mutated at, at the, the ATM, ATM phosphorylation, phosphorylation site, site abrogated, abrogated an, an S-phase, S-phase checkpoint, checkpoint induced, induced by, by ionizing, ionizing radiation, radiation in, in normal, normal cells, cells and, and failed, failed to, to compensate, compensate for, for this, this functional, functional deficiency, deficiency in, in NBS, NBS cells, cells ., . These, These observations, observations link, link ATM, ATM and, and p95/nbs1, p95/nbs1 in, in a, a common, common signalling, signalling pathway, pathway and, and provide, provide an, an explanation, explanation for, for phenotypic, phenotypic similarities, similarities in, in these, these two, two diseases.., diseases.. Classical, Classical phenylketonuria, phenylketonuria is, is an, an autosomal, autosomal recessive, recessive disease, disease caused, caused by, by a, a deficiency, deficiency of, of hepatic, hepatic phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . The, The abolition, abolition of, of an, an invariant, invariant BamHI, BamHI site, site located, located in, in the, the coding, coding sequence, sequence of, of the, the PAH, PAH gene, gene (, ( exon, exon 7, 7 ), ) led, led to, to the, the recognition, recognition of, of two, two new, new point, point mutations, mutations at, at codon, codon 272, 272 and, and 273, 273 (, ( 272gly, 272gly --, -- --, -- stop, stop and, and 273ser, 273ser --, -- --, -- phe, phe ,, , respectively, respectively ), ) ., . Both, Both mutations, mutations were, were detected, detected in, in north, north eastern, eastern France, France or, or Belgium, Belgium and, and occurred, occurred on, on the, the background, background of, of RFLP, RFLP haplotype, haplotype 7, 7 alleles, alleles ., . The, The present, present study, study supports, supports the, the view, view that, that the, the clinical, clinical heterogeneity, heterogeneity in, in PKU, PKU is, is accounted, accounted for, for by, by the, the large, large variety, variety of, of mutant, mutant genotypes, genotypes associated, associated with, with PAH, PAH deficiencies.., deficiencies.. Ataxia-telangiectasia, Ataxia-telangiectasia (, ( A-T, A-T ), ) and, and Nijmegen, Nijmegen breakage, breakage syndrome, syndrome (, ( NBS, NBS ), ) are, are recessive, recessive genetic, genetic disorders, disorders with, with susceptibility, susceptibility to, to cancer, cancer and, and similar, similar cellular, cellular phenotypes, phenotypes ., . The, The protein, protein product, product of, of the, the gene, gene responsible, responsible for, for A-T, A-T ,, , designated, designated ATM, ATM ,, , is, is a, a member, member of, of a, a family, family of, of kinases, kinases characterized, characterized by, by a, a carboxy-terminal, carboxy-terminal phosphatidylinositol, phosphatidylinositol 3-kinase-like, 3-kinase-like domain, domain ., . The, The NBS1, NBS1 protein, protein is, is specifically, specifically mutated, mutated in, in patients, patients with, with Nijmegen, Nijmegen breakage, breakage syndrome, syndrome and, and forms, forms a, a complex, complex with, with the, the DNA, DNA repair, repair proteins, proteins Rad50, Rad50 and, and Mrel1, Mrel1 ., . Here, Here we, we show, show that, that phosphorylation, phosphorylation of, of NBS1, NBS1 ,, , induced, induced by, by ionizing, ionizing radiation, radiation ,, , requires, requires catalytically, catalytically active, active ATM, ATM ., . Complexes, Complexes containing, containing ATM, ATM and, and NBS1, NBS1 exist, exist in, in vivo, vivo in, in both, both untreated, untreated cells, cells and, and cells, cells treated, treated with, with ionizing, ionizing radiation, radiation ., . We, We have, have identified, identified two, two residues, residues of, of NBS1, NBS1 ,, , Ser, Ser 278, 278 and, and Ser, Ser 343, 343 that, that are, are phosphorylated, phosphorylated in, in vitro, vitro by, by ATM, ATM and, and whose, whose modification, modification in, in vivo, vivo is, is essential, essential for, for the, the cellular, cellular response, response to, to DNA, DNA damage, damage ., . This, This response, response includes, includes S-phase, S-phase checkpoint, checkpoint activation, activation ,, , formation, formation of, of the, the NBS1/Mrel1/Rad50, NBS1/Mrel1/Rad50 nuclear, nuclear foci, foci and, and rescue, rescue of, of hypersensitivity, hypersensitivity to, to ionizing, ionizing radiation, radiation ., . Together, Together ,, , these, these results, results demonstrate, demonstrate a, a biochemical, biochemical link, link between, between cell-cycle, cell-cycle checkpoints, checkpoints activated, activated by, by DNA, DNA damage, damage and, and DNA, DNA repair, repair in, in two, two genetic, genetic diseases, diseases with, with overlapping, overlapping phenotypes.., phenotypes.. The, The mutation, mutation causing, causing myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) has, has recently, recently been, been identified, identified as, as an, an unstable, unstable CTG, CTG trinucleotide, trinucleotide repeat, repeat located, located in, in the, the 3, 3 untranslated, untranslated region, region of, of a, a gene, gene encoding, encoding for, for a, a protein, protein with, with putative, putative serine-threonine, serine-threonine protein, protein kinase, kinase activity, activity ., . In, In this, this report, report we, we present, present the, the genomic, genomic sequences, sequences of, of the, the human, human and, and murine, murine DM, DM kinase, kinase gene, gene ., . A, A comparison, comparison of, of these, these sequences, sequences with, with each, each other, other and, and with, with known, known cDNA, cDNA sequences, sequences from, from both, both species, species ,, , led, led us, us to, to predict, predict a, a translation, translation initiation, initiation codon, codon ,, , as, as well, well as, as determine, determine the, the organization, organization of, of the, the DM, DM kinase, kinase gene, gene ., . Several, Several polymorphisms, polymorphisms within, within the, the human, human DM, DM kinase, kinase gene, gene have, have been, been identified, identified ,, , and, and PCR, PCR assays, assays to, to detect, detect two, two of, of these, these are, are described, described ., . The, The complete, complete sequence, sequence and, and characterization, characterization of, of the, the structure, structure of, of the, the DM, DM kinase, kinase gene, gene ,, , as, as well, well as, as the, the identification, identification of, of novel, novel polymorphisms, polymorphisms within, within the, the gene, gene ,, , represent, represent an, an important, important step, step in, in a, a further, further understanding, understanding of, of the, the genetics, genetics of, of myotonic, myotonic dystrophy, dystrophy and, and the, the molecular, molecular biology, biology of, of the, the gene.., gene.. Deletions, Deletions and, and other, other abnormalities, abnormalities of, of human, human chromosome, chromosome 15q11-q13, 15q11-q13 are, are associated, associated with, with two, two developmental, developmental disorders, disorders ,, , Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) and, and Angelman, Angelman syndrome, syndrome (, ( AS, AS ), ) ., . Loss, Loss of, of expression, expression of, of imprinted, imprinted ,, , paternally, paternally expressed, expressed genes, genes has, has been, been implicated, implicated in, in PWS, PWS ., . However, However ,, , the, the number, number of, of imprinted, imprinted genes, genes that, that contribute, contribute to, to PWS, PWS ,, , and, and the, the range, range over, over which, which the, the imprinting, imprinting signal, signal acts, acts to, to silence, silence one, one copy, copy of, of the, the gene, gene in, in a, a parent-of-origin-specific, parent-of-origin-specific manner, manner ,, , are, are unknown, unknown ., . To, To identify, identify additional, additional imprinted, imprinted genes, genes that, that could, could contribute, contribute to, to the, the PWS, PWS phenotype, phenotype and, and to, to understand, understand the, the regional, regional control, control of, of imprinting, imprinting in, in 15q11-q13, 15q11-q13 ,, , we, we have, have constructed, constructed an, an imprinted, imprinted transcript, transcript map, map of, of the, the PWS-AS, PWS-AS deletion, deletion interval, interval ., . The, The imprinting, imprinting status, status of, of 22, 22 expressed, expressed sequence, sequence tags, tags derived, derived from, from the, the radiation-hybrid, radiation-hybrid human, human transcript, transcript maps, maps or, or physical, physical maps, maps was, was determined, determined in, in a, a reverse, reverse transcriptase-PCR, transcriptase-PCR assay, assay and, and correlated, correlated with, with the, the position, position of, of the, the transcripts, transcripts on, on the, the physical, physical map, map ., . Seven, Seven new, new paternally, paternally expressed, expressed transcripts, transcripts localize, localize to, to an, an approximately, approximately 1, 1 ., . 5-Mb, 5-Mb domain, domain surrounding, surrounding the, the SNRPN-associated, SNRPN-associated imprinting, imprinting center, center ,, , which, which already, already includes, includes four, four imprinted, imprinted ,, , paternally, paternally expressed, expressed genes, genes ., . All, All other, other tested, tested new, new transcripts, transcripts in, in the, the deletion, deletion region, region were, were expressed, expressed from, from both, both alleles, alleles ., . A, A domain, domain of, of exclusive, exclusive paternal, paternal expression, expression surrounding, surrounding the, the imprinting, imprinting center, center suggests, suggests strong, strong regional, regional control, control of, of the, the imprinting, imprinting process, process ., . This, This study, study provides, provides the, the means, means for, for further, further investigation, investigation of, of additional, additional genes, genes that, that cause, cause or, or modify, modify the, the phenotypes, phenotypes associated, associated with, with rearrangements, rearrangements of, of 15q11-q13, 15q11-q13 ., . For, For genetic, genetic counseling, counseling and, and predictive, predictive testing, testing in, in families, families with, with inherited, inherited breast-ovarian, breast-ovarian cancer, cancer ,, , penetrances, penetrances and, and expressions, expressions of, of the, the underlying, underlying mutations, mutations should, should be, be known, known ., . We, We have, have previously, previously reported, reported two, two BRCA1, BRCA1 founder, founder mutations, mutations in, in the, the Norwegian, Norwegian population, population ., . Index, Index cases, cases for, for the, the present, present study, study were, were found, found two, two different, different ways, ways through, through a, a series, series of, of consecutive, consecutive ovarian, ovarian cancers, cancers (, ( n, n =, = 16, 16 ), ) and, and through, through our, our family, family cancer, cancer clinic, clinic (, ( n, n =, = 14, 14 ), ) ., . Altogether, Altogether ,, , 20, 20 of, of the, the patients, patients had, had BRCA1, BRCA1 1675delA, 1675delA ,, , and, and 10, 10 had, had 1135insA, 1135insA ., . Their, Their relatives, relatives were, were described, described with, with respect, respect to, to absence/presence, absence/presence of, of breast, breast and/or, and/or ovarian, ovarian cancer, cancer ., . Of, Of 133, 133 living, living female, female relatives, relatives ,, , 83, 83 (, ( 62, 62 %, % ), ) were, were tested, tested for, for the, the presence, presence of, of a, a mutation, mutation ., . No, No difference, difference ,, , in, in penetrance, penetrance and, and expression, expression ,, , between, between the, the two, two mutations, mutations were, were found, found ,, , whereas, whereas differences, differences according, according to, to method, method of, of ascertainment, ascertainment were, were seen, seen ., . The, The overall, overall findings, findings were, were that, that disease, disease started, started to, to occur, occur at, at age, age 30, 30 years, years and, and that, that by, by age, age 50, 50 years, years 48, 48 %, % of, of the, the mutation-carrying, mutation-carrying women, women had, had experienced, experienced breast, breast and/or, and/or ovarian, ovarian cancer, cancer ., . More, More ovarian, ovarian cancers, cancers than, than breast, breast cancers, cancers were, were recorded, recorded ., . Both, Both penetrance, penetrance and, and expression, expression (, ( breast, breast cancer, cancer vs., vs. ovarian, ovarian cancer, cancer ), ) were, were different, different from, from those, those in, in reports, reports of, of the, the Ashkenazi, Ashkenazi founder, founder mutations, mutations ., . Whether, Whether the, the reported, reported differences, differences reflect, reflect true, true differences, differences and/or, and/or methodological, methodological problems, problems is, is discussed, discussed ., . An, An observed, observed excess, excess of, of mutation, mutation carriers, carriers could, could not, not be, be accounted, accounted for, for by, by methodological, methodological problems, problems ;, ; possible, possible explanations, explanations were, were a, a ``, `` true, true ``, `` low, low penetrance, penetrance or, or preferential, preferential segregation.., segregation.. Individuals, Individuals with, with subtotal, subtotal complement, complement C6, C6 deficiency, deficiency possess, possess a, a C6, C6 molecule, molecule that, that is, is 14, 14 %, % shorter, shorter than, than normal, normal C6, C6 and, and present, present in, in low, low but, but detectable, detectable concentrations, concentrations (, ( 1-2, 1-2 %, % of, of the, the normal, normal mean, mean ), ) ., . We, We now, now show, show that, that this, this dysmorphic, dysmorphic C6, C6 is, is bactericidally, bactericidally active, active and, and lacks, lacks an, an epitope, epitope that, that was, was mapped, mapped to, to the, the most, most carboxy-terminal, carboxy-terminal part, part of, of C6, C6 using, using C6, C6 cDNA, cDNA fragments, fragments expressed, expressed as, as fusion, fusion proteins, proteins in, in the, the pUEX, pUEX expression, expression system, system ., . We, We thus, thus predicted, predicted that, that the, the abnormal, abnormal C6, C6 molecule, molecule might, might be, be carboxy-terminally, carboxy-terminally truncated, truncated and, and sought, sought a, a mutation, mutation in, in an, an area"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", area approximately, approximately 14, 14 %, % from, from the, the carboxy-terminal, carboxy-terminal end, end of, of the, the coding, coding sequence, sequence ., . By, By sequencing, sequencing PCR-amplified, PCR-amplified products, products from, from this, this region, region ,, , we, we found, found ,, , in, in three, three individuals, individuals from, from two, two families, families ,, , a, a mutation, mutation that, that might, might plausibly, plausibly be, be responsible, responsible for, for the, the defect, defect ., . All, All three, three have, have an, an abnormal, abnormal 5, 5 splice, splice donor, donor site, site of, of intron, intron 15, 15 ,, , which, which would, would probably, probably prevent, prevent splicing, splicing ., . An, An in-frame, in-frame stop, stop codon, codon is, is found, found 17, 17 codons, codons downstream, downstream from, from the, the intron, intron boundary, boundary ,, , which, which would, would lead, lead to, to a, a truncated, truncated polypeptide, polypeptide 13, 13 ., . 5, 5 %, % smaller, smaller than, than normal, normal C6, C6 ., . This, This result, result was, was unexpected, unexpected ,, , as, as earlier, earlier studies, studies mapped, mapped the, the C5b, C5b binding, binding site, site ,, , or, or a, a putative, putative enzymatic, enzymatic region, region ,, , to, to this, this part, part of, of C6, C6 ., . Interestingly, Interestingly ,, , all, all three, three subjects, subjects were, were probably, probably heterozygous, heterozygous for, for both, both subtotal, subtotal C6, C6 and, and complete, complete C6, C6 deficiency, deficiency ., . To, To investigate, investigate the, the nature, nature of, of somatic, somatic von, von Hippel-Lindau, Hippel-Lindau (, ( VHL, VHL ), ) mutations, mutations ,, , we, we analyzed, analyzed 173, 173 primary, primary sporadic, sporadic human, human renal, renal cell, cell carcinomas, carcinomas for, for mutations, mutations of, of the, the VHL, VHL tumor, tumor suppressor, suppressor gene, gene ,, , using, using polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) and, and single-strand, single-strand conformational, conformational polymorphism, polymorphism analysis, analysis (, ( SSCP, SSCP ), ) of, of DNA, DNA ., . We, We detected, detected abnormal, abnormal SSCP, SSCP pattern, pattern in, in 73, 73 samples, samples ., . After, After sequencing, sequencing ,, , we, we identified, identified microdeletions, microdeletions in, in 58, 58 %, % of, of cases, cases ,, , microinsertions, microinsertions in, in 17, 17 %, % ,, , nonsense, nonsense mutations, mutations in, in 8, 8 %, % ,, , and, and missense, missense mutations, mutations in, in 17, 17 %, % ., . Among, Among these, these mutations, mutations ,, , 50, 50 %, % correspond, correspond to, to new, new mutations, mutations ., . VHL, VHL mutations, mutations were, were found, found only, only in, in the, the nonpapillary, nonpapillary renal, renal cell, cell carcinoma, carcinoma (, ( RCC, RCC ), ) subtype, subtype ,, , as, as previously, previously reported, reported ., . To, To compare, compare somatic, somatic and, and germline, germline mutations, mutations ,, , we, we used, used the, the VHL, VHL database, database ,, , which, which includes, includes 507, 507 mutations, mutations ., . The, The study, study of, of mutational, mutational events, events revealed, revealed a, a significant, significant difference, difference between, between somatic, somatic and, and germline, germline mutations, mutations with, with mutations, mutations leading, leading to, to truncated, truncated proteins, proteins observed, observed in, in 78, 78 %, % of, of somatic, somatic mutations, mutations vs, vs only, only 37, 37 %, % in, in germline, germline mutations, mutations (, ( P, P <, < 0, 0 ., . 001, 001 ), ) ., . We, We postulated, postulated that, that a, a specific, specific pattern, pattern of, of VHL, VHL mutations, mutations is, is associated, associated with, with sporadic, sporadic RCC, RCC ., . This, This pattern, pattern corresponds, corresponds to, to mutations, mutations leading, leading mainly, mainly to, to truncated, truncated proteins, proteins with, with few, few specific, specific missense, missense mutations, mutations ., . We, We then, then analyzed, analyzed the, the occurrence, occurrence of, of RCC, RCC in, in VHL, VHL families, families ,, , based, based on, on the, the nature, nature of, of mutations, mutations ., . We, We observed, observed RCC, RCC in, in at, at least, least one, one member, member of, of the, the VHL, VHL families, families in, in 77, 77 %, % of, of cases, cases with, with mutations, mutations leading, leading to, to truncated, truncated proteins, proteins versus, versus 55, 55 %, % in, in cases, cases with, with missense, missense mutations, mutations (, ( P, P <, < 0, 0 ., . 05, 05 ), ) ., . Thus, Thus ,, , mutations, mutations resulting, resulting in, in truncated, truncated proteins, proteins may, may lead, lead to, to a, a higher, higher risk, risk of, of RCC, RCC in, in VHL, VHL patients, patients The, The size, size of, of the, the (, ( CAG, CAG ), ) n, n repeat, repeat array, array in, in the, the 3, 3 ', ' end, end of, of the, the MJD1, MJD1 gene, gene and, and the, the haplotype, haplotype at, at a, a series, series of, of microsatellite, microsatellite markers, markers surrounding, surrounding the, the MJD1, MJD1 gene, gene were, were examined, examined in, in a, a large, large cohort, cohort of, of Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects affected, affected with, with Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) ., . Our, Our data, data provide, provide five, five novel, novel observations, observations ., . First, First ,, , MJD, MJD is, is associated, associated with, with expansion, expansion fo, fo the, the array, array from, from the, the normal, normal range, range of, of 14-37, 14-37 repeats, repeats to, to 68-84, 68-84 repeats, repeats in, in most, most Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects ,, , but, but no, no subjects, subjects were, were observed, observed with, with expansions, expansions intermediate, intermediate in, in size, size between, between those, those of, of the, the normal, normal and, and MJD, MJD affected, affected groups, groups ., . Second, Second ,, , the, the expanded, expanded allele, allele associated, associated with, with MJD, MJD displays, displays inter-generational, inter-generational instability, instability ,, , particularly, particularly in, in male, male meioses, meioses ,, , and, and this, this instability, instability was, was associated, associated with, with the, the clinical, clinical phenomenon, phenomenon of, of anticipation, anticipation ., . Third, Third ,, , the, the size, size of, of the, the expanded, expanded allele, allele is, is not, not only, only inversely, inversely correlated, correlated with, with the, the age-of-onset, age-of-onset of, of MJD, MJD (, ( r, r =, = -0.738, -0.738 ,, , p, p <, < 0.001, 0.001 ), ) ,, , but, but is, is also, also correlated, correlated with, with the, the frequency, frequency of, of other, other clinical, clinical features, features [, [ e.g, e.g ., . pseudoexophthalmos, pseudoexophthalmos and, and pyramidal, pyramidal signs, signs were, were more, more frequent, frequent in, in subjects, subjects with, with large, large repeats, repeats (, ( p, p <, < 0.001, 0.001 and, and p, p <, < 0.05, 0.05 respectively, respectively ), ) ], ] ., . Fourth, Fourth ,, , the, the disease, disease phenotype, phenotype is, is significantly, significantly more, more severe, severe and, and had, had an, an early, early age, age of, of onset, onset (, ( 16, 16 years, years ), ) in, in a, a subject, subject homozygous, homozygous for, for the, the expanded, expanded allele, allele ,, , which, which contrasts, contrasts with, with Huntington, Huntington disease, disease and, and suggests, suggests that, that the, the expanded, expanded allele, allele in, in the, the MJD1, MJD1 gene, gene could, could exert, exert its, its effect, effect either, either by, by a, a dominant, dominant negative, negative effect, effect (, ( putatively, putatively excluded, excluded in, in HD, HD ), ) or, or by, by a, a gain, gain of, of function, function effect, effect as, as proposed, proposed for, for HD, HD ., . Finally, Finally ,, , Japanese, Japanese and, and Caucasian, Caucasian subjects, subjects affected, affected with, with MJD, MJD share, share haplotypes, haplotypes at, at several, several markers, markers surrounding, surrounding the, the MJD1, MJD1 gene, gene ,, , which, which are, are uncommon, uncommon in, in the, the normal, normal Japanese, Japanese and, and Caucasian, Caucasian population, population ,, , and, and which, which suggests, suggests the, the existence, existence either, either of, of common, common founders, founders in, in these, these populations, populations or, or of, of chromosomes, chromosomes susceptible, susceptible to, to pathologic, pathologic expansion, expansion of, of the, the CAG, CAG repeat, repeat in, in the, the MJD1, MJD1 gene.The, gene.The mechanism, mechanism by, by which, which (, ( CTG, CTG ), ) n, n expansion, expansion in, in the, the 3, 3 UTR, UTR of, of the, the DMPK, DMPK gene, gene causes, causes myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is unknown, unknown ., . We, We identified, identified four, four RNA, RNA splicing, splicing factors, factors --, -- hnRNP, hnRNP C, C ,, , U2AF, U2AF (, ( U2, U2 auxiliary, auxiliary factor, factor ), ) ,, , PTB, PTB (, ( polypyrimidine, polypyrimidine tract, tract binding, binding protein, protein ), ) ,, , and, and PSF, PSF (, ( PTB, PTB associated, associated splicing, splicing factor, factor ), ) --, -- that, that bind, bind to, to two, two short, short regions, regions 3, 3 of, of the, the (, ( CUG, CUG ), ) n, n ,, , and, and found, found a, a novel, novel 3, 3 DMPK, DMPK exon, exon resulting, resulting in, in an, an mRNA, mRNA lacking, lacking the, the repeats, repeats ., . We, We propose, propose that, that the, the (, ( CUG, CUG ), ) n, n is, is an, an essential, essential cis, cis acting, acting element, element for, for this, this splicing, splicing event, event ., . In, In contrast, contrast to, to (, ( CUG, CUG ), ) n, n containing, containing mRNAs, mRNAs ,, , the, the novel, novel isoform, isoform is, is not, not retained, retained in, in the, the nucleus, nucleus in, in DM, DM cells, cells ,, , resulting, resulting in, in imbalances, imbalances in, in relative, relative levels, levels of, of cytoplasmic, cytoplasmic DMPK, DMPK mRNA, mRNA isoforms, isoforms and, and a, a new, new dominant, dominant effect, effect of, of the, the mutation, mutation on, on DMPK.., DMPK.. Hereditary, Hereditary hemochromatosis, hemochromatosis (, ( HH, HH ), ) is, is a, a common, common autosomal, autosomal recessive, recessive disorder, disorder characterized, characterized by, by tissue, tissue iron, iron deposition, deposition secondary, secondary to, to excessive, excessive dietary, dietary iron, iron absorption, absorption ., . We, We recently, recently reported, reported that, that HFE, HFE ,, , the, the protein, protein defective, defective in, in HH, HH ,, , was, was physically, physically associated, associated with, with the, the transferrin, transferrin receptor, receptor (, ( TfR, TfR ), ) in, in duodenal, duodenal crypt, crypt cells, cells and, and proposed, proposed that, that mutations, mutations in, in HFE, HFE attenuate, attenuate the, the uptake, uptake of, of transferrin-bound, transferrin-bound iron, iron from, from plasma, plasma by, by duodenal, duodenal crypt, crypt cells, cells ,, , leading, leading to, to up-regulation, up-regulation of, of transporters, transporters for, for dietary, dietary iron, iron ., . Here, Here ,, , we, we tested, tested the, the hypothesis, hypothesis that, that HFE-/-, HFE-/- mice, mice have, have increased, increased duodenal, duodenal expression, expression of, of the, the divalent, divalent metal, metal transporter, transporter (, ( DMT1, DMT1 ), ) ., . By, By 4, 4 weeks, weeks of, of age, age ,, , the, the HFE-/-, HFE-/- mice, mice demonstrated, demonstrated iron, iron loading, loading when, when compared, compared with, with HFE, HFE +/+, +/+ littermates, littermates ,, , with, with elevated, elevated transferrin, transferrin saturations, saturations (, ( 68, 68 ., . 4, 4 %, % vs., vs. 49, 49 ., . 8, 8 %, % ), ) and, and elevated, elevated liver, liver iron, iron concentrations, concentrations (, ( 985, 985 micrograms, micrograms vs., vs. 381, 381 micrograms, micrograms ), ) ., . By, By using, using Northern, Northern blot, blot analyses, analyses ,, , we, we quantitated, quantitated duodenal, duodenal expression, expression of, of both, both classes, classes of, of DMT1, DMT1 transcripts, transcripts one, one containing, containing an, an iron, iron responsive, responsive element, element (, ( IRE, IRE ), ) ,, , called, called DMT1, DMT1 (, ( IRE, IRE ), ) ,, , and, and one, one containing, containing no, no IRE, IRE ,, , called, called DMT1, DMT1 (, ( non-IRE, non-IRE ), ) ., . The, The positive, positive control, control for, for DMT1, DMT1 up-regulation, up-regulation was, was a, a murine, murine model, model of, of dietary, dietary iron, iron deficiency, deficiency that, that demonstrated, demonstrated greatly, greatly increased, increased levels, levels of, of duodenal, duodenal DMT1, DMT1 (, ( IRE, IRE ), ) mRNA, mRNA ., . HFE-/-, HFE-/- mice, mice also, also demonstrated, demonstrated an, an increase, increase in, in duodenal, duodenal DMT1, DMT1 (, ( IRE, IRE ), ) mRNA, mRNA (, ( average, average 7, 7 ., . 7-fold, 7-fold ), ) ,, , despite, despite their, their elevated, elevated transferrin, transferrin saturation, saturation and, and hepatic, hepatic iron, iron content, content ., . Duodenal, Duodenal expression, expression of, of DMT1, DMT1 (, ( non-IRE, non-IRE ), ) was, was not, not increased, increased ,, , nor, nor was, was hepatic, hepatic expression, expression of, of DMT1, DMT1 increased, increased ., . These, These data, data support, support the, the model, model for, for HH, HH in, in which, which HFE, HFE mutations, mutations lead, lead to, to inappropriately, inappropriately low, low crypt, crypt cell, cell iron, iron ,, , with, with resultant, resultant stabilization, stabilization of, of DMT1, DMT1 (, ( IRE, IRE ), ) mRNA, mRNA ,, , up-regulation, up-regulation of, of DMT1, DMT1 ,, , and, and increased, increased absorption, absorption of, of dietary, dietary iron.Two, iron.Two yeast, yeast artificial, artificial chromosomes, chromosomes (, ( YACs, YACs ), ) spanning, spanning a, a total, total distance, distance of, of 1, 1 ., . 1, 1 megabase, megabase pairs, pairs of, of DNA, DNA around, around the, the MCC, MCC (, ( for, for mutated, mutated in, in colorectal, colorectal carcinoma, carcinoma ), ) and, and APC, APC (, ( for, for adenomatous, adenomatous polyposis, polyposis coli, coli ), ) genes, genes at, at 5q21, 5q21 have, have been, been isolated, isolated and, and characterized, characterized ., . Starting, Starting from, from the, the MCC, MCC gene, gene ,, , a, a strategy, strategy was, was undertaken, undertaken to, to identify, identify constitutional, constitutional submicroscopic, submicroscopic deletions, deletions in, in familial, familial adenomatous, adenomatous polyposis, polyposis patients, patients that, that might, might considerably, considerably narrow, narrow down, down the, the position, position of, of the, the APC, APC gene, gene ., . To, To this, this end, end ,, , YACs, YACs identified, identified by, by the, the MCC, MCC gene, gene were, were screened, screened across, across a, a chromosome, chromosome 5-specific, 5-specific cosmid, cosmid library, library to, to provide, provide a, a source, source of, of DNA, DNA probes, probes for, for genomic, genomic scanning, scanning ., . The, The cosmids, cosmids isolated, isolated from, from these, these experiments, experiments were, were used, used to, to screen, screen a, a panel, panel of, of somatic, somatic cell, cell hybrids, hybrids containing, containing chromosome, chromosome 5, 5 segregated, segregated from, from patients, patients suspected, suspected to, to carry, carry putative, putative interstitial, interstitial deletions, deletions ., . This, This screening, screening approach, approach led, led to, to the, the confirmation, confirmation of, of a, a small, small heterozygous, heterozygous deletion, deletion in, in a, a polyposis, polyposis patient, patient that, that overlaps, overlaps one, one of, of the, the two, two isolated, isolated YACs, YACs ., . This, This YAC, YAC has, has been, been shown, shown to, to contain, contain the, the entire, entire APC, APC gene, gene ,, , in, in addition, addition to, to a, a significant, significant portion, portion of, of DNA, DNA flanking, flanking the, the 5, 5 end, end of, of the, the gene, gene ,, , and, and should, should therefore, therefore prove, prove a, a valuable, valuable resource, resource for, for functional, functional studies, studies by, by transfer, transfer to, to colorectal, colorectal tumor-derived, tumor-derived cell, cell lines, lines ., . Analbuminemia, Analbuminemia was, was fortuitously, fortuitously detected, detected in, in a, a nonedematous, nonedematous 12-year-old, 12-year-old American, American Indian, Indian girl, girl with, with atopic, atopic dermatitis, dermatitis ,, , mild, mild bronchial, bronchial asthma, asthma ,, , a, a mild, mild seizure, seizure disorder, disorder ,, , and, and hyperlipoproteinemia, hyperlipoproteinemia with, with a, a corneal, corneal arcus, arcus ., . Immunologic, Immunologic methods, methods revealed, revealed trace, trace amounts, amounts (, ( 17, 17 mg/100, mg/100 ml, ml ), ) of, of apparently, apparently normal, normal serum, serum albumin, albumin ., . The, The patients, patients parents, parents were, were remotely, remotely related, related ., . The, The pedigree, pedigree and, and clinical, clinical findings, findings were, were compatible, compatible with, with autosomal, autosomal recessive, recessive transmission, transmission of, of analbuminemia, analbuminemia ., . Heterozygotes, Heterozygotes had, had subnormal, subnormal levels, levels of, of serum, serum albumin, albumin ., . The, The Gc-locus, Gc-locus is, is closely, closely linked, linked to, to the, the structural, structural albumin, albumin locus, locus ., . Gc-protein, Gc-protein levels, levels were, were normal, normal in, in the, the patient, patient and, and together, together with, with normal, normal chromosomal, chromosomal banding, banding studies, studies make, make it, it unlikely, unlikely that, that a, a chromosomal, chromosomal deletion, deletion caused, caused analbuminemia, analbuminemia ., . Gc-types, Gc-types in, in the, the family, family were, were compatible, compatible with, with ,, , but, but did, did not, not prove, prove ,, , linkage, linkage of, of analbuminemia, analbuminemia to, to the, the Gc-locus, Gc-locus ., . These, These findings, findings suggest, suggest a, a ``, `` thalassemia, thalassemia ``, `` -like, -like mutation, mutation for, for this, this disorder.., disorder.. A, A controlled, controlled ,, , double-blind, double-blind therapeutic, therapeutic trial, trial with, with the, the drug, drug mazindol, mazindol ,, , a, a growth, growth hormone, hormone inhibitor, inhibitor ,, , was, was performed, performed in, in a, a pair, pair of, of 7, 7 1/2, 1/2 year-old, year-old monozygotic, monozygotic twins, twins ,, , with, with Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . The, The rationale, rationale for, for this, this trial, trial was, was based, based on, on a, a patient, patient (, ( reported, reported previously, previously ), ) affected, affected simultaneously, simultaneously with, with DMD, DMD and, and growth, growth hormone, hormone (, ( GH, GH ), ) deficiency, deficiency ,, , who, who is, is showing, showing a, a benign, benign course, course of, of the, the dystrophic, dystrophic process, process and, and is, is still, still walking, walking at, at 18, 18 years, years ., . One, One of, of the, the twins, twins received, received 2, 2 mg, mg of, of mazindol, mazindol daily, daily ,, , while, while the, the other, other received, received a, a placebo, placebo ., . The, The assessment, assessment ,, , repeated, repeated every, every 2, 2 months, months ,, , included, included weight, weight and, and height, height measurements, measurements ,, , functional, functional and, and motor, motor ability, ability tests, tests ,, , ergometry, ergometry and, and determinations, determinations of, of serum, serum enzymes, enzymes and, and GH, GH levels, levels ., . After, After one, one year, year of, of trial, trial the, the code, code was, was broken, broken and, and it, it was, was seen, seen that, that the, the twin, twin under, under placebo, placebo treatment, treatment was, was strikingly, strikingly worse, worse than, than his, his brother, brother ,, , the, the progression, progression of, of whose, whose condition, condition was, was practically, practically arrested, arrested ., . These, These results, results strongly, strongly suggest, suggest that, that treatment, treatment with, with a, a GH, GH inhibitor, inhibitor is, is beneficial, beneficial for, for DMD, DMD patients.., patients.. Mutation, Mutation in, in the, the gene, gene encoding, encoding the, the recently, recently isolated, isolated WASP, WASP protein, protein has, has now, now been, been identified, identified as, as the, the genetic, genetic defect, defect responsible, responsible for, for the, the X-linked, X-linked Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) ,, , a, a primary, primary immunodeficiency, immunodeficiency disease, disease associated, associated with, with extensive, extensive phenotypic, phenotypic variability, variability ., . To, To elucidate, elucidate the, the range, range of, of WASP, WASP mutations, mutations responsible, responsible for, for WAS, WAS ,, , we, we used, used PCR-SSCP, PCR-SSCP analysis, analysis to, to screen, screen for, for WASP, WASP gene, gene mutation, mutation in, in 19, 19 unrelated, unrelated boys, boys with, with the, the diagnosis, diagnosis of, of classical, classical or, or attenuated, attenuated WAS, WAS or, or isolated, isolated thrombocytopenia, thrombocytopenia ., . All, All 19, 19 patients, patients had, had WASP, WASP mutations, mutations ,, , each, each of, of which, which localized, localized to, to the, the initial, initial three, three or, or terminal, terminal three, three exons, exons of, of the, the gene, gene ,, , and, and the, the majority, majority of, of which, which were, were unique, unique in, in each, each case, case ., . However, However ,, , a, a missense, missense mutation, mutation which, which results, results in, in substitution, substitution of, of the, the arginine, arginine at, at WAS, WAS codon, codon 86, 86 was, was identified, identified in, in three, three boys, boys with, with severe, severe WAS, WAS as, as well, well as, as in, in one, one boy, boy presenting, presenting with, with thrombocytopenia, thrombocytopenia alone, alone ., . While, While the, the three, three mutations, mutations found, found in, in the, the isolated, isolated thrombocytopenia, thrombocytopenia patients, patients leave, leave the, the reading, reading frame, frame intact, intact ,, , about, about one-half, one-half of, of the, the gene, gene alterations, alterations detected, detected in, in both, both severe, severe and, and attenuated, attenuated WAS, WAS patients, patients result, result in, in frameshifted, frameshifted transcript, transcript and, and premature, premature translation, translation termination, termination ., . These, These findings, findings therefore, therefore confirm, confirm the, the association, association of, of WAS, WAS with, with WASP, WASP mutation, mutation and, and identify, identify WASP, WASP mutation, mutation as, as a, a cause, cause for, for isolated, isolated congenital, congenital thrombocytopenia, thrombocytopenia in, in males, males ., . While, While the, the WASP, WASP gene, gene defects, defects responsible, responsible for, for isolated, isolated thrombocytopenia, thrombocytopenia and, and other, other mild, mild presentations, presentations of, of WAS, WAS do, do not, not appear, appear distinct, distinct from, from those, those resulting, resulting in, in severe, severe WAS, WAS ,, , these, these data, data indicate, indicate that, that analysis, analysis of, of WASP, WASP gene, gene mutation, mutation provides, provides a, a valuable, valuable tool, tool for, for distinguishing, distinguishing the, the spectrum, spectrum of, of WAS, WAS patients, patients and, and the, the subset, subset of, of males, males with, with isolated, isolated thrombocytopenia, thrombocytopenia who, who represent, represent mild, mild cases, cases of, of WAS.., WAS.. Huntington, Huntington disease, disease (, ( HD, HD ), ) has, has been, been shown, shown to, to be, be associated, associated with, with an, an expanded, expanded CAG, CAG repeat, repeat within, within a, a novel, novel gene, gene on, on 4p16, 4p16 ., . 3, 3 (, ( IT15, IT15 ), ) ., . A, A total, total of, of 30, 30 of, of 1, 1 ,, , 022, 022 affected, affected persons, persons (, ( 2, 2 ., . 9, 9 %, % of, of our, our cohort, cohort ), ) did, did not, not have, have an, an expanded, expanded CAG, CAG in, in the, the disease, disease range, range ., . The, The reasons, reasons for, for not, not observing, observing expansion, expansion in, in affected, affected individuals, individuals are, are important, important for, for determining, determining the, the sensitivity, sensitivity of, of using, using repeat, repeat length, length both, both for, for diagnosis, diagnosis of, of affected, affected patients, patients and, and for, for predictive, predictive testing, testing programs, programs and, and may, may have, have biological, biological relevance, relevance for, for the, the understanding, understanding of, of the, the molecular, molecular mechanism, mechanism underlying, underlying HD, HD ., . Here, Here we, we show, show that, that the, the majority, majority (, ( 18, 18 ), ) of, of the, the individuals, individuals with, with normal, normal sized, sized alleles, alleles represent, represent misdiagnosis, misdiagnosis ,, , sample, sample mix-up, mix-up ,, , or, or clerical, clerical error, error ., . The, The remaining, remaining 12, 12 patients, patients represent, represent possible, possible phenocopies, phenocopies for, for HD, HD ., . In, In at, at least, least four, four cases, cases ,, , family, family studies, studies of, of these, these phenocopies, phenocopies excluded, excluded 4p16, 4p16 ., . 3, 3 as, as the, the region, region responsible, responsible for, for the, the phenotype, phenotype ., . Mutations, Mutations in, in the, the HD, HD gene, gene that, that are, are other, other than, than CAG, CAG expansion, expansion have, have not, not been, been excluded, excluded for, for the, the remaining, remaining eight, eight cases, cases ;, ; however, however ,, , in, in as, as many, many as, as seven, seven of, of these, these persons, persons ,, , retrospective, retrospective review, review of, of these, these patients, patients clinical, clinical features, features identified, identified characteristics, characteristics not, not typical, typical for, for HD, HD ., . This, This study, study shows, shows that, that on, on rare, rare occasions, occasions mutations, mutations in, in other, other ,, , as-yet-undefined, as-yet-undefined genes, genes can, can present, present with, with a, a clinical, clinical phenotype, phenotype very, very similar, similar to, to that, that of, of HD, HD An, An obligate, obligate carrier, carrier of, of the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) who, who was, was also, also heterozygous, heterozygous for, for the, the A, A and, and B, B types, types of, of X-linked, X-linked glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase was, was found, found ., . With, With her, her it, it became, became possible, possible to, to determine, determine whether, whether allelic, allelic exclusion, exclusion occurs, occurs in, in particular, particular cell-types, cell-types of, of the, the WAS, WAS carrier, carrier ., . If, If so, so ,, , the, the remaining, remaining cells, cells of, of a, a particular, particular cell-type, cell-type would, would express, express only, only the, the normal, normal X, X chromosome, chromosome and, and only, only one, one glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase isoenzyme, isoenzyme would, would be, be demonstrable, demonstrable ., . This, This carrier, carrier had, had only, only the, the B, B isoenzyme, isoenzyme of, of glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase in, in platelets, platelets and, and thymus-derived, thymus-derived T, T lymphocytes, lymphocytes ,, , although, although both, both isoenzymes, isoenzymes A, A and, and B, B were, were present, present in, in erythrocytes, erythrocytes and, and neutrophils, neutrophils ., . These, These findings, findings suggest, suggest that, that selection, selection against, against the, the WAS, WAS gene, gene occurs, occurs in, in platelets, platelets and, and thymus-derived, thymus-derived T, T lymphocytes, lymphocytes and, and that, that the, the defects, defects associated, associated with, with WAS, WAS expressed, expressed in, in these, these cell-types, cell-types may, may be, be implicated, implicated in, in the, the genesis, genesis of, of the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome.., syndrome.. We, We previously, previously reported, reported nine, nine children, children with, with an, an autosomally, autosomally recessive, recessive form, form of, of congenital, congenital hypothyroidism, hypothyroidism due, due to, to an, an iodide, iodide transport, transport defect, defect in, in a, a large, large Hutterite, Hutterite family, family with, with extensive, extensive consanguinity, consanguinity living, living in, in central, central Canada, Canada ., . Since, Since the, the original, original report, report ,, , we, we have, have diagnosed, diagnosed congenital, congenital hypothyroidism, hypothyroidism by, by newborn, newborn TSH, TSH screening, screening in, in 9, 9 additional, additional children, children from, from the, the family, family ., . We, We performed, performed direct, direct sequencing, sequencing of, of the, the PCR, PCR products, products of, of each, each NIS, NIS (, ( sodium/iodide, sodium/iodide symporter, symporter ), ) gene, gene exon, exon with, with flanking, flanking introns, introns amplified, amplified from, from genomic, genomic DNA, DNA extracted, extracted from, from peripheral, peripheral blood, blood cells, cells of, of the, the patients, patients ., . We, We identified, identified a, a novel, novel NIS, NIS gene, gene mutation, mutation ,, , G395R, G395R (, ( Gly395, Gly395 --, -- >, > Arg, Arg ;, ; GGA, GGA --, -- >, > AGA, AGA ), ) ,, , in, in 10, 10 patients, patients examined, examined in, in the, the present, present study, study ., . All, All of, of the, the parents, parents tested, tested were, were heterozygous, heterozygous for, for the, the mutation, mutation ,, , suggesting, suggesting that, that the, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "the patients, patients were, were homozygous, homozygous ., . The, The mutation, mutation was, was located, located in, in the, the 10th, 10th transmembrane, transmembrane helix, helix ., . Expression, Expression experiments, experiments by, by transfection, transfection of, of the, the mutant, mutant NIS, NIS complimentary, complimentary DNA, DNA into, into COS-7, COS-7 cells, cells showed, showed no, no perchlorate-sensitive, perchlorate-sensitive iodide, iodide uptake, uptake ,, , confirming, confirming that, that the, the mutation, mutation is, is the, the direct, direct cause, cause of, of the, the iodide, iodide transport, transport defect, defect in, in these, these patients, patients ., . A, A patient, patient who, who showed, showed an, an intermediate, intermediate saliva/serum, saliva/serum technetium, technetium ratio, ratio (, ( 14, 14 ., . 0, 0 ;, ; normal, normal ,, , >, > or, or =, = 20, 20 ), ) and, and was, was considered, considered to, to have, have a, a partial, partial or, or less, less severe, severe defect, defect in, in the, the previous, previous report, report (, ( IX-24, IX-24 ), ) did, did not, not have, have a, a NIS, NIS gene, gene mutation, mutation ., . It, It is, is now, now possible, possible to, to use, use gene, gene diagnostics, diagnostics of, of this, this unique, unique NIS, NIS mutation, mutation to, to identify, identify patients, patients with, with congenital, congenital hypothyroidism, hypothyroidism due, due to, to an, an iodide, iodide transport, transport defect, defect in, in this, this family, family and, and to, to determine, determine the, the carrier, carrier state, state of, of potential, potential parents, parents for, for genetic, genetic counseling, counseling and, and arranging, arranging rapid, rapid and, and early, early diagnosis, diagnosis of, of their, their infants, infants ., . Hypoxanthine, Hypoxanthine --, -- guanine, guanine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ), ) is, is a, a purine, purine salvage, salvage enzyme, enzyme that, that catalyzes, catalyzes the, the conversion, conversion of, of hypoxanthine, hypoxanthine to, to inosine, inosine monophosphate, monophosphate and, and guanine, guanine to, to guanosine, guanosine monophosphate, monophosphate ., . Previous, Previous studies, studies of, of mutant, mutant HPRT, HPRT proteins, proteins analyzed, analyzed at, at the, the molecular, molecular level, level have, have shown, shown a, a significant, significant heterogeneity, heterogeneity ., . This, This investigation, investigation further, further verifies, verifies this, this heterogeneity, heterogeneity and, and identifies, identifies insertions, insertions ,, , deletions, deletions ,, , and, and point, point mutations, mutations ., . The, The direct, direct sequencing, sequencing of, of the, the polymerase, polymerase chain, chain reaction-amplified, reaction-amplified product, product of, of reverse-transcribed, reverse-transcribed HPRT, HPRT mRNA, mRNA enabled, enabled the, the rapid, rapid identification, identification of, of the, the mutations, mutations found, found in, in 17, 17 previously, previously uncharacterized, uncharacterized cell, cell lines, lines derived, derived from, from patients, patients with, with the, the Lesch-Nyhan, Lesch-Nyhan syndrome.., syndrome.. A, A new, new CT, CT pattern, pattern was, was observed, observed in, in 2, 2 patients, patients with, with adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) ., . This, This pattern, pattern ,, , which, which the, the authors, authors call, call Type, Type II, II ,, , is, is characterized, characterized by, by the, the absence, absence of, of posterior, posterior periventricular, periventricular areas, areas of, of decreased, decreased attenuation, attenuation around, around the, the trigone, trigone on, on non-contrast, non-contrast scans, scans after, after contrast, contrast infusion, infusion ,, , however, however ,, , there, there is, is striking, striking enhancement, enhancement of, of various, various white-matter, white-matter structures, structures (, ( tracts, tracts or, or fiber, fiber systems, systems ), ) such, such as, as the, the internal, internal capsules, capsules ,, , corpus, corpus callosum, callosum ,, , corona, corona radiata, radiata ,, , forceps, forceps major, major ,, , and, and cerebral, cerebral peduncles, peduncles ., . This, This is, is different, different from, from numerous, numerous previous, previous descriptions, descriptions of, of the, the CT, CT pattern, pattern in, in ALD, ALD ., . Type, Type II, II ALD, ALD does, does not, not appear, appear to, to have, have been, been seen, seen in, in any, any other, other leukoencephalopathy, leukoencephalopathy and, and is, is probably, probably specific, specific for, for a, a phenotypic, phenotypic variant, variant or, or an, an evolving, evolving stage, stage of, of ALD.., ALD.. Protein, Protein S, S deficiency, deficiency is, is a, a recognized, recognized risk, risk factor, factor for, for venous, venous thrombosis, thrombosis ., . Of, Of all, all the, the inherited, inherited thrombophilic, thrombophilic conditions, conditions ,, , it, it remains, remains the, the most, most difficult, difficult to, to diagnose, diagnose because, because of, of phenotypic, phenotypic variability, variability ,, , which, which can, can lead, lead to, to inconclusive, inconclusive results, results ., . We, We have, have overcome, overcome this, this problem, problem by, by studying, studying a, a cohort, cohort of, of patients, patients from, from a, a single, single center, center where, where the, the diagnosis, diagnosis was, was confirmed, confirmed at, at the, the genetic, genetic level, level ., . Twenty-eight, Twenty-eight index, index patients, patients with, with protein, protein S, S deficiency, deficiency and, and a, a PROS1, PROS1 gene, gene defect, defect were, were studied, studied ,, , together, together with, with 109, 109 first-degree, first-degree relatives, relatives ., . To, To avoid, avoid selection, selection bias, bias ,, , we, we confined, confined analysis, analysis of, of total, total and, and free, free protein, protein S, S levels, levels and, and thrombotic, thrombotic risk, risk to, to the, the patients, patients relatives, relatives ., . In, In this, this group, group of, of relatives, relatives ,, , a, a low, low free, free protein, protein S, S level, level was, was the, the most, most reliable, reliable predictor, predictor of, of a, a PROS1, PROS1 gene, gene defect, defect (, ( sensitivity, sensitivity 97, 97 ., . 7, 7 %, % ,, , specificity, specificity 100, 100 %, % ), ) ., . First-degree, First-degree relatives, relatives with, with a, a PROS1, PROS1 gene, gene defect, defect had, had a, a 5, 5 ., . 0-fold, 0-fold higher, higher risk, risk of, of thrombosis, thrombosis (, ( 95, 95 %, % confidence, confidence interval, interval ,, , 1, 1 ., . 5-16, 5-16 ., . 8, 8 ), ) than, than those, those with, with a, a normal, normal PROS1, PROS1 gene, gene and, and no, no other, other recognized, recognized thrombophilic, thrombophilic defect, defect ., . Although, Although pregnancy/puerperium, pregnancy/puerperium and, and immobility/trauma, immobility/trauma were, were important, important precipitating, precipitating factors, factors for, for thrombosis, thrombosis ,, , almost, almost half, half of, of the, the events, events were, were spontaneous, spontaneous ., . Relatives, Relatives with, with splice-site, splice-site or, or major, major structural, structural defects, defects in, in the, the PROS1, PROS1 gene, gene were, were more, more likely, likely to, to have, have had, had a, a thrombotic, thrombotic event, event and, and had, had significantly, significantly lower, lower total, total and, and free, free protein, protein S, S levels, levels than, than those, those relatives, relatives having, having missense, missense mutations, mutations ., . We, We conclude, conclude that, that persons, persons with, with PROS1, PROS1 gene, gene defects, defects and, and protein, protein S, S deficiency, deficiency are, are at, at increased, increased risk, risk of, of thrombosis, thrombosis and, and that, that free, free protein, protein S, S estimation, estimation offers, offers the, the most, most reliable, reliable way, way of, of diagnosing, diagnosing the, the deficiency, deficiency ., . (, ( Blood, Blood ., . 2000, 2000 ;, ; 95, 95 1935-1941, 1935-1941 ), ) .X-linked, .X-linked Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EDMD, EDMD ), ) is, is a, a relatively, relatively rare, rare benign, benign neuromuscular, neuromuscular disorder, disorder which, which can, can vary, vary remarkably, remarkably in, in onset, onset ,, , course, course and, and severity, severity ., . In, In the, the present, present study, study ,, , a, a TCTAC, TCTAC deletion, deletion spanning, spanning the, the nucleotides, nucleotides 631-635, 631-635 of, of the, the emerin, emerin gene, gene caused, caused an, an unusually, unusually severe, severe disease, disease phenotype, phenotype including, including loss, loss of, of ambulation, ambulation and, and severe, severe muscle, muscle wasting, wasting in, in two, two affected, affected brothers, brothers ., . The, The same, same mutation, mutation has, has been, been reported, reported previously, previously in, in an, an unrelated, unrelated family, family showing, showing a, a significantly, significantly milder, milder phenotype, phenotype ., . The, The interfamilial, interfamilial heterogeneity, heterogeneity in, in distribution, distribution and, and in, in severity, severity of, of the, the features, features in, in the, the two, two families, families point, point to, to environmental, environmental or, or genetic, genetic modification, modification as, as the, the cause, cause of, of clinical, clinical variability, variability in, in Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy.., dystrophy.. SCA3, SCA3 ,, , the, the gene, gene for, for spinal, spinal cerebellar, cerebellar ataxia, ataxia 3, 3 ,, , was, was recently, recently mapped, mapped to, to a, a 15-cM, 15-cM interval, interval between, between D14S67, D14S67 and, and D14S81, D14S81 on, on chromosome, chromosome 14q, 14q ,, , by, by linkage, linkage analysis, analysis in, in two, two families, families of, of French, French ancestry, ancestry ., . The, The SCA3, SCA3 candidate, candidate region, region has, has now, now been, been refined, refined by, by linkage, linkage analysis, analysis with, with four, four new, new microsatellite, microsatellite markers, markers (, ( D14S256, D14S256 ,, , D14S291, D14S291 ,, , D14S280, D14S280 ,, , and, and AFM343vf1, AFM343vf1 ), ) in, in the, the same, same two, two families, families ,, , in, in which, which 19, 19 additional, additional individuals, individuals were, were genotyped, genotyped ,, , and, and in, in a, a third, third French, French family, family ., . Combined, Combined two-point, two-point linkage, linkage analyses, analyses show, show that, that the, the new, new markers, markers ,, , D14S280, D14S280 and, and AFM343vf1, AFM343vf1 ,, , are, are tightly, tightly linked, linked to, to the, the SCA3, SCA3 locus, locus ,, , with, with maximal, maximal lod, lod scores, scores ,, , at, at recombination, recombination fraction, fraction ,, , (, ( theta, theta ), ) =, = ., . 00, 00 ,, , of, of 7, 7 ., . 05, 05 and, and 13, 13 ., . 70, 70 ,, , respectively, respectively ., . Combined, Combined multipoint, multipoint and, and recombinant, recombinant haplotype, haplotype analyses, analyses localize, localize the, the SCA3, SCA3 locus, locus to, to a, a 3-cM, 3-cM interval, interval flanked, flanked by, by D14S291, D14S291 and, and D14S81, D14S81 ., . The, The same, same allele, allele for, for D14S280, D14S280 segregates, segregates with, with the, the disease, disease locus, locus in, in the, the three, three kindreds, kindreds ., . This, This allele, allele is, is frequent, frequent in, in the, the French, French population, population ,, , however, however ,, , and, and linkage, linkage disequilibrium, disequilibrium is, is not, not clearly, clearly established, established ., . The, The SCA3, SCA3 locus, locus remains, remains within, within the, the 29-cM, 29-cM region, region on, on 14q24, 14q24 ., . 3-q32, 3-q32 ., . 2, 2 containing, containing the, the gene, gene for, for the, the Machado-Joseph, Machado-Joseph disease, disease ,, , which, which is, is clinically, clinically related, related to, to the, the phenotype, phenotype determined, determined by, by SCA3, SCA3 ,, , but, but it, it can, can not, not yet, yet be, be concluded, concluded that, that both, both diseases, diseases result, result from, from alterations, alterations of, of the, the same, same gene, gene A, A 40-year-old, 40-year-old man, man with, with childhood-onset, childhood-onset Tourette, Tourette syndrome, syndrome (, ( TS, TS ), ) developed, developed Huntington, Huntington disease, disease (, ( HD, HD ), ) ., . We, We believe, believe this, this to, to be, be the, the first, first reported, reported case, case of, of childhood-onset, childhood-onset TS, TS with, with adult, adult onset, onset HD, HD ., . Discovery, Discovery of, of other, other cases, cases with, with both, both disorders, disorders may, may provide, provide clues, clues to, to the, the pathophysiology, pathophysiology of, of both, both conditions.., conditions.. Lowe, Lowe syndrome, syndrome ,, , also, also known, known as, as oculocerebrorenal, oculocerebrorenal syndrome, syndrome ,, , is, is caused, caused by, by mutations, mutations in, in the, the X, X chromosome-encoded, chromosome-encoded OCRL, OCRL gene, gene ., . The, The OCRL, OCRL protein, protein is, is 51, 51 %, % identical, identical to, to inositol, inositol polyphosphate, polyphosphate 5-phosphatase, 5-phosphatase II, II (, ( 5-phosphatase, 5-phosphatase II, II ), ) from, from human, human platelets, platelets over, over a, a span, span of, of 744, 744 aa, aa ,, , suggesting, suggesting that, that OCRL, OCRL may, may be, be a, a similar, similar enzyme, enzyme ., . We, We engineered, engineered a, a construct, construct of, of the, the OCRL, OCRL cDNA, cDNA that, that encodes, encodes amino, amino acids, acids homologous, homologous to, to the, the platelet, platelet 5-phosphatase, 5-phosphatase for, for expression, expression in, in baculovirus-infected, baculovirus-infected Sf9, Sf9 insect, insect cells, cells ., . This, This cDNA, cDNA encodes, encodes aa, aa 264-968, 264-968 of, of the, the OCRL, OCRL protein, protein ., . The, The recombinant, recombinant protein, protein was, was found, found to, to catalyze, catalyze the, the reactions, reactions also, also carried, carried out, out by, by platelet, platelet 5-phosphatase, 5-phosphatase II, II ., . Thus, Thus OCRL, OCRL converts, converts inositol, inositol 1, 1 ,, , 4, 4 ,, , 5-trisphosphate, 5-trisphosphate to, to inositol, inositol 1, 1 ,, , 4-bisphosphate, 4-bisphosphate ,, , and, and it, it converts, converts inositol, inositol 1, 1 ,, , 3, 3 ,, , 4, 4 ,, , 5-tetrakisphosphate, 5-tetrakisphosphate to, to inositol, inositol 1, 1 ,, , 3, 3 ,, , 4-trisphosphate, 4-trisphosphate ., . Most, Most important, important ,, , the, the enzyme, enzyme converts, converts phosphatidylinositol, phosphatidylinositol 4, 4 ,, , 5-bisphosphate, 5-bisphosphate to, to phosphatidylinositol, phosphatidylinositol 4-phosphate, 4-phosphate ., . The, The relative, relative ability, ability of, of OCRL, OCRL to, to catalyze, catalyze the, the three, three reactions, reactions is, is different, different from, from that, that of, of 5-phosphatase, 5-phosphatase II, II and, and from, from that, that of, of another, another 5-phosphatase, 5-phosphatase isoenzyme, isoenzyme from, from platelets, platelets ,, , 5-phosphatase, 5-phosphatase I, I ., . The, The recombinant, recombinant OCRL, OCRL protein, protein hydrolyzes, hydrolyzes the, the phospholipid, phospholipid substrate, substrate 10-, 10- to, to 30-fold, 30-fold better, better than, than 5-phosphatase, 5-phosphatase II, II ,, , and, and 5-phosphatase, 5-phosphatase I, I does, does not, not cleave, cleave the, the lipid, lipid at, at all, all ., . We, We also, also show, show that, that OCRL, OCRL functions, functions as, as a, a phosphatidylinositol, phosphatidylinositol 4, 4 ,, , 5-bisphosphate, 5-bisphosphate 5-phosphatase, 5-phosphatase in, in OCRL-expressing, OCRL-expressing Sf9, Sf9 cells, cells ., . These, These results, results suggest, suggest that, that OCRL, OCRL is, is mainly, mainly a, a lipid, lipid phosphatase, phosphatase that, that may, may control, control cellular, cellular levels, levels of, of a, a critical, critical metabolite, metabolite ,, , phosphatidylinositol, phosphatidylinositol 4, 4 ,, , 5-bisphosphate, 5-bisphosphate ., . Deficiency, Deficiency of, of this, this enzyme, enzyme apparently, apparently causes, causes the, the protean, protean manifestations, manifestations of, of Lowe, Lowe syndrome.., syndrome.. Van, Van der, der Woude, Woude syndrome, syndrome (, ( VWS, VWS ), ) is, is an, an autosomal, autosomal dominant, dominant disorder, disorder comprising, comprising cleft, cleft lip, lip and/or, and/or cleft, cleft palate, palate and, and lip, lip pits, pits ., . We, We reported, reported previously, previously a, a family, family whose, whose underlying, underlying mutation, mutation is, is a, a 500-800, 500-800 kb, kb deletion, deletion localized, localized to, to chromosome, chromosome bands, bands 1q32-q41, 1q32-q41 [, [ Sander, Sander et, et al., al. ,, , 1994, 1994 Hum, Hum Mol, Mol Genet, Genet 3, 3 576-578, 576-578 ], ] ., . Along, Along with, with cleft, cleft lip/palate, lip/palate and, and lip, lip pits, pits ,, , affected, affected relatives, relatives exhibit, exhibit developmental, developmental delays, delays ,, , suggesting, suggesting that, that the, the function, function of, of a, a gene, gene nearby, nearby may, may also, also be, be disrupted, disrupted ., . To, To further, further localize, localize the, the VWS, VWS gene, gene we, we searched, searched for, for other, other deletions, deletions that, that cause, cause VWS, VWS ., . An, An allele, allele loss, loss assay, assay was, was performed, performed using, using a, a novel, novel highly, highly polymorphic, polymorphic marker, marker ,, , D1S3753, D1S3753 ., . From, From a, a panel, panel of, of 37, 37 unrelated, unrelated individuals, individuals ,, , we, we detected, detected an, an allele, allele loss, loss in, in one, one family, family ,, , indicating, indicating the, the presence, presence of, of a, a deletion, deletion ., . In, In this, this family, family ,, , the, the phenotype, phenotype in, in three, three generations, generations of, of affected, affected individuals, individuals was, was confined, confined to, to the, the cardinal, cardinal signs, signs of, of VWS, VWS ., . Surprisingly, Surprisingly ,, , mapping, mapping of, of the, the new, new deletion, deletion showed, showed that, that it, it extended, extended 0, 0 ., . 2-1, 2-1 Mb, Mb beyond, beyond the, the proximal, proximal breakpoint, breakpoint for, for the, the deletion, deletion described, described previously, previously ., . No, No deletions, deletions were, were detected, detected in, in seven, seven cases, cases of, of popliteal, popliteal pterygia, pterygia syndrome, syndrome ,, , 76, 76 cases, cases of, of mixed, mixed syndromic, syndromic forms, forms of, of cleft, cleft lip, lip and, and palate, palate ,, , and, and 178, 178 cases, cases of, of nonsyndromic, nonsyndromic cleft, cleft lip, lip and, and palate, palate ., . Mucopolysaccharidosis, Mucopolysaccharidosis IVA, IVA (, ( MPS, MPS IVA, IVA ), ) is, is an, an autosomal, autosomal recessive, recessive disorder, disorder caused, caused by, by a, a deficiency, deficiency in, in N-acetylgalactosamine-6-sulfatase, N-acetylgalactosamine-6-sulfatase (, ( GALNS, GALNS ), ) ., . We, We found, found two, two separate, separate deletions, deletions of, of nearly, nearly 8, 8 ., . 0, 0 and, and 6, 6 ., . 0, 0 kb, kb in, in the, the GALNS, GALNS gene, gene ,, , including, including some, some exons, exons ., . There, There are, are Alu, Alu repetitive, repetitive elements, elements near, near the, the breakpoints, breakpoints of, of the, the 8, 8 ., . 0-kb, 0-kb deletion, deletion ,, , and, and this, this deletion, deletion resulted, resulted from, from an, an Alu-Alu, Alu-Alu recombination, recombination ., . The, The other, other 6, 6 ., . 0-kb, 0-kb deletion, deletion involved, involved illegitimate, illegitimate recombinational, recombinational events, events between, between incomplete, incomplete short, short direct, direct repeats, repeats of, of 8, 8 bp, bp at, at deletion, deletion breakpoints, breakpoints ., . The, The same, same rearrangement, rearrangement has, has been, been observed, observed in, in a, a heteroallelic, heteroallelic state, state in, in four, four unrelated, unrelated patients, patients ., . This, This is, is the, the first, first documentation, documentation of, of a, a common, common double, double deletion, deletion a, a gene, gene that, that is, is not, not a, a member, member of, of a, a gene, gene cluster.A, cluster.A DNA, DNA marker, marker C7, C7 ,, , localised, localised Xp21, Xp21 ., . 1-Xp21, 1-Xp21 ., . 3, 3 ,, , has, has been, been studied, studied in, in kindreds, kindreds segregating, segregating for, for Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( BMD, BMD ), ) ., . In, In DMD, DMD families, families four, four crossovers, crossovers were, were observed, observed in, in 38, 38 informative, informative meioses, meioses between, between C7, C7 and, and the, the DMD, DMD locus, locus (, ( theta, theta =, = 0, 0 ., . 12, 12 ,, , z, z max, max =, = +, + 2, 2 ., . 72, 72 ), ) ., . In, In BMD, BMD families, families no, no recombinants, recombinants were, were observed, observed in, in the, the 16, 16 informative, informative meioses, meioses studied, studied ., . These, These data, data are, are consistent, consistent with, with the, the localisation, localisation of, of the, the mutations, mutations in, in these, these disorders, disorders being, being in, in the, the same, same region, region of, of Xp21, Xp21 ., . Studies, Studies in, in families, families also, also segregating, segregating for, for the, the DNA, DNA marker, marker 754, 754 support, support the, the previously, previously reported, reported physical, physical order, order of, of these, these loci, loci as, as X, X centromere-754-DMD-BMD-C7-X, centromere-754-DMD-BMD-C7-X telomere, telomere ., . A, A recombination, recombination fraction, fraction of, of 0, 0 ., . 11, 11 (, ( z, z max, max =, = +, + 5, 5 ., . 58, 58 ), ) was, was found, found between, between DMD-754, DMD-754 by, by combining, combining our, our previously, previously published, published data, data with, with the, the data, data presented, presented here, here ., . C7, C7 and, and 754, 754 thus, thus provide, provide good, good bridging, bridging markers, markers for, for the, the diagnosis, diagnosis of, of DMD, DMD and, and BMD, BMD We, We have, have analyzed, analyzed a, a single, single multi-affected, multi-affected breast/ovarian, breast/ovarian cancer, cancer pedigree, pedigree (, ( BOV3, BOV3 ), ) and, and have, have shown, shown consistent, consistent inheritance, inheritance of, of markers, markers on, on chromosome, chromosome 17q, 17q with, with the, the disease, disease confirming, confirming that, that this, this family, family is, is due, due to, to the, the BRCA1, BRCA1 gene, gene ., . Analysis, Analysis of, of 17q, 17q haplotypes, haplotypes shows, shows a, a recombination, recombination event, event in, in a, a bilateral, bilateral breast, breast cancer, cancer case, case which, which suggests, suggests that, that the, the BRCA1, BRCA1 gene, gene lies, lies distal, distal to, to D17S857, D17S857 ;, ; D17S857, D17S857 is, is thus, thus the, the new, new proximal, proximal boundary, boundary for, for the, the region, region containing, containing BRCA1, BRCA1 ., . Combining, Combining this, this information, information with, with previously, previously published, published mapping, mapping information, information suggests, suggests that, that BRCA1, BRCA1 is, is contained, contained in, in a, a region, region estimated, estimated at, at 1-1, 1-1 ., . 5, 5 Mb, Mb in, in length, length ., . All, All seven, seven breast, breast tumour/blood, tumour/blood pairs, pairs examined, examined from, from this, this family, family show, show loss, loss of, of heterozygosity, heterozygosity in, in the, the tumours, tumours ., . The, The allel, allel retained, retained in, in each, each tumour, tumour was, was from, from the, the disease-bearing, disease-bearing chromosome, chromosome implicating, implicating BRCA1, BRCA1 as, as a, a tumour, tumour suppressor, suppressor gene, gene ., . We, We have, have sequenced, sequenced the, the 17, 17 beta-oestradiol, beta-oestradiol dehydrogenase, dehydrogenase genes, genes (, ( EDH17B1, EDH17B1 and, and EDH17B2, EDH17B2 ), ) which, which have, have been, been suggested, suggested as, as candidate, candidate genes, genes for, for BRCA1, BRCA1 in, in four, four members, members of, of this, this family, family ., . No, No germline, germline mutations, mutations were, were detected, detected ., . A, A new, new platelet-specific, platelet-specific alloantigen, alloantigen ,, , termed, termed Sit, Sit (, ( a, a ), ) ,, , was, was identified, identified in, in a, a severe, severe case, case of, of neonatal, neonatal alloimmune, alloimmune thrombocytopenia, thrombocytopenia ., . The, The Sit, Sit (, ( a, a ), ) alloantigen, alloantigen is, is of, of low, low frequency, frequency (, ( 1/400, 1/400 ), ) in, in the, the German, German population, population ., . Immunochemical, Immunochemical studies, studies demonstrated, demonstrated that, that the, the Sit, Sit (, ( a, a ), ) epitopes, epitopes reside, reside on, on platelet, platelet glycoprotein, glycoprotein (, ( GP, GP ), ) Ia, Ia ., . Nucleotide, Nucleotide sequence, sequence analysis, analysis of, of GPIa, GPIa cDNA, cDNA derived, derived from, from Sit, Sit (, ( a, a ), ) -positive, -positive platelets, platelets showed, showed C, C (, ( 2531, 2531 ), ) --, -- >, > T, T (, ( 2531, 2531 ), ) point, point mutation, mutation ,, , resulting, resulting in, in Thr, Thr (, ( 799, 799 ), ) Met, Met dimorphism, dimorphism ., . Analysis, Analysis of, of genomic, genomic DNA, DNA from, from 22, 22 Sit, Sit (, ( a, a ), ) -negative, -negative normal, normal individuals, individuals showed, showed that, that the, the Thr, Thr (, ( 799, 799 ), ) is, is encoded, encoded by, by ACG, ACG (, ( 2532, 2532 ), ) (, ( 90, 90 ., . 9, 9 %, % ), ) or, or ACA, ACA (, ( 2532, 2532 ), ) (, ( 9, 9 ., . 1, 1 %, % ), ) ., . To, To establish, establish a, a DNA, DNA typing, typing technique, technique ,, , we, we elucidated, elucidated the, the organization, organization of, of the, the GPIa, GPIa gene, gene adjacent, adjacent to, to the, the polymorphic, polymorphic bases, bases ., . The, The introns, introns (, ( 421, 421 bp, bp and, and 1, 1 ., . 2, 2 kb, kb ), ) encompass, encompass a, a 142-bp, 142-bp exon, exon with, with the, the 2, 2 polymorphic, polymorphic bases, bases 2531, 2531 and, and 2532, 2532 ., . Polymerase, Polymerase chain, chain reaction-restriction, reaction-restriction fragment, fragment length, length polymorphism, polymorphism analysis, analysis on, on DNA, DNA derived, derived from, from 100, 100 donors, donors using, using the, the restriction, restriction enzyme, enzyme Mae, Mae III, III showed, showed that, that the, the Met, Met (, ( 799, 799 ), ) form, form of, of GPIa, GPIa is, is restricted, restricted to, to Sit, Sit (, ( a, a ), ) (, ( +, + ), ) phenotype, phenotype ., . Analysis, Analysis of, of stable, stable Chinese, Chinese hamster, hamster ovary, ovary transfectants, transfectants expressing, expressing allele-specific, allele-specific recombinant, recombinant forms, forms of, of GPIa, GPIa showed, showed that, that anti-Sit, anti-Sit (, ( a, a ), ) exclusively, exclusively reacted, reacted with, with the, the Glu, Glu (, ( 505, 505 ), ) Met, Met (, ( 799, 799 ), ) ,, , but, but not, not with, with the, the Glu, Glu (, ( 505, 505 ), ) Thr, Thr (, ( 799, 799 ), ) and, and the, the Lys, Lys (, ( 505, 505 ), ) Thr, Thr (, ( 799, 799 ), ) isoforms, isoforms ., . In, In contrast, contrast ,, , anti-Br, anti-Br (, ( a, a ), ) (, ( HPA-5b, HPA-5b ), ) only, only recognized, recognized the, the Lys, Lys (, ( 505, 505 ), ) Thr, Thr (, ( 799, 799 ), ) form, form ,, , whereas, whereas anti-Br, anti-Br (, ( b, b ), ) (, ( HPA-5a, HPA-5a ), ) reacted, reacted with, with both, both Glu, Glu (, ( 505, 505 ), ) Thr, Thr (, ( 799, 799 ), ) and, and Glu, Glu (, ( 505, 505 ), ) Met, Met (, ( 799, 799 ), ) isoforms, isoforms ., . These, These results, results demonstrated, demonstrated that, that the, the Met, Met (, ( 799, 799 ), ) is, is responsible, responsible for, for formation, formation of, of the, the Sit, Sit (, ( a, a ), ) alloantigenic, alloantigenic determinants, determinants ,, , whereas, whereas amino, amino acid, acid 505, 505 (, ( Lys, Lys or, or Glu, Glu ), ) specifically, specifically controls, controls the, the expression, expression of, of Br, Br (, ( a, a ), ) and, and Br, Br (, ( b, b ), ) epitopes, epitopes ,, , respectively, respectively ., . Platelet, Platelet aggregation, aggregation responses, responses of, of Sit, Sit (, ( a, a ), ) (, ( +, + ), ) individuals, individuals were, were diminished, diminished in, in response, response to, to collagen, collagen ,, , indicating, indicating that, that the, the Thr, Thr (, ( 799, 799 ), ) Met, Met mutation, mutation affects, affects the, the function, function of, of the, the GPIa/IIa, GPIa/IIa complex, complex A, A novel, novel procedure, procedure is, is presented, presented to, to estimate, estimate the, the ratio, ratio of, of male, male to, to female, female mutation, mutation rates, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "rates for, for Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . X-specific, X-specific restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms are, are used, used to, to establish, establish DNA, DNA haplotypes, haplotypes in, in three-generation, three-generation DMD, DMD families, families ., . From, From the, the proportion, proportion of, of DMD, DMD patients, patients who, who have, have inherited, inherited their, their maternal, maternal grandfathers, grandfathers X, X chromosome, chromosome ,, , the, the ratio, ratio of, of mutation, mutation rates, rates can, can be, be calculated, calculated ., . In, In contrast, contrast to, to classical, classical methods, methods ,, , the, the proposed, proposed procedure, procedure is, is not, not restricted, restricted to, to sporadic, sporadic or, or familiar, familiar cases, cases nor, nor is, is any, any information, information on, on the, the carrier, carrier status, status of, of female, female relatives, relatives required.., required.. Genetically, Genetically determined, determined C3, C3 deficiency, deficiency in, in Brittany, Brittany spaniel, spaniel dogs, dogs shares, shares a, a number, number of, of biochemical, biochemical and, and clinical, clinical characteristics, characteristics with, with the, the human, human disorder, disorder ., . In, In humans, humans ,, , the, the gene, gene for, for C3, C3 deficiency, deficiency is, is a, a null, null gene, gene that, that is, is allelic, allelic to, to the, the structural, structural gene, gene for, for C3, C3 and, and is, is not, not linked, linked to, to the, the major, major histocompatibility, histocompatibility locus, locus ., . The, The current, current study, study used, used allotype, allotype analysis, analysis of, of canine, canine C3, C3 in, in order, order to, to demonstrate, demonstrate that, that the, the gene, gene for, for C3, C3 deficiency, deficiency in, in these, these dogs, dogs is, is also, also a, a null, null gene, gene allelic, allelic to, to the, the structural, structural gene, gene for, for C3, C3 ., . In, In addition, addition ,, , preliminary, preliminary pedigree, pedigree analysis, analysis suggests, suggests that, that the, the gene, gene for, for canine, canine C3, C3 deficiency, deficiency is, is apparently, apparently not, not closely, closely linked, linked to, to the, the major, major histocompatibility, histocompatibility complex, complex of, of the, the dog, dog ., . Thus, Thus ,, , it, it appears, appears that, that C3, C3 deficiency, deficiency in, in Brittany, Brittany spaniel, spaniel dogs, dogs not, not only, only shares, shares biochemical, biochemical and, and clinical, clinical features, features with, with C3, C3 deficiency, deficiency in, in humans, humans ,, , but, but also, also shares, shares some, some genetic, genetic characteristics, characteristics with, with the, the human, human disorder.., disorder.. We, We report, report a, a novel, novel mutation, mutation in, in the, the XK, XK gene, gene (, ( XK, XK ), ) in, in a, a Japanese, Japanese patient, patient with, with McLeod, McLeod syndrome, syndrome ., . A, A 50-year-old, 50-year-old man, man showed, showed progressive, progressive muscular, muscular atrophy, atrophy ,, , choreic, choreic movement, movement ,, , elevated, elevated level, level of, of serum, serum creatinine, creatinine kinase, kinase ,, , and, and acanthocytosis, acanthocytosis ., . The, The expression, expression level, level of, of all, all the, the Kell, Kell antigens, antigens in, in erythrocyte, erythrocyte was, was decreased, decreased and, and molecular, molecular analysis, analysis revealed, revealed a, a single-base, single-base (, ( T, T ), ) deletion, deletion at, at the, the nucleotide, nucleotide position, position 1095, 1095 in, in XK, XK ., . This, This deletion, deletion caused, caused a, a frameshift, frameshift in, in translation, translation ,, , leading, leading to, to a, a premature, premature stop, stop codon, codon at, at the, the amino, amino acid, acid position, position 408, 408 ., . We, We conclude, conclude this, this single-base, single-base deletion, deletion causes, causes defective, defective Kx, Kx protein, protein ,, , which, which is, is responsible, responsible for, for the, the McLeod, McLeod phenotype, phenotype in, in this, this patient.., patient.. We, We identified, identified the, the alpha-cardiac, alpha-cardiac actin, actin gene, gene (, ( ACTC, ACTC ), ) as, as a, a novel, novel disease, disease gene, gene in, in a, a pedigree, pedigree suffering, suffering from, from familial, familial hypertrophic, hypertrophic cardiomyopathy, cardiomyopathy (, ( FHC, FHC ), ) ., . Linkage, Linkage analyses, analyses excluded, excluded all, all the, the previously, previously reported, reported FHC, FHC loci, loci as, as possible, possible disease, disease loci, loci in, in the, the family, family studied, studied ,, , with, with lod, lod scores, scores varying, varying between, between -2, -2 ., . 5, 5 and, and -6, -6 ., . 0, 0 0, 0 ., . Further, Further linkage, linkage analyses, analyses of, of plausible, plausible candidate, candidate genes, genes highly, highly expressed, expressed in, in the, the adult, adult human, human heart, heart identified, identified ACTC, ACTC as, as the, the most, most likely, likely disease, disease gene, gene ,, , showing, showing a, a maximal, maximal lod, lod score, score of, of 3, 3 ., . 6, 6 6, 6 ., . Mutation, Mutation analysis, analysis of, of ACTC, ACTC revealed, revealed an, an Ala295Ser, Ala295Ser mutation, mutation in, in exon, exon 5, 5 close, close to, to 2, 2 missense, missense mutations, mutations recently, recently described, described to, to cause, cause the, the inherited, inherited form, form of, of idiopathic, idiopathic dilated, dilated cardiomyopathy, cardiomyopathy (, ( IDC, IDC ), ) ., . The, The EWS, EWS gene, gene ,, , which, which maps, maps to, to band, band q12, q12 of, of human, human chromosome, chromosome 22, 22 ,, , is, is involved, involved in, in a, a wide, wide variety, variety of, of human, human solid, solid tumors, tumors including, including Ewing, Ewing sarcoma, sarcoma ,, , related, related primitive, primitive neuroectodermal, neuroectodermal tumors, tumors ,, , malignant, malignant melanoma, melanoma of, of soft, soft parts, parts and, and desmoplastic, desmoplastic small, small round, round cell, cell tumors, tumors ., . In, In these, these tumors, tumors ,, , the, the EWS, EWS is, is fused, fused to, to genes, genes encoding, encoding transcriptional, transcriptional activators/repressors, activators/repressors ,, , like, like Fli-1, Fli-1 or, or erg, erg or, or ATF, ATF 1, 1 or, or wt1, wt1 ., . To, To better, better understand, understand the, the function, function of, of the, the EWS, EWS protein, protein ,, , we, we cloned, cloned the, the EWS, EWS cDNA, cDNA ., . Sequence, Sequence analysis, analysis of, of this, this cDNA, cDNA revealed, revealed differential, differential splicing, splicing involving, involving two, two exons, exons encoding, encoding 72, 72 amino, amino acids, acids ., . Both, Both alternatively, alternatively spliced, spliced transcripts, transcripts ,, , EWS, EWS and, and EWS-b, EWS-b ,, , are, are expressed, expressed in, in a, a variety, variety of, of cells, cells ., . Because, Because EWS, EWS proteins, proteins contain, contain putative, putative conserved, conserved RNA, RNA binding, binding motifs, motifs ,, , we, we studied, studied the, the RNA, RNA binding, binding properties, properties of, of the, the EWS, EWS protein, protein ., . The, The EWS-b, EWS-b protein, protein binds, binds to, to RNA, RNA in, in vitro, vitro and, and ,, , specifically, specifically ,, , to, to poly, poly G, G and, and poly, poly U, U ., . The, The RNA, RNA binding, binding activity, activity was, was localized, localized to, to the, the carboxy, carboxy terminal, terminal 86, 86 amino, amino acids, acids ,, , which, which constitute, constitute RGG, RGG box, box ., . Thus, Thus the, the amino, amino terminal, terminal domain, domain of, of EWS, EWS (, ( NTD-EWS, NTD-EWS ), ) ,, , which, which is, is involved, involved in, in chromosome, chromosome translocation, translocation may, may regulate, regulate the, the specificity, specificity of, of RNA, RNA binding, binding activity, activity of, of EWS, EWS ., . An, An EWS-erg, EWS-erg chimeric, chimeric protein, protein ,, , which, which is, is found, found in, in Ewings, Ewings sarcoma, sarcoma cells, cells ,, , functions, functions as, as a, a transcriptional, transcriptional activator, activator ., . Mutational, Mutational analysis, analysis of, of EWS-erg, EWS-erg chimeric, chimeric protein, protein revealed, revealed that, that NTD-EWS, NTD-EWS functions, functions as, as a, a regulatory, regulatory domain, domain for, for the, the transcriptional, transcriptional activation, activation properties, properties of, of EWS-erg, EWS-erg chimeric, chimeric protein.., protein.. Tay-Sachs, Tay-Sachs disease, disease (, ( TSD, TSD ), ) is, is an, an autosomal, autosomal recessive, recessive genetic, genetic disorder, disorder resulting, resulting from, from mutation, mutation of, of the, the HEXA, HEXA gene, gene encoding, encoding the, the alpha-subunit, alpha-subunit of, of the, the lysosomal, lysosomal enzyme, enzyme ,, , beta-N-acetylhexosaminidase, beta-N-acetylhexosaminidase A, A (, ( Hex, Hex A, A ), ) ., . We, We have, have discovered, discovered that, that a, a Tay-Sachs, Tay-Sachs mutation, mutation ,, , IVS-9, IVS-9 +, + 1, 1 G, G --, -- >, > A, A ,, , first, first detected, detected by, by Akli, Akli et, et al, al ., . (, ( Genomics, Genomics 11, 11 124-134, 124-134 ,, , 1991, 1991 ), ) ,, , is, is a, a common, common disease, disease allele, allele in, in non-Jewish, non-Jewish Caucasians, Caucasians (, ( 10/58, 10/58 alleles, alleles examined, examined ), ) ., . A, A PCR-based, PCR-based diagnostic, diagnostic test, test ,, , which, which detects, detects an, an NlaIII, NlaIII site, site generated, generated by, by the, the mutation, mutation ,, , revealed, revealed a, a frequency, frequency among, among enzyme-defined, enzyme-defined carriers, carriers of, of 9/64, 9/64 (, ( 14, 14 %, % ), ) ., . Most, Most of, of those, those carrying, carrying the, the allele, allele trace, trace their, their origins, origins to, to the, the United, United Kingdom, Kingdom ,, , Ireland, Ireland ,, , or, or Western, Western Europe, Europe ., . It, It was, was not, not identified, identified among, among 12, 12 Black, Black American, American TSD, TSD alleles, alleles or, or in, in any, any of, of 18, 18 Ashkenazi, Ashkenazi Jewish, Jewish ,, , enzyme-defined, enzyme-defined carriers, carriers who, who did, did not, not carry, carry any, any of, of the, the mutations, mutations common, common to, to this, this population, population ., . No, No normally, normally spliced, spliced RNA, RNA was, was detected, detected in, in PCR, PCR products, products generated, generated from, from reverse, reverse transcription, transcription of, of RNA, RNA carrying, carrying the, the IVS-9, IVS-9 mutation, mutation ., . Instead, Instead ,, , the, the low, low levels, levels of, of mRNA, mRNA from, from this, this allele, allele were, were comprised, comprised of, of aberrant, aberrant species, species resulting, resulting from, from the, the use, use of, of either, either of, of two, two cryptic, cryptic donor, donor sites, sites ,, , one, one truncating, truncating exon, exon 9, 9 and, and the, the other, other within, within IVS-9, IVS-9 ,, , spliced, spliced to, to exon, exon 10, 10 ., . Numerous, Numerous additional, additional splice, splice products, products were, were detected, detected ,, , most, most involving, involving skipping, skipping of, of one, one or, or more, more surrounding, surrounding exons, exons ., . Together, Together with, with a, a recently, recently identified, identified allele, allele responsible, responsible for, for Hex, Hex A, A pseudodeficiency, pseudodeficiency (, ( Triggs-Raine, Triggs-Raine et, et al, al ., . Am, Am J, J Hum, Hum Genet, Genet ,, , 1992, 1992 ), ) ,, , these, these two, two alleles, alleles accounted, accounted for, for almost, almost 50, 50 %, % (, ( 29/64, 29/64 ), ) of, of TSD, TSD or, or carrier, carrier alleles, alleles ascertained, ascertained by, by enzyme, enzyme screening, screening tests, tests in, in non-Jewish, non-Jewish Caucasians.., Caucasians.. The, The mutation, mutation underlying, underlying myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) has, has been, been identified, identified as, as an, an expansion, expansion of, of a, a polymorphic, polymorphic CTG-repeat, CTG-repeat in, in a, a gene, gene encoding, encoding protein, protein kinase, kinase activity, activity ., . Brain, Brain and, and heart, heart transcripts, transcripts of, of the, the DM-kinase, DM-kinase (, ( DMR-B15, DMR-B15 ), ) gene, gene are, are subject, subject to, to alternative, alternative RNA, RNA splicing, splicing in, in both, both human, human and, and mouse, mouse ., . The, The unstable, unstable [, [ CTG, CTG ], ] 5-30, 5-30 motif, motif is, is found, found uniquely, uniquely in, in humans, humans ,, , although, although the, the flanking, flanking nucleotides, nucleotides are, are also, also present, present in, in mouse, mouse ., . Characterization, Characterization of, of the, the DM, DM region, region of, of both, both species, species reveals, reveals another, another active, active gene, gene (, ( DMR-N9, DMR-N9 ), ) in, in close, close proximity, proximity to, to the, the kinase, kinase gene, gene ., . DMR-N9, DMR-N9 transcripts, transcripts ,, , mainly, mainly expressed, expressed in, in brain, brain and, and testis, testis ,, , possess, possess a, a single, single ,, , large, large open, open reading, reading frame, frame ,, , but, but the, the function, function of, of its, its protein, protein product, product is, is unknown, unknown ., . Clinical, Clinical manifestation, manifestation of, of DM, DM may, may be, be caused, caused by, by the, the expanded, expanded CTG-repeat, CTG-repeat compromising, compromising the, the (, ( alternative, alternative ), ) expression, expression of, of DM-kinase, DM-kinase or, or DMR-N9, DMR-N9 proteins.., proteins.. A, A 47-year-old, 47-year-old woman, woman with, with paroxysmal, paroxysmal nocturnal, nocturnal haemoglobinuria, haemoglobinuria (, ( PNH, PNH ), ) was, was found, found to, to have, have an, an inherited, inherited deficiency, deficiency in, in the, the ninth, ninth complement, complement component, component (, ( C9, C9 ), ) ., . In, In complement-sensitivity, complement-sensitivity lysis, lysis tests, tests ,, , 80, 80 %, % of, of her, her erythrocytes, erythrocytes were, were markedly, markedly complement-sensitive, complement-sensitive (, ( PNH-III, PNH-III ), ) ., . Laser, Laser cytofluorimetry, cytofluorimetry with, with a, a monoclonal, monoclonal antibody, antibody against, against decay-accelerating, decay-accelerating factor, factor (, ( DAF, DAF ), ) revealed, revealed that, that 95, 95 %, % of, of her, her erythrocytes, erythrocytes were, were DAF-negative, DAF-negative ., . Surprisingly, Surprisingly ,, , she, she has, has suffered, suffered only, only mild, mild haemolysis, haemolysis and, and has, has never, never experienced, experienced massive, massive spontaneous, spontaneous haemolysis, haemolysis ., . Gross, Gross haemoglobinuria, haemoglobinuria and, and jaundice, jaundice occurred, occurred only, only after, after receiving, receiving postoperative, postoperative transfusion, transfusion of, of whole, whole blood, blood ., . In, In her, her serum, serum ,, , C9, C9 was, was not, not detectable, detectable either, either by, by immunological, immunological or, or by, by functional, functional assays, assays ., . Both, Both the, the Ham, Ham test, test and, and the, the sugar, sugar water, water test, test using, using normal, normal human, human serum, serum or, or plasma, plasma yielded, yielded marked, marked haemolysis, haemolysis of, of the, the patients, patients erythrocytes, erythrocytes ., . When, When the, the patients, patients serum, serum or, or plasma, plasma was, was used, used ,, , only, only a, a trace, trace of, of lysis, lysis was, was detected, detected ., . Addition, Addition of, of purified, purified human, human C9, C9 to, to her, her plasma, plasma fully, fully restored, restored haemolysis, haemolysis ., . These, These observations, observations indicated, indicated that, that C9, C9 may, may play, play a, a critical, critical role, role in, in haemolytic, haemolytic attacks, attacks in, in patients, patients with, with PNH, PNH and, and that, that characteristic, characteristic haemolysis, haemolysis in, in PNH, PNH may, may be, be tempered, tempered by, by coexisting, coexisting C9, C9 deficiency.., deficiency.. Germline, Germline mutations, mutations in, in the, the tumor, tumor suppressor, suppressor gene, gene ,, , BRCA1, BRCA1 ,, , predispose, predispose individuals, individuals to, to breast, breast and, and ovarian, ovarian cancers, cancers ., . Using, Using a, a combination, combination of, of affinity-, affinity- and, and conventional, conventional chromatographic, chromatographic techniques, techniques ,, , we, we have, have isolated, isolated a, a predominant, predominant form, form of, of a, a multiprotein, multiprotein BRCA1-containing, BRCA1-containing complex, complex from, from human, human cells, cells displaying, displaying chromatin-remodeling, chromatin-remodeling activity, activity ., . Mass, Mass spectrometric, spectrometric sequencing, sequencing of, of components, components of, of this, this complex, complex indicated, indicated that, that BRCA1, BRCA1 is, is associated, associated with, with a, a SWI/SNF-related, SWI/SNF-related complex, complex ., . We, We show, show that, that BRCA1, BRCA1 can, can directly, directly interact, interact with, with the, the BRG1, BRG1 subunit, subunit of, of the, the SWI/SNF, SWI/SNF complex, complex ., . Moreover, Moreover ,, , p53-mediated, p53-mediated stimulation, stimulation of, of transcription, transcription by, by BRCA1, BRCA1 was, was completely, completely abrogated, abrogated by, by either, either a, a dominant-negative, dominant-negative mutant, mutant of, of BRG1, BRG1 or, or the, the cancer-causing, cancer-causing deletion, deletion in, in exon, exon 11, 11 of, of BRCA1, BRCA1 ., . These, These findings, findings reveal, reveal a, a direct, direct function, function for, for BRCA1, BRCA1 in, in transcriptional, transcriptional control, control through, through modulation, modulation of, of chromatin, chromatin structure.., structure.. In, In this, this study, study we, we describe, describe a, a three-generation, three-generation family, family in, in which, which two, two siblings, siblings were, were affected, affected by, by Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . Immunohistochemical, Immunohistochemical analysis, analysis of, of muscle, muscle dystrophin, dystrophin and, and haplotype, haplotype analysis, analysis of, of the, the DMD, DMD locus, locus revealed, revealed that, that the, the X, X chromosome, chromosome carrying, carrying the, the DMD, DMD gene, gene was, was transmitted, transmitted from, from the, the healthy, healthy maternal, maternal grandfather, grandfather to, to his, his three, three daughters, daughters ,, , including, including the, the probands, probands mother, mother ., . These, These findings, findings indicate, indicate that, that the, the grandfather, grandfather was, was a, a germinal, germinal mosaic, mosaic for, for the, the DMD, DMD gene, gene ., . The, The definition, definition of, of the, the carrier, carrier status, status in, in two, two possible, possible carriers, carriers led, led us, us to, to give, give accurate, accurate genetic, genetic counselling, counselling and, and to, to prevent, prevent the, the birth, birth of, of an, an affected, affected boy, boy ., . The, The results, results of, of this, this study, study demonstrate, demonstrate the, the usefulness, usefulness of, of haplotype, haplotype analysis, analysis and, and immunohistochemical, immunohistochemical muscle, muscle dystrophin, dystrophin studies, studies to, to detect, detect hidden, hidden germinal, germinal mosaicism, mosaicism and, and to, to improve, improve genetic, genetic counselling.., counselling.. Germline, Germline mutations, mutations of, of the, the Brca1, Brca1 tumor, tumor suppressor, suppressor gene, gene predispose, predispose women, women to, to breast, breast and, and ovarian, ovarian cancers, cancers ., . To, To study, study mechanisms, mechanisms underlying, underlying BRCA1-related, BRCA1-related tumorigenesis, tumorigenesis ,, , we, we derived, derived mouse, mouse embryonic, embryonic fibroblast, fibroblast cells, cells carrying, carrying a, a targeted, targeted deletion, deletion of, of exon, exon 11, 11 of, of the, the Brca1, Brca1 gene, gene ., . We, We show, show that, that the, the mutant, mutant cells, cells maintain, maintain an, an intact, intact G1-S, G1-S cell, cell cycle, cycle checkpoint, checkpoint and, and proliferate, proliferate poorly, poorly ., . However, However ,, , a, a defective, defective G2-M, G2-M checkpoint, checkpoint in, in these, these cells, cells is, is accompanied, accompanied by, by extensive, extensive chromosomal, chromosomal abnormalities, abnormalities ., . Mutant, Mutant fibroblasts, fibroblasts contain, contain multiple, multiple ,, , functional, functional centrosomes, centrosomes ,, , which, which lead, lead to, to unequal, unequal chromosome, chromosome segregation, segregation ,, , abnormal, abnormal nuclear, nuclear division, division ,, , and, and aneuploidy, aneuploidy ., . These, These data, data uncover, uncover an, an essential, essential role, role of, of BRCA1, BRCA1 in, in maintaining, maintaining genetic, genetic stability, stability through, through the, the regulation, regulation of, of centrosome, centrosome duplication, duplication and, and the, the G2-M, G2-M checkpoint, checkpoint and, and provide, provide a, a molecular, molecular basis, basis for, for the, the role, role of, of BRCA1, BRCA1 in, in tumorigenesis.., tumorigenesis.. We, We report, report a, a mutation, mutation within, within the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) gene, gene that, that causes, causes aberrant, aberrant splicing, splicing of, of the, the mRNA, mRNA and, and that, that is, is in, in tight, tight association, association with, with chromosomal, chromosomal haplotypes, haplotypes 6, 6 ,, , 10, 10 ,, , and, and 36, 36 ., . Because, Because of, of the, the high, high frequency, frequency of, of these, these particular, particular haplotypes, haplotypes in, in Bulgaria, Bulgaria ,, , Italy, Italy ,, , and, and Turkey, Turkey ,, , it, it appears, appears to, to be, be one, one of, of the, the more, more frequent, frequent defects, defects in, in the, the PAH, PAH gene, gene causing, causing classical, classical phenylketonuria, phenylketonuria in, in this, this part, part of, of Europe, Europe ., . The, The mutation, mutation is, is a, a G, G to, to A, A transition, transition at, at position, position 546, 546 in, in intron, intron 10, 10 of, of the, the PAH, PAH gene, gene ,, , 11, 11 bp, bp upstream, upstream from, from the, the intron, intron 10/exon, 10/exon 11, 11 boundary, boundary ., . It, It activates, activates a, a cryptic, cryptic splice, splice site, site and, and results, results in, in an, an in-frame, in-frame insertion, insertion of, of 9, 9 nucleotides, nucleotides between, between exon, exon 10, 10 and, and exon, exon 11, 11 of, of the, the processed, processed mRNA, mRNA ., . Normal, Normal amounts, amounts of, of liver, liver PAH, PAH protein, protein are, are present, present in, in homozygous, homozygous patients, patients ,, , but, but no, no catalytic, catalytic activity, activity can, can be, be detected, detected ., . This, This loss, loss of, of enzyme, enzyme activity, activity is, is probably, probably caused, caused by, by conformational, conformational changes, changes resulting, resulting from, from the, the insertion, insertion of, of three, three additional, additional amino, amino acids, acids (, ( Gly-Leu-Gln, Gly-Leu-Gln ), ) between, between the, the normal, normal sequences, sequences encoded, encoded by, by exon, exon 10, 10 and, and exon, exon 11.., 11.. Mucopolysaccharidosis, Mucopolysaccharidosis IVA, IVA (, ( MPS, MPS IVA, IVA ;, ; OMIM, OMIM #, # 253000, 253000 ), ) ,, , a, a lysosomal, lysosomal storage, storage disorder, disorder caused, caused by, by a, a deficiency, deficiency of, of N, N -acetylgalactosamine-6-sulfate, -acetylgalactosamine-6-sulfate sulfatase, sulfatase (, ( GALNS, GALNS ), ) ,, , has, has variable, variable clinical, clinical phenotypes, phenotypes ., . To, To date, date we, we have, have identified, identified 65, 65 missense, missense mutations, mutations in, in the, the GALNS, GALNS gene, gene from, from MPS, MPS IVA, IVA patients, patients ,, , but, but the, the correlation, correlation between, between genotype, genotype and, and phenotype, phenotype has, has remained, remained unclear, unclear ., . We, We studied, studied 17, 17 missense, missense mutations, mutations using, using biochemical, biochemical approaches, approaches and, and 32, 32 missense, missense mutations, mutations ,, , using, using structural, structural analyses, analyses ., . Fifteen, Fifteen missense, missense mutations, mutations and, and two, two newly, newly engineered, engineered active, active site, site mutations, mutations (, ( C79S, C79S ,, , C79T, C79T ), ) were, were characterized, characterized by, by transient, transient expression, expression analysis, analysis ., . Mutant, Mutant proteins, proteins ,, , except, except for, for C79S, C79S and, and C79T, C79T ,, , were, were destabilized, destabilized and, and detected, detected as, as insoluble, insoluble precursor, precursor forms, forms while, while the, the C79S, C79S and, and C79T, C79T mutants, mutants were, were of, of a, a soluble, soluble mature, mature size, size ., . Mutants, Mutants found, found in, in the, the severe, severe phenotype, phenotype had, had no, no activity, activity ., . Mutants, Mutants found, found in, in the, the mild, mild phenotype, phenotype had, had a, a considerable, considerable residual, residual activity, activity (, ( 1, 1 ., . 3-13, 3-13 ., . 3, 3 %, % of, of wild-type, wild-type GALNS, GALNS activity, activity ), ) ., . Sulfatases, Sulfatases ,, , including, including GALNS, GALNS ,, , are, are members, members of, of a, a highly, highly conserved, conserved gene, gene family, family sharing, sharing an, an extensive, extensive sequence, sequence homology, homology ., . Thus, Thus ,, , a, a tertiary, tertiary structural, structural model, model of, of human, human GALNS, GALNS was, was constructed, constructed from, from the, the X-ray, X-ray crystal, crystal structure, structure of, of N, N -acetylgalacto-samine-4-sulfatase, -acetylgalacto-samine-4-sulfatase and, and arylsulfatase, arylsulfatase A, A ,, , using, using homology, homology modeling, modeling ,, , and, and 32, 32 missense, missense mutations, mutations were, were investigated, investigated ., . Consequently, Consequently ,, , we, we propose, propose that, that there, there are, are at, at least, least three, three different, different reasons, reasons for, for the, the severe, severe phenotype, phenotype (, ( i, i ), ) destruction, destruction of, of the, the hydrophobic, hydrophobic core, core or, or modification, modification of, of the, the packing, packing ;, ; (, ( ii, ii ), ) removal, removal of, of a, a salt, salt bridge, bridge to, to destabilize, destabilize the, the entire, entire conformation, conformation ;, ; (, ( iii, iii ), ) modification, modification of, of the, the active, active site, site ., . In, In contrast, contrast ,, , mild, mild mutations, mutations were, were mostly, mostly located, located on, on the, the surface, surface of, of the, the GALNS, GALNS protein, protein ., . These, These studies, studies shed, shed further, further light, light on, on the, the genotype-phenotype, genotype-phenotype correlation, correlation of, of MPS, MPS IVA, IVA and, and structure-function, structure-function relationship, relationship in, in the, the sulfatase, sulfatase family.A, family.A family, family in, in which, which two, two male, male siblings, siblings were, were affected, affected with, with Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) was, was studied, studied using, using G-6-PD, G-6-PD isoenzymes, isoenzymes as, as an, an X-linked, X-linked marker, marker in, in order, order to, to investigate, investigate the, the nature, nature of, of cellular, cellular abnormalities, abnormalities ., . Isolated, Isolated peripheral, peripheral blood, blood cell, cell types, types from, from the, the doubly, doubly heterozygous, heterozygous mother, mother of, of the, the affected, affected males, males seemingly, seemingly failed, failed to, to express, express the, the G-6-PD, G-6-PD allele, allele in, in cis, cis position, position with, with the, the WAS, WAS allele, allele while, while her, her cultured, cultured skin, skin fibroblasts, fibroblasts expressed, expressed both, both G-6-PD, G-6-PD alleles, alleles ., . Additionally, Additionally ,, , a, a histogram, histogram analysis, analysis of, of platelet, platelet size, size revealed, revealed a, a single, single population, population of, of abnormally, abnormally small, small platelets, platelets in, in the, the affected, affected propositus, propositus ,, , whereas, whereas the, the heterozygous, heterozygous mother, mother had, had no, no appreciable, appreciable small, small platelet, platelet subpopulation, subpopulation ., . In, In vitro, vitro culture, culture of, of hemopoietic, hemopoietic progenitor, progenitor cells, cells of, of the, the heterozygous, heterozygous mother, mother showed, showed that, that the, the majority, majority of, of progenitor, progenitor cells, cells did, did not, not express, express the, the WAS, WAS allele, allele ., . However, However ,, , a, a small, small number, number of, of cells, cells expressing, expressing the, the G-6-PD, G-6-PD type, type linked, linked with, with the, the WAS, WAS allele, allele were, were detected, detected ., . The, The proportion, proportion of, of the, the latter, latter progenitors, progenitors was, was significantly, significantly higher, higher among, among more, more primitive, primitive progenitors, progenitors (, ( those, those giving, giving rise, rise to, to later, later appearing, appearing colonies, colonies ), ) ., . This, This observation, observation suggests, suggests that, that selection, selection against, against cells, cells expressing, expressing the, the Wiskott-Aldrich, Wiskott-Aldrich defect, defect takes, takes place, place in, in the, the hemopoietic, hemopoietic system, system of, of the, the heterozygous, heterozygous female, female and, and offers, offers a, a possible, possible means, means of, of carrier, carrier detection, detection in, in some, some women, women ., . Linkage, Linkage studies, studies in, in this, this family, family revealed, revealed one, one example, example of, of probable, probable recombination, recombination between, between the, the loci, loci for, for WAS, WAS and, and G-6-PD, G-6-PD among, among three, three informative, informative subjects, subjects ,, , suggesting, suggesting that, that these, these two, two loci, loci may, may not, not be, be closely, closely linked, linked on, on the, the X-chromosome.., X-chromosome.. We, We describe, describe an, an 11-year-old, 11-year-old girl, girl suffering, suffering from, from recurrent, recurrent meningitis, meningitis with, with a, a complete, complete absence, absence of, of the, the seventh, seventh component, component of, of complement, complement (, ( C7, C7 ), ) ., . Diagnosis, Diagnosis was, was established, established by, by haemolytic, haemolytic titration, titration and, and western, western blotting, blotting ., . The, The patients, patients serum, serum lacked, lacked the, the 85, 85 kDa, kDa C7, C7 chain, chain ., . Haemolytic, Haemolytic activity, activity of, of serum, serum was, was reconstituted, reconstituted with, with either, either pooled, pooled normal, normal human, human serum, serum or, or with, with purified, purified C7, C7 ., . The, The relatives, relatives (, ( parents, parents and, and one, one sister, sister ), ) had, had half-normal, half-normal levels, levels of, of both, both immunochemically, immunochemically and, and functionally, functionally determined, determined C7, C7 ,, , indicating, indicating a, a heterozygous, heterozygous state, state for, for C7, C7 deficiency.., deficiency.. Enlarged, Enlarged vestibular, vestibular aqueduct, aqueduct (, ( EVA, EVA )"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", ) ,, , known, known as, as the, the most, most common, common form, form of, of inner, inner ear, ear abnormality, abnormality ,, , has, has recently, recently been, been of, of particular, particular genetic, genetic interest, interest because, because this, this anomaly, anomaly is, is inherited, inherited in, in a, a recessive, recessive manner, manner ., . The, The locus, locus for, for non-syndromic, non-syndromic sensorineural, sensorineural hearing, hearing loss, loss with, with EVA, EVA has, has been, been mapped, mapped to, to the, the same, same chromosomal, chromosomal region, region ,, , 7q31, 7q31 ,, , as, as the, the Pendred, Pendred syndrome, syndrome locus, locus ., . In, In the, the present, present study, study ,, , seven, seven mutations, mutations in, in the, the PDS, PDS gene, gene (, ( PDS, PDS ), ) ,, , the, the gene, gene responsible, responsible for, for Pendred, Pendred syndrome, syndrome ,, , have, have been, been found, found in, in families, families of, of non-syndromic, non-syndromic sensorineural, sensorineural hearing, hearing loss, loss with, with EVA, EVA ., . One, One family, family is, is homozygous, homozygous ,, , three, three families, families are, are compound, compound heterozygotes, heterozygotes ,, , and, and two, two families, families are, are heterozygous, heterozygous but, but with, with no, no other, other mutation, mutation detected, detected ., . The, The present, present results, results provide, provide evidence, evidence that, that mutations, mutations in, in PDS, PDS cause, cause both, both syndromic, syndromic and, and non-syndromic, non-syndromic hearing, hearing loss.., loss.. Retinoblastoma, Retinoblastoma is, is a, a childhood, childhood tumor, tumor that, that can, can arise, arise because, because of, of mutant, mutant alleles, alleles acquired, acquired as, as somatic, somatic or, or germinal, germinal mutations, mutations ., . The, The mutant, mutant allele, allele can, can be, be carried, carried in, in the, the germ, germ line, line ., . The, The mutations, mutations creating, creating these, these alleles, alleles act, act by, by inactivating, inactivating copies, copies of, of a, a recessive, recessive oncogene, oncogene located, located within, within band, band q14, q14 of, of chromosome, chromosome 13, 13 and, and termed, termed the, the RB1, RB1 locus, locus ., . We, We have, have reported, reported isolation, isolation of, of a, a cDNA, cDNA fragment, fragment that, that recognizes, recognizes chromosomal, chromosomal sequences, sequences possessing, possessing many, many of, of the, the attributes, attributes of, of the, the retinoblastoma, retinoblastoma gene, gene associated, associated with, with the, the RB1, RB1 locus, locus ., . We, We now, now report, report that, that this, this segment, segment is, is additionally, additionally the, the target, target of, of somatic, somatic mutations, mutations in, in mesenchymal, mesenchymal tumors, tumors among, among patients, patients having, having no, no apparent, apparent predisposition, predisposition to, to retinoblastoma, retinoblastoma and, and no, no previous, previous evidence, evidence of, of retinoblastoma, retinoblastoma ., . These, These tumors, tumors provide, provide additional, additional evidence, evidence that, that the, the cloned, cloned sequences, sequences are, are representative, representative of, of a, a gene, gene that, that is, is a, a frequent, frequent target, target of, of inactivation, inactivation during, during tumorigenesis, tumorigenesis ., . Sequence, Sequence analysis, analysis of, of this, this cDNA, cDNA provides, provides little, little insight, insight into, into its, its normal, normal functional, functional role.., role.. Of, Of 26, 26 patients, patients with, with autoimmune, autoimmune chronic, chronic active, active hepatitis, hepatitis (, ( CAH, CAH ), ) starting, starting in, in childhood, childhood 18, 18 (, ( 69, 69 %, % ), ) had, had low, low C4, C4 and, and 5, 5 (, ( 19, 19 %, % ), ) had, had low, low C3, C3 serum, serum levels, levels ., . Impaired, Impaired hepatic, hepatic synthesis, synthesis and, and immune-consumption, immune-consumption were, were unlikely, unlikely since, since transferrin, transferrin levels, levels were, were normal, normal in, in all, all patients, patients ,, , albumin, albumin levels, levels were, were persistently, persistently low, low in, in only, only 3, 3 ,, , and, and only, only 3, 3 had, had raised, raised levels, levels of, of activation, activation fragment, fragment C3d, C3d ., . C4d, C4d was, was normal, normal in, in all, all patients, patients studied, studied ., . In, In the, the families, families of, of 12, 12 probands, probands with, with low, low C4, C4 ,, , 7, 7 parents, parents had, had low, low C4, C4 and, and 2, 2 had, had levels, levels which, which were, were at, at the, the lower, lower limit, limit of, of normal, normal ., . 5, 5 of, of 10, 10 siblings, siblings from, from 5, 5 families, families had, had low, low C4, C4 ., . These, These results, results suggest, suggest that, that low, low C4, C4 levels, levels in, in CAH, CAH are, are genetically, genetically determined, determined ., . C4, C4 phenotyping, phenotyping in, in 20, 20 patients, patients and, and in, in 26, 26 parents, parents showed, showed that, that 90, 90 %, % and, and 81, 81 %, % ,, , respectively, respectively ,, , had, had null, null allotypes, allotypes at, at either, either the, the C4A, C4A or, or C4B, C4B locus, locus compared, compared with, with 59, 59 %, % in, in controls, controls ,, , indicating, indicating that, that defective, defective expression, expression of, of structural, structural genes, genes may, may contribute, contribute to, to the, the observed, observed C4, C4 deficiency.., deficiency.. In, In 16, 16 families, families with, with myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) a, a novel, novel approach, approach based, based on, on use, use of, of allele-specific, allele-specific oligonucleotides, oligonucleotides has, has been, been employed, employed to, to study, study the, the linkage, linkage relationship, relationship between, between the, the apolipoprotein, apolipoprotein E, E (, ( APOE, APOE ), ) gene, gene and, and DM, DM ., . Synthetic, Synthetic oligonucleotides, oligonucleotides ,, , designed, designed to, to discriminate, discriminate between, between APOE, APOE alleles, alleles epsilon, epsilon 3, 3 and, and epsilon, epsilon 4, 4 ,, , enabled, enabled us, us to, to distinguish, distinguish heterozygous, heterozygous carriers, carriers in, in a, a hybridization, hybridization assay, assay ., . In, In a, a subset, subset of, of families, families ,, , the, the relevant, relevant segment, segment of, of the, the APOE, APOE gene, gene was, was enzymatically, enzymatically amplified, amplified to, to increase, increase the, the sensitivity, sensitivity of, of the, the method, method ., . For, For DM, DM and, and APOE, APOE ,, , a, a maximum, maximum lod, lod score, score (, ( zmax, zmax of, of 7, 7 ., . 47, 47 was, was obtained, obtained at, at a, a recombination, recombination frequency, frequency (, ( theta, theta ), ) of, of 0, 0 ., . 047, 047 (, ( male, male theta, theta =, = female, female theta, theta ), ) ., . No, No recombination, recombination (, ( maximum, maximum lod, lod score, score of, of 5, 5 ., . 61, 61 at, at theta, theta =, = 0, 0 ., . 0, 0 ), ) was, was found, found between, between APOE, APOE and, and the, the apolipoprotein, apolipoprotein CII, CII (, ( APOC2, APOC2 ), ) gene, gene ., . These, These results, results suggest, suggest that, that ,, , in, in addition, addition to, to APOC2, APOC2 ,, , APOE, APOE is, is a, a useful, useful marker, marker for, for presymptomatic, presymptomatic DM, DM diagnosis.We, diagnosis.We provide, provide genetic, genetic evidence, evidence supporting, supporting the, the identity, identity of, of the, the candidate, candidate gene, gene for, for BRCA1, BRCA1 through, through the, the characterization, characterization of, of germline, germline mutations, mutations in, in 63, 63 breast, breast cancer, cancer patients, patients and, and 10, 10 ovarian, ovarian cancer, cancer patients, patients in, in ten, ten families, families with, with cancer, cancer linked, linked to, to chromosome, chromosome 17q21, 17q21 ., . Nine, Nine different, different mutations, mutations were, were detected, detected by, by screening, screening BRCA1, BRCA1 DNA, DNA and, and RNA, RNA by, by single-strand, single-strand conformation, conformation polymorphism, polymorphism analysis, analysis and, and direct, direct sequencing, sequencing ., . Seven, Seven mutations, mutations lead, lead to, to protein, protein truncations, truncations at, at sites, sites throughout, throughout the, the gene, gene ., . One, One missense, missense mutation, mutation (, ( which, which occurred, occurred independently, independently in, in two, two families, families ), ) leads, leads to, to loss, loss of, of a, a cysteine, cysteine in, in the, the zinc, zinc binding, binding domain, domain ., . An, An intronic, intronic single, single basepair, basepair substitution, substitution destroys, destroys an, an acceptor, acceptor site, site and, and activates, activates a, a cryptic, cryptic splice, splice site, site ,, , leading, leading to, to a, a 59, 59 basepair, basepair insertion, insertion and, and chain, chain termination, termination ., . The, The four, four families, families with, with both, both breast, breast and, and ovarian, ovarian cancer, cancer had, had chain, chain termination, termination mutations, mutations in, in the, the N-terminal, N-terminal half, half of, of the, the protein.., protein.. We, We have, have analyzed, analyzed the, the stability, stability of, of microsatellites, microsatellites in, in cell, cell lines, lines derived, derived from, from human, human ovarian, ovarian cancers, cancers and, and found, found that, that 5, 5 out, out of, of 10, 10 of, of the, the ovarian, ovarian tumor, tumor cell, cell lines, lines are, are genetically, genetically unstable, unstable at, at the, the majority, majority of, of the, the loci, loci analyzed, analyzed ., . In, In clones, clones and, and subclones, subclones derived, derived serially, serially from, from one, one of, of these, these cell, cell lines, lines (, ( 2774, 2774 ;, ; serous, serous cystadenocarcinoma, cystadenocarcinoma ), ) ,, , a, a very, very high, high proportion, proportion of, of microsatellites, microsatellites distributed, distributed in, in many, many different, different regions, regions of, of the, the genome, genome change, change their, their size, size in, in a, a mercurial, mercurial fashion, fashion ., . We, We conclude, conclude that, that genomic, genomic instability, instability in, in ovarian, ovarian tumors, tumors is, is a, a dynamic, dynamic and, and ongoing, ongoing process, process whose, whose high, high frequency, frequency may, may have, have been, been previously, previously underestimated, underestimated by, by PCR-based, PCR-based allelotyping, allelotyping of, of bulk, bulk tumor, tumor tissue, tissue ., . We, We have, have identified, identified the, the source, source of, of the, the genetic, genetic instability, instability in, in one, one ovarian, ovarian tumor, tumor as, as a, a point, point mutation, mutation (, ( R524P, R524P ), ) in, in the, the human, human mismatch-repair, mismatch-repair gene, gene MSH2, MSH2 (, ( Salmonella, Salmonella MutS, MutS homologue, homologue ), ) ,, , which, which has, has recently, recently been, been shown, shown to, to be, be involved, involved in, in hereditary, hereditary nonpolyposis, nonpolyposis colorectal, colorectal cancer, cancer ., . Patient, Patient 2774, 2774 was, was a, a 38-year-old, 38-year-old heterozygote, heterozygote ,, , and, and her, her normal, normal tissue, tissue carried, carried both, both mutant, mutant and, and wild-type, wild-type alleles, alleles of, of the, the human, human MSH2, MSH2 gene, gene ., . However, However the, the wild-type, wild-type allele, allele was, was lost, lost at, at some, some point, point early, early during, during tumorigenesis, tumorigenesis so, so that, that DNA, DNA isolated, isolated either, either from, from the, the patients, patients ovarian, ovarian tumor, tumor or, or from, from the, the 2774, 2774 cell, cell line, line carries, carries only, only the, the mutant, mutant allele, allele of, of the, the human, human MSH2, MSH2 gene, gene ., . The, The genetic, genetic instability, instability observed, observed in, in the, the tumor, tumor and, and cell, cell line, line DNA, DNA ,, , together, together with, with the, the germ-line, germ-line mutation, mutation in, in a, a mismatch-repair, mismatch-repair gene, gene ,, , suggest, suggest that, that the, the MSH2, MSH2 gene, gene is, is involved, involved in, in the, the onset, onset and/or, and/or progression, progression in, in a, a subset, subset of, of ovarian, ovarian cancer.., cancer.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is caused, caused by, by deficiency, deficiency of, of the, the hepatic, hepatic enzyme, enzyme phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . A, A full-length, full-length human, human PAH, PAH cDNA, cDNA sequence, sequence has, has been, been inserted, inserted into, into pzip-neoSV, pzip-neoSV (, ( X, X ), ) ,, , which, which is, is a, a retroviral, retroviral vector, vector containing, containing the, the bacterial, bacterial neo, neo gene, gene ., . The, The recombinant, recombinant has, has been, been transfected, transfected into, into psi, psi 2, 2 cells, cells ,, , which, which provide, provide synthesis, synthesis of, of the, the retroviral, retroviral capsid, capsid ., . Recombinant, Recombinant virus, virus was, was detected, detected in, in the, the culture, culture medium, medium of, of the, the transfected, transfected psi, psi 2, 2 cells, cells ,, , which, which is, is capable, capable of, of transmitting, transmitting the, the human, human PAH, PAH gene, gene into, into mouse, mouse NIH, NIH 3T3, 3T3 cells, cells by, by infection, infection leading, leading to, to stable, stable incorporation, incorporation of, of the, the recombinant, recombinant provirus, provirus ., . Infected, Infected cells, cells express, express PAH, PAH mRNA, mRNA ,, , immunoreactive, immunoreactive PAH, PAH protein, protein ,, , and, and exhibit, exhibit pterin-dependent, pterin-dependent phenylalanine, phenylalanine hydroxylase, hydroxylase activity, activity ., . The, The recombinant, recombinant virus, virus is, is also, also capable, capable of, of infecting, infecting a, a mouse, mouse hepatoma, hepatoma cell, cell line, line that, that does, does not, not normally, normally synthesize, synthesize PAH, PAH ., . PAH, PAH activity, activity is, is present, present in, in the, the cellular, cellular extracts, extracts and, and the, the entire, entire hydroxylation, hydroxylation system, system is, is reconstituted, reconstituted in, in the, the hepatoma, hepatoma cells, cells infected, infected with, with the, the recombinant, recombinant viruses, viruses ., . Thus, Thus ,, , recombinant, recombinant viruses, viruses containing, containing human, human PAH, PAH cDNA, cDNA provide, provide a, a means, means for, for introducing, introducing functional, functional PAH, PAH into, into mammalian, mammalian cells, cells of, of hepatic, hepatic origin, origin and, and can, can potentially, potentially be, be introduced, introduced into, into whole, whole animals, animals as, as a, a model, model for, for somatic, somatic gene, gene therapy, therapy for, for PKU.., PKU.. Amelogenins, Amelogenins are, are an, an heterogenous, heterogenous family, family of, of proteins, proteins produced, produced by, by ameloblasts, ameloblasts of, of the, the enamel, enamel organ, organ during, during tooth, tooth development, development ., . Disturbances, Disturbances of, of enamel, enamel formation, formation occur, occur in, in amelogenesis, amelogenesis imperfecta, imperfecta ,, , a, a clinically, clinically heterogenous, heterogenous group, group of, of inherited, inherited disorders, disorders characterised, characterised by, by defective, defective enamel, enamel biomineralisation, biomineralisation ., . An, An amelogenin, amelogenin gene, gene ,, , AMGX, AMGX ,, , has, has been, been mapped, mapped to, to the, the short, short of, of the, the X, X chromosome, chromosome (, ( Xp22, Xp22 ., . 1-p22, 1-p22 ., . 3, 3 ), ) and, and has, has been, been implicated, implicated in, in the, the molecular, molecular pathology, pathology of, of X-linked, X-linked amelogenesis, amelogenesis imperfecta, imperfecta (, ( AIH1, AIH1 ), ) ., . We, We have, have identified, identified three, three families, families exhibiting, exhibiting AIH1, AIH1 and, and screened, screened the, the AMGX, AMGX gene, gene for, for mutations, mutations using, using single-strand, single-strand conformational, conformational polymorphism, polymorphism analysis, analysis and, and DNA, DNA sequencing, sequencing ., . Three, Three novel, novel mutations, mutations were, were identified, identified a, a C-T, C-T substitution, substitution in, in exon, exon 5, 5 ,, , and, and a, a G-T, G-T substitution, substitution and, and single, single cytosine, cytosine deletion, deletion in, in exon, exon 6, 6 ,, , confirming, confirming the, the existence, existence of, of extensive, extensive allelic, allelic heterogeneity, heterogeneity in, in this, this condition, condition ., . The, The identification, identification of, of family-specific, family-specific mutations, mutations will, will enable, enable early, early identification, identification of, of affected, affected individuals, individuals and, and correlation, correlation of, of clinical, clinical phenotype, phenotype with, with genotype, genotype will, will facilitate, facilitate an, an objective, objective system, system of, of disease, disease classification, classification ., . Pendred, Pendred syndrome, syndrome is, is the, the most, most common, common form, form of, of syndromic, syndromic deafness, deafness and, and characterized, characterized by, by congenital, congenital sensorineural, sensorineural hearing, hearing loss, loss and, and goitre, goitre ., . This, This disorder, disorder was, was mapped, mapped to, to chromosome, chromosome 7, 7 and, and the, the gene, gene causing, causing Pendred, Pendred syndrome, syndrome (, ( PDS, PDS ), ) was, was subsequently, subsequently identified, identified by, by positional, positional cloning, cloning ., . PDS, PDS encodes, encodes a, a putative, putative transmembrane, transmembrane protein, protein designated, designated pendrin, pendrin ., . Pendrin, Pendrin is, is closely, closely related, related to, to a, a family, family of, of sulfate, sulfate transport, transport proteins, proteins that, that includes, includes the, the rat, rat sulfate-anion, sulfate-anion transporter, transporter (, ( encoded, encoded by, by Sat-1, Sat-1 ;, ; 29, 29 %, % amino, amino acid, acid sequence, sequence identity, identity ), ) ,, , the, the human, human diastrophic, diastrophic dysplasia, dysplasia sulfate, sulfate transporter, transporter (, ( encoded, encoded by, by DTD, DTD ;, ; 32, 32 %, % ), ) and, and the, the human, human sulfate, sulfate transporter, transporter downregulated, downregulated in, in adenoma, adenoma (, ( encoded, encoded by, by DRA, DRA ;, ; 45, 45 %, % ), ) ., . On, On the, the basis, basis of, of this, this homology, homology and, and the, the presence, presence of, of a, a slightly, slightly modified, modified sulfate-transporter, sulfate-transporter signature, signature sequence, sequence comprising, comprising its, its putative, putative second, second transmembrane, transmembrane domain, domain ,, , pendrin, pendrin has, has been, been proposed, proposed to, to function, function as, as a, a sulfate, sulfate transporter, transporter ., . We, We were, were unable, unable to, to detect, detect evidence, evidence of, of sulfate, sulfate transport, transport following, following the, the expression, expression of, of pendrin, pendrin in, in Xenopus, Xenopus laevis, laevis oocytes, oocytes by, by microinjection, microinjection of, of PDS, PDS cRNA, cRNA or, or in, in Sf9, Sf9 cells, cells following, following infection, infection with, with PDS-recombinant, PDS-recombinant baculovirus, baculovirus ., . The, The rates, rates of, of transport, transport for, for iodide, iodide and, and chloride, chloride were, were significantly, significantly increased, increased following, following the, the expression, expression of, of pendrin, pendrin in, in both, both cell, cell systems, systems ., . Our, Our results, results demonstrate, demonstrate that, that pendrin, pendrin functions, functions as, as a, a transporter, transporter of, of chloride, chloride and, and iodide, iodide ,, , but, but not, not sulfate, sulfate ,, , and, and may, may provide, provide insight, insight into, into thyroid, thyroid physiology, physiology and, and the, the pathophysiology, pathophysiology of, of Pendred, Pendred syndrome.., syndrome.. Immunogenetic, Immunogenetic analysis, analysis of, of a, a homozygous, homozygous C2-deficient, C2-deficient individual, individual and, and family, family members, members demonstrated, demonstrated linkage, linkage of, of HLA-A25, HLA-A25 ,, , B18, B18 and, and C2o, C2o ., . HLA-D, HLA-D typing, typing showed, showed that, that 5, 5 members, members typed, typed with, with homozygous, homozygous Dw2, Dw2 typing, typing cells, cells from, from an, an individual, individual with, with C2, C2 deficiency, deficiency but, but not, not with, with Dw2, Dw2 typing, typing cells, cells from, from 2, 2 individuals, individuals with, with normal, normal C2, C2 ., . The, The homozygous, homozygous C2-deficient, C2-deficient propositus, propositus and, and brother, brother were, were HLA-A, HLA-A and, and B, B homozygous, homozygous but, but heterozygous, heterozygous at, at the, the HLA-D, HLA-D and, and glyoxalase, glyoxalase I, I loci, loci ., . Therefore, Therefore ,, , in, in this, this family, family ,, , the, the C2o, C2o gene, gene is, is linked, linked with, with two, two distinct, distinct haplotypes, haplotypes HLA-A25, HLA-A25 ,, , B18, B18 ,, , Dw2, Dw2 ,, , GLO1, GLO1 and, and HLA-A25, HLA-A25 ,, , B18, B18 ,, , D, D unknown, unknown ,, , GL02, GL02 ., . These, These results, results could, could be, be explained, explained by, by an, an ancestral, ancestral recombinant, recombinant event, event ,, , which, which occurred, occurred between, between the, the C2o, C2o locus, locus and, and HLA-D, HLA-D locus, locus in, in which, which C2o, C2o segregated, segregated with, with HLA-B, HLA-B ., . This, This would, would suggest, suggest that, that the, the locus, locus for, for the, the C2o, C2o gene, gene maps, maps between, between HLA-B, HLA-B and, and HLA-D, HLA-D on, on the, the sixth, sixth chromosome.., chromosome.. The, The known, known Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene products, products ,, , the, the muscle-, muscle- and, and brain-type, brain-type dystrophin, dystrophin isoforms, isoforms ,, , are, are 427-kDa, 427-kDa proteins, proteins translated, translated from, from 14-kilobase, 14-kilobase (, ( kb, kb ), ) mRNAs, mRNAs ., . Recently, Recently we, we described, described a, a 6, 6 ., . 5-kb, 5-kb mRNA, mRNA that, that also, also is, is transcribed, transcribed from, from the, the DMD, DMD gene, gene ., . Cloning, Cloning and, and in, in vitro, vitro transcription, transcription and, and translation, translation of, of the, the entire, entire coding, coding region, region show, show that, that the, the 6, 6 ., . 5-kb, 5-kb mRNA, mRNA encodes, encodes a, a 70, 70 ., . 8-kDa, 8-kDa protein, protein that, that is, is a, a major, major product, product of, of the, the DMD, DMD gene, gene ., . It, It contains, contains the, the C-terminal, C-terminal and, and the, the cysteine-rich, cysteine-rich domains, domains of, of dystrophin, dystrophin ,, , seven, seven additional, additional amino, amino acids, acids at, at the, the N, N terminus, terminus ,, , and, and some, some modifications, modifications formed, formed by, by alternative, alternative splicing, splicing in, in the, the C-terminal, C-terminal domain, domain ., . It, It lacks, lacks the, the entire, entire large, large domain, domain of, of spectrin-like, spectrin-like repeats, repeats and, and the, the actin-binding, actin-binding N-terminal, N-terminal domain, domain of, of dystrophin, dystrophin ., . This, This protein, protein is, is the, the major, major DMD, DMD gene, gene product, product in, in brain, brain and, and other, other nonmuscle, nonmuscle tissues, tissues but, but is, is undetectable, undetectable in, in skeletal, skeletal muscle, muscle extracts.Two, extracts.Two brothers, brothers ,, , 6, 6 and, and 13, 13 years, years old, old ,, , had, had histidinemia, histidinemia ., . On, On the, the basis, basis of, of clinical, clinical and, and biochemical, biochemical observations, observations ,, , the, the younger, younger boy, boy was, was considered, considered to, to have, have a, a classical, classical type, type of, of the, the disease, disease ,, , while, while the, the older, older boy, boy had, had an, an atypical, atypical form, form characterized, characterized by, by partial, partial impairment, impairment of, of the, the skin, skin histidase, histidase activity, activity and, and a, a moderately, moderately prolonged, prolonged half-life, half-life of, of blood, blood histidine, histidine ., . The, The mother, mother is, is a, a heterozygous, heterozygous carrier, carrier ,, , while, while the, the father, father and, and sister, sister seem, seem to, to be, be normal.., normal.. The, The Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome is, is a, a severe, severe X, X chromosome-linked, chromosome-linked human, human disease, disease caused, caused by, by a, a virtual, virtual absence, absence of, of hypoxanthine-guanine, hypoxanthine-guanine phosphoribosyltransferase, phosphoribosyltransferase (, ( HPRT, HPRT ), ) activity, activity ., . A, A partial, partial deficiency, deficiency in, in the, the activity, activity of, of this, this enzyme, enzyme can, can result, result in, in gouty, gouty arthritis, arthritis ., . To, To determine, determine the, the genetic, genetic basis, basis for, for reduction, reduction or, or loss, loss of, of enzyme, enzyme activity, activity ,, , we, we have, have amplified, amplified and, and sequenced, sequenced the, the coding, coding region, region of, of HPRT, HPRT cDNA, cDNA from, from four, four patients, patients one, one with, with Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome (, ( HPRTPerth, HPRTPerth ), ) and, and three, three with, with partial, partial deficiencies, deficiencies of, of HPRT, HPRT activity, activity ,, , which, which have, have been, been designated, designated HPRTUrangan, HPRTUrangan ,, , HPRTSwan, HPRTSwan and, and HPRTToowong, HPRTToowong ., . In, In all, all four, four patients, patients ,, , the, the only, only mutation, mutation identified, identified was, was a, a single, single base, base substitution, substitution in, in exons, exons 2, 2 or, or 3, 3 of, of the, the coding, coding region, region ,, , which, which in, in each, each case, case predicts, predicts a, a single, single amino, amino acid, acid substitution, substitution in, in the, the translated, translated protein, protein ., . Each, Each base, base change, change was, was confirmed, confirmed by, by allele-specific, allele-specific amplification, amplification of, of the, the patients, patients genomic, genomic DNA, DNA ., . It, It is, is interesting, interesting to, to note, note that, that the, the mutation, mutation found, found for, for HPRTPerth, HPRTPerth is, is identical, identical to, to that, that reported, reported for, for HPRTFlint, HPRTFlint ., . It, It appears, appears that, that the, the two, two mutations, mutations are, are de, de novo, novo events.., events.. Lipid, Lipid metabolism, metabolism was, was studied, studied in, in cultured, cultured skin, skin fibroblasts, fibroblasts from, from patients, patients with, with the, the inherited, inherited disorder, disorder ,, , Sjogren-Larsson, Sjogren-Larsson syndrome, syndrome (, ( SLS, SLS ), ) ., . Intact, Intact SLS, SLS fibroblasts, fibroblasts incubated, incubated in, in the, the presence, presence of, of [, [ 1-14C, 1-14C ], ] palmitate, palmitate accumulated, accumulated more, more radioactive, radioactive hexadecanol, hexadecanol than, than did, did normal, normal cells, cells ,, , whereas, whereas incorporation, incorporation of, of radioactivity, radioactivity into, into other, other cellular, cellular lipids, lipids was, was unaltered, unaltered ., . The, The hexadecanol, hexadecanol content, content of, of SLS, SLS fibroblasts, fibroblasts was, was abnormally, abnormally elevated, elevated ., . Hexadecanol, Hexadecanol accumulation, accumulation was, was not, not due, due to, to increased, increased fatty, fatty alcohol, alcohol synthesis, synthesis nor, nor its, its deficient, deficient utilization, utilization for, for glycerol, glycerol ether, ether synthesis, synthesis ., . The, The half-life, half-life of, of intracellular, intracellular hexadecanol, hexadecanol loaded, loaded into, into SLS, SLS fibroblasts, fibroblasts was, was increased, increased (, ( 70, 70 min, min ), ) compared, compared with, with normal, normal (, ( 15, 15 min, min ), ) ,, , and, and intact, intact SLS, SLS fibroblasts, fibroblasts showed, showed impaired, impaired oxidation, oxidation of, of [, [ 14C, 14C ], ] -hexadecanol, -hexadecanol to, to fatty, fatty acid, acid ., . Fatty, Fatty alcohol, alcohol NAD, NAD +, + oxidoreductase, oxidoreductase ,, , the, the enzyme, enzyme catalyzing, catalyzing this, this reaction, reaction ,, , was, was deficient, deficient in, in SLS, SLS fibroblasts, fibroblasts ., . Mean, Mean total, total activity, activity in, in SLS, SLS fibroblasts, fibroblasts (, ( n, n =, = 5, 5 ), ) was, was 13, 13 %, % of, of that, that in, in normal, normal fibroblasts, fibroblasts ,, , and, and palmitoyl, palmitoyl CoA-inhibitable, CoA-inhibitable activity, activity was, was 1, 1 %, % of, of normal, normal ., . Fibroblasts, Fibroblasts from, from two, two obligate, obligate SLS, SLS heterozygotes, heterozygotes had, had enzyme, enzyme activities, activities intermediate, intermediate between, between that, that in, in normal, normal fibroblasts, fibroblasts and, and individuals, individuals with, with SLS, SLS ., . These, These results, results suggest, suggest that, that the, the primary, primary defect, defect in, in SLS, SLS is, is deficiency, deficiency of, of fatty, fatty alcohol, alcohol NAD, NAD +, + oxidoreductase, oxidoreductase ., . SLS, SLS represents, represents the, the first, first inherited, inherited disorder, disorder in, in man, man associated, associated with, with an, an isolated, isolated abnormality, abnormality in, in fatty, fatty alcohol, alcohol metabolism.., metabolism.. Glycerol, Glycerol kinase, kinase (, ( GK, GK ), ) represents, represents the, the primary, primary entry, entry of, of glycerol, glycerol into, into glucose, glucose and, and triglyceride, triglyceride metabolism, metabolism ., . Impaired, Impaired glucose, glucose tolerance, tolerance (, ( IGT, IGT ), ) and, and hypertriglyceridemia, hypertriglyceridemia are, are associated, associated with, with an, an increased, increased risk, risk of, of diabetes, diabetes mellitus, mellitus and, and cardiovascular, cardiovascular disease, disease ., . The, The relationship, relationship between, between glycerol, glycerol and, and the, the risk, risk of, of IGT, IGT ,, , however, however ,, , is, is poorly, poorly understood, understood ., . We, We therefore, therefore undertook, undertook the, the study, study of, of fasting, fasting plasma, plasma glycerol, glycerol levels, levels in, in a, a cohort, cohort of, of 1, 1 ,, , 056, 056 unrelated, unrelated men, men and, and women, women of, of French-Canadian, French-Canadian descent, descent ., . Family, Family screening, screening in, in the, the initial, initial cohort, cohort identified, identified 18, 18 men, men from, from five, five families, families with, with severe, severe hyperglycerolemia, hyperglycerolemia (, ( values, values above, above 2, 2 ., . 0, 0 mmol/liter, mmol/liter ), ) and, and demonstrated, demonstrated an, an X-linked, X-linked pattern, pattern of, of inheritance, inheritance ., . Linkage, Linkage analysis, analysis of, of the, the data, data from, from 12, 12 microsatellite, microsatellite markers, markers surrounding, surrounding the, the Xp21, Xp21 ., . 3, 3 GK, GK gene, gene resulted, resulted in, in a, a peak, peak LOD, LOD score, score of, of 3, 3 ., . 46, 46 ,, , centered, centered around, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "around marker, marker DXS8039, DXS8039 ., . In, In addition, addition ,, , since, since all, all of, of the, the families, families originated, originated in, in a, a population, population with, with a, a proven, proven founder, founder effect-the, effect-the Saguenay, Saguenay Lac-St., Lac-St. -Jean, -Jean region, region of, of Quebec-a, Quebec-a common, common disease, disease haplotype, haplotype was, was sought, sought ., . Indeed, Indeed ,, , a, a six-marker, six-marker haplotype, haplotype extending, extending over, over a, a region, region of, of 5, 5 ., . 5, 5 cM, cM was, was observed, observed in, in all, all families, families ., . Resequencing, Resequencing of, of the, the GK, GK gene, gene in, in family, family members, members led, led to, to the, the discovery, discovery of, of a, a N288D, N288D missense, missense mutation, mutation in, in exon, exon 10, 10 ,, , which, which resulted, resulted in, in the, the substitution, substitution of, of a, a highly, highly conserved, conserved asparagine, asparagine residue, residue by, by a, a negatively, negatively charged, charged aspartic, aspartic acid, acid ., . Aspartylglucosaminuria, Aspartylglucosaminuria (, ( AGU, AGU ), ) is, is a, a recessive, recessive autosomally, autosomally inherited, inherited lysosomal, lysosomal storage, storage disorder, disorder due, due to, to deficiency, deficiency of, of the, the enzyme, enzyme aspartylglucosaminidase, aspartylglucosaminidase (, ( AGA, AGA ), ) ., . The, The structural, structural gene, gene for, for this, this human, human enzyme, enzyme (, ( AGA, AGA ), ) has, has been, been assigned, assigned to, to the, the region, region 4q21, 4q21 --, -- --, -- qter, qter ., . We, We determined, determined the, the AGA, AGA activity, activity in, in cultured, cultured fibroblasts, fibroblasts of, of a, a girl, girl with, with a, a 46, 46 ,, , XX, XX ,, , del, del (, ( 4, 4 ), ) (, ( q33, q33 ), ) karyotype, karyotype ., . The, The results, results indicate, indicate that, that the, the girl, girl is, is a, a hemizygote, hemizygote for, for AGA, AGA ,, , permitting, permitting the, the assignment, assignment of, of human, human AGA, AGA to, to the, the region, region 4q33, 4q33 --, -- --, -- qter.., qter.. Congenital, Congenital afibrinogenemia, afibrinogenemia is, is a, a rare, rare ,, , autosomal, autosomal ,, , recessive, recessive disorder, disorder characterized, characterized by, by the, the complete, complete absence, absence of, of detectable, detectable fibrinogen, fibrinogen ., . We, We previously, previously identified, identified the, the first, first causative, causative mutations, mutations in, in a, a nonconsanguineous, nonconsanguineous Swiss, Swiss family, family ;, ; the, the 4, 4 affected, affected persons, persons have, have homozygous, homozygous deletions, deletions of, of approximately, approximately 11, 11 kb, kb of, of the, the fibrinogen, fibrinogen alpha, alpha (, ( FGA, FGA ), ) gene, gene ., . Haplotype, Haplotype data, data implied, implied that, that these, these deletions, deletions occurred, occurred on, on distinct, distinct ancestral, ancestral chromosomes, chromosomes ,, , suggesting, suggesting that, that this, this region, region may, may be, be susceptible, susceptible to, to deletion, deletion by, by a, a common, common mechanism, mechanism ., . We, We subsequently, subsequently showed, showed that, that all, all the, the deletions, deletions were, were identical, identical to, to the, the base, base pair, pair and, and probably, probably resulted, resulted from, from a, a nonhomologous, nonhomologous recombination, recombination mediated, mediated by, by 7-bp, 7-bp direct, direct repeats, repeats ., . In, In this, this study, study ,, , we, we have, have collected, collected data, data on, on 13, 13 additional, additional unrelated, unrelated patients, patients to, to identify, identify the, the causative, causative mutations, mutations and, and to, to determine, determine the, the prevalence, prevalence of, of the, the 11-kb, 11-kb deletion, deletion ., . A, A common, common recurrent, recurrent mutation, mutation ,, , at, at the, the donor, donor splice, splice site, site of, of FGA, FGA intron, intron 4, 4 (, ( IVS4, IVS4 +, + 1, 1 G, G >, > T, T ), ) ,, , accounted, accounted for, for 14, 14 of, of the, the 26, 26 (, ( 54, 54 %, % ), ) alleles, alleles ., . One, One patient, patient was, was heterozygous, heterozygous for, for the, the previously, previously identified, identified deletion, deletion ., . Three, Three more, more frameshift, frameshift mutations, mutations ,, , 2, 2 nonsense, nonsense mutations, mutations ,, , and, and a, a second, second splice, splice site, site mutation, mutation were, were also, also identified, identified ., . Consequently, Consequently ,, , 86, 86 %, % of, of afibrinogenemia, afibrinogenemia alleles, alleles analyzed, analyzed to, to date, date have, have truncating, truncating mutations, mutations of, of FGA, FGA ,, , though, though mutations, mutations in, in all, all 3, 3 fibrinogen, fibrinogen genes, genes ,, , FGG, FGG ,, , FGA, FGA ,, , and, and FGB, FGB ,, , might, might be, be predicted, predicted to, to cause, cause congenital, congenital afibrinogenemia.., afibrinogenemia.. The, The patient, patient ,, , H., H. Chr, Chr ., . B., B. ,, , was, was among, among the, the first, first reported, reported with, with hyperuricemia, hyperuricemia and, and central, central nervous, nervous system, system symptoms, symptoms ., . He, He has, has been, been found, found to, to have, have a, a variant, variant of, of hypoxanthine, hypoxanthine guanine, guanine phosphoribosyl, phosphoribosyl transferase, transferase (, ( HPRT, HPRT ;, ; E., E. C., C. 2, 2 ., . 4, 4 ., . 2, 2 ., . 8, 8 ), ) distinct, distinct from, from the, the enzyme, enzyme present, present in, in patients, patients with, with the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome ., . The, The patient, patient had, had chroeoathetosis, chroeoathetosis ,, , spasticity, spasticity ,, , dysarthric, dysarthric speech, speech ,, , and, and hyperuricemia, hyperuricemia ., . However, However ,, , his, his intelligence, intelligence was, was normal, normal and, and he, he had, had no, no evidence, evidence of, of self-mutilation, self-mutilation ., . There, There was, was no, no activity, activity of, of HPRT, HPRT in, in the, the lysates, lysates of, of erythrocytes, erythrocytes and, and cultured, cultured fibroblasts, fibroblasts when, when analyzed, analyzed in, in the, the usual, usual manner, manner ., . Using, Using a, a newly, newly developed, developed method, method for, for the, the study, study of, of purine, purine metabolism, metabolism in, in intact, intact cultured, cultured cells, cells ,, , this, this patient, patient was, was found, found to, to metabolize, metabolize some, some 9, 9 %, % of, of 8-14C-hypoxanthine, 8-14C-hypoxanthine ,, , and, and 90, 90 %, % of, of the, the isotope, isotope utilized, utilized was, was converted, converted to, to adenine, adenine and, and guanine, guanine nucleotides, nucleotides ., . In, In contrast, contrast ,, , cells, cells from, from patients, patients with, with the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome were, were virtually, virtually completely, completely unable, unable to, to convert, convert hypoxanthine, hypoxanthine to, to nucleotides, nucleotides ., . The, The patients, patients fibroblasts, fibroblasts were, were even, even more, more efficient, efficient in, in the, the metabolism, metabolism of, of 8-14C-guanine, 8-14C-guanine ,, , which, which was, was utilized, utilized to, to the, the extent, extent of, of 27, 27 %, % ,, , over, over 80, 80 %, % of, of which, which was, was converted, converted to, to guanine, guanine and, and adenine, adenine nucleotides, nucleotides ., . The, The growth, growth of, of the, the cultured, cultured fibroblasts, fibroblasts of, of this, this patient, patient was, was intermediate, intermediate in, in media, media containing, containing hypoxanthine, hypoxanthine aminopterin, aminopterin thymidine, thymidine (, ( HAT, HAT ), ) ,, , whereas, whereas the, the growth, growth of, of Lesch-Nyhan, Lesch-Nyhan cells, cells was, was inhibited, inhibited and, and normal, normal cells, cells grew, grew normally, normally ., . Similarly, Similarly in, in 8-azaguanine, 8-azaguanine ,, , 6-thioguanine, 6-thioguanine ,, , and, and 8-azahypoxanthine, 8-azahypoxanthine ,, , the, the growth, growth of, of the, the patients, patients cells, cells was, was intermediate, intermediate between, between normal, normal and, and Lesch-Nyhan, Lesch-Nyhan cells, cells ., . These, These observations, observations provide, provide further, further evidence, evidence for, for genetic, genetic heterogeneity, heterogeneity among, among patients, patients with, with disorders, disorders in, in purine, purine metabolism, metabolism involving, involving the, the HPRT, HPRT gene, gene ., . They, They document, document that, that this, this famous, famous patient, patient did, did not, not have, have the, the Lesch-Nyhan, Lesch-Nyhan syndrome, syndrome Canavan, Canavan disease, disease is, is an, an autosomal, autosomal recessive, recessive leukodystrophy, leukodystrophy caused, caused by, by the, the deficiency, deficiency of, of aspartoacylase, aspartoacylase (, ( ASPA, ASPA ), ) ., . Sixty-four, Sixty-four probands, probands were, were analyzed, analyzed for, for mutations, mutations in, in the, the ASPA, ASPA gene, gene ., . Three, Three point, point mutations, mutations --, -- 693C, 693C --, -- >, > A, A ,, , 854A, 854A --, -- >, > C, C ,, , and, and 914C, 914C --, -- >, > A, A --, -- were, were identified, identified in, in the, the coding, coding sequence, sequence ., . The, The 693C, 693C --, -- >, > A, A and, and 914C, 914C --, -- >, > A, A base, base changes, changes ,, , resulting, resulting in, in nonsense, nonsense tyr231, tyr231 --, -- >, > ter, ter and, and missense, missense ala305, ala305 --, -- >, > glu, glu mutations, mutations ,, , respectively, respectively ,, , lead, lead to, to complete, complete loss, loss of, of ASPA, ASPA activity, activity in, in in, in vitro, vitro expression, expression studies, studies ., . The, The 854A, 854A --, -- >, > C, C transversion, transversion converted, converted glu, glu to, to ala, ala in, in codon, codon 285, 285 ., . The, The glu285, glu285 --, -- >, > ala, ala mutant, mutant ASPA, ASPA has, has 2, 2 ., . 5, 5 %, % of, of the, the activity, activity expressed, expressed by, by the, the wild-type, wild-type enzyme, enzyme ., . A, A fourth, fourth mutation, mutation ,, , 433, 433 --, -- 2, 2 (, ( A, A --, -- >, > G, G ), ) transition, transition ,, , was, was identified, identified at, at the, the splice-acceptor, splice-acceptor site, site in, in intron, intron 2, 2 ., . The, The splice-site, splice-site mutation, mutation would, would lead, lead to, to skipping, skipping of, of exon, exon 3, 3 ,, , accompanied, accompanied by, by a, a frameshift, frameshift ,, , and, and thus, thus would, would produce, produce aberrant, aberrant ASPA, ASPA ., . Of, Of the, the 128, 128 unrelated, unrelated Canavan, Canavan chromosomes, chromosomes analyzed, analyzed ,, , 88, 88 were, were from, from probands, probands of, of Ashkenazi, Ashkenazi Jewish, Jewish descent, descent ., . The, The glu285, glu285 --, -- >, > ala, ala mutation, mutation was, was predominant, predominant (, ( 82, 82 ., . 9, 9 %, % ), ) in, in this, this population, population ,, , followed, followed by, by the, the tyr231, tyr231 --, -- >, > ter, ter (, ( 14, 14 ., . 8, 8 %, % ), ) and, and 433, 433 --, -- 2, 2 (, ( A, A --, -- >, > G, G ), ) (, ( 1, 1 ., . 1, 1 %, % ), ) mutations, mutations ., . The, The three, three mutations, mutations account, account for, for 98, 98 ., . 8, 8 %, % of, of the, the Canavan, Canavan chromosomes, chromosomes of, of Ashkenazi, Ashkenazi Jewish, Jewish origin, origin ., . The, The ala305, ala305 --, -- >, > glu, glu mutation, mutation was, was found, found exclusively, exclusively in, in non-Jewish, non-Jewish probands, probands of, of European, European descent, descent and, and constituted, constituted 60, 60 %, % of, of the, the 40, 40 mutant, mutant chromosomes, chromosomes ., . Predominant, Predominant occurrence, occurrence of, of certain, certain mutations, mutations among, among Ashkenazi, Ashkenazi Jewish, Jewish and, and non-Jewish, non-Jewish patients, patients with, with Canavan, Canavan disease, disease would, would suggest, suggest a, a founding-father, founding-father effect, effect in, in propagation, propagation of, of these, these mutant, mutant chromosomes, chromosomes Small, Small (, ( 100-260, 100-260 kb, kb ), ) ,, , nested, nested deletions, deletions were, were characterized, characterized in, in DNA, DNA from, from two, two unrelated, unrelated patients, patients with, with familial, familial adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) ., . Three, Three candidate, candidate genes, genes located, located within, within the, the deleted, deleted region, region were, were ascertained, ascertained and, and a, a previous, previous candidate, candidate gene, gene ,, , MCC, MCC ,, , was, was shown, shown to, to be, be located, located outside, outside the, the deleted, deleted region, region ., . One, One of, of the, the new, new genes, genes contained, contained sequence, sequence identical, identical to, to SRP19, SRP19 ,, , the, the gene, gene coding, coding for, for the, the 19, 19 kd, kd component, component of, of the, the ribosomal, ribosomal signal, signal recognition, recognition particle, particle ., . The, The second, second ,, , provisionally, provisionally designated, designated DP1, DP1 (, ( deleted, deleted in, in polyposis, polyposis 1, 1 ), ) ,, , was, was found, found to, to be, be transcribed, transcribed in, in the, the same, same orientation, orientation as, as MCC, MCC ., . Two, Two other, other cDNAs, cDNAs ,, , DP2, DP2 and, and DP3, DP3 ,, , were, were found, found to, to overlap, overlap ,, , forming, forming a, a single, single gene, gene ,, , DP2, DP2 ., . 5, 5 ,, , that, that is, is transcribed, transcribed in, in the, the same, same orientation, orientation as, as SRP19, SRP19 ., . Von, Von Hippel-Lindau, Hippel-Lindau (, ( VHL, VHL ), ) disease, disease is, is a, a hereditary, hereditary tumor, tumor syndrome, syndrome characterized, characterized by, by predisposition, predisposition for, for bilateral, bilateral and, and multi-centric, multi-centric hemangioblastoma, hemangioblastoma in, in the, the retina, retina and, and central, central nervous, nervous system, system ,, , pheochromocytoma, pheochromocytoma ,, , renal, renal cell, cell carcinoma, carcinoma ,, , and, and cysts, cysts in, in the, the kidney, kidney ,, , pancreas, pancreas ,, , and, and epididymis, epididymis ., . We, We describe, describe five, five families, families for, for which, which direct, direct sequencing, sequencing of, of the, the coding, coding region, region of, of the, the VHL, VHL gene, gene had, had failed, failed to, to identify, identify the, the family-specific, family-specific mutation, mutation ., . Further, Further molecular, molecular analysis, analysis revealed, revealed deletions, deletions involving, involving the, the VHL, VHL gene, gene in, in each, each of, of these, these families, families ., . In, In four, four families, families ,, , partial, partial deletions, deletions of, of one, one or, or more, more exons, exons were, were detected, detected by, by Southern, Southern blot, blot analysis, analysis ., . In, In the, the fifth, fifth family, family ,, , FISH, FISH analysis, analysis demonstrated, demonstrated the, the deletion, deletion of, of the, the entire, entire VHL, VHL gene, gene ., . Our, Our results, results show, show that, that (, ( quantitative, quantitative ), ) Southern, Southern blot, blot analysis, analysis is, is a, a sensitive, sensitive method, method for, for detecting, detecting germline, germline deletions, deletions of, of the, the VHL, VHL gene, gene and, and should, should be, be implemented, implemented in, in routine, routine DNA, DNA diagnosis, diagnosis for, for VHL, VHL disease, disease ., . Our, Our data, data support, support the, the previously, previously established, established observation, observation that, that families, families with, with a, a germline, germline deletion, deletion have, have a, a low, low risk, risk for, for pheochromocytoma, pheochromocytoma ., . Further, Further unraveling, unraveling of, of genotype-phenotype, genotype-phenotype correlations, correlations in, in VHL, VHL disease, disease has, has revealed, revealed that, that families, families with, with a, a full, full or, or partial, partial deletion, deletion of, of the, the VHL, VHL gene, gene exhibit, exhibit a, a phenotype, phenotype with, with a, a preponderance, preponderance of, of central, central nervous, nervous system, system hemangioblastoma.., hemangioblastoma.. Fragile, Fragile X, X syndrome, syndrome ,, , a, a common, common form, form of, of inherited, inherited mental, mental retardation, retardation ,, , is, is mainly, mainly caused, caused by, by massive, massive expansion, expansion of, of CGG, CGG triplet, triplet repeats, repeats located, located in, in the, the 5-untranslated, 5-untranslated region, region of, of the, the fragile, fragile X, X mental, mental retardation-1, retardation-1 (, ( FMR1, FMR1 ), ) gene, gene ., . In, In patients, patients with, with fragile, fragile X, X syndrome, syndrome ,, , the, the expanded, expanded CGG, CGG triplet, triplet repeats, repeats are, are hypermethylated, hypermethylated and, and the, the expression, expression of, of the, the FMR1, FMR1 gene, gene is, is repressed, repressed ,, , which, which leads, leads to, to the, the absence, absence of, of FMR1, FMR1 protein, protein (, ( FMRP, FMRP ), ) and, and subsequent, subsequent mental, mental retardation, retardation ., . FMRP, FMRP is, is an, an RNA-binding, RNA-binding protein, protein that, that shuttles, shuttles between, between the, the nucleus, nucleus and, and cytoplasm, cytoplasm ., . This, This protein, protein has, has been, been implicated, implicated in, in protein, protein translation, translation as, as it, it is, is found, found associated, associated with, with polyribosomes, polyribosomes and, and the, the rough, rough endoplasmic, endoplasmic reticulum, reticulum ., . We, We discuss, discuss here, here the, the recent, recent progress, progress made, made towards, towards understanding, understanding the, the molecular, molecular mechanism, mechanism of, of CGG, CGG repeat, repeat expansion, expansion and, and physiological, physiological function, function (, ( s, s ), ) of, of FMRP, FMRP ., . These, These studies, studies will, will not, not only, only help, help to, to illuminate, illuminate the, the molecular, molecular basis, basis of, of the, the general, general class, class of, of human, human diseases, diseases with, with trinucleotide, trinucleotide repeat, repeat expansion, expansion but, but also, also provide, provide an, an avenue, avenue to, to understand, understand aspects, aspects of, of human, human cognition, cognition and, and intelligence.., intelligence.. A, A total, total of, of 362, 362 males, males from, from various, various regions, regions of, of Papua, Papua New, New Guinea, Guinea were, were screened, screened for, for red, red cell, cell glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) activity, activity ., . Twenty-six, Twenty-six G6PD, G6PD deficient, deficient individuals, individuals were, were identified, identified ., . Biochemical, Biochemical characterization, characterization of, of G6PD, G6PD purified, purified from, from these, these subjects, subjects has, has revealed, revealed 13, 13 new, new variants, variants and, and several, several copies, copies of, of previously, previously described, described forms, forms of, of G6PD, G6PD ., . This, This study, study illustrates, illustrates the, the extreme, extreme heterogeneity, heterogeneity of, of G6PD, G6PD deficiency, deficiency among, among the, the people, people of, of Papua, Papua New, New Guinea.., Guinea.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is an, an autosomal, autosomal recessive, recessive disorder, disorder of, of amino, amino acid, acid metabolism, metabolism caused, caused by, by a, a deficiency, deficiency of, of the, the hepatic, hepatic enzyme, enzyme phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ;, ; phenylalanine, phenylalanine 4-monooxygenase, 4-monooxygenase ,, , EC, EC 1, 1 ., . 14, 14 ., . 16, 16 ., . 1, 1 ), ) ., . A, A cDNA, cDNA clone, clone for, for human, human PAH, PAH has, has previously, previously been, been used, used to, to assign, assign the, the corresponding, corresponding gene, gene to, to human, human chromosome, chromosome 12, 12 ., . To, To define, define the, the regional, regional map, map position, position of, of the, the disease, disease locus, locus and, and the, the PAH, PAH gene, gene on, on human, human chromosome, chromosome 12, 12 ,, , DNA, DNA was, was isolated, isolated from, from human-hamster, human-hamster somatic, somatic cell, cell hybrids, hybrids with, with various, various deletions, deletions of, of human, human chromosome, chromosome 12, 12 and, and was, was analyzed, analyzed by, by Southern, Southern blot, blot analysis, analysis using, using the, the human, human cDNA, cDNA PAH, PAH clone, clone as, as a, a hybridization, hybridization probe, probe ., . From, From these, these results, results ,, , together, together with, with detailed, detailed biochemical, biochemical and, and cytogenetic, cytogenetic characterization, characterization of, of the, the hybrid, hybrid cells, cells ,, , the, the region, region on, on chromosome, chromosome 12, 12 containing, containing the, the human, human PAH, PAH gene, gene has, has been, been defined, defined as, as 12q14, 12q14 ., . 3, 3 --, -- --, -- qter, qter 3, 3 --, -- --, -- qter, qter ., . The, The PAH, PAH map, map position, position on, on chromosome, chromosome 12, 12 was, was further, further localized, localized by, by in, in situ, situ hybridization, hybridization of, of 125I-labeled, 125I-labeled human, human PAH, PAH cDNA, cDNA to, to chromosomes, chromosomes prepared, prepared from, from a, a human, human lymphoblastoid, lymphoblastoid cell, cell line, line ., . Results, Results of, of these, these experiments, experiments demonstrated, demonstrated that, that the, the region, region on, on chromosome, chromosome 12, 12 containing, containing the, the PAH, PAH gene, gene and, and the, the PKU, PKU locus, locus in, in man, man is, is 12q22, 12q22 --, -- --, -- 12q24, 12q24 ., . 1, 1 ., . These, These results, results not, not only, only provide, provide a, a regionalized, regionalized map, map position, position for, for a, a major, major human, human disease, disease locus, locus but, but also, also can, can serve, serve as, as a, a reference, reference point, point for, for linkage, linkage analysis, analysis with, with other, other DNA, DNA markers, markers on, on human, human chromosome, chromosome 12, 12 The, The molecular, molecular basis, basis of, of cholesteryl, cholesteryl ester, ester transfer, transfer protein, protein (, ( CETP, CETP ), ) deficiency, deficiency was, was investigated, investigated in, in 4, 4 unrelated, unrelated CETP-deficient, CETP-deficient families, families ., . The, The high, high density, density lipoprotein-cholesterol, lipoprotein-cholesterol levels, levels of, of the, the probands, probands exceeded, exceeded 150, 150 mg/dl, mg/dl ., . The, The plasma, plasma of, of the, the probands, probands was, was totally, totally deficient, deficient in, in CETP, CETP activity, activity and, and mass, mass ., . The, The genomic, genomic DNA, DNA of, of the, the patients, patients was, was amplified, amplified by, by polymerase, polymerase chain, chain reaction, reaction ,, , using, using two, two oligonucleotide, oligonucleotide primers, primers located, located in, in the, the intron, intron 12, 12 and, and 14, 14 of, of the, the CETP, CETP gene, gene ,, , and, and the, the amplified, amplified products, products were, were directly, directly sequenced, sequenced ., . Two, Two patients, patients were, were homozygous, homozygous for, for a, a G-to-A, G-to-A change, change at, at the, the 5-splice, 5-splice donor, donor site, site of, of the, the intron, intron 14, 14 ., . The, The G-to-A, G-to-A change, change would, would cause, cause impaired, impaired splicing, splicing of, of pre-messenger, pre-messenger RNA, RNA ., . The, The other, other two, two probands, probands were, were heterozygous, heterozygous for, for the, the mutation, mutation ,, , but, but totally, totally lacked, lacked CETP, CETP ., . Their, Their lipoprotein, lipoprotein patterns, patterns were, were also, also similar, similar to, to those, those of, of the, the two, two homozygotes, homozygotes ., . Thus, Thus ,, , other, other genetic, genetic defects, defects or, or metabolic, metabolic factors, factors influencing, influencing CETP, CETP expression, expression are, are implicated, implicated ., . The, The data, data suggest, suggest that, that the, the G-to-A, G-to-A mutation, mutation may, may be, be common, common in, in human, human plasma, plasma CETP, CETP deficiency, deficiency ., . Furthermore, Furthermore ,, , there, there could, could be, be compound, compound heterozygotes, heterozygotes who, who totally, totally lack, lack plasma, plasma CETP, CETP and, and have, have lipoprotein, lipoprotein profiles, profiles similar, similar to, to those, those of, of homozygotes.., homozygotes.. Type, Type I, I von, von Willebrand, Willebrand disease, disease (, ( vWD, vWD ), ) is, is characterized, characterized by, by equally, equally low, low plasma, plasma concentrations, concentrations of, of von, von Willebrand, Willebrand factor, factor antigen, antigen (, ( vWF, vWF Ag, Ag ), ) and, and ristocetin, ristocetin cofactor, cofactor (, ( RiCof, RiCof ), ) and, and by, by the, the presence, presence of, of all, all vWF, vWF multimers, multimers in, in sodium, sodium dodecyl, dodecyl sulfate, sulfate (, ( SDS, SDS ), ) -agarose, -agarose gel, gel electrophoresis, electrophoresis ., . For, For 17, 17 patients, patients (, ( 13, 13 kindreds, kindreds ), ) diagnosed, diagnosed with, with these, these criteria, criteria ,, , we, we have, have studied, studied the, the platelet, platelet contents, contents of, of vWF, vWF Ag, Ag and, and RiCof, RiCof and, and the, the changes, changes of, of these, these in, in plasma, plasma after, after DDAVP, DDAVP infusion, infusion ., . Platelet, Platelet vWF, vWF Ag, Ag and, and RiCof, RiCof were, were normal, normal in, in four, four kindreds, kindreds (, ( called, called ``, `` platelet, platelet normal, normal ``, `` subgroup, subgroup ), ) ;, ; following, following 1-deamino-8-D-arginine, 1-deamino-8-D-arginine vasopressin, vasopressin ;, ; plasma, plasma vWF, vWF Ag, Ag ,, , RiCof, RiCof and, and the, the bleeding, bleeding time, time (, ( BT, BT ), ) became, became normal, normal ., . In, In six, six kindreds, kindreds ,, , platelet, platelet vWF, vWF Ag, Ag and, and RiCof, RiCof were, were equally, equally low, low (, ( platelet, platelet low, low ), ) ;, ; after, after DDAVP, DDAVP ,, , plasma, plasma vWF, vWF Ag, Ag and, and RiCof, RiCof remained, remained low, low ,, , and, and the, the BT, BT was, was prolonged, prolonged ., . In, In three, three additional, additional kindreds, kindreds ,, , platelets, platelets contained, contained normal, normal concentrations, concentrations of, of vWF, vWF Ag, Ag ,, , but, but RiCof, RiCof was, was very, very low, low (, ( platelet, platelet discordant, discordant ), ) ;, ; even, even though, though a, a complete, complete set, set of, of multimers, multimers was, was found, found in, in plasma, plasma and, and platelets, platelets ,, , there, there was, was a, a relatively, relatively small, small amount, amount of, of large, large multimers, multimers ., . After, After DDAVP, DDAVP ,, , plasma, plasma vWF, vWF Ag, Ag became, became normal, normal ,, , but, but RiCof, RiCof remained, remained low, low and, and the, the BT, BT was, was very, very prolonged, prolonged ., . These, These findings, findings demonstrated, demonstrated that, that there, there can, can be, be an, an abnormal, abnormal vWF, vWF (, ( RiCof, RiCof less, less than, than vWF, vWF Ag, Ag ), ) even, even in, in type, type I, I vWD, vWD ,, , coexisting, coexisting with, with a, a complete, complete set, set of, of vWF, vWF multimers, multimers (, ( platelet, platelet discordant, discordant ), ) ;, ; that, that the, the abnormal, abnormal vWF, vWF can, can be, be shown, shown more, more clearly, clearly in, in platelets, platelets than, than in, in plasma, plasma or, or else, else in, in plasma, plasma after, after DDAVP, DDAVP infusion, infusion ;, ; and, and that, that DDAVP, DDAVP normalizes, normalizes the, the BT, BT only, only in, in those, those patients, patients with, with normal, normal platelet, platelet levels, levels of, of both, both vWF, vWF Ag, Ag and, and RiCof, RiCof (, ( platelet, platelet normal, normal ), ) .., .. It, It has, has been, been shown, shown from, from pulsed-field, pulsed-field gel, gel electrophoresis, electrophoresis (, ( PFGE, PFGE ), ) that, that the, the monoamine, monoamine oxidase, oxidase genes, genes A, A and, and B, B (, ( MAOA, MAOA &, & MAOB, MAOB ), ) and, and DXS7, DXS7 loci, loci are, are physically, physically very, very close, close ., . We, We have, have therefore, therefore extended, extended studies, studies on, on their, their relationship, relationship through, through the, the characterisation, characterisation of, of a, a 650, 650 kb, kb YAC, YAC isolated, isolated using, using L1, L1 ., . 28, 28 (, ( recognising, recognising the, the DXS7, DXS7 locus, locus ), ) as, as a, a probe, probe ., . Restriction, Restriction mapping, mapping of, of the, the YAC, YAC indicates, indicates that, that it, it contains, contains both, both MAOA, MAOA and, and MAOB, MAOB genes, genes in, in addition, addition to, to the, the DXS7, DXS7 locus, locus ., . The, The map, map derived, derived from, from the, the YL1, YL1 ., . 28-YAC, 28-YAC is, is compatible, compatible both, both with, with the, the map, map from, from an, an independently, independently derived, derived YAC, YAC carrying, carrying MAOA, MAOA and, and B, B genes, genes and, and with, with the, the long, long range, range genomic, genomic map, map for, for the, the region, region ., . A, A series, series of, of subclones, subclones prepared, prepared from, from a, a phage, phage library, library (, ( lambda, lambda DASH, DASH II, II ), ) of, of the, the YAC, YAC have, have been, been characterised, characterised and, and have, have been, been employed, employed to, to determine, determine the, the end"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", end point, point of, of the, the deletion, deletion of, of a, a Norrie, Norrie disease, disease (, ( NDP, NDP ), ) patient, patient who, who has, has been, been shown, shown to, to lack, lack both, both DXS7, DXS7 and, and MAO, MAO coding, coding sequences, sequences ., . The, The pattern, pattern of, of retention, retention of, of subclones, subclones in, in the, the deletion, deletion patient, patient place, place the, the end, end point, point of, of the, the deletion, deletion within, within 30-130, 30-130 kb, kb of, of the, the proximal, proximal end, end of, of the, the YAC, YAC ., . By, By combining, combining the, the data, data with, with established, established recombination, recombination analysis, analysis ,, , we, we provide, provide evidence, evidence that, that all, all or, or part, part of, of the, the NDP, NDP lies, lies in, in the, the interval, interval of, of approximately, approximately 250kb, 250kb within, within the, the YAC.We, YAC.We have, have searched, searched for, for mutations, mutations in, in the, the choroideremia, choroideremia gene, gene (, ( CHM, CHM ), ) in, in patients, patients from, from 12, 12 Danish, Danish families, families in, in which, which CHM, CHM is, is segregating, segregating ., . Employing, Employing polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) ,, , single, single strand, strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) analysis, analysis ,, , and, and direct, direct DNA, DNA sequencing, sequencing ,, , different, different mutations, mutations have, have been, been identified, identified in, in 6, 6 patients, patients ., . All, All the, the mutations, mutations will, will interfere, interfere with, with the, the correct, correct translation, translation of, of the, the mRNA, mRNA predicting, predicting a, a truncated, truncated protein, protein or, or no, no gene, gene product, product at, at all.., all.. Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) is, is the, the most, most common, common inherited, inherited ataxia, ataxia ., . About, About 98, 98 %, % of, of mutant, mutant alleles, alleles have, have an, an expansion, expansion of, of a, a GAA, GAA trinucleotide, trinucleotide repeat, repeat in, in intron, intron 1, 1 of, of the, the affected, affected gene, gene ,, , FRDA, FRDA ., . The, The other, other 2, 2 %, % are, are point, point mutations, mutations ., . Of, Of the, the 17, 17 point, point mutations, mutations so, so far, far described, described ,, , three, three appear, appear to, to be, be more, more common, common ., . One, One of, of these, these is, is the, the G130V, G130V mutation, mutation in, in exon, exon 4, 4 of, of FRDA, FRDA ., . G130V, G130V ,, , when, when present, present with, with an, an expanded, expanded GAA, GAA repeat, repeat on, on the, the other, other allele, allele ,, , is, is associated, associated with, with an, an atypical, atypical FRDA, FRDA phenotype, phenotype ., . Haplotype, Haplotype analysis, analysis was, was undertaken, undertaken on, on the, the four, four families, families who, who have, have been, been described, described with, with this, this mutation, mutation ., . The, The results, results suggest, suggest a, a common, common founder, founder for, for this, this mutation, mutation ., . Although, Although marked, marked differences, differences in, in extragenic, extragenic marker, marker haplotypes, haplotypes were, were seen, seen in, in one, one family, family ,, , similar, similar intragenic, intragenic haplotyping, haplotyping suggests, suggests the, the same, same mutation, mutation founder, founder for, for this, this family, family with, with the, the differences, differences explicable, explicable by, by two, two recombination, recombination events.., events.. Cholesteryl, Cholesteryl ester, ester transfer, transfer protein, protein (, ( CETP, CETP ), ) transfers, transfers cholesteryl, cholesteryl ester, ester from, from high, high density, density lipoprotein, lipoprotein (, ( HDL, HDL ), ) to, to apo, apo B-containing, B-containing lipoproteins, lipoproteins ., . The, The hyperalphalipoproteinemia, hyperalphalipoproteinemia caused, caused by, by CETP, CETP deficiency, deficiency is, is fairly, fairly common, common in, in Japan, Japan and, and one, one of, of the, the most, most common, common mutations, mutations in, in the, the CETP, CETP gene, gene is, is the, the splicing, splicing defect, defect of, of the, the intron, intron 14, 14 ,, , the, the allelic, allelic frequency, frequency of, of which, which has, has been, been shown, shown to, to be, be 0, 0 ., . 0049, 0049 in, in the, the Japanese, Japanese general, general population, population ., . Recently, Recently ,, , we, we have, have reported, reported a, a missense, missense mutation, mutation in, in exon, exon 15, 15 of, of the, the CETP, CETP gene, gene (, ( 442D, 442D G, G ), ) ,, , showing, showing a, a dominant, dominant effect, effect on, on the, the CETP, CETP activity, activity and, and HDL-cholesterol, HDL-cholesterol level, level ., . In, In the, the current, current study, study ,, , we, we determined, determined the, the frequency, frequency of, of this, this new, new mutation, mutation in, in Japanese, Japanese hyperalphalipoproteinemic, hyperalphalipoproteinemic (, ( HDL-cholesterol, HDL-cholesterol >, > or, or =, = 100, 100 mg/dl, mg/dl ), ) subjects, subjects ., . A, A rapid, rapid and, and easy, easy screening, screening method, method for, for this, this new, new mutation, mutation was, was developed, developed using, using a, a polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) -mediated, -mediated site-directed, site-directed mutagenesis, mutagenesis ., . Among, Among 117, 117 Japanese, Japanese hyperalphalipoproteinemic, hyperalphalipoproteinemic subjects, subjects (, ( HDL-cholesterol, HDL-cholesterol ;, ; 116, 116 ., . 7, 7 +/-, +/- 16, 16 ., . 5, 5 mg/dl, mg/dl ,, , mean, mean +/-, +/- S., S. D., D. ), ) without, without the, the intron, intron 14, 14 splice, splice defect, defect ,, , three, three homozygotes, homozygotes (, ( 2, 2 ., . 5, 5 %, % ), ) and, and 34, 34 heterozygotes, heterozygotes (, ( 29, 29 ., . 1, 1 %, % ), ) were, were found, found to, to have, have the, the 442D, 442D G, G mutation, mutation ., . The, The relative, relative allelic, allelic frequency, frequency of, of this, this mutation, mutation was, was calculated, calculated to, to be, be 0, 0 ., . 17, 17 ., . One, One of, of the, the homozygotes, homozygotes for, for the, the 442D, 442D G, G mutation, mutation was, was the, the patient, patient previously, previously described, described by, by us, us as, as having, having hyperalphalipoproteinemia, hyperalphalipoproteinemia with, with corneal, corneal opacity, opacity and, and coronary, coronary heart, heart disease, disease ., . This, This was, was the, the first, first reported, reported subject, subject homozygous, homozygous for, for the, the CETP, CETP deficiency, deficiency who, who also, also demonstrated, demonstrated atherosclerotic, atherosclerotic symptoms, symptoms ., . In, In homozygous, homozygous subjects, subjects ,, , CETP, CETP activity, activity ranged, ranged from, from 37, 37 %, % to, to 62, 62 %, % of, of the, the normal, normal value, value ,, , which, which was, was consistent, consistent with, with the, the results, results obtained, obtained from, from the, the transient, transient expression, expression experiment, experiment previously, previously reported, reported ;, ; however, however ,, , the, the specific, specific activity, activity of, of CETP, CETP was, was not, not as, as low, low as, as expected, expected ., . (, ( ABSTRACT, ABSTRACT TRUNCATED, TRUNCATED AT, AT 250, 250 WORDS, WORDS ), ) Borjeson-Forssman-Lehmann, Borjeson-Forssman-Lehmann syndrome, syndrome (, ( BFLS, BFLS ), ) is, is a, a syndromal, syndromal X-linked, X-linked mental, mental retardation, retardation ,, , which, which maps, maps by, by linkage, linkage to, to the, the q26, q26 region, region of, of the, the human, human X, X chromosome, chromosome ., . We, We have, have identified, identified a, a male, male patient, patient with, with BFLS-like, BFLS-like features, features and, and a, a duplication, duplication ,, , 46, 46 ,, , Y, Y ,, , dup, dup (, ( X, X ), ) (, ( q26q28, q26q28 ), ) ,, , inherited, inherited from, from his, his phenotypically, phenotypically normal, normal mother, mother ., . Fluorescence, Fluorescence in, in situ, situ hybridisation, hybridisation using, using yeast, yeast artificial, artificial chromosome, chromosome clones, clones from, from Xq26, Xq26 localised, localised the, the duplication, duplication breakpoint, breakpoint to, to an, an approximately, approximately 400-kb, 400-kb interval, interval in, in the, the Xq26, Xq26 ., . 3, 3 region, region between, between DXS155, DXS155 and, and DXS294/DXS730, DXS294/DXS730 ., . Database, Database searches, searches and, and analysis, analysis of, of available, available genomic, genomic DNA, DNA sequence, sequence from, from the, the region, region revealed, revealed the, the presence, presence of, of the, the fibroblast, fibroblast growth, growth factor, factor homologous, homologous factor, factor gene, gene ,, , FHF2, FHF2 ,, , within, within the, the duplication, duplication breakpoint, breakpoint interval, interval ., . The, The gene, gene structure, structure of, of FHF2, FHF2 was, was determined, determined and, and two, two new, new exons, exons were, were identified, identified ,, , including, including a, a new, new 5, 5 end, end exon, exon ,, , 1B, 1B ., . FHF2, FHF2 is, is a, a large, large gene, gene extending, extending over, over approximately, approximately 200, 200 kb, kb in, in Xq26, Xq26 ., . 3, 3 and, and is, is composed, composed of, of at, at least, least seven, seven exons, exons ., . It, It shows, shows tissue-specific, tissue-specific alternative, alternative splicing, splicing and, and alternative, alternative transcription, transcription starts, starts ., . Northern, Northern blot, blot hybridisation, hybridisation showed, showed highest, highest expression, expression in, in brain, brain and, and skeletal, skeletal muscle, muscle ., . The, The FHF2, FHF2 gene, gene localisation, localisation and, and tissue-specific, tissue-specific expression, expression pattern, pattern suggest, suggest it, it to, to be, be a, a candidate, candidate gene, gene for, for familial, familial cases, cases of, of the, the BFLS, BFLS syndrome, syndrome and, and other, other syndromal, syndromal and, and non-specific, non-specific forms, forms of, of X-linked, X-linked mental, mental retardation, retardation mapping, mapping to, to the, the region.Taking, region.Taking advantage, advantage of, of the, the illegitimate, illegitimate transcription, transcription of, of the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) gene, gene ,, , we, we have, have been, been able, able to, to analyse, analyse the, the PAH, PAH cDNA, cDNA sequence, sequence of, of hyperphenylalaninemic, hyperphenylalaninemic children, children in, in circulating, circulating lymphocytes, lymphocytes ., . Using, Using this, this approach, approach ,, , we, we have, have also, also identified, identified 3, 3 novel, novel mutations, mutations in, in cDNA, cDNA from, from liver, liver and, and lymphocytes, lymphocytes of, of two, two patients, patients ., . One, One mutation, mutation ,, , detected, detected by, by the, the abnormal, abnormal pattern, pattern of, of migration, migration of, of an, an amplified, amplified fragment, fragment ,, , is, is a, a C, C to, to T, T transition, transition in, in the, the splice, splice acceptor, acceptor site, site of, of intron, intron 10, 10 ,, , which, which resulted, resulted in, in the, the skipping, skipping of, of exon, exon 11, 11 with, with the, the premature, premature termination, termination of, of RNA, RNA translation, translation downstream, downstream from, from exon, exon 12, 12 (, ( -3, -3 IVS10, IVS10 ), ) ., . The, The other, other two, two mutations, mutations are, are missense, missense mutations, mutations in, in exons, exons 10, 10 and, and 11, 11 (, ( respectively, respectively ,, , L333F, L333F and, and E390G, E390G ), ) ., . The, The present, present study, study supports, supports the, the view, view that, that circulating, circulating lymphocytes, lymphocytes give, give easy, easy access, access to, to PAH, PAH gene, gene transcripts, transcripts whose, whose nucleotide, nucleotide sequence, sequence is, is identical, identical to, to that, that reported, reported in, in liver, liver and, and therefore, therefore represent, represent a, a useful, useful tool, tool for, for molecular, molecular genetic, genetic studies, studies in, in phenylketonuria.., phenylketonuria.. The, The axonal, axonal chemoattractant, chemoattractant netrin-1, netrin-1 guides, guides spinal, spinal commissural, commissural axons, axons by, by activating, activating its, its receptor, receptor DCC, DCC (, ( Deleted, Deleted in, in Colorectal, Colorectal Cancer, Cancer ), ) ., . We, We have, have found, found that, that chemical, chemical inhibitors, inhibitors of, of metalloproteases, metalloproteases potentiate, potentiate netrin-mediated, netrin-mediated axon, axon outgrowth, outgrowth in, in vitro, vitro ., . We, We have, have also, also found, found that, that DCC, DCC is, is a, a substrate, substrate for, for metalloprotease-dependent, metalloprotease-dependent ectodomain, ectodomain shedding, shedding ,, , and, and that, that the, the inhibitors, inhibitors block, block proteolytic, proteolytic processing, processing of, of DCC, DCC and, and cause, cause an, an increase, increase in, in DCC, DCC protein, protein levels, levels on, on axons, axons within, within spinal, spinal cord, cord explants, explants ., . Thus, Thus ,, , potentiation, potentiation of, of netrin, netrin activity, activity by, by inhibitors, inhibitors may, may result, result from, from stabilization, stabilization of, of DCC, DCC on, on the, the axons, axons ,, , and, and proteolytic, proteolytic activity, activity may, may regulate, regulate axon, axon migration, migration by, by controlling, controlling the, the number, number of, of functional, functional extracellular, extracellular axon, axon guidance, guidance receptors.., receptors.. Linkage, Linkage studies, studies using, using restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms were, were conducted, conducted in, in the, the X-linked, X-linked disorder, disorder ,, , choroideremia, choroideremia ,, , designated, designated TCD, TCD for, for Progressive, Progressive Tapeto-Choroidal, Tapeto-Choroidal Dystrophy, Dystrophy ., . Previously, Previously demonstrated, demonstrated close, close linkage, linkage with, with locus, locus DXYS1, DXYS1 was, was confirmed, confirmed (, ( lod, lod 11, 11 ., . 44, 44 at, at 0, 0 recombination, recombination distance, distance ), ) ., . In, In addition, addition ,, , locus, locus DXYS12, DXYS12 was, was found, found to, to be, be closely, closely linked, linked with, with TCD, TCD (, ( lod, lod 3, 3 ., . 31, 31 at, at 0, 0 recombination, recombination distance, distance ), ) ., . The, The disease, disease mainly, mainly occurs, occurs in, in three, three large, large kindreds, kindreds in, in remote, remote Northern, Northern Finland, Finland ., . While, While formal, formal genealogical, genealogical proof, proof is, is lacking, lacking ,, , all, all presently, presently living, living (, ( more, more than, than 80, 80 affected, affected males, males and, and 120, 120 carrier, carrier females, females ), ) probably, probably originate, originate from, from a, a common, common founder, founder couple, couple born, born in, in 1644, 1644 and, and 1646, 1646 ,, , twelve, twelve generations, generations ago, ago ., . All, All 36, 36 patients, patients and, and 48, 48 carriers, carriers tested, tested from, from the, the three, three kindreds, kindreds had, had the, the same, same haplotype, haplotype (, ( TCD/DXYS1, TCD/DXYS1 ,, , 11kb/DXYS12, 11kb/DXYS12 ,, , 1, 1 ., . 6kb, 6kb ), ) ., . Given, Given that, that at, at least, least 105, 105 female, female meioses, meioses transmitting, transmitting TCD, TCD have, have occurred, occurred since, since 1650, 1650 in, in these, these kindreds, kindreds ,, , extremely, extremely close, close linkage, linkage between, between TCD, TCD ,, , DXYS1, DXYS1 and, and DXYS12, DXYS12 is, is suggested, suggested ., . The, The above, above haplotype, haplotype is, is a, a very, very useful, useful diagnostic, diagnostic tool, tool in, in these, these TCD, TCD families, families ., . We, We suggest, suggest that, that our, our historical-genealogical, historical-genealogical approach, approach to, to linkage, linkage analysis, analysis may, may be, be possible, possible elsewhere, elsewhere in, in similar, similar isolated, isolated populations, populations The, The early, early growth, growth response, response 2, 2 gene, gene (, ( EGR2, EGR2 ), ) is, is a, a Cys2His2zinc, Cys2His2zinc finger, finger transcription, transcription factor, factor which, which is, is thought, thought to, to play, play a, a role, role in, in the, the regulation, regulation of, of peripheral, peripheral nervous, nervous system, system myelination, myelination ., . This, This idea, idea is, is based, based partly, partly on, on the, the phenotype, phenotype of, of homozygous, homozygous Krox20, Krox20 (, ( Egr2, Egr2 ), ) knockout, knockout mice, mice ,, , which, which display, display hypomyelination, hypomyelination of, of the, the PNS, PNS and, and a, a block, block of, of Schwann, Schwann cells, cells at, at an, an early, early stage, stage of, of differentiation, differentiation ., . Mutations, Mutations in, in the, the human, human EGR2, EGR2 gene, gene have, have recently, recently been, been associated, associated with, with the, the inherited, inherited peripheral, peripheral neuropathies, neuropathies Charcot-Marie-Tooth, Charcot-Marie-Tooth type, type 1, 1 ,, , Dejerine-Sottas, Dejerine-Sottas syndrome, syndrome and, and congenital, congenital hypomyelinating, hypomyelinating neuropathy, neuropathy ., . Three, Three of, of the, the four, four EGR2, EGR2 mutations, mutations are, are dominant, dominant and, and occur, occur within, within the, the zinc, zinc finger, finger DNA-binding, DNA-binding domain, domain ., . The, The fourth, fourth mutation, mutation is, is recessive, recessive and, and affects, affects the, the inhibitory, inhibitory domain, domain (, ( R1, R1 ), ) that, that binds, binds the, the NAB, NAB transcriptional, transcriptional co-repressors, co-repressors ., . A, A combination, combination of, of DNA-binding, DNA-binding assays, assays and, and transcriptional, transcriptional analysis, analysis was, was used, used to, to determine, determine the, the functional, functional consequences, consequences of, of these, these mutations, mutations ., . The, The zinc, zinc finger, finger mutations, mutations affect, affect DNA, DNA binding, binding and, and the, the amount, amount of, of residual, residual binding, binding directly, directly correlates, correlates with, with disease, disease severity, severity ., . The, The R1, R1 domain, domain mutation, mutation prevents, prevents interaction, interaction of, of EGR2, EGR2 with, with the, the NAB, NAB co-repressors, co-repressors and, and thereby, thereby increases, increases transcriptional, transcriptional activity, activity ., . These, These data, data provide, provide insight, insight into, into the, the possible, possible disease, disease mechanisms, mechanisms underlying, underlying EGR2, EGR2 mutations, mutations and, and the, the reason, reason for, for varying, varying severity, severity and, and differences, differences in, in inheritance, inheritance patterns.., patterns.. von, von Willebrand, Willebrand disease, disease (, ( vWD, vWD ), ) ,, , the, the most, most common, common inherited, inherited bleeding, bleeding disorder, disorder in, in humans, humans ,, , can, can result, result from, from either, either a, a quantitative, quantitative or, or a, a qualitative, qualitative defect, defect in, in the, the adhesive, adhesive glycoprotein, glycoprotein ,, , von, von Willebrand, Willebrand factor, factor (, ( vWF, vWF ), ) ., . Molecular, Molecular studies, studies of, of vWD, vWD have, have been, been limited, limited by, by the, the large, large size, size of, of the, the vWF, vWF gene, gene and, and difficulty, difficulty in, in obtaining, obtaining the, the vWF, vWF mRNA, mRNA from, from patients, patients ., . By, By use, use of, of an, an adaptation, adaptation of, of the, the polymerase, polymerase chain, chain reaction, reaction ,, , vWF, vWF mRNA, mRNA was, was amplified, amplified and, and sequenced, sequenced from, from peripheral, peripheral blood, blood platelets, platelets ., . A, A silent, silent vWF, vWF allele, allele was, was identified, identified ,, , resulting, resulting from, from a, a cis, cis defect, defect in, in vWF, vWF mRNA, mRNA transcription, transcription or, or processing, processing ., . In, In two, two type, type IIA, IIA vWD, vWD patients, patients ,, , two, two different, different but, but adjacent, adjacent missense, missense mutations, mutations were, were identified, identified ,, , the, the locations, locations of, of which, which may, may identify, identify an, an important, important vWF, vWF functional, functional domain, domain ., . Expression, Expression in, in heterologous, heterologous cells, cells of, of recombinant, recombinant vWF, vWF containing, containing one, one of, of these, these latter, latter mutations, mutations reproduced, reproduced the, the characteristic, characteristic structural, structural abnormality, abnormality seen, seen in, in type, type IIA, IIA vWD, vWD plasma.., plasma.. Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) and, and Angelman, Angelman syndrome, syndrome (, ( AS, AS ), ) result, result from, from the, the loss, loss of, of function, function of, of imprinted, imprinted genes, genes in, in human, human chromosome, chromosome 15q11-q13, 15q11-q13 ., . The, The central, central part, part of, of mouse, mouse chromosome, chromosome 7, 7 is, is homologous, homologous to, to human, human 15q11-q13, 15q11-q13 ,, , with, with conservation, conservation of, of both, both gene, gene order, order and, and imprinted, imprinted features, features ., . We, We report, report here, here the, the characterization, characterization of, of a, a transgene, transgene insertion, insertion (, ( Epstein-Barr, Epstein-Barr virus, virus Latent, Latent Membrane, Membrane Protein, Protein 2A, 2A ,, , LMP2A, LMP2A ), ) into, into mouse, mouse chromosome, chromosome 7C, 7C ,, , which, which has, has resulted, resulted in, in mouse, mouse models, models for, for PWS, PWS and, and AS, AS dependent, dependent on, on the, the sex, sex of, of the, the transmitting, transmitting parent, parent ., . Epigenotype, Epigenotype (, ( allelic, allelic expression, expression and, and DNA, DNA methylation, methylation ), ) and, and fluorescence, fluorescence in, in situ, situ hybridization, hybridization analyses, analyses indicate, indicate that, that the, the transgene-induced, transgene-induced mutation, mutation has, has generated, generated a, a complete, complete deletion, deletion of, of the, the PWS/AS-homologous, PWS/AS-homologous region, region but, but has, has not, not deleted, deleted flanking, flanking loci, loci ., . Because, Because the, the intact, intact chromosome, chromosome 7, 7 ,, , opposite, opposite the, the deleted, deleted homolog, homolog ,, , maintains, maintains the, the correct, correct imprint, imprint in, in somatic, somatic cells, cells of, of PWS, PWS and, and AS, AS mice, mice and, and establishes, establishes the, the correct, correct imprint, imprint in, in male, male and, and female, female germ, germ cells, cells of, of AS, AS mice, mice ,, , homologous, homologous association, association and, and replication, replication asynchrony, asynchrony are, are not, not part, part of, of the, the imprinting, imprinting mechanism, mechanism ., . This, This heritable-deletion, heritable-deletion mouse, mouse model, model will, will be, be particularly, particularly useful, useful for, for the, the identification, identification of, of the, the etiological, etiological genes, genes and, and mechanisms, mechanisms ,, , phenotypic, phenotypic basis, basis ,, , and, and investigation, investigation of, of therapeutic, therapeutic approaches, approaches for, for PWS.., PWS.. Chromosomal, Chromosomal translocations, translocations in, in human, human lipomas, lipomas frequently, frequently create, create fusion, fusion transcripts, transcripts encoding, encoding high, high mobility, mobility group, group (, ( HMG, HMG ), ) I-C, I-C DNA-binding, DNA-binding domains, domains and, and C-terminal, C-terminal sequences, sequences from, from different, different presumed, presumed transcription, transcription factors, factors ,, , suggesting, suggesting a, a potential, potential role, role for, for HMG, HMG I-C, I-C in, in the, the development, development of, of lipomas, lipomas ., . To, To evaluate, evaluate the, the role, role of, of the, the HMG, HMG I-C, I-C component, component ,, , the, the three, three DNA-binding, DNA-binding domains, domains of, of HMG, HMG I-C, I-C have, have now, now been, been expressed, expressed in, in transgenic, transgenic mice, mice ., . Despite, Despite the, the ubiquitous, ubiquitous expression, expression of, of the, the truncated, truncated HMG, HMG I-C, I-C protein, protein ,, , the, the transgenic, transgenic mice, mice develop, develop a, a selective, selective abundance, abundance of, of fat, fat tissue, tissue early, early in, in life, life ,, , show, show marked, marked adipose, adipose tissue, tissue inflammation, inflammation ,, , and, and have, have an, an abnormally, abnormally high, high incidence, incidence of, of lipomas, lipomas ., . These, These findings, findings demonstrate, demonstrate that, that the, the DNA-binding, DNA-binding domains, domains of, of HMG, HMG I-C, I-C ,, , in, in the, the absence, absence of, of a, a C-terminal, C-terminal fusion, fusion partner, partner ,, , are, are sufficient, sufficient to, to perturb, perturb adipogenesis, adipogenesis and, and predispose, predispose to, to lipomas, lipomas ., . We, We provide, provide data, data supporting, supporting the, the central, central utility, utility of, of this, this animal, animal model, model as, as a, a tool, tool to, to understand, understand the, the molecular, molecular mechanisms, mechanisms underlying, underlying the, the development, development of, of one, one of, of the, the most, most common, common kind, kind of, of human, human benign, benign tumors.., tumors.. The, The frequency, frequency ,, , origin, origin ,, , and, and phenotypic, phenotypic expression, expression of, of a, a germline, germline MSH2, MSH2 gene, gene mutation, mutation previously, previously identified, identified in, in seven, seven kindreds, kindreds with, with hereditary, hereditary non-polyposis, non-polyposis cancer, cancer syndrome, syndrome (, ( HNPCC, HNPCC ), ) was, was investigated, investigated ., . The, The mutation, mutation (, ( A, A --, -- >, > T, T at, at nt943, nt943 +, + 3, 3 ), ) disrupts, disrupts the, the 3, 3 splice, splice site, site of, of exon, exon 5, 5 leading, leading to, to the, the deletion, deletion of, of this, this exon, exon from, from MSH2, MSH2 mRNA, mRNA and, and represents, represents the, the only, only frequent, frequent MSH2, MSH2 mutation, mutation so, so far, far reported, reported ., . Although, Although this, this mutation, mutation was, was initially, initially detected, detected in, in four, four of, of 33, 33 colorectal, colorectal cancer, cancer families, families analysed, analysed from, from eastern, eastern England, England ,, , more, more extensive, extensive analysis, analysis has, has reduced, reduced the, the frequency, frequency to, to four, four of, of 52, 52 (, ( 8, 8 %, % ), ) English, English HNPCC, HNPCC kindreds, kindreds analysed, analysed ., . In, In contrast, contrast ,, , the, the MSH2, MSH2 mutation, mutation was, was identified, identified in, in 10, 10 of, of 20, 20 (, ( 50, 50 %, % ), ) separately, separately identified, identified colorectal, colorectal families, families from, from Newfoundland, Newfoundland ., . To, To investigate, investigate the, the origin, origin of, of this, this mutation, mutation in, in colorectal, colorectal cancer, cancer families, families from, from England, England (, ( n, n =, = 4, 4 ), ) ,, , Newfoundland, Newfoundland (, ( n, n =, = 10, 10 ), ) ,, , and, and the, the United, United States, States (, ( n, n =, = 3, 3 ), ) ,, , haplotype, haplotype analysis, analysis using, using microsatellite, microsatellite markers, markers linked, linked to, to MSH2, MSH2 was, was performed, performed ., . Within, Within the, the English, English and, and US, US families, families there, there was, was little, little evidence, evidence for, for a, a recent, recent common, common origin, origin of, of the, the MSH2, MSH2 splice, splice site, site mutation, mutation in, in most, most families, families ., . In, In contrast, contrast ,, , a, a common, common haplotype, haplotype was, was identified, identified at, at the, the two, two flanking, flanking markers, markers (, ( CA5, CA5 and, and D2S288, D2S288 ), ) in, in eight, eight of, of the, the Newfoundland, Newfoundland families, families ., . These, These findings, findings suggested, suggested a, a founder, founder effect, effect within, within Newfoundland, Newfoundland similar, similar to, to that, that reported, reported by, by others, others for, for two"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", two MLH1, MLH1 mutations, mutations in, in Finnish, Finnish HNPCC, HNPCC families, families ., . We, We calculated, calculated age, age related, related risks, risks of, of all, all ,, , colorectal, colorectal ,, , endometrial, endometrial ,, , and, and ovarian, ovarian cancers, cancers in, in nt943, nt943 +, + 3, 3 A, A --, -- >, > T, T MSH2, MSH2 mutation, mutation carriers, carriers (, ( n, n =, = 76, 76 ), ) for, for all, all patients, patients and, and for, for men, men and, and women, women separately, separately ., . For, For both, both sexes, sexes combined, combined ,, , the, the penetrances, penetrances at, at age, age 60, 60 years, years for, for all, all cancers, cancers and, and for, for colorectal, colorectal cancer, cancer were, were 0, 0 ., . 86, 86 and, and 0, 0 ., . 57, 57 ,, , respectively, respectively ., . The, The risk, risk of, of colorectal, colorectal cancer, cancer was, was significantly, significantly higher, higher (, ( p, p <, < 0, 0 ., . 01, 01 ), ) in, in males, males than, than females, females (, ( 0, 0 ., . 63, 63 v, v 0, 0 ., . 30, 30 and, and 0, 0 ., . 84, 84 v, v 0, 0 ., . 44, 44 at, at ages, ages 50, 50 and, and 60, 60 years, years ,, , respectively, respectively ), ) ., . For, For females, females there, there was, was a, a high, high risk, risk of, of endometrial, endometrial cancer, cancer (, ( 0, 0 ., . 5, 5 at, at age, age 60, 60 years, years ), ) and, and premenopausal, premenopausal ovarian, ovarian cancer, cancer (, ( 0, 0 ., . 2, 2 at, at 50, 50 years, years ), ) ., . These, These intersex, intersex differences, differences in, in colorectal, colorectal cancer, cancer risks, risks have, have implications, implications for, for screening, screening programmes, programmes and, and for, for attempts, attempts to, to identify, identify colorectal, colorectal cancer, cancer susceptibility, susceptibility modifiers.We, modifiers.We have, have identified, identified a, a new, new mutation, mutation of, of Norrie, Norrie disease, disease (, ( ND, ND ), ) gene, gene in, in two, two Japanese, Japanese males, males from, from unrelated, unrelated families, families ;, ; they, they showed, showed typical, typical ocular, ocular features, features of, of ND, ND but, but no, no mental, mental retardation, retardation or, or hearing, hearing impairment, impairment ., . A, A mutation, mutation was, was found, found in, in both, both patients, patients at, at the, the initiation, initiation codon, codon of, of exon, exon 2, 2 of, of the, the ND, ND gene, gene (, ( ATG, ATG to, to GTG, GTG ), ) ,, , with, with otherwise, otherwise normal, normal nucleotide, nucleotide sequences, sequences ., . Their, Their mothers, mothers had, had the, the normal, normal and, and mutant, mutant types, types of, of the, the gene, gene ,, , which, which was, was expected, expected for, for heterozygotes, heterozygotes of, of the, the disease, disease ., . The, The mutation, mutation of, of the, the initiation, initiation codon, codon would, would cause, cause the, the failure, failure of, of ND, ND gene, gene expression, expression or, or a, a defect, defect in, in translation, translation thereby, thereby truncating, truncating the, the amino, amino terminus, terminus of, of ND, ND protein, protein ., . In, In view, view of, of the, the rarity, rarity and, and marked, marked heterogeneity, heterogeneity of, of mutations, mutations in, in the, the ND, ND gene, gene ,, , the, the present, present apparently, apparently unrelated, unrelated Japanese, Japanese families, families who, who have, have lived, lived in, in the, the same, same area, area for, for over, over two, two centuries, centuries presumably, presumably share, share the, the origin, origin of, of the, the mutation.., mutation.. Several, Several BRCA1, BRCA1 mutations, mutations have, have now, now been, been found, found to, to occur, occur in, in geographically, geographically diverse, diverse breast, breast and, and ovarian, ovarian cancer, cancer families, families ., . To, To investigate, investigate mutation, mutation origin, origin and, and mutation-specific, mutation-specific phenotypes, phenotypes due, due to, to BRCA1, BRCA1 ,, , we, we constructed, constructed a, a haplotype, haplotype of, of nine, nine polymorphic, polymorphic markers, markers within, within or, or immediately, immediately flanking, flanking the, the BRCA1, BRCA1 locus, locus in, in a, a set, set of, of 61, 61 breast/ovarian, breast/ovarian cancer, cancer families, families selected, selected for, for having, having one, one of, of six, six recurrent, recurrent BRCA1, BRCA1 mutations, mutations ., . Tests, Tests of, of both, both mutations, mutations and, and family-specific, family-specific differences, differences in, in age, age at, at diagnosis, diagnosis were, were not, not significant, significant ., . A, A comparison, comparison of, of the, the six, six mutations, mutations in, in the, the relative, relative proportions, proportions of, of cases, cases of, of breast, breast and, and ovarian, ovarian cancer, cancer was, was suggestive, suggestive of, of an, an effect, effect (, ( P, P =, = ., . 069, 069 ), ) ,, , with, with 57, 57 %, % of, of women, women presumed, presumed affected, affected because, because of, of the, the 1294, 1294 del, del 40, 40 BRCA1, BRCA1 mutation, mutation having, having ovarian, ovarian cancer, cancer ,, , compared, compared with, with 14, 14 %, % of, of affected, affected women, women with, with the, the splice-site, splice-site mutation, mutation in, in intron, intron 5, 5 of, of BRCA1, BRCA1 ., . For, For the, the BRCA1, BRCA1 mutations, mutations studied, studied here, here ,, , the, the individual, individual mutations, mutations are, are estimated, estimated to, to have, have arisen, arisen 9-170, 9-170 generations, generations ago, ago ., . In, In general, general ,, , a, a high, high degree, degree of, of haplotype, haplotype conservation, conservation across, across the, the region, region was, was observed, observed ,, , with, with haplotype, haplotype differences, differences most, most often, often due, due to, to mutations, mutations in, in the, the short-tandem-repeat, short-tandem-repeat markers, markers ,, , although, although some, some likely, likely instances, instances of, of recombination, recombination also, also were, were observed, observed ., . For, For several, several of, of the, the instances, instances ,, , there, there was, was evidence, evidence for, for multiple, multiple ,, , independent, independent ,, , BRCA1, BRCA1 mutational, mutational events, events ., . A, A new, new glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) variant, variant associated, associated with, with chronic, chronic nonspherocytic, nonspherocytic hemolytic, hemolytic anemia, anemia was, was reported, reported ., . The, The patient, patient ,, , a, a 6-year-old, 6-year-old Japanese, Japanese male, male ,, , was, was noticed, noticed to, to have, have hemolytic, hemolytic anemia, anemia soon, soon after, after birth, birth ,, , and, and a, a diagnosis, diagnosis of, of G6PD, G6PD deficiency, deficiency was, was made, made at, at the, the age, age of, of 2, 2 ., . He, He had, had episodes, episodes of, of hemolytic, hemolytic crisis, crisis several, several times, times after, after upper, upper respiratory, respiratory infection, infection ., . G6PD, G6PD activity, activity of, of the, the patient, patient was, was 5, 5 ., . 5, 5 %, % of, of normal, normal ., . The, The enzymatic, enzymatic characteristics, characteristics were, were examined, examined when, when he, he was, was 5, 5 years, years old, old ,, , and, and his, his G6PD, G6PD showed, showed faster-than-normal, faster-than-normal electrophoretic, electrophoretic mobility, mobility ,, , low, low Km, Km G6P, G6P ,, , high, high Km, Km NADP, NADP ,, , low, low Ki, Ki NADPH, NADPH ,, , normal, normal utilization, utilization of, of substrate, substrate analogues, analogues ,, , heat, heat instability, instability ,, , and, and a, a normal, normal pH, pH optimum, optimum curve, curve ., . From, From these, these results, results ,, , this, this was, was considered, considered to, to be, be a, a new, new variant, variant and, and was, was designated, designated G6PD, G6PD Nagano, Nagano ., . Infection-induced, Infection-induced hemolysis, hemolysis and, and chronic, chronic hemolytic, hemolytic anemia, anemia seem, seem to, to be, be due, due to, to markedly, markedly impaired, impaired enzyme, enzyme activity, activity and, and thermal, thermal instability, instability ., . We, We report, report on, on nine, nine patients, patients with, with craniofrontonasal, craniofrontonasal dysplasia, dysplasia (, ( CFND, CFND ), ) ., . Seven, Seven classical, classical cases, cases had, had facial, facial features, features suggestive, suggestive of, of frontonasal, frontonasal dysplasia, dysplasia and, and coronal, coronal craniosynostosis, craniosynostosis ., . Extracranial, Extracranial abnormalities, abnormalities such, such as, as brittle, brittle nails, nails with, with prominent, prominent longitudinal, longitudinal grooves, grooves or, or syndactyly, syndactyly of, of fingers, fingers and, and toes, toes were, were observed, observed in, in individual, individual patients, patients ., . In, In two, two families, families the, the father, father of, of classical, classical cases, cases showed, showed a, a milder, milder pattern, pattern of, of abnormalities, abnormalities ,, , consistent, consistent with, with the, the diagnosis, diagnosis ., . We, We present, present a, a 2-, 2- to, to 13-year, 13-year follow-up, follow-up on, on our, our patients, patients ., . Hypotonia, Hypotonia and, and laxity, laxity of, of joints, joints are, are common, common and, and may, may necessitate, necessitate supportive, supportive measures, measures ., . Mild, Mild developmental, developmental delay, delay was, was noted, noted in, in three, three out, out of, of six, six classical, classical cases, cases studied, studied in, in detail, detail ., . Unlike, Unlike almost, almost all, all other, other X-linked, X-linked disorders, disorders ,, , clinical, clinical expression, expression in, in CFND, CFND is, is generally, generally much, much more, more severe, severe in, in females, females than, than in, in males, males ., . In, In contrast, contrast to, to previous, previous reports, reports of, of this, this condition, condition ,, , one, one of, of our, our severely, severely affected, affected cases, cases is, is a, a male.., male.. A, A C-to-T, C-to-T transition, transition in, in exon, exon 4, 4 of, of the, the PLP, PLP gene, gene was, was found, found in, in 2, 2 affected, affected males, males and, and two, two obligate, obligate carriers, carriers in, in a, a German, German family, family with, with Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease ., . The, The mutation, mutation ,, , which, which causes, causes loss, loss of, of an, an HphI, HphI site, site and, and changes, changes amino, amino acid, acid 155, 155 from, from threonine, threonine to, to isoleucine, isoleucine ,, , was, was absent, absent from, from 108, 108 normal, normal chromosomes, chromosomes ., . There, There are, are 5, 5 concordances, concordances and, and 1, 1 discrepancy, discrepancy between, between these, these results, results and, and those, those obtained, obtained by, by magnetic, magnetic resonance, resonance imaging, imaging in, in this, this family.., family.. The, The Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) is, is an, an X-linked, X-linked recessive, recessive disorder, disorder characterized, characterized by, by thrombocytopenia, thrombocytopenia ,, , small, small platelets, platelets ,, , eczema, eczema ,, , recurrent, recurrent infections, infections ,, , and, and immunodeficiency, immunodeficiency ., . Besides, Besides the, the classic, classic WAS, WAS phenotype, phenotype ,, , there, there is, is a, a group, group of, of patients, patients with, with congenital, congenital X-linked, X-linked thrombocytopenia, thrombocytopenia (, ( XLT, XLT ), ) who, who have, have small, small platelets, platelets but, but only, only transient, transient eczema, eczema ,, , if, if any, any ,, , and, and minimal, minimal immune, immune deficiency, deficiency ., . Because, Because the, the gene, gene responsible, responsible for, for WAS, WAS has, has been, been sequenced, sequenced ,, , it, it was, was possible, possible to, to correlate, correlate the, the WAS, WAS phenotypes, phenotypes with, with WAS, WAS gene, gene mutations, mutations ., . Using, Using a, a fingerprinting, fingerprinting screening, screening technique, technique ,, , we, we determined, determined the, the approximate, approximate location, location of, of the, the mutation, mutation in, in 13, 13 unrelated, unrelated WAS, WAS patients, patients with, with mild, mild to, to severe, severe clinical, clinical symptoms, symptoms ., . Direct, Direct sequence, sequence analysis, analysis of, of cDNA, cDNA and, and genomic, genomic DNA, DNA obtained, obtained from, from patient-derived, patient-derived cell, cell lines, lines showed, showed 12, 12 unique, unique mutations, mutations distributed, distributed throughout, throughout the, the WAS, WAS gene, gene ,, , including, including insertions, insertions ,, , deletions, deletions ,, , and, and point, point mutations, mutations resulting, resulting in, in amino, amino acid, acid substitutions, substitutions ,, , termination, termination ,, , exon, exon skipping, skipping ,, , or, or splicing, splicing defects, defects ., . Of, Of 4, 4 unrelated, unrelated patients, patients with, with the, the XLT, XLT phenotype, phenotype ,, , 3, 3 had, had missense, missense mutations, mutations affecting, affecting exon, exon 2, 2 and, and 1, 1 had, had a, a splice-site, splice-site mutation, mutation affecting, affecting exon, exon 9, 9 ., . Patients, Patients with, with classic, classic WAS, WAS had, had more, more complex, complex mutations, mutations ,, , resulting, resulting in, in termination, termination codons, codons ,, , frameshift, frameshift ,, , and, and early, early termination, termination ., . These, These findings, findings provide, provide direct, direct evidence, evidence that, that XLT, XLT and, and WAS, WAS are, are caused, caused by, by mutations, mutations of, of the, the same, same gene, gene and, and suggest, suggest that, that severe, severe clinical, clinical phenotypes, phenotypes are, are associated, associated with, with complex, complex mutations.., mutations.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) is, is an, an autosomal, autosomal recessive, recessive disease, disease due, due to, to deficiency, deficiency of, of a, a hepatic, hepatic enzyme, enzyme ,, , phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . The, The absence, absence of, of PAH, PAH activity, activity results, results in, in typical, typical PKU, PKU while, while persistence, persistence of, of a, a residual, residual enzyme, enzyme activity, activity gives, gives rise, rise to, to variant, variant forms, forms of, of the, the disease, disease ., . We, We report, report here, here a, a 3-base, 3-base pair, pair in-frame, in-frame deletion, deletion of, of the, the PAH, PAH gene, gene (, ( delta, delta 194, 194 ), ) in, in a, a mild, mild variant, variant ,, , with, with markedly, markedly reduced, reduced affinity, affinity of, of the, the enzyme, enzyme for, for phenylalanine, phenylalanine (, ( Km, Km =, = 160, 160 nM, nM ), ) ,, , and, and we, we provide, provide functional, functional evidence, evidence for, for responsibility, responsibility of, of the, the deletion, deletion in, in the, the mutant, mutant phenotype, phenotype ., . Since, Since the, the deletion, deletion was, was located, located in, in the, the third, third exon, exon of, of the, the gene, gene ,, , which, which presents, presents no, no homology, homology with, with other, other hydroxylases, hydroxylases ,, , we, we suggest, suggest that, that exon, exon 3, 3 is, is involved, involved in, in the, the specificity, specificity of, of the, the enzyme, enzyme for, for phenylalanine, phenylalanine ., . Finally, Finally ,, , since, since none, none of, of the, the 98, 98 PKU, PKU patients, patients tested, tested were, were found, found to, to carry, carry this, this particular, particular deletion, deletion ,, , our, our study, study suggests, suggests that, that this, this molecular, molecular event, event probably, probably occurred, occurred recently, recently on, on the, the background, background of, of a, a haplotype, haplotype 2, 2 gene, gene in, in Portugal.., Portugal.. Friedreich, Friedreich ataxia, ataxia ,, , an, an autosomal, autosomal recessive, recessive neurodegenerative, neurodegenerative disease, disease ,, , is, is the, the most, most common, common of, of the, the inherited, inherited ataxias, ataxias ., . The, The recent, recent discovery, discovery of, of the, the gene, gene that, that is, is mutated, mutated in, in this, this condition, condition ,, , FRDA, FRDA ,, , has, has led, led to, to rapid, rapid advances, advances in, in the, the understanding, understanding of, of the, the pathogenesis, pathogenesis of, of Friedreich, Friedreich ataxia, ataxia ., . About, About 98, 98 %, % of, of mutant, mutant alleles, alleles have, have an, an expansion, expansion of, of a, a GAA, GAA trinucleotide, trinucleotide repeat, repeat in, in intron, intron 1, 1 of, of the, the gene, gene ., . This, This leads, leads to, to reduced, reduced levels, levels of, of the, the protein, protein ,, , frataxin, frataxin ., . There, There is, is mounting, mounting evidence, evidence to, to suggest, suggest that, that Friedreich, Friedreich ataxia, ataxia is, is the, the result, result of, of accumulation, accumulation of, of iron, iron in, in mitochondria, mitochondria leading, leading to, to excess, excess production, production of, of free, free radicals, radicals ,, , which, which then, then results, results in, in cellular, cellular damage, damage and, and death, death ., . Currently, Currently there, there is, is no, no known, known treatment, treatment that, that alters, alters the, the natural, natural course, course of, of the, the disease, disease ., . The, The discovery, discovery of, of the, the FRDA, FRDA gene, gene and, and its, its possible, possible function, function has, has raised, raised hope, hope that, that rational, rational therapeutic, therapeutic strategies, strategies will, will be, be developed.., developed.. Primary, Primary dystonias, dystonias are, are movement, movement disorders, disorders with, with dystonia, dystonia as, as a, a major, major symptom, symptom ., . They, They are, are frequently, frequently inherited, inherited as, as Mendelian, Mendelian traits, traits ., . There, There are, are at, at least, least eight, eight clinically, clinically distinct, distinct autosomal, autosomal dominant, dominant and, and two, two X-linked, X-linked recessive, recessive forms, forms ., . In, In addition, addition ,, , pedigree, pedigree analyses, analyses suggest, suggest the, the occurrence, occurrence of, of an, an autosomal, autosomal recessive, recessive variant, variant ., . The, The clinical, clinical classification, classification is, is increasingly, increasingly being, being replaced, replaced by, by a, a genetic, genetic one, one ., . To, To date, date gene, gene loci, loci have, have been, been identified, identified in, in at, at least, least six, six autosomal, autosomal dominant, dominant forms, forms ,, , i., i. e., e. ,, , in, in idiopathic, idiopathic torsion, torsion dystonia, dystonia (, ( 9q34, 9q34 ), ) ,, , focal, focal dystonia, dystonia (, ( 18p, 18p ), ) ,, , adult-onset, adult-onset idiopathic, idiopathic torsion, torsion dystonia, dystonia of, of mixed, mixed type, type (, ( 8p21-q22, 8p21-q22 ), ) ,, , dopa-responsive, dopa-responsive dystonia, dystonia (, ( 14q22, 14q22 ., . 1-q22, 1-q22 ., . 2, 2 ), ) ,, , and, and paroxysmal, paroxysmal dystonic, dystonic choreoathetosis, choreoathetosis (, ( 2q25-q33, 2q25-q33 ;, ; 1p21-p13, 1p21-p13 ., . 3, 3 ), ) ., . Gene, Gene loci, loci in, in the, the X-linked, X-linked recessive, recessive forms, forms have, have been, been assigned, assigned to, to Xq13, Xq13 ., . 1, 1 in, in the, the X-linked, X-linked dystonia, dystonia parkinsonism, parkinsonism syndrome, syndrome and, and to, to Xq22, Xq22 in, in X-linked, X-linked sensorineural, sensorineural deafness, deafness ,, , dystonia, dystonia ,, , and, and mental, mental retardation, retardation ., . The, The disease, disease genes, genes have, have been, been identified, identified in, in two, two autosomal, autosomal dominant, dominant forms, forms and, and in, in one, one X-linked, X-linked recessive, recessive form, form ., . Mutations, Mutations in, in a, a gene, gene coding, coding for, for an, an ATP-binding, ATP-binding protein, protein were, were detected, detected in, in idiopathic, idiopathic torsion, torsion dystonia, dystonia (, ( DYT1, DYT1 ), ) ,, , and, and the, the GTP, GTP cyclohydrolase, cyclohydrolase 1, 1 gene, gene is, is mutated, mutated in, in dopa-responsive, dopa-responsive dystonia, dystonia (, ( DYT5, DYT5 ), ) ., . In, In sensorineural, sensorineural deafness, deafness ,, , dystonia, dystonia ,, , and, and mental, mental retardation, retardation ,, , mutations, mutations were, were found, found in, in the, the gene, gene DDP, DDP coding, coding for, for a, a polypeptide, polypeptide of, of unknown, unknown function, function ., . This, This article, article reviews, reviews the, the clinical, clinical and, and molecular, molecular genetics, genetics of, of primary, primary dystonias, dystonias ,, , critically, critically discusses, discusses present, present findings, findings ,, , and, and proposes, proposes referring, referring to, to the, the known, known forms, forms ,, , most, most of, of which, which can, can be, be distinguished, distinguished by, by genetic, genetic criteria, criteria ,, , as, as dystonias, dystonias 1-12.Friedreich, 1-12.Friedreich ataxia, ataxia is, is an, an autosomal, autosomal recessive, recessive disorder, disorder caused, caused by, by mutations, mutations in, in the, the FRDA, FRDA gene, gene that, that encodes, encodes a, a 210-amino, 210-amino acid, acid protein, protein called, called frataxin, frataxin ., . An, An expansion, expansion of, of a, a GAA, GAA trinucleotide, trinucleotide repeat, repeat in, in intron, intron 1, 1 of, of the, the gene, gene is, is present, present in, in more, more than, than 95, 95 %, % of, of mutant, mutant alleles, alleles ., . Of, Of the, the 83, 83 people, people we, we studied, studied who, who have, have mutations, mutations in, in FRDA, FRDA ,, , 78, 78 are, are homozygous, homozygous for, for an, an expanded, expanded GAA, GAA repeat, repeat ;, ; the, the other, other five, five patients, patients have, have an, an expansion, expansion in, in one, one allele, allele and, and a, a point, point mutation, mutation in, in the, the other, other ., . Here, Here we, we present, present a, a detailed, detailed clinical, clinical and, and genetic, genetic study, study of, of a, a subset, subset of, of 51, 51 patients, patients homozygous, homozygous for, for an, an expansion, expansion of, of the, the GAA, GAA repeat, repeat ., . We, We found, found a, a correlation, correlation between, between the, the size, size of, of the, the smaller, smaller of, of the, the two, two expanded, expanded alleles, alleles and, and age, age at, at onset, onset ,, , age, age into, into wheelchair, wheelchair ,, , scoliosis, scoliosis ,, , impaired, impaired vibration, vibration sense, sense ,, , and, and the, the presence, presence of, of foot, foot deformity, deformity ., . There"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", There was, was no, no significant, significant correlation, correlation between, between the, the size, size of, of the, the smaller, smaller allele, allele and, and cardiomyopathy, cardiomyopathy ,, , diabetes, diabetes mellitus, mellitus ,, , loss, loss of, of proprioception, proprioception ,, , or, or bladder, bladder symptoms, symptoms ., . The, The larger, larger allele, allele size, size correlated, correlated with, with bladder, bladder symptoms, symptoms and, and the, the presence, presence of, of foot, foot deformity, deformity ., . The, The duration, duration of, of disease, disease is, is correlated, correlated with, with wheelchair, wheelchair use, use and, and the, the presence, presence of, of diabetes, diabetes ,, , scoliosis, scoliosis ,, , bladder, bladder symptoms, symptoms and, and impaired, impaired proprioception, proprioception ,, , and, and vibration, vibration sense, sense but, but no, no other, other complications, complications studied.., studied.. A, A 51/2-year-old, 51/2-year-old black, black girl, girl with, with recurrent, recurrent meningococcal, meningococcal meningitis, meningitis and, and absence, absence of, of the, the sixth, sixth component, component of, of complement, complement (, ( C6, C6 ), ) is, is reported, reported ., . To, To explore, explore the, the pathogenesis, pathogenesis of, of recurrent, recurrent neisserial, neisserial infections, infections in, in C6, C6 deficiency, deficiency ,, , a, a detailed, detailed analysis, analysis of, of her, her immune, immune competence, competence was, was conducted, conducted ., . Her, Her serum, serum had, had normal, normal chemotactic, chemotactic ,, , opsonic, opsonic ,, , alternative, alternative complement, complement pathway, pathway ,, , and, and specific, specific antibody, antibody activity, activity ,, , but, but lacked, lacked complement-mediated, complement-mediated bacteriolytic, bacteriolytic activity, activity ., . In, In addition, addition ,, , her, her C6-deficient, C6-deficient serum, serum was, was indistinguishable, indistinguishable from, from normal, normal serum, serum in, in a, a complement-dependent, complement-dependent assay, assay of, of phagocyte, phagocyte bactericidal, bactericidal activity, activity ., . Absent, Absent bacteriolysis, bacteriolysis remains, remains the, the only, only consistent, consistent defect, defect associated, associated with, with recurrent, recurrent neisserial, neisserial infections, infections and, and absence, absence of, of one, one of, of the, the late-acting, late-acting complement, complement components.., components.. OBJECTIVES, OBJECTIVES A, A Japanese, Japanese family, family with, with cerebrotendinous, cerebrotendinous xanthomatosis, xanthomatosis (, ( CTX, CTX ), ) was, was investigated, investigated for, for a, a sequence, sequence alteration, alteration in, in the, the sterol, sterol 27-hydroxylase, 27-hydroxylase gene, gene (, ( CYP27, CYP27 ), ) ., . The, The expression, expression of, of CYP27, CYP27 has, has been, been mostly, mostly explored, explored using, using cultured, cultured fibroblasts, fibroblasts ,, , prompting, prompting the, the examination, examination of, of the, the transcripts, transcripts from, from blood, blood leucocytes, leucocytes as, as a, a simple, simple and, and rapid, rapid technique, technique ., . METHODS, METHODS An, An alteration, alteration in, in CYP27, CYP27 of, of the, the proband, proband was, was searched, searched for, for by, by polymerase, polymerase chain, chain reaction-single, reaction-single strand, strand conformation, conformation polymorphism, polymorphism (, ( PCR-SSCP, PCR-SSCP ), ) analysis, analysis and, and subsequent, subsequent sequencing, sequencing ., . Samples, Samples of, of RNA, RNA were, were subjected, subjected to, to reverse, reverse transcription, transcription PCR, PCR (, ( RT-PCR, RT-PCR ), ) and, and the, the product, product of, of the, the proband, proband was, was amplified, amplified with, with nested, nested primers, primers and, and sequenced, sequenced ., . RESULTS, RESULTS A, A homozygous, homozygous G, G to, to A, A transition, transition at, at the, the 5, 5 end, end of, of intron, intron 7, 7 was, was detected, detected in, in the, the patient, patient ., . In, In RT-PCR, RT-PCR analysis, analysis ,, , only, only a, a truncated, truncated transcript, transcript was, was detected, detected in, in the, the patient, patient ,, , whereas, whereas both, both normal, normal and, and truncated, truncated transcripts, transcripts were, were detected, detected in, in the, the siblings, siblings ., . The, The sequencing, sequencing of, of the, the patients, patients cDNA, cDNA fragment, fragment disclosed, disclosed a, a direct, direct conjuction, conjuction of, of exon, exon 6, 6 and, and exon, exon 8, 8 ., . CONCLUSION, CONCLUSION The, The mutation, mutation at, at splice, splice donor, donor site, site and, and the, the truncation, truncation of, of mRNA, mRNA were, were identical, identical with, with those, those of, of a, a recently, recently reported, reported Italian, Italian patient, patient ,, , although, although different, different in, in symptomatology, symptomatology ., . The, The application, application of, of blood, blood leucocytes, leucocytes can, can be, be a, a simple, simple technique, technique on, on analysing, analysing a, a constructive, constructive abnormality, abnormality of, of CYP27, CYP27 mRNA.., mRNA.. Prostatic, Prostatic tissue, tissue specimens, specimens derived, derived from, from transurethral, transurethral resections, resections of, of patients, patients with, with metastatic, metastatic prostate, prostate cancer, cancer were, were analyzed, analyzed for, for genetic, genetic alterations, alterations in, in the, the hormone-binding, hormone-binding domain, domain of, of the, the androgen, androgen receptor, receptor (, ( AR, AR ), ) gene, gene ., . Direct, Direct sequencing, sequencing of, of the, the polymerase, polymerase chain, chain reaction-derived, reaction-derived DNAs, DNAs of, of 6, 6 of, of 24, 24 specimens, specimens revealed, revealed a, a codon, codon 877, 877 mutation, mutation (, ( ACT, ACT --, -- >, > GCT, GCT ,, , Thr, Thr --, -- >, > Ala, Ala ), ) in, in the, the hormone-binding, hormone-binding domain, domain of, of the, the AR, AR gene, gene ., . This, This same, same AR, AR mutation, mutation has, has been, been reported, reported previously, previously in, in a, a metastatic, metastatic prostate, prostate cancer, cancer cell, cell line, line ,, , LNCaP, LNCaP ,, , where, where this, this mutation, mutation confers, confers upon, upon the, the AR, AR an, an altered, altered ligand-binding, ligand-binding specificity, specificity which, which is, is stimulated, stimulated by, by estrogens, estrogens ,, , progestagens, progestagens ,, , and, and antiandrogens, antiandrogens ., . It, It is, is possible, possible that, that analogous, analogous to, to an, an activated/altered, activated/altered growth, growth factor, factor receptor, receptor oncogene, oncogene ,, , codon, codon 877, 877 mutant, mutant AR, AR with, with altered, altered ligand, ligand binding, binding may, may provide, provide a, a selective, selective growth, growth advantage, advantage in, in the, the genesis, genesis of, of a, a subset, subset of, of advanced, advanced prostate, prostate cancer, cancer ., . Although, Although estrogens, estrogens are, are used, used infrequently, infrequently ,, , antiandrogens, antiandrogens are, are used, used increasingly, increasingly in, in hormonal, hormonal therapy, therapy for, for patients, patients with, with advanced, advanced prostate, prostate cancer, cancer ., . The, The stimulatory, stimulatory effect, effect of, of these, these therapeutic, therapeutic agents, agents on, on the, the codon, codon 877, 877 mutant, mutant AR, AR further, further suggests, suggests that, that this, this frequently, frequently observed, observed AR, AR mutation, mutation may, may contribute, contribute to, to the, the treatment, treatment refractory, refractory disease.., disease.. Mutations, Mutations in, in the, the gene, gene ATM, ATM are, are responsible, responsible for, for the, the genetic, genetic disorder, disorder ataxia-telangiectasia, ataxia-telangiectasia (, ( A-T, A-T ), ) ,, , which, which is, is characterized, characterized by, by cerebellar, cerebellar dysfunction, dysfunction ,, , radiosensitivity, radiosensitivity ,, , chromosomal, chromosomal instability, instability and, and cancer, cancer predisposition, predisposition ., . Both, Both the, the A-T, A-T phenotype, phenotype and, and the, the similarity, similarity of, of the, the ATM, ATM protein, protein to, to other, other DNA-damage, DNA-damage sensors, sensors suggests, suggests a, a role, role for, for ATM, ATM in, in biochemical, biochemical pathways, pathways involved, involved in, in the, the recognition, recognition ,, , signalling, signalling and, and repair, repair of, of DNA, DNA double-strand, double-strand breaks, breaks (, ( DSBs, DSBs ), ) ., . There, There are, are strong, strong parallels, parallels between, between the, the pattern, pattern of, of radiosensitivity, radiosensitivity ,, , chromosomal, chromosomal instability, instability and, and cancer, cancer predisposition, predisposition in, in A-T, A-T patients, patients and, and that, that in, in patients, patients with, with Nijmegen, Nijmegen breakage, breakage syndrome, syndrome (, ( NBS, NBS ), ) ., . The, The protein, protein defective, defective in, in NBS, NBS ,, , nibrin, nibrin (, ( encoded, encoded by, by NBS1, NBS1 ), ) ,, , forms, forms a, a complex, complex with, with MRE11, MRE11 and, and RAD50, RAD50 (, ( refs, refs 1, 1 ,, , 2, 2 ), ) ., . This, This complex, complex localizes, localizes to, to DSBs, DSBs within, within 30, 30 minutes, minutes after, after cellular, cellular exposure, exposure to, to ionizing, ionizing radiation, radiation (, ( IR, IR ), ) and, and is, is observed, observed in, in brightly, brightly staining, staining nuclear, nuclear foci, foci after, after a, a longer, longer period, period of, of time, time ., . The, The overlap, overlap between, between clinical, clinical and, and cellular, cellular phenotypes, phenotypes in, in A-T, A-T and, and NBS, NBS suggests, suggests that, that ATM, ATM and, and nibrin, nibrin may, may function, function in, in the, the same, same biochemical, biochemical pathway, pathway ., . Here, Here we, we demonstrate, demonstrate that, that nibrin, nibrin is, is phosphorylated, phosphorylated within, within one, one hour, hour of, of treatment, treatment of, of cells, cells with, with IR, IR ., . This, This response, response is, is abrogated, abrogated in, in A-T, A-T cells, cells that, that either, either do, do not, not express, express ATM, ATM protein, protein or, or express, express near, near full-length, full-length mutant, mutant protein, protein ., . We, We also, also show, show that, that ATM, ATM physically, physically interacts, interacts with, with and, and phosphorylates, phosphorylates nibrin, nibrin on, on serine, serine 343, 343 both, both in, in vivo, vivo and, and in, in vitro, vitro ., . Phosphorylation, Phosphorylation of, of this, this site, site appears, appears to, to be, be functionally, functionally important, important because, because mutated, mutated nibrin, nibrin (, ( S343A, S343A ), ) does, does not, not completely, completely complement, complement radiosensitivity, radiosensitivity in, in NBS, NBS cells, cells ., . ATM, ATM phosphorylation, phosphorylation of, of nibrin, nibrin does, does not, not affect, affect nibrin-MRE11-RAD50, nibrin-MRE11-RAD50 association, association as, as revealed, revealed by, by radiation-induced, radiation-induced foci, foci formation, formation ., . Our, Our data, data provide, provide a, a biochemical, biochemical explanation, explanation for, for the, the similarity, similarity in, in phenotype, phenotype between, between A-T, A-T and, and NBS.., NBS.. Myotonic, Myotonic dystrophy, dystrophy (, ( DM, DM ), ) is, is the, the most, most common, common form, form of, of adult, adult muscular, muscular dystrophy, dystrophy ,, , with, with a, a prevalence, prevalence of, of 2-14, 2-14 per, per 100, 100 ,, , 000, 000 individuals, individuals ., . The, The disease, disease is, is characterized, characterized by, by progressive, progressive muscle, muscle weakness, weakness and, and sustained, sustained muscle, muscle contraction, contraction ,, , often, often with, with a, a wide, wide range, range of, of accompanying, accompanying symptoms, symptoms ., . The, The age, age at, at onset, onset and, and severity, severity of, of the, the disease, disease show, show extreme, extreme variation, variation ,, , both, both within, within and, and between, between families, families ., . Despite, Despite its, its clinical, clinical variability, variability ,, , this, this dominant, dominant condition, condition segregates, segregates as, as a, a single, single locus, locus at, at chromosome, chromosome 19q13, 19q13 ., . 3, 3 in, in every, every population, population studied, studied ., . It, It is, is flanked, flanked by, by the, the tightly, tightly linked, linked genetic, genetic markers, markers ERCC1, ERCC1 proximally, proximally and, and D19S51, D19S51 distally, distally ;, ; these, these define, define the, the DM, DM critical, critical region, region ., . We, We report, report the, the isolation, isolation of, of an, an expressed, expressed sequence, sequence from, from this, this region, region which, which detects, detects a, a DNA, DNA fragment, fragment that, that is, is larger, larger in, in affected, affected individuals, individuals than, than in, in normal, normal siblings, siblings or, or unaffected, unaffected controls, controls ., . The, The size, size of, of this, this fragment, fragment varies, varies between, between affected, affected siblings, siblings ,, , and, and increases, increases in, in size, size through, through generations, generations in, in parallel, parallel with, with increasing, increasing severity, severity of, of the, the disease, disease ., . We, We postulate, postulate that, that this, this unstable, unstable DNA, DNA sequence, sequence is, is the, the molecular, molecular feature, feature that, that underlies, underlies DM, DM ., . Mutations, Mutations in, in the, the brain, brain specific, specific P/Q, P/Q type, type Ca2, Ca2 +, + channel, channel alpha1, alpha1 subunit, subunit gene, gene ,, , CACNA1A, CACNA1A ,, , have, have been, been identified, identified in, in three, three clinically, clinically distinct, distinct disorders, disorders ,, , viz, viz ., . episodic, episodic ataxia, ataxia type, type 2, 2 (, ( EA-2, EA-2 ), ) ,, , familial, familial hemiplegic, hemiplegic migraine, migraine (, ( FHM, FHM ), ) and, and spinocerebellar, spinocerebellar ataxia, ataxia 6, 6 (, ( SCA6, SCA6 ), ) ., . For, For individuals, individuals with, with EA-2, EA-2 ,, , the, the mutations, mutations described, described thus, thus far, far are, are presumed, presumed to, to result, result in, in a, a truncated, truncated protein, protein product, product ., . Several, Several different, different missense, missense mutations, mutations have, have been, been identified, identified in, in patients, patients with, with FHM, FHM ., . At, At least, least two, two of, of these, these mutations, mutations have, have been, been identified, identified on, on two, two different, different chromosome, chromosome 19p13, 19p13 haplotypes, haplotypes and, and thus, thus represent, represent recurrent, recurrent mutations, mutations ., . In, In the, the present, present study, study ,, , we, we have, have screened, screened several, several individuals, individuals for, for mutations, mutations in, in all, all 47, 47 exons, exons in, in the, the CACNA1A, CACNA1A gene, gene by, by single-strand, single-strand conformation, conformation analysis, analysis ., . We, We have, have characterised, characterised a, a novel, novel missense, missense mutation, mutation ,, , G5260A, G5260A ,, , in, in exon, exon 32, 32 in, in a, a family, family segregating, segregating for, for EA-2, EA-2 ., . The, The consequence, consequence of, of this, this mutation, mutation is, is an, an amino, amino acid, acid substitution, substitution at, at a, a highly, highly conserved, conserved position, position within, within the, the CACNA1A, CACNA1A gene, gene ., . This, This represents, represents the, the first, first point, point mutation, mutation not, not resulting, resulting in, in a, a proposed, proposed truncated, truncated protein, protein ., . Furthermore, Furthermore ,, , this, this mutation, mutation has, has been, been detected, detected in, in a, a family, family member, member with, with mild, mild clinical, clinical signs, signs including, including only, only migraine, migraine ., . Additionally, Additionally ,, , a, a second, second previously, previously identified, identified recurrent, recurrent muta, muta tion, tion ,, , C2272T, C2272T ,, , in, in exon, exon 16, 16 has, has been, been discovered, discovered in, in a, a patient, patient with, with FHM.., FHM.. Inactivation, Inactivation of, of the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene product, product initiates, initiates colorectal, colorectal tumorigenesis, tumorigenesis ., . Patients, Patients with, with familial, familial APC, APC (, ( FAP, FAP ), ) carry, carry germ-line, germ-line mutations, mutations in, in the, the APC, APC gene, gene and, and develop, develop multiple, multiple colorectal, colorectal adenomas, adenomas and, and subsequent, subsequent carcinomas, carcinomas early, early in, in life, life ., . The, The severity, severity of, of the, the disease, disease correlates, correlates with, with the, the position, position of, of the, the inherited, inherited APC, APC mutation, mutation (, ( genotype-phenotype, genotype-phenotype correlation, correlation ), ) ., . Together, Together with, with the, the fact, fact that, that both, both germ-line, germ-line and, and sporadic, sporadic APC, APC mutations, mutations cluster, cluster in, in the, the central, central region, region of, of the, the APC, APC gene, gene ,, , this, this points, points to, to a, a dominant, dominant negative, negative effect, effect of, of certain, certain APC, APC mutants, mutants ., . Loss, Loss of, of APC, APC function, function was, was recently, recently shown, shown to, to result, result in, in enhanced, enhanced beta-catenin-/Tcf-mediated, beta-catenin-/Tcf-mediated transcription, transcription in, in colon, colon epithelial, epithelial cells, cells ., . Here, Here ,, , we, we provide, provide experimental, experimental evidence, evidence for, for a, a dominant, dominant negative, negative effect, effect of, of APC, APC gene, gene products, products associated, associated with, with severe, severe polyposis, polyposis ., . Wild-type, Wild-type APC, APC activity, activity in, in beta-catenin-/Tcf-mediated, beta-catenin-/Tcf-mediated transcription, transcription was, was strongly, strongly inhibited, inhibited by, by a, a mutant, mutant APC, APC that, that is, is truncated, truncated at, at codon, codon 1309, 1309 ., . In, In contrast, contrast ,, , mutant, mutant APC, APC gene, gene products, products that, that are, are associated, associated with, with attenuated, attenuated polyposis, polyposis (, ( codon, codon 386, 386 or, or 1465, 1465 ), ) interfered, interfered only, only weakly, weakly with, with wild-type, wild-type APC, APC activity, activity ., . These, These results, results suggest, suggest a, a molecular, molecular explanation, explanation for, for the, the genotype-phenotype, genotype-phenotype correlation, correlation in, in FAP, FAP patients, patients and, and support, support the, the idea, idea that, that colorectal, colorectal tumor, tumor growth, growth might, might be, be ,, , in, in part, part ,, , driven, driven by, by selection, selection for, for a, a mutation, mutation in, in the, the mutation, mutation cluster, cluster region.., region.. Piebaldism, Piebaldism is, is an, an autosomal, autosomal dominant, dominant genetic, genetic disorder, disorder characterized, characterized by, by cogenital, cogenital patches, patches of, of skin, skin and, and hair, hair from, from which, which melanocytes, melanocytes are, are completely, completely absent, absent ., . A, A similar, similar disorder, disorder of, of mouse, mouse ,, , dominant, dominant white, white spotting, spotting (, ( W, W ), ) ,, , results, results from, from mutations, mutations of, of the, the c-Kit, c-Kit protooncogene, protooncogene ,, , which, which encodes, encodes and, and receptor, receptor for, for mast/stem, mast/stem cell, cell growth, growth factor, factor ., . We, We identified, identified a, a KIT, KIT gene, gene mutation, mutation in, in a, a proband, proband with, with classic, classic autosomal, autosomal dominant, dominant piebaldism, piebaldism ., . This, This mutation, mutation results, results in, in a, a Gly, Gly --, -- --, -- Arg, Arg substitution, substitution at, at codon, codon 664, 664 ,, , within, within the, the tyrosine, tyrosine kinase, kinase domain, domain ., . This, This substitution, substitution was, was not, not seen, seen in, in any, any normal, normal individuals, individuals and, and was, was completely, completely linked, linked to, to the, the piebald, piebald phenotype, phenotype in, in the, the probands, probands family, family ., . Piebaldism, Piebaldism in, in this, this family, family thus, thus appears, appears to, to be, be the, the human, human homologue, homologue to, to dominant, dominant white, white spotting, spotting (, ( W, W ), ) of, of the, the mouse.., mouse.. Metachromatic, Metachromatic leukodystrophy, leukodystrophy (, ( MLD, MLD ), ) is, is an, an autosomal, autosomal recessive, recessive lysosomal, lysosomal storage, storage disorder, disorder caused, caused by, by a, a deficiency, deficiency of, of arylsulfatase, arylsulfatase A, A (, ( ARSA, ARSA ;, ; EC, EC 3, 3 ., . 1, 1 ., . 6, 6 ., . 8, 8 ), ) ., . The, The 8, 8 ARSA, ARSA exons, exons and, and adjacent, adjacent intron, intron boundaries, boundaries from, from a, a patient, patient with, with late-infantile, late-infantile metachromatic, metachromatic leukodystrophy, leukodystrophy were, were polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) amplified, amplified in, in seven, seven discrete, discrete reactions, reactions ., . Amplified, Amplified ARSA, ARSA exons, exons were, were analysed, analysed for, for the, the presence, presence of, of sequence, sequence alterations, alterations by, by single-strand, single-strand conformation, conformation polymorphism, polymorphism analysis, analysis ,, , followed, followed by, by direct, direct sequencing, sequencing of, of PCR, PCR products, products ., . The, The patient, patient was, was found, found to, to be, be homozygous, homozygous for, for a, a C, C --, -- >, > T, T transition, transition in, in exon, exon IV, IV that, that results, results in, in the, the substitution, substitution of, of a, a highly, highly conserved, conserved threonine, threonine residue, residue at, at amino, amino acid, acid 274, 274 with, with a, a methionine, methionine (, ( T274M, T274M ), ) ., . Analysis, Analysis of, of a, a further, further 29, 29 MLD, MLD patients, patients revealed, revealed the, the presence, presence of, of five, five additional, additional homozygotes, homozygotes for, for T274M, T274M ., . All, All 6, 6 T274M, T274M homozygotes, homozygotes (, ( representing, representing four, four families, families ), ) were, were of, of Lebanese, Lebanese descent, descent ,, , and, and all, all were, were known, known to, to be, be the, the result, result of, of consanguineous, consanguineous marriages, marriages ., . The, The altered, altered amino, amino acid, acid is, is rigidly, rigidly conserved, conserved among, among 10, 10 sulfatases, sulfatases from, from Escherichia, Escherichia coli, coli to, to humans, humans ;, ; therefore, therefore ,, , it, it is, is most, most likely, likely that, that the, the resultant, resultant mutant, mutant protein, protein will, will have, have little, little or, or no, no enzyme, enzyme activity, activity ., . This, This is, is consistent, consistent with, with the, the very, very low, low ARSA, ARSA activity, activity measured, measured in, in these, these patients, patients and, and their, their uniformly, uniformly severe, severe clinical, clinical presentation, presentation Recently, Recently ,, , the, the gene, gene for, for the, the most, most common, common peroxisomal, peroxisomal disorder, disorder ,, , X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( X-ALD, X-ALD ), ) ,, , has, has been, been described, described encoding, encoding a, a peroxisomal, peroxisomal membrane, membrane transporter, transporter protein, protein ., . We, We analyzed, analyzed the, the entire, entire protein-coding, protein-coding sequence, sequence of, of this, this gene, gene by, by reverse-transcription, reverse-transcription PCR, PCR ,, , SSCP, SSCP ,, , and, and DNA, DNA sequencing, sequencing in, in five, five patients, patients with, with different, different clinical, clinical expression, expression of, of X-ALD, X-ALD and, and in, in their, their female, female relatives, relatives ;, ; these, these clinical, clinical expressions, expressions were, were cerebral, cerebral childhood, childhood ALD, ALD ,, , adrenomyeloneuropathy, adrenomyeloneuropathy (, ( AMN, AMN ), ) ,, , and, and ``, `` Addison, Addison disease, disease only, only ``, `` (, ( ADO, ADO ), ) phenotype, phenotype ., . In, In the, the three, three patients, patients exhibiting, exhibiting the, the classical, classical picture, picture of, of severe, severe childhood, childhood ALD, ALD we, we identified, identified in, in the, the 5, 5 portion, portion of, of the, the X-ALD, X-ALD gene, gene a, a 38-bp, 38-bp deletion, deletion that, that causes, causes a, a frameshift, frameshift mutation, mutation ,, , a, a 3-bp, 3-bp deletion, deletion leading, leading to, to a, a deletion, deletion of, of an, an amino, amino acid, acid in, in the, the ATP-binding, ATP-binding domain, domain of, of the, the ALD, ALD protein, protein ,, , and, and a, a missense, missense mutation, mutation ., . In, In the, the patient, patient with, with the, the clinical, clinical phenotype, phenotype of, of AMN, AMN ,, , a, a nonsense, nonsense mutation, mutation in, in codon, codon 212, 212 ,, , along, along with, with a, a second, second site, site mutation, mutation at, at codon, codon 178, 178 ,, , was, was observed, observed ., . Analysis, Analysis of, of the, the patient, patient with, with the, the ADO, ADO phenotype, phenotype revealed, revealed a, a further, further missense, missense mutation, mutation at, at a, a highly, highly conserved, conserved position, position in, in the, the ALDP/PMP70, ALDP/PMP70 comparison, comparison ., . The, The disruptive, disruptive nature, nature of, of two, two mutations, mutations (, ( i., i. e., e. ,, , the, the frameshift, frameshift and, and the, the nonsense, nonsense mutation, mutation ), ) in, in patients, patients with, with biochemically, biochemically proved, proved childhood, childhood ALD, ALD and, and AMN, AMN further, further strongly, strongly supports, supports the, the hypothesis, hypothesis that, that alterations, alterations in, in this, this gene, gene play, play a, a crucial, crucial role, role in, in the, the pathogenesis, pathogenesis of, of X-ALD, X-ALD ., . Since, Since the, the current, current biochemical, biochemical techniques, techniques for, for X-ALD, X-ALD carrier, carrier detection, detection in, in affected, affected families, families lack, lack sufficient, sufficient reliability, reliability ,, , our, our procedure, procedure described, described for, for systematic, systematic mutation, mutation scanning, scanning is, is also, also capable, capable of, of improving, improving genetic, genetic counseling, counseling and, and prenatal, prenatal diagnosis, diagnosis Atelosteogenesis, Atelosteogenesis type, type II, II (, ( AO, AO II, II ), ) is, is a, a neonatally, neonatally lethal, lethal chondrodysplasia, chondrodysplasia whose, whose clinical, clinical and, and histological, histological characteristics, characteristics resemble, resemble those, those of, of another, another chondrodysplasia, chondrodysplasia ,, , the, the much, much less, less severe, severe diastrophic, diastrophic dysplasia, dysplasia (, ( DTD, DTD ), ) ., . The, The similarity, similarity suggests, suggests a, a shared, shared pathogenesis, pathogenesis involving, involving lesions, lesions in, in the, the same, same biochemical, biochemical pathway, pathway and, and perhaps, perhaps the, the same, same gene, gene ., . DTD, DTD is, is caused, caused by, by mutations, mutations in, in the, the recently, recently identified, identified diastrophic, diastrophic dysplasia, dysplasia sulfate-transporter, sulfate-transporter gene, gene (, ( DTDST, DTDST ), ) ., . Here, Here ,, , we, we report, report that, that AOII, AOII patients, patients also, also have, have DTDST, DTDST mutations, mutations ,, , which, which lead, lead to, to defective, defective uptake, uptake of, of inorganic, inorganic sulfate, sulfate and, and insufficient, insufficient sulfation, sulfation of, of macromolecules, macromolecules by, by patient, patient mesenchymal, mesenchymal cells, cells in, in vitro, vitro ., . Together, Together with, with our, our recent, recent observation, observation that, that a, a third, third even, even more, more severe, severe chondrodysplasia, chondrodysplasia ,, , achondrogenesis, achondrogenesis type, type IB, IB ,, , is, is also, also caused, caused by, by mutations, mutations in, in DTDST, DTDST ,, , these, these results, results demonstrate, demonstrate a, a phenotypic, phenotypic series, series of, of three, three chondrodysplasias, chondrodysplasias of, of increasing, increasing severity, severity caused, caused by, by lesions, lesions in, in a, a single, single sulfate-transporter, sulfate-transporter gene, gene ., . The, The severity, severity of, of the, the phenotype, phenotype appears, appears to, to be, be correlated, correlated with, with the, the predicted, predicted effect, effect of, of the, the mutations, mutations on, on the, the residual, residual activity, activity of, of the, the DTDST, DTDST protein.., protein.. X-linked, X-linked recessive, recessive Emery-Dreifuss, Emery-Dreifuss muscular, muscular dystrophy, dystrophy (, ( EDMD, EDMD ), ) is, is an, an inherited, inherited muscle, muscle disorder, disorder characterized, characterized by, by the, the clinical, clinical triad, triad of, of progressive, progressive wasting, wasting of, of humero-peroneal, humero-peroneal muscles, muscles ,, , early, early contractures, contractures of, of the, the elbows, elbows ,, , Achilles, Achilles tendons, tendons and, and postcervical, postcervical muscles, muscles ,, , and, and cardiac, cardiac conduction, conduction block, block with, with a, a high, high risk, risk of, of sudden, sudden death, death ., . The, The gene, gene for, for EDMD, EDMD on, on Xq28, Xq28 encodes, encodes a, a novel, novel protein, protein named, named emerin, emerin that, that localizes, localizes at, at the, the nuclear, nuclear membrane, membrane of, of skeletal, skeletal ,, , cardiac, cardiac and, and smooth, smooth muscles, muscles and, and some, some other, other non-muscle, non-muscle tissues, tissues ., . To, To investigate, investigate a, a possible, possible physiological, physiological role, role for, for emerin, emerin ,, , we, we examined, examined the, the ultrastructural, ultrastructural localization, localization of, of the, the protein, protein in, in human, human skeletal, skeletal muscle, muscle and, and HeLa, HeLa cells, cells ,, , using, using ultrathin, ultrathin cryosections, cryosections ., . We, We found, found that, that the, the immune-labeled, immune-labeled colloidal, colloidal gold, gold particles, particles were, were localized, localized on, on the, the nucleoplasmic, nucleoplasmic surface, surface of, of the, the inner, inner nuclear, nuclear membrane, membrane ,, , but, but not, not on, on the, the nuclear, nuclear pore, pore ., . Emerin, Emerin stayed, stayed on, on the, the cytoplasmic, cytoplasmic surface, surface of, of the, the nuclear, nuclear lamina, lamina ,, , even, even after, after detergent, detergent treatment, treatment that, that solubilizes, solubilizes membrane, membrane lipids, lipids and, and washes, washes out, out membrane, membrane proteins, proteins ., . These, These results, results suggest, suggest that, that emerin, emerin anchors, anchors at, at the, the inner, inner nuclear, nuclear membrane, membrane through, through the, the hydrophobic, hydrophobic stretch, stretch ,, , and, and protrudes, protrudes from, from the, the hydrophilic, hydrophilic region, region to, to the, the nucleoplasm, nucleoplasm where, where it, it interacts, interacts with, with the, the nuclear, nuclear lamina, lamina ., . We, We speculate, speculate that, that emerin, emerin contributes, contributes to, to maintain, maintain the, the nuclear, nuclear structure, structure and, and stability, stability ,, , as, as well, well as, as nuclear, nuclear functions, functions ,, , particularly, particularly in, in muscle, muscle tissues, tissues that, that have, have severe, severe stress, stress with, with rigorous, rigorous contraction-relaxation, contraction-relaxation movements, movements and, and calcium, calcium flux.., flux.. The, The Zellweger, Zellweger spectrum, spectrum of, of disease, disease ,, , encompassing, encompassing Zellweger, Zellweger syndrome, syndrome and, and the, the progressively, progressively milder, milder phenotypes, phenotypes of, of neonatal, neonatal adrenoleukodystrophy, adrenoleukodystrophy and, and infantile, infantile Refsum, Refsum disease, disease ,, , is, is due, due to, to a, a failure, failure to, to form, form functional, functional peroxisomes, peroxisomes ., . Cell, Cell fusion, fusion complementation, complementation studies, studies demonstrated, demonstrated that, that these, these diseases, diseases are, are genetically, genetically heterogeneous, heterogeneous ,, , with, with two-thirds, two-thirds of, of all, all patients, patients lying, lying within, within a, a single, single complementation, complementation group, group ,, , CG1, CG1 ., . Molecular, Molecular genetic, genetic and, and cell, cell biology, biology studies, studies have, have shown, shown that, that PEX1, PEX1 is, is deficient, deficient in, in many, many CG1, CG1 patients, patients ., . However, However ,, , previous, previous studies, studies have, have focused, focused on, on mildly, mildly affected, affected patients, patients and, and there, there is, is still, still no, no report, report of, of two, two mutant, mutant PEX1, PEX1 alleles, alleles in, in any, any Zellweger, Zellweger syndrome, syndrome patient, patient ., . Furthermore, Furthermore ,, , mutations, mutations in, in the, the PMP70, PMP70 gene, gene have, have also, also been, been identified, identified in, in two, two Zellweger, Zellweger syndrome, syndrome patients, patients from, from CG1, CG1 ,, , raising, raising the, the possibility, possibility that, that CG1, CG1 patients, patients may, may represent, represent a, a mixture, mixture of, of PEX1-deficient, PEX1-deficient and, and PMP70-deficient, PMP70-deficient individuals, individuals ., . To, To address, address the, the molecular, molecular basis, basis of, of disease, disease in, in Zellweger, Zellweger syndrome, syndrome patients, patients from, from CG1, CG1 ,, , we, we examined, examined all, all 24, 24 PEX1, PEX1 exons, exons in, in four, four patients, patients ,, , including, including both, both patients, patients that, that have, have mutations, mutations in, in PMP70, PMP70 ., . PEX1, PEX1 mutations, mutations were, were detected, detected in, in all, all four, four patients, patients ,, , including, including a, a 1-bp, 1-bp insertion, insertion (, ( c., c. 2097insT, 2097insT ), ) in, in exon, exon 13, 13 that, that was, was present, present in, in three, three of, of the, the four, four patients, patients ., . Subsequent, Subsequent studies, studies demonstrated, demonstrated that, that this, this mutation, mutation is, is present, present in, in one-half, one-half of, of all, all CG1, CG1 patients, patients and, and correlates, correlates with, with the, the Zellweger, Zellweger syndrome, syndrome phenotype, phenotype ., . As, As this, this mutation, mutation leads, leads to, to a, a loss, loss of, of protein, protein function, function its, its frequency, frequency makes, makes it, it the, the most, most common, common cause, cause of, of Zellweger, Zellweger syndrome, syndrome ,, , helping, helping to, to explain, explain the, the high, high percentage, percentage of, of patients, patients that, that belong, belong to, to CG1, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CG1 ., . Ankylosing, Ankylosing spondylitis, spondylitis (, ( AS, AS ), ) is, is a, a common, common and, and highly, highly familial, familial rheumatic, rheumatic disorder, disorder ., . The, The sibling, sibling recurrence, recurrence risk, risk ratio, ratio for, for the, the disease, disease is, is 63, 63 and, and heritability, heritability assessed, assessed in, in twins, twins >, > 90, 90 %, % ., . Although, Although MHC, MHC genes, genes ,, , including, including HLA-B27, HLA-B27 ,, , contribute, contribute only, only 20-50, 20-50 %, % of, of the, the genetic, genetic risk, risk for, for the, the disease, disease ,, , no, no non-MHC, non-MHC gene, gene has, has yet, yet been, been convincingly, convincingly demonstrated, demonstrated to, to influence, influence either, either susceptibility, susceptibility to, to the, the disease, disease or, or its, its phenotypic, phenotypic expression, expression ., . Previous, Previous linkage, linkage and, and association, association studies, studies have, have suggested, suggested the, the presence, presence of, of a, a susceptibility, susceptibility gene, gene for, for AS, AS close, close to, to ,, , or, or within, within ,, , the, the cytochrome, cytochrome P450, P450 2D6, 2D6 gene, gene (, ( CYP2D6, CYP2D6 ,, , debrisoquine, debrisoquine hydroxylase, hydroxylase ), ) located, located at, at chromosome, chromosome 22q13.1, 22q13.1 ., . We, We performed, performed a, a linkage, linkage study, study of, of chromosome, chromosome 22, 22 in, in 200, 200 families, families with, with AS, AS affected, affected sibling-pairs, sibling-pairs ., . Association, Association of, of alleles, alleles of, of the, the CYP2D6, CYP2D6 gene, gene was, was examined, examined by, by both, both case-control, case-control and, and within-family, within-family means, means ., . For, For case-control, case-control studies, studies ,, , 617, 617 unrelated, unrelated individuals, individuals with, with AS, AS (, ( 361, 361 probands, probands from, from sibling-pair, sibling-pair and, and parent-case, parent-case trio, trio families, families and, and 256, 256 unrelated, unrelated non-familial, non-familial sporadic, sporadic cases, cases ), ) and, and 402, 402 healthy, healthy ethnically, ethnically matched, matched controls, controls were, were employed, employed ., . For, For within-family, within-family association, association studies, studies ,, , 361, 361 families, families including, including 161, 161 parent-case, parent-case trios, trios and, and 200, 200 affected, affected sibling-pair, sibling-pair families, families were, were employed, employed ., . Homozygosity, Homozygosity for, for poor, poor metabolizer, metabolizer alleles, alleles was, was found, found to, to be, be associated, associated with, with AS, AS ., . Heterozygosity, Heterozygosity for, for the, the most, most frequent, frequent poor, poor metabolizer, metabolizer allele, allele (, ( CYP2D6*4, CYP2D6*4 ), ) was, was not, not associated, associated with, with increased, increased susceptibility, susceptibility to, to AS, AS ., . Significant, Significant within-family, within-family association, association of, of CYP2D6*4, CYP2D6*4 alleles, alleles and, and AS, AS was, was demonstrated, demonstrated ., . Weak, Weak linkage, linkage was, was also, also demonstrated, demonstrated between, between CYP2D6, CYP2D6 and, and AS, AS ., . We, We postulate, postulate that, that altered, altered metabolism, metabolism of, of a, a natural, natural toxin, toxin or, or antigen, antigen by, by the, the CYP2D6, CYP2D6 gene, gene may, may increase, increase susceptibility, susceptibility to, to AS, AS ., . Factor, Factor X, X deficiency, deficiency is, is a, a rare, rare haemorrhagic, haemorrhagic condition, condition ,, , normally, normally inherited, inherited as, as an, an autosomal, autosomal recessive, recessive trait, trait ,, , in, in which, which a, a variable, variable clinical, clinical presentation, presentation correlates, correlates poorly, poorly with, with laboratory, laboratory phenotype, phenotype ., . The, The factor, factor X, X (, ( F10, F10 ), ) genes, genes of, of 14, 14 unrelated, unrelated individuals, individuals with, with factor, factor X, X deficiency, deficiency (, ( 12, 12 familial, familial and, and two, two sporadic, sporadic cases, cases ), ) were, were sequenced, sequenced yielding, yielding a, a total, total of, of 13, 13 novel, novel mutations, mutations ., . Family, Family studies, studies were, were performed, performed in, in order, order to, to distinguish, distinguish the, the contributions, contributions of, of individual, individual mutant, mutant F10, F10 alleles, alleles to, to the, the clinical, clinical and, and laboratory, laboratory phenotypes, phenotypes ., . Missense, Missense mutations, mutations were, were studied, studied by, by means, means of, of molecular, molecular modelling, modelling ,, , whereas, whereas single, single basepair, basepair substitutions, substitutions in, in splice, splice sites, sites and, and the, the 5, 5 flanking, flanking region, region were, were examined, examined by, by in, in vitro, vitro splicing, splicing assay, assay and, and luciferase, luciferase reporter, reporter gene, gene assay, assay respectively, respectively ., . The, The deletion, deletion allele, allele of, of a, a novel, novel hexanucleotide, hexanucleotide insertion/deletion, insertion/deletion polymorphism, polymorphism in, in the, the F10, F10 gene, gene promoter, promoter region, region was, was shown, shown by, by reporter, reporter gene, gene assay, assay ,, , to, to reduce, reduce promoter, promoter activity, activity by, by approximately, approximately 20, 20 %, % ., . One, One family, family manifesting, manifesting an, an autosomal, autosomal dominant, dominant pattern, pattern of, of inheritance, inheritance possessed, possessed three, three clinically, clinically affected, affected members, members who, who were, were heterozygous, heterozygous for, for a, a splice-site, splice-site mutation, mutation that, that was, was predicted, predicted to, to lead, lead to, to the, the production, production of, of a, a truncated, truncated protein, protein product, product ., . A, A model, model which, which accounts, accounts for, for the, the dominant, dominant negative, negative effect, effect of, of this, this lesion, lesion is, is presented, presented ., . Variation, Variation in, in the, the antigen, antigen level, level of, of heterozygous, heterozygous relatives, relatives of, of probands, probands was, was found, found to, to be, be significantly, significantly higher, higher between, between families, families than, than within, within families, families ,, , consistent, consistent with, with the, the view, view that, that the, the nature, nature of, of the, the F10, F10 lesion, lesion (, ( s, s ), ) segregating, segregating in, in a, a given, given family, family is, is a, a prime, prime determinant, determinant of, of the, the laboratory, laboratory phenotype, phenotype ., . By, By contrast, contrast ,, , no, no such, such relationship, relationship could, could be, be discerned, discerned between, between laboratory, laboratory phenotype, phenotype and, and polymorphism, polymorphism genotype.., genotype.. The, The gene, gene Prph2, Prph2 encodes, encodes a, a photoreceptor-specific, photoreceptor-specific membrane, membrane glycoprotein, glycoprotein ,, , peripherin-2, peripherin-2 (, ( also, also known, known as, as peripherin/rds, peripherin/rds ), ) ,, , which, which is, is inserted, inserted into, into the, the rims, rims of, of photoreceptor, photoreceptor outer, outer segment, segment discs, discs in, in a, a complex, complex with, with rom-1, rom-1 (, ( ref, ref ., . 2, 2 ), ) ., . The, The complex, complex is, is necessary, necessary for, for the, the stabilization, stabilization of, of the, the discs, discs ,, , which, which are, are renewed, renewed constantly, constantly throughout, throughout life, life ,, , and, and which, which contain, contain the, the visual, visual pigments, pigments necessary, necessary for, for photon, photon capture, capture ., . Mutations, Mutations in, in Prph2, Prph2 have, have been, been shown, shown to, to result, result in, in a, a variety, variety of, of photoreceptor, photoreceptor dystrophies, dystrophies ,, , including, including autosomal, autosomal dominant, dominant retinitis, retinitis pigmentosa, pigmentosa and, and macular, macular dystrophy, dystrophy ., . A, A common, common feature, feature of, of these, these diseases, diseases is, is the, the loss, loss of, of photoreceptor, photoreceptor function, function ,, , also, also seen, seen in, in the, the retinal, retinal degeneration, degeneration slow, slow (, ( rds, rds or, or Prph2, Prph2 Rd2/Rd2, Rd2/Rd2 ), ) mouse, mouse ,, , which, which is, is homozygous, homozygous for, for a, a null, null mutation, mutation in, in Prph2, Prph2 ., . It, It is, is characterized, characterized by, by a, a complete, complete failure, failure to, to develop, develop photoreceptor, photoreceptor discs, discs and, and outer, outer segments, segments ,, , downregulation, downregulation of, of rhodopsin, rhodopsin and, and apoptotic, apoptotic loss, loss of, of photoreceptor, photoreceptor cells, cells ., . The, The electroretinograms, electroretinograms (, ( ERGs, ERGs ), ) of, of Prph2Rd2/Rd2, Prph2Rd2/Rd2 mice, mice have, have greatly, greatly diminished, diminished a-wave, a-wave and, and b-wave, b-wave amplitudes, amplitudes ,, , which, which decline, decline to, to virtually, virtually undetectable, undetectable concentrations, concentrations by, by two, two months, months ., . Subretinal, Subretinal injection, injection of, of recombinant, recombinant adeno-associated, adeno-associated virus, virus (, ( AAV, AAV ), ) encoding, encoding a, a Prph2, Prph2 transgene, transgene results, results in, in stable, stable generation, generation of, of outer, outer segment, segment structures, structures and, and formation, formation of, of new, new stacks, stacks of, of discs, discs containing, containing both, both perpherin-2, perpherin-2 and, and rhodopsin, rhodopsin ,, , which, which in, in many, many cases, cases are, are morphologically, morphologically similar, similar to, to normal, normal outer, outer segments, segments ., . Moreover, Moreover ,, , the, the re-establishment, re-establishment of, of the, the structural, structural integrity, integrity of, of the, the photoreceptor, photoreceptor layer, layer also, also results, results in, in electrophysiological, electrophysiological correction, correction ., . These, These studies, studies demonstrate, demonstrate for, for the, the first, first time, time that, that a, a complex, complex ultrastructural, ultrastructural cell, cell defect, defect can, can be, be corrected, corrected both, both morphologically, morphologically and, and functionally, functionally by, by in, in vivo, vivo gene, gene transfer.., transfer.. A, A total, total of, of 630, 630 haplotypes, haplotypes for, for the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) gene, gene locus, locus were, were established, established in, in five, five groups, groups of, of Polynesians, Polynesians comprising, comprising Samoans, Samoans ,, , Tongans, Tongans ,, , Cook, Cook Islanders, Islanders ,, , Maori, Maori ,, , and, and Niueans, Niueans ., . Considerable, Considerable genetic, genetic continuity, continuity was, was demonstrated, demonstrated between, between these, these widely, widely dispersed, dispersed populations, populations ,, , since, since three, three common, common haplotypes, haplotypes (, ( 4, 4 ,, , 1, 1 ,, , and, and 7, 7 ), ) constituted, constituted over, over 95, 95 %, % of, of alleles, alleles ., . A, A control, control group, group of, of individuals, individuals from, from Southeast, Southeast Asia, Asia shared, shared the, the same, same major, major haplotypes, haplotypes ,, , 4, 4 ,, , 1, 1 ,, , and, and 7, 7 ,, , with, with Polynesians, Polynesians ., . These, These data, data provide, provide further, further support, support for, for the, the theories, theories of, of genetic, genetic homogeneity, homogeneity and, and of, of Asian, Asian affinities, affinities of, of the, the Polynesian, Polynesian precursor, precursor populations, populations ., . The, The absence, absence of, of severe, severe phenylketonuria, phenylketonuria (, ( PKU, PKU ), ) in, in both, both Polynesians, Polynesians and, and Southeast, Southeast Asians, Asians is, is consistent, consistent with, with the, the lack, lack of, of PAH, PAH haplotypes, haplotypes 2, 2 and, and 3, 3 ,, , on, on which, which the, the severe, severe PKU, PKU mutants, mutants have, have arisen, arisen among, among Caucasians.., Caucasians.. Alveolar, Alveolar rhabdomyosarcoma, rhabdomyosarcoma is, is an, an aggressive, aggressive pediatric, pediatric cancer, cancer of, of striated, striated muscle, muscle characterized, characterized in, in 60, 60 %, % of, of cases, cases by, by a, a t, t (, ( 2, 2 ;, ; 13, 13 ), ) (, ( q35, q35 ;, ; q14, q14 ), ) ., . This, This results, results in, in the, the fusion, fusion of, of PAX3, PAX3 ,, , a, a developmental, developmental transcription, transcription factor, factor required, required for, for limb, limb myogenesis, myogenesis ,, , with, with FKHR, FKHR ,, , a, a member, member of, of the, the forkhead, forkhead family, family of, of transcription, transcription factors, factors ., . The, The resultant, resultant PAX3-FKHR, PAX3-FKHR gene, gene possesses, possesses transforming, transforming properties, properties ;, ; however, however ,, , the, the effects, effects of, of this, this chimeric, chimeric oncogene, oncogene on, on gene, gene expression, expression are, are largely, largely unknown, unknown ., . To, To investigate, investigate the, the actions, actions of, of these, these transcription, transcription factors, factors ,, , both, both Pax3, Pax3 and, and PAX3-FKHR, PAX3-FKHR were, were introduced, introduced into, into NIH, NIH 3T3, 3T3 cells, cells ,, , and, and the, the resultant, resultant gene, gene expression, expression changes, changes were, were analyzed, analyzed with, with a, a murine, murine cDNA, cDNA microarray, microarray containing, containing 2, 2 ,, , 225, 225 elements, elements ., . We, We found, found that, that PAX3-FKHR, PAX3-FKHR but, but not, not PAX3, PAX3 activated, activated a, a myogenic, myogenic transcription, transcription program, program including, including the, the induction, induction of, of transcription, transcription factors, factors MyoD, MyoD ,, , Myogenin, Myogenin ,, , Six1, Six1 ,, , and, and Slug, Slug as, as well, well as, as a, a battery, battery of, of genes, genes involved, involved in, in several, several aspects, aspects of, of muscle, muscle function, function ., . Notable, Notable among, among this, this group, group were, were the, the growth, growth factor, factor gene, gene Igf2, Igf2 and, and its, its binding, binding protein, protein Igfbp5, Igfbp5 ., . Relevance, Relevance of, of this, this model, model was, was suggested, suggested by, by verification, verification that, that three, three of, of these, these genes, genes (, ( IGFBP5, IGFBP5 ,, , HSIX1, HSIX1 ,, , and, and Slug, Slug ), ) were, were also, also expressed, expressed in, in alveolar, alveolar rhabdomyosarcoma, rhabdomyosarcoma cell, cell lines, lines ., . This, This study, study utilizes, utilizes cDNA, cDNA microarrays, microarrays to, to elucidate, elucidate the, the pattern, pattern of, of gene, gene expression, expression induced, induced by, by an, an oncogenic, oncogenic transcription, transcription factor, factor and, and demonstrates, demonstrates the, the profound, profound myogenic, myogenic properties, properties of, of PAX3-FKHR, PAX3-FKHR in, in NIH, NIH 3T3, 3T3 cells.., cells.. In, In situ, situ hybridization, hybridization of, of a, a cDNA, cDNA probe, probe for, for the, the esterase, esterase D, D gene, gene (, ( ESD, ESD ), ) was, was carried, carried out, out on, on human, human chromosomes, chromosomes ., . The, The probe, probe hybridized, hybridized most, most strongly, strongly to, to 13q14, 13q14 ., . 2, 2 and, and 13q14, 13q14 ., . 3, 3 ., . This, This observation, observation raises, raises doubts, doubts concerning, concerning the, the most, most recently, recently published, published assignment, assignment of, of ESD, ESD to, to 13q14, 13q14 ., . 1, 1 ., . A, A deletion, deletion in, in an, an individual, individual with, with retinoblastoma, retinoblastoma was, was reported, reported to, to separate, separate the, the closely, closely linked, linked ESD, ESD and, and retinoblastoma, retinoblastoma (, ( RB1, RB1 ), ) loci, loci ,, , placing, placing ESD, ESD proximal, proximal to, to RB1, RB1 ., . Quantitative, Quantitative in, in situ, situ hybridization, hybridization studies, studies of, of this, this deletion, deletion do, do not, not confirm, confirm this, this interpretation, interpretation ., . Rather, Rather ,, , they, they suggest, suggest that, that ESD, ESD is, is missing, missing from, from the, the deleted, deleted chromosome, chromosome 13, 13 and, and duplicated, duplicated on, on the, the normal, normal homolog, homolog ., . From, From these, these findings, findings ,, , we, we conclude, conclude that, that the, the deletion, deletion in, in this, this individual, individual can, can not, not be, be used, used to, to determine, determine the, the orientation, orientation nor, nor the, the sublocalization, sublocalization of, of ESD, ESD and, and RB1, RB1 within, within the, the 13q14, 13q14 region, region ., . We, We show, show that, that hypomorphic, hypomorphic mutations, mutations in, in hMRE11, hMRE11 ,, , but, but not, not in, in ATM, ATM ,, , are, are present, present in, in certain, certain individuals, individuals with, with an, an ataxia-telangiectasia-like, ataxia-telangiectasia-like disorder, disorder (, ( ATLD, ATLD ), ) ., . The, The cellular, cellular features, features resulting, resulting from, from these, these hMRE11, hMRE11 mutations, mutations are, are similar, similar to, to those, those seen, seen in, in A-T, A-T as, as well, well as, as NBS, NBS and, and include, include hypersensitivity, hypersensitivity to, to ionizing, ionizing radiation, radiation ,, , radioresistant, radioresistant DNA, DNA synthesis, synthesis ,, , and, and abrogation, abrogation of, of ATM-dependent, ATM-dependent events, events ,, , such, such as, as the, the activation, activation of, of Jun, Jun kinase, kinase following, following exposure, exposure to, to gamma, gamma irradiation, irradiation ., . Although, Although the, the mutant, mutant hMre11, hMre11 proteins, proteins retain, retain some, some ability, ability to, to interact, interact with, with hRad50, hRad50 and, and Nbs1, Nbs1 ,, , formation, formation of, of ionizing, ionizing radiation-induced, radiation-induced hMre11, hMre11 and, and Nbs1, Nbs1 foci, foci was, was absent, absent in, in hMRE11, hMRE11 mutant, mutant cells, cells ., . These, These data, data demonstrate, demonstrate that, that ATM, ATM and, and the, the hMre11/hRad50/Nbs1, hMre11/hRad50/Nbs1 protein, protein complex, complex act, act in, in the, the same, same DNA, DNA damage, damage response, response pathway, pathway and, and link, link hMre11, hMre11 to, to the, the complex, complex pathology, pathology of, of A-T.., A-T.. A, A probe, probe for, for the, the 5, 5 end, end of, of the, the Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene was, was used, used to, to study, study expression, expression of, of the, the gene, gene in, in normal, normal human, human muscle, muscle ,, , myogenic, myogenic cell, cell cultures, cultures ,, , and, and muscle, muscle from, from patients, patients with, with DMD, DMD ., . Expression, Expression was, was found, found in, in RNA, RNA from, from normal, normal fetal, fetal muscle, muscle ,, , adult, adult cardiac, cardiac and, and skeletal, skeletal muscle, muscle ,, , and, and cultured, cultured muscle, muscle after, after myoblast, myoblast fusion, fusion ., . In, In DMD, DMD muscle, muscle ,, , expression, expression of, of this, this portion, portion of, of the, the gene, gene was, was also, also revealed, revealed by, by in, in situ, situ RNA, RNA hybridization, hybridization ,, , particularly, particularly in, in regenerating, regenerating muscle, muscle fibers.., fibers.. A, A linkage, linkage study, study in, in 30, 30 Becker, Becker muscular, muscular dystrophy, dystrophy (, ( BMD, BMD ), ) kindreds, kindreds using, using three, three cloned, cloned DNA, DNA sequences, sequences from, from the, the X, X chromosome, chromosome which, which demonstrate, demonstrate restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms (, ( RFLPs, RFLPs ), ) ,, , suggests, suggests that, that the, the BMD, BMD gene, gene is, is located, located on, on the, the short, short arm, arm of, of the, the X, X chromosome, chromosome ,, , in, in the, the p21, p21 region, region ., . The, The genes, genes for, for Becker, Becker and, and Duchenne, Duchenne dystrophies, dystrophies must, must therefore, therefore be, be closely, closely linked, linked ,, , if, if not, not allelic, allelic ,, , and, and any, any future, future DNA, DNA probes, probes found, found to, to be, be of, of practical, practical use, use in, in one, one disorder, disorder should, should be, be equally, equally applicable, applicable to, to the, the other, other ., . The, The linkage, linkage analysis, analysis also, also provides, provides data, data on, on the, the frequency, frequency of, of recombination, recombination along, along the, the short, short arm, arm of, of the, the X, X chromosome, chromosome ,, , and, and across, across the, the centromeric, centromeric region.., region.. Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) ,, , the, the most, most frequently, frequently inherited, inherited ataxia, ataxia ,, , is, is due, due in, in the, the vast, vast majority, majority of, of cases, cases to, to a, a large, large expansion, expansion of, of an, an intronic, intronic GAA, GAA repeat, repeat ., . Using, Using linkage, linkage disequilibrium, disequilibrium analysis, analysis based, based on, on haplotype, haplotype data, data of, of seven, seven polymorphic, polymorphic markers, markers close, close to, to the, the frataxin, frataxin gene, gene ,, , the, the age, age of, of FRDA, FRDA founding, founding mutational, mutational event, event (, ( s, s ), ) is, is estimated, estimated to, to be, be at, at least, least 682, 682 +/-203, +/-203 generations, generations (, ( 95, 95 %, % confidence, confidence interval, interval 564-801, 564-801 g, g ), ) ,, , a, a dating, dating which, which is, is consistent, consistent with, with little, little or, or no, no negative, negative selection, selection and, and provides, provides further, further evidence, evidence for, for an, an ancient, ancient spread, spread of, of a, a pre-mutation, pre-mutation (, ( at-risk, at-risk alleles, alleles ), ) in, in western, western Europe.., Europe.. Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) is, is a, a complex, complex neurogenetic, neurogenetic disorder, disorder ., . The, The phenotype, phenotype is, is likely, likely to, to be, be a, a contiguous, contiguous gene, gene syndrome, syndrome involving, involving genes, genes which, which are, are paternally, paternally expressed, expressed only, only ,, , located, located in, in the, the human, human 15q11-q13, 15q11-q13 region, region ., . Four, Four mouse, mouse models, models of, of PWS, PWS have, have been, been reported, reported but, but these, these do, do not, not definitively, definitively allow, allow the, the delineation, delineation of, of the, the critical, critical region, region and, and the, the associated, associated genes, genes involved, involved in, in the, the aetiology, aetiology of, of PWS, PWS ., . Moreover, Moreover ,, , targeted, targeted mutagenesis, mutagenesis of, of mouse, mouse homologues, homologues of, of the, the human, human candidate, candidate PWS, PWS genes, genes does, does not, not appear, appear to, to result, result in, in any, any of, of the, the features, features of, of PWS, PWS ., . Therefore, Therefore ,, , the, the isolation, isolation of, of new, new genes, genes in, in this, this region, region remains, remains crucial, crucial for, for a, a better, better understanding, understanding of, of the, the molecular, molecular basis, basis of, of PWS, PWS ., . In, In this, this manuscript, manuscript ,, , we, we report, report the, the characterization, characterization of, of MAGEL2, MAGEL2 and, and its, its mouse, mouse homologue, homologue Magel2, Magel2 ., . These, These are, are located, located in, in the, the human, human 15q11-q13, 15q11-q13 and, and mouse, mouse 7C, 7C regions, regions ,, , in, in close, close proximity, proximity to, to NDN/Ndn, NDN/Ndn ., . By, By northern, northern blot, blot analysis, analysis we, we did, did not, not detect, detect any, any expression, expression of, of MAGEL2/Magel2, MAGEL2/Magel2 but, but by, by RT-PCR, RT-PCR analysis, analysis ,, , specific, specific expression, expression was, was detected, detected in, in fetal, fetal and, and adult, adult brain, brain and, and in, in placenta, placenta ., . Both, Both genes, genes are, are intronless, intronless with, with tandem, tandem direct, direct repeat, repeat sequences, sequences contained, contained within, within a, a CpG, CpG island, island in, in the, the 5-untranscribed, 5-untranscribed region, region ., . The, The transcripts, transcripts encode, encode putative, putative proteins, proteins that, that are, are homologous, homologous to, to the, the MAGE, MAGE proteins, proteins and, and NDN, NDN ., . Moreover, Moreover ,, , MAGEL2/Magel2, MAGEL2/Magel2 are, are expressed, expressed only, only from, from the, the paternal, paternal allele, allele in, in brain, brain ,, , suggesting, suggesting a, a potential, potential role, role in, in the, the aetiology, aetiology of, of PWS, PWS and, and its, its mouse, mouse model, model ,, , respectively.., respectively.. Phenylketonuria, Phenylketonuria (, ( PKU, PKU ), ) ,, , a, a disorder, disorder of, of amino, amino acid, acid metabolism, metabolism prevalent, prevalent among, among Caucasians, Caucasians and, and other, other ethnic, ethnic groups, groups ,, , is, is caused, caused primarily, primarily by, by a, a deficiency, deficiency of, of the, the hepatic, hepatic enzyme, enzyme phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) ., . PKU, PKU is, is a, a highly, highly heterogeneous, heterogeneous disorder, disorder ,, , with, with more, more than, than 60, 60 molecular, molecular lesions, lesions identified, identified in, in the, the PAH, PAH gene, gene ., . The, The haplotype, haplotype associations, associations ,, , relative, relative frequencies, frequencies ,, , and, and distributions, distributions of, of five, five prevalent, prevalent PAH, PAH mutations, mutations (, ( R158Q, R158Q ,, , R261Q, R261Q ,, , IVS10nt546, IVS10nt546 ,, , R408W, R408W ,, , and, and IVS12n1, IVS12n1 ), ) were, were established, established in, in a, a comprehensive, comprehensive European, European sample, sample population, population and, and subsequently, subsequently were, were examined, examined to, to determine, determine the, the potential, potential roles, roles of, of several, several genetic, genetic mechanisms, mechanisms in, in explaining, explaining the, the present, present distribution, distribution of, of the, the major, major PKU, PKU alleles, alleles ., . Each, Each of, of these, these five, five mutations, mutations was, was strongly, strongly associated, associated with, with only, only one, one of, of the, the more, more than, than 70, 70 chromosomal, chromosomal haplotypes, haplotypes defined, defined by, by eight, eight RFLPs, RFLPs in, in or, or near, near the, the PAH, PAH gene, gene ., . These, These findings, findings suggest, suggest that, that each, each of, of these, these mutations, mutations arose, arose through, through a, a single, single founding, founding event, event that, that occurred, occurred within, within time, time periods, periods ranging, ranging from, from several, several hundred, hundred to, to several, several thousand, thousand years, years ago, ago ., . From, From the, the significant, significant differences, differences observed, observed in, in the, the relative, relative frequencies, frequencies and, and distributions, distributions of, of these, these five, five alleles, alleles throughout, throughout Europe, Europe ,, , four, four of, of these, these putative, putative founding, founding events, events could, could be, be localized, localized to, to specific, specific ethnic, ethnic subgroups, subgroups ., . Together, Together ,, , these, these data, data suggest, suggest that, that there, there were, were multiple, multiple ,, , geographically, geographically and, and ethnically, ethnically distinct, distinct origins, origins for, for PKU, PKU within, within the, the European, European population.., population.. The, The Rho-family, Rho-family GTPase, GTPase ,, , Cdc42, Cdc42 ,, , can, can regulate, regulate the, the actin, actin cytoskeleton, cytoskeleton through, through activation, activation of, of Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome protein, protein (, ( WASP, WASP ), ) family, family members, members ., . Activation, Activation relieves, relieves an, an autoinhibitory, autoinhibitory contact, contact between, between the, the GTPase-binding, GTPase-binding domain, domain and, and the, the carboxy-terminal, carboxy-terminal region, region of, of WASP, WASP proteins, proteins ., . Here, Here we, we report, report the, the autoinhibited, autoinhibited structure, structure of, of the, the GTPase-binding, GTPase-binding domain, domain of, of WASP, WASP ,, , which, which can, can be, be induced, induced by, by the, the C-terminal, C-terminal region, region or, or by, by organic, organic co-solvents, co-solvents ., . In, In the, the autoinhibited, autoinhibited complex, complex ,, , intramolecular, intramolecular interactions, interactions with, with the, the GTPase-binding, GTPase-binding domain, domain occlude, occlude residues, residues of, of the, the C, C terminus, terminus that, that regulate, regulate the, the Arp2/3, Arp2/3 actin-nucleating, actin-nucleating complex, complex ., . Binding, Binding of, of Cdc42, Cdc42 to, to the, the GTPase-binding, GTPase-binding domain, domain causes, causes a, a dramatic, dramatic conformational, conformational change, change ,, , resulting, resulting in, in disruption, disruption of, of the, the hydrophobic, hydrophobic core, core and, and release, release of, of the, the C, C terminus, terminus ,, , enabling, enabling its, its interaction, interaction with, with the, the actin, actin regulatory, regulatory machinery, machinery ., . These, These data, data show, show that, that intrinsically, intrinsically unstructured, unstructured peptides, peptides such, such as, as the, the GTPase-binding, GTPase-binding domain, domain of, of WASP, WASP can, can be, be induced, induced into, into distinct, distinct structural, structural and, and functional, functional states, states depending, depending on, on context.., context.. A, A highly, highly informative, informative microsatellite, microsatellite marker, marker ,, , DXS426, DXS426 ,, , which, which maps, maps proximal, proximal to, to DXS7, DXS7 in, in the, the interval, interval Xp11, Xp11 ., . 4-Xp11, 4-Xp11 4-Xp11, 4-Xp11 ., . 23, 23 ,, , has, has been, been used, used to, to refine, refine further, further the, the localisation, localisation of, of the, the gene, gene for, for Norrie, Norrie disease, disease (, ( NDP, NDP ), ) ., . The, The results, results from, from a, a multiply, multiply informative, informative crossover, crossover localize, localize the, the NDP, NDP gene, gene proximal, proximal to, to DXS7, DXS7 ., . In, In conjunction, conjunction with, with information, information from, from 2, 2 NDP, NDP patients, patients who, who have, have a, a deletion, deletion for, for DXS7, DXS7 but, but not, not for, for DSX426, DSX426 ,, , our, our data, data indicate, indicate that, that the, the NDP, NDP gene, gene lies, lies between, between DXS7, DXS7 and, and DXS426, DXS426 on, on proximal, proximal Xp.beta-Oxidation, Xp.beta-Oxidation of, of long-chain, long-chain fatty, fatty acids, acids provides, provides the, the major, major source, source of, of energy, energy in, in the, the heart, heart ., . Defects, Defects in, in enzymes, enzymes of, of the, the beta-oxidation, beta-oxidation pathway, pathway cause, cause sudden, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "sudden ,, , unexplained, unexplained death, death in, in childhood, childhood ,, , acute, acute hepatic, hepatic encephalopathy, encephalopathy or, or liver, liver failure, failure ,, , skeletal, skeletal myopathy, myopathy ,, , and, and cardiomyopathy, cardiomyopathy ., . Very-long-chain, Very-long-chain acyl-CoA, acyl-CoA dehydrogenase, dehydrogenase [, [ VLCAD, VLCAD ;, ; very-long-chain-acyl-CoA, very-long-chain-acyl-CoA (, ( acceptor, acceptor ), ) 2, 2 ,, , 3-oxidoreductase, 3-oxidoreductase ,, , EC, EC 1, 1 ., . 3, 3 3, 3 ., . 99, 99 99, 99 ., . 13, 13 ], ] catalyzes, catalyzes the, the first, first step, step in, in beta-oxidation, beta-oxidation ., . We, We have, have isolated, isolated the, the human, human VLCAD, VLCAD cDNA, cDNA and, and gene, gene and, and determined, determined the, the complete, complete nucleotide, nucleotide sequences, sequences ., . Polymerase, Polymerase chain, chain reaction, reaction amplification, amplification of, of VLCAD, VLCAD mRNA, mRNA and, and genomic, genomic exons, exons defined, defined the, the molecular, molecular defects, defects in, in two, two patients, patients with, with VLCAD, VLCAD deficiency, deficiency who, who presented, presented with, with unexplained, unexplained cardiac, cardiac arrest, arrest and, and cardiomyopathy, cardiomyopathy ., . In, In one, one ,, , a, a homozygous, homozygous mutation, mutation in, in the, the consensus, consensus dinucleotide, dinucleotide of, of the, the donor, donor splice, splice site, site (, ( g, g +, + 1, 1 --, -- >, > a, a ), ) was, was associated, associated with, with universal, universal skipping, skipping of, of the, the prior, prior exon, exon (, ( exon, exon 11, 11 ), ) ., . The, The second, second patient, patient was, was a, a compound, compound heterozygote, heterozygote ,, , with, with a, a missense, missense mutation, mutation ,, , C1837, C1837 --, -- >, > T, T ,, , changing, changing the, the arginine, arginine at, at residue, residue 613, 613 to, to tryptophan, tryptophan on, on one, one allele, allele and, and a, a single, single base, base deletion, deletion at, at the, the intron-exon, intron-exon 6, 6 boundary, boundary as, as the, the second, second mutation, mutation ., . This, This initial, initial delineation, delineation of, of human, human mutations, mutations in, in VLCAD, VLCAD suggests, suggests that, that VLCAD, VLCAD deficiency, deficiency reduces, reduces myocardial, myocardial fatty, fatty acid, acid beta-oxidation, beta-oxidation and, and energy, energy production, production and, and is, is associated, associated with, with cardiomyopathy, cardiomyopathy and, and sudden, sudden death, death in, in childhood, childhood ., . Golden, Golden retriever, retriever muscular, muscular dystrophy, dystrophy (, ( GRMD, GRMD ), ) is, is a, a spontaneous, spontaneous ,, , X-linked, X-linked ,, , progressively, progressively fatal, fatal disease, disease of, of dogs, dogs and, and is, is also, also a, a homologue, homologue of, of Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . Two-thirds, Two-thirds of, of DMD, DMD patients, patients carry, carry detectable, detectable deletions, deletions in, in their, their dystrophin, dystrophin gene, gene ., . The, The defect, defect underlying, underlying the, the remaining, remaining one-third, one-third of, of DMD, DMD patients, patients is, is undetermined, undetermined ., . Analysis, Analysis of, of the, the canine, canine dystrophin, dystrophin gene, gene in, in normal, normal and, and GRMD, GRMD dogs, dogs has, has failed, failed to, to demonstrate, demonstrate any, any detectable, detectable loss, loss of, of exons, exons ., . Here, Here ,, , we, we have, have demonstrated, demonstrated a, a RNA, RNA processing, processing error, error in, in GRMD, GRMD that, that results, results from, from a, a single, single base, base change, change in, in the, the 3, 3 consensus, consensus splice, splice site, site of, of intron, intron 6, 6 ., . The, The seventh, seventh exon, exon is, is then, then skipped, skipped ,, , which, which predicts, predicts a, a termination, termination of, of the, the dystrophin, dystrophin reading, reading frame, frame within, within its, its N-terminal, N-terminal domain, domain in, in exon, exon 8, 8 ., . This, This is, is the, the first, first example, example of, of dystrophin, dystrophin deficiency, deficiency caused, caused by, by a, a splice-site, splice-site mutation.., mutation.. Two, Two recent, recent studies, studies have, have suggested, suggested the, the involvement, involvement of, of serum, serum amyloid, amyloid A, A (, ( SAA, SAA ), ) and, and P, P (, ( APCS, APCS ), ) genes, genes in, in familial, familial Mediterranean, Mediterranean fever, fever (, ( MEF, MEF ), ) ., . To, To test, test the, the role, role of, of SAA, SAA and, and APCS, APCS in, in MEF, MEF and, and MEF-amyloidosis, MEF-amyloidosis ,, , we, we studied, studied 17, 17 informative, informative families, families (, ( 15, 15 Armenians, Armenians ,, , 2, 2 non-Ashkenazi, non-Ashkenazi Jews, Jews ), ) and, and 8, 8 MEF, MEF patients, patients with, with amyloidosis, amyloidosis using, using a, a candidate, candidate gene, gene approach, approach ., . No, No evidence, evidence for, for any, any MEF-associated, MEF-associated polymorphism, polymorphism was, was found, found in, in any, any of, of the, the 41, 41 Armenian, Armenian and, and Jewish, Jewish MEF, MEF patients, patients tested, tested ., . Our, Our family, family studies, studies allowed, allowed us, us to, to rule, rule out, out tight, tight linkage, linkage between, between SAA, SAA and, and MEF, MEF (, ( lod, lod score, score =, = -2, -2 ., . 16, 16 ,, , theta, theta less, less than, than or, or equal, equal to, to 0, 0 ., . 06, 06 ), ) ., . For, For APCS, APCS we, we found, found that, that the, the allele, allele frequency, frequency in, in the, the MEF-amyloidosis, MEF-amyloidosis patients, patients was, was similar, similar to, to that, that in, in 18, 18 unrelated, unrelated MEF, MEF patients, patients without, without amyloidosis, amyloidosis and, and their, their 33, 33 healthy, healthy parents, parents ., . Screening, Screening for, for the, the G6PD, G6PD deficiency, deficiency was, was carried, carried out, out at, at the, the Maternity, Maternity Division, Division of, of the, the Galliera, Galliera Hospital, Hospital in, in Genoa, Genoa ,, , Italy, Italy ., . Two, Two groups, groups of, of subjects, subjects with, with hyperbilirubinaemia, hyperbilirubinaemia of, of non-immunological, non-immunological origin, origin were, were examined, examined (, ( a, a ), ) 302, 302 newborn, newborn babies, babies of, of Sardinian, Sardinian extraction, extraction (, ( on, on cord, cord blood, blood ), ) and, and (, ( b, b ), ) 201, 201 newborn, newborn babies, babies of, of south, south Italian, Italian ancestry, ancestry (, ( on, on peripheral, peripheral blood, blood ), ) ., . Among, Among 503, 503 subjects, subjects ,, , 43, 43 showed, showed an, an enzyme, enzyme deficiency, deficiency ;, ; in, in 39, 39 the, the defect, defect was, was of, of the, the Mediterranean, Mediterranean type, type ., . In, In one, one case, case ,, , previously, previously described, described ,, , the, the enzyme, enzyme was, was of, of the, the A-, A- type, type ., . In, In the, the remaining, remaining cases, cases three, three different, different variants, variants were, were identified, identified ., . In, In the, the present, present work, work these, these three, three cases, cases ,, , each, each with, with severe, severe neonatal, neonatal jaundice, jaundice ,, , are, are reported, reported ., . Their, Their parents, parents originated, originated from, from Calabria, Calabria ,, , from, from Sardinia, Sardinia and, and from, from Sicily, Sicily ., . The, The abnormal, abnormal enzymes, enzymes are, are respectively, respectively designated, designated as, as GdDcbrousse-like, GdDcbrousse-like ,, , GdGallura, GdGallura and, and GdAgrigento.., GdAgrigento.. Endocrine, Endocrine neoplasms, neoplasms have, have been, been reported, reported occasionally, occasionally in, in patients, patients with, with familial, familial adenomatous, adenomatous polyposis, polyposis (, ( FAP, FAP ), ) ., . An, An adrenocorotical, adrenocorotical carcinoma, carcinoma was, was studied, studied in, in a, a patient, patient with, with a, a family, family history, history of, of FAP, FAP ., . Loss, Loss of, of heterozygosity, heterozygosity (, ( LOH, LOH ), ) in, in the, the region, region close, close to, to the, the adenomatous, adenomatous polyposis, polyposis coli, coli (, ( APC, APC ), ) gene, gene was, was detected, detected in, in this, this carcinoma, carcinoma ,, , and, and evidence, evidence was, was obtained, obtained that, that there, there was, was a, a loss, loss of, of the, the normal, normal allele, allele of, of the, the APC, APC gene, gene ., . This, This is, is the, the first, first demonstration, demonstration of, of LOH, LOH at, at the, the APC, APC locus, locus in, in adrenocortical, adrenocortical tumors, tumors ., . The, The present, present results, results and, and our, our previous, previous data, data on, on LOH, LOH in, in a, a recurring, recurring desmoid, desmoid tumor, tumor suggest, suggest that, that the, the heterozygous, heterozygous mutant/wild-type, mutant/wild-type condition, condition of, of the, the APC, APC gene, gene may, may give, give rise, rise to, to benign, benign tumors, tumors ,, , and, and that, that functional, functional loss, loss of, of this, this gene, gene leads, leads to, to development, development of, of tumors, tumors not, not only, only in, in the, the colon, colon but, but also, also in, in other, other various, various parts, parts of, of the, the body, body in, in FAP, FAP patients.., patients.. Complement, Complement deficiency, deficiency states, states in, in myasthenia, myasthenia gravis, gravis (, ( MG, MG ), ) have, have not, not been, been reported, reported previously, previously ., . We, We describe, describe a, a 19-year-old, 19-year-old woman, woman with, with typical, typical MG, MG and, and heterozygous, heterozygous C2, C2 deficiency, deficiency ,, , along, along with, with HLA, HLA typing, typing of, of the, the patient, patient and, and her, her immediate, immediate family.., family.. The, The clinical, clinical use, use of, of molecular, molecular analyses, analyses in, in recessive, recessive disorders, disorders relies, relies on, on the, the exact, exact characterization, characterization of, of both, both mutant, mutant alleles, alleles in, in the, the affected, affected patient, patient ., . This, This can, can be, be problematic, problematic when, when only, only part, part of, of the, the gene, gene is, is examined, examined or, or when, when relevant, relevant DNA, DNA alterations, alterations are, are not, not recognized, recognized by, by standard, standard methods, methods ., . We, We present, present a, a child, child in, in whom, whom phenylketonuria, phenylketonuria was, was apparently, apparently caused, caused by, by homozygosity, homozygosity for, for the, the mutation, mutation E390G, E390G in, in exon, exon 11, 11 of, of the, the phenylalanine, phenylalanine hydroxylase, hydroxylase (, ( PAH, PAH ), ) gene, gene ., . However, However ,, , the, the clinical, clinical severity, severity of, of the, the disease, disease was, was not, not quite, quite as, as mild, mild as, as expected, expected ,, , the, the mutation, mutation was, was not, not identified, identified in, in the, the father, father despite, despite confirmed, confirmed paternity, paternity ,, , and, and the, the paternal, paternal allele, allele showed, showed a, a highly, highly unusual, unusual pattern, pattern of, of polymorphic, polymorphic markers, markers in, in the, the PAH, PAH gene, gene ., . Presence, Presence of, of a, a large, large deletion, deletion involving, involving exons, exons 9, 9 ,, , 10, 10 and, and 11, 11 of, of the, the phenylalanine, phenylalanine hydroxylase, hydroxylase gene, gene was, was confirmed, confirmed by, by long-range, long-range PCR, PCR ., . Diagnostic, Diagnostic DNA, DNA analyses, analyses should, should include, include a, a comprehensive, comprehensive examination, examination of, of the, the whole, whole relevant, relevant gene, gene in, in the, the patient, patient and, and confirmation, confirmation of, of carrier, carrier status, status in, in both, both parents.., parents.. The, The human, human X-linked, X-linked gene, gene encoding, encoding glucose, glucose 6-phosphate, 6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) is, is highly, highly polymorphic, polymorphic ;, ; more, more than, than 300, 300 G6PD, G6PD variants, variants have, have been, been identified, identified ., . G6PD, G6PD deficiency, deficiency in, in different, different geographical, geographical areas, areas appears, appears to, to have, have arisen, arisen through, through independent, independent mutational, mutational events, events ,, , but, but within, within the, the same, same population, population it, it may, may also, also be, be heterogeneous, heterogeneous ., . One, One example, example is, is the, the island, island of, of Sardinia, Sardinia ,, , where, where careful, careful clinical, clinical and, and biochemical, biochemical studies, studies have, have identified, identified four, four different, different G6PD, G6PD variants, variants ., . We, We cloned, cloned and, and sequenced, sequenced the, the four, four G6PD, G6PD variants, variants from, from Sardinia, Sardinia and, and found, found that, that only, only two, two mutations, mutations are, are responsible, responsible for, for G6PD, G6PD deficiency, deficiency in, in this, this area, area one, one mutation, mutation is, is the, the cause, cause of, of the, the G6PD, G6PD Seattle-like, Seattle-like phenotype, phenotype ,, , a, a milder, milder form, form of, of G6PD, G6PD deficiency, deficiency ;, ; the, the other, other mutation, mutation is, is responsible, responsible for, for all, all forms, forms of, of very, very severe, severe G6PD, G6PD deficiency, deficiency in, in Sardinia, Sardinia and, and ,, , possibly, possibly ,, , in, in the, the Mediterranean.., Mediterranean.. Two, Two siblings, siblings with, with chronic, chronic discoid, discoid lupus, lupus erythematosus, erythematosus and, and several, several family, family members, members were, were found, found with, with heterozygous, heterozygous C2, C2 deficiency, deficiency ., . An, An association, association with, with histocompatibility, histocompatibility markers, markers HLA-B18, HLA-B18 and, and HLA-Dw2, HLA-Dw2 was, was demonstrated, demonstrated ,, , and, and the, the slow, slow allotype, allotype of, of factor, factor B, B was, was present, present ., . Linkage, Linkage studies, studies in, in this, this family, family suggested, suggested a, a close, close linkage, linkage between, between the, the C2, C2 deficiency, deficiency gene, gene and, and genes, genes coding, coding for, for B18, B18 ,, , Dw2, Dw2 ,, , and, and BfS, BfS antigens, antigens ., . One, One HLA-ACB/DBf, HLA-ACB/DBf recombinant, recombinant was, was observed, observed showing, showing closer, closer linkage, linkage between, between HLA-D, HLA-D and, and Bf, Bf than, than between, between HLA-B, HLA-B and, and Bf.., Bf.. A, A strong, strong candidate, candidate for, for the, the 17q-linked, 17q-linked BRCA1, BRCA1 gene, gene ,, , which, which influences, influences susceptibility, susceptibility to, to breast, breast and, and ovarian, ovarian cancer, cancer ,, , has, has been, been identified, identified by, by positional, positional cloning, cloning methods, methods ., . Probable, Probable predisposing, predisposing mutations, mutations have, have been, been detected, detected in, in five, five of, of eight, eight kindreds, kindreds presumed, presumed to, to segregate, segregate BRCA1, BRCA1 susceptibility, susceptibility alleles, alleles ., . The, The mutations, mutations include, include an, an 11-base, 11-base pair, pair deletion, deletion ,, , a, a 1-base, 1-base pair, pair insertion, insertion ,, , a, a stop, stop codon, codon ,, , a, a missense, missense substitution, substitution ,, , and, and an, an inferred, inferred regulatory, regulatory mutation, mutation ., . The, The BRCA1, BRCA1 gene, gene is, is expressed, expressed in, in numerous, numerous tissues, tissues ,, , including, including breast, breast and, and ovary, ovary ,, , and, and encodes, encodes a, a predicted, predicted protein, protein of, of 1863, 1863 amino, amino acids, acids ., . This, This protein, protein contains, contains a, a zinc, zinc finger, finger domain, domain in, in its, its amino-terminal, amino-terminal region, region ,, , but, but is, is otherwise, otherwise unrelated, unrelated to, to previously, previously described, described proteins, proteins ., . Identification, Identification of, of BRCA1, BRCA1 should, should facilitate, facilitate early, early diagnosis, diagnosis of, of breast, breast and, and ovarian, ovarian cancer, cancer susceptibility, susceptibility in, in some, some individuals, individuals as, as well, well as, as a, a better, better understanding, understanding of, of breast, breast cancer, cancer biology.., biology.. The, The locus, locus for, for Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) ,, , a, a severe, severe neurodegenerative, neurodegenerative disease, disease ,, , is, is tightly, tightly linked, linked to, to markers, markers D9S5, D9S5 and, and D9S15, D9S15 ,, , and, and analysis, analysis of, of rare, rare recombination, recombination events, events has, has suggested, suggested the, the order, order cen-FRDA-D9S5-D9S15-qter, cen-FRDA-D9S5-D9S15-qter ., . We, We report, report here, here the, the construction, construction of, of a, a YAC, YAC contig, contig extending, extending 800, 800 kb, kb centromeric, centromeric to, to D9S5, D9S5 and, and the, the isolation, isolation of, of five, five new, new microsatellite, microsatellite markers, markers from, from this, this region, region ., . In, In order, order to, to map, map these, these markers, markers with, with respect, respect to, to the, the FRDA, FRDA locus, locus ,, , all, all within, within a, a 1-cM, 1-cM confidence, confidence interval, interval ,, , we, we sought, sought to, to increase, increase the, the genetic, genetic information, information of, of available, available FRDA, FRDA families, families by, by considering, considering homozygosity, homozygosity by, by descent, descent and, and association, association with, with founder, founder haplotypes, haplotypes in, in isolated, isolated populations, populations ., . This, This approach, approach allowed, allowed us, us to, to identify, identify one, one phase-known, phase-known recombination, recombination and, and one, one probable, probable historic, historic recombination, recombination on, on haplotypes, haplotypes from, from Reunion, Reunion Island, Island patients, patients ,, , both, both of, of which, which place, place three, three of, of the, the five, five markers, markers proximal, proximal to, to FRDA, FRDA ., . This, This represents, represents the, the first, first identification, identification of, of close, close FRDA, FRDA flanking, flanking markers, markers on, on the, the centromeric, centromeric side, side ., . The, The two, two other, other markers, markers allowed, allowed us, us to, to narrow, narrow the, the breakpoint, breakpoint of, of a, a previously, previously identified, identified distal, distal recombination, recombination that, that is, is >, > 180, 180 kb, kb from, from D9S5, D9S5 (, ( 26P, 26P ), ) ., . Taken, Taken together, together ,, , the, the results, results place, place the, the FRDA, FRDA locus, locus in, in a, a 450-kb, 450-kb interval, interval ,, , which, which is, is small, small enough, enough for, for direct, direct search, search of, of candidate, candidate genes, genes ., . A, A detailed, detailed rare, rare cutter, cutter restriction, restriction map, map and, and a, a cosmid, cosmid contig, contig covering, covering this, this interval, interval were, were constructed, constructed and, and should, should facilitate, facilitate the, the search, search of, of genes, genes in, in this, this region.., region.. We, We recently, recently mapped, mapped the, the gene, gene for, for ataxia-telangiectasia, ataxia-telangiectasia group, group A, A (, ( ATA, ATA ), ) to, to chromosome, chromosome 11q22-23, 11q22-23 by, by linkage, linkage analysis, analysis ,, , using, using the, the genetic, genetic markers, markers THY1, THY1 and, and pYNB3, pYNB3 ., . 12, 12 (, ( D11S144, D11S144 ), ) ., . The, The most, most likely, likely order, order was, was cent-AT-S144-THY1, cent-AT-S144-THY1 ., . The, The present, present paper, paper describes, describes further, further mapping, mapping of, of the, the AT, AT locus, locus by, by means, means of, of a, a panel, panel of, of 10, 10 markers, markers that, that span, span approximately, approximately 60, 60 cM, cM in, in the, the 11q22-23, 11q22-23 region, region centered, centered around, around S144, S144 and, and THY1, THY1 ., . Location, Location scores, scores indicate, indicate that, that three, three contiguous, contiguous subsegments, subsegments within, within the, the [, [ S144-THY1, S144-THY1 ], ] segment, segment ,, , as, as well, well as, as three, three contiguous, contiguous segments, segments telomeric, telomeric to, to THY1, THY1 ,, , are, are each, each unlikely, unlikely to, to contain, contain the, the AT, AT locus, locus ,, , while, while the, the more, more centromeric, centromeric [, [ STMY-S144, STMY-S144 ], ] segment, segment is, is most, most likely, likely to, to contain, contain the, the AT, AT locus, locus ., . These, These data, data ,, , together, together with, with recent, recent refinements, refinements in, in the, the linkage, linkage and, and physical, physical maps, maps of, of 11q22-23, 11q22-23 ,, , place, place the, the AT, AT locus, locus at, at 11q23, 11q23 ., . High, High level, level expression, expression of, of the, the nm23-H1, nm23-H1 gene, gene ,, , which, which encodes, encodes for, for a, a nucleoside, nucleoside diphosphate, diphosphate kinase, kinase ,, , has, has been, been found, found to, to correlate, correlate with, with diminished, diminished metastasis, metastasis in, in some, some tumors, tumors but, but not, not in, in others, others ., . We, We have, have previously, previously identified, identified the, the protein, protein product, product of, of the, the nm23-H1, nm23-H1 gene, gene in, in two-dimensional, two-dimensional electrophoretic, electrophoretic gels, gels and, and have, have designated, designated it, it p19/nm23, p19/nm23 ., . In, In neuroblastoma, neuroblastoma ,, , higher, higher levels, levels of, of p19/nm23, p19/nm23 ,, , which, which are, are associated, associated with, with amplification, amplification of, of the, the N-myc, N-myc oncogene, oncogene ,, , large, large tumor, tumor mass, mass ,, , and, and metastasis, metastasis ,, , were, were observed, observed in, in advanced, advanced stage, stage tumors, tumors compared, compared with, with limited, limited stage, stage disease, disease ., . Because, Because of, of the, the variable, variable expression, expression of, of nm23-H1, nm23-H1 in, in different, different tumors, tumors ,, , we, we have, have investigated, investigated the, the relationship, relationship between, between amounts, amounts of, of the, the protein, protein and, and cell, cell proliferation, proliferation ., . The, The levels, levels of, of p19/nm23, p19/nm23 were, were compared, compared between, between resting, resting and, and mitotically, mitotically stimulated, stimulated normal, normal human, human PBLs, PBLs and, and in, in leukemia, leukemia cells, cells ., . The, The amount, amount of, of p19/nm23, p19/nm23 increased, increased in, in normal, normal lymphocytes, lymphocytes in, in response, response to, to mitotic, mitotic stimulation, stimulation and, and paralleled, paralleled the, the increase, increase in, in DNA, DNA synthesis, synthesis ., . In, In leukemia, leukemia cells, cells obtained, obtained from, from patients, patients with, with different, different subtypes, subtypes of, of acute, acute leukemia, leukemia ,, , p19/nm23, p19/nm23 levels, levels were, were also, also increased, increased relative, relative to, to resting, resting normal, normal lymphocytes, lymphocytes ., . Treatment, Treatment of, of mitotically, mitotically stimulated, stimulated lymphocytes, lymphocytes with, with cyclosporin, cyclosporin ,, , which, which inhibits, inhibits proliferation, proliferation ,, , blocked, blocked the, the increase, increase in, in p19/nm23, p19/nm23 ;, ; treatment, treatment of, of the, the leukemia, leukemia cell, cell line, line HL-60, HL-60 with, with dimethylsulfoxide, dimethylsulfoxide ,, , which, which induces, induces terminal, terminal differentiation, differentiation ,, , resulted, resulted in, in diminished, diminished levels, levels of, of p19/nm23, p19/nm23 ., . Our, Our data, data therefore, therefore provide, provide evidence, evidence that, that nm23-H1, nm23-H1 expression, expression is, is related, related to, to cell, cell proliferative, proliferative activity.., activity.. Pyruvate, Pyruvate carboxylase, carboxylase (, ( E., E. C., C. 6, 6 ., . 4, 4 ., . 1, 1 ., . 1, 1 ), ) activity, activity was, was determined, determined in, in the, the circulating, circulating peripheral, peripheral lymphocytes, lymphocytes and, and cultured, cultured skin, skin fibroblasts, fibroblasts from, from the, the family, family of, of a, a patient, patient with, with hepatic, hepatic ,, , cerebral, cerebral ,, , renal, renal cortical, cortical ,, , leukocyte, leukocyte ,, , and, and fibroblast, fibroblast pyruvate, pyruvate carboxylase, carboxylase deficiency, deficiency (, ( PC, PC Portland, Portland deficiency, deficiency ), ) ., . Lymphocyte, Lymphocyte activities, activities were, were mother, mother ,, , 33, 33 --, -- 39, 39 %, % ;, ; father, father ,, , 11, 11 --, -- 29, 29 %, % ;, ; brother, brother ,, , 82, 82 --, -- 103, 103 %, % ;, ; and, and sister, sister ,, , 38, 38 --, -- 48, 48 %, % of, of the, the lowest, lowest normal, normal ., . Fibroblasts, Fibroblasts from, from the, the patients, patients mother, mother and, and father, father had, had 42, 42 and, and 34, 34 %, % ,, , respectively, respectively ,, , of, of the, the activity, activity of, of the, the lowest, lowest normal, normal ., . These, These data, data demonstrate, demonstrate that, that the, the disease, disease is, is inherited, inherited in, in an, an autosomal, autosomal recessive, recessive manner, manner and, and that, that lymphocytes, lymphocytes and, and fibroblasts, fibroblasts can, can be, be used, used to, to detect, detect carriers, carriers ., . Neither, Neither pyruvate, pyruvate carboxylase, carboxylase nor, nor mitochondrial, mitochondrial PEPCK, PEPCK activity, activity in, in lymphocytes, lymphocytes was, was increased, increased by, by a, a 21-hr, 21-hr fast, fast ., . Five, Five male, male Japanese, Japanese patients, patients with, with complex, complex glycerol, glycerol kinase, kinase deficiency, deficiency (, ( CGKD, CGKD ), ) and, and their, their relatives, relatives were, were studied, studied clinically, clinically ,, , cytogenetically, cytogenetically ,, , and, and molecular-genetically, molecular-genetically ., . All, All patients, patients had, had muscular, muscular dystrophy, dystrophy or, or muscle, muscle weakness, weakness ,, , mental, mental retardation, retardation ,, , congenital, congenital adrenal, adrenal hypoplasia, hypoplasia ,, , and, and glycerol, glycerol kinase, kinase deficiency, deficiency ., . High-resolution, High-resolution GTG-banded, GTG-banded chromosomes, chromosomes showed, showed a, a microdeletion, microdeletion in, in the, the Xp21, Xp21 region, region in, in all, all four, four patients, patients examined, examined and, and in, in all, all five, five mothers, mothers ., . Southern, Southern hybridizations, hybridizations ,, , after, after digestions, digestions by, by restriction, restriction endonucleases, endonucleases ,, , with, with various, various cloned, cloned DNAs, DNAs (, ( D2, D2 ,, , 99-6, 99-6 ,, , B24, B24 ,, , C7, C7 ,, , L1-4, L1-4 ,, , cDMD13-14, cDMD13-14 ,, , J66-HI, J66-HI ,, , P20, P20 ,, , J-Bir, J-Bir ,, , ERT87-30, ERT87-30 ,, , ERT87-15, ERT87-15 ,, , ERT87-8, ERT87-8 ,, , ERT87-1, ERT87-1 ,, , XJ-1, XJ-1 ., . 1, 1 ,, , 754, 754 ,, , cx5, cx5 ., . 7, 7 ,, , and, and OTC-1, OTC-1 ), ) that, that are, are located, located around, around Xp21, Xp21 also, also showed, showed a, a deletion, deletion in, in the, the genome, genome of, of all, all patients, patients and, and mothers, mothers ., . Although, Although the, the deletion, deletion differed, differed in, in size, size among, among patients, patients ,, , a, a segment, segment commonly, commonly absent, absent was, was located, located between, between the, the genomic, genomic sequences, sequences corresponding, corresponding to, to L1-4, L1-4 and, and cDMD13-14, cDMD13-14 ., . This, This finding, finding indicated, indicated that, that the, the gene, gene coding, coding for, for glycerol, glycerol kinase, kinase (, ( GK, GK ), ) is, is located, located within, within this, this segment, segment ., . A, A comparison, comparison of, of the, the clinical, clinical manifestations, manifestations of, of the, the present, present five, five patients, patients and, and reported, reported CGKD, CGKD or, or Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) patients, patients with, with DNA, DNA deletion, deletion suggests, suggests the, the existence, existence of, of a, a certain, certain gene, gene responsible, responsible for, for gonadotropin, gonadotropin deficiency, deficiency (, ( GTD, GTD )"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", ) ., . The, The result, result of, of the, the present, present study, study and, and results, results of, of previous, previous studies, studies suggest, suggest that, that genes, genes for, for ornithine, ornithine transcarbamylase, transcarbamylase (, ( OTC, OTC ), ) ,, , DMD, DMD ,, , and, and GK, GK and, and putative, putative genes, genes responsible, responsible for, for congenital, congenital adrenal, adrenal hypoplasia, hypoplasia (, ( AHC, AHC ), ) and, and GTD, GTD are, are arranged, arranged from, from telomere, telomere to, to centromere, centromere as, as pter, pter --, -- GTD, GTD --, -- AHC, AHC --, -- GK, GK --, -- DMD, DMD --, -- OTC, OTC --, -- cen, cen We, We report, report on, on the, the first, first patient, patient identified, identified with, with myotonic, myotonic dystrophy, dystrophy and, and Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) ., . The, The family, family of, of the, the propositus, propositus had, had a, a strong, strong history, history of, of myotonic, myotonic dystrophy, dystrophy ,, , and, and there, there was, was an, an intrafamilial, intrafamilial pathological, pathological expansion, expansion of, of the, the responsible, responsible CTG, CTG repeat, repeat between, between the, the mildly, mildly affected, affected mother, mother (, ( 160, 160 repeats, repeats ;, ; normal, normal 27, 27 repeats, repeats ), ) and, and her, her more, more severely, severely affected, affected son, son (, ( 650, 650 repeats, repeats ), ) ,, , and, and his, his sister, sister (, ( 650, 650 repeats, repeats ), ) ., . The, The propositus, propositus was, was an, an isolated, isolated case, case of, of Duchenne, Duchenne muscular, muscular dystrophy, dystrophy with, with marked, marked dystrophin, dystrophin deficiency, deficiency in, in muscle, muscle biopsy, biopsy ., . The, The patient, patient was, was still, still ambulatory, ambulatory post, post age, age 16, 16 ., . Myotonic, Myotonic dystrophy, dystrophy could, could interfere, interfere to, to some, some extent, extent with, with the, the progression, progression of, of Duchenne, Duchenne dystrophy, dystrophy ., . However, However ,, , other, other interpretations, interpretations are, are possible, possible ., . Twelve, Twelve percent, percent of, of dystrophin, dystrophin revertant, revertant fibers, fibers as, as observed, observed by, by immunohistochemistry, immunohistochemistry could, could be, be sufficient, sufficient to, to ameliorate, ameliorate typical, typical DMD, DMD clinical, clinical severity, severity ,, , or, or the, the patient, patient may, may present, present a, a somatic, somatic mosaic, mosaic ., . The, The pathophysiological, pathophysiological interactions, interactions of, of these, these two, two unlinked, unlinked disorders, disorders are, are discussed, discussed at, at the, the clinical, clinical and, and histopathological, histopathological levels.., levels.. The, The differential, differential diagnosis, diagnosis of, of the, the genetic, genetic bleeding, bleeding disorders, disorders ,, , hemophilia, hemophilia A, A and, and von, von Willebrand, Willebrand disease, disease ,, , is, is occasionally, occasionally confounded, confounded by, by the, the close, close molecular, molecular relationship, relationship of, of coagulation, coagulation factor, factor VIII, VIII and, and von, von Willebrand, Willebrand factor, factor (, ( vWF, vWF ), ) ., . This, This report, report describes, describes the, the autosomal, autosomal inheritance, inheritance of, of a, a hemophilia, hemophilia A, A phenotype, phenotype due, due to, to a, a mutation, mutation of, of vWF, vWF that, that results, results in, in defective, defective factor, factor VIII, VIII binding, binding ., . The, The proband, proband was, was a, a female, female patient, patient with, with low, low levels, levels of, of factor, factor VIII, VIII activity, activity ., . Polymerase, Polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) amplification, amplification and, and DNA, DNA sequencing, sequencing were, were employed, employed to, to examine, examine exons, exons encoding, encoding the, the putative, putative factor, factor VIII, VIII binding, binding domain, domain of, of vWF, vWF ., . The, The patient, patient was, was found, found to, to be, be homozygous, homozygous for, for a, a single, single point, point mutation, mutation causing, causing a, a Thr, Thr --, -- >, > Met, Met substitution, substitution at, at amino, amino acid, acid position, position 28, 28 in, in the, the mature, mature vWF, vWF subunit, subunit ., . The, The phenotypic, phenotypic expression, expression of, of the, the mutation, mutation was, was determined, determined to, to be, be recessive, recessive because, because heterozygous, heterozygous family, family members, members were, were clinically, clinically unaffected, unaffected ., . Recombinant, Recombinant vWF, vWF containing, containing the, the observed, observed amino, amino acid, acid substitution, substitution was, was expressed, expressed in, in COS-1, COS-1 cells, cells ., . The, The mutant, mutant vWF, vWF was, was processed, processed and, and secreted, secreted normally, normally ,, , and, and was, was functionally, functionally equivalent, equivalent to, to wild-type, wild-type vWF, vWF in, in its, its ability, ability to, to bind, bind to, to platelets, platelets ., . However, However ,, , the, the mutant, mutant failed, failed to, to bind, bind factor, factor VIII, VIII ,, , demonstrating, demonstrating that, that the, the mutation, mutation was, was functionally, functionally related, related to, to the, the observed, observed hemophilia, hemophilia phenotype, phenotype ., . The, The family, family we, we describe, describe demonstrates, demonstrates the, the recessive, recessive inheritance, inheritance of, of a, a recently, recently recognized, recognized class, class of, of genetic, genetic bleeding, bleeding disorders, disorders ,, , we, we call, call ``, `` autosomal, autosomal hemophilia., hemophilia. ``, `` We, We conclude, conclude that, that vWF, vWF mutation, mutation may, may be, be an, an under, under recognized, recognized cause, cause of, of hemophilia, hemophilia ,, , especially, especially in, in cases, cases where, where the, the inheritance, inheritance pattern, pattern is, is not, not consistent, consistent with, with X-linked, X-linked transmission, transmission ., . X-linked, X-linked Adrenoleukodystrophy, Adrenoleukodystrophy (, ( X-ALD, X-ALD ), ) is, is the, the most, most frequent, frequent peroxisomal, peroxisomal disease, disease ., . It, It mainly, mainly involves, involves the, the nervous, nervous system, system white, white matter, matter ,, , adrenal, adrenal cortex, cortex and, and testes, testes ., . Several, Several distinct, distinct clinical, clinical phenotypes, phenotypes are, are known, known ., . The, The principal, principal biochemical, biochemical abnormality, abnormality is, is the, the accumulation, accumulation of, of saturated, saturated very-long-chain, very-long-chain fatty, fatty acids, acids (, ( VLCFAs, VLCFAs >, > C22, C22 0, 0 ,, , mainly, mainly C26, C26 0, 0 ), ) ,, , which, which is, is due, due to, to impaired, impaired capacity, capacity for, for beta-oxidation, beta-oxidation in, in peroxisomes, peroxisomes ., . Diagnosis, Diagnosis is, is usually, usually based, based on, on the, the VLCFA, VLCFA levels, levels in, in plasma, plasma or, or cultured, cultured skin, skin fibroblasts, fibroblasts in, in both, both patients, patients and, and carriers, carriers ., . In, In 0, 0 ., . 1, 1 %, % of, of affected, affected males, males ,, , however, however ,, , the, the plasma, plasma C26, C26 0, 0 level, level is, is borderline, borderline normal, normal ,, , and, and 15, 15 %, % of, of obligate, obligate female, female carriers, carriers have, have normal, normal results, results ., . Effective, Effective mutation, mutation detection, detection in, in these, these families, families is, is therefore, therefore fundamental, fundamental to, to unambiguously, unambiguously determine, determine the, the genetic, genetic status, status of, of each, each individual, individual at, at risk, risk ., . Of, Of particular, particular concern, concern are, are female, female members, members of, of kindreds, kindreds segregating, segregating X-ALD, X-ALD mutations, mutations ,, , because, because normal, normal VLCFA, VLCFA levels, levels do, do not, not guarantee, guarantee lack, lack of, of carrier, carrier status, status ., . We, We describe, describe a, a fast, fast method, method for, for detection, detection of, of X-ALD, X-ALD mutations, mutations ., . The, The method, method is, is based, based on, on SSCP, SSCP analysis, analysis of, of nested, nested PCR, PCR fragments, fragments followed, followed by, by sequence-determination, sequence-determination reactions, reactions ., . Using, Using this, this methodology, methodology we, we have, have found, found X-ALD, X-ALD mutations, mutations in, in 30, 30 kindreds, kindreds ,, , including, including 15, 15 not, not previously, previously reported, reported ., . We, We analysed, analysed 50, 50 probands, probands with, with a, a family, family history, history of, of breast, breast and/or, and/or ovarian, ovarian cancer, cancer for, for germline, germline mutations, mutations in, in the, the coding, coding region, region of, of the, the BRCA1, BRCA1 candidate, candidate gene, gene ,, , using, using single-strand, single-strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) analysis, analysis on, on PCR-amplified, PCR-amplified genomic, genomic DNA, DNA ., . A, A total, total of, of eight, eight putative, putative disease-causing, disease-causing alterations, alterations were, were identified, identified four, four of, of these, these are, are frameshifts, frameshifts and, and two, two are, are nonsense, nonsense mutations, mutations ., . In, In addition, addition ,, , we, we found, found two, two missense, missense mutations, mutations ,, , one, one of, of which, which changes, changes the, the final, final cysteine, cysteine of, of the, the BRCA1, BRCA1 zinc, zinc finger, finger motif, motif to, to glycine, glycine ., . These, These data, data are, are consistent, consistent with, with a, a tumour, tumour suppressor, suppressor model, model ,, , and, and support, support the, the notion, notion that, that this, this candidate, candidate gene, gene is, is in, in fact, fact BRCA1, BRCA1 ., . The, The heterogeneity, heterogeneity of, of mutations, mutations ,, , coupled, coupled with, with the, the large, large size, size of, of the, the gene, gene ,, , indicates, indicates that, that clinical, clinical application, application of, of BRCA1, BRCA1 mutation, mutation testing, testing will, will be, be technically, technically challenging.., challenging.. BACKGROUND, BACKGROUND AND, AND METHODS, METHODS ., . The, The prevention, prevention of, of Tay-Sachs, Tay-Sachs disease, disease (, ( GM2, GM2 gangliosidosis, gangliosidosis ,, , type, type 1, 1 ), ) depends, depends on, on the, the identification, identification of, of carriers, carriers of, of the, the gene, gene for, for this, this autosomal, autosomal recessive, recessive disorder, disorder ., . We, We compared, compared the, the enzyme-based, enzyme-based test, test widely, widely used, used in, in screening, screening for, for Tay-Sachs, Tay-Sachs disease, disease with, with a, a test, test based, based on, on analysis, analysis of, of DNA, DNA ., . We, We developed, developed methods, methods to, to detect, detect the, the three, three mutations, mutations in, in the, the HEXA, HEXA gene, gene that, that occur, occur with, with high, high frequency, frequency among, among Ashkenazi, Ashkenazi Jews, Jews two, two mutations, mutations cause, cause infantile, infantile Tay-Sachs, Tay-Sachs disease, disease ,, , and, and the, the third, third causes, causes the, the adult-onset, adult-onset form, form of, of the, the disease, disease ., . DNA, DNA segments, segments containing, containing these, these mutation, mutation sites, sites were, were amplified, amplified with, with the, the polymerase, polymerase chain, chain reaction, reaction and, and analyzed, analyzed for, for the, the presence, presence of, of the, the mutations, mutations ., . RESULTS, RESULTS ., . Among, Among 62, 62 Ashkenazi, Ashkenazi obligate, obligate carriers, carriers of, of Tay-Sachs, Tay-Sachs disease, disease ,, , the, the three, three specific, specific mutations, mutations accounted, accounted for, for all, all but, but one, one of, of the, the mutant, mutant alleles, alleles (, ( 98, 98 percent, percent ), ) ., . In, In 216, 216 Ashkenazi, Ashkenazi carriers, carriers identified, identified by, by the, the enzyme, enzyme test, test ,, , DNA, DNA analysis, analysis showed, showed that, that 177, 177 (, ( 82, 82 percent, percent ), ) had, had one, one of, of the, the identified, identified mutations, mutations ., . Of, Of the, the 177, 177 ,, , 79, 79 percent, percent had, had the, the exon, exon 11, 11 insertion, insertion mutation, mutation ,, , 18, 18 percent, percent had, had the, the intron, intron 12, 12 splice-junction, splice-junction mutation, mutation ,, , and, and 3, 3 percent, percent had, had the, the less, less severe, severe exon, exon 7, 7 mutation, mutation associated, associated with, with adult-onset, adult-onset disease, disease ., . The, The results, results of, of the, the enzyme, enzyme tests, tests in, in the, the 39, 39 subjects, subjects (, ( 18, 18 percent, percent ), ) who, who were, were defined, defined as, as carriers, carriers but, but in, in whom, whom DNA, DNA analysis, analysis did, did not, not identify, identify a, a mutant, mutant allele, allele were, were probably, probably false, false positive, positive (, ( although, although there, there remains, remains some, some possibility, possibility of, of unidentified, unidentified mutations, mutations ), ) ., . In, In addition, addition ,, , of, of 152, 152 persons, persons defined, defined as, as noncarriers, noncarriers by, by the, the enzyme-based, enzyme-based test, test ,, , 1, 1 was, was identified, identified as, as a, a carrier, carrier by, by DNA, DNA analysis, analysis (, ( i., i. e, e e., e. ,, , a, a false, false negative, negative enzyme-test, enzyme-test result, result ), ) ., . CONCLUSIONS, CONCLUSIONS ., . The, The increased, increased specificity, specificity and, and predictive, predictive value, value of, of the, the DNA-based, DNA-based test, test make, make it, it a, a useful, useful adjunct, adjunct to, to the, the diagnostic, diagnostic tests, tests currently, currently used, used to, to screen, screen for, for carriers, carriers of, of Tay-Sachs, Tay-Sachs disease, disease ., . An, An antibody, antibody against, against the, the synthetic, synthetic C-terminal, C-terminal peptides, peptides deduced, deduced from, from the, the cDNA, cDNA of, of the, the gene, gene responsible, responsible for, for X-linked, X-linked adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) was, was produced, produced to, to characterize, characterize the, the product, product of, of the, the ALD, ALD gene, gene ., . The, The antibody, antibody reacted, reacted with, with the, the 80, 80 kDa, kDa band, band protein, protein in, in control, control fibroblasts, fibroblasts ,, , while, while no, no bands, bands were, were detected, detected in, in the, the fibroblasts, fibroblasts from, from a, a patient, patient with, with ALD, ALD (, ( #, # 163, 163 ), ) ,, , in, in which, which mRNA, mRNA of, of the, the ALD, ALD gene, gene was, was undetectable, undetectable based, based on, on Northern, Northern blot, blot analysis, analysis ., . The, The 293T, 293T cells, cells transfected, transfected with, with the, the full-coding, full-coding cDNA, cDNA inserted, inserted in, in the, the expression, expression vector, vector produced, produced a, a new, new 80, 80 kDa, kDa protein, protein ,, , as, as detected, detected by, by Western, Western blot, blot ., . In, In an, an immunocytological, immunocytological study, study ,, , the, the staining, staining was, was in, in a, a punctate, punctate pattern, pattern ,, , in, in the, the normal, normal fibroblasts, fibroblasts ., . However, However ,, , there, there was, was no, no punctate, punctate staining, staining in, in the, the #, # 163, 163 cells, cells ., . These, These data, data thus, thus indicate, indicate that, that the, the ALD, ALD gene, gene encodes, encodes an, an 80, 80 kDa, kDa membrane, membrane protein.., protein.. The, The event, event triggering, triggering malignant, malignant proliferation, proliferation in, in 70, 70 %, % of, of retinoblastoma, retinoblastoma tumours, tumours is, is loss, loss of, of heterozygosity, heterozygosity for, for chromosome, chromosome 13q14, 13q14 ,, , whereby, whereby the, the normal, normal retinoblastoma, retinoblastoma gene, gene (, ( RB1, RB1 ), ) allele, allele is, is lost, lost and, and an, an already, already mutated, mutated RB1, RB1 allele, allele remains, remains in, in the, the tumour, tumour ., . The, The first, first allele, allele suffers, suffers a, a mutational, mutational event, event --, -- deletion, deletion ,, , duplication, duplication or, or point, point mutation, mutation (, ( manuscript, manuscript in, in preparation, preparation ), ) --, -- either, either in, in the, the germ, germ line, line (, ( all, all bilateral, bilateral patients, patients ), ) or, or in, in a, a somatic, somatic retinal, retinal cell, cell (, ( most, most unilateral, unilateral patients, patients ), ) ., . Most, Most bilateral, bilateral patients, patients have, have no, no family, family history, history of, of retinoblastoma, retinoblastoma and, and are, are presumed, presumed to, to have, have new, new germline, germline mutations, mutations which, which arose, arose in, in the, the egg, egg ,, , sperm, sperm or, or early, early embryo, embryo ., . We, We have, have determined, determined the, the parental, parental origin, origin of, of the, the retained, retained allele, allele in, in nine, nine retinoblastoma, retinoblastoma tumours, tumours from, from eight, eight unrelated, unrelated non-familial, non-familial cases, cases by, by using, using RB1-linked, RB1-linked genetic, genetic markers, markers ., . Six, Six tumours, tumours retained, retained the, the paternal, paternal allele, allele and, and three, three retained, retained the, the maternal, maternal allele, allele ., . Of, Of the, the three, three unilateral, unilateral tumours, tumours ,, , only, only one, one retained, retained the, the paternal, paternal RB1, RB1 allele, allele ., . Thus, Thus ,, , there, there is, is no, no evidence, evidence that, that the, the paternal, paternal RB1, RB1 allele, allele is, is preferentially, preferentially retained, retained in, in retinoblastoma, retinoblastoma ,, , as, as has, has been, been suggested, suggested to, to be, be the, the case, case in, in osteosarcoma, osteosarcoma ., . By, By contrast, contrast ,, , tumours, tumours from, from four, four of, of the, the five, five bilateral, bilateral patients, patients retained, retained the, the paternal, paternal RB1, RB1 allele, allele ., . This, This suggests, suggests either, either that, that new, new germline, germline RB1, RB1 mutations, mutations arise, arise more, more frequently, frequently during, during spermatogenesis, spermatogenesis than, than during, during oogenesis, oogenesis ,, , or, or that, that imprinting, imprinting in, in the, the early, early embryo, embryo affects, affects chromosomal, chromosomal susceptibility, susceptibility to, to mutation.., mutation.. Mutations, Mutations at, at the, the ataxia-telangiectasia, ataxia-telangiectasia (, ( A-T, A-T ), ) locus, locus on, on chromosome, chromosome band, band 11q22, 11q22 cause, cause a, a distinctive, distinctive autosomal, autosomal recessive, recessive syndrome, syndrome in, in homozygotes, homozygotes and, and predispose, predispose heterozygotes, heterozygotes to, to cancer, cancer ,, , ischemic, ischemic heart, heart disease, disease ,, , and, and early, early mortality, mortality ., . PCR, PCR amplification, amplification from, from genomic, genomic DNA, DNA and, and automated, automated sequencing, sequencing of, of the, the entire, entire coding, coding region, region (, ( 66, 66 exons, exons ), ) and, and splice, splice junctions, junctions detected, detected 77, 77 mutations, mutations (, ( 85, 85 %, % ), ) in, in 90, 90 A-T, A-T chromosomes, chromosomes ., . Heteroduplex, Heteroduplex analysis, analysis detected, detected another, another 42, 42 mutations, mutations at, at the, the A-T, A-T locus, locus ., . Out, Out of, of a, a total, total of, of 71, 71 unique, unique mutations, mutations ,, , 50, 50 were, were found, found only, only in, in a, a single, single family, family ,, , and, and 51, 51 had, had not, not been, been reported, reported previously, previously ., . Most, Most (, ( 58/71, 58/71 ,, , 82, 82 %, % ), ) mutations, mutations were, were frameshift, frameshift and, and nonsense, nonsense mutations, mutations that, that are, are predicted, predicted to, to cause, cause truncation, truncation of, of the, the A-T, A-T protein, protein ;, ; the, the less, less common, common mutation, mutation types, types were, were missense, missense (, ( 9/71, 9/71 ,, , 13, 13 %, % ), ) ,, , splicing, splicing (, ( 3/71, 3/71 ,, , 4, 4 %, % ), ) and, and one, one in-frame, in-frame deletion, deletion ,, , 2546, 2546 3, 3 (, ( 1/71, 1/71 ,, , 1, 1 %, % ), ) ., . The, The mean, mean survival, survival and, and height, height distribution, distribution of, of 134, 134 A-T, A-T patients, patients correlated, correlated significantly, significantly with, with the, the specific, specific mutations, mutations present, present in, in the, the patients, patients ., . Patients, Patients homozygous, homozygous for, for a, a single, single truncating, truncating mutation, mutation ,, , typically, typically near, near the, the N-terminal, N-terminal end, end of, of the, the gene, gene ,, , or, or heterozygous, heterozygous for, for the, the in-frame, in-frame deletion, deletion 2546, 2546 3, 3 ,, , were, were shorter, shorter and, and had, had significantly, significantly shorter, shorter survival, survival than, than those, those heterozygous, heterozygous for, for a, a splice, splice site, site or, or missense, missense mutation, mutation ,, , or, or heterozygous, heterozygous for, for two, two truncating, truncating mutations, mutations ., . Alterations, Alterations of, of the, the length, length or, or amino, amino acid, acid composition, composition of, of the, the A-T, A-T gene, gene product, product affect, affect the, the A-T, A-T clinical, clinical phenotype, phenotype in, in different, different ways, ways ., . Mutation, Mutation analysis, analysis at, at the, the A-T, A-T locus, locus may, may help, help estimate, estimate the, the prognosis, prognosis of, of A-T, A-T patients.., patients.. We, We have, have re-examined, re-examined an, an extended, extended myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) family, family ,, , previously, previously described, described in, in 1955, 1955 ,, , in, in order, order to, to study, study the, the long, long term, term effects, effects of, of anticipation, anticipation in, in DM, DM and, and in, in particular, particular the, the implications, implications for, for families, families affected, affected by, by this, this disease, disease ., . This, This follow, follow up, up study, study provides, provides data, data on, on 35, 35 gene, gene carriers, carriers and, and 46, 46 asymptomatic, asymptomatic at, at risk, risk family, family members, members in, in five, five generations, generations ., . Clinical, Clinical anticipation, anticipation ,, , defined, defined as, as the, the cascade, cascade of, of mild, mild ,, , adult, adult ,, , childhood, childhood ,, , or, or congenital, congenital disease, disease in, in subsequent, subsequent generations, generations ,, , appeared, appeared to, to be, be a, a relentless, relentless process, process ,, , occurring, occurring in, in all, all affected, affected branches, branches of, of the, the family, family ., . The, The cascade, cascade was, was found, found to, to proceed, proceed asynchronously, asynchronously in, in the, the different, different branches, branches ,, , mainly, mainly because, because of, of an, an unequal, unequal number, number of, of generations, generations with, with mild, mild disease, disease ., . The, The transition, transition from, from the, the mild, mild to, to the, the adult, adult type, type was, was associated, associated with, with transmission, transmission through, through a, a male, male parent, parent ., . Stable, Stable transmission, transmission of, of the, the asymptomatic/mild, asymptomatic/mild phenotype, phenotype showed, showed a, a female, female transmission, transmission bias, bias ., . We, We further, further examined, examined the, the extent, extent and, and causes, causes of, of gene, gene loss, loss in, in this, this pedigree, pedigree ., . Gene, Gene loss, loss in, in the, the patient, patient group, group was, was complete, complete ,, , owing, owing to, to infertility, infertility of, of the, the male, male patients, patients with, with adult, adult onset, onset disease, disease and, and the, the fact, fact that, that mentally, mentally retarded, retarded patients, patients did, did not, not procreate, procreate ., . Out, Out of, of the, the 46, 46 at, at risk, risk subjects, subjects in, in the, the two, two youngest, youngest generations, generations ,, , only, only one, one was, was found, found to, to have, have a, a full, full mutation, mutation ., . This, This is, is the, the only, only subject, subject who, who may, may transmit, transmit the, the gene, gene to, to the, the sixth, sixth generation, generation ., . No, No protomutation, protomutation carriers, carriers were, were found, found in, in the, the fourth, fourth and, and fifth, fifth generations, generations ., . Therefore, Therefore it, it is, is highly, highly probable, probable that, that the, the DM, DM gene, gene will, will be, be eliminated, eliminated from, from this, this pedigree, pedigree within, within one, one generation, generation ., . The, The high, high population, population frequency, frequency of, of DM, DM can, can at, at present, present not, not be, be explained, explained by, by the, the contribution, contribution of, of asymptomatic, asymptomatic cases, cases in, in the, the younger, younger generations, generations of, of known, known families, families ,, , but, but is, is probably, probably caused, caused by, by the, the events, events in, in the, the ancestral, ancestral generations.., generations.. We, We report, report new, new mutations, mutations in, in exon, exon 9, 9 of, of the, the WT1, WT1 gene, gene that, that did, did not, not alter, alter the, the ratio, ratio of, of +/-, +/- KTS, KTS splice, splice isoforms, isoforms in, in two, two unrelated, unrelated patients, patients with, with Frasier, Frasier syndrome, syndrome (, ( FS, FS ), ) ., . The, The mutation, mutation of, of intron, intron 9, 9 inducing, inducing defective, defective alternative, alternative splicing, splicing was, was reported, reported to, to be, be responsible, responsible for, for this, this syndrome, syndrome ., . The, The mutations, mutations found, found in, in our, our cases, cases occurred, occurred in, in the, the same, same exon, exon of, of the, the WT1, WT1 gene, gene as, as detected, detected in, in Denys-Drash, Denys-Drash syndrome, syndrome (, ( DDS, DDS ), ) and, and could, could not, not be, be explained, explained by, by the, the previously, previously proposed, proposed mechanism, mechanism ., . The, The results, results suggest, suggest that, that the, the two, two syndromes, syndromes originate, originate from, from the, the same, same WT1, WT1 gene, gene abnormality, abnormality ., . From, From a, a molecular, molecular biological, biological point, point of, of view, view ,, , we, we concluded, concluded that, that the, the two, two diseases, diseases were, were not, not separable, separable ,, , and, and that, that FS, FS should, should be, be included, included as, as an, an atypical, atypical form, form of, of DDS.., DDS.. Friedreich, Friedreich ataxia, ataxia (, ( FRDA, FRDA ), ) ,, , the, the most, most common, common of, of the, the inherited, inherited ataxias, ataxias ,, , is, is an, an autosomal, autosomal recessive, recessive degenerative, degenerative disorder, disorder ,, , characterized, characterized clinically, clinically by, by onset, onset before, before the, the age, age of, of 25, 25 of, of progressive, progressive gait, gait and, and limb, limb ataxia, ataxia ,, , absence, absence of, of deep, deep tendon, tendon reflexes, reflexes ,, , extensor, extensor plantar, plantar responses, responses ,, , and, and loss, loss of, of position, position and, and vibration, vibration sense, sense in, in the, the lower, lower limbs, limbs ., . FRDA, FRDA is, is caused, caused by, by a, a GAA, GAA triplet, triplet expansion, expansion in, in the, the first, first intron, intron of, of the, the FRDA, FRDA gene, gene on, on chromosome, chromosome 9q13, 9q13 in, in 97, 97 %, % of, of patients, patients ., . The, The FRDA, FRDA gene, gene encodes, encodes a, a widely, widely expressed, expressed 210-aa, 210-aa protein, protein ,, , frataxin, frataxin ,, , which, which is, is located, located in, in mitochondria, mitochondria and, and is, is severely, severely reduced, reduced in, in FRDA, FRDA patients, patients ., . Frataxin, Frataxin function, function is, is still, still unknown, unknown but, but the, the knockout, knockout of, of the, the yeast, yeast frataxin, frataxin homologue, homologue gene, gene (, ( YFH1, YFH1 ), ) showed, showed a, a severe, severe defect, defect of, of mitochondrial, mitochondrial respiration, respiration and, and loss, loss of, of mtDNA, mtDNA associated, associated with, with elevated, elevated intramitochondrial, intramitochondrial iron, iron ., . Here, Here we, we report, report in, in vivo, vivo evidence, evidence of, of impaired, impaired mitochondrial, mitochondrial respiration, respiration in, in skeletal, skeletal muscle, muscle of, of FRDA, FRDA patients, patients ., . Using, Using phosphorus, phosphorus magnetic, magnetic resonance, resonance spectroscopy, spectroscopy we, we demonstrated, demonstrated a, a maximum, maximum rate, rate of, of muscle, muscle mitochondrial, mitochondrial ATP, ATP production, production (, ( V, V (, ( max, max ), ) ), ) below, below the, the normal, normal range, range in, in all, all 12, 12 FRDA, FRDA patients, patients and, and a, a strong, strong negative, negative correlation, correlation between, between mitochondrial, mitochondrial V, V (, ( max, max ), ) and, and the, the number, number of, of GAA, GAA repeats, repeats in, in the, the smaller, smaller allele, allele ., . Our, Our results, results show, show that, that FRDA, FRDA is, is a, a nuclear-encoded, nuclear-encoded mitochondrial, mitochondrial disorder, disorder affecting, affecting oxidative, oxidative phosphorylation, phosphorylation and, and give, give a, a rationale, rationale for, for treatments, treatments aimed, aimed to, to improve, improve mitochondrial, mitochondrial function, function in, in this, this condition.., condition.. A, A new, new glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) variant, variant with, with severe, severe erythrocytic, erythrocytic G6PD, G6PD deficiency, deficiency and, and a, a unique, unique pH, pH optimum, optimum is, is described, described in, in a, a young, young patient, patient with, with chronic, chronic nonspherocytic, nonspherocytic hemolytic, hemolytic anemia, anemia (, ( CNSHA, CNSHA ), ) and, and familial, familial amyloidotic, amyloidotic polyneuropathy, polyneuropathy (, ( FAP, FAP ), ) ., . Chronic, Chronic hemolysis, hemolysis was, was present, present in, in the, the absence, absence of, of infections, infections ,, , oxidant, oxidant drugs, drugs or, or ingestion, ingestion of, of faba, faba beans, beans ., . Residual, Residual enzyme, enzyme activity, activity was, was about, about 2, 2 ., . 6, 6 %, % and, and 63, 63 %, % of, of normal, normal activity, activity in, in erythrocytes, erythrocytes and, and leucocytes, leucocytes ,, , respectively, respectively ., . A, A molecular, molecular study, study using, using standard, standard methods, methods showed, showed G6PD, G6PD in, in the, the patient, patient to, to have, have normal, normal electrophoretic, electrophoretic mobility, mobility (, ( at, at pH, pH 7, 7 ., . 0, 0 ,, , 8, 8 ., . 0, 0 and, and 8, 8 ., . 8, 8 ), ) ,, , normal, normal apparent, apparent affinity, affinity for, for substrates, substrates (, ( Km, Km ,, , G6P, G6P and, and NADP, NADP ), ) and, and a, a slightly, slightly abnormal, abnormal utilization, utilization of, of substrate, substrate analogues, analogues (, ( decreased, decreased deamino-NADP, deamino-NADP and, and increased, increased 2-deoxyglucose-6-phosphate, 2-deoxyglucose-6-phosphate utilization, utilization ), ) ., . Heat, Heat stability, stability was, was found, found to, to be, be markedly, markedly decreased, decreased (, ( 8, 8 %, % of, of residual, residual activity, activity after, after 20, 20 min, min of, of incubation, incubation at, at 46, 46 degrees, degrees C, C ), ) and, and a, a particular, particular characteristic, characteristic of, of this, this enzyme, enzyme was, was a, a biphasic, biphasic pH, pH curve, curve with, with a, a greatly, greatly increased, increased activity, activity at, at low, low pH, pH ., . Although, Although molecular, molecular characteristics, characteristics of, of this, this variant, variant closely, closely resemble, resemble those, those of, of G6PD, G6PD Bangkok, Bangkok and, and G6PD, G6PD Duarte, Duarte ,, , it, it can, can be, be distinguished, distinguished from, from these, these and, and all, all other, other previously, previously reported, reported variants, variants by, by virtue, virtue of, of its, its unusual, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "unusual pH, pH curve, curve ., . Therefore, Therefore the, the present, present variant, variant has, has been, been designated, designated G6PD, G6PD Clinic, Clinic to, to distinguish, distinguish it, it from, from other, other G6PD, G6PD variants, variants previously, previously described, described In, In two, two unrelated, unrelated families, families ,, , males, males have, have been, been identified, identified who, who suffer, suffer from, from choroideremia, choroideremia and, and at, at the, the same, same time, time have, have an, an interstitial, interstitial deletion, deletion on, on the, the proximal, proximal long, long arm, arm of, of the, the X, X chromosome, chromosome ., . By, By high-resolution, high-resolution banding, banding we, we have, have characterized, characterized the, the deletion, deletion chromosomes, chromosomes as, as del, del (, ( X, X ), ) (, ( q21, q21 ., . 1-q21, 1-q21 1-q21, 1-q21 ., . 33, 33 ), ) and, and del, del (, ( X, X ), ) (, ( q21, q21 ., . 2-q21, 2-q21 2-q21, 2-q21 ., . 31, 31 ), ) respectively, respectively ., . By, By Southern, Southern blot, blot analysis, analysis we, we have, have mapped, mapped ten, ten different, different polymorphic, polymorphic DNA, DNA loci, loci relative, relative to, to the, the position, position of, of the, the deletion, deletion and, and the, the choroideremia, choroideremia locus, locus TCD, TCD ., . One, One probe, probe ,, , p31, p31 ,, , was, was shown, shown to, to cover, cover one, one of, of the, the breakpoints, breakpoints of, of the, the smallest, smallest deletion, deletion ., . The, The following, following order, order of, of the, the loci, loci was, was suggested, suggested by, by deletion, deletion mapping, mapping cen-DXS106-DXS72-TCD-, cen-DXS106-DXS72-TCD- (, ( DXYS1/DXYS23/DXYS5, DXYS1/DXYS23/DXYS5 ), ) -, - DXYS2-, DXYS2- (, ( DXYS12/DXS3, DXYS12/DXS3 ), ) -, - (, ( DXS17/DXS101, DXS17/DXS101 ), ) -, - Xqter.Interstitial, Xqter.Interstitial cytogenetic, cytogenetic deletions, deletions involving, involving the, the paternally, paternally derived, derived chromosome, chromosome 15q11-13, 15q11-13 have, have been, been described, described in, in patients, patients with, with the, the Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . We, We report, report a, a child, child with, with PWS, PWS and, and a, a de, de novo, novo unbalanced, unbalanced karyotype, karyotype -45, -45 ,, , XY, XY ,, , -9, -9 ,, , -15, -15 ,, , +, + der, der (, ( 9, 9 ), ) t, t (, ( 9, 9 ;, ; 15, 15 ), ) (, ( q34, q34 ;, ; q13, q13 ), ) ., . Molecular, Molecular studies, studies with, with the, the DNA, DNA probe, probe pML34, pML34 confirmed, confirmed that, that only, only a, a single, single Prader, Prader Willi, Willi critical, critical region, region (, ( PWCR, PWCR 15q11, 15q11 ., . 2-q12, 2-q12 ), ) copy, copy was, was present, present ., . Hybridisation, Hybridisation of, of patient, patient and, and parental, parental DNA, DNA with, with the, the multi-allelic, multi-allelic probe, probe CMW1, CMW1 ,, , which, which maps, maps to, to pter-15q13, pter-15q13 ,, , showed, showed that, that the, the chromosome, chromosome involved, involved in, in the, the translocation, translocation was, was paternal, paternal in, in origin, origin ., . This, This is, is the, the first, first example, example of, of a, a paternally-derived, paternally-derived PWCR, PWCR allele, allele loss, loss caused, caused by, by an, an unbalanced, unbalanced translocation, translocation that, that has, has arisen, arisen de, de novo, novo ., . CONTEXT, CONTEXT Most, Most hereditary, hereditary ovarian, ovarian cancers, cancers are, are associated, associated with, with germline, germline mutations, mutations in, in BRCA1, BRCA1 or, or BRCA2, BRCA2 ., . Attempts, Attempts to, to define, define the, the clinical, clinical significance, significance of, of BRCA, BRCA mutation, mutation status, status in, in ovarian, ovarian cancer, cancer have, have produced, produced conflicting, conflicting results, results ,, , especially, especially regarding, regarding survival, survival ., . OBJECTIVE, OBJECTIVE To, To determine, determine whether, whether hereditary, hereditary ovarian, ovarian cancers, cancers have, have distinct, distinct clinical, clinical and, and pathological, pathological features, features compared, compared with, with sporadic, sporadic (, ( nonhereditary, nonhereditary ), ) ovarian, ovarian cancers, cancers ., . DESIGN, DESIGN AND, AND SETTING, SETTING Retrospective, Retrospective cohort, cohort study, study of, of a, a consecutive, consecutive series, series of, of 933, 933 ovarian, ovarian cancers, cancers diagnosed, diagnosed and, and treated, treated at, at our, our institution, institution ,, , which, which is, is a, a comprehensive, comprehensive cancer, cancer center, center as, as designated, designated by, by the, the National, National Cancer, Cancer Institute, Institute ,, , over, over a, a 12-year, 12-year period, period (, ( December, December 1986, 1986 to, to August, August 1998, 1998 ), ) ., . PATIENTS, PATIENTS The, The study, study was, was restricted, restricted to, to patients, patients of, of Jewish, Jewish origin, origin because, because of, of the, the ease, ease of, of BRCA1, BRCA1 and, and BRCA2, BRCA2 genotyping, genotyping in, in this, this ethnic, ethnic group, group ., . From, From the, the 189, 189 patients, patients who, who identified, identified themselves, themselves as, as Jewish, Jewish ,, , 88, 88 hereditary, hereditary cases, cases were, were identified, identified with, with the, the presence, presence of, of a, a germline, germline founder, founder mutation, mutation in, in BRCA1, BRCA1 or, or BRCA2, BRCA2 ., . The, The remaining, remaining 101, 101 cases, cases from, from the, the same, same series, series not, not associated, associated with, with a, a BRCA, BRCA mutation, mutation and, and 2, 2 additional, additional groups, groups (, ( Gynecologic, Gynecologic Oncology, Oncology Group, Group protocols, protocols 52, 52 and, and 111, 111 ), ) with, with ovarian, ovarian cancer, cancer from, from clinical, clinical trials, trials (, ( for, for the, the survival, survival analysis, analysis ), ) were, were included, included for, for comparison, comparison ., . MAIN, MAIN OUTCOME, OUTCOME MEASURES, MEASURES Age, Age at, at diagnosis, diagnosis ,, , surgical, surgical stage, stage ,, , histologic, histologic cell, cell type, type and, and grade, grade ,, , and, and surgical, surgical outcome, outcome ;, ; and, and response, response to, to chemotherapy, chemotherapy and, and survival, survival for, for advanced-stage, advanced-stage (, ( II, II and, and IV, IV ), ) cases, cases ., . RESULTS, RESULTS Hereditary, Hereditary cancers, cancers were, were rarely, rarely diagnosed, diagnosed before, before age, age 40, 40 years, years and, and were, were common, common after, after age, age 60, 60 years, years ,, , with, with mean, mean age, age at, at diagnosis, diagnosis being, being significantly, significantly younger, younger for, for BRCA1-, BRCA1- vs, vs BRCA2-linked, BRCA2-linked patients, patients (, ( 54, 54 vs, vs 62, 62 years, years ;, ; P, P =, = ., . 04, 04 ), ) ., . Histology, Histology ,, , grade, grade ,, , stage, stage ,, , and, and success, success of, of cytoreductive, cytoreductive surgery, surgery were, were similar, similar for, for hereditary, hereditary and, and sporadic, sporadic cases, cases ., . The, The hereditary, hereditary group, group had, had a, a longer, longer disease-free, disease-free interval, interval following, following primary, primary chemotherapy, chemotherapy in, in comparison, comparison with, with the, the nonhereditary, nonhereditary group, group ,, , with, with a, a median, median time, time to, to recurrence, recurrence of, of 14, 14 months, months and, and 7, 7 months, months ,, , respectively, respectively (, ( P, P <, < ., . 001, 001 ), ) ., . Those, Those with, with hereditary, hereditary cancers, cancers had, had improved, improved survival, survival compared, compared with, with the, the nonhereditary, nonhereditary group, group (, ( P, P =, = ., . 004, 004 ), ) ., . For, For stage, stage III, III cancers, cancers ,, , BRCA, BRCA mutation, mutation status, status was, was an, an independent, independent prognostic, prognostic variable, variable (, ( P, P =, = ., . 03, 03 ), ) ., . CONCLUSIONS, CONCLUSIONS Although, Although BRCA-associated, BRCA-associated hereditary, hereditary ovarian, ovarian cancers, cancers in, in this, this population, population have, have surgical, surgical and, and pathological, pathological characteristics, characteristics similar, similar to, to those, those of, of sporadic, sporadic cancers, cancers ,, , advanced-stage, advanced-stage hereditary, hereditary cancer, cancer patients, patients survive, survive longer, longer than, than nonhereditary, nonhereditary cancer, cancer patients, patients ., . Age, Age penetrance, penetrance is, is greater, greater for, for BRCA1-linked, BRCA1-linked than, than for, for BRCA2-linked, BRCA2-linked cancers, cancers in, in this, this population.Denys-Drash, population.Denys-Drash syndrome, syndrome is, is a, a rare, rare human, human developmental, developmental disorder, disorder affecting, affecting the, the urogenital, urogenital system, system and, and leading, leading to, to renal, renal failure, failure ,, , intersex, intersex disorders, disorders and, and Wilms, Wilms tumour, tumour ., . In, In this, this report, report ,, , four, four individuals, individuals with, with this, this syndrome, syndrome are, are described, described carrying, carrying germline, germline point, point mutations, mutations in, in the, the Wilms, Wilms tumour, tumour suppressor, suppressor gene, gene ,, , WT1, WT1 ., . Three, Three of, of these, these mutations, mutations were, were in, in the, the zinc, zinc finger, finger domains, domains of, of WT1, WT1 ., . The, The fourth, fourth occurred, occurred within, within intron, intron 9, 9 ,, , preventing, preventing splicing, splicing at, at one, one of, of the, the alternatively, alternatively chosen, chosen splice, splice donor, donor sites, sites of, of exon, exon 9, 9 when, when assayed, assayed in, in vitro, vitro ., . These, These results, results provide, provide genetic, genetic evidence, evidence for, for distinct, distinct functional, functional roles, roles of, of the, the WT1, WT1 isoforms, isoforms in, in urogenital, urogenital development.., development.. Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) is, is an, an X-linked, X-linked recessive, recessive genetic, genetic disorder, disorder for, for which, which the, the biochemical, biochemical defect, defect is, is as, as yet, yet unknown, unknown ., . Recently, Recently ,, , two, two cloned, cloned segments, segments of, of human, human X-chromosome, X-chromosome DNA, DNA have, have been, been described, described which, which detect, detect structural, structural alterations, alterations within, within or, or near, near the, the genetic, genetic locus, locus responsible, responsible for, for the, the disorder, disorder ., . Both, Both of, of these, these cloned, cloned segments, segments were, were described, described as, as tightly, tightly linked, linked to, to the, the locus, locus and, and were, were capable, capable of, of detecting, detecting deletions, deletions in, in the, the DNA, DNA of, of boys, boys affected, affected with, with DMD, DMD ., . In, In an, an attempt, attempt to, to determine, determine more, more precisely, precisely the, the occurrence, occurrence of, of these, these deletions, deletions within, within a, a large, large population, population of, of DMD, DMD patients, patients and, and the, the accuracy, accuracy of, of one, one of, of the, the segments, segments ,, , DXS164, DXS164 (, ( pERT87, pERT87 ), ) ,, , in, in determining, determining the, the inheritance, inheritance of, of the, the DMD, DMD X, X chromosome, chromosome ,, , the, the subclones, subclones 1, 1 ,, , 8, 8 and, and 15, 15 were, were made, made available, available to, to many, many investigators, investigators throughout, throughout the, the world, world ., . Here, Here we, we describe, describe the, the combined, combined results, results of, of more, more than, than 20, 20 research, research laboratories, laboratories with, with respect, respect to, to the, the occurrence, occurrence of, of deletions, deletions at, at the, the DXS164, DXS164 locus, locus in, in DNA, DNA samples, samples isolated, isolated from, from patients, patients with, with DMD, DMD and, and Becker, Becker muscular, muscular dystrophy, dystrophy (, ( BMD, BMD ), ) ., . The, The results, results indicate, indicate that, that the, the DXS164, DXS164 locus, locus apparently, apparently recombines, recombines with, with DMD, DMD 5, 5 %, % of, of the, the time, time ,, , but, but is, is probably, probably located, located between, between independent, independent sites, sites of, of mutation, mutation which, which yield, yield DMD, DMD ., . The, The breakpoints, breakpoints of, of some, some deletions, deletions are, are delineated, delineated within, within the, the DXS164, DXS164 locus, locus ,, , and, and it, it is, is evident, evident that, that the, the deletions, deletions at, at the, the DMD, DMD locus, locus are, are frequent, frequent and, and extremely, extremely large.., large.. A, A pair, pair of, of female, female monozygotic, monozygotic (, ( MZ, MZ ), ) twins, twins ,, , heterozygous, heterozygous carriers, carriers for, for a, a deletion, deletion in, in the, the DMD, DMD gene, gene and, and discordant, discordant for, for the, the clinical, clinical manifestations, manifestations of, of Duchenne, Duchenne muscular, muscular dystrophy, dystrophy ,, , were, were analyzed, analyzed by, by molecular, molecular studies, studies ,, , in, in situ, situ hybridization, hybridization ,, , and, and methylation, methylation pattern, pattern of, of X, X chromosomes, chromosomes to, to search, search for, for opposite, opposite X, X inactivation, inactivation as, as an, an explanation, explanation of, of their, their clinical, clinical discordance, discordance ., . Results, Results in, in lymphocytes, lymphocytes and, and skin, skin fibroblast, fibroblast cell, cell lines, lines suggest, suggest a, a partial, partial mirror, mirror inactivation, inactivation with, with the, the normal, normal X, X chromosome, chromosome preferentially, preferentially active, active in, in the, the unaffected, unaffected twin, twin ,, , and, and the, the maternal, maternal deleted, deleted X, X chromosome, chromosome preferentially, preferentially active, active in, in the, the affected, affected twin, twin ., . A, A review, review shows, shows that, that MZ, MZ female, female twins, twins discordant, discordant for, for X-linked, X-linked diseases, diseases are, are not, not uncommon, uncommon ., . Twinning, Twinning and, and X, X inactivation, inactivation may, may be, be interrelated, interrelated and, and could, could explain, explain the, the female, female twins, twins discordant, discordant for, for X-linked, X-linked traits.., traits.. A, A small-for-gestational-age, small-for-gestational-age infant, infant ,, , found, found to, to have, have analbuminemia, analbuminemia in, in the, the neonatal, neonatal period, period ,, , is, is reported, reported and, and the, the twelve, twelve cases, cases recorded, recorded in, in the, the world, world literature, literature are, are reviewed, reviewed ., . Patients, Patients lacking, lacking this, this serum, serum protein, protein are, are essentially, essentially asymptomatic, asymptomatic ,, , apart, apart from, from minimal, minimal ankle, ankle edema, edema and, and ease, ease of, of fatigue, fatigue ., . Apparent, Apparent compensatory, compensatory mechanisms, mechanisms which, which come, come into, into play, play when, when serum, serum albumin, albumin is, is low, low include, include prolonged, prolonged half-life, half-life of, of albumin, albumin and, and transferrin, transferrin ,, , an, an increase, increase in, in serum, serum globulins, globulins ,, , beta, beta lipoprotein, lipoprotein ,, , and, and glycoproteins, glycoproteins ,, , arterial, arterial hypotension, hypotension with, with reduced, reduced capillary, capillary hydrostatic, hydrostatic pressure, pressure ,, , and, and the, the ability, ability to, to respond, respond with, with rapid, rapid sodium, sodium and, and chloride, chloride diuresis, diuresis in, in response, response to, to small, small volume, volume changes, changes ., . Examination, Examination of, of plasma, plasma amino, amino acids, acids ,, , an, an investigation, investigation not, not previously, previously reported, reported ,, , revealed, revealed an, an extremely, extremely low, low plasma, plasma tryptophan, tryptophan level, level ,, , a, a finding, finding which, which may, may be, be important, important in, in view, view of, of the, the role, role of, of tryptophan, tryptophan in, in albumin, albumin synthesis.., synthesis.. Gaucher, Gaucher disease, disease (, ( GD, GD ), ) is, is an, an inherited, inherited deficiency, deficiency of, of beta-glucocerebrosidase, beta-glucocerebrosidase (, ( EC, EC 3, 3 ., . 1, 1 ., . 2, 2 ., . 45, 45 ,, , gene, gene symbol, symbol GBA, GBA ), ) ., . In, In type, type I, I GD, GD ,, , the, the CNS, CNS is, is not, not involved, involved (, ( nonneuronopathic, nonneuronopathic ), ) ,, , whereas, whereas in, in type, type II, II GD, GD (, ( acute, acute neuronopathic, neuronopathic ), ) CNS, CNS involvement, involvement is, is early, early and, and rapidly, rapidly progressive, progressive ,, , while, while in, in type, type III, III GD, GD (, ( subacute, subacute neuronopathic, neuronopathic ), ) CNS, CNS involvement, involvement occurs, occurs later, later and, and is, is slowly, slowly progressive, progressive ., . The, The T6433C, T6433C (, ( L444P, L444P ), ) substitution, substitution is, is prevalent, prevalent in, in type, type GD, GD II, II ., . It, It may, may occur, occur alone, alone as, as a, a single, single base-pair, base-pair mutation, mutation but, but often, often is, is found, found as, as part, part of, of a, a complex, complex allele, allele containing, containing additional, additional GBA, GBA nucleotide, nucleotide substitutions, substitutions ,, , G6468C, G6468C (, ( A456P, A456P ), ) and, and G6482C, G6482C (, ( V460V, V460V ), ) ,, , without, without (, ( recNciI, recNciI ), ) or, or with, with (, ( recTL, recTL ), ) G5957C, G5957C (, ( D409H, D409H ), ) ., . This, This complex, complex allele, allele is, is presumed, presumed to, to have, have formed, formed by, by recombination, recombination (, ( crossover, crossover ,, , fusion, fusion ), ) of, of the, the structural, structural gene, gene with, with the, the pseudogene, pseudogene ,, , which, which contains, contains the, the mutated, mutated sequences, sequences ., . Two, Two complex, complex alleles, alleles have, have never, never been, been demonstrated, demonstrated to, to coexist, coexist in, in any, any individual, individual ., . We, We devised, devised a, a selective, selective PCR, PCR method, method for, for the, the specific, specific amplification, amplification of, of the, the normal, normal and/or, and/or fusion, fusion gene, gene ., . Using, Using this, this procedure, procedure we, we demonstrated, demonstrated the, the fusion, fusion gene, gene in, in homozygous, homozygous form, form for, for the, the first, first time, time ,, , in, in a, a Macedonian/Ashkenazi, Macedonian/Ashkenazi Jewish, Jewish GD, GD type, type II, II fetus, fetus ., . Both, Both parents, parents were, were carriers, carriers of, of the, the recombination, recombination ., . This, This was, was confirmed, confirmed by, by direct, direct sequence, sequence analysis, analysis ., . A, A previous, previous conceptus, conceptus in, in this, this family, family was, was stillborn, stillborn at, at 36, 36 weeks, weeks ,, , with, with features, features of, of severe, severe type, type II, II GD, GD ., . Neonates, Neonates showing, showing a, a severe, severe clinical, clinical phenotype, phenotype ,, , analogous, analogous to, to the, the early, early neonatal, neonatal lethal, lethal disease, disease occurring, occurring in, in mice, mice homozygous, homozygous for, for a, a null, null allele, allele produced, produced by, by targeted, targeted disruption, disruption of, of GBA, GBA ,, , have, have been, been described, described elsewhere, elsewhere ,, , but, but the, the specific, specific mutations, mutations in, in these, these cases, cases have, have not, not yet, yet been, been characterized, characterized ., . (, ( ABSTRACT, ABSTRACT TRUNCATED, TRUNCATED AT, AT 250, 250 WORDS, WORDS ), ) Hereditary, Hereditary progressive, progressive dystonia, dystonia with, with marked, marked diurnal, diurnal fluctuation, fluctuation (, ( HPD, HPD ;, ; dopa-responsive, dopa-responsive dystonia, dystonia ,, , DRD, DRD ), ) have, have been, been recently, recently found, found to, to be, be caused, caused by, by a, a genetic, genetic defect, defect in, in the, the GTP, GTP cyclohydrolase, cyclohydrolase I, I (, ( GCH1, GCH1 ), ) gene, gene ., . In, In this, this study, study ,, , we, we quantified, quantified the, the mRNA, mRNA level, level of, of GCH1, GCH1 in, in phytohemagglutinin, phytohemagglutinin (, ( PHA, PHA ), ) -stimulated, -stimulated mononuclear, mononuclear blood, blood cells, cells from, from one, one Japanese, Japanese family, family that, that do, do not, not have, have a, a mutation, mutation in, in the, the coding, coding region, region or, or splice, splice junctions, junctions of, of the, the gene, gene ., . The, The results, results showed, showed that, that the, the amounts, amounts of, of the, the GCH1, GCH1 mRNA, mRNA were, were decreased, decreased to, to about, about 40, 40 %, % of, of the, the normal, normal level, level in, in both, both patients, patients and, and carriers, carriers ., . In, In addition, addition ,, , we, we found, found that, that the, the GCH1, GCH1 mRNA, mRNA was, was transcribed, transcribed from, from only, only one, one allele, allele ,, , indicating, indicating that, that the, the other, other allele, allele was, was in, in an, an inactive, inactive state, state ., . These, These results, results suggest, suggest that, that some, some novel, novel mutations, mutations should, should exist, exist on, on one, one of, of the, the alleles, alleles in, in some, some unknown, unknown region, region of, of the, the GCH1, GCH1 gene, gene ,, , and, and may, may decrease, decrease the, the GCH1, GCH1 mRNA, mRNA causing, causing the, the HPD/DRD, HPD/DRD symptoms.., symptoms.. Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) is, is an, an X-linked, X-linked recessive, recessive immunodeficiency, immunodeficiency characterized, characterized by, by thrombocytopenia, thrombocytopenia ,, , eczema, eczema ,, , and, and recurrent, recurrent infections, infections ,, , and, and caused, caused by, by mutations, mutations in, in the, the WAS, WAS protein, protein (, ( WASP, WASP ), ) gene, gene ., . WASP, WASP contains, contains several, several functional, functional domains, domains through, through which, which it, it interacts, interacts with, with proteins, proteins involved, involved in, in intracellular, intracellular signaling, signaling and, and regulation, regulation of, of the, the actin, actin cytoskeleton, cytoskeleton ., . In, In this, this report, report ,, , 17, 17 WASP, WASP gene, gene mutations, mutations were, were identified, identified ,, , 12, 12 of, of which, which are, are novel, novel ., . DNA, DNA of, of affected, affected males, males and, and obligate, obligate carriers, carriers was, was PCR, PCR amplified, amplified and, and analyzed, analyzed by, by SSCA, SSCA ,, , heteroduplex, heteroduplex analysis, analysis ,, , and, and direct, direct sequencing, sequencing ., . The, The effects, effects of, of the, the mutations, mutations at, at the, the mRNA, mRNA and, and protein, protein level, level were, were ascertained, ascertained by, by RT-PCR, RT-PCR and, and Western, Western blot, blot analyses, analyses ., . All, All missense, missense mutations, mutations were, were located, located in, in exons, exons 1-4, 1-4 ., . Most, Most of, of the, the nonsense, nonsense ,, , frameshift, frameshift and, and splice, splice site, site mutations, mutations were, were found, found in, in exons, exons 6-11, 6-11 ., . Mutations, Mutations that, that alter, alter splice, splice sites, sites led, led to, to the, the synthesis, synthesis of, of several, several types, types of, of mRNAs, mRNAs ,, , a, a fraction, fraction of, of which, which represented, represented the, the normally, normally spliced, spliced product, product ., . The, The presence, presence of, of normally, normally spliced, spliced transcripts, transcripts was, was correlated, correlated with, with a, a milder, milder phenotype, phenotype ., . When, When one, one such, such case, case was, was studied, studied by, by Western, Western blotting, blotting ,, , reduced, reduced amounts, amounts of, of normal-size, normal-size WASP, WASP were, were present, present ., . In, In other, other cases, cases as, as well, well ,, , a, a correlation, correlation was, was found, found between, between the, the amount, amount of, of normal, normal or, or mutant, mutant WASP, WASP present, present and, and the, the phenotypes, phenotypes of, of the, the affected, affected individuals, individuals ., . No, No protein, protein was, was detected, detected in, in two, two individuals, individuals with, with severe, severe WAS, WAS ., . Reduced, Reduced levels, levels of, of a, a normal-size, normal-size WASP, WASP with, with a, a missense, missense mutation, mutation were, were seen, seen in, in two, two individuals, individuals with, with XLT, XLT ., . It, It is, is concluded, concluded that, that mutation, mutation analysis, analysis at, at the, the DNA, DNA level, level is, is not, not sufficient, sufficient for, for predicting, predicting clinical, clinical course, course ., . Studies, Studies at, at the, the transcript, transcript and, and protein, protein level, level are, are needed, needed for, for a, a better, better assessment.., assessment.. A, A total, total of, of 3000, 3000 men, men living, living in, in Yamaguchi, Yamaguchi were, were screened, screened for, for glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency using, using Beutlers, Beutlers spot, spot test, test and, and three, three types, types of, of starch, starch gel, gel electrophoresis, electrophoresis ., . These, These electrophoresis, electrophoresis used, used a, a phosphate, phosphate buffer, buffer system, system at, at pH, pH 7, 7 ., . 0, 0 ,, , a, a TRIS-EDTA-borate, TRIS-EDTA-borate buffer, buffer system, system at, at pH, pH 8, 8 ., . 6, 6 ,, , and, and a, a TRIS-hydrochloride, TRIS-hydrochloride buffer, buffer system, system at, at pH, pH 8.., 8.. Fifteen, Fifteen G6PD-deficient, G6PD-deficient variants, variants were, were found, found at, at the, the rate, rate of, of 0, 0 ., . 5, 5 %, % and, and classified, classified into, into four, four groups, groups ., . As, As new, new variants, variants ,, , G6PD, G6PD Konan, Konan ,, , Kamiube, Kamiube ,, , and, and Kiwa, Kiwa were, were identified, identified ., . These, These three, three variants, variants had, had a, a mild, mild to, to moderate, moderate G6PD, G6PD deficiency, deficiency and, and were, were not, not associated, associated with, with any, any clinical, clinical signs, signs ., . G6PD, G6PD Konan, Konan had, had fast, fast electrophoretic, electrophoretic mobility, mobility as, as compared, compared with, with normal, normal levels, levels ,, , G6PD, G6PD Kiwa, Kiwa had, had slightly, slightly elevated, elevated electrophoretic, electrophoretic mobility, mobility ,, , and, and G6PD, G6PD Kamiube, Kamiube had, had normal, normal electrophoretic, electrophoretic mobility, mobility ., . These, These three, three variants, variants had, had normal, normal levels, levels of, of Km, Km G6P, G6P ,, , Km, Km NADP, NADP ,, , and, and Ki, Ki NADPH, NADPH ,, , normal, normal utilizations, utilizations of, of both, both 2-deoxy-G6P, 2-deoxy-G6P and, and deamino-NAPD, deamino-NAPD ,, , normal, normal heat, heat stability, stability ,, , and, and a, a normal, normal pH, pH curve, curve ., . The, The other, other variant, variant was, was G6PD, G6PD Ube, Ube ,, , which, which we, we had, had previously, previously found, found in, in Yamaguchi, Yamaguchi (, ( Nakashima, Nakashima et, et al., al. ,, , 1977, 1977 ), ) ., . One, One boy, boy with, with G6PD, G6PD Ube, Ube was, was Korean, Korean Abnormalities, Abnormalities of, of chromosome, chromosome region, region 15q11-13, 15q11-13 are, are associated, associated with, with Angelman, Angelman syndrome, syndrome (, ( AS, AS ), ) and, and Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . Differences, Differences between, between the, the methylation, methylation patterns, patterns of, of the, the region, region of, of chromosome, chromosome 15q11-13, 15q11-13 which, which hybridizes, hybridizes to, to the, the highly, highly conserved, conserved DNA, DNA ,, , DN34, DN34 ,, , in, in normal, normal individuals, individuals and, and in, in patients, patients with, with AS, AS and, and PWS, PWS have, have been, been described, described ., . We, We report, report on, on a, a family, family in, in which, which first, first cousins, cousins are, are affected, affected by, by AS, AS and, and PWS, PWS as, as a, a result, result of, of a, a familial, familial paracentric, paracentric inversion, inversion of, of 15q11-q13, 15q11-q13 ., . The, The results, results of, of the, the studies, studies on, on this, this family, family demonstrate, demonstrate the, the differences, differences in, in the, the methylation, methylation patterns, patterns in, in the, the 2, 2 conditions, conditions and, and the, the phenomenon, phenomenon of, of genomic, genomic imprinting, imprinting ,, , whereby, whereby genetic, genetic information, information is, is expressed, expressed differently, differently dependent, dependent on, on the, the parent, parent of, of origin.., "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "origin.. Recently, Recently ,, , we, we and, and others, others have, have isolated, isolated a, a candidate, candidate gene, gene for, for X, X linked, linked Norrie, Norrie disease, disease (, ( ND, ND ), ) which, which was, was found, found to, to be, be deleted, deleted or, or disrupted, disrupted in, in several, several patients, patients ., . As, As a, a prerequisite, prerequisite for, for the, the identification, identification of, of point, point mutations, mutations in, in the, the ND, ND gene, gene we, we have, have established, established the, the exon-intron, exon-intron structure, structure of, of this, this gene, gene ., . In, In 17, 17 unrelated, unrelated patients, patients and, and 15, 15 controls, controls ,, , PCR, PCR products, products derived, derived from, from the, the promoter, promoter region, region ,, , exons, exons 1, 1 and, and 2, 2 as, as well, well as, as the, the coding, coding part, part of, of exon, exon 3, 3 were, were analysed, analysed with, with the, the single, single strand, strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) technique, technique ., . In, In 12, 12 patients, patients altered, altered PCR, PCR fragments, fragments were, were detected, detected which, which were, were studied, studied in, in detail, detail by, by direct, direct sequencing, sequencing ., . Eleven, Eleven different, different mutations, mutations were, were found, found ,, , and, and all, all but, but one, one are, are likely, likely to, to give, give rise, rise to, to significant, significant structural, structural changes, changes in, in the, the predicted, predicted protein, protein ., . These, These findings, findings ,, , and, and the, the absence, absence of, of functionally, functionally relevant, relevant base, base changes, changes in, in healthy, healthy controls, controls ,, , emphasize, emphasize the, the causal, causal role, role of, of this, this candidate, candidate gene, gene in, in Norrie, Norrie disease, disease and, and pave, pave the, the way, way for, for reliable, reliable diagnosis, diagnosis and, and carrier, carrier detection.., detection.. Kniest, Kniest dysplasia, dysplasia is, is a, a moderately, moderately severe, severe chondrodysplasia, chondrodysplasia phenotype, phenotype that, that results, results from, from mutations, mutations in, in the, the gene, gene for, for type, type II, II collagen, collagen ,, , COL2A1, COL2A1 ., . Characteristics, Characteristics of, of the, the disorder, disorder include, include a, a short, short trunk, trunk and, and extremities, extremities ,, , mid-face, mid-face hypoplasia, hypoplasia ,, , cleft, cleft palate, palate ,, , myopia, myopia ,, , retinal, retinal detachment, detachment ,, , and, and hearing, hearing loss, loss ., . Recently, Recently ,, , deletions, deletions of, of all, all or, or part, part of, of exon, exon 12, 12 have, have been, been identified, identified in, in individuals, individuals with, with Kniest, Kniest dysplasia, dysplasia ,, , suggesting, suggesting that, that mutations, mutations within, within this, this region, region of, of the, the protein, protein may, may primarily, primarily result, result in, in the, the Kniest, Kniest dysplasia, dysplasia phenotype, phenotype ., . We, We used, used SSCP, SSCP to, to analyze, analyze an, an amplified, amplified genomic, genomic DNA, DNA fragment, fragment containing, containing exon, exon 12, 12 from, from seven, seven individuals, individuals with, with Kniest, Kniest dysplasia, dysplasia ., . An, An abnormality, abnormality was, was identified, identified in, in one, one patient, patient ., . DNA, DNA sequence, sequence analysis, analysis demonstrated, demonstrated that, that the, the patient, patient was, was heterozygous, heterozygous for, for a, a G, G to, to A, A transition, transition that, that implied, implied substitution, substitution of, of glycine103, glycine103 of, of the, the triple, triple helical, helical domain, domain by, by aspartate, aspartate ., . The, The mutation, mutation was, was not, not observed, observed in, in DNA, DNA from, from either, either of, of the, the clinically, clinically unaffected, unaffected parents, parents of, of the, the proband, proband ., . Protein, Protein microsequencing, microsequencing demonstrated, demonstrated expression, expression of, of the, the abnormal, abnormal allele, allele in, in cartilage, cartilage ., . These, These data, data demonstrate, demonstrate that, that point, point mutations, mutations which, which result, result in, in single, single amino, amino acid, acid substitutions, substitutions can, can produce, produce Kniest, Kniest dysplasia, dysplasia and, and further, further support, support the, the hypothesis, hypothesis that, that alteration, alteration of, of a, a domain, domain ,, , which, which includes, includes the, the region, region encoded, encoded by, by exon, exon 12, 12 ,, , in, in the, the type, type II, II collagen, collagen protein, protein leads, leads to, to this, this disorder.., disorder.. van, van der, der Woude, Woude syndrome, syndrome (, ( vWS, vWS ,, , MIM, MIM 119300, 119300 ), ) is, is a, a rare, rare autosomal, autosomal dominant, dominant clefting, clefting condition, condition with, with cardinal, cardinal features, features of, of mucous, mucous cysts, cysts (, ( lower-lip, lower-lip pits, pits ), ) and, and clefts, clefts to, to the, the lip, lip and/or, and/or palate, palate ., . The, The vWS, vWS gene, gene has, has been, been assigned, assigned to, to a, a locus, locus in, in 1q32-q41, 1q32-q41 by, by linkage, linkage analysis, analysis and, and physical, physical mapping, mapping ., . We, We have, have investigated, investigated 5, 5 novel, novel vWS, vWS families, families through, through probands, probands attended, attended for, for cleft, cleft lip, lip and/or, and/or palate, palate repair, repair at, at the, the Department, Department of, of Maxillofacial, Maxillofacial Surgery, Surgery of, of Hopital, Hopital Trousseau, Trousseau ,, , Paris, Paris ,, , in, in order, order to, to tentatively, tentatively refine, refine the, the genetic, genetic map, map of, of the, the vWS, vWS region, region in, in 1q32-q41, 1q32-q41 and, and possibly, possibly identify, identify unlinked, unlinked pedigrees, pedigrees ., . Linkage, Linkage analysis, analysis was, was carried, carried out, out to, to 6, 6 microsatellite, microsatellite markers, markers (, ( D1S249, D1S249 ,, , D1S425, D1S425 ,, , D1S491, D1S491 ,, , D1S205, D1S205 ,, , D1S414, D1S414 ,, , D1S425, D1S425 ), ) ,, , yielding, yielding a, a maximum, maximum cumulative, cumulative LOD, LOD score, score of, of Z, Z =, = 3, 3 ., . 27, 27 at, at theta, theta =, = 0, 0 ., . 00, 00 for, for D1S245, D1S245 ., . The, The innermost, innermost four, four markers, markers were, were found, found to, to be, be tightly, tightly linked, linked to, to one, one another, another ,, , with, with no, no evidence, evidence for, for recombination, recombination ., . Our, Our results, results support, support linkage, linkage of, of vWS, vWS within, within a, a region, region of, of tightly, tightly linked, linked markers, markers and, and do, do not, not favour, favour locus, locus heterogeneity, heterogeneity of, of the, the disease, disease trait.Cutaneous, trait.Cutaneous and, and ocular, ocular pigmentation, pigmentation were, were evaluated, evaluated in, in 29, 29 individuals, individuals with, with the, the Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . Criteria, Criteria for, for hypopigmentation, hypopigmentation included, included the, the presence, presence of, of type, type I, I or, or II, II skin, skin ,, , the, the lightest, lightest skin, skin type, type in, in the, the family, family by, by history, history ,, , and, and iris, iris translucency, translucency on, on globe, globe transillumination, transillumination ., . On, On the, the basis, basis of, of these, these criteria, criteria ,, , 48, 48 %, % of, of the, the PWS, PWS individuals, individuals were, were hypopigmented, hypopigmented ., . The, The presence, presence of, of hypopigmentation, hypopigmentation correlated, correlated with, with a, a small, small interstitial, interstitial deletion, deletion on, on the, the proximal, proximal long, long arm, arm of, of chromosome, chromosome 15, 15 ;, ; however, however ,, , this, this deletion, deletion was, was also, also found, found in, in individuals, individuals who, who did, did not, not meet, meet the, the full, full criteria, criteria for, for hypopigmentation, hypopigmentation ., . Hairbulb, Hairbulb tyrosinase, tyrosinase activity, activity and, and glutathione, glutathione content, content ,, , as, as well, well as, as urine, urine cysteinyldopa, cysteinyldopa excretion, excretion ,, , were, were low, low in, in PWS, PWS individuals, individuals with, with and, and without, without hypopigmentation, hypopigmentation and, and did, did not, not separate, separate these, these two, two groups, groups ., . We, We conclude, conclude that, that hypopigmentation, hypopigmentation is, is found, found in, in a, a significant, significant proportion, proportion of, of individuals, individuals with, with PWS, PWS and, and that, that the, the hypopigmentation, hypopigmentation may, may be, be associated, associated with, with a, a deletion, deletion of, of the, the long, long arm, arm of, of chromosome, chromosome 15, 15 ., . The, The mechanism, mechanism for, for the, the hypopigmentation, hypopigmentation is, is unknown.., unknown.. The, The discovery, discovery of, of a, a large, large kindred, kindred with, with a, a heritable, heritable deficiency, deficiency of, of the, the fifth, fifth component, component of, of complement, complement (, ( C5, C5 ), ) has, has permitted, permitted the, the accumulation, accumulation of, of new, new clinical, clinical ,, , genetic, genetic and, and immunologic, immunologic data, data concerning, concerning the, the role, role of, of C5, C5 in, in human, human subjects, subjects ., . The, The proband, proband ,, , who, who has, has had, had nine, nine episodes, episodes of, of disseminated, disseminated gonococcal, gonococcal infection, infection ,, , has, has a, a hemolytic, hemolytic C5, C5 level, level of, of approximately, approximately 0, 0 ., . 5, 5 per, per cent, cent of, of normal, normal ., . No, No C5, C5 protein, protein was, was detectable, detectable ,, , but, but low, low levels, levels of, of functional, functional C5, C5 activity, activity could, could be, be found, found using, using a, a sensitive, sensitive bactericidal, bactericidal assay, assay ., . The, The probands, probands twin, twin as, as well, well as, as another, another sister, sister also, also had, had extremely, extremely low, low levels, levels of, of hemolytic, hemolytic C5, C5 (, ( approximately, approximately 0, 0 ., . 5, 5 per, per cent, cent normal, normal ), ) ,, , but, but both, both these, these subjects, subjects have, have been, been healthy, healthy ., . Hemolytic, Hemolytic complement, complement and, and bacteriolytic, bacteriolytic activity, activity could, could be, be restored, restored by, by the, the addition, addition of, of purified, purified C5, C5 ., . No, No chemotactic, chemotactic activity, activity for, for polymorphonuclear, polymorphonuclear leukocytes, leukocytes could, could be, be generated, generated in, in the, the C5-deficient, C5-deficient serums, serums upon, upon activation, activation of, of either, either the, the classic, classic or, or alternative, alternative pathways, pathways ,, , again, again demonstrating, demonstrating the, the importance, importance of, of C5, C5 in, in human, human subjects, subjects for, for the, the production, production of, of chemotactic, chemotactic factors, factors ., . The, The chemotactic, chemotactic responsiveness, responsiveness of, of the, the patients, patients polymorphonuclear, polymorphonuclear leukocytes, leukocytes and, and monocytes, monocytes to, to preformed, preformed chemotactic, chemotactic factors, factors was, was not, not depressed, depressed ., . Twenty-two, Twenty-two of, of 32, 32 other, other family, family members, members from, from three, three generations, generations had, had depressed, depressed whole, whole hemolytic, hemolytic complement, complement levels, levels ., . In, In 19, 19 of, of 30, 30 family, family members, members ,, , levels, levels of, of hemolytic, hemolytic C5, C5 ranged, ranged from, from 13, 13 to, to 64, 64 per, per cent, cent of, of normal, normal ., . No, No linkage, linkage for, for C5, C5 deficiency, deficiency and, and the, the A, A or, or B, B loci, loci of, of the, the major, major histocompatibility, histocompatibility complex, complex could, could be, be found, found ., . These, These data, data suggest, suggest an, an autosomal, autosomal codominant, codominant mode, mode of, of inheritance, inheritance of, of C5, C5 deficiency, deficiency ., . Deficiency, Deficiency of, of C5, C5 is, is compatible, compatible with, with good, good health, health ,, , but, but it, it can, can be, be associated, associated with, with repeated, repeated disseminated, disseminated gonococcal, gonococcal infection, infection Deficiency, Deficiency of, of glucose-6-phosphate, glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) is, is usually, usually found, found at, at high, high frequencies, frequencies in, in areas, areas of, of the, the world, world where, where malaria, malaria has, has been, been endemic, endemic ., . The, The frequency, frequency and, and genetic, genetic basis, basis of, of G6PD, G6PD deficiency, deficiency have, have been, been studied, studied in, in Africa, Africa ,, , around, around the, the Mediterranean, Mediterranean ,, , and, and in, in the, the Far, Far East, East ,, , but, but little, little such, such information, information is, is available, available about, about the, the situation, situation in, in India, India ., . To, To determine, determine the, the extent, extent of, of heterogeneity, heterogeneity of, of G6PD, G6PD ,, , we, we have, have studied, studied several, several different, different Indian, Indian populations, populations by, by screening, screening for, for G6PD, G6PD deficiency, deficiency ,, , followed, followed by, by molecular, molecular analysis, analysis of, of deficient, deficient alleles, alleles ., . The, The frequency, frequency of, of G6PD, G6PD deficiency, deficiency varies, varies between, between 3, 3 %, % and, and 15, 15 %, % in, in different, different tribal, tribal and, and urban, urban groups, groups ., . Remarkably, Remarkably ,, , a, a previously, previously unreported, unreported deficient, deficient variant, variant ,, , G6PD, G6PD Orissa, Orissa (, ( 44, 44 Ala, Ala --, -- >, > Gly, Gly ), ) ,, , is, is responsible, responsible for, for most, most of, of the, the G6PD, G6PD deficiency, deficiency in, in tribal, tribal Indian, Indian populations, populations but, but is, is not, not found, found in, in urban, urban populations, populations ,, , where, where most, most of, of the, the G6PD, G6PD deficiency, deficiency is, is due, due to, to the, the G6PD, G6PD Mediterranean, Mediterranean (, ( 188, 188 Ser, Ser --, -- >, > Phe, Phe ), ) variant, variant ., . The, The KmNADP, KmNADP of, of G6PD, G6PD Orissa, Orissa is, is fivefold, fivefold higher, higher than, than that, that of, of the, the normal, normal enzyme, enzyme ., . This, This may, may be, be due, due to, to the, the fact, fact that, that the, the alanine, alanine residue, residue that, that is, is replaced, replaced by, by glycine, glycine is, is part, part of, of a, a putative, putative coenzyme-binding, coenzyme-binding site.., site.. Denys-Drash, Denys-Drash syndrome, syndrome is, is a, a rare, rare human, human condition, condition in, in which, which severe, severe urogenital, urogenital aberrations, aberrations result, result in, in renal, renal failure, failure ,, , pseudohermaphroditism, pseudohermaphroditism ,, , and, and Wilms, Wilms tumor, tumor (, ( nephroblastoma, nephroblastoma ), ) ., . To, To investigate, investigate its, its possible, possible role, role ,, , we, we have, have analyzed, analyzed the, the coding, coding exons, exons of, of the, the Wilms, Wilms tumor, tumor suppressor, suppressor gene, gene (, ( WT1, WT1 ), ) for, for germline, germline mutations, mutations ., . In, In ten, ten independent, independent cases, cases of, of Denys-Drash, Denys-Drash syndrome, syndrome ,, , point, point mutations, mutations in, in the, the zinc, zinc finger, finger domains, domains of, of one, one WT1, WT1 gene, gene copy, copy were, were found, found ., . Nine, Nine of, of these, these mutations, mutations are, are found, found within, within exon, exon 9, 9 (, ( zinc, zinc finger, finger III, III ), ) ;, ; the, the remaining, remaining mutation, mutation is, is in, in exon, exon 8, 8 (, ( zinc, zinc finger, finger II, II ), ) ., . These, These mutations, mutations directly, directly affect, affect DNA, DNA sequence, sequence recognition, recognition ., . In, In two, two families, families analyzed, analyzed ,, , the, the mutations, mutations were, were shown, shown to, to arise, arise de, de novo, novo ., . Wilms, Wilms tumors, tumors from, from three, three individuals, individuals and, and one, one juvenile, juvenile granulosa, granulosa cell, cell tumor, tumor demonstrate, demonstrate reduction, reduction to, to homozygosity, homozygosity for, for the, the mutated, mutated WT1, WT1 allele, allele ., . Our, Our results, results provide, provide evidence, evidence of, of a, a direct, direct role, role for, for WT1, WT1 in, in Denys-Drash, Denys-Drash syndrome, syndrome and, and thus, thus urogenital, urogenital system, system development.., development.. A, A family, family of, of domestic, domestic cats, cats was, was found, found that, that exhibited, exhibited clinical, clinical and, and biochemical, biochemical abnormalities, abnormalities consistent, consistent with, with mucopolysaccharidosis, mucopolysaccharidosis VII, VII ,, , an, an autosomal, autosomal recessive, recessive lysosomal, lysosomal storage, storage disorder, disorder caused, caused by, by beta-glucuronidase, beta-glucuronidase deficiency, deficiency ., . beta-Glucuronidase, beta-Glucuronidase activity, activity was, was undetectable, undetectable in, in affected, affected cat, cat fibroblasts, fibroblasts and, and restored, restored by, by retroviral, retroviral gene, gene transfer, transfer of, of rat, rat beta-glucuronidase, beta-glucuronidase cDNA, cDNA ., . beta-Glucuronidase, beta-Glucuronidase mRNA, mRNA was, was normal, normal in, in affected, affected cat, cat testis, testis by, by Northern, Northern blot, blot analysis, analysis ., . Normal, Normal feline, feline beta-glucuronidase, beta-glucuronidase cDNA, cDNA was, was cloned, cloned and, and characterized, characterized ,, , and, and amplified, amplified from, from affected, affected cat, cat fibroblasts, fibroblasts by, by reverse, reverse transcription, transcription coupled, coupled polymerase, polymerase chain, chain reaction, reaction ., . There, There was, was a, a G-to-A, G-to-A transition, transition in, in the, the affected, affected cat, cat cDNA, cDNA that, that predicted, predicted an, an E351K, E351K substitution, substitution ,, , destroyed, destroyed a, a BssSI, BssSI site, site ,, , and, and eliminated, eliminated GUSB, GUSB enzymatic, enzymatic activity, activity in, in expression, expression studies, studies ., . Multiple, Multiple species, species comparison, comparison and, and the, the crystal, crystal structure, structure of, of human, human beta-glucuronidase, beta-glucuronidase indicated, indicated that, that E351, E351 is, is a, a highly, highly conserved, conserved residue, residue most, most likely, likely essential, essential in, in maintenance, maintenance of, of the, the enzymes, enzymes conformation, conformation ., . BssSI, BssSI digestion, digestion of, of polymerase, polymerase chain, chain reaction, reaction products, products amplified, amplified from, from genomic, genomic DNA, DNA indicated, indicated that, that affected, affected cats, cats were, were homozygous, homozygous and, and cats, cats with, with half-normal, half-normal beta-glucuronidase, beta-glucuronidase activity, activity were, were heterozygous, heterozygous for, for the, the missense, missense mutation, mutation ., . Carriers, Carriers identified, identified in, in this, this manner, manner produced, produced affected, affected kittens, kittens in, in prospective, prospective breedings, breedings ,, , and, and a, a feline, feline MPS, MPS VII, VII breeding, breeding colony, colony has, has been, been established.., established.. Papillon-Lefevre, Papillon-Lefevre syndrome, syndrome ,, , or, or keratosis, keratosis palmoplantaris, palmoplantaris with, with periodontopathia, periodontopathia (, ( PLS, PLS ,, , MIM, MIM 245000, 245000 ), ) ,, , is, is an, an autosomal, autosomal recessive, recessive disorder, disorder that, that is, is mainly, mainly ascertained, ascertained by, by dentists, dentists because, because of, of the, the severe, severe periodontitis, periodontitis that, that afflicts, afflicts patients, patients ., . Both, Both the, the deciduous, deciduous and, and permanent, permanent dentitions, dentitions are, are affected, affected ,, , resulting, resulting in, in premature, premature tooth, tooth loss, loss ., . Palmoplantar, Palmoplantar keratosis, keratosis ,, , varying, varying from, from mild, mild psoriasiform, psoriasiform scaly, scaly skin, skin to, to overt, overt hyperkeratosis, hyperkeratosis ,, , typically, typically develops, develops within, within the, the first, first three, three years, years of, of life, life ., . Keratosis, Keratosis also, also affects, affects other, other sites, sites such, such as, as elbows, elbows and, and knees, knees ., . Most, Most PLS, PLS patients, patients display, display both, both periodontitis, periodontitis and, and hyperkeratosis, hyperkeratosis ., . Some, Some patients, patients have, have only, only palmoplantar, palmoplantar keratosis, keratosis or, or periodontitis, periodontitis ,, , and, and in, in rare, rare individuals, individuals the, the periodontitis, periodontitis is, is mild, mild and, and of, of late, late onset, onset ., . The, The PLS, PLS locus, locus has, has been, been mapped, mapped to, to chromosome, chromosome 11q14-q21, 11q14-q21 (, ( refs, refs 7, 7 ,, , 8, 8 ,, , 9, 9 ), ) ., . Using, Using homozygosity, homozygosity mapping, mapping in, in eight, eight small, small consanguineous, consanguineous families, families ,, , we, we have, have narrowed, narrowed the, the candidate, candidate region, region to, to a, a 1, 1 ., . 2-cM, 2-cM interval, interval between, between D11S4082, D11S4082 and, and D11S931, D11S931 ., . The, The gene, gene (, ( CTSC, CTSC ), ) encoding, encoding the, the lysosomal, lysosomal protease, protease cathepsin, cathepsin C, C (, ( or, or dipeptidyl, dipeptidyl aminopeptidase, aminopeptidase I, I ), ) lies, lies within, within this, this interval, interval ., . We, We defined, defined the, the genomic, genomic structure, structure of, of CTSC, CTSC and, and found, found mutations, mutations in, in all, all eight, eight families, families ., . In, In two, two of, of these, these families, families we, we used, used a, a functional, functional assay, assay to, to demonstrate, demonstrate an, an almost, almost total, total loss, loss of, of cathepsin, cathepsin C, C activity, activity in, in PLS, PLS patients, patients and, and reduced, reduced activity, activity in, in obligate, obligate carriers, carriers ., . The, The breast, breast and, and ovarian, ovarian cancer, cancer susceptibility, susceptibility gene, gene ,, , BRCA1, BRCA1 ,, , has, has been, been cloned, cloned and, and shown, shown to, to encode, encode a, a zinc-finger, zinc-finger protein, protein of, of unknown, unknown function, function ., . Mutations, Mutations in, in BRCA1, BRCA1 account, account for, for at, at least, least 80, 80 %, % of, of families, families with, with both, both breast, breast and, and ovarian, ovarian cancer, cancer ,, , as, as well, well as, as some, some non-familial, non-familial sporadic, sporadic ovarian, ovarian cancers, cancers ., . The, The loss, loss of, of wild-type, wild-type BRCA1, BRCA1 in, in tumours, tumours of, of individuals, individuals carrying, carrying one, one nonfunctional, nonfunctional BRCA1, BRCA1 allele, allele suggests, suggests that, that BRCA1, BRCA1 encodes, encodes a, a tumour, tumour suppressor, suppressor that, that may, may inhibit, inhibit the, the proliferation, proliferation of, of mammary, mammary epithelial, epithelial cells, cells ., . To, To examine, examine the, the role, role of, of BRCA1, BRCA1 in, in normal, normal tissue, tissue growth, growth and, and differentiation, differentiation ,, , and, and to, to generate, generate a, a potential, potential model, model for, for the, the cancer, cancer susceptibility, susceptibility associated, associated with, with loss, loss of, of BRCA1, BRCA1 function, function ,, , we, we have, have created, created a, a mouse, mouse line, line carrying, carrying a, a mutation, mutation in, in one, one Brca1, Brca1 allele, allele ., . Analysis, Analysis of, of mice, mice homozygous, homozygous for, for the, the mutant, mutant allele, allele indicate, indicate that, that Brca1, Brca1 is, is critical, critical for, for normal, normal development, development ,, , as, as these, these mice, mice died, died in, in utero, utero between, between 10, 10 and, and 13, 13 days, days of, of gestation, gestation (, ( E10-E13, E10-E13 ), ) ., . Abnormalities, Abnormalities in, in Brca1-deficient, Brca1-deficient embryos, embryos were, were most, most evident, evident in, in the, the neural, neural tube, tube ,, , with, with 40, 40 %, % of, of the, the embryos, embryos presenting, presenting with, with varying, varying degrees, degrees of, of spina, spina bifida, bifida and, and anencephaly, anencephaly ., . In, In addition, addition ,, , the, the neuroepithelium, neuroepithelium in, in Brca1-deficient, Brca1-deficient embryos, embryos appeared, appeared disorganized, disorganized ,, , with, with signs, signs of, of both, both rapid, rapid proliferation, proliferation and, and excessive, excessive cell, cell death.., death.. A, A Saudi, Saudi Arab, Arab boy, boy presented, presented in, in early, early childhood, childhood with, with thrombocytopenia, thrombocytopenia ,, , morphologically, morphologically large, large and, and normal, normal sized, sized platelets, platelets ,, , increased, increased mean, mean platelet, platelet volume, volume ,, , and, and a, a hypermegakaryocytic, hypermegakaryocytic bone, bone marrow, marrow ., . There, There was, was no, no clinical, clinical and, and laboratory, laboratory evidence, evidence of, of any, any significant, significant immunological, immunological abnormalities, abnormalities ., . Similar, Similar findings, findings in, in two, two other, other brothers, brothers suggested, suggested strongly, strongly that, that they, they were, were all, all suffering, suffering from, from an, an X, X linked, linked recessive, recessive thrombocytopenic, thrombocytopenic disorder, disorder ., . Results, Results of, of DNA, DNA analysis, analysis with, with the, the probe, probe M27, M27 beta, beta are, are consistent, consistent with, with X, X linkage, linkage and, and indicate, indicate also, also that, that the, the locus, locus of, of the, the relevant, relevant gene, gene lies, lies close, close to, to or, or is, is identical, identical to, to the, the locus, locus of, of the, the gene, gene for, for the, the Wiskott-Aldrich, Wiskott-Aldrich syndrome, syndrome (, ( WAS, WAS ), ) ., . Because, Because of"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", of various, various features, features which, which include, include the, the presence, presence of, of large, large and, and normal, normal sized, sized platelets, platelets (, ( rather, rather than, than small, small platelets, platelets ), ) and, and freedom, freedom from, from significant, significant immune, immune deficiencies, deficiencies ,, , it, it is, is likely, likely that, that the, the X, X linked, linked recessive, recessive thrombocytopenia, thrombocytopenia in, in this, this family, family is, is an, an isolated, isolated entity, entity quite, quite distinct, distinct from, from the, the classical, classical WAS, WAS phenotype, phenotype ., . However, However ,, , a, a modified, modified expression, expression of, of the, the WAS, WAS gene, gene producing, producing a, a mild, mild phenotypic, phenotypic variant, variant can, can not, not be, be excluded, excluded entirely.., entirely.. We, We described, described 6, 6 patients, patients (, ( from, from 3, 3 families, families ), ) affected, affected with, with cerebrotendinous, cerebrotendinous xanthomatosis, xanthomatosis (, ( CTX, CTX ), ) ., . All, All are, are Sephardic, Sephardic Jews, Jews of, of Moroccan, Moroccan extraction, extraction ., . In, In view, view of, of the, the small, small number, number of, of CTX, CTX patients, patients diagnosed, diagnosed in, in the, the world, world (, ( a, a total, total of, of 50, 50 including, including our, our 6, 6 patients, patients ), ) ,, , we, we are, are probably, probably dealing, dealing with, with an, an ethnic, ethnic subgroup, subgroup with, with a, a high, high CTX, CTX gene, gene frequency, frequency ,, , which, which we, we have, have estimated, estimated to, to be, be 1/108, 1/108 ., . Since, Since there, there are, are differences, differences in, in expression, expression in, in this, this disease, disease ,, , we, we recommend, recommend cholestanol, cholestanol study, study in, in cases, cases of, of undiagnosed, undiagnosed cataract, cataract or, or tendinous, tendinous xanthomas, xanthomas in, in childhood, childhood or, or early, early adolescence, adolescence ., . The, The diagnosis, diagnosis in, in CTX, CTX is, is important, important not, not only, only for, for genetic, genetic counseling, counseling ,, , but, but also, also in, in veiw, veiw of, of possible, possible treatment.., treatment.. Plasma, Plasma HDL, HDL are, are a, a negative, negative risk, risk factor, factor for, for atherosclerosis, atherosclerosis ., . Cholesteryl, Cholesteryl ester, ester transfer, transfer protein, protein (, ( CETP, CETP ;, ; 476, 476 amino, amino acids, acids ), ) transfers, transfers cholesteryl, cholesteryl ester, ester from, from HDL, HDL to, to other, other lipoproteins, lipoproteins ., . Subjects, Subjects with, with homozygous, homozygous CETP, CETP deficiency, deficiency caused, caused by, by a, a gene, gene splicing, splicing defect, defect have, have markedly, markedly elevated, elevated HDL, HDL ;, ; however, however ,, , heterozygotes, heterozygotes have, have only, only mild, mild increases, increases in, in HDL, HDL ., . We, We describe, describe two, two probands, probands with, with a, a CETP, CETP missense, missense mutation, mutation (, ( 442, 442 D, D G, G ), ) ., . Although, Although heterozygous, heterozygous ,, , they, they have, have threefold, threefold increases, increases in, in HDL, HDL concentration, concentration and, and markedly, markedly decreased, decreased plasma, plasma CETP, CETP mass, mass and, and activity, activity ,, , suggesting, suggesting that, that the, the mutation, mutation has, has dominant, dominant effects, effects on, on CETP, CETP and, and HDL, HDL in, in vivo, vivo ., . Cellular, Cellular expression, expression of, of mutant, mutant cDNA, cDNA results, results in, in secretion, secretion of, of only, only 30, 30 %, % of, of wild, wild type, type CETP, CETP activity, activity ., . Moreover, Moreover ,, , coexpression, coexpression of, of wild, wild type, type and, and mutant, mutant cDNAs, cDNAs leads, leads to, to inhibition, inhibition of, of wild, wild type, type secretion, secretion and, and activity, activity ., . The, The dominant, dominant effects, effects of, of the, the CETP, CETP missense, missense mutation, mutation during, during cellular, cellular expression, expression probably, probably explains, explains why, why the, the probands, probands have, have markedly, markedly increased, increased HDL, HDL in, in the, the heterozygous, heterozygous state, state ,, , and, and suggests, suggests that, that the, the active, active molecular, molecular species, species of, of CETP, CETP may, may be, be multimeric.., multimeric.. A, A total, total of, of 63, 63 families, families with, with Huntington, Huntington disease, disease (, ( HD, HD ), ) were, were examined, examined for, for linkage, linkage between, between HD, HD and, and G8, G8 (, ( D4S10, D4S10 ), ) ., . The, The families, families included, included 57, 57 Caucasian, Caucasian ,, , four, four Black, Black American, American ,, , and, and two, two Japanese, Japanese ., . The, The combined, combined maximum, maximum lod, lod score, score was, was 87, 87 ., . 69, 69 at, at theta, theta =, = 0, 0 ., . 04, 04 (, ( 99, 99 %, % confidence, confidence interval, interval 0, 0 ., . 018-0, 018-0 ., . 071, 071 ), ) ., . The, The maximum, maximum frequency, frequency of, of recombination, recombination was, was 0, 0 ., . 03, 03 in, in males, males and, and 0, 0 ., . 05, 05 in, in females, females ., . Fifty-seven, Fifty-seven families, families gave, gave positive, positive lod, lod scores, scores ;, ; five, five small, small families, families gave, gave mildly, mildly negative, negative lod, lod scores, scores ., . The, The maximum, maximum likelihood, likelihood estimate, estimate of, of alpha, alpha ,, , the, the proportion, proportion of, of linked, linked loci, loci ,, , was, was 1, 1 ., . 0, 0 with, with a, a lower, lower 99, 99 %, % confidence, confidence interval, interval of, of 0, 0 ., . 88, 88 ., . These, These data, data suggest, suggest that, that there, there is, is only, only one, one HD, HD locus, locus ,, , although, although a, a second, second rare, rare locus, locus can, can not, not be, be ruled, ruled out, out ., . Severe, Severe von, von Willebrand, Willebrand disease, disease is, is characterized, characterized by, by undetectable, undetectable or, or trace, trace quantities, quantities of, of von, von Willebrand, Willebrand factor, factor in, in plasma, plasma and, and tissue, tissue stores, stores ., . We, We have, have studied, studied the, the genomic, genomic DNA, DNA of, of 10, 10 affected, affected individuals, individuals from, from six, six families, families with, with this, this disorder, disorder using, using probes, probes from, from the, the 5, 5 and, and 3, 3 ends, ends of, of the, the vWF, vWF cDNA, cDNA and, and with, with a, a probe, probe extending, extending from, from the, the 5, 5 end, end into, into the, the central, central region, region ., . Southern, Southern blots, blots of, of restriction, restriction endonuclease, endonuclease digests, digests and, and gene, gene dosage, dosage analysis, analysis measurements, measurements carried, carried out, out with, with quantitative, quantitative slot, slot blots, blots of, of undigested, undigested genomic, genomic DNA, DNA separated, separated these, these patients, patients into, into three, three groups, groups ., . The, The first, first group, group consisted, consisted of, of a, a family, family with, with complete, complete homozygous, homozygous deletions, deletions of, of the, the vWF, vWF gene, gene in, in the, the four, four probands, probands ., . Gene, Gene dosage, dosage analysis, analysis was, was consistent, consistent with, with heterozygous, heterozygous deletions, deletions in, in both, both of, of the, the asymptomatic, asymptomatic parents, parents and, and four, four asymptomatic, asymptomatic siblings, siblings of, of this, this kindred, kindred (, ( P, P less, less than, than 0, 0 ., . 01, 01 ), ) ., . The, The second, second group, group was, was comprised, comprised of, of a, a family, family in, in which, which there, there was, was a, a complete, complete heterozygous, heterozygous deletion, deletion of, of the, the vWF, vWF gene, gene in, in the, the proband, proband and, and one, one asymptomatic, asymptomatic parent, parent ,, , suggesting, suggesting that, that a, a different, different type, type of, of genetic, genetic abnormality, abnormality was, was inherited, inherited from, from the, the other, other parent, parent ., . Thus, Thus ,, , the, the patient, patient appeared, appeared to, to be, be doubly, doubly heterozygous, heterozygous for, for interacting, interacting genetic, genetic abnormalities, abnormalities affecting, affecting vWF, vWF expression, expression ., . In, In the, the third, third group, group ,, , no, no gene, gene deletions, deletions could, could be, be detected, detected ., . Alloantibodies, Alloantibodies developed, developed only, only in, in the, the kindred, kindred with, with homozygous, homozygous deletions, deletions ., . These, These techniques, techniques should, should prove, prove useful, useful in, in identifying, identifying carriers, carriers of, of severe, severe von, von Willebrand, Willebrand disease, disease and, and also, also in, in defining, defining patients, patients predictably, predictably at, at risk, risk of, of developing, developing alloantibodies, alloantibodies to, to vWF, vWF ., . Germline, Germline mutations, mutations in, in the, the RB1, RB1 gene, gene confer, confer hereditary, hereditary predisposition, predisposition to, to retinoblastoma, retinoblastoma ., . We, We have, have performed, performed a, a mutation, mutation survey, survey of, of the, the RB1, RB1 gene, gene in, in 232, 232 patients, patients with, with hereditary, hereditary or, or non, non hereditary, hereditary retinoblastoma, retinoblastoma ., . We, We systematically, systematically explored, explored all, all 27, 27 exons, exons and, and flanking, flanking sequences, sequences as, as well, well as, as the, the promotor, promotor ., . All, All types, types of, of point, point mutations, mutations are, are represented, represented and, and are, are found, found unequally, unequally distributed, distributed along, along the, the RB1, RB1 gene, gene sequence, sequence ., . In, In the, the population, population we, we studied, studied ,, , exons, exons 3, 3 ,, , 8, 8 ,, , 18, 18 and, and 19, 19 are, are preferentially, preferentially altered, altered ., . The, The range, range of, of frequency, frequency of, of detection, detection of, of germline, germline mutations, mutations is, is about, about 20, 20 %, % ,, , indicating, indicating that, that other, other mechanisms, mechanisms of, of inactivation, inactivation of, of RB1, RB1 should, should be, be involved, involved ., . The, The spectrum, spectrum of, of mutations, mutations presented, presented here, here should, should help, help to, to improve, improve the, the clinical, clinical management, management of, of retinoblastoma, retinoblastoma and, and to, to understand, understand the, the molecular, molecular mechanisms, mechanisms leading, leading to, to tumorigenesis.., tumorigenesis.. The, The nosology, nosology of, of the, the inborn, inborn errors, errors of, of myelin, myelin metabolism, metabolism has, has been, been stymied, stymied by, by the, the lack, lack of, of molecular, molecular genetic, genetic analysis, analysis ., . Historically, Historically ,, , Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease has, has encompassed, encompassed a, a host, host of, of neurologic, neurologic disorders, disorders that, that present, present with, with a, a deficit, deficit of, of myelin, myelin ,, , the, the membrane, membrane elaborated, elaborated by, by glial, glial cells, cells that, that encircles, encircles and, and successively, successively enwraps, enwraps axons, axons ., . We, We describe, describe here, here a, a Pelizaeus-Merzbacher, Pelizaeus-Merzbacher pedigree, pedigree of, of the, the classical, classical type, type ,, , with, with X-linked, X-linked inheritance, inheritance ,, , a, a typical, typical clinical, clinical progression, progression ,, , and, and a, a pathologic, pathologic loss, loss of, of myelinating, myelinating cells, cells and, and myelin, myelin in, in the, the central, central nervous, nervous system, system ., . To, To discriminate, discriminate variants, variants of, of Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease ,, , a, a set, set of, of oligonucleotide, oligonucleotide primers, primers was, was constructed, constructed to, to polymerase-chain-reaction, polymerase-chain-reaction (, ( PCR, PCR ), ) amplify, amplify and, and sequence, sequence the, the gene, gene encoding, encoding proteolipid, proteolipid protein, protein (, ( PLP, PLP ), ) ,, , a, a structural, structural protein, protein that, that comprises, comprises half, half of, of the, the protein, protein of, of the, the myelin, myelin sheath, sheath ., . The, The PLP, PLP gene, gene in, in one, one of, of two, two affected, affected males, males and, and the, the carrier, carrier mother, mother of, of this, this family, family exhibited, exhibited a, a single, single base, base difference, difference in, in the, the more, more than, than 2, 2 kb, kb of, of the, the PLP, PLP gene, gene sequenced, sequenced ,, , a, a C, C --, -- --, -- T, T transition, transition that, that would, would create, create a, a serine, serine substitution, substitution for, for proline, proline at, at the, the carboxy, carboxy end, end of, of the, the protein, protein ., . Our, Our results, results delineate, delineate the, the clinical, clinical features, features of, of Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease ,, , define, define the, the possible, possible molecular, molecular pathology, pathology of, of this, this dysmyelinating, dysmyelinating disorder, disorder ,, , and, and address, address the, the molecular, molecular classification, classification of, of inborn, inborn errors, errors of, of myelin, myelin metabolism, metabolism ., . Patients, Patients with, with the, the classical, classical form, form (, ( type, type I, I ), ) and, and the, the more, more severely, severely affected, affected ,, , connatal, connatal variant, variant of, of Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease (, ( type, type II, II ), ) would, would be, be predicted, predicted to, to display, display mutation, mutation at, at the, the PLP, PLP locus, locus ., . The, The other, other variants, variants (, ( types, types III-VI, III-VI ), ) ,, , which, which have, have sometimes, sometimes been, been categorized, categorized as, as Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease ,, , may, may represent, represent mutations, mutations in, in genes, genes encoding, encoding other, other structural, structural myelin, myelin proteins, proteins or, or proteins, proteins critical, critical to, to myelination.., myelination.. We, We have, have identified, identified a, a novel, novel gene, gene containing, containing CAG, CAG repeats, repeats and, and mapped, mapped it, it to, to chromosome, chromosome 14q32, 14q32 ., . 1, 1 ,, , the, the genetic, genetic locus, locus for, for Machado-Joseph, Machado-Joseph disease, disease (, ( MJD, MJD ), ) ., . In, In normal, normal individuals, individuals the, the gene, gene contains, contains between, between 13, 13 and, and 36, 36 CAG, CAG repeats, repeats ,, , whereas, whereas most, most of, of the, the clinically, clinically diagnosed, diagnosed patients, patients and, and all, all of, of the, the affected, affected members, members of, of a, a family, family with, with the, the clinical, clinical and, and pathological, pathological diagnosis, diagnosis of, of MJD, MJD show, show expansion, expansion of, of the, the repeat-number, repeat-number (, ( from, from 68-79, 68-79 ), ) ., . Southern, Southern blot, blot analyses, analyses and, and genomic, genomic cloning, cloning demonstrates, demonstrates the, the existence, existence of, of related, related genes, genes ., . These, These results, results raise, raise the, the possibility, possibility that, that similar, similar abnormalities, abnormalities in, in related, related genes, genes may, may give, give rise, rise to, to diseases, diseases similar, similar to, to MJD, MJD ., . A, A portion, portion of, of the, the Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene transcript, transcript from, from human, human fetal, fetal skeletal, skeletal muscle, muscle and, and mouse, mouse adult, adult heart, heart was, was sequenced, sequenced ,, , representing, representing approximately, approximately 25, 25 percent, percent of, of the, the total, total ,, , 14-kb, 14-kb DMD, DMD transcript, transcript ., . The, The nucleic, nucleic acid, acid and, and predicted, predicted amino, amino acid, acid sequences, sequences from, from the, the two, two species, species are, are nearly, nearly 90, 90 percent, percent homologous, homologous ., . The, The amino, amino acid, acid sequence, sequence that, that is, is predicted, predicted from, from this, this portion, portion of, of the, the DMD, DMD gene, gene indicates, indicates that, that the, the protein, protein product, product might, might serve, serve a, a structural, structural role, role in, in muscle, muscle ,, , but, but the, the abundance, abundance and, and tissue, tissue distribution, distribution of, of the, the messenger, messenger RNA, RNA suggests, suggests that, that the, the DMD, DMD protein, protein is, is not, not nebulin.., nebulin.. To, To ascertain, ascertain the, the molecular, molecular mechanism, mechanism that, that causes, causes murine, murine C5, C5 deficiency, deficiency ,, , genomic, genomic and, and cDNA, cDNA libraries, libraries were, were constructed, constructed from, from mouse, mouse liver, liver DNA, DNA and, and mRNA, mRNA employing, employing the, the congenic, congenic strains, strains B10, B10 ., . D2/nSnJ, D2/nSnJ and, and B10, B10 ., . D2/oSnJ, D2/oSnJ that, that are, are sufficient, sufficient and, and deficient, deficient for, for C5, C5 ,, , respectively, respectively ., . Genomic, Genomic fragments, fragments were, were isolated, isolated which, which correspond, correspond to, to PvuII, PvuII and, and HindIII, HindIII restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms associated, associated with, with C5, C5 deficiency, deficiency ., . Sequence, Sequence analyses, analyses demonstrated, demonstrated that, that each, each of, of these, these polymorphisms, polymorphisms resulted, resulted from, from single, single base, base pair, pair substitutions, substitutions and, and that, that neither, neither substitution, substitution would, would probably, probably cause, cause or, or contribute, contribute to, to the, the C5, C5 deficiency, deficiency ., . Sequence, Sequence analyses, analyses of, of C5, C5 sufficient, sufficient and, and deficient, deficient cDNAs, cDNAs revealed, revealed a, a 2, 2 base-pair, base-pair deletion, deletion in, in the, the deficient, deficient cDNAs, cDNAs ., . The, The ``, `` TA, TA ``, `` deletion, deletion was, was located, located near, near the, the 5, 5 end, end of, of the, the cDNA, cDNA ., . This, This deletion, deletion shifts, shifts the, the reading, reading frame, frame of, of the, the C5, C5 mRNA, mRNA so, so that, that the, the termination, termination codon, codon UGA, UGA is, is present, present 4, 4 base, base pairs, pairs downstream, downstream from, from the, the deletion, deletion ., . Genomic, Genomic DNA, DNA was, was amplified, amplified and, and sequenced, sequenced corresponding, corresponding to, to the, the area, area surrounding, surrounding the, the 2-base, 2-base pair, pair deletion, deletion ., . Six, Six C5-deficient, C5-deficient strains, strains ,, , A/HeJ, A/HeJ ,, , AKR/J, AKR/J ,, , DBA/2J, DBA/2J ,, , NZB/B1NJ, NZB/B1NJ ,, , SWR/J, SWR/J ,, , and, and B10, B10 ., . D2/oSnJ, D2/oSnJ ,, , and, and four, four C5-sufficient, C5-sufficient strains, strains ,, , Balb/CJ, Balb/CJ ,, , C57Bl/6J, C57Bl/6J ,, , DBA/1J, DBA/1J ,, , and, and B10, B10 ., . D2/nSnJ, D2/nSnJ ,, , were, were analyzed, analyzed ., . The, The sequencing, sequencing data, data revealed, revealed that, that the, the 2, 2 base, base pairs, pairs were, were deleted, deleted from, from the, the C5, C5 gene, gene of, of each, each deficient, deficient mouse, mouse tested, tested but, but not, not from, from the, the C5, C5 gene, gene of, of any, any sufficient, sufficient mouse, mouse ., . These, These data, data demonstrate, demonstrate that, that 1, 1 ), ) there, there is, is an, an identical, identical 2-base, 2-base pair, pair deletion, deletion in, in an, an exon, exon of, of the, the C5, C5 gene, gene in, in several, several different, different C5-deficient, C5-deficient mouse, mouse strains, strains ;, ; 2, 2 ), ) the, the mRNA, mRNA transcribed, transcribed from, from the, the C5D, C5D gene, gene retains, retains this, this deletion, deletion ;, ; and, and 3, 3 ), ) this, this mutation, mutation should, should result, result in, in C5, C5 protein, protein deficiency.We, deficiency.We describe, describe the, the first, first cases, cases ,, , to, to our, our knowledge, knowledge ,, , of, of C9, C9 deficiency, deficiency in, in Europe, Europe that, that were, were detected, detected in, in a, a Swiss, Swiss family, family ,, , of, of which, which two, two members, members --, -- one, one with, with a, a complete, complete deficiency, deficiency and, and the, the other, other with, with approximately, approximately half-normal, half-normal C9, C9 levels, levels --, -- experienced, experienced bacterial, bacterial meningitis, meningitis ., . The, The index, index patient, patient ,, , a, a 56-year-old, 56-year-old white, white man, man with, with a, a history, history of, of purulent, purulent meningitis, meningitis at, at the, the age, age of, of 23, 23 years, years ,, , presented, presented with, with an, an acute, acute meningococcal, meningococcal meningitis, meningitis ., . No, No impairment, impairment of, of cellular, cellular immunity, immunity or, or immunoglobulin, immunoglobulin deficiency, deficiency could, could be, be found, found ., . Complement, Complement assays, assays showed, showed a, a complete, complete deficiency, deficiency of, of the, the C9, C9 component, component ,, , while, while the, the other, other individual, individual component, component levels, levels were, were normal, normal and, and the, the hemolytic, hemolytic activity, activity (, ( measured, measured using, using the, the CH50, CH50 assay, assay ), ) was, was only, only slightly, slightly reduced, reduced ., . A, A family, family study, study revealed, revealed complete, complete C9, C9 deficiency, deficiency in, in the, the patients, patients healthy, healthy brother, brother and, and half-normal, half-normal C9, C9 concentrations, concentrations in, in his, his sister, sister ,, , his, his son, son (, ( who, who also, also had, had experienced, experienced an, an episode, episode of, of bacterial, bacterial meningitis, meningitis ), ) ,, , and, and his, his niece, niece ,, , consistent, consistent with, with an, an inherited, inherited C9, C9 deficiency, deficiency ., . This, This first, first case, case of, of recurrent, recurrent meningitis, meningitis in, in a, a white, white patient, patient with, with complete, complete C9, C9 deficiency, deficiency suggests, suggests that, that this, this complement, complement defect, defect may, may also, also be, be a, a risk, risk factor, factor for, for bacterial, bacterial ,, , especially, especially neisserial, neisserial ,, , infections.., infections.. An, An allogeneic, allogeneic bone, bone marrow, marrow transplant, transplant (, ( BMT, BMT ), ) from, from a, a normal, normal HLA, HLA identical, identical sibling, sibling donor, donor was, was performed, performed in, in a, a 13-year-old, 13-year-old boy, boy with, with rapidly, rapidly progressive, progressive adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) ., . Engraftment, Engraftment and, and complete, complete hematologic, hematologic recovery, recovery occurred, occurred within, within 4, 4 weeks, weeks ,, , but, but neurologic, neurologic deterioration, deterioration continued, continued ., . The, The patient, patient died, died of, of an, an adenovirus, adenovirus infection, infection 141, 141 days, days after, after BMT, BMT ., . ALD, ALD is, is characterized, characterized by, by abnormally, abnormally high, high plasma, plasma levels, levels of, of very, very long, long chain, chain fatty, fatty acids, acids (, ( VLCFA, VLCFA ), ) as, as a, a result, result of, of impaired, impaired capacity, capacity to, to degrade, degrade them, them ., . Ten, Ten days, days after, after BMT, BMT ,, , the, the white, white blood, blood cell, cell VLCFA, VLCFA levels, levels and, and enzyme, enzyme activity, activity became, became normal, normal ;, ; after, after 3, 3 months, months ,, , there, there was, was progressive, progressive reduction, reduction of, of plasma, plasma VLCFA, VLCFA to, to levels, levels only, only slightly, slightly above, above normal.., normal.. Glucose-6-phosphate, Glucose-6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency in, in RBCs, RBCs was, was found, found significantly, significantly more, more frequently, frequently in, in 210, 210 male, male cataractous, cataractous patients, patients than, than in, in 672, 672 control, control subjects, subjects of, of Sardinian, Sardinian origin, origin ., . The, The frequency, frequency of, of the, the deficiency, deficiency was, was increasingly, increasingly higher, higher in, in presenile, presenile cataracts, cataracts ., . In, In the, the G6PD-deficient, G6PD-deficient group, group ,, , the, the incidence, incidence of, of cortical, cortical and, and total, total cataracts, cataracts was, was also, also increased, increased ., . It, It is, is suggested, suggested that, that decrease, decrease of, of the, the G6PD, G6PD activity, activity in, in the, the lens, lens ,, , which, which accompanies, accompanies its, its deficiency, deficiency in, in the, the erythrocyte, erythrocyte ,, , might, might play, play a, a role, role in, in the, the cataracto-genesis, cataracto-genesis of, of these, these patients, patients ., . Moreover, Moreover ,, , G6PD, G6PD deficiency, deficiency should, should be, be added, added to, to other, other conditions, conditions ,, , such, such as, as the, the galactosemic, galactosemic states, states and, and riboflavin, riboflavin deficiency, deficiency ,, , where, where cataracts, cataracts represent, represent a, a sensitive, sensitive indicator, indicator of, of metabolic, metabolic abnormalities, abnormalities of, of the, the RBC.., RBC.. Von, Von Hippel-Lindau, Hippel-Lindau disease, disease (, ( VHL, VHL ), ) is, is an, an autosomal, autosomal dominant, dominant disorder, disorder with, with inherited, inherited susceptibility, susceptibility to, to various, various forms, forms of, of cancer, cancer ,, , including, including hemangioblastomas, hemangioblastomas of, of the, the central, central nervous, nervous system, system ,, , phaeochromocytomas, phaeochromocytomas ,, , pancreatic, pancreatic malignancies, malignancies ,, , and, and renal, renal cell, cell carcinomas, carcinomas ., . Renal, Renal cell, cell carcinomas, carcinomas constitute, constitute a, a particularly, particularly frequent, frequent cause, cause of, of death, death in, in this, this disorder, disorder ,, , occurring, occurring as, as bilateral, bilateral and, and multifocal, multifocal tumours, tumours ,, , and, and presenting, presenting at, at an, an earlier, earlier age, age than, than in, in sporadic, sporadic ,, , non-familial, non-familial cases, cases of, of this, this tumour, tumour type, type ., . We, We report, report here, here that, that the, the VHL, VHL gene, gene is, is linked, linked to, to the, the locus, locus encoding, encoding the, the human, human homologoue, homologoue of, of the, the RAF1, RAF1 oncogene, oncogene ,, , which, which maps, maps to, to chromosome, chromosome 3p25, 3p25 (, ( ref, ref ., . 4, 4 ), ) ., . Crossovers, Crossovers with, with the, the VHL, VHL locus, locus suggest, suggest that, that the, the defect, defect responsible, responsible for, for the, the VHL, VHL phenotype, phenotype is, is not, not a, a mutation, mutation in, in the, the RAF1, RAF1 gene, gene itself, itself ., . An, An alternative, alternative or, or prior, prior event, event to, to oncogene, oncogene activation, activation in, in tumour, tumour formation, formation may, may be, be the, the inactivation, inactivation of, of a, a putative, putative tumour, tumour suppressor, suppressor which, which can, can be, be associated, associated with, with both, both the, the inherited, inherited and, and sporadic, sporadic forms, forms of, of the, the cancer, cancer ., . Sporadic, Sporadic renal, renal cell, cell carcinomas, carcinomas have, have previously, previously been, been associated, associated with, with the, the loss, loss of, of regions, regions on, on chromosome, chromosome 3p, 3p (, ( refs, refs 5, 5 ,, , 6, 6 ), ) ., . Consequently, Consequently ,, , sporadic, sporadic and, and VHL-associated, VHL-associated forms, forms of, of renal, renal cell, cell carcinoma, carcinoma might, might both, both result, result from, from alterations, alterations causing, causing loss, loss of, of function, function of, of the, the same, same tumour, tumour suppressor, suppressor gene, gene on, on this, this chromosome.., chromosome.. The, The Lowe, Lowe oculocerebrorenal, oculocerebrorenal syndrome, syndrome (, ( OCRL, OCRL ), ) is, is characterized, characterized by, by congenital, congenital cataract, cataract ,, , mental, mental retardation, retardation ,, , and, and defective, defective renal, renal tubular, tubular function, function ., . A, A map, map assignment, assignment of, of OCRL, OCRL to, to Xq24-q26, Xq24-q26 has, has been, been made, made previously, previously by, by linkage, linkage analysis, analysis with, with DXS42, DXS42 at, at Xq24-q26, Xq24-q26 (, ( theta, theta =, = 0, 0 ,, , z, z =, = 5, 5 ., . 09, 09 ), ) and, and with, with DXS10, DXS10 at, at Xq26, Xq26 (, ( theta, theta =, = 0, 0 ,, , z, z =, = 6, 6 ., . 45, 45 ), ) ., . Two, Two additional, additional families, families were, were studied, studied and, and three, three additional, additional polymorphisms, polymorphisms were, were identified, identified at, at DXS42, DXS42 by, by using, using a, a 35-kb, 35-kb sequence, sequence isolated, isolated with, with the, the probe, probe detecting, detecting the, the original, original polymorphism, polymorphism at, at DXS42, DXS42 ., . With, With additional, additional OCRL, OCRL families, families made, made informative, informative for, for DXS42, DXS42 ,, , theta, theta remained, remained 0, 0 with, with z, z =, = 6, 6 ., . 63, 63 ;, ; and, and for, for DXS10, DXS10 theta, theta =, = 0, 0 ., . 03, 03 and, and z, z =, = 7, 7 ., . 07, 07 ., . Evidence, Evidence for, for placing, placing OCRL, OCRL at, at Xq25, Xq25 also, also comes, comes from, from a, a female, female with, with Lowe, Lowe syndrome, syndrome and, and an, an X, X ;, ; 3, 3 translocation, translocation ., . We, We have, have used, used the, the Xq25, Xq25 breakpoint, breakpoint in, in this, this patient, patient to, to determine, determine the, the position, position of, of OCRL, OCRL relative, relative to, to the, the two, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "two linked, linked markers, markers ., . Each, Each derivative, derivative chromosome, chromosome was, was isolated, isolated away, away from, from its, its normal, normal counterpart, counterpart in, in somatic, somatic cell, cell hybrids, hybrids ., . DXS42, DXS42 was, was mapped, mapped to, to the, the derivative, derivative chromosome, chromosome X, X containing, containing Xpterq25, Xpterq25 ,, , and, and DXS10, DXS10 was, was mapped, mapped to, to the, the derivative, derivative chromosome, chromosome 3, 3 containing, containing Xq25-qter, Xq25-qter ., . The, The markers, markers DXS10, DXS10 and, and DXS42, DXS42 therefore, therefore show, show tight, tight linkage, linkage with, with OCRL, OCRL in, in six, six families, families and, and flank, flank the, the Xq25, Xq25 breakpoint, breakpoint in, in a, a female, female patient, patient with, with an, an X, X ;, ; 3, 3 translocation, translocation ., . Linkage, Linkage analysis, analysis with, with flanking, flanking markers, markers was, was used, used to, to assess, assess OCRL, OCRL carrier, carrier status, status in, in women, women at, at risk, risk ., . Results, Results ,, , when, when compared, compared with, with carrier, carrier determination, determination by, by ophthalmologic, ophthalmologic examination, examination ,, , indicated, indicated that, that the, the slit-lamp, slit-lamp exam, exam can, can be, be a, a sensitive, sensitive and, and specific, specific method, method of, of carrier, carrier determination, determination in, in many, many cases, cases Motor, Motor incoordination, incoordination ,, , immune, immune deficiencies, deficiencies ,, , and, and an, an increased, increased risk, risk of, of cancer, cancer are, are the, the characteristic, characteristic features, features of, of the, the hereditary, hereditary disease, disease ataxia-telangiectasia, ataxia-telangiectasia (, ( A-T, A-T ), ) ,, , which, which is, is caused, caused by, by mutations, mutations in, in the, the ATM, ATM gene, gene ., . Through, Through gene, gene targeting, targeting ,, , we, we have, have generated, generated a, a line, line of, of Atm, Atm mutant, mutant mice, mice ,, , Atm, Atm (, ( y/y, y/y ), ) mice, mice ., . In, In contrast, contrast to, to other, other Atm, Atm mutant, mutant mice, mice ,, , Atm, Atm (, ( y/y, y/y ), ) mice, mice show, show a, a lower, lower incidence, incidence of, of thymic, thymic lymphoma, lymphoma and, and survive, survive beyond, beyond a, a few, few months, months of, of age, age ., . Atm, Atm (, ( y/y, y/y ), ) mice, mice exhibit, exhibit deficits, deficits in, in motor, motor learning, learning indicative, indicative of, of cerebellar, cerebellar dysfunction, dysfunction ., . Even, Even though, though we, we found, found no, no gross, gross cerebellar, cerebellar degeneration, degeneration in, in older, older Atm, Atm (, ( y/y, y/y ), ) animals, animals ,, , ectopic, ectopic and, and abnormally, abnormally differentiated, differentiated Purkinje, Purkinje cells, cells were, were apparent, apparent in, in mutant, mutant mice, mice of, of all, all ages, ages ., . These, These findings, findings establish, establish that, that some, some neuropathological, neuropathological abnormalities, abnormalities seen, seen in, in A-T, A-T patients, patients also, also are, are present, present in, in Atm, Atm mutant, mutant mice, mice ., . In, In addition, addition ,, , we, we report, report a, a previously, previously unrecognized, unrecognized effect, effect of, of Atm, Atm deficiency, deficiency on, on development, development or, or maintenance, maintenance of, of CD4, CD4 (, ( +, + ), ) 8, 8 (, ( +, + ), ) thymocytes, thymocytes ., . We, We discuss, discuss these, these findings, findings in, in the, the context, context of, of the, the hypothesis, hypothesis that, that abnormal, abnormal development, development of, of Purkinje, Purkinje cells, cells and, and lymphocytes, lymphocytes contributes, contributes to, to the, the pathogenesis, pathogenesis of, of A-T.., A-T.. The, The high, high prevalence, prevalence of, of glucose, glucose 6-phosphate, 6-phosphate dehydrogenase, dehydrogenase (, ( G6PD, G6PD ), ) deficiency, deficiency in, in African, African populations, populations is, is due, due almost, almost entirely, entirely to, to the, the enzyme, enzyme variant, variant A-, A- ,, , which, which differs, differs from, from the, the wild-type, wild-type G6PD, G6PD B, B by, by two, two amino, amino acid, acid replacements, replacements ,, , 68, 68 Val, Val --, -- >, > Met, Met and, and 126, 126 Asn, Asn --, -- >, > Asp, Asp ., . The, The non-deficient, non-deficient polymorphic, polymorphic variant, variant G6PD, G6PD A, A contains, contains only, only the, the mutation, mutation 126, 126 Asn, Asn --, -- >, > Asp, Asp ., . The, The frequencies, frequencies of, of the, the G6PD, G6PD A, A and, and of, of the, the G6PD, G6PD A-, A- genes, genes in, in parts, parts of, of Africa, Africa are, are both, both about, about 0, 0 ., . 2, 2 ., . The, The 68, 68 Val, Val --, -- >, > Met, Met mutation, mutation has, has not, not been, been found, found in, in a, a B, B background, background ., . This, This could, could be, be because, because the, the 68, 68 Val, Val --, -- >, > Met, Met mutation, mutation happened, happened to, to arise, arise in, in an, an A, A gene, gene in, in the, the first, first instance, instance ,, , or, or because, because the, the 68, 68 Val, Val --, -- >, > Met, Met mutation, mutation alone, alone is, is not, not sufficient, sufficient to, to cause, cause G6PD, G6PD deficiency, deficiency ., . We, We have, have approached, approached this, this question, question by, by producing, producing G6PD, G6PD B, B ,, , A, A ,, , A-, A- ,, , and, and G6PD, G6PD 68, 68 Val, Val --, -- >, > Met, Met in, in a, a bacterial, bacterial expression, expression system, system and, and analysing, analysing their, their biochemical, biochemical properties, properties ., . With, With each, each single, single mutation, mutation we, we found, found a, a slight, slight decrease, decrease in, in both, both the, the specific, specific activity, activity and, and the, the yield, yield of, of enzyme, enzyme when, when compared, compared to, to G6PD, G6PD B, B ., . When, When both, both mutations, mutations were, were introduced, introduced together, together ,, , there, there was, was a, a roughly, roughly additive, additive effect, effect on, on specific, specific activity, activity ,, , but, but a, a much, much more, more drastic, drastic effect, effect on, on enzyme, enzyme yield, yield (, ( 4, 4 %, % of, of normal, normal ), ) ., . This, This synergistic, synergistic effect, effect was, was also, also demonstrated, demonstrated on, on thermal, thermal stability, stability ,, , especially, especially at, at low, low NADP, NADP concentrations, concentrations ., . Comparable, Comparable results, results were, were produced, produced when, when the, the replacement, replacement 119, 119 Gln, Gln --, -- >, > Glu, Glu was, was studied, studied instead, instead of, of 126, 126 Asn, Asn --, -- >, > Asp, Asp ., . We, We infer, infer that, that the, the coexistence, coexistence of, of the, the two, two mutations, mutations is, is responsible, responsible for, for enzyme, enzyme deficiency, deficiency in, in G6PD, G6PD A-, A- because, because they, they act, act synergistically, synergistically in, in causing, causing instability, instability of, of the, the enzyme, enzyme ., . We, We describe, describe oligonucleotide, oligonucleotide primer, primer sequences, sequences that, that can, can be, be used, used to, to amplify, amplify eight, eight exons, exons plus, plus the, the muscle, muscle promoter, promoter of, of the, the dystrophin, dystrophin gene, gene in, in a, a single, single multiplex, multiplex polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) ., . When, When used, used in, in conjunction, conjunction with, with an, an existing, existing primer, primer set, set ,, , these, these two, two multiplex, multiplex reactions, reactions detect, detect about, about 98, 98 %, % of, of deletions, deletions in, in patients, patients with, with Duchenne, Duchenne or, or Becker, Becker muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ,, , BMD, BMD ), ) ., . Furthermore, Furthermore ,, , these, these primers, primers amplify, amplify most, most of, of the, the exons, exons in, in the, the deletion, deletion prone, prone ``, `` hot, hot spot, spot ``, `` region, region around, around exons, exons 44, 44 to, to 53, 53 ,, , allowing, allowing determination, determination of, of deletion, deletion endpoints, endpoints and, and prediction, prediction of, of mutational, mutational effects, effects on, on the, the translational, translational reading, reading frame, frame ., . Thus, Thus ,, , use, use of, of these, these PCR-based, PCR-based assays, assays will, will allow, allow deletion, deletion detection, detection and, and prenatal, prenatal diagnosis, diagnosis for, for most, most DMD/BMD, DMD/BMD patients, patients in, in a, a fraction, fraction of, of the, the time, time required, required for, for Southern, Southern blot, blot analysis.., analysis.. We, We previously, previously reported, reported a, a recombination, recombination in, in an, an individual, individual with, with myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) which, which placed, placed the, the markers, markers D19S19, D19S19 and, and APOC2, APOC2 on, on the, the same, same side, side of, of the, the DM, DM locus, locus ., . Haplotyping, Haplotyping of, of this, this family, family with, with more, more recently, recently characterized, characterized probes, probes which, which are, are either, either tightly, tightly linked, linked to, to DM, DM or, or distal, distal to, to the, the linkage, linkage group, group at, at q13, q13 ., . 2, 2 shows, shows that, that the, the DM, DM locus, locus is, is distal, distal to, to APOC2, APOC2 ., . This, This is, is confirmed, confirmed by, by other, other recombinants, recombinants where, where DM, DM segregates, segregates with, with distal, distal probes, probes ., . Additional, Additional marker, marker to, to marker, marker recombinations, recombinations in, in unaffected, unaffected individuals, individuals are, are reported, reported and, and support, support the, the order, order and, and orientation, orientation of, of the, the DM, DM linkage, linkage group, group as, as pter-, pter- (, ( INSR, INSR ,, , LDLR, LDLR ,, , S9, S9 ), ) -, - (, ( S19, S19 ,, , BCL3, BCL3 ,, , APOC2, APOC2 ), ) -, - (, ( CKMM, CKMM ,, , DM, DM ), ) -, - (, ( S22, S22 ,, , +, + +, + +, + PRKCG, PRKCG ), ) -qter, -qter ., . The, The data, data presented, presented here, here can, can not, not determine, determine whether, whether DM, DM is, is proximal, proximal or, or distal, distal to, to CKMM, CKMM ., . The, The consequences, consequences of, of this, this probe, probe order, order for, for antenatal, antenatal diagnosis, diagnosis and, and future, future research, research aiming, aiming to, to isolate, isolate the, the gene, gene which, which is, is affected, affected in, in DM, DM are, are discussed, discussed ., . The, The gene, gene for, for ataxia-telangiectasia, ataxia-telangiectasia ,, , ATM, ATM ,, , spans, spans about, about 150, 150 kb, kb of, of genomic, genomic DNA, DNA ., . ATM, ATM mutations, mutations are, are found, found along, along the, the entire, entire gene, gene ,, , with, with no, no evidence, evidence of, of a, a mutational, mutational hot, hot spot, spot ., . Using, Using DNA, DNA as, as the, the starting, starting material, material ,, , we, we screened, screened the, the ATM, ATM gene, gene in, in 92, 92 A-T, A-T patients, patients ,, , using, using an, an optimized, optimized single-strand, single-strand conformation, conformation polymorphism, polymorphism (, ( SSCP, SSCP ), ) technique, technique that, that detected, detected all, all previously, previously known, known mutations, mutations in, in the, the polymerase, polymerase chain, chain reaction, reaction (, ( PCR, PCR ), ) segments, segments being, being analyzed, analyzed ., . To, To expedite, expedite screening, screening ,, , we, we sequentially, sequentially loaded, loaded the, the SSCP, SSCP gels, gels with, with three, three different, different sets, sets of, of PCR, PCR products, products that, that were, were pretested, pretested to, to avoid, avoid overlapping, overlapping patterns, patterns ., . Many, Many of, of the, the DNA, DNA changes, changes we, we detected, detected were, were intragenic, intragenic polymorphisms, polymorphisms ., . Of, Of an, an expected, expected 177, 177 unknown, unknown mutations, mutations ,, , we, we detected, detected approximately, approximately 70, 70 %, % ,, , mostly, mostly protein, protein truncating, truncating mutations, mutations (, ( that, that would, would have, have been, been detectable, detectable by, by protein, protein truncation, truncation testing, testing if, if RNA, RNA starting, starting material, material had, had been, been available, available ), ) ., . Mutations, Mutations have, have now, now been, been defined, defined for, for every, every exon, exon of, of the, the ATM, ATM gene, gene ., . Herein, Herein ,, , we, we present, present 35, 35 new, new mutations, mutations and, and 34, 34 new, new intragenic, intragenic polymorphisms, polymorphisms or, or rare, rare variants, variants within, within the, the ATM, ATM gene, gene ., . This, This is, is the, the most, most comprehensive, comprehensive compilation, compilation of, of ATM, ATM polymorphisms, polymorphisms assembled, assembled to, to date, date ., . Defining, Defining polymorphic, polymorphic sites, sites as, as well, well as, as mutations, mutations in, in the, the ATM, ATM gene, gene will, will be, be of, of great, great importance, importance in, in designing, designing automated, automated methods, methods for, for detecting, detecting mutations.., mutations.. Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) and, and Angelman, Angelman syndrome, syndrome (, ( AS, AS ), ) are, are distinct, distinct neurobehavioral, neurobehavioral disorders, disorders that, that most, most often, often arise, arise from, from a, a 4-Mb, 4-Mb deletion, deletion of, of chromosome, chromosome 15q11-q13, 15q11-q13 during, during paternal, paternal or, or maternal, maternal gametogenesis, gametogenesis ,, , respectively, respectively ., . At, At a, a de, de novo, novo frequency, frequency of, of approximately, approximately ., . 67-1/10, 67-1/10 ,, , 000, 000 births, births ,, , these, these deletions, deletions represent, represent a, a common, common structural, structural chromosome, chromosome change, change in, in the, the human, human genome, genome ., . To, To elucidate, elucidate the, the mechanism, mechanism underlying, underlying these, these events, events ,, , we, we characterized, characterized the, the regions, regions that, that contain, contain two, two proximal, proximal breakpoint, breakpoint clusters, clusters and, and a, a distal, distal cluster, cluster ., . Novel, Novel DNA, DNA sequences, sequences potentially, potentially associated, associated with, with the, the breakpoints, breakpoints were, were positionally, positionally cloned, cloned from, from YACs, YACs within, within or, or near, near these, these regions, regions ., . Analyses, Analyses of, of rodent-human, rodent-human somatic-cell, somatic-cell hybrids, hybrids ,, , YAC, YAC contigs, contigs ,, , and, and FISH, FISH of, of normal, normal or, or rearranged, rearranged chromosomes, chromosomes 15, 15 identified, identified duplicated, duplicated sequences, sequences (, ( the, the END, END repeats, repeats ), ) at, at or, or near, near the, the breakpoints, breakpoints ., . The, The END-repeat, END-repeat units, units are, are derived, derived from, from large, large genomic, genomic duplications, duplications of, of a, a novel, novel gene, gene (, ( HERC2, HERC2 ), ) ,, , many, many copies, copies of, of which, which are, are transcriptionally, transcriptionally active, active in, in germline, germline tissues, tissues ., . One, One of, of five, five PWS/AS, PWS/AS patients, patients analyzed, analyzed to, to date, date has, has an, an identifiable, identifiable ,, , rearranged, rearranged HERC2, HERC2 transcript, transcript derived, derived from, from the, the deletion, deletion event, event ., . We, We postulate, postulate that, that the, the END, END repeats, repeats flanking, flanking 15q11-q13, 15q11-q13 mediate, mediate homologous, homologous recombination, recombination resulting, resulting in, in deletion, deletion ., . Furthermore, Furthermore ,, , we, we propose, propose that, that active, active transcription, transcription of, of these, these repeats, repeats in, in male, male and, and female, female germ, germ cells, cells may, may facilitate, facilitate the, the homologous, homologous recombination, recombination process, process ., . We, We have, have constructed, constructed a, a physical, physical map, map covering, covering over, over 4, 4 Mb, Mb of, of human, human chromosome, chromosome 8q24, 8q24 ., . 1, 1 and, and used, used this, this map, map to, to refine, refine the, the locations, locations of, of the, the genes, genes responsible, responsible for, for Langer-Giedion, Langer-Giedion syndrome, syndrome ., . The, The map, map is, is composed, composed of, of overlapping, overlapping YAC, YAC clones, clones that, that were, were identified, identified and, and ordered, ordered in, in relation, relation to, to sequence, sequence tagged, tagged sites, sites mapped, mapped to, to the, the Langer-Giedion, Langer-Giedion chromosomal, chromosomal region, region on, on somatic, somatic cell, cell hybrids, hybrids ., . The, The minimal, minimal region, region of, of overlap, overlap of, of Langer-Giedion, Langer-Giedion syndrome, syndrome deletions, deletions ,, , previously, previously identified, identified by, by analysis, analysis of, of 15, 15 patients, patients ,, , was, was placed, placed on, on the, the map, map by, by analysis, analysis of, of 2, 2 patients, patients whose, whose deletions, deletions define, define the, the endpoints, endpoints ., . The, The chromosome, chromosome 8, 8 breakpoint, breakpoint of, of a, a balanced, balanced t, t (, ( 8, 8 ;, ; 9, 9 ), ) (, ( q24, q24 ., . 11, 11 ;, ; q33, q33 ., . 3, 3 ), ) translocation, translocation from, from a, a patient, patient with, with trichorhinophalangeal, trichorhinophalangeal syndrome, syndrome (, ( TRPS, TRPS I, I ), ) was, was found, found to, to be, be located, located just, just within, within the, the proximal, proximal end, end of, of the, the minimal, minimal deletion, deletion region, region ., . A, A deletion, deletion of, of 8q24, 8q24 ., . 11-q24, 11-q24 ., . 3, 3 in, in a, a patient, patient with, with multiple, multiple exostoses, exostoses was, was found, found to, to overlap, overlap the, the distal, distal end, end of, of the, the LGS, LGS deletion, deletion region, region ,, , indicating, indicating that, that the, the EXT1, EXT1 gene, gene is, is distal, distal to, to the, the TRPS1, TRPS1 gene, gene and, and supporting, supporting the, the hypothesis, hypothesis that, that Langer-Giedion, Langer-Giedion syndrome, syndrome is, is due, due to, to loss, loss of, of functional, functional copies, copies of, of both, both the, the TRPS1, TRPS1 and, and the, the EXT1, EXT1 genes, genes A, A susceptibility, susceptibility gene, gene for, for hereditary, hereditary breast-ovarian, breast-ovarian cancer, cancer ,, , BRCA1, BRCA1 ,, , has, has been, been assigned, assigned by, by linkage, linkage analysis, analysis to, to chromosome, chromosome 17q21, 17q21 ., . Candidate, Candidate genes, genes in, in this, this region, region include, include EDH17B2, EDH17B2 ,, , which, which encodes, encodes estradiol, estradiol 17, 17 beta-hydroxysteroid, beta-hydroxysteroid dehydrogenase, dehydrogenase II, II (, ( 17, 17 beta-HSD, beta-HSD II, II ), ) ,, , and, and RARA, RARA ,, , the, the gene, gene for, for retinoic, retinoic acid, acid receptor, receptor alpha, alpha ., . We, We have, have typed, typed 22, 22 breast, breast and, and breast-ovarian, breast-ovarian cancer, cancer families, families with, with eight, eight polymorphisms, polymorphisms from, from the, the chromosome, chromosome 17q12-21, 17q12-21 region, region ,, , including, including two, two in, in the, the EDH17B2, EDH17B2 gene, gene ., . Genetic, Genetic recombination, recombination with, with the, the breast, breast cancer, cancer trait, trait excludes, excludes RARA, RARA from, from further, further consideration, consideration as, as a, a candidate, candidate gene, gene for, for BRCA1, BRCA1 ., . Both, Both BRCA1, BRCA1 and, and EDH17B2, EDH17B2 map, map to, to a, a 6, 6 cM, cM interval, interval (, ( between, between THRA1, THRA1 and, and D17S579, D17S579 ), ) and, and no, no recombination, recombination was, was observed, observed between, between the, the two, two genes, genes ., . However, However ,, , direct, direct sequencing, sequencing of, of overlapping, overlapping PCR, PCR products, products containing, containing the, the entire, entire EDH17B2, EDH17B2 gene, gene in, in four, four unrelated, unrelated affected, affected women, women did, did not, not uncover, uncover any, any sequence, sequence variation, variation ,, , other, other than, than previously, previously described, described polymorphisms, polymorphisms ., . Mutations, Mutations in, in the, the EDH17B2, EDH17B2 gene, gene ,, , therefore, therefore do, do not, not appear, appear to, to be, be responsible, responsible for, for the, the hereditary, hereditary breast-ovarian, breast-ovarian cancer, cancer syndrome, syndrome ., . Single, Single meiotic, meiotic crossovers, crossovers in, in affected, affected women, women suggest, suggest that, that BRCA1, BRCA1 is, is flanked, flanked by, by the, the loci, loci RARA, RARA and, and D17S78.., D17S78.. Homozygous, Homozygous C2, C2 deficiency, deficiency in, in a, a 19-year-old, 19-year-old boy, boy was, was associated, associated with, with variable, variable immunodeficiency, immunodeficiency manifested, manifested by, by marked, marked hypoimmunoglobulinemia, hypoimmunoglobulinemia and, and impaired, impaired antibody, antibody responses, responses ,, , normal, normal circulating, circulating B, B lymphocytes, lymphocytes ,, , and, and subnormal, subnormal T-cell, T-cell functions, functions ., . Neither, Neither antilymphocytic, antilymphocytic autoantibodies, autoantibodies nor, nor chromosomal, chromosomal abnormalities, abnormalities were, were found, found ., . Serum, Serum immunoglobulin, immunoglobulin levels, levels were, were within, within normal, normal limits, limits in, in his, his parents, parents and, and brother, brother who, who were, were heterozygous, heterozygous for, for C2, C2 deficiency, deficiency ., . The, The patients, patients lymphocytes, lymphocytes were, were homozygous, homozygous at, at the, the HLA-D, HLA-D locus, locus but, but expressed, expressed an, an antigen, antigen different, different from, from DW2.., DW2.. Flow, Flow cytometry, cytometry and, and recombinant, recombinant DNA, DNA techniques, techniques have, have been, been used, used to, to obtain, obtain reagents, reagents for, for a, a molecular, molecular analysis, analysis of, of the, the Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) ., . HindIII, HindIII total-digest, total-digest libraries, libraries were, were prepared, prepared in, in lambda, lambda phage, phage Charon, Charon 21A, 21A from, from flow-sorted, flow-sorted inverted, inverted duplicated, duplicated no, no ., . 15, 15 human, human chromosomes, chromosomes and, and propagated, propagated on, on recombination-proficient, recombination-proficient (, ( LE392, LE392 ), ) and, and recBC-, recBC- ,, , sbcB-, sbcB- (, ( DB1257, DB1257 ), ) bacteria, bacteria ., . Twelve, Twelve distinct, distinct chromosome, chromosome 15-specific, 15-specific probes, probes have, have been, been isolated, isolated ., . Eight, Eight localized, localized to, to the, the region, region 15q11, 15q11 --, -- --, -- 13, 13 ., . Four, Four of, of these, these eight, eight sublocalized, sublocalized to, to band, band 15q11, 15q11 ., . 2, 2 and, and are, are shown, shown to, to be, be deleted, deleted in, in DNA, DNA of, of one, one of, of two, two patients, patients examined, examined with, with the, the PWS, PWS ., . Heteroduplex, Heteroduplex analysis, analysis of, of two, two of, of these, these clones, clones ,, , which, which grew, grew on, on DB1257, DB1257 but, but not, not on, on LE392, LE392 ,, , revealed, revealed stem-loop, stem-loop structures, structures in, in the, the inserts, inserts ,, , indicative, indicative of, of inverted, inverted ,, , repeated, repeated DNA, DNA elements, elements ., . Such, Such DNA, DNA repeats, repeats might, might account, account for, for some, some of, of the, the cloning, cloning instability, instability of, of DNA, DNA segments, segments from, from proximal, proximal 15q, 15q ., . Analysis, Analysis of, of the, the genetic, genetic and, and physical, physical instability, instability associated, associated with, with the, the repeated, repeated sequences, sequences we, we have, have isolated, isolated from, from band, band 15q11, 15q11 ., . 2, 2 may, may elucidate, elucidate the, the molecular, molecular basis, basis for, for the, the instability, instability of, of this, this chromosomal, chromosomal region, region in, in patients, patients with, with the, the PWS, PWS or, or other, other diseases, diseases associated, associated with, with chromosomal, chromosomal abnormalities, abnormalities in, in the, the proximal, proximal long, long arm, arm of, of human, human chromosome, chromosome 15, 15 The, The trinucleotide, trinucleotide expansion, expansion mutation, mutation causing, causing myotonic, myotonic dystrophy, dystrophy is, is in, in the, the 3, 3 untranslated, untranslated region, region of, of a, a protein, protein kinase, kinase gene, gene ., . The, The molecular, molecular mechanisms, mechanisms by, by which, which the, the expanded, expanded repeat, repeat causes, causes the, the clinically, clinically variable, variable and, and multisystemic, multisystemic disease, disease ,, , myotonic, myotonic dystrophy, dystrophy ,, , are, are not, not understood, understood ., . It, It has, has been, been particularly, particularly difficult, difficult to, to rationalize, rationalize the, the dominant, dominant inheritance, inheritance with, with the, the fact, fact that, that the, the expansion, expansion mutation, mutation lies, lies outside, outside of, of the, the protein-encoding, protein-encoding gene, gene elements, elements ,, , and, and should, should not, not be, be translated, translated into, into protein, protein ., . Here, Here we, we use, use muscle, muscle biopsies, biopsies from, from classical, classical adult-onset, adult-onset myotonic, myotonic dystrophy, dystrophy patients, patients to, to study, study the, the accumulation, accumulation of, of transcripts, transcripts from, from both, both the, the normal, normal and, and expanded, expanded DM, DM kinase, kinase genes, genes in, in patient, patient muscle, muscle ,, , and, and compare, compare the, the results, results to, to normal, normal and, and myopathic, myopathic controls, controls ., . We, We found, found relatively, relatively small, small decreases, decreases of, of DM, DM kinase, kinase RNA, RNA in, in the, the total, total RNA, RNA pool, pool from, from muscle, muscle ;, ; however, however ,, , these, these reductions, reductions were, were not, not disease, disease specific, specific ., . Analysis, Analysis of, of poly, poly (, ( A, A ), ) +, + RNA, RNA showed, showed dramatic, dramatic decreases, decreases of, of both, both the, the mutant, mutant and, and normal, normal DM, DM kinase, kinase RNAs, RNAs ,, , and, and these, these changes, changes were, were disease-specific, disease-specific ., . Our, Our findings, findings are, are consistent, consistent with, with a, a novel, novel molecular, molecular pathogenetic, pathogenetic mechanism, mechanism for, for myotonic, myotonic dystrophy, dystrophy both, both the, the normal, normal and, and expanded, expanded DM, DM kinase, kinase genes, genes are, are transcribed, transcribed in, in patient, patient muscle, muscle ,, , but, but the, the abnormal, abnormal expansion-containing, expansion-containing RNA, RNA has, has a, a dominant, dominant effect, effect on, on RNA, RNA metabolism, metabolism by, by preventing, preventing the, the accumulation, accumulation of, of poly, poly (, ( A, A ), ) +, + RNA, RNA ., . The, The ability, ability of, of the, the expansion, expansion mutation, mutation to, to alter, alter accumulation, accumulation of, of poly, poly (, ( A, A ), ) +, + RNA, RNA in, in trans, trans suggests, suggests that, that myotonic, myotonic dystrophy, dystrophy may, may be, be the, the first, first example, example of, of a, a dominant-negative, dominant-negative mutation, mutation manifested, manifested at, at the, the RNA, RNA level.., level.. McLeod, McLeod syndrome, syndrome is, is an, an X-linked, X-linked multisystem, multisystem disorder, disorder characterized, characterized by, by abnormalities, abnormalities in, in the, the neuromuscular, neuromuscular and, and hematopoietic, hematopoietic systems, systems ., . We, We have, have assembled, assembled a, a cosmid, cosmid contig, contig of, of 360, 360 kb, kb that, that encompasses, encompasses the, the McLeod, McLeod gene, gene locus, locus ., . A, A 50, 50 kb, kb deletion, deletion was, was detected, detected by, by screening, screening DNA, DNA from, from patients, patients with, with radiolabeled, radiolabeled whole, whole cosmids, cosmids ,, , and, and two, two transcription, transcription units, units were, were identified, identified within, within this, this deletion, deletion ., . The, The mRNA, mRNA expression, expression pattern, pattern of, of one, one of, of them, them ,, , designated, designated as, as XK, XK ,, , correlates, correlates closely, closely to, to the, the McLeod, McLeod phenotype, phenotype ., . XK, XK encodes, encodes a, a novel, novel protein, protein with, with structural, structural characteristics, characteristics of, of prokaryotic, prokaryotic and, and eukaryotic, eukaryotic membrane, membrane transport, transport proteins, proteins ., . Nucleotide, Nucleotide sequence, sequence analysis, analysis of, of XK, XK from, from two, two unrelated, unrelated McLeod, McLeod patients, patients has, has identified, identified point, point mutations, mutations at, at conserved, conserved splice, splice donor, donor and, and acceptor, acceptor sites, sites ., . These, These findings, findings provide, provide direct, direct evidence, evidence that, that XK, XK is, is responsible, responsible for, for McLeod, McLeod syndrome.., syndrome.. Very, Very long, long chain, chain acyl-CoA, acyl-CoA dehydrogenase, dehydrogenase (, ( VLCAD, VLCAD ), ) deficiency, deficiency is, is a, a life-threatening, life-threatening disorder, disorder of, of mitochondrial, mitochondrial fatty, fatty acid, acid beta-oxidation, beta-oxidation ., . We, We identified, identified four, four novel, novel mutations, mutations in, in three, three unrelated, unrelated patients, patients ., . All, All patients, patients had, had the, the severe, severe childhood, childhood form, form of, of VLCAD, VLCAD deficiency, deficiency with, with early, early onset, onset and, and high, high mortality, mortality ., . Immunoblot, Immunoblot analysis, analysis revealed, revealed that, that VLCAD, VLCAD protein, protein was, was undetectable, undetectable in, in patients, patients 2, 2 and, and 3, 3 ,, , whereas, whereas normal-size, normal-size VLCAD, VLCAD protein, protein and, and an, an aberrant, aberrant form, form of, of VLCAD, VLCAD (, ( 4kDa, 4kDa smaller, smaller ), ) were, were detected, detected in, in patient, patient 1, 1 ."
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ", . As, As expected, expected ,, , null, null mutations, mutations were, were found, found in, in patients, patients 2, 2 and, and 3, 3 patient, patient 2, 2 is, is homozygous, homozygous for, for a, a frameshift, frameshift mutation, mutation ,, , del, del 4, 4 bp, bp at, at 798-801, 798-801 ,, , and, and patient, patient 3, 3 is, is homozygous, homozygous for, for a, a nonsense, nonsense mutation, mutation 65C, 65C >, > A, A (, ( S22X, S22X ), ) ., . Patient, Patient 1, 1 was, was homozygous, homozygous for, for a, a complex, complex mutant, mutant allele, allele containing, containing two, two alterations, alterations ,, , including, including a, a 194C, 194C >, > T, T transition, transition (, ( P65L, P65L ), ) and, and 739A, 739A >, > C, C transversion, transversion (, ( K247Q, K247Q ), ) ;, ; in, in the, the case, case of, of P65L, P65L ,, , the, the amino, amino acid, acid change, change does, does not, not reduce, reduce enzyme, enzyme activity, activity ., . However, However ,, , the, the nucleotide, nucleotide change, change resulted, resulted in, in exon, exon 3, 3 skipping, skipping ,, , whereas, whereas the, the latter, latter K247Q, K247Q mutation, mutation had, had a, a drastic, drastic effect, effect on, on enzyme, enzyme activity, activity ., . We, We verified, verified these, these events, events by, by in, in vivo, vivo splicing, splicing experiments, experiments and, and transient, transient expression, expression analysis, analysis of, of mutant, mutant cDNAs, cDNAs ., . The, The P65L, P65L mutation, mutation locates, locates 11, 11 bases, bases upstream, upstream of, of a, a splice, splice donor, donor site, site of, of intron, intron 3, 3 ., . This, This is, is an, an example, example of, of an, an exonic, exonic mutation, mutation which, which affects, affects exon-splicing.., exon-splicing.. Huntington, Huntington disease, disease (, ( HD, HD ), ) is, is caused, caused by, by expansion, expansion of, of a, a glutamine, glutamine repeat, repeat in, in the, the amino-terminal, amino-terminal region, region of, of huntingtin, huntingtin ., . Despite, Despite its, its widespread, widespread expression, expression ,, , mutant, mutant huntingtin, huntingtin induces, induces selective, selective neuronal, neuronal loss, loss in, in striatal, striatal neurons, neurons ., . Here, Here we, we report, report that, that ,, , in, in mutant, mutant mice, mice expressing, expressing HD, HD repeats, repeats ,, , the, the production, production and, and aggregation, aggregation of, of N-terminal, N-terminal huntingtin, huntingtin fragments, fragments preferentially, preferentially occur, occur in, in HD-affected, HD-affected neurons, neurons and, and their, their processes, processes and, and axonal, axonal terminals, terminals ., . N-terminal, N-terminal fragments, fragments of, of mutant, mutant huntingtin, huntingtin form, form aggregates, aggregates and, and induce, induce neuritic, neuritic degeneration, degeneration in, in cultured, cultured striatal, striatal neurons, neurons ., . N-terminal, N-terminal mutant, mutant huntingtin, huntingtin also, also binds, binds to, to synaptic, synaptic vesicles, vesicles and, and inhibits, inhibits their, their glutamate, glutamate uptake, uptake in, in vitro, vitro ., . The, The specific, specific processing, processing and, and accumulation, accumulation of, of toxic, toxic fragments, fragments of, of N-terminal, N-terminal huntingtin, huntingtin in, in HD-affected, HD-affected striatal, striatal neurons, neurons ,, , especially, especially in, in their, their neuronal, neuronal processes, processes and, and axonal, axonal terminals, terminals ,, , may, may contribute, contribute to, to the, the selective, selective neuropathology, neuropathology of, of HD.., HD.. BACKGROUND, BACKGROUND AND, AND OBJECTIVES, OBJECTIVES Mutations, Mutations of, of the, the peripherin/RDS, peripherin/RDS gene, gene have, have been, been reported, reported in, in autosomal, autosomal dominant, dominant retinitis, retinitis pigmentosa, pigmentosa ,, , pattern, pattern macular, macular dystrophy, dystrophy ,, , and, and retinitis, retinitis punctata, punctata albescens, albescens ., . We, We report, report herein, herein the, the occurrence, occurrence of, of three, three separate, separate phenotypes, phenotypes within, within a, a single, single family, family with, with a, a novel, novel 3-base, 3-base pair, pair deletion, deletion of, of codon, codon 153, 153 or, or 154, 154 of, of the, the peripherin/RDS, peripherin/RDS gene, gene ., . DESIGN, DESIGN Case, Case reports, reports with, with clinical, clinical features, features ,, , fluorescein, fluorescein angiography, angiography ,, , kinetic, kinetic perimetry, perimetry ,, , electrophysiological, electrophysiological studies, studies ,, , and, and molecular, molecular genetics, genetics ., . SETTING, SETTING University, University medical, medical centers, centers ., . PATIENTS, PATIENTS A, A 75-year-old, 75-year-old woman, woman ,, , her, her two, two daughters, daughters (, ( aged, aged 44, 44 and, and 50, 50 years, years ), ) ,, , and, and her, her 49-year-old, 49-year-old son, son were, were screened, screened for, for peripherin/RDS, peripherin/RDS mutations, mutations because, because of, of the, the presence, presence of, of multiple, multiple phenotypes, phenotypes within, within the, the same, same family, family ., . RESULTS, RESULTS The, The mother, mother presented, presented at, at age, age 63, 63 years, years with, with a, a profoundly, profoundly abnormal, abnormal electroretinogram, electroretinogram (, ( ERG, ERG ), ) and, and adult-onset, adult-onset retinitis, retinitis pigmentosa, pigmentosa that, that progressed, progressed dramatically, dramatically over, over 12, 12 years, years ,, , with, with marked, marked loss, loss of, of peripheral, peripheral visual, visual field, field ., . One, One daughter, daughter developed, developed pattern, pattern macular, macular dystrophy, dystrophy at, at age, age 31, 31 years, years ., . At, At age, age 44, 44 years, years ,, , her, her ERG, ERG was, was moderately, moderately abnormal, abnormal but, but her, her clinical, clinical disease, disease was, was limited, limited to, to the, the macula, macula ., . Another, Another daughter, daughter presented, presented at, at age, age 42, 42 years, years with, with macular, macular degeneration, degeneration and, and over, over 10, 10 years, years developed, developed the, the clinical, clinical picture, picture of, of fundus, fundus flavimaculatus, flavimaculatus ., . Her, Her peripheral, peripheral visual, visual field, field was, was preserved, preserved but, but her, her ERG, ERG was, was moderately, moderately abnormal, abnormal ., . The, The son, son had, had onset, onset of, of macular, macular degeneration, degeneration at, at age, age 44, 44 years, years ., . Pericentral, Pericentral scotomas, scotomas were, were present, present and, and the, the ERG, ERG was, was markedly, markedly abnormal, abnormal ., . Fluorescein, Fluorescein angiography, angiography revealed, revealed punctate, punctate pigment, pigment epithelial, epithelial transmission, transmission defects, defects ., . CONCLUSIONS, CONCLUSIONS A, A 3-base, 3-base pair, pair deletion, deletion of, of codon, codon 153, 153 or, or 154, 154 of, of the, the peripherin/RDS, peripherin/RDS gene, gene can, can produce, produce clinically, clinically disparate, disparate phenotypes, phenotypes even, even within, within the, the same, same family.., family.. The, The PAX6, PAX6 gene, gene is, is involved, involved in, in ocular, ocular morphogenesis, morphogenesis ,, , and, and PAX6, PAX6 mutations, mutations have, have been, been detected, detected in, in various, various types, types of, of ocular, ocular anomalies, anomalies ,, , including, including aniridia, aniridia ,, , Peters, Peters anomaly, anomaly ,, , corneal, corneal dystrophy, dystrophy ,, , congenital, congenital cataract, cataract ,, , and, and foveal, foveal hypoplasia, hypoplasia ., . The, The gene, gene encodes, encodes a, a transcriptional, transcriptional regulator, regulator that, that recognizes, recognizes target, target genes, genes through, through its, its paired-type, paired-type DNA-binding, DNA-binding domain, domain ., . The, The paired, paired domain, domain is, is composed, composed of, of two, two distinct, distinct DNA-binding, DNA-binding subdomains, subdomains ,, , the, the N-terminal, N-terminal subdomain, subdomain (, ( NTS, NTS ), ) and, and the, the C-terminal, C-terminal subdomain, subdomain (, ( CTS, CTS ), ) ,, , which, which bind, bind respective, respective consensus, consensus DNA, DNA sequences, sequences ., . The, The human, human PAX6, PAX6 gene, gene produces, produces two, two alternative, alternative splice, splice isoforms, isoforms that, that have, have the, the distinct, distinct structure, structure of, of the, the paired, paired domain, domain ., . The, The insertion, insertion ,, , into, into the, the NTS, NTS ,, , of, of 14, 14 additional, additional amino, amino acids, acids encoded, encoded by, by exon, exon 5a, 5a abolishes, abolishes the, the DNA-binding, DNA-binding activity, activity of, of the, the NTS, NTS and, and unmasks, unmasks the, the DNA-binding, DNA-binding ability, ability of, of the, the CTS, CTS ., . Thus, Thus ,, , exon, exon 5a, 5a appears, appears to, to function, function as, as a, a molecular, molecular switch, switch that, that specifies, specifies target, target genes, genes ., . We, We ascertained, ascertained a, a novel, novel missense, missense mutation, mutation in, in four, four pedigrees, pedigrees with, with Peters, Peters anomaly, anomaly ,, , congenital, congenital cataract, cataract ,, , Axenfeldt, Axenfeldt anomaly, anomaly ,, , and/or, and/or foveal, foveal hypoplasia, hypoplasia ,, , which, which ,, , to, to our, our knowledge, knowledge ,, , is, is the, the first, first mutation, mutation identified, identified in, in the, the splice-variant, splice-variant region, region ., . A, A T, T --, -- >, > A, A transition, transition at, at the, the 20th, 20th nucleotide, nucleotide position, position of, of exon, exon 5a, 5a results, results in, in a, a Val, Val --, -- >, > Asp, Asp (, ( GTC, GTC --, -- >, > GAC, GAC ), ) substitution, substitution at, at the, the 7th, 7th codon, codon of, of the, the alternative, alternative splice, splice region, region ., . Functional, Functional analyses, analyses demonstrated, demonstrated that, that the, the V54D, V54D mutation, mutation slightly, slightly increased, increased NTS, NTS binding, binding and, and decreased, decreased CTS, CTS transactivation, transactivation activity, activity to, to almost, almost half.., half.. Utilizing, Utilizing the, the CEPH, CEPH reference, reference panel, panel and, and genotypic, genotypic data, data for, for 53, 53 markers, markers ,, , we, we have, have constructed, constructed a, a 20-locus, 20-locus multipoint, multipoint genetic, genetic map, map of, of human, human chromosome, chromosome 4, 4 ., . New, New RFLPs, RFLPs are, are reported, reported for, for four, four loci, loci ., . The, The map, map integrates, integrates a, a high-resolution, high-resolution genetic, genetic map, map of, of 4p16, 4p16 into, into a, a continuous, continuous map, map extending, extending to, to 4q31, 4q31 and, and an, an unlinked, unlinked cluster, cluster of, of three, three loci, loci at, at 4q35, 4q35 ., . The, The 20, 20 linked, linked markers, markers form, form a, a continuous, continuous linkage, linkage group, group of, of 152, 152 cM, cM in, in males, males and, and 202, 202 cM, cM in, in females, females ., . Likely, Likely genetic, genetic locations, locations are, are provided, provided for, for 25, 25 polymorphic, polymorphic anonymous, anonymous sequences, sequences and, and 28, 28 gene-specific, gene-specific RFLPs, RFLPs ., . The, The map, map was, was constructed, constructed employing, employing the, the LINKAGE, LINKAGE and, and CRIMAP, CRIMAP computational, computational methodologies, methodologies to, to build, build the, the multipoint, multipoint map, map via, via a, a stepwise, stepwise algorithm, algorithm ., . A, A detailed, detailed 10-point, 10-point map, map of, of the, the 4p16, 4p16 region, region constructed, constructed from, from the, the CEPH, CEPH panel, panel provides, provides evidence, evidence for, for heterogeneity, heterogeneity in, in the, the linkage, linkage maps, maps constructed, constructed from, from families, families segregating, segregating for, for Huntington, Huntington disease, disease (, ( HD, HD ), ) ., . It, It additionally, additionally provides, provides evidence, evidence for, for position-specific, position-specific recombination, recombination frequencies, frequencies in, in the, the telomeric, telomeric region, region of, of 4p.., 4p.. The, The recently, recently cloned, cloned human, human breast, breast and, and ovarian, ovarian cancer, cancer susceptibility, susceptibility gene, gene ,, , BRCA1, BRCA1 ,, , is, is located, located on, on human, human chromosome, chromosome 17q21, 17q21 ., . We, We have, have isolated, isolated murine, murine genomic, genomic clones, clones containing, containing Brca1, Brca1 as, as a, a first, first step, step in, in generating, generating a, a mouse, mouse model, model for, for the, the loss, loss of, of BRCA1, BRCA1 function, function ., . A, A mouse, mouse genomic, genomic library, library was, was screened, screened using, using probes, probes corresponding, corresponding to, to exon, exon 11, 11 of, of the, the human, human BRCA1, BRCA1 gene, gene ., . Two, Two overlapping, overlapping mouse, mouse clones, clones were, were identified, identified that, that hybridized, hybridized to, to human, human BRCA1, BRCA1 exons, exons 9-12, 9-12 ., . Sequence, Sequence analysis, analysis of, of 1, 1 ., . 4, 4 kb, kb of, of the, the region, region of, of these, these clones, clones corresponding, corresponding to, to part, part of, of human, human exon, exon 11, 11 revealed, revealed 72, 72 %, % nucleic, nucleic acid, acid identity, identity but, but only, only 50, 50 %, % amino, amino acid, acid identity, identity with, with the, the human, human gene, gene ., . The, The longest, longest of, of the, the mouse, mouse Brca1, Brca1 genomic, genomic clones, clones maps, maps to, to chromosome, chromosome 11D, 11D ,, , as, as determined, determined by, by two-color, two-color fluorescence, fluorescence in, in situ, situ hybridization, hybridization ., . The, The synteny, synteny to, to human, human chromosome, chromosome 17, 17 was, was confirmed, confirmed by, by cohybridization, cohybridization with, with the, the mouse, mouse probe, probe for, for the, the NF1-gene, NF1-gene ., . This, This comparative, comparative study, study confirms, confirms that, that the, the relative, relative location, location of, of the, the BRCA1, BRCA1 gene, gene has, has been, been conserved, conserved between, between mice, mice and, and humans, humans ., . We, We identified, identified a, a patient, patient suffering, suffering from, from late-infantile, late-infantile metachromatic, metachromatic leukodystrophy, leukodystrophy (, ( MLD, MLD ), ) who, who has, has a, a residual, residual arylsulfatase, arylsulfatase A, A (, ( ARSA, ARSA ), ) activity, activity of, of about, about 10, 10 %, % ., . Fibroblasts, Fibroblasts of, of the, the patient, patient show, show significant, significant sulfatide, sulfatide degradation, degradation activity, activity exceeding, exceeding that, that of, of adult, adult MLD, MLD patients, patients ., . Analysis, Analysis of, of the, the ARSA, ARSA gene, gene in, in this, this patient, patient revealed, revealed heterozygosity, heterozygosity for, for two, two new, new mutant, mutant alleles, alleles in, in one, one allele, allele ,, , deletion, deletion of, of C, C 447, 447 in, in exon, exon 2, 2 leads, leads to, to a, a frameshift, frameshift and, and to, to a, a premature, premature stop, stop codon, codon at, at amino, amino acid, acid position, position 105, 105 ;, ; in, in the, the second, second allele, allele ,, , a, a G, G --, -- >, > A, A transition, transition in, in exon, exon 5, 5 causes, causes a, a Gly309, Gly309 --, -- >, > Ser, Ser substitution, substitution ., . Transient, Transient expression, expression of, of the, the mutant, mutant Ser309-ARSA, Ser309-ARSA resulted, resulted in, in only, only 13, 13 %, % enzyme, enzyme activity, activity of, of that, that observed, observed in, in cells, cells expressing, expressing normal, normal ARSA, ARSA ., . The, The mutant, mutant ARSA, ARSA is, is correctly, correctly targeted, targeted to, to the, the lysosomes, lysosomes but, but is, is unstable, unstable ., . These, These findings, findings are, are in, in contrast, contrast to, to previous, previous results, results showing, showing that, that the, the late-infantile, late-infantile type, type of, of MLD, MLD is, is always, always associated, associated with, with the, the complete, complete absence, absence of, of ARSA, ARSA activity, activity ., . The, The expression, expression of, of the, the mutant, mutant ARSA, ARSA protein, protein may, may be, be influenced, influenced by, by particular, particular features, features of, of oligodendrocytes, oligodendrocytes ,, , such, such that, that the, the level, level of, of mutant, mutant enzyme, enzyme is, is lower, lower in, in these, these cells, cells than, than in, in others.., others.. Prader-Willi, Prader-Willi syndrome, syndrome (, ( PWS, PWS ), ) is, is a, a neurogenetic, neurogenetic disease, disease characterized, characterized by, by infantile, infantile hypotonia, hypotonia ,, , gonadal, gonadal hypoplasia, hypoplasia ,, , obsessive, obsessive behaviour, behaviour and, and neonatal, neonatal feeding, feeding difficulties, difficulties followed, followed by, by hyperphagia, hyperphagia ,, , leading, leading to, to profound, profound obesity, obesity ., . PWS, PWS is, is due, due to, to a, a lack, lack of, of paternal, paternal genetic, genetic information, information at, at 15q11-q13, 15q11-q13 (, ( ref, ref ., . 2, 2 ), ) ., . Five, Five imprinted, imprinted ,, , paternally, paternally expressed, expressed genes, genes map, map to, to the, the PWS, PWS region, region ,, , MKRN3, MKRN3 (, ( ref, ref ., . 3, 3 ), ) ,, , NDN, NDN (, ( ref, ref ., . 4, 4 ), ) ,, , NDNL1, NDNL1 (, ( ref, ref ., . 5, 5 ), ) ,, , SNRPN, SNRPN (, ( refs, refs 6-8, 6-8 ), ) and, and IPW, IPW (, ( ref, ref ., . 9, 9 ), ) ,, , as, as well, well as, as two, two poorly, poorly characterized, characterized framents, framents designated, designated PAR-1, PAR-1 and, and PAR-5, PAR-5 (, ( ref, ref ., . 10, 10 ), ) ., . Imprinting, Imprinting of, of this, this region, region involves, involves a, a bipartite, bipartite imprinting, imprinting centre, centre (, ( IC, IC ), ) ,, , which, which overlaps, overlaps SNRPN, SNRPN (, ( refs, refs 10, 10 ,, , 11, 11 ), ) ., . Deletion, Deletion of, of the, the SNRPN, SNRPN promoter/exon, promoter/exon 1, 1 region, region (, ( the, the PWS, PWS IC, IC element, element ), ) appears, appears to, to impair, impair the, the establishment, establishment of, of the, the paternal, paternal imprint, imprint in, in the, the male, male germ, germ line, line and, and leads, leads to, to PWS, PWS ., . Here, Here we, we report, report a, a PWS, PWS family, family in, in which, which the, the father, father is, is mosaic, mosaic for, for an, an IC, IC deletion, deletion on, on his, his paternal, paternal chromosome, chromosome ., . The, The deletion, deletion chromosome, chromosome has, has acquired, acquired a, a maternal, maternal methylation, methylation imprint, imprint in, in his, his somatic, somatic cells, cells ., . We, We have, have made, made identical, identical findings, findings in, in chimaeric, chimaeric mice, mice generated, generated from, from two, two independent, independent embryonic, embryonic stem, stem (, ( ES, ES ), ) cell, cell lines, lines harbouring, harbouring a, a similar, similar deletion, deletion ., . Our, Our studies, studies demonstrate, demonstrate that, that the, the PWS, PWS IC, IC element, element is, is not, not only, only required, required for, for the, the establishment, establishment of, of the, the paternal, paternal imprint, imprint ,, , but, but also, also for, for its, its postzygotic, postzygotic maintenance.., maintenance.. Galactosemia, Galactosemia is, is an, an autosomal, autosomal recessive, recessive disorder, disorder of, of human, human galactose, galactose metabolism, metabolism caused, caused by, by deficiency, deficiency of, of the, the enzyme, enzyme galactose-1-phosphate, galactose-1-phosphate uridyl, uridyl transferase, transferase (, ( GALT, GALT ), ) ., . The, The molecular, molecular basis, basis of, of this, this disorder, disorder is, is at, at present, present not, not well, well understood, understood ., . We, We report, report here, here two, two missense, missense mutations, mutations which, which result, result in, in low, low or, or undetectable, undetectable enzymatic, enzymatic activity, activity ., . First, First ,, , we, we identified, identified at, at nucleotide, nucleotide 591, 591 a, a transition, transition which, which substitutes, substitutes glutamine, glutamine 188, 188 by, by arginine, arginine ., . The, The mutated, mutated glutamine, glutamine is, is not, not only, only highly, highly conserved, conserved in, in evolution, evolution (, ( conserved, conserved also, also in, in Escherichia, Escherichia coli, coli and, and Saccharomyces, Saccharomyces cerevisiae, cerevisiae ), ) ,, , but, but is, is also, also two, two amino, amino acid, acid residues, residues downstream, downstream from, from the, the active, active site, site histidine-proline-histidine, histidine-proline-histidine triad, triad and, and results, results in, in about, about 10, 10 %, % of, of normal, normal enzymatic, enzymatic activity, activity ., . The, The arginine, arginine 188, 188 mutation, mutation is, is the, the most, most common, common galactosemia, galactosemia mutation, mutation characterized, characterized to, to date, date ., . It, It accounts, accounts for, for one-fourth, one-fourth of, of the, the galactosemia, galactosemia alleles, alleles studied, studied ., . Second, Second ,, , we, we report, report the, the substitution, substitution of, of arginine, arginine 333, 333 by, by tryptophan, tryptophan ,, , caused, caused by, by a, a transition, transition at, at nucleotide, nucleotide 1025, 1025 ., . The, The area, area surrounding, surrounding this, this missense, missense mutation, mutation is, is the, the most, most highly, highly conserved, conserved domain, domain in, in the, the homologous, homologous enzymes, enzymes from, from E., E. coli, coli ,, , yeast, yeast ,, , and, and humans, humans ,, , and, and this, this mutation, mutation results, results in, in undetectable, undetectable enzymatic, enzymatic activity, activity ,, , suggesting, suggesting that, that this, this is, is a, a severe, severe mutation, mutation ., . This, This second, second mutation, mutation appears, appears to, to be, be rare, rare ,, , since, since it, it was, was found, found only, only in, in the, the patient, patient we, we sequenced, sequenced ., . Our, Our data, data provide, provide further, further evidence, evidence for, for the, the heterogeneity, heterogeneity of, of galactosemia, galactosemia at, at the, the molecular, molecular level, level ,, , heterogeneity, heterogeneity which, which might, might be, be related, related to, to the, the variable, variable clinical, clinical outcome, outcome observed, observed in, in this, this disorder.., disorder.. OBJECTIVE, OBJECTIVE To, To monitor, monitor the, the effects, effects of, of dietary, dietary treatment, treatment in, in adult-onset, adult-onset adrenoleukodystrophy, adrenoleukodystrophy (, ( ALD, ALD ), ) by, by means, means of, of somatosensory, somatosensory evoked, evoked potentials, potentials (, ( SEPs, SEPs ), ) and, and motor, motor evoked, evoked potentials, potentials (, ( MEPs, MEPs ), ) ., . BACKGROUND, BACKGROUND SEPs, SEPs and, and MEPs, MEPs have, have proved, proved useful, useful in, in revealing, revealing signs, signs of, of progressively, progressively severe, severe ,, , central, central dying-back, dying-back axonopathy, axonopathy in, in early, early stages, stages of, of adult-onset, adult-onset ALD, ALD ., . METHODS, METHODS Eight, Eight patients, patients with, with adult-onset, adult-onset ALD, ALD underwent, underwent clinical, clinical examination, examination ,, , brain, brain and, and spine, spine MRI, MRI ,, , and, and SEP, SEP and, and MEP, MEP studies, studies before, before and, and after, after 3, 3 years, years of, of Lorenzos, Lorenzos oil, oil dietary, dietary therapy, therapy ., . RESULTS, RESULTS Before, Before treatment, treatment ,, , brain, brain MRI, MRI was, was normal, normal in, in five, five patients, patients ., . Three, Three of, of these, these patients, patients had, had pure, pure spinal, spinal SEP, SEP abnormalities, abnormalities and, and in, in the, the remaining, remaining two, two patients, patients SEPs, SEPs showed, showed signs, signs of, of involvement, involvement of, of both, both the, the spinal, spinal and, and cerebral, cerebral somatosensory, somatosensory tracts, tracts ., . After, After treatment, treatment ,, , the, the three, three patients, patients with, with pure, pure spinal, spinal abnormalities, abnormalities showed, showed clinical, clinical and, and neurophysiologic, neurophysiologic worsening, worsening ,, , whereas, whereas the, the two, two patients, patients with, with a, a more, more advanced, advanced stage, stage of, of disease, disease (, ( exhibited, exhibited by, by SEPs, SEPs ), ) showed, showed substantially, substantially unchanged, unchanged clinical, clinical and, and neurophysiologic, neurophysiologic features, features ., . The, The patients, patients with, with abnormal, abnormal brain, brain MRI, MRI at, at the, the onset, onset of, of treatment, treatment showed, showed clinical, clinical and, and neurophysiologic, neurophysiologic worsening, worsening ., . CONCLUSIONS, CONCLUSIONS Lorenzos, Lorenzos oil, oil therapy, therapy had, had no, no effect, effect on, on patients, patients with, with evidence, evidence of, of inflammatory, inflammatory brain, brain lesions, lesions ., . Moreover, Moreover ,, , in, in patients, patients without, without clear, clear signs, signs of, of inflammatory, inflammatory damage, damage ,, , this, this treatment, treatment does, does not, not modify, modify significantly, significantly the, the natural, natural course, course of, of the, the disease, disease ., . However, However ,, , because, because effective, effective treatments, treatments should, should begin, begin before, before the, the onset, onset of, of severe, severe neurologic, neurologic symptoms, symptoms ,, , SEPs, SEPs and, and MEPs, MEPs should, should be, be considered, considered to, to evaluate, evaluate the, the effectiveness, effectiveness of, of other, other experimental, experimental treatments, treatments in, in the, the patient, patient with, with a, a negative, negative brain, brain MRI.Sjogren-Larsson, MRI.Sjogren-Larsson syndrome, syndrome (, ( SLS, SLS ), ) is, is an, an autosomal, autosomal recessive, recessive disorder, disorder characterized, characterized by, by ichthyosis, ichthyosis ,, , mental, mental retardation, retardation ,, , spasticity, spasticity ,, , and, and deficient, deficient activity, activity of, of fatty, fatty aldehyde, aldehyde dehydrogenase, dehydrogenase (, ( FALDH, FALDH ), ) ., . To, To define, define the, the molecular, molecular defects, defects causing, causing SLS, SLS ,, , we, we performed, performed mutation, mutation analysis, analysis of, of the, the FALDH, FALDH gene, gene in, in probands, probands from, from 63, 63 kindreds, kindreds with, with SLS, SLS ., . Among, Among these, these patients, patients ,, , 49, 49 different, different mutations-including, mutations-including 10, 10 deletions, deletions ,, , 2, 2 insertions, insertions ,, , 22, 22 amino, amino acid, acid substitutions, substitutions ,, , 3, 3 nonsense, nonsense mutations, mutations ,, , 9, 9 splice-site, splice-site defects, defects ,, , and, and 3, 3 complex, complex mutations-were, mutations-were found, found ., . All, All of, of the, the patients, patients with, with SLS, SLS were, were found, found to, to carry, carry mutations, mutations ., . Nineteen, Nineteen of, of the, the missense, missense mutations, mutations resulted, resulted in, in a, a severe, severe reduction, reduction of, of FALDH, FALDH enzyme, enzyme catalytic, catalytic activity, activity when, when expressed, expressed in, in mammalian, mammalian cells, cells ,, , but, but one, one mutation, mutation (, ( 798G, 798G --, -- >, > C, C [, [ K266N, K266N ], ] ), ) seemed, seemed to, to have, have a, a greater, greater effect, effect on, on mRNA, mRNA stability, stability ., . The, The splice-site, splice-site mutations, mutations led, led to, to exon, exon skipping, skipping or, or utilization, utilization of, of cryptic, cryptic acceptor-splice, acceptor-splice sites, sites ., . Thirty-seven, Thirty-seven mutations, mutations were, were private, private ,, , and, and 12, 12 mutations, mutations were, were seen, seen in, in two, two or, or more, more probands, probands of, of European, European or, or Middle, Middle Eastern, Eastern descent, descent ., . Four, Four single-nucleotide, single-nucleotide polymorphisms, polymorphisms (, ( SNPs, SNPs ), ) were, were found, found in, in the, the FALDH, FALDH gene, gene ., . At, At least, least four, four of, of the, the common, common mutations, mutations (, ( 551C, 551C --, -- >, > T, T ,, , 682C, 682C --, -- >, > T, T ,, , 733G, 733G --, -- >, > A, A ,, , and, and 798, 798 +, + 1delG, 1delG ), ) were, were associated, associated with, with multiple, multiple SNP, SNP haplotypes, haplotypes ,, , suggesting, suggesting that, that these, these mutations, mutations originated, originated independently, independently on, on more, more than, than one, one occasion, occasion or, or were, were ancient, ancient SLS, SLS genes, genes that, that had, had undergone, undergone intragenic, intragenic recombination, recombination ., . Our, Our results, results demonstrate, demonstrate that, that SLS, SLS is, is caused, caused by, by a, a strikingly, strikingly heterogeneous, heterogeneous group, group of, of mutations, mutations in, in the, the FALDH, FALDH gene, gene and, and provide, provide a, a framework, framework for, for understanding, understanding the, the genetic, genetic basis, basis of, of SLS, SLS and, and the, the development, development of, of DNA-based, DNA-based diagnostic, diagnostic tests.., tests.. Molecular, Molecular ,, , kinetic, kinetic ,, , and, and functional, functional studies, studies were, were carried, carried out, out on, on erythrocytes, erythrocytes and, and leukocytes, leukocytes in, in a, a Spanish, Spanish male, male with, with G6PD, G6PD deficiency, deficiency ,, , congenital, congenital nonspherocytic, nonspherocytic hemolytic, hemolytic anemia, anemia (, ( CNSHA, CNSHA ), ) ,, , and, and increased, increased susceptibility, susceptibility to, to infections, infections ., . G6PD, G6PD activity, activity was, was absent, absent in, in patients, patients red, red cells, cells and, and was, was about, about 2, 2 %, % of, of normal, normal in, in leukocytes, leukocytes ., . Molecular, Molecular studies, studies using, using standard, standard methods, methods (, ( WHO, WHO ,, , 1967, 1967 ), ) showed, showed G6PD, G6PD in, in the, the patient, patient to, to have, have a, a slightly, slightly fast, fast electrophoretic, electrophoretic mobility, mobility at, at pH, pH 8, 8 ., . 0, 0 with, with otherwise, otherwise normal, normal properties, properties (, ( heat, heat stability, stability at, at 46, 46 degrees, degrees C, C ,, , apparent, apparent affinity, affinity for, for substrates, substrates ,, , optimum, optimum pH, pH ,, , and, and utilization, utilization of, of substrate, substrate analogues, analogues ), ) ., . Other, Other tests, tests showed, showed the, the patients, patients granulocytes, granulocytes to, to engulf, engulf latex, latex particles, particles normally, normally ,, , but, but to, to have, have impaired, impaired reduction, reduction of, of nitroblue, nitroblue tetrazolium, tetrazolium and, and ferricytochrome-c, ferricytochrome-c as, as well, well as, as reduced, reduced iodination, iodination ., . Chemotaxis, Chemotaxis and, and random, random migration, migration of, of the, the patients, patients granulocytes, granulocytes were, were normal, normal as, as were, were myeloperoxidase, myeloperoxidase ,, , leukocyte, leukocyte alkaline, alkaline phosphatase, phosphatase (, ( LAP, LAP ), ) ,, , and, and ultrastructural, ultrastructural features, features ., . The, The molecular, molecular characteristics, characteristics of, of G6PD, G6PD in, in the, the patient, patient differed, differed from, from those, those of, of all, all previously, previously reported, reported variants, variants associated, associated with, with CNSHA, CNSHA ,, , so, so the, the present, present variant, variant was, was provisionally, provisionally called, called G6PD, G6PD Barcelona, Barcelona to, to distinguish, distinguish it, it from, from other, other G6PD, G6PD variants, variants previously, previously described, described ., . Possible, Possible mechanisms, mechanisms for, for the, the severe, severe deficiency, deficiency of, of G6PD, G6PD in, in erythrocytes, erythrocytes and, and granulocytes, granulocytes was, was investigated, investigated by, by studies, studies on, on the, the immunologic, immunologic specific, specific activity, activity of, of the, the mutant, mutant enzyme, enzyme ., . Mutation, Mutation or, or deletion, deletion of, of the, the PAX6, PAX6 gene, gene underlies, underlies many, many cases, cases of, of aniridia, aniridia ., . Three, Three lines, lines of, of evidence, evidence now, now converge, converge to, to implicate, implicate PAX6, PAX6 more, more widely, widely in, in anterior, anterior segment, segment malformations, malformations including, including Peters, Peters anomaly, anomaly ., . First, First ,, , a, a child, child with, with Peters, Peters anomaly, anomaly is, is deleted, deleted for, for one, one copy, copy of, of PAX6, PAX6 ., . Second, Second ,, , affected, affected members, members of, of a, a family, family with, with dominantly, dominantly inherited, inherited anterior, anterior segment, segment malformations, malformations ,, , including, including Peters, Peters anomaly, anomaly are, are heterozygous, heterozygous for, for an, an R26G, R26G mutation, mutation in, in the, the PAX6, PAX6 paired, paired box, box ., . Third, Third ,, , a, a proportion, proportion of, of Sey/+, Sey/+ Smalleye, "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Smalleye mice, mice ,, , heterozygous, heterozygous for, for a, a nonsense, nonsense mutation, mutation in, in murine, murine Pax-6, Pax-6 ,, , have, have an, an ocular, ocular phenotype, phenotype resembling, resembling Peters, Peters anomaly, anomaly ., . We, We therefore, therefore propose, propose that, that a, a variety, variety of, of anterior, anterior segment, segment anomalies, anomalies may, may be, be associated, associated with, with PAX6, PAX6 mutations.., mutations.. Prostate, Prostate cancer, cancer clusters, clusters in, in some, some families, families ,, , and, and an, an estimated, estimated 5, 5 %, % -10, -10 %, % of, of all, all cases, cases are, are estimated, estimated to, to result, result from, from inheritance, inheritance of, of prostate, prostate cancer-susceptibility, cancer-susceptibility genes, genes ., . We, We previously, previously reported, reported evidence, evidence of, of linkage, linkage to, to the, the 1q24-25, 1q24-25 region, region (, ( HPC1, HPC1 ), ) in, in 91, 91 North, North American, American and, and Swedish, Swedish families, families each, each with, with multiple, multiple cases, cases of, of prostate, prostate cancer, cancer (, ( Smith, Smith et, et al, al ., . 1996, 1996 ), ) ., . In, In the, the present, present report, report we, we analyze, analyze 40, 40 (, ( 12, 12 original, original and, and 28, 28 newly, newly identified, identified ), ) Swedish, Swedish families, families with, with hereditary, hereditary prostate, prostate cancer, cancer (, ( HPC, HPC ), ) that, that ,, , on, on the, the basis, basis of, of 40, 40 markers, markers spanning, spanning a, a 25-cM, 25-cM interval, interval within, within 1q24-25, 1q24-25 ,, , have, have evidence, evidence of, of linkage, linkage ., . In, In the, the complete, complete set, set of, of families, families ,, , a, a maximum, maximum two-point, two-point LOD, LOD score, score of, of 1, 1 ., . 10, 10 was, was observed, observed at, at D1S413, D1S413 (, ( at, at a, a recombination, recombination fraction, fraction [, [ theta, theta ], ] of, of ., . 1, 1 ), ) ,, , with, with a, a maximum, maximum NPL, NPL (, ( nonparametric, nonparametric linkage, linkage ), ) Z, Z score, score of, of 1, 1 ., . 64, 64 at, at D1S202, D1S202 (, ( P, P =, = ., . 05, 05 ), ) ., . The, The evidence, evidence of, of linkage, linkage to, to this, this region, region originated, originated almost, almost exclusively, exclusively from, from the, the subset, subset of, of 12, 12 early-onset, early-onset (, ( age, age <, < 65, 65 years, years ), ) families, families ,, , which, which yielded, yielded a, a maximum, maximum LOD, LOD score, score of, of 2, 2 ., . 38, 38 at, at D1S413, D1S413 (, ( straight, straight theta, theta =, = 0, 0 ), ) and, and an, an NPL, NPL Z, Z score, score of, of 1, 1 ., . 95, 95 at, at D1S422, D1S422 (, ( P, P =, = ., . 03, 03 ), ) ., . Estimates, Estimates from, from heterogeneity, heterogeneity tests, tests suggest, suggest that, that ,, , within, within Sweden, Sweden ,, , as, as many, many as, as 50, 50 %, % of, of early-onset, early-onset families, families had, had evidence, evidence of, of linkage, linkage to, to the, the HPC1, HPC1 region, region ., . These, These results, results are, are consistent, consistent with, with the, the hypothesis, hypothesis of, of linkage, linkage to, to HPC1, HPC1 in, in a, a subset, subset of, of families, families with, with prostate, prostate cancer, cancer ,, , particularly, particularly those, those with, with an, an early, early age, age at, at diagnosis, diagnosis ., . The, The order, order of, of fourteen, fourteen polymorphic, polymorphic markers, markers localised, localised to, to the, the long, long arm, arm of, of human, human chromosome, chromosome 19, 19 has, has been, been established, established by, by multipoint, multipoint mapping, mapping in, in a, a set, set of, of 40, 40 CEPH, CEPH (, ( Centre, Centre dEtude, dEtude de, de Polymorphisme, Polymorphisme Humain, Humain ,, , Paris, Paris ), ) reference, reference families, families ., . We, We report, report here, here the, the linkage, linkage relationship, relationship of, of the, the myotonic, myotonic dystrophy, dystrophy (, ( DM, DM ), ) locus, locus to, to twelve, twelve of, of these, these markers, markers as, as studied, studied in, in 45, 45 families, families with, with DM, DM ., . The, The resulting, resulting genetic, genetic map, map is, is supported, supported by, by the, the localisation, localisation of, of the, the DNA, DNA markers, markers in, in a, a panel, panel of, of somatic, somatic cell, cell hybrids, hybrids ., . Ten, Ten of, of the, the twelve, twelve markers, markers have, have been, been shown, shown to, to be, be proximal, proximal to, to the, the DM, DM gene, gene and, and two, two ,, , PRKCG, PRKCG and, and D19S22, D19S22 ,, , distal, distal but, but at, at distances, distances of, of approximately, approximately 25, 25 cM, cM and, and 15, 15 cM, cM ,, , respectively, respectively ., . The, The closest, closest proximal, proximal markers, markers are, are APOC2, APOC2 (, ( apolipoprotein, apolipoprotein C-II, C-II ), ) and, and CKM, CKM (, ( creatine, creatine kinase, kinase ,, , muscle, muscle ), ) approximately, approximately 3, 3 cM, cM and, and 2, 2 cM, cM from, from the, the DM, DM gene, gene respectively, respectively ,, , in, in the, the order, order APOC2-CKM-DM, APOC2-CKM-DM ., . The, The distance, distance between, between APOC2, APOC2 ,, , CKM, CKM and, and DM, DM (, ( of, of the, the order, order of, of 2, 2 million, million base, base pairs, pairs ), ) and, and their, their known, known orientation, orientation should, should permit, permit directional, directional chromosome, chromosome walking, walking and, and jumping, jumping ., . The, The data, data presented, presented here, here should, should enable, enable us, us to, to determine, determine whether, whether or, or not, not new, new markers, markers are, are distal, distal to, to APOC2/CKM, APOC2/CKM and, and thus, thus potentially, potentially flank, flank the, the DM, DM gene.., gene.. Large, Large intergenerational, intergenerational repeat, repeat expansions, expansions of, of the, the CAG, CAG trinucleotide, trinucleotide repeat, repeat in, in the, the HD, HD gene, gene have, have been, been well, well documented, documented for, for the, the male, male germline, germline ., . We, We describe, describe a, a recurrent, recurrent large, large expansion, expansion of, of a, a maternal, maternal allele, allele with, with 36, 36 CAG, CAG repeats, repeats (, ( to, to 66, 66 and, and 57, 57 repeats, repeats ,, , respectively, respectively ,, , in, in two, two daughters, daughters ), ) associated, associated with, with onset, onset of, of Huntington, Huntington disease, disease (, ( HD, HD ), ) in, in the, the second, second and, and third, third decade, decade in, in a, a family, family without, without history, history of, of HD, HD ., . Our, Our findings, findings give, give evidence, evidence of, of a, a gonadal, gonadal mosaicism, mosaicism in, in the, the unaffected, unaffected mother, mother ., . We, We hypothesize, hypothesize that, that large, large expansions, expansions also, also occur, occur in, in the, the female, female germline, germline and, and that, that a, a negative, negative selection, selection of, of oocytes, oocytes with, with long, long repeats, repeats might, might explain, explain the, the different, different instability, instability behavior, behavior of, of the, the male, male and, and the, the female, female germlines.., germlines.. Inherited, Inherited mutations, mutations in, in the, the E-cadherin, E-cadherin gene, gene (, ( CDH1, CDH1 ), ) were, were described, described recently, recently in, in three, three Maori, Maori kindreds, kindreds with, with familial, familial gastric, gastric cancer, cancer ., . Familial, Familial gastric, gastric cancer, cancer is, is genetically, genetically heterogeneous, heterogeneous and, and it, it is, is not, not clear, clear what, what proportion, proportion of, of gastric, gastric cancer, cancer susceptibility, susceptibility in, in non-Maori, non-Maori populations, populations is, is due, due to, to germline, germline CDH1, CDH1 mutations, mutations ., . Therefore, Therefore ,, , we, we screened, screened eight, eight familial, familial gastric, gastric cancer, cancer kindreds, kindreds of, of British, British and, and Irish, Irish origin, origin for, for germline, germline CDH1, CDH1 mutations, mutations ,, , by, by SSCP, SSCP analysis, analysis of, of all, all 16, 16 exons, exons and, and flanking, flanking sequences, sequences ., . Each, Each family, family contained, contained (, ( i, i ), ) two, two cases, cases of, of gastric, gastric cancer, cancer in, in first, first degree, degree relatives, relatives with, with one, one affected, affected before, before age, age 50, 50 years, years ;, ; or, or (, ( ii, ii ), ) three, three or, or more, more cases, cases of, of gastric, gastric cancer, cancer ., . Novel, Novel germline, germline CDH1, CDH1 mutations, mutations (, ( a, a nonsense, nonsense and, and a, a splice, splice site, site ), ) were, were detected, detected in, in two, two families, families (, ( 25, 25 %, % ), ) ., . Both, Both mutations, mutations were, were predicted, predicted to, to truncate, truncate the, the E-cadherin, E-cadherin protein, protein in, in the, the signal, signal peptide, peptide domain, domain ., . In, In one, one family, family there, there was, was evidence, evidence of, of non-penetrance, non-penetrance and, and susceptibility, susceptibility to, to both, both gastric, gastric and, and colorectal, colorectal cancer, cancer ;, ; thus, thus ,, , in, in addition, addition to, to six, six cases, cases of, of gastric, gastric cancer, cancer ,, , a, a CDH1, CDH1 mutation, mutation carrier, carrier developed, developed colorectal, colorectal cancer, cancer at, at age, age 30, 30 years, years ., . We, We have, have confirmed, confirmed that, that germline, germline mutations, mutations in, in the, the CDH1, CDH1 gene, gene cause, cause familial, familial gastric, gastric cancer, cancer in, in non-Maori, non-Maori populations, populations ., . However, However ,, , only, only a, a minority, minority of, of familial, familial gastric, gastric cancers, cancers can, can be, be accounted, accounted for, for by, by CDH1, CDH1 mutations, mutations ., . Loss, Loss of, of E-cadherin, E-cadherin function, function has, has been, been implicated, implicated in, in the, the pathogenesis, pathogenesis of, of sporadic, sporadic colorectal, colorectal and, and other, other cancers, cancers ,, , and, and our, our findings, findings provide, provide evidence, evidence that, that germline, germline CDH1, CDH1 mutations, mutations predispose, predispose to, to early, early onset, onset colorectal, colorectal cancer, cancer ., . Thus, Thus ,, , CDH1, CDH1 should, should be, be investigated, investigated as, as a, a cause, cause of, of inherited, inherited susceptibility, susceptibility to, to both, both gastric, gastric and, and colorectal, colorectal cancers.We, cancers.We have, have identified, identified a, a Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) pedigree, pedigree where, where the, the disease, disease is, is associated, associated with, with a, a molecular, molecular deletion, deletion within, within the, the DMD, DMD locus, locus ., . We, We have, have examined, examined the, the meiotic, meiotic segregation, segregation products, products of, of the, the common, common female, female ancestor, ancestor using, using marker, marker restriction, restriction fragment, fragment length, length polymorphisms, polymorphisms (, ( RFLPs, RFLPs ), ) detected, detected by, by probes, probes that, that lie, lie within, within this, this deletion, deletion ., . These, These studies, studies show, show that, that this, this female, female has, has transmitted, transmitted three, three distinct, distinct types, types of, of X, X chromosome, chromosome to, to her, her offspring, offspring ., . This, This observation, observation may, may be, be explained, explained by, by postulating, postulating that, that the, the mutation, mutation arose, arose as, as a, a postzygotic, postzygotic deletion, deletion within, within this, this common, common ancestor, ancestor ,, , who, who was, was consequently, consequently germinally, germinally mosaic.., mosaic.. Complementary, Complementary DNA, DNA clones, clones were, were isolated, isolated that, that represent, represent the, the 5, 5 terminal, terminal 2, 2 ., . 5, 5 kilobases, kilobases of, of the, the murine, murine Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( Dmd, Dmd ), ) messenger, messenger RNA, RNA (, ( mRNA, mRNA ), ) ., . Mouse, Mouse Dmd, Dmd mRNA, mRNA was, was detectable, detectable in, in skeletal, skeletal and, and cardiac, cardiac muscle, muscle and, and at, at a, a level, level approximately, approximately 90, 90 percent, percent lower, lower in, in brain, brain ., . Dmd, Dmd mRNA, mRNA is, is also, also present, present ,, , but, but at, at much, much lower, lower than, than normal, normal levels, levels ,, , in, in both, both the, the muscle, muscle and, and brain, brain of, of three, three different, different strains, strains of, of dystrophic, dystrophic mdx, mdx mice, mice ., . The, The identification, identification of, of Dmd, Dmd mRNA, mRNA in, in brain, brain raises, raises the, the possibility, possibility of, of a, a relation, relation between, between human, human Duchenne, Duchenne muscular, muscular dystrophy, dystrophy (, ( DMD, DMD ), ) gene, gene expression, expression and, and the, the mental, mental retardation, retardation found, found in, in some, some DMD, DMD males, males ., . These, These results, results also, also provide, provide evidence, evidence that, that the, the mdx, mdx mutations, mutations are, are allelic, allelic variants, variants of, of mouse, mouse Dmd, Dmd gene, gene mutations, mutations ., . Two, Two peroxisomal, peroxisomal targeting, targeting signals, signals ,, , PTS1, PTS1 and, and PTS2, PTS2 ,, , are, are involved, involved in, in the, the import, import of, of proteins, proteins into, into the, the peroxisome, peroxisome matrix, matrix ., . Human, Human patients, patients with, with fatal, fatal generalized, generalized peroxisomal, peroxisomal deficiency, deficiency disorders, disorders fall, fall into, into at, at least, least nine, nine genetic, genetic complementation, complementation groups, groups ., . Cells, Cells from, from many, many of, of these, these patients, patients are, are deficient, deficient in, in the, the import, import of, of PTS1-containing, PTS1-containing proteins, proteins ,, , but, but the, the causes, causes of, of the, the protein-import, protein-import defect, defect in, in these, these patients, patients are, are unknown, unknown ., . We, We have, have cloned, cloned and, and sequenced, sequenced the, the human, human cDNA, cDNA homologue, homologue (, ( PTS1R, PTS1R ), ) of, of the, the Pichia, Pichia pastoris, pastoris PAS8, PAS8 gene, gene ,, , the, the PTS1, PTS1 receptor, receptor (, ( McCollum, McCollum ,, , D., D. ,, , E., E. Monosov, Monosov ,, , and, and S., S. Subramani, Subramani ., . 1993, 1993 ., . J, J ., . Cell, Cell Biol, Biol ., . 121, 121 761-774, 761-774 ), ) ., . The, The PTS1R, PTS1R mRNA, mRNA is, is expressed, expressed in, in all, all human, human tissues, tissues examined, examined ., . Antibodies, Antibodies to, to the, the human, human PTS1R, PTS1R recognize, recognize this, this protein, protein in, in human, human ,, , monkey, monkey ,, , rat, rat ,, , and, and hamster, hamster cells, cells ., . The, The protein, protein is, is localized, localized mainly, mainly in, in the, the cytosol, cytosol but, but is, is also, also found, found to, to be, be associated, associated with, with peroxisomes, peroxisomes ., . Part, Part of, of the, the peroxisomal, peroxisomal PTS1R, PTS1R protein, protein is, is tightly, tightly bound, bound to, to the, the peroxisomal, peroxisomal membrane, membrane ., . Antibodies, Antibodies to, to PTS1R, PTS1R inhibit, inhibit peroxisomal, peroxisomal protein-import, protein-import of, of PTS1-containing, PTS1-containing proteins, proteins in, in a, a permeabilized, permeabilized CHO, CHO cell, cell system, system ., . In, In vitro-translated, vitro-translated PTS1R, PTS1R protein, protein specifically, specifically binds, binds a, a serine-lysine-leucine-peptide, serine-lysine-leucine-peptide ., . A, A PAS8-PTS1R, PAS8-PTS1R fusion, fusion protein, protein complements, complements the, the P., P. pastoris, pastoris pas8, pas8 mutant, mutant ., . The, The PTS1R, PTS1R cDNA, cDNA also, also complements, complements the, the PTS1, PTS1 protein-import, protein-import defect, defect in, in skin, skin fibroblasts, fibroblasts from, from patients, patients --, -- belonging, belonging to, to complementation, complementation group, group two, two --, -- diagnosed, diagnosed as, as having, having neonatal, neonatal adrenoleukodystrophy, adrenoleukodystrophy or, or Zellweger, Zellweger syndrome, syndrome ., . The, The PTS1R, PTS1R gene, gene has, has been, been localized, localized to, to a, a chromosomal, chromosomal location, location where, where no, no other, other peroxisomal, peroxisomal disorder, disorder genes, genes are, are known, known to, to map, map ., . Our, Our findings, findings represent, represent the, the only, only case, case in, in which, which the, the molecular, molecular basis, basis of, of the, the protein-import, protein-import deficiency, deficiency in, in human, human peroxisomal, peroxisomal disorders, disorders is, is understood, understood ., . Three, Three forms, forms of, of X-linked, X-linked spastic, spastic paraplegia, paraplegia (, ( SPG, SPG ), ) have, have been, been defined, defined ., . One, One locus, locus (, ( SPG, SPG 1, 1 ), ) maps, maps to, to Xq28, Xq28 while, while two, two clinically, clinically distinct, distinct forms, forms map, map to, to Xq22, Xq22 (, ( SPG2, SPG2 ), ) ., . A, A rare, rare X-linked, X-linked dysmyelinating, dysmyelinating disorder, disorder of, of the, the central, central nervous, nervous system, system ,, , Pelizaeus-Merzbacher, Pelizaeus-Merzbacher disease, disease (, ( PMD, PMD ), ) ,, , has, has also, also been, been mapped, mapped to, to Xq21-q22, Xq21-q22 ,, , and, and is, is caused, caused by, by mutations, mutations in, in the, the proteolipid, proteolipid protein, protein gene, gene (, ( PLP, PLP ), ) which, which encodes, encodes two, two myelin, myelin proteins, proteins ,, , PLP, PLP and, and DM20, DM20 ., . While, While narrowing, narrowing the, the genetic, genetic interval, interval containing, containing SPG2, SPG2 in, in a, a large, large pedigree, pedigree ,, , we, we found, found that, that PLP, PLP was, was the, the closest, closest marker, marker to, to the, the disease, disease locus, locus ,, , implicating, implicating PLP, PLP as, as a, a possible, possible candidate, candidate gene, gene ., . We, We have, have found, found that, that a, a point, point mutation, mutation (, ( His139Tyr, His139Tyr ), ) in, in exon, exon 3B, 3B of, of an, an affected, affected male, male produces, produces a, a mutant, mutant PLP, PLP but, but a, a normal, normal DM20, DM20 ,, , and, and segregates, segregates with, with the, the disease, disease (, ( Zmax, Zmax =, = 6, 6 ., . 63, 63 ,, , theta, theta =, = 0, 0 ., . 00, 00 ), ) ., . It, It appears, appears ,, , therefore, therefore ,, , that, that SPG2, SPG2 and, and PMD, PMD are, are allelic, allelic disorders\n"
     ]
    }
   ],
   "source": [
    "print(*map(' '.join, bigrms), sep=', ')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style>\n",
       "    .dataframe thead tr:only-child th {\n",
       "        text-align: right;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: left;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>WNT</td>\n",
       "      <td>NNP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>signalling</td>\n",
       "      <td>VBG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>orchestrates</td>\n",
       "      <td>VBZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>a</td>\n",
       "      <td>DT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>number</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>of</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>developmental</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>programs</td>\n",
       "      <td>NNS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>.</td>\n",
       "      <td>.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>In</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>response</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>to</td>\n",
       "      <td>TO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>this</td>\n",
       "      <td>DT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>stimulus</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>,</td>\n",
       "      <td>,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>cytoplasmic</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>beta-catenin</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>(</td>\n",
       "      <td>(</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>encoded</td>\n",
       "      <td>VBN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>by</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>CTNNB1</td>\n",
       "      <td>NNP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>)</td>\n",
       "      <td>)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>is</td>\n",
       "      <td>VBZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>stabilized</td>\n",
       "      <td>VBN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>,</td>\n",
       "      <td>,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>enabling</td>\n",
       "      <td>VBG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>downstream</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>transcriptional</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>activation</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>by</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>CTNNB1</td>\n",
       "      <td>NNP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>mutations</td>\n",
       "      <td>NNS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>228</th>\n",
       "      <td>is</td>\n",
       "      <td>VBZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>229</th>\n",
       "      <td>greater</td>\n",
       "      <td>JJR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>230</th>\n",
       "      <td>than</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>in</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>232</th>\n",
       "      <td>all</td>\n",
       "      <td>DT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>233</th>\n",
       "      <td>other</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>234</th>\n",
       "      <td>human</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>235</th>\n",
       "      <td>tumours</td>\n",
       "      <td>NNS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>236</th>\n",
       "      <td>examined</td>\n",
       "      <td>VBD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>237</th>\n",
       "      <td>thus</td>\n",
       "      <td>RB</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>238</th>\n",
       "      <td>far</td>\n",
       "      <td>RB</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>239</th>\n",
       "      <td>,</td>\n",
       "      <td>,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>and</td>\n",
       "      <td>CC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>241</th>\n",
       "      <td>directly</td>\n",
       "      <td>RB</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>242</th>\n",
       "      <td>implicates</td>\n",
       "      <td>VBZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>243</th>\n",
       "      <td>beta-catenin/LEF</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>244</th>\n",
       "      <td>misregulation</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>245</th>\n",
       "      <td>as</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>246</th>\n",
       "      <td>the</td>\n",
       "      <td>DT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>247</th>\n",
       "      <td>major</td>\n",
       "      <td>JJ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>248</th>\n",
       "      <td>cause</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>249</th>\n",
       "      <td>of</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>hair</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>matrix</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>cell</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>tumorigenesis</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>in</td>\n",
       "      <td>IN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>humans..</td>\n",
       "      <td>NN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>256 rows  2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                    0    1\n",
       "0                 WNT  NNP\n",
       "1          signalling  VBG\n",
       "2        orchestrates  VBZ\n",
       "3                   a   DT\n",
       "4              number   NN\n",
       "5                  of   IN\n",
       "6       developmental   JJ\n",
       "7            programs  NNS\n",
       "8                   .    .\n",
       "9                  In   IN\n",
       "10           response   NN\n",
       "11                 to   TO\n",
       "12               this   DT\n",
       "13           stimulus   NN\n",
       "14                  ,    ,\n",
       "15        cytoplasmic   JJ\n",
       "16       beta-catenin   NN\n",
       "17                  (    (\n",
       "18            encoded  VBN\n",
       "19                 by   IN\n",
       "20             CTNNB1  NNP\n",
       "21                  )    )\n",
       "22                 is  VBZ\n",
       "23         stabilized  VBN\n",
       "24                  ,    ,\n",
       "25           enabling  VBG\n",
       "26         downstream   JJ\n",
       "27    transcriptional   JJ\n",
       "28         activation   NN\n",
       "29                 by   IN\n",
       "..                ...  ...\n",
       "226            CTNNB1  NNP\n",
       "227         mutations  NNS\n",
       "228                is  VBZ\n",
       "229           greater  JJR\n",
       "230              than   IN\n",
       "231                in   IN\n",
       "232               all   DT\n",
       "233             other   JJ\n",
       "234             human   JJ\n",
       "235           tumours  NNS\n",
       "236          examined  VBD\n",
       "237              thus   RB\n",
       "238               far   RB\n",
       "239                 ,    ,\n",
       "240               and   CC\n",
       "241          directly   RB\n",
       "242        implicates  VBZ\n",
       "243  beta-catenin/LEF   JJ\n",
       "244     misregulation   NN\n",
       "245                as   IN\n",
       "246               the   DT\n",
       "247             major   JJ\n",
       "248             cause   NN\n",
       "249                of   IN\n",
       "250              hair   NN\n",
       "251            matrix   NN\n",
       "252              cell   NN\n",
       "253     tumorigenesis   NN\n",
       "254                in   IN\n",
       "255          humans..   NN\n",
       "\n",
       "[256 rows x 2 columns]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(tokens)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "raw",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "''"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('A', 'DT'),\n",
       " ('common', 'JJ'),\n",
       " ('human', 'JJ'),\n",
       " ('skin', 'FW'),\n",
       " ('tumour', 'NN'),\n",
       " ('caused', 'VBD'),\n",
       " ('activating', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('beta-catenin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('WNT', 'NNP'),\n",
       " ('signalling', 'VBG'),\n",
       " ('orchestrates', 'NNS'),\n",
       " ('number', 'NN'),\n",
       " ('developmental', 'JJ'),\n",
       " ('programs', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('response', 'NN'),\n",
       " ('stimulus', 'NN'),\n",
       " (',', ','),\n",
       " ('cytoplasmic', 'JJ'),\n",
       " ('beta-catenin', 'NN'),\n",
       " ('(', '('),\n",
       " ('encoded', 'JJ'),\n",
       " ('CTNNB1', 'NNP'),\n",
       " (')', ')'),\n",
       " ('stabilized', 'VBD'),\n",
       " (',', ','),\n",
       " ('enabling', 'VBG'),\n",
       " ('downstream', 'JJ'),\n",
       " ('transcriptional', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('members', 'NNS'),\n",
       " ('LEF/TCF', 'NNP'),\n",
       " ('family', 'NN'),\n",
       " ('.', '.'),\n",
       " ('One', 'CD'),\n",
       " ('target', 'NN'),\n",
       " ('genes', 'NNS'),\n",
       " ('beta-catenin/TCF', 'JJ'),\n",
       " ('encodes', 'NNS'),\n",
       " ('c-MYC', 'JJ'),\n",
       " (',', ','),\n",
       " ('explaining', 'VBG'),\n",
       " ('constitutive', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('WNT', 'NNP'),\n",
       " ('pathway', 'RB'),\n",
       " ('lead', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " (',', ','),\n",
       " ('particularly', 'RB'),\n",
       " ('colon', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Most', 'JJS'),\n",
       " ('colon', 'NN'),\n",
       " ('cancers', 'NNS'),\n",
       " ('arise', 'VBP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('gene', 'NN'),\n",
       " ('encoding', 'VBG'),\n",
       " ('adenomatous', 'JJ'),\n",
       " ('polyposis', 'NN'),\n",
       " ('coli', 'NN'),\n",
       " ('(', '('),\n",
       " ('APC', 'NNP'),\n",
       " (')', ')'),\n",
       " (',', ','),\n",
       " ('protein', 'RB'),\n",
       " ('required', 'VBN'),\n",
       " ('ubiquitin-mediated', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('beta-catenin', 'NN'),\n",
       " (',', ','),\n",
       " ('small', 'JJ'),\n",
       " ('percentage', 'NN'),\n",
       " ('colon', 'NN'),\n",
       " ('cancers', 'NNS'),\n",
       " ('harbour', 'VBP'),\n",
       " ('beta-catenin-stabilizing', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Recently', 'RB'),\n",
       " (',', ','),\n",
       " ('discovered', 'VBD'),\n",
       " ('transgenic', 'JJ'),\n",
       " ('mice', 'NN'),\n",
       " ('expressing', 'VBG'),\n",
       " ('activated', 'VBN'),\n",
       " ('beta-catenin', 'NN'),\n",
       " ('predisposed', 'JJ'),\n",
       " ('developing', 'VBG'),\n",
       " ('skin', 'JJ'),\n",
       " ('tumours', 'NNS'),\n",
       " ('resembling', 'VBG'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Given', 'VBN'),\n",
       " ('skin', 'JJ'),\n",
       " ('adult', 'NN'),\n",
       " ('mice', 'NN'),\n",
       " ('also', 'RB'),\n",
       " ('exhibits', 'VBZ'),\n",
       " ('signs', 'NNS'),\n",
       " ('de', 'IN'),\n",
       " ('novo', 'FW'),\n",
       " ('hair-follicle', 'JJ'),\n",
       " ('morphogenesis', 'NN'),\n",
       " (',', ','),\n",
       " ('wondered', 'VBD'),\n",
       " ('whether', 'IN'),\n",
       " ('human', 'JJ'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('might', 'MD'),\n",
       " ('originate', 'VB'),\n",
       " ('hair', 'NN'),\n",
       " ('matrix', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " ('whether', 'IN'),\n",
       " ('might', 'MD'),\n",
       " ('possess', 'VB'),\n",
       " ('beta-catenin-stabilizing', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Here', 'RB'),\n",
       " (',', ','),\n",
       " ('explore', 'RB'),\n",
       " ('cell', 'NN'),\n",
       " ('origin', 'JJ'),\n",
       " ('aetiology', 'NN'),\n",
       " ('common', 'JJ'),\n",
       " ('human', 'JJ'),\n",
       " ('skin', 'FW'),\n",
       " ('tumour', 'NN'),\n",
       " ('.', '.'),\n",
       " ('We', 'PRP'),\n",
       " ('found', 'VBD'),\n",
       " ('nuclear', 'JJ'),\n",
       " ('LEF-1', 'JJ'),\n",
       " ('dividing', 'VBG'),\n",
       " ('tumour', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " (',', ','),\n",
       " ('providing', 'VBG'),\n",
       " ('biochemical', 'JJ'),\n",
       " ('evidence', 'NN'),\n",
       " ('pilomatricomas', 'NN'),\n",
       " ('derived', 'VBD'),\n",
       " ('hair', 'JJ'),\n",
       " ('matrix', 'JJ'),\n",
       " ('cells', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('At', 'IN'),\n",
       " ('least', 'JJS'),\n",
       " ('75', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('tumours', 'NN'),\n",
       " ('possess', 'NN'),\n",
       " ('mutations', 'NNS'),\n",
       " ('affecting', 'VBG'),\n",
       " ('amino-terminal', 'JJ'),\n",
       " ('segment', 'NN'),\n",
       " (',', ','),\n",
       " ('normally', 'RB'),\n",
       " ('involved', 'JJ'),\n",
       " ('phosphorylation-dependent', 'JJ'),\n",
       " (',', ','),\n",
       " ('ubiquitin-mediated', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('protein', 'NN'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('percentage', 'NN'),\n",
       " ('CTNNB1', 'NNP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('greater', 'JJR'),\n",
       " ('human', 'JJ'),\n",
       " ('tumours', 'NNS'),\n",
       " ('examined', 'VBD'),\n",
       " ('thus', 'RB'),\n",
       " ('far', 'RB'),\n",
       " (',', ','),\n",
       " ('directly', 'RB'),\n",
       " ('implicates', 'VBZ'),\n",
       " ('beta-catenin/LEF', 'JJ'),\n",
       " ('misregulation', 'NN'),\n",
       " ('major', 'JJ'),\n",
       " ('cause', 'NN'),\n",
       " ('hair', 'NN'),\n",
       " ('matrix', 'NN'),\n",
       " ('cell', 'NN'),\n",
       " ('tumorigenesis', 'NN'),\n",
       " ('humans..', 'NN'),\n",
       " ('HFE', 'NNP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('analysis', 'NN'),\n",
       " ('711', 'CD'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('probands', 'NNS'),\n",
       " (':', ':'),\n",
       " ('evidence', 'NN'),\n",
       " ('S65C', 'NNP'),\n",
       " ('implication', 'NN'),\n",
       " ('mild', 'NN'),\n",
       " ('form', 'NN'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Hereditary', 'JJ'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('(', '('),\n",
       " ('HH', 'NNP'),\n",
       " (')', ')'),\n",
       " ('common', 'JJ'),\n",
       " ('autosomal', 'JJ'),\n",
       " ('recessive', 'JJ'),\n",
       " ('genetic', 'JJ'),\n",
       " ('disorder', 'NN'),\n",
       " ('iron', 'NN'),\n",
       " ('metabolism', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('HFE', 'NNP'),\n",
       " ('candidate', 'NN'),\n",
       " ('gene', 'NN'),\n",
       " ('encoding', 'VBG'),\n",
       " ('HLA', 'NNP'),\n",
       " ('class', 'NN'),\n",
       " ('I-like', 'NNP'),\n",
       " ('protein', 'NN'),\n",
       " ('involved', 'VBN'),\n",
       " ('HH', 'NNP'),\n",
       " ('identified', 'JJ'),\n",
       " ('1996', 'CD'),\n",
       " ('.', '.'),\n",
       " ('Two', 'CD'),\n",
       " ('missense', 'JJ'),\n",
       " ('mutations', 'NNS'),\n",
       " ('described', 'VBD'),\n",
       " ('C282Y', 'NNP'),\n",
       " (',', ','),\n",
       " ('accounting', 'VBG'),\n",
       " ('80', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('90', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " (',', ','),\n",
       " ('H63D', 'NNP'),\n",
       " (',', ','),\n",
       " ('associated', 'VBN'),\n",
       " ('milder', 'NN'),\n",
       " ('form', 'NN'),\n",
       " ('disease', 'NN'),\n",
       " ('representing', 'VBG'),\n",
       " ('40', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('70', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('non-C282Y', 'JJ'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('We', 'PRP'),\n",
       " ('report', 'VBP'),\n",
       " ('analysis', 'NN'),\n",
       " ('C282Y', 'NNP'),\n",
       " (',', ','),\n",
       " ('H63D', 'NNP'),\n",
       " (',', ','),\n",
       " ('193A', 'CD'),\n",
       " ('--', ':'),\n",
       " ('>', 'JJ'),\n",
       " ('T', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('leading', 'VBG'),\n",
       " ('S65C', 'NNP'),\n",
       " ('missense', 'NN'),\n",
       " ('substitution', 'NN'),\n",
       " ('large', 'JJ'),\n",
       " ('series', 'NN'),\n",
       " ('probands', 'VBZ'),\n",
       " ('controls', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('results', 'NNS'),\n",
       " ('confirm', 'VBP'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('main', 'JJ'),\n",
       " ('mutation', 'NN'),\n",
       " ('involved', 'VBN'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " (',', ','),\n",
       " ('accounting', 'VBG'),\n",
       " ('85', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('carrier', 'NN'),\n",
       " ('chromosomes', 'NNS'),\n",
       " (',', ','),\n",
       " ('whereas', 'NNS'),\n",
       " ('H63D', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('represented', 'VBD'),\n",
       " ('39', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'VBZ'),\n",
       " ('carry', 'VBP'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('mutation', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('addition', 'NN'),\n",
       " (',', ','),\n",
       " ('screening', 'VBG'),\n",
       " ('showed', 'VBD'),\n",
       " ('S65C', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('significantly', 'RB'),\n",
       " ('enriched', 'VBD'),\n",
       " ('probands', 'NNS'),\n",
       " ('least', 'JJS'),\n",
       " ('one', 'CD'),\n",
       " ('chromosome', 'NN'),\n",
       " ('without', 'IN'),\n",
       " ('assigned', 'JJ'),\n",
       " ('mutation', 'NN'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('substitution', 'NN'),\n",
       " ('accounted', 'VBD'),\n",
       " ('7', 'CD'),\n",
       " ('.', '.'),\n",
       " ('8', 'CD'),\n",
       " ('%', 'NN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'VBZ'),\n",
       " ('neither', 'CC'),\n",
       " ('C282Y', 'NNP'),\n",
       " ('H63D', 'NNP'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('enrichment', 'JJ'),\n",
       " ('S65C', 'NNP'),\n",
       " ('among', 'IN'),\n",
       " ('HH', 'NNP'),\n",
       " ('chromosomes', 'NNS'),\n",
       " ('suggests', 'VBZ'),\n",
       " ('S65C', 'NNP'),\n",
       " ('substitution', 'NN'),\n",
       " ('associated', 'VBN'),\n",
       " ('mild', 'JJ'),\n",
       " ('form', 'NN'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Germline', 'NNP'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('population-based', 'JJ'),\n",
       " ('series', 'NN'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('objective', 'JJ'),\n",
       " ('study', 'NN'),\n",
       " ('provide', 'VBP'),\n",
       " ('accurate', 'JJ'),\n",
       " ('frequency', 'NN'),\n",
       " ('estimates', 'NNS'),\n",
       " ('breast', 'VBD'),\n",
       " ('cancer', 'NN'),\n",
       " ('susceptibility', 'NN'),\n",
       " ('gene', 'NN'),\n",
       " ('1', 'CD'),\n",
       " ('(', '('),\n",
       " ('BRCA1', 'NNP'),\n",
       " (')', ')'),\n",
       " ('germline', 'NN'),\n",
       " ('alterations', 'NNS'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('population', 'NN'),\n",
       " ('.', '.'),\n",
       " ('To', 'TO'),\n",
       " ('achieve', 'VB'),\n",
       " ('this', 'DT'),\n",
       " (',', ','),\n",
       " ('determined', 'VBD'),\n",
       " ('prevalence', 'NN'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('population-based', 'JJ'),\n",
       " ('series', 'NN'),\n",
       " ('consecutive', 'JJ'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('first', 'JJ'),\n",
       " ('population-based', 'JJ'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('study', 'NN'),\n",
       " ('reporting', 'VBG'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('derived', 'VBD'),\n",
       " ('comprehensive', 'JJ'),\n",
       " ('screen', 'NN'),\n",
       " ('entire', 'JJ'),\n",
       " ('coding', 'NN'),\n",
       " ('region', 'NN'),\n",
       " ('.', '.'),\n",
       " ('One', 'CD'),\n",
       " ('hundred', 'VBD'),\n",
       " ('seven', 'CD'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('analyzed', 'VBD'),\n",
       " ('BRCA1', 'NNP'),\n",
       " ('alterations', 'NNS'),\n",
       " ('using', 'VBG'),\n",
       " ('RNase', 'NNP'),\n",
       " ('mismatch', 'NN'),\n",
       " ('cleavage', 'NN'),\n",
       " ('assay', 'VBP'),\n",
       " ('followed', 'VBN'),\n",
       " ('direct', 'JJ'),\n",
       " ('sequencing', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Two', 'CD'),\n",
       " ('truncating', 'VBG'),\n",
       " ('mutations', 'NNS'),\n",
       " (',', ','),\n",
       " ('962del4', 'CD'),\n",
       " ('3600del11', 'CD'),\n",
       " (',', ','),\n",
       " ('identified', 'VBN'),\n",
       " ('.', '.'),\n",
       " ('Both', 'DT'),\n",
       " ('patients', 'NNS'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('breast', 'NN'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Several', 'JJ'),\n",
       " ('novel', 'RB'),\n",
       " ('well', 'RB'),\n",
       " ('previously', 'RB'),\n",
       " ('reported', 'VBN'),\n",
       " ('uncharacterized', 'JJ'),\n",
       " ('variants', 'NNS'),\n",
       " ('also', 'RB'),\n",
       " ('identified', 'VBN'),\n",
       " (',', ','),\n",
       " ('associated', 'VBN'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('cancer', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('frequency', 'NN'),\n",
       " ('distribution', 'NN'),\n",
       " ('common', 'JJ'),\n",
       " ('polymorphisms', 'NN'),\n",
       " ('determined', 'VBD'),\n",
       " ('91', 'CD'),\n",
       " ('Caucasian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('cases', 'NNS'),\n",
       " ('series', 'NN'),\n",
       " ('24', 'CD'),\n",
       " ('sister', 'NN'),\n",
       " ('controls', 'NNS'),\n",
       " ('using', 'VBG'),\n",
       " ('allele-specific', 'JJ'),\n",
       " ('amplification', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('rare', 'JJ'),\n",
       " ('form', 'NN'),\n",
       " ('Q356R', 'NNP'),\n",
       " ('polymorphism', 'NN'),\n",
       " ('significantly', 'RB'),\n",
       " ('(', '('),\n",
       " ('P', 'NNP'),\n",
       " ('=', 'VBZ'),\n",
       " ('0', 'CD'),\n",
       " ('.', '.'),\n",
       " ('03', 'CD'),\n",
       " (')', ')'),\n",
       " ('associated', 'VBN'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " (',', ','),\n",
       " ('suggesting', 'VBG'),\n",
       " ('polymorphism', 'NN'),\n",
       " ('may', 'MD'),\n",
       " ('influence', 'VB'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('risk', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('summary', 'JJ'),\n",
       " (',', ','),\n",
       " ('data', 'NNS'),\n",
       " ('suggest', 'VBP'),\n",
       " ('role', 'NN'),\n",
       " ('uncharacterized', 'JJ'),\n",
       " ('variants', 'NNS'),\n",
       " ('rare', 'JJ'),\n",
       " ('forms', 'NNS'),\n",
       " ('polymorphisms', 'VBP'),\n",
       " ('determining', 'VBG'),\n",
       " ('ovarian', 'JJ'),\n",
       " ('cancer', 'NN'),\n",
       " ('risk', 'NN'),\n",
       " (',', ','),\n",
       " ('highlight', 'JJ'),\n",
       " ('necessity', 'NN'),\n",
       " ('screen', 'NN'),\n",
       " ('missense', 'NN'),\n",
       " ('alterations', 'NNS'),\n",
       " ('well', 'RB'),\n",
       " ('truncating', 'VBG'),\n",
       " ('mutations', 'NNS'),\n",
       " ('population', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Identification', 'NNP'),\n",
       " ('APC2', 'NNP'),\n",
       " (',', ','),\n",
       " ('homologue', 'VBP'),\n",
       " ('adenomatous', 'JJ'),\n",
       " ('polyposis', 'NN'),\n",
       " ('coli', 'VB'),\n",
       " ('tumour', 'NN'),\n",
       " ('suppressor', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('adenomatous', 'JJ'),\n",
       " ('polyposis', 'NN'),\n",
       " ('coli', 'NN'),\n",
       " ('(', '('),\n",
       " ('APC', 'NNP'),\n",
       " (')', ')'),\n",
       " ('tumour-suppressor', 'NN'),\n",
       " ('protein', 'NN'),\n",
       " ('controls', 'VBZ'),\n",
       " ('Wnt', 'NNP'),\n",
       " ('signalling', 'VBG'),\n",
       " ('pathway', 'RB'),\n",
       " ('forming', 'VBG'),\n",
       " ('complex', 'JJ'),\n",
       " ('glycogen', 'NN'),\n",
       " ('synthase', 'NN'),\n",
       " ('kinase', 'NN'),\n",
       " ('3beta', 'CD'),\n",
       " ('(', '('),\n",
       " ('GSK-3beta', 'NNP'),\n",
       " (')', ')'),\n",
       " (',', ','),\n",
       " ('axin/conductin', 'JJ'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Complex', 'JJ'),\n",
       " ('formation', 'NN'),\n",
       " ('induces', 'NNS'),\n",
       " ('rapid', 'JJ'),\n",
       " ('degradation', 'NN'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('In', 'IN'),\n",
       " ('colon', 'NN'),\n",
       " ('carcinoma', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " (',', ','),\n",
       " ('loss', 'NN'),\n",
       " ('APC', 'NNP'),\n",
       " ('leads', 'VBZ'),\n",
       " ('accumulation', 'NN'),\n",
       " ('betacatenin', 'NN'),\n",
       " ('nucleus', 'NN'),\n",
       " (',', ','),\n",
       " ('binds', 'VBZ'),\n",
       " ('activates', 'NNS'),\n",
       " ('Tcf-4', 'NNP'),\n",
       " ('transcription', 'NN'),\n",
       " ('factor', 'NN'),\n",
       " ('(', '('),\n",
       " ('reviewed', 'VBN'),\n",
       " ('[', 'RB'),\n",
       " ('1', 'CD'),\n",
       " (']', 'JJ'),\n",
       " ('[', '$'),\n",
       " ('2', 'CD'),\n",
       " (']', 'NN'),\n",
       " (')', ')'),\n",
       " ('.', '.'),\n",
       " ('Here', 'RB'),\n",
       " (',', ','),\n",
       " ('report', 'NN'),\n",
       " ('identification', 'NN'),\n",
       " ('genomic', 'JJ'),\n",
       " ('structure', 'NN'),\n",
       " ('APC', 'NNP'),\n",
       " ('homologues', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Mammalian', 'JJ'),\n",
       " ('APC2', 'NNP'),\n",
       " (',', ','),\n",
       " ('closely', 'RB'),\n",
       " ('resembles', 'VBZ'),\n",
       " ('APC', 'NNP'),\n",
       " ('overall', 'JJ'),\n",
       " ('domain', 'NN'),\n",
       " ('structure', 'NN'),\n",
       " (',', ','),\n",
       " ('functionally', 'RB'),\n",
       " ('analyzed', 'VBN'),\n",
       " ('shown', 'VBN'),\n",
       " ('contain', 'NN'),\n",
       " ('two', 'CD'),\n",
       " ('SAMP', 'NNP'),\n",
       " ('domains', 'NNS'),\n",
       " (',', ','),\n",
       " ('required', 'VBN'),\n",
       " ('binding', 'NN'),\n",
       " ('conductin', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Like', 'IN'),\n",
       " ('APC', 'NNP'),\n",
       " (',', ','),\n",
       " ('APC2', 'NNP'),\n",
       " ('regulates', 'VBZ'),\n",
       " ('formation', 'JJ'),\n",
       " ('active', 'JJ'),\n",
       " ('betacatenin-Tcf', 'NN'),\n",
       " ('complexes', 'NNS'),\n",
       " (',', ','),\n",
       " ('demonstrated', 'VBD'),\n",
       " ('using', 'VBG'),\n",
       " ('transient', 'JJ'),\n",
       " ('transcriptional', 'JJ'),\n",
       " ('activation', 'NN'),\n",
       " ('assays', 'NNS'),\n",
       " ('APC', 'NNP'),\n",
       " ('-/-', 'NNP'),\n",
       " ('colon', 'NN'),\n",
       " ('carcinoma', 'NN'),\n",
       " ('cells', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('Human', 'NNP'),\n",
       " ('APC2', 'NNP'),\n",
       " ('maps', 'VBZ'),\n",
       " ('chromosome', 'VB'),\n",
       " ('19p13', 'CD'),\n",
       " ('.', '.'),\n",
       " ('3', 'CD'),\n",
       " ('.', '.'),\n",
       " ('APC', 'NNP'),\n",
       " ('APC2', 'NNP'),\n",
       " ('may', 'MD'),\n",
       " ('therefore', 'VB'),\n",
       " ('comparable', 'JJ'),\n",
       " ('functions', 'NNS'),\n",
       " ('development', 'NN'),\n",
       " ('cancer', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Familial', 'JJ'),\n",
       " ('deficiency', 'NN'),\n",
       " ('seventh', 'JJ'),\n",
       " ('component', 'NN'),\n",
       " ('complement', 'NN'),\n",
       " ('associated', 'VBN'),\n",
       " ('recurrent', 'JJ'),\n",
       " ('bacteremic', 'JJ'),\n",
       " ('infections', 'NNS'),\n",
       " ('due', 'JJ'),\n",
       " ('Neisseria', 'NNP'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('serum', 'JJ'),\n",
       " ('29-year', 'JJ'),\n",
       " ('old', 'JJ'),\n",
       " ('woman', 'NN'),\n",
       " ('recent', 'JJ'),\n",
       " ('episode', 'NN'),\n",
       " ('disseminated', 'VBD'),\n",
       " ('gonococcal', 'JJ'),\n",
       " ('infection', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('meningococcal', 'JJ'),\n",
       " ('meningitis', 'NN'),\n",
       " ('arthritis', 'NN'),\n",
       " ('child', 'NN'),\n",
       " ('found', 'VBD'),\n",
       " ('lack', 'RB'),\n",
       " ('serum', 'JJ'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('complement', 'NN'),\n",
       " ('activity', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('seventh', 'JJ'),\n",
       " ('component', 'NN'),\n",
       " ('complement', 'NN'),\n",
       " ('(', '('),\n",
       " ('C7', 'NNP'),\n",
       " (')', ')'),\n",
       " ('detected', 'VBD'),\n",
       " ('functional', 'JJ'),\n",
       " ('immunochemical', 'JJ'),\n",
       " ('assays', 'NNS'),\n",
       " (',', ','),\n",
       " ('whereas', 'JJ'),\n",
       " ('components', 'NNS'),\n",
       " ('normal', 'JJ'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('immunochemical', 'JJ'),\n",
       " ('assessment', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Her', 'PRP$'),\n",
       " ('fresh', 'JJ'),\n",
       " ('serum', 'NN'),\n",
       " ('lacked', 'VBD'),\n",
       " ('complement-mediated', 'JJ'),\n",
       " ('bactericidal', 'NN'),\n",
       " ('activity', 'NN'),\n",
       " ('Neisseria', 'NNP'),\n",
       " ('gonorrhoeae', 'NN'),\n",
       " (',', ','),\n",
       " ('addition', 'NN'),\n",
       " ('fresh', 'JJ'),\n",
       " ('normal', 'JJ'),\n",
       " ('serum', 'NN'),\n",
       " ('purified', 'VBD'),\n",
       " ('C7', 'NNP'),\n",
       " ('restored', 'VBD'),\n",
       " ('bactericidal', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('well', 'RB'),\n",
       " ('hemolytic', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('absence', 'NN'),\n",
       " ('functional', 'JJ'),\n",
       " ('C7', 'NNP'),\n",
       " ('activity', 'NN'),\n",
       " ('could', 'MD'),\n",
       " ('accounted', 'VB'),\n",
       " ('basis', 'NN'),\n",
       " ('inhibitor', 'NN'),\n",
       " ('.', '.'),\n",
       " ('Opsonization', 'NNP'),\n",
       " ('generation', 'NN'),\n",
       " ('chemotactic', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('functioned', 'VBD'),\n",
       " ('normally', 'RB'),\n",
       " ('.', '.'),\n",
       " ('Complete', 'JJ'),\n",
       " ('absence', 'NN'),\n",
       " ('C7', 'NNP'),\n",
       " ('also', 'RB'),\n",
       " ('found', 'VBD'),\n",
       " ('one', 'CD'),\n",
       " ('sibling', 'VBG'),\n",
       " ('clinical', 'JJ'),\n",
       " ('syndrome', 'JJ'),\n",
       " ('meningococcal', 'JJ'),\n",
       " ('meningitis', 'NN'),\n",
       " ('arthritis', 'NN'),\n",
       " ('child', 'NN'),\n",
       " ('siblings', 'NNS'),\n",
       " ('clinically', 'RB'),\n",
       " ('well', 'RB'),\n",
       " ('eight-year-old', 'JJ'),\n",
       " ('son', 'NN'),\n",
       " ('.', '.'),\n",
       " ('HLA', 'NNP'),\n",
       " ('histocompatibility', 'NN'),\n",
       " ('typing', 'VBG'),\n",
       " ('family', 'NN'),\n",
       " ('members', 'NNS'),\n",
       " ('demonstrate', 'VBP'),\n",
       " ('evidence', 'NN'),\n",
       " ('genetic', 'JJ'),\n",
       " ('linkage', 'NN'),\n",
       " ('C7', 'NNP'),\n",
       " ('deficiency', 'NN'),\n",
       " ('major', 'JJ'),\n",
       " ('histocompatibility', 'NN'),\n",
       " ('loci', 'NN'),\n",
       " ('.', '.'),\n",
       " ('This', 'DT'),\n",
       " ('report', 'NN'),\n",
       " ('represents', 'VBZ'),\n",
       " ('first', 'JJ'),\n",
       " ('cases', 'NNS'),\n",
       " ('C7', 'NNP'),\n",
       " ('deficiency', 'NN'),\n",
       " ('associated', 'VBN'),\n",
       " ('infectious', 'JJ'),\n",
       " ('complications', 'NNS'),\n",
       " ('suggests', 'VBZ'),\n",
       " ('bactericidal', 'JJ'),\n",
       " ('activity', 'NN'),\n",
       " ('may', 'MD'),\n",
       " ('important', 'JJ'),\n",
       " ('host', 'NN'),\n",
       " ('defense', 'NN'),\n",
       " ('bacteremic', 'JJ'),\n",
       " ('neisseria', 'JJ'),\n",
       " ('infections', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('GCH1', 'NNP'),\n",
       " ('mutation', 'NN'),\n",
       " ('patient', 'NN'),\n",
       " ('adult-onset', 'JJ'),\n",
       " ('oromandibular', 'JJ'),\n",
       " ('dystonia', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('authors', 'NNS'),\n",
       " ('report', 'VBP'),\n",
       " ('mutation', 'NN'),\n",
       " ('exon', 'RB'),\n",
       " ('5', 'CD'),\n",
       " ('GCH1', 'NNP'),\n",
       " ('patient', 'JJ'),\n",
       " ('adult-onset', 'JJ'),\n",
       " ('oromandibular', 'JJ'),\n",
       " ('dystonia', 'NN'),\n",
       " ('obvious', 'JJ'),\n",
       " ('family', 'NN'),\n",
       " ('history', 'NN'),\n",
       " ('dystonia', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('patient', 'NN'),\n",
       " ('responded', 'VBD'),\n",
       " ('positively', 'RB'),\n",
       " ('treatment', 'NN'),\n",
       " ('L-dopa', 'NNP'),\n",
       " ('.', '.'),\n",
       " ('These', 'DT'),\n",
       " ('findings', 'NNS'),\n",
       " ('demonstrate', 'VBP'),\n",
       " ('GCH1', 'NNP'),\n",
       " ('mutations', 'NNS'),\n",
       " ('must', 'MD'),\n",
       " ('considered', 'VBN'),\n",
       " ('even', 'RB'),\n",
       " ('patients', 'NNS'),\n",
       " ('dystonic', 'JJ'),\n",
       " ('symptoms', 'NNS'),\n",
       " ('typical', 'JJ'),\n",
       " ('dopa-responsive', 'JJ'),\n",
       " ('dystonia', 'NN'),\n",
       " ('.', '.'),\n",
       " ('The', 'DT'),\n",
       " ('hereditary', 'JJ'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('protein', 'NN'),\n",
       " (',', ','),\n",
       " ('HFE', 'NNP'),\n",
       " (',', ','),\n",
       " ('specifically', 'RB'),\n",
       " ('regulates', 'VBZ'),\n",
       " ('transferrin-mediated', 'JJ'),\n",
       " ('iron', 'NN'),\n",
       " ('uptake', 'NN'),\n",
       " ('HeLa', 'NNP'),\n",
       " ('cells', 'NNS'),\n",
       " ('.', '.'),\n",
       " ('HFE', 'NNP'),\n",
       " ('protein', 'JJ'),\n",
       " ('product', 'NN'),\n",
       " ('gene', 'NN'),\n",
       " ('mutated', 'VBD'),\n",
       " ('autosomal', 'JJ'),\n",
       " ('recessive', 'JJ'),\n",
       " ('disease', 'NN'),\n",
       " ('hereditary', 'JJ'),\n",
       " ('hemochromatosis', 'NN'),\n",
       " ('(', '('),\n",
       " ('Feder', 'NNP'),\n",
       " (',', ','),\n",
       " ('J.', 'NNP'),\n",
       " ('N.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Gnirke', 'NNP'),\n",
       " (',', ','),\n",
       " ('A.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Thomas', 'NNP'),\n",
       " (',', ','),\n",
       " ('W.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Tsuchihashi', 'NNP'),\n",
       " (',', ','),\n",
       " ('Z.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Ruddy', 'NNP'),\n",
       " (',', ','),\n",
       " ('D.', 'NNP'),\n",
       " ('A.', 'NN'),\n",
       " (',', ','),\n",
       " ('Basava', 'NNP'),\n",
       " (',', ','),\n",
       " ('A.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Dormishian', 'NNP'),\n",
       " (',', ','),\n",
       " ('F.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Domingo', 'NNP'),\n",
       " (',', ','),\n",
       " ('R.', 'NNP'),\n",
       " ('J.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Ellis', 'NNP'),\n",
       " (',', ','),\n",
       " ('M.', 'NNP'),\n",
       " ('C.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Fullan', 'NNP'),\n",
       " (',', ','),\n",
       " ('A.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Hinton', 'NNP'),\n",
       " (',', ','),\n",
       " ('L.', 'NNP'),\n",
       " ('M.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Jones', 'NNP'),\n",
       " (',', ','),\n",
       " ('N.', 'NNP'),\n",
       " ('L.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Kimmel', 'NNP'),\n",
       " (',', ','),\n",
       " ('B.', 'NNP'),\n",
       " ('E.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Kronmal', 'NNP'),\n",
       " (',', ','),\n",
       " ('G.', 'NNP'),\n",
       " ('S.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Lauer', 'NNP'),\n",
       " (',', ','),\n",
       " ('P.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Lee', 'NNP'),\n",
       " (',', ','),\n",
       " ('V.', 'NNP'),\n",
       " ('K.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Loeb', 'NNP'),\n",
       " (',', ','),\n",
       " ('D.', 'NNP'),\n",
       " ('B.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Mapa', 'NNP'),\n",
       " (',', ','),\n",
       " ('F.', 'NNP'),\n",
       " ('A.', 'NNP'),\n",
       " (',', ','),\n",
       " ('McClelland', 'NNP'),\n",
       " (',', ','),\n",
       " ('E.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Meyer', 'NNP'),\n",
       " (',', ','),\n",
       " ('N.', 'NNP'),\n",
       " ('C.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Mintier', 'NNP'),\n",
       " (',', ','),\n",
       " ('G.', 'NNP'),\n",
       " ('A.', 'NN'),\n",
       " (',', ','),\n",
       " ('Moeller', 'NNP'),\n",
       " (',', ','),\n",
       " ('N.', 'NNP'),\n",
       " (',', ','),\n",
       " ('Moore', 'NNP'),\n",
       " ...]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokens = preprocess(data)\n",
    "tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "token = nltk.word_tokenize(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['A',\n",
       " 'common',\n",
       " 'human',\n",
       " 'skin',\n",
       " 'tumour',\n",
       " 'caused',\n",
       " 'activating',\n",
       " 'mutations',\n",
       " 'beta-catenin',\n",
       " '.',\n",
       " 'WNT',\n",
       " 'signalling',\n",
       " 'orchestrates',\n",
       " 'number',\n",
       " 'developmental',\n",
       " 'programs',\n",
       " '.',\n",
       " 'In',\n",
       " 'response',\n",
       " 'stimulus',\n",
       " ',',\n",
       " 'cytoplasmic',\n",
       " 'beta-catenin',\n",
       " '(',\n",
       " 'encoded',\n",
       " 'CTNNB1',\n",
       " ')',\n",
       " 'stabilized',\n",
       " ',',\n",
       " 'enabling',\n",
       " 'downstream',\n",
       " 'transcriptional',\n",
       " 'activation',\n",
       " 'members',\n",
       " 'LEF/TCF',\n",
       " 'family',\n",
       " '.',\n",
       " 'One',\n",
       " 'target',\n",
       " 'genes',\n",
       " 'beta-catenin/TCF',\n",
       " 'encodes',\n",
       " 'c-MYC',\n",
       " ',',\n",
       " 'explaining',\n",
       " 'constitutive',\n",
       " 'activation',\n",
       " 'WNT',\n",
       " 'pathway',\n",
       " 'lead',\n",
       " 'cancer',\n",
       " ',',\n",
       " 'particularly',\n",
       " 'colon',\n",
       " '.',\n",
       " 'Most',\n",
       " 'colon',\n",
       " 'cancers',\n",
       " 'arise',\n",
       " 'mutations',\n",
       " 'gene',\n",
       " 'encoding',\n",
       " 'adenomatous',\n",
       " 'polyposis',\n",
       " 'coli',\n",
       " '(',\n",
       " 'APC',\n",
       " ')',\n",
       " ',',\n",
       " 'protein',\n",
       " 'required',\n",
       " 'ubiquitin-mediated',\n",
       " 'degradation',\n",
       " 'beta-catenin',\n",
       " ',',\n",
       " 'small',\n",
       " 'percentage',\n",
       " 'colon',\n",
       " 'cancers',\n",
       " 'harbour',\n",
       " 'beta-catenin-stabilizing',\n",
       " 'mutations',\n",
       " '.',\n",
       " 'Recently',\n",
       " ',',\n",
       " 'discovered',\n",
       " 'transgenic',\n",
       " 'mice',\n",
       " 'expressing',\n",
       " 'activated',\n",
       " 'beta-catenin',\n",
       " 'predisposed',\n",
       " 'developing',\n",
       " 'skin',\n",
       " 'tumours',\n",
       " 'resembling',\n",
       " 'pilomatricomas',\n",
       " '.',\n",
       " 'Given',\n",
       " 'skin',\n",
       " 'adult',\n",
       " 'mice',\n",
       " 'also',\n",
       " 'exhibits',\n",
       " 'signs',\n",
       " 'de',\n",
       " 'novo',\n",
       " 'hair-follicle',\n",
       " 'morphogenesis',\n",
       " ',',\n",
       " 'wondered',\n",
       " 'whether',\n",
       " 'human',\n",
       " 'pilomatricomas',\n",
       " 'might',\n",
       " 'originate',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cells',\n",
       " 'whether',\n",
       " 'might',\n",
       " 'possess',\n",
       " 'beta-catenin-stabilizing',\n",
       " 'mutations',\n",
       " '.',\n",
       " 'Here',\n",
       " ',',\n",
       " 'explore',\n",
       " 'cell',\n",
       " 'origin',\n",
       " 'aetiology',\n",
       " 'common',\n",
       " 'human',\n",
       " 'skin',\n",
       " 'tumour',\n",
       " '.',\n",
       " 'We',\n",
       " 'found',\n",
       " 'nuclear',\n",
       " 'LEF-1',\n",
       " 'dividing',\n",
       " 'tumour',\n",
       " 'cells',\n",
       " ',',\n",
       " 'providing',\n",
       " 'biochemical',\n",
       " 'evidence',\n",
       " 'pilomatricomas',\n",
       " 'derived',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cells',\n",
       " '.',\n",
       " 'At',\n",
       " 'least',\n",
       " '75',\n",
       " '%',\n",
       " 'tumours',\n",
       " 'possess',\n",
       " 'mutations',\n",
       " 'affecting',\n",
       " 'amino-terminal',\n",
       " 'segment',\n",
       " ',',\n",
       " 'normally',\n",
       " 'involved',\n",
       " 'phosphorylation-dependent',\n",
       " ',',\n",
       " 'ubiquitin-mediated',\n",
       " 'degradation',\n",
       " 'protein',\n",
       " '.',\n",
       " 'This',\n",
       " 'percentage',\n",
       " 'CTNNB1',\n",
       " 'mutations',\n",
       " 'greater',\n",
       " 'human',\n",
       " 'tumours',\n",
       " 'examined',\n",
       " 'thus',\n",
       " 'far',\n",
       " ',',\n",
       " 'directly',\n",
       " 'implicates',\n",
       " 'beta-catenin/LEF',\n",
       " 'misregulation',\n",
       " 'major',\n",
       " 'cause',\n",
       " 'hair',\n",
       " 'matrix',\n",
       " 'cell',\n",
       " 'tumorigenesis',\n",
       " 'humans..',\n",
       " 'HFE',\n",
       " 'mutations',\n",
       " 'analysis',\n",
       " '711',\n",
       " 'hemochromatosis',\n",
       " 'probands',\n",
       " ':',\n",
       " 'evidence',\n",
       " 'S65C',\n",
       " 'implication',\n",
       " 'mild',\n",
       " 'form',\n",
       " 'hemochromatosis',\n",
       " '.',\n",
       " 'Hereditary',\n",
       " 'hemochromatosis',\n",
       " '(',\n",
       " 'HH',\n",
       " ')',\n",
       " 'common',\n",
       " 'autosomal',\n",
       " 'recessive',\n",
       " 'genetic',\n",
       " 'disorder',\n",
       " 'iron',\n",
       " 'metabolism',\n",
       " '.',\n",
       " 'The',\n",
       " 'HFE',\n",
       " 'candidate',\n",
       " 'gene',\n",
       " 'encoding',\n",
       " 'HLA',\n",
       " 'class',\n",
       " 'I-like',\n",
       " 'protein',\n",
       " 'involved',\n",
       " 'HH',\n",
       " 'identified',\n",
       " '1996',\n",
       " '.',\n",
       " 'Two',\n",
       " 'missense',\n",
       " 'mutations',\n",
       " 'described',\n",
       " 'C282Y',\n",
       " ',',\n",
       " 'accounting',\n",
       " '80',\n",
       " '%',\n",
       " '90',\n",
       " '%',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " ',',\n",
       " 'H63D',\n",
       " ',',\n",
       " 'associated',\n",
       " 'milder',\n",
       " 'form',\n",
       " 'disease',\n",
       " 'representing',\n",
       " '40',\n",
       " '%',\n",
       " '70',\n",
       " '%',\n",
       " 'non-C282Y',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " '.',\n",
       " 'We',\n",
       " 'report',\n",
       " 'analysis',\n",
       " 'C282Y',\n",
       " ',',\n",
       " 'H63D',\n",
       " ',',\n",
       " '193A',\n",
       " '--',\n",
       " '>',\n",
       " 'T',\n",
       " 'substitution',\n",
       " 'leading',\n",
       " 'S65C',\n",
       " 'missense',\n",
       " 'substitution',\n",
       " 'large',\n",
       " 'series',\n",
       " 'probands',\n",
       " 'controls',\n",
       " '.',\n",
       " 'The',\n",
       " 'results',\n",
       " 'confirm',\n",
       " 'C282Y',\n",
       " 'substitution',\n",
       " 'main',\n",
       " 'mutation',\n",
       " 'involved',\n",
       " 'hemochromatosis',\n",
       " ',',\n",
       " 'accounting',\n",
       " '85',\n",
       " '%',\n",
       " 'carrier',\n",
       " 'chromosomes',\n",
       " ',',\n",
       " 'whereas',\n",
       " 'H63D',\n",
       " 'substitution',\n",
       " 'represented',\n",
       " '39',\n",
       " '%',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'carry',\n",
       " 'C282Y',\n",
       " 'mutation',\n",
       " '.',\n",
       " 'In',\n",
       " 'addition',\n",
       " ',',\n",
       " 'screening',\n",
       " 'showed',\n",
       " 'S65C',\n",
       " 'substitution',\n",
       " 'significantly',\n",
       " 'enriched',\n",
       " 'probands',\n",
       " 'least',\n",
       " 'one',\n",
       " 'chromosome',\n",
       " 'without',\n",
       " 'assigned',\n",
       " 'mutation',\n",
       " '.',\n",
       " 'This',\n",
       " 'substitution',\n",
       " 'accounted',\n",
       " '7',\n",
       " '.',\n",
       " '8',\n",
       " '%',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'neither',\n",
       " 'C282Y',\n",
       " 'H63D',\n",
       " '.',\n",
       " 'This',\n",
       " 'enrichment',\n",
       " 'S65C',\n",
       " 'among',\n",
       " 'HH',\n",
       " 'chromosomes',\n",
       " 'suggests',\n",
       " 'S65C',\n",
       " 'substitution',\n",
       " 'associated',\n",
       " 'mild',\n",
       " 'form',\n",
       " 'hemochromatosis',\n",
       " '.',\n",
       " 'Germline',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'population-based',\n",
       " 'series',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " '.',\n",
       " 'The',\n",
       " 'objective',\n",
       " 'study',\n",
       " 'provide',\n",
       " 'accurate',\n",
       " 'frequency',\n",
       " 'estimates',\n",
       " 'breast',\n",
       " 'cancer',\n",
       " 'susceptibility',\n",
       " 'gene',\n",
       " '1',\n",
       " '(',\n",
       " 'BRCA1',\n",
       " ')',\n",
       " 'germline',\n",
       " 'alterations',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'population',\n",
       " '.',\n",
       " 'To',\n",
       " 'achieve',\n",
       " 'this',\n",
       " ',',\n",
       " 'determined',\n",
       " 'prevalence',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'population-based',\n",
       " 'series',\n",
       " 'consecutive',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " '.',\n",
       " 'This',\n",
       " 'first',\n",
       " 'population-based',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'study',\n",
       " 'reporting',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'derived',\n",
       " 'comprehensive',\n",
       " 'screen',\n",
       " 'entire',\n",
       " 'coding',\n",
       " 'region',\n",
       " '.',\n",
       " 'One',\n",
       " 'hundred',\n",
       " 'seven',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " 'analyzed',\n",
       " 'BRCA1',\n",
       " 'alterations',\n",
       " 'using',\n",
       " 'RNase',\n",
       " 'mismatch',\n",
       " 'cleavage',\n",
       " 'assay',\n",
       " 'followed',\n",
       " 'direct',\n",
       " 'sequencing',\n",
       " '.',\n",
       " 'Two',\n",
       " 'truncating',\n",
       " 'mutations',\n",
       " ',',\n",
       " '962del4',\n",
       " '3600del11',\n",
       " ',',\n",
       " 'identified',\n",
       " '.',\n",
       " 'Both',\n",
       " 'patients',\n",
       " 'family',\n",
       " 'history',\n",
       " 'breast',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " '.',\n",
       " 'Several',\n",
       " 'novel',\n",
       " 'well',\n",
       " 'previously',\n",
       " 'reported',\n",
       " 'uncharacterized',\n",
       " 'variants',\n",
       " 'also',\n",
       " 'identified',\n",
       " ',',\n",
       " 'associated',\n",
       " 'family',\n",
       " 'history',\n",
       " 'cancer',\n",
       " '.',\n",
       " 'The',\n",
       " 'frequency',\n",
       " 'distribution',\n",
       " 'common',\n",
       " 'polymorphisms',\n",
       " 'determined',\n",
       " '91',\n",
       " 'Caucasian',\n",
       " 'cancer',\n",
       " 'cases',\n",
       " 'series',\n",
       " '24',\n",
       " 'sister',\n",
       " 'controls',\n",
       " 'using',\n",
       " 'allele-specific',\n",
       " 'amplification',\n",
       " '.',\n",
       " 'The',\n",
       " 'rare',\n",
       " 'form',\n",
       " 'Q356R',\n",
       " 'polymorphism',\n",
       " 'significantly',\n",
       " '(',\n",
       " 'P',\n",
       " '=',\n",
       " '0',\n",
       " '.',\n",
       " '03',\n",
       " ')',\n",
       " 'associated',\n",
       " 'family',\n",
       " 'history',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " ',',\n",
       " 'suggesting',\n",
       " 'polymorphism',\n",
       " 'may',\n",
       " 'influence',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'risk',\n",
       " '.',\n",
       " 'In',\n",
       " 'summary',\n",
       " ',',\n",
       " 'data',\n",
       " 'suggest',\n",
       " 'role',\n",
       " 'uncharacterized',\n",
       " 'variants',\n",
       " 'rare',\n",
       " 'forms',\n",
       " 'polymorphisms',\n",
       " 'determining',\n",
       " 'ovarian',\n",
       " 'cancer',\n",
       " 'risk',\n",
       " ',',\n",
       " 'highlight',\n",
       " 'necessity',\n",
       " 'screen',\n",
       " 'missense',\n",
       " 'alterations',\n",
       " 'well',\n",
       " 'truncating',\n",
       " 'mutations',\n",
       " 'population',\n",
       " '.',\n",
       " 'Identification',\n",
       " 'APC2',\n",
       " ',',\n",
       " 'homologue',\n",
       " 'adenomatous',\n",
       " 'polyposis',\n",
       " 'coli',\n",
       " 'tumour',\n",
       " 'suppressor',\n",
       " '.',\n",
       " 'The',\n",
       " 'adenomatous',\n",
       " 'polyposis',\n",
       " 'coli',\n",
       " '(',\n",
       " 'APC',\n",
       " ')',\n",
       " 'tumour-suppressor',\n",
       " 'protein',\n",
       " 'controls',\n",
       " 'Wnt',\n",
       " 'signalling',\n",
       " 'pathway',\n",
       " 'forming',\n",
       " 'complex',\n",
       " 'glycogen',\n",
       " 'synthase',\n",
       " 'kinase',\n",
       " '3beta',\n",
       " '(',\n",
       " 'GSK-3beta',\n",
       " ')',\n",
       " ',',\n",
       " 'axin/conductin',\n",
       " 'betacatenin',\n",
       " '.',\n",
       " 'Complex',\n",
       " 'formation',\n",
       " 'induces',\n",
       " 'rapid',\n",
       " 'degradation',\n",
       " 'betacatenin',\n",
       " '.',\n",
       " 'In',\n",
       " 'colon',\n",
       " 'carcinoma',\n",
       " 'cells',\n",
       " ',',\n",
       " 'loss',\n",
       " 'APC',\n",
       " 'leads',\n",
       " 'accumulation',\n",
       " 'betacatenin',\n",
       " 'nucleus',\n",
       " ',',\n",
       " 'binds',\n",
       " 'activates',\n",
       " 'Tcf-4',\n",
       " 'transcription',\n",
       " 'factor',\n",
       " '(',\n",
       " 'reviewed',\n",
       " '[',\n",
       " '1',\n",
       " ']',\n",
       " '[',\n",
       " '2',\n",
       " ']',\n",
       " ')',\n",
       " '.',\n",
       " 'Here',\n",
       " ',',\n",
       " 'report',\n",
       " 'identification',\n",
       " 'genomic',\n",
       " 'structure',\n",
       " 'APC',\n",
       " 'homologues',\n",
       " '.',\n",
       " 'Mammalian',\n",
       " 'APC2',\n",
       " ',',\n",
       " 'closely',\n",
       " 'resembles',\n",
       " 'APC',\n",
       " 'overall',\n",
       " 'domain',\n",
       " 'structure',\n",
       " ',',\n",
       " 'functionally',\n",
       " 'analyzed',\n",
       " 'shown',\n",
       " 'contain',\n",
       " 'two',\n",
       " 'SAMP',\n",
       " 'domains',\n",
       " ',',\n",
       " 'required',\n",
       " 'binding',\n",
       " 'conductin',\n",
       " '.',\n",
       " 'Like',\n",
       " 'APC',\n",
       " ',',\n",
       " 'APC2',\n",
       " 'regulates',\n",
       " 'formation',\n",
       " 'active',\n",
       " 'betacatenin-Tcf',\n",
       " 'complexes',\n",
       " ',',\n",
       " 'demonstrated',\n",
       " 'using',\n",
       " 'transient',\n",
       " 'transcriptional',\n",
       " 'activation',\n",
       " 'assays',\n",
       " 'APC',\n",
       " '-/-',\n",
       " 'colon',\n",
       " 'carcinoma',\n",
       " 'cells',\n",
       " '.',\n",
       " 'Human',\n",
       " 'APC2',\n",
       " 'maps',\n",
       " 'chromosome',\n",
       " '19p13',\n",
       " '.',\n",
       " '3',\n",
       " '.',\n",
       " 'APC',\n",
       " 'APC2',\n",
       " 'may',\n",
       " 'therefore',\n",
       " 'comparable',\n",
       " 'functions',\n",
       " 'development',\n",
       " 'cancer',\n",
       " '.',\n",
       " 'Familial',\n",
       " 'deficiency',\n",
       " 'seventh',\n",
       " 'component',\n",
       " 'complement',\n",
       " 'associated',\n",
       " 'recurrent',\n",
       " 'bacteremic',\n",
       " 'infections',\n",
       " 'due',\n",
       " 'Neisseria',\n",
       " '.',\n",
       " 'The',\n",
       " 'serum',\n",
       " '29-year',\n",
       " 'old',\n",
       " 'woman',\n",
       " 'recent',\n",
       " 'episode',\n",
       " 'disseminated',\n",
       " 'gonococcal',\n",
       " 'infection',\n",
       " 'history',\n",
       " 'meningococcal',\n",
       " 'meningitis',\n",
       " 'arthritis',\n",
       " 'child',\n",
       " 'found',\n",
       " 'lack',\n",
       " 'serum',\n",
       " 'hemolytic',\n",
       " 'complement',\n",
       " 'activity',\n",
       " '.',\n",
       " 'The',\n",
       " 'seventh',\n",
       " 'component',\n",
       " 'complement',\n",
       " '(',\n",
       " 'C7',\n",
       " ')',\n",
       " 'detected',\n",
       " 'functional',\n",
       " 'immunochemical',\n",
       " 'assays',\n",
       " ',',\n",
       " 'whereas',\n",
       " 'components',\n",
       " 'normal',\n",
       " 'hemolytic',\n",
       " 'immunochemical',\n",
       " 'assessment',\n",
       " '.',\n",
       " 'Her',\n",
       " 'fresh',\n",
       " 'serum',\n",
       " 'lacked',\n",
       " 'complement-mediated',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'Neisseria',\n",
       " 'gonorrhoeae',\n",
       " ',',\n",
       " 'addition',\n",
       " 'fresh',\n",
       " 'normal',\n",
       " 'serum',\n",
       " 'purified',\n",
       " 'C7',\n",
       " 'restored',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'well',\n",
       " 'hemolytic',\n",
       " 'activity',\n",
       " '.',\n",
       " 'The',\n",
       " 'absence',\n",
       " 'functional',\n",
       " 'C7',\n",
       " 'activity',\n",
       " 'could',\n",
       " 'accounted',\n",
       " 'basis',\n",
       " 'inhibitor',\n",
       " '.',\n",
       " 'Opsonization',\n",
       " 'generation',\n",
       " 'chemotactic',\n",
       " 'activity',\n",
       " 'functioned',\n",
       " 'normally',\n",
       " '.',\n",
       " 'Complete',\n",
       " 'absence',\n",
       " 'C7',\n",
       " 'also',\n",
       " 'found',\n",
       " 'one',\n",
       " 'sibling',\n",
       " 'clinical',\n",
       " 'syndrome',\n",
       " 'meningococcal',\n",
       " 'meningitis',\n",
       " 'arthritis',\n",
       " 'child',\n",
       " 'siblings',\n",
       " 'clinically',\n",
       " 'well',\n",
       " 'eight-year-old',\n",
       " 'son',\n",
       " '.',\n",
       " 'HLA',\n",
       " 'histocompatibility',\n",
       " 'typing',\n",
       " 'family',\n",
       " 'members',\n",
       " 'demonstrate',\n",
       " 'evidence',\n",
       " 'genetic',\n",
       " 'linkage',\n",
       " 'C7',\n",
       " 'deficiency',\n",
       " 'major',\n",
       " 'histocompatibility',\n",
       " 'loci',\n",
       " '.',\n",
       " 'This',\n",
       " 'report',\n",
       " 'represents',\n",
       " 'first',\n",
       " 'cases',\n",
       " 'C7',\n",
       " 'deficiency',\n",
       " 'associated',\n",
       " 'infectious',\n",
       " 'complications',\n",
       " 'suggests',\n",
       " 'bactericidal',\n",
       " 'activity',\n",
       " 'may',\n",
       " 'important',\n",
       " 'host',\n",
       " 'defense',\n",
       " 'bacteremic',\n",
       " 'neisseria',\n",
       " 'infections',\n",
       " '.',\n",
       " 'GCH1',\n",
       " 'mutation',\n",
       " 'patient',\n",
       " 'adult-onset',\n",
       " 'oromandibular',\n",
       " 'dystonia',\n",
       " '.',\n",
       " 'The',\n",
       " 'authors',\n",
       " 'report',\n",
       " 'mutation',\n",
       " 'exon',\n",
       " '5',\n",
       " 'GCH1',\n",
       " 'patient',\n",
       " 'adult-onset',\n",
       " 'oromandibular',\n",
       " 'dystonia',\n",
       " 'obvious',\n",
       " 'family',\n",
       " 'history',\n",
       " 'dystonia',\n",
       " '.',\n",
       " 'The',\n",
       " 'patient',\n",
       " 'responded',\n",
       " 'positively',\n",
       " 'treatment',\n",
       " 'L-dopa',\n",
       " '.',\n",
       " 'These',\n",
       " 'findings',\n",
       " 'demonstrate',\n",
       " 'GCH1',\n",
       " 'mutations',\n",
       " 'must',\n",
       " 'considered',\n",
       " 'even',\n",
       " 'patients',\n",
       " 'dystonic',\n",
       " 'symptoms',\n",
       " 'typical',\n",
       " 'dopa-responsive',\n",
       " 'dystonia',\n",
       " '.',\n",
       " 'The',\n",
       " 'hereditary',\n",
       " 'hemochromatosis',\n",
       " 'protein',\n",
       " ',',\n",
       " 'HFE',\n",
       " ',',\n",
       " 'specifically',\n",
       " 'regulates',\n",
       " 'transferrin-mediated',\n",
       " 'iron',\n",
       " 'uptake',\n",
       " 'HeLa',\n",
       " 'cells',\n",
       " '.',\n",
       " 'HFE',\n",
       " 'protein',\n",
       " 'product',\n",
       " 'gene',\n",
       " 'mutated',\n",
       " 'autosomal',\n",
       " 'recessive',\n",
       " 'disease',\n",
       " 'hereditary',\n",
       " 'hemochromatosis',\n",
       " '(',\n",
       " 'Feder',\n",
       " ',',\n",
       " 'J.',\n",
       " 'N.',\n",
       " ',',\n",
       " 'Gnirke',\n",
       " ',',\n",
       " 'A.',\n",
       " ',',\n",
       " 'Thomas',\n",
       " ',',\n",
       " 'W.',\n",
       " ',',\n",
       " 'Tsuchihashi',\n",
       " ',',\n",
       " 'Z.',\n",
       " ',',\n",
       " 'Ruddy',\n",
       " ',',\n",
       " 'D.',\n",
       " 'A.',\n",
       " ',',\n",
       " 'Basava',\n",
       " ',',\n",
       " 'A.',\n",
       " ',',\n",
       " 'Dormishian',\n",
       " ',',\n",
       " 'F.',\n",
       " ',',\n",
       " 'Domingo',\n",
       " ',',\n",
       " 'R.',\n",
       " 'J.',\n",
       " ',',\n",
       " 'Ellis',\n",
       " ',',\n",
       " 'M.',\n",
       " 'C.',\n",
       " ',',\n",
       " 'Fullan',\n",
       " ',',\n",
       " 'A.',\n",
       " ',',\n",
       " 'Hinton',\n",
       " ',',\n",
       " 'L.',\n",
       " 'M.',\n",
       " ',',\n",
       " 'Jones',\n",
       " ',',\n",
       " 'N.',\n",
       " 'L.',\n",
       " ',',\n",
       " 'Kimmel',\n",
       " ',',\n",
       " 'B.',\n",
       " 'E.',\n",
       " ',',\n",
       " 'Kronmal',\n",
       " ',',\n",
       " 'G.',\n",
       " 'S.',\n",
       " ',',\n",
       " 'Lauer',\n",
       " ',',\n",
       " 'P.',\n",
       " ',',\n",
       " 'Lee',\n",
       " ',',\n",
       " 'V.',\n",
       " 'K.',\n",
       " ',',\n",
       " 'Loeb',\n",
       " ',',\n",
       " 'D.',\n",
       " 'B.',\n",
       " ',',\n",
       " 'Mapa',\n",
       " ',',\n",
       " 'F.',\n",
       " 'A.',\n",
       " ',',\n",
       " 'McClelland',\n",
       " ',',\n",
       " 'E.',\n",
       " ',',\n",
       " 'Meyer',\n",
       " ',',\n",
       " 'N.',\n",
       " 'C.',\n",
       " ',',\n",
       " 'Mintier',\n",
       " ',',\n",
       " 'G.',\n",
       " 'A.',\n",
       " ',',\n",
       " 'Moeller',\n",
       " ',',\n",
       " 'N.',\n",
       " ',',\n",
       " 'Moore',\n",
       " ...]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "token"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
